Hanford thyroid disease study; final report by Davis, Scott, Ph. D et al.
HANFORD THYROID DISEASE STUDY
FINAL REPORT
Study Management Team
Scott Davis, Ph.D., Principal Investigator (Epidemiology)
Kenneth J. Kopecky, Ph.D., Co-Investigator (Biostatistics)
Thomas E. Hamilton, M.D., Ph.D., Co-Investigator (Endocrinology)
This Report Was Prepared by the HTDS Study Management Team
And the Following HTDS Staff 
Lynn E. Onstad, Sc.M.,  Statistical Research Associate
Beth L. King, B.A., Project Manager
Mark S. Saporito, M.A., Systems Analyst
With Special Assistance From
Christy R. Callahan, B.A.
Fred Hutchinson Cancer Research Center
CDC Contract Number 200-89-0716
June 21, 2002
Acknowledgments
Many individuals have contributed to the success of the Hanford Thyroid Disease Study. We wish
to express our deep appreciation to Ms. Peggy Adams Myers for her leadership as Project Manager from
the beginning of the study through the release of the Draft Final Report, and to Ms. Beth King as Project
Manager thereafter. We also extend a special acknowledgment to several persons who supervised or were
responsible for major components of the study: Lynn Onstad (data operations and statistical analysis);
Mark Saporito (programming); Sandy Walbrek (administrative support); Beth King (tracing and
recruiting); Theresa Taggart (travel); Esther Kohler (CATI); Surena Khatir (database support); and Thula
Weisel and Laurie Shields (clinic operations). Ms. Dana Mirick provided invaluable statistical support. 
Dr. Bruce Amundson provided expertise in family and rural medicine, and was a member of the
Study Management Team through August, 1998. 
We also wish to thank the many additional staff who worked on this project for their valuable
contributions in the following areas: 1) administrative support: Teri Kopp, Cathy Voigt, Nancy McMillan,
Sara Smith, Tricia Christopherson, Janice Findley, Iona McKenzie, Georgia Green, Kimberly Green, Berta
Nicole-Blades, Carroll Haymon, Donna Johnson, Steve Walbrek, Christy Callahan; 2) tracing and
recruiting: Kathy Koons, Allan Jaeger, Elizabeth Acorda, Meg Woods, Judith Dietert, Karen Queen, Dick
Young, Anna Marie Biasini, Jana Carr, Carolyn Tuman, Jesse Winter; 3) CATI: Bruce Cummins, Shannon
Greer, Kathy Vickers, Jaime Roberts-Jones, Eileen Bennoff, Sue Kung; 4) clinics: Steve Minor, Esther
Ricardo-Bulis, Mari Hooten-Lee, Sally Kirk, Holly Roberts, Michael Weygint, Melanie Bartmess, Lynne
Brosnahan; 5) thyroid ultrasound: Theresa Stanfel-Hull, David Sherman, Jeremy Hodges, Carmen Fletcher;
6) medical records: Susan DeNeef, Sherry Shanabarger; 7) data operations: Bernie Moore, Elizabeth
Carosso, Meri Gilman, Jennifer Sporleder, Jan Kikuchi, Bill Mullin, Liza Noonan, Chuck Wiggins, Belen
Gallardo, and especially Linda Joos (deceased). 
Along with Drs. Hamilton and Griep, the following endocrinologists examined study participants
in the HTDS clinics: Drs. Gayle Brewer, Ken Gross, Gary Treece, Mike Tuttle. Dr. Bruce Kulander
provided pathology review and consultation for all fine needle aspiration and histology materials. Drs.
Keith Wang, Jack Hirsch, John Denney, and Robert Schor provided thyroid ultrasound review and
consultation for all ultrasound exams. The following consultants provided valuable assistance in the
following areas: 1) CATI questionnaire design and implementation: Drs. Donald Dillman, John Tarnai,
Ronald Fisher, and Ms. Ellen Lammiman; 2) birth and death certificate access and retrieval from the State
of Washington: Dr. Floyd Frost and Mr. Eugene Sobota; 3) history of Hanford: Dr. Michelle Stenejhem; 4)
statistical and design issues: Dr. Duncan Thomas,  Dr. Dana Flanders, and Dr. Dan Stram; and 5) Anti-Tg
assay and results: Dr. Carol Spencer.  
We especially acknowledge the contributions of Dr. Robert W. Day, President and Director
Emeritus of the Fred Hutchinson Cancer Research Center, for his support of this project and his
encouragement through all stages of the research. He greatly facilitated the conduct of this complex
endeavor. 
We extend a special thank you to Dr. John Till, who served as the Chairman of the Technical
Steering Panel (TSP) of the Hanford Environmental Dose Reconstruction Project, for his assistance and
support throughout the project, and to each member of the TSP for their guidance and encouragement. Dr.
David Price was particularly helpful in issues related to milk consumption and the development of the
dosimetry questionnaire, and Ms. Mary Lou Blazek provided valuable assistance in matters related to
public communications.  Dr. Bruce Napier of Battelle Pacific Northwest Laboratories was especially
helpful in developing the dosimetry (CATI) interview, and in matters related to the implementation of the
computer system for estimating individual thyroid doses. We also thank the many volunteers who so kindly
gave of their time to assist in the testing and revision of the interview instruments that were used for
dosimetry (CATI) and in the clinic (in-person interview). 
We wish to acknowledge the dedicated service and valuable contributions provided by members
of the federal Advisory Committee convened to advise the CDC on the conduct of the HTDS. The
following individuals served on the committee for the entire course of the study: Dr. Larry Jecha
(Chairman), Dr. Arthur Schneider (thyroid specialist), Mr. Lou Stone (Native American representative).
Others who contributed to the committee and who were members for varying lengths of time include: Dr.
Owen Hoffman (dosimetry), Dr. Marlene McKetty (dosimetry), Dr. Genevieve Matanoski (epidemiology),
Dr. Maureen Hatch (epidemiology), Ms. Kristine Gebbie (State of Washington), Ms. Elizabeth Ward (State
of Washington), Mr. Jim Thomas (regional community), and Dr. Sara Cate (regional community). Two
consultants representing the Hanford Downwinder’s Coalition also contributed to the deliberations of the
committee: Ms. Pam Hofer and Ms. Judith Jurji. 
Several organizations have provided valuable assistance in the conduct of this study: Pacific
Medical Center, Seattle Laboratory of Pathology, Seattle Nuclear Medicine, The Seattle Foundation, and
the following sites which provided space for one or more HTDS clinics: Our Lady of Lourdes Business
Health Center, Pasco, Washington; Deaconess Medical Center, Spokane, Washington; Southwest
Washington Medical Center, Vancouver, Washington; Internal Medicine Associates of Yakima, Yakima,
Washington; St. Mary Regional Medical Center, Walla Walla, Washington; Central Washington Hospital,
Wenatchee, Washington; Mt. Carmel Hospital, Colville, Washington; Okanogan Valley Clinic, Omak,
Washington; and St. Vincent Hospital and Medical Center, Portland, Oregon.
Finally, we gratefully acknowledge the substantial contributions that each and every study
participant made in willingly giving of their time and personal information, as well as the contributions
made by many family members.  Without such unselfish dedication on the part of so many people, this
study would not have been possible. The overall success of this effort is due primarily to the participants. 
TABLE OF CONTENTS 
 
 
EXECUTIVE SUMMARY 
 
I. INTRODUCTION ………………..……………………………………………………...1
     
II. BACKGROUND …………………..….………………………………………………….4 
 A. Historical Perspective ……….…..………………………………………………….4 
 B. Ionizing Radiation and Thyroid Disease ……….…………………………………...9 
  B.1. Thyroid Neoplasia: Exposure to External Photon Radiation  …….………...9 
  B.2. Thyroid Neoplasia: Exposure to Radioactive Iodine …………….………..10 
   B.2.a. Medical Exposures to Radioiodine ……………………….……….10 
   B.2.b. Environmental Exposures to Radioiodine ……………….………..11 
    B.2.b.1. Utah ……………………………………………………….11 
    B.2.b.2. Marshall Islands …..…………………………………..……11 
    B.2.b.3 Chernobyl ……………………………………………..……12 
   B.2.c. Relative Biological Effectiveness of I-131 in the Induction of  
Thyroid Cancer …………………………………………………….13 
  B.3. Hypothyroidism …………………………………………………………...14 
  B.4. Autoimmune Thyroiditis …………………………………………………..14 
 C. Ionizing Radiation and Parathyroid Disease ……………………………………...16 
  C.1. Hyperparathyroidism:  Exposure to External Photon Radiation ……..…...16 
  C.2. Hyperparathyroidism:  Exposure to Radioactive Iodine ……………..……17 
 D. Ultrasound-Detected Abnormalities of the Thyroid (Thyroid UDAs) ………..…...18 
  D.1. Prevalence of Thyroid UDAs …………………………………………….18 
  D.2. Specificity of Thyroid Ultrasonography in Predicting Thyroid Cancer …...19 
  D.3. Ionizing Radiation and Thyroid UDAs …………………………………….20 
 
III. STUDY OBJECTIVES …………………………….………………………………..…21 
 
IV. STUDY DESIGN …………………………………………………………………….....22 
 A. Eligibility Criteria ………………………………………………………………....22 
  A.1. Mother's Residence at the Time of the Particpant's Birth ……………..…..22 
  A.2. Year of Birth …………………………………………………………..…...30 
  A.3. Other Possible Criteria ………………………………………………..…..33 
 B. Definition of Evaluable Participant ……………………………………………..…34 
 C. Outcome Criteria ………………………………………………………………..…35 
  C.1. Thyroid Cancer …………………………………………………………....35 
  C.2. Benign Thyroid Nodule ………………………………………………….....35 
  C.3. Any Thyroid Nodule …………………………………………………….…36 
  C.4. Hypothyroidism …………………………………………………………...36 
  C.5. Autoimmune (Hashimoto’s) Thyroiditis ……………………………….….36 
  C.6. Graves Disease …………………………………………………….……...37 
  C.7. Autoimmune Thyroid Disease ……………………………………..………37 
  C.8. Hyperthyroidism ………………………………………………….……….37 
HTDS Final Report: June 21, 2002 – Table of Contents                                                                                                             iii 
  C.9. Multinodular Thyroid Gland …………………………………….…….…..38 
  C.10. Simple Goiter …………………………………………………….…….…..38 
  C.11. Other Thyroid Disease ………………………………………….…….…...38 
  C.12. Ultrasound-Detected Abnormalities of the Thyroid (Thyroid UDAs) ..……39 
  C.13. Hyperparathyroidism ………………………………………………..…….39 
 
V. FIELD PROCEDURES AND METHODS, RESULTS OF DATA  
COLLECTION PROCESS ………………………………..…………………………..40 
 A. Cohort Definition, Subject Identification and Selection …..………………………40 
  A.1. Background ………………………………………..………………………40 
   A.1.a. Objectives …………………………………..……………………...40 
   A.1.b. Definition of the Cohort ……………………..…………………….40 
  A.2. Plan …………………………………………………..……………………41 
   A.2.a. Protocol Plan ………………………………..…………………….41 
    A.2.a.1. Rationale ……………………………..…………………….41 
    A.2.a.2. Completeness Required for Success ……….…………………...43 
   A.2.b. Plans for Assessing the Need for Change in the Full Study ……....43 
  A.3. Revisions ……………………………………………………………….…44 
   A.3.a. Rationale for Revisions made in the Transition Sample …………..44 
   A.3.b. Rationale for Revisions made in the Full Study ..…………………44 
  A.4. Outcome and Final Results ……………………………………………….45 
  A.5. Summary of Full Study Power Calculations, as Presented in HTDS Pilot 
Study Report ………………………………………………………………47 
 B. Tracing Potential Participants ……………………………………………………..52 
  B.1.  Background ……………………………………………………………….52 
   B.1.a. Objectives of Tracing ……………………………………………..52 
   B.1.b. History of Tracing Efforts Around Hanford ………………………52 
   B.1.c. Overview of Tracing Efforts ………………………………………53 
   B.1.d. Staffing and Logistics ……………………………………………..55 
  B.2. Revisions to the Original Protocol Plan …………………………………..55 
   B.2.a. Deletion of Ineffective Sources of Information and Addition of  
New Sources ……………………………………………………….55 
   B.2.b. Addition of Computer On-line Database Information …………….56 
  B.3. Final Tracing Process ……………………………………………………..56 
   B.3.a. Linkages with Publicly Available Data Sources …………………..56 
   B.3.b. Manual Tracing Resources ………………………………………..58 
   B.3.c. Unlocated Potential Participants ………………………………….63 
  B.4. Outcome and Final Results ………………………………………………..68 
   B.4.a. Results from the Pilot Study Sample ……………………………….68 
    B.4.a.1. Results by Strata …………………………………………….68 
   B.4.b. Results from Transition Sample ……………………………………68 
    B.4.b.1. Results by Strata …………………………………………….68 
   B.4.c. Results for the Full Study Sample …………………………………75 
    B.4.c.1. Results by Strata …………………………………………….76 
   B.4.d. Overall Results for the Full Study …………………………………78 
    B.4.d.1. Success in Locating Study Potential Participants ……………..…78 
    B.4.d.2. Current Residence of Living Potential Participants ………………81 
HTDS Final Report: June 21, 2002 – Table of Contents                                                                                                             iv 
    B.4.d.3. Death Certificates Obtained for Deceased Potential Participants ….82 
 C. Recruiting ………………………………………………………………………….84 
  C.1. Background ………………………………………………………………..84 
   C.1.a. Objectives of Recruiting …………………………………………..84 
  C.2. Recruiting Procedures ……………………………………………………84 
   C.2.a. Initial Written Contact and Attempt to Contact by Phone ………..84 
   C.2.b. Telephone Contact with the Potential Participant ………………..85 
   C.2.c. Confirmation of Agreement to Participate and Six Month Letter …86 
   C.2.d. Refusals and Second Attempts …………………………………….86 
   C.2.e. Second Request for Participation …………………………………86 
  C.3. Outcome and Results ………………………………………………………87 
   C.3.a. Results for the Pilot Study Sample ……………………………..…87 
   C.3.b. Results from the Transition Sample ……………………………….91 
   C.3.c. Results for the Full Study Sample …………………………………95 
   C.3.d. Results for the Entire Study ……………………………………….98 
    C.3.d.1. Agreement on First Attempt vs. Second Attempt (conversions) ……102 
    C.3.d.2. Refusal ……………………………………………………103 
    C.3.d.3. Success in Converting Refusals/Withdrawals by Reason for Refusal .104 
    C.3.d.4. Success in Converting Refusals/Withdrawals by “Strength” of  
Refusal ……………………………………………………105 
   C.3.e. Conclusions …………………………………………………..….106 
 D. Computer Assisted Telephone Interview …………………………………….….107 
  D.1. Background ……………………………………………………………...107 
   D.1.a. Objectives of the Interview ………………………………………107 
   D.1.b. Historical Perspective and Special Challenges ……………….…107 
  D.2. Content and Design of the CATI …………………………………..…….108 
   D.2.a. Development of a Cognitive Approach to Enhance Long-term 
Recall …………………………………………………..……..…108 
   D.2.b. Development and Testing of the CATI ………………….…….…109 
   D.2.c. Final Process and Procedures ……………………………..……110 
    D.2.c.1. Conducting the Interview ……………………………..……110 
    D.2.c.2. Quality Control …………………………………..………..111 
  D.3. Outcome and Results ………………………………………………….…112 
   D.3.a. Pilot Study Results ………………………………………..…..…112 
   D.3.b. Transition Sample Results ……………………………………….112 
   D.3.c. Results for the Full Study Sample …………………………….…112 
   D.3.d. Overall Results for the Entire Study ……………………………112 
   D.3.e.  Conclusions ………………………………………………..……112 
    D.3.e.1. Quality of the Data …………………………………………113 
  D.4. Attempts to Administer the CATI to Respondents for Deceased Potential 
Participants ……………………………………………………………..115 
   D.4.a. Development of a Revised CATI for Deceased Potential  
Participants …………………………………………………..…115 
   D.4.b. Conducting a CATI for Deceased Potential Participants ……….116 
  D.5. Success of the CATI Component ……………………………………...…116 
 E. Scheduling ………………………………………………………………………118 
  E.1. Background ………………………………………………………………118 
HTDS Final Report: June 21, 2002 – Table of Contents                                                                                                             v 
  E.2. Objectives of Scheduling …………………………………………………118 
  E.3. Final Process and Procedures ……………………………………………119 
  E.4. Outcome ………………………………………………………………….120 
   E.4.a. Results for the Pilot Study Sample ……………………………….120 
   E.4.b. Results for the Transition Sample ……………………………..…120 
   E.4.c. Results for the Full Study Sample ………………………………..121 
   E.4.d. Overall Results for the Entire Study………………………………121 
   E.4.e. Conclusions ………………………………………………………124 
 F. Clinical Evaluation ………………………………………………………………125 
  F.1. Background ……………………………………………………………...125 
   F.1.a. Objectives for Clinical Evaluations …………………………..…125 
   F.1.b. Rationale ………..……………………………………………….125 
  F.2. Clinic Procedures ………………………………………………………..125 
   F.2.a. Clinic Locations and Schedules ………………………………….125 
   F.2.b. Clinical Evaluation Process …………………………………..…125 
   F.2.c. Clinic Staffing ……………………………………………………126 
   F.2.d. Efforts to Reduce Physician and Ultrasonographer Bias ….……126 
  F.3. Serum Sample   ……………………………………………………………127 
   F.3.a. Laboratory Studies ………………………………………………..127 
   F.3.b. Changes in Laboratory Assays ………………………………..…127 
    F.3.b.1. AMA to Anti-TPO ………………………………………….127 
    F.3.b.2. TSH Methods - RIA, EIA-1, EIA-2 ……………………………127 
    F.3.b.3. Parathyroid Hormone Methods ………………………………128 
    F.3.b.4. Anti-TG ……………………………………………..……128 
  F.4. Inclusion of an Ultrasound Exam …………………………………….…128 
  F.5. Ultrasound Follow-up Program …………………………………………128 
F.5.a. Purpose of the Ultrasound Follow-up Program …………………128 
   F.5.b. Discontinuation of the Ultrasound Follow-up Program …………129 
  F.6. Physicians …………………………………………………………….…129 
  F.7. FNA Criteria ……………………………………………………………130 
  F.8.  Thyroid Nuclear Scan Criteria ………………………………………..…131 
  F.9. Training and Quality Control …………………………………………...132 
   F.9.a. Training …………………………………………………………..132 
   F.9.b. Ultrasonographer Quality Control ………………………………132 
   F.9.c. Radiology Quality Control Program ……………………………133 
  F.10. Outcome and Results …………………………………………….………134 
   F.10.a. Results for the Pilot Study Sample ……………………………….134 
   F.10.b. Results for the Transition Sample ………………………….….…135 
   F.10.c. Results for the Full Study Sample …………………………..……135 
   F.10.d. Overall Results for the Entire Study ……………………………136 
   F.10.e. Conclusions ………………………………………………………136 
 G. In-Person Interview ………………………………………………………..……137 
  G.1. Background ………………………………………………………………137 
  G.2. Objectives of the In-Person Interview …………………………………..137 
  G.3. Development and Revision of the Questionnaire ………………………..137 
  G.4. Procedures for the In-Person Interview ………………………………….138 
  G.5. Training and Quality Control ……………………………………………138 
HTDS Final Report: June 21, 2002 – Table of Contents                                                                                                             vi 
  G.6. Outcome and Results …………………………………………………….139 
  G.7. Quality of In-Person Interview and Expanded In-Person Interview Data .139 
  G.8. Conclusions ……………………………………………………………..141 
 H. Medical Review and Final Diagnosis Determination ……………………………142 
  H.1. Background ………………………………………………………………142 
   H.1.a. Objectives of Medical Review and Final Diagnosis  
Determination ……………………………………………………142 
   H.1.b. Rationale …………………………………………………………142 
  H.2. Medical Review and Final Diagnosis Determination ……………………142 
   H.2.a. Medical Review Process …………………………………………142 
   H.2.b. Additional Tests ………………………………………………….143 
   H.2.c. Communication of Medical Review Results to Participants and  
Their Health Care Providers ………………………………….…143 
   H.2.d. Fact Sheets ………………………………………………………144 
   H.2.e. Final Diagnosis Determination ………………………………….144 
   H.2.f.  Dating of Diagnoses ………………………………………………145 
  H.3. Outcome and Results …………………………………………………….145 
   H.3.a. Number of Cases Reviewed and Follow-up Procedures  
Recommended ……………………………………………………145 
   H.3.b. Conclusions ………………………………………………………145 
 I. Historical and Post-Clinic Medical Records and Specimens ……………….……146 
  I.1. Background ……………………………………………………………146 
   I.1.a. Objectives of Obtaining Medical Records …………………….…146 
  I.2. Process and Procedures Used ………………………………………..…146 
   I.2.a. Historical Medical Records …………………………………..…146 
   I.2.b. Post-Clinic Medical Records …………………………………….147 
   I.2.c. Blinding the Reviewer to Radiation Exposure …………………..147 
   I.2.d. Cause of Death Coding ……………………………………….…147 
  I.3. Outcome and Results …………………………………………………….148 
   I.3.a. Historical Records ……………………………………………….148 
   I.3.b. Historical Pathology and Cytology Slides ……………………….149 
   I.3.c. Post-Clinic Medical Records and Slides …………………………149 
   I.3.d. Cause of Death Coding ……………………………………….…149 
  I.4. Potential Impact of Medical Records and Slides That Were Not  
Obtained …………………………………………………………………150 
  I.5. Conclusions ………………………………………………………………150 
 J. Data Management ………………………………………………………………152 
  J.1. Objectives of Data Management ………………………………………...152 
  J.2. Data Management Procedures ……………………………………..……152 
   J.2.a. General Procedures ……………………………………………..152 
   J.2.b. Tracking System ………………………………………………….153 
J.2.c. CATI …………………………………………………………..…154 
   J.2.d. Clinic In-Person Interview ……………………………………….154 
   J.2.e. Clinic Data Forms, Final Diagnosis Determination Form, Refusal 
Questionnaire, Cause of Death Form and Dating of Diagnoses ...155 
   J.2.f. ICD9 Cause of Death Coding ……………………………………156 
   J.2.g. Problems Forms ………………………………………………….156 
HTDS Final Report: June 21, 2002 – Table of Contents                                                                                                             vii 
  J.3. Outcome and Results …………………………………………………….156 
   J.3.a. Tracking System …………………………………………………156 
   J.3.b. CATI ………………………………………………………….…157 
   J.3.c. Clinic In-Person Interview ………………………………………157 
   J.3.d. Clinic Data Forms, Refusal Questionnaires, Cause of Death  
Form, and Dating of Diagnoses ………………………………….157 
   J.3.e. Problems Forms ………………………………………………….157 
 K. Data Quality Control ………………………………………………………….…158 
  K.1. In-Person Interview Questionnaire Data ………………………….……158 
  K.2. CATI Data ……………………………………………………………….158 
  K.3. Scenario File Construction ……………………………………………...158 
  K.4. Dose Calculation …………………………………………………………158 
  K.5. Computer Programming …………………………………………………163 
  K.6 Mortality Data ……………………………………………………………164 
 
VI. RADIATION DOSE ESTIMATION ……………………………………………….165 
 A. Background …………………………………………………………………..….165 
  A.1. Objectives of Dose Estimation …………………………………….….…165 
  A.2. History of the HEDR Project …………………………………………....165 
  A.3. Special Challenges of Dose Estimation for HTDS ………………………166 
   A.3.a. HEDR Dose Models ………………………………………..……166 
   A.3.b. Technical Issues ………………………………………………….167 
   A.3.c. Logistics ………………………………………………………….168 
 B. Dose Estimation Procedures ………………………………………………..……169 
  B.1. Staffing and Logistics ……………………………………………………169 
  B.2. Revisions of the HEDR Model and Computer Programs ……………..…169 
 C. Doses from the Nevada Test Site …………………………………………..……170 
 
VII. SPECIAL CONSIDERATIONS ……………………………………………….……172 
 A. Assessment of the Feasibility of a Health Study in Native American Populations 172 
  A.1. Background ……………………………………………………………...172 
  A.2. Initially Recommended Study Design and Guidelines for Assessing  
Feasibility ………………………………………………………………172 
  A.3. Modified Guidelines for Assessing Feasibility ……………………..……173 
  A.4. Final Assessment of Feasibility ………………………………………….174 
 B. Coordination with the Advisory Committee ………………………………….…177 
 C. Public Information ……………………………………………………………….178 
 
VIII. STATISTICAL METHODS …………………………………………………………180 
 A. General Approach ………………………………………………………….……180 
  A.1. Objectives of the Statistical Analysis …………………………………….180 
   A.1.a. Estimation and Testing of Dose-Response Relationships ….……181 
   A.1.b. Confounding and Effect Modification …………………….…..…182 
   A.1.c. Shape of Dose-Response Relationships ………………………….182 
  A.2. Estimation and Significance Testing …………………………………….182 
 B. Definitions of Variables ………………………………………………………...183 
  B.1. Process Information ……………………………………………………..183 
HTDS Final Report: June 21, 2002 – Table of Contents                                                                                                             viii 
   B.1.a. Stratification Factors …………………………………………….183 
   B.1.b. Tracing Outcome ……………………………………………..….183 
   B.1.c. Cause of Death ……………………………………………….…183 
   B.1.d. Contacting Outcomes ……………………………………………184 
   B.1.e. Recruiting Outcomes …………………………………………..184 
   B.1.f. Dosimetry Data Collection …………………………………..….184 
   B.1.g. Clinic Participation ……………………………………………..185 
   B.1.h. Requests for Medical Records or Slides …………………………185 
  B.2. Characteristics of Living Evaluable Participants ……………………….185 
   B.2.a. Demographic Data ……………………………………………….185 
   B.2.b. Residence History ………………………………………….……185 
   B.2.c. Dosimetric Data …………………………………………………185 
   B.2.d. Age at Exposure ………………………………………………….186 
   B.2.e. Medical and Dental Radiation Exposure History of Participant ..187 
   B.2.f. Occupational History ……………………………………………187 
   B.2.g. Smoking History …………………………………………………187 
   B.2.h. Exposure to 131I from the Nevada Test Site ……………………..188 
  B.3. Analyses of Exposures and Outcomes …………………………………..188 
   B.3.a. Exposure Data …………………………………………………..188 
   B.3.b. Alternative Representations of Exposure ………………………..190 
    B.3.b.1 Geostrata …………………………………………………190 
    B.3.b.2. Dichotomous Exposure Variable …………………………….191 
   B.3.c. Outcome Data ……………………………………………………192 
 C. Analytic Methods ………………………………………………………………..193 
  C.1. Statistical Models for Analyses of Exposures and Outcomes ……………193 
   C.1.a. Inferences About Dose-response Relationships:   Models for 
Objective 1 ………………………………………………………193 
    C.1.a.1. Alternative Point Estimates of Dose to Thyroid from Hanford 131I …195 
    C.1.a.2. Sensitivity of Results to Large Doses …………………………195 
    C.1.a.3. Dose Estimates for Out-of-Area Participants ………………….196 
   C.1.b. Inferences About Dose-response Relationships:   Models for 
Objective 2 ………………………………………………………197 
   C.1.c. Inferences About Dose-response Relationships:   Models for 
Objective 3 ………………………………………………………197 
   C.1.d. Inferences About Dose-response Relationships for Numbers  
of UDAs …………………………………………………………197 
  C.2. Calculational Methods for Inferential Analyses …………………………197 
   C.2.a. Analyses Ignoring Dose Uncertainties …………………………..198 
    C.2.a.1. Maximum Likelihood Analyses of the Sex-stratified Linear  
Probability Model …………………………………………198 
    C.2.a.2. Maximum Likelihood Analyses of Logistic Models ……………..201 
    C.2.a.3. Maximum Likelihood Analyses of Dose-Response Models for  
Laboratory Values, Thyroid Mass, and Numbers of UDAs ………202 
    C.2.a.4. Least Squares Analyses ……………………………………..202 
   C.2.b. Confidence Intervals …………………………………………….203 
    C.2.b.1. Linear Probability Model …………………………………...203 
    C.2.b.2. Logistic Models ……………………………………………203 
HTDS Final Report: June 21, 2002 – Table of Contents                                                                                                             ix 
    C.2.b.3. Models Fit by Method of Least Squares ……………………….204 
    C.2.b.4. Confidence Level and Bonferroni Adjustment ………………….204 
   C.2.c. Analyses of the Effect of Dose Uncertainties ……………………205 
    C.2.c.1. General Approach …………………………………………205 
    C.2.c.2. Descriptive Analysis of Effects of Dose Uncertainty …………….205 
    C.2.c.3. Estimation of B with Adjustment for Dose Uncertainty ………….206 
    C.2.c.4. Out-of-Area Participants ……………………………………207 
 D. Exposures from the Nevada Test Site ……………………………………………208 
  D.1. General Approach ……………………………………………………….208 
  D.2. Handling of Disease Outcome Variables in Analyses Involving  
NTS Doses ……………………………………………………………….208 
 
IX. RESULTS …………………………………………………………………………….210 
 A. Characteristics of the Living Evaluable Participants ……………………………210 
  A.1. History of Diagnostic X-Rays, Fluoroscopy, Thyroid Nuclear Scans,  
and other Nuclear Medicine Procedures ………………………………..212 
  A.2. History of Radiation Treatment …………………………………………213 
  A.3. History of Dental X-rays …………………………………………………213 
  A.4. Occupational History ……………………………………………………213 
  A.5. Smoking History …………………………………………………………213 
  A.6. Dietary Factors ………………………………………………………….216 
   A.6.a. Raw Cow’s Milk and Milk Products …………………………….216 
   A.6.b. Processed Cow’s Milk and Milk Products ………………………218 
   A.6.c. Goat’s Milk and Milk Products ………………………………….220 
   A.6.d. Total Milk and Milk Products ……………………………………222 
   A.6.e. Fruit ……………………………………………………………..224 
   A.6.f. Vegetables ……………………………………………………….226 
   A.6.g. Free Range Chicken Eggs ……………………………………….228 
  A.7. Age Distribution for the Alternative Representations to Exposure ………230 
 B. Estimated Radiation Doses to the Thyroid from Hanford 131I …………….…….231 
  B.1. Calculation of Estimated Thyroid Radiation Doses for In-Area  
Participants ………………………………………………………..….…231 
  B.2. Point Estimates and Uncertainty of Doses ………………………………232 
  B.3. Distributions of Primary Dose Estimates ……………………………….238 
  B.4 Implications for Statistical Power ……………………………………….249 
  B.5. Out-of-Area Participants ………………………………………………..256 
 C. Thyroid Cancer ………………………………………………………………….258 
  C.1. Occurrence of Thyroid Cancer …………………………………………..258 
   C.1.a Pathways to Diagnosis of Thyroid Cancer ………………………259 
  C.2. Analysis of Thyroid Cancer Risk …………………………………………260 
   C.2.a. Primary Analysis …………………………………………………260 
   C.2.b. Alternative Definition for Diagnosis of Thyroid Cancer ………..265 
   C.2.c. Effect of Including Incidental Diagnoses of Thyroid Cancer ……265 
   C.2.d. Alternative Dose-Response Functions …………………………..265 
   C.2.e. Effect of Excluding Participants in High Dose Categories ……..265 
   C.2.f. Effect of Excluding Okanogan and Ferry/Stevens Geostrata ……265 
HTDS Final Report: June 21, 2002 – Table of Contents                                                                                                             x 
   C.2.g. Analysis of Thyroid Cancer in Relation to Alternative Dose  
Estimates ………………………………………………………..266 
   C.2.h. Scoping Analyses Regarding Out-of-Area Participants ………....266 
   C.2.i. Analysis of Thyroid Cancer in Relation to Alternative  
Representations of Exposure ……………………………………266 
    C.2.i.1. Analysis by Geostratum ……………………………………266 
    C.2.i.2. Analysis by Dichotomous Exposure Variable …………………..267 
   C.2.j. Confounding and Effect Modification …………………………..267 
   C.2.k. Uncertainty ………………………………………………………267 
 D. Benign Thyroid Nodule  ………………………………………………………….269 
  D.1. Occurrence of Benign Thyroid Nodule ………………………………….269 
   D.1.a. Additional Disease Outcomes Related to Benign Thyroid Nodule .271 
    D.1.a.1 Benign Thyroid Nodules and Nodules Suspicious for Thyroid  
Follicular Adenoma ………………………………………..271 
    D.1.a.2. Benign Thyroid Nodule Excluding Non-neoplastic Disease ……..271 
    D.1.a.3. Solitary Benign Thyroid Nodule Detected without Ultrasound …..272 
    D.1.a.4. Benign Thyroid Nodule Excluding Colloid-Only Nodules ……….272 
    D.1.a.5. Benign Colloid Nodules ……………………………………..273 
   D.1.b. Pathways to Diagnosis of Benign Thyroid Nodules and Thyroid 
Nodules Suspicious for Follicular Neoplasm ……………………273 
  D.2. Analysis of Benign Thyroid Nodule Risk ……………………………..…274 
   D.2.a. Primary Analysis ………………………………………………..274 
   D.2.b. Alternative Definitions for Diagnosis of Benign Thyroid Nodule ..280 
   D.2.c. Additional Disease Outcomes Related to Benign Thyroid Nodule .280 
    D.2.c.1. Benign Thyroid Nodules and Nodules Suspicious for Follicular  
Neoplasm …………………………………………………280 
    D.2.c.2 Benign Thyroid Nodule Excluding Non-neoplastic Disease ……...280 
    D.2.c.3. Solitary Benign Thyroid Nodule Detected Without Ultrasound …...280 
    D.2.c.4. Benign Thyroid Nodule Excluding Colloid-Only Nodules ….…….280 
    D.2.c.5 Benign Colloid Nodules …………………………………….281 
   D.2.d. Alternative Dose-Response Functions …………………………..281 
   D.2.e.  Effect of Excluding Participants in High Dose Categories ……..281 
   D.2.f. Effect of Excluding Okanogan and Ferry/Stevens Geostrata ……281 
   D.2.g. Analysis of Benign Thyroid Nodules in Relation to Alternative  
Dose Estimates …………………………………………………..281 
   D.2.h. Scoping Analysis Regarding Out-of-Area Participants …………281 
   D.2.i. Analysis of Benign Thyroid Nodule in Relation to Alternative 
Representations of Exposure …………………………………….282 
    D.2.i.1. Analysis by Geostratum …………………………………….282 
    D.2.i.2. Analysis by Dichotomous Exposure Variable …………………..282 
   D.2.j. Confounding and Effect Modification ……………………………283 
   D.2.k. Uncertainty ………………………………………………………286 
 E. Total Thyroid Neoplasia …………………………………………………………289 
  E.1. Occurrence of Total Thyroid Neoplasia …………………………………289 
  E.2. Analysis of Total Thyroid Neoplasia Risk ……………………………….289 
   E.2.a. Primary Analysis ………………………………………….……..289 
   E.2.b. Alternative Dose-Response Functions …………………………..294 
HTDS Final Report: June 21, 2002 – Table of Contents                                                                                                             xi 
   E.2.c. Effect of Excluding Participants in High Dose Categories ……..294 
   E.2.d. Effect of Excluding Okanogan and Ferry/Stevens Geostrata …...294 
   E.2.e. Analysis of Total Thyroid Neoplasia in Relation to Alternative  
Dose Estimates …………………………………………………..294 
   E.2.f. Scoping Analysis Regarding Out-of-Area Participants …….……294 
   E.2.g. Analysis of Total Thyroid Neoplasia in Relation to Alternative 
Representations of Exposure …………………………………….294 
    E.2.g.1. Analysis by Geostratum …………………………………….295 
    E.2.g.2. Analysis by Dichotomous Exposure Variable ………………….295 
   E.2.h. Confounding and Effect Modification …………………………..295 
   E.2.i. Uncertainty ………………………………………………………296 
 F. Any Thyroid Nodule ………..……………………………………………………298 
  F.1. Occurrence of Any Thyroid Nodule ….…………………………………..298 
   F.1.a. Additional Disease Outcomes Related to Any Thyroid Nodule ….298 
    F.1.a.1. Any Solitary Thyroid Nodule Detected without Ultrasound ………298 
  F.2. Analysis of Any Thyroid Nodule Risk ……………………………………299 
   F.2.a. Primary Analysis ………………………………………………..299 
   F.2.b. Alternative Definitions for Diagnosis of Any Thyroid Nodule …..304 
   F.2.c. Additional Disease Outcomes Related to Any Thyroid Nodule ….304 
    F.2.c.1. Any Solitary Thyroid Nodule Detected Without Ultrasound ……..304 
   F.2.d. Alternative Dose-Response Functions ………………………….304 
   F.2.e. Effect of Excluding Participants in High Dose Categories ………304 
   F.2.f. Effect of Excluding Okanogan and Ferry/Stevens Geostrata ……304 
   F.2.g. Analysis of Any Thyroid Nodule in Relation to Alternative Dose 
Estimates ………………………………………………………..305 
   F.2.h. Scoping Analysis Regarding Out-of-Area Participants …………305 
   F.2.i. Analysis of Any Thyroid Nodule in Relation to Alternative 
Representations of Exposure ……………………………………305 
    F.2.i.1. Analysis by Geostratum ……………………………………305 
    F.2.i.2. Analysis by Dichotomous Exposure Variable ………………….306 
   F.2.j. Confounding and Effect Modification …………………………..306 
   F.2.k. Uncertainty ………………………………………………………309 
 G. Hypothyroidism  …………………………………………………………….……312 
  G.1. Occurrence of Hypothyroidism …………………………………….……312 
   G.1.a. Permanent Hypothyroidism ………………………………….…..313 
  G.2. Analysis of Hypothyroidism Risk …………………………………….…..313 
   G.2.a. Primary Analysis …………………………………………………313 
   G.2.b. Alternative Definitions for Diagnosis of Hypothyroidism ……….321 
   G.2.c. Permanent Hypothyroidism …………………………………….321 
   G.2.d. Alternative Dose-Response Functions …………………………..321 
   G.2.e. Effect of Excluding Participants in High Dose Categories …….321 
   G.2.f. Effect of Excluding Okanogan and Ferry/Stevens Geostrata ……321 
   G.2.g. Analysis of Hypothyroidism in Relation to Alternative Dose  
Estimates ………………………………………………………..322 
   G.2.h. Scoping Analysis Regarding Out-of-Area Participants …………322 
HTDS Final Report: June 21, 2002 – Table of Contents                                                                                                             xii 
   G.2.i. Analysis of Hypothyroidism in Relation to Alternative  
Representations of Exposure ……………………………….……322 
    G.2.i.1. Analysis by Geostratum ……………………………….……322 
    G.2.i.2. Analysis by Dichotomous Exposure Variable ………….….……324 
   G.2.j. Confounding and Effect Modification …………………….……..325 
   G.2.k. Uncertainty ………………………………………………………328 
 H. Autoimmune (Hashimoto’s) Thyroiditis …………………………………….…..331 
  H.1. Occurrence of Autoimmune (Hashimoto’s) Thyroiditis …………………331 
   H.1.a. Additional Outcomes Related to Assay for Anti-Thyroid  
Immune Response ………………………………………………..331 
   H.1.b. Additional Outcomes Related to Autoimmune Thyroiditis and 
Hypothyroidism ……………………………………………….…332 
  H.2. Analysis of Autoimmune (Hashimoto’s) Thyroiditis Risk ……….……….333 
   H.2.a. Primary Analysis ……………………………………….………..333 
   H.2.b. Alternative Definitions for Diagnosis of Autoimmune  
(Hashimoto’s) Thyroiditis ……………………………….………340 
    H.2.b.1. Additional Outcomes Related to Assay for Antithyroid Immune  
Response ………………………………………….………340 
    H.2.b.2. Additional Outcomes Related to Autoimmune (Hashimoto’s)  
Thyroiditis and Hypothyroidism ……………………….……..340 
   H.2.c. Alternative Dose-Response Functions …………………….…..…340 
   H.2.d. Effect of Excluding Participants in High Dose Categories .……..341 
   H.2.e. Effect of Excluding Okanogan and Ferry/Stevens Geostrata ……341 
   H.2.f. Analysis of Autoimmune (Hashimoto’s) Thyroiditis in Relation  
to Alternative Dose Estimates ………………………….………..341 
   H.2.g. Scoping Analysis Regarding Out-of-Area Participants …………341 
   H.2.h. Analysis of Autoimmune (Hashimoto’s) Thyroiditis in Relation  
to Alternative Representations of Exposure …………….……….341 
    H.2.h.1. Analysis by Geostratum …………………………………….341 
    H.2.h.2. Analysis by Dichotomous Exposure Variable ………………….342 
   H.2.i. Confounding and Effect Modification ……………………………342 
   H.2.j. Uncertainty ………………………………………………………345 
 I. Graves Disease …………………………………………………………………..347 
  I.1. Occurrence of Graves Disease …………………………………………..347 
  I.2. Analysis of Graves Disease Risk …………………………………………347 
   I.2.a. Primary Analysis ……………………………………….………..347 
   I.2.b. Alternative Definitions for Diagnosis of Graves Disease ……….353 
   I.2.c. Alternative Dose-Response Functions …………………………..353 
   I.2.d. Effect of Excluding Participants in High Dose Categories ……..353 
   I.2.e. Effect of Excluding Okanogan and Ferry/Stevens Geostrata ……353 
   I.2.f. Analysis of Graves Disease in Relation to Alternative Dose  
Estimates ……………………………………………….………..353 
   I.2.g. Scoping Analysis Regarding Out-of-Area Participants …………353 
   I.2.h. Analysis of Graves Disease in Relation to Alternative  
Representations of Exposure .……………………………………354 
    I.2.h.1. Analysis by Geostratum …………………………………….354 
    I.2.h.2. Analysis by Dichotomous Exposure Variable ………….……….354 
HTDS Final Report: June 21, 2002 – Table of Contents                                                                                                             xiii 
   I.2.i. Confounding and Effect Modification ……………………………355 
   I.2.j. Uncertainty ………………………………………………………359 
 J. Autoimmune Thyroid Disease …………………………………………………..361 
  J.1. Occurrence of Autoimmune Thyroid Disease ……………………………361 
  J.2. Analysis of Autoimmune Thyroid Disease Risk ………………………….361 
   J.2.a. Primary Analysis ……………………………………….………..361 
   J.2.b. Alternative Definitions for Diagnosis of Autoimmune Thyroid  
Disease …………………………………………………………..366 
   J.2.c. Alternative Dose-Response Functions ………………….………..366 
   J.2.d. Effect of Excluding Participants in High Dose Categories ………366 
   J.2.e. Effect of Excluding Okanogan and Ferry/Stevens Geostrata ……366 
   J.2.f. Analysis of Autoimmune Thyroid Disease in Relation to  
lternative Dose Estimates ……………………………………….366 
   J.2.g. Scoping Analysis Regarding Out-of-Area Participants …………367 
   J.2.h. Analysis of Autoimmune Thyroid Disease in Relation to  
Alternative Representations of Exposure …………………….….367 
    J.2.h.1. Analysis by Geostratum ………………………………….…367 
    J.2.h.2. Analysis by Dichotomous Exposure Variable ……………….…367 
   J.2.i. Confounding and Effect Modification ……………………………368 
   J.2.j. Uncertainty ………………………………………………………372 
 K. Hyperthyroidism ………………………………………………………………..374 
  K.1. Occurrence of Hyperthyroidism …………………………………………374 
   K.1.a. Non-iatrogenic Hyperthyroidism ………………………………..375 
  K.2. Analysis of Hyperthyroidism Risk ……………………………………….375 
   K.2.a. Primary Analysis ………………………………………………..375 
   K.2.b. Alternative Definitions for Diagnosis of Hyperthyroidism ………380 
    K.2.b.1. Non-iatrogenic Hyperthyroidism ………………………380 
   K.2.c. Alternative Dose-Response Functions …………………………..380 
   K.2.d. Effect of Excluding Participants in High Dose Categories ……..380 
   K.2.e. Effect of Excluding Okanogan and Ferry/Stevens Geostrata ……380 
   K.2.f. Analysis of Hyperthyroidism in Relation to Alternative Dose 
Estimates ………………………………………………………..381 
   K.2.g. Scoping Analysis Regarding Out-of-Area Participants …………381 
   K.2.h. Analysis of Hyperthyroidism in Relation to Alternative 
Representations of Exposure ………………………………….…381 
    K.2.h.1. Analysis by Geostratum …………………………………….381 
    K.2.h.2. Analysis by Dichotomous Exposure Variable ………………….381 
   K.2.i. Confounding and Effect Modification …………………………..381 
   K.2.j. Uncertainty ………………………………………………………381 
 L. Multinodular Thyroid Gland …………………………………………………….388 
  L.1. Occurrence of Multinodular Thyroid Gland …………………………….388 
  L.2. Analysis of Multinodular Thyroid Gland Risk …………………………..389 
   L.2.a. Primary Analysis ………………………………………………..389 
   L.2.b. Alternative Definitions for Diagnosis of Multinodular Thyroid  
Gland ……………………………………………………………394 
   L.2.c. Alternative Dose-Response Functions …………………………..394 
HTDS Final Report: June 21, 2002 – Table of Contents                                                                                                             xiv 
   L.2.d. Effect of Excluding Participants in High Dose Categories ……..394 
   L.2.e. Effect of Excluding Okanogan and Ferry/Stevens Geostrata …..394 
   L.2.f. Analysis of Multinodular Thyroid Gland in Relation to  
Alternative Dose Estimates ……………………………………..394 
   L.2.g. Scoping Analysis Regarding Out-of-Area Participants …………395 
   L.2.h. Analysis of Multinodular Thyroid Gland in Relation to  
Alternative Representations of Exposure ……………………….395 
    L.2.h.1. Analysis by Geostratum ……………………………………395 
    L.2.h.2. Analysis by Dichotomous Exposure Variable ………………….395 
   L.2.i. Confounding and Effect Modification ……………………………396 
   L.2.j. Uncertainty ………………………………………………………399 
 M. Simple Goiter ……………………………………………………………………402 
  M.1. Occurrence of Simple Goiter ……………………………………………402 
  M.2. Analysis of Simple Goiter Risk …………………………………………..403 
   M.2.a. Primary Analysis …………………………………………………403 
   M.2.b. Alternative Definitions for Diagnosis of Simple Goiter …………408 
   M.2.c. Alternative Dose-Response Functions ………………………….408 
   M.2.d. Effect of Excluding Participants in High Dose Categories ……..408 
   M.2.e. Effect of Excluding Okanogan and Ferry/Stevens Geostrata …..408 
   M.2.f. Analysis of Simple Goiter in Relation to Alternative Dose  
Estimates ………………………………………………………..408 
   M.2.g. Scoping Analysis Regarding Out-of-Area Participants …………409 
   M.2.h. Analysis of Simple Goiter in Relation to Alternative Representations 
of Exposure ………………………………………………………409 
    M.2.h.1. Analysis by Geostratum …………………………………….409 
    M.2.h.2. Analysis by Dichotomous Exposure Variable …………………..410 
   M.2.i. Confounding and Effect Modification …………………………..410 
   M.2.j. Uncertainty ………………………………………………………411 
 N. Other Thyroid Disease  …………………………………………………………..413 
  N.1. Occurrence of Other Thyroid Disease …………………………………..413 
 O. Hyperparathyroidism …………………………………………………………….416 
  O.1. Occurrence of Hyperparathyroidism ……………………………………416 
  O.2. Analysis of Hyperparathyroidism Risk ………………………………….416 
   O.2.a. Primary Analysis ……………………………………………….416 
   O.2.b. Alternative Definitions for Diagnosis of Hyperparathyroidism …421 
    O.2.b.1 Effect of Including Probable Diagnoses of Hyperparathyroidism   ...421 
   O.2.c. Alternative Dose-Response Functions …………………………..421 
   O.2.d. Effect of Excluding Participants in High Dose Categories ……..421 
   O.2.e. Effect of Excluding Okanogan and Ferry/Stevens Geostrata ……421 
   O.2.f. Analysis of Hyperparathyroidism in Relation to Alternative  
Dose Estimates …………………………………………………..422 
   O.2.g. Scoping Analysis Regarding Out-of-Area Participants ………….422 
   O.2.h. Analysis of Hyperparathyroidism in Relation to Alternative 
Representations of Exposure …………………………………….422 
    O.2.h.1. Analysis by Geostratum …………………………………….422 
    O.2.h.2. Analysis by Dichotomous Exposure Variable ………………….423 
   O.2.i. Confounding and Effect Modification ……………………………423 
HTDS Final Report: June 21, 2002 – Table of Contents                                                                                                             xv 
   O.2.j. Uncertainty ………………………………………………………423 
 P. Ultrasound-Detected Abnormalities of the Thyroid (Thyroid UDAs) ………….425 
  P.1. Occurrence of Ultrasound-Detected Abnormalities of the Thyroid ……..425 
   P.1.a. Additional Outcomes Related to Ultrasound-Detected  
Abnormalities of the Thyroid ……………………………………425 
    P.1.a.1 Thyroid UDAs by Size ………………………………………425 
  P.2. Analysis of Any Ultrasound-Detected Abnormality Risk ………………..425 
   P.2.a. Primary Analysis ………………………………………………..425  
   P.2.b. Effect of Using Alternative Size Criteria for Thyroid UDAs …….431 
   P.2.c. Alternative Dose-Response Functions …………………………..431 
   P.2.d. Effect of Excluding Participants in High Dose Categories ……..431 
   P.2.e. Effect of Excluding Okanogan and Ferry/Stevens Geostrata ……431 
   P.2.f. Analysis of Ultrasound-Detected Abnormalities in Relation to 
Alternative Dose Estimates ……………………………….……..431 
   P.2.g. Scoping Analysis Regarding Out-of-Area Participants ….………432 
   P.2.h. Analysis of Any Thyroid UDAs In Relation to Alternative 
Representations of Exposure …………………………….………432 
    P.2.h.1. Analysis by Geostratum …………………………….………432 
    P.2.h.2. Analysis by Dichotomous Exposure Variable ………….……….432 
   P.2.i. Confounding and Effect Modification …………………….……..433 
   P.2.j. Uncertainty ……………………………………………………...437 
   P.2.k. Analyses of numbers of Thyroid UDAs ……………………….…438 
  P.3. Palpable Ultrasound-Detected Abnormalities of the Thyroid ………..…446 
   P.3.a. Primary Analysis ……………………………………………..…446 
   P.3.b. Alternative Dose-Response Functions ………………………..…451 
   P.3.c. Effect of Excluding Participants in High Dose Categories ………451 
   P.3.d. Effect of Excluding Okanogan and Ferry/Stevens Geostrata ……451 
   P.3.e. Analysis of Palpable Thyroid UDAs in Relation to Alternative  
Dose Estimates ……………………………………………..……451 
   P.3.f. Scoping Analysis Regarding Out-of-Area Participants …………451 
   P.3.g. Analysis of Palpable Thyroid UDAs In Relation to Alternative 
Representations of Exposure ………………………………….…452 
    P.3.g.1. Analysis By Geostratum ………………………………….…452 
    P.3.g.2. Analysis by Dichotomous Exposure Variable ……………….….452 
   P.3.h. Confounding and Effect Modification ……………………….…..453 
   P.3.i. Uncertainty ………………………………………………………456 
  P.4. Nonpalpable Focal Ultrasound-Detected Abnormalities of the Thyroid ..458 
   P.4.a. Primary Analysis …………………………………………..……458 
   P.4.b. Alternative Dose-Response Functions …………………………..463 
   P.4.c. Effect of Excluding Participants in High Dose Categories ……..463 
   P.4.d. Effect of Excluding Okanogan and Ferry/Stevens Geostrata ……463 
   P.4.e. Analysis of Nonpalpable Focal Thyroid UDAs in Relation to 
Alternative Dose Estimates …………………………………...…463 
   P.4.f. Scoping Analysis Regarding Out-of-Area Participants …………463 
   P.4.g. Analysis of Nonpalpable Focal Thyroid UDAs in Relation to 
Alternative Representations of Exposure ……………………….464 
    P.4.g.1. Analysis by Geostratum ……………………………….……464 
HTDS Final Report: June 21, 2002 – Table of Contents                                                                                                             xvi 
    P.4.g.2. Analysis by Dichotomous Exposure Variable ………………….464 
   P.4.h. Confounding and Effect Modification …………………………..465 
   P.4.i. Uncertainty ………………………………………………………468 
  P.5. Diffuse Ultrasound-Detected Abnormalities of the Thyroid …………….469 
   P.5.a. Primary Analysis ………………………………………………..469 
   P.5.b. Alternative Dose-Response Functions …………………………..474 
   P.5.c. Effect of Excluding Participants in High Dose Categories …..….474 
   P.5.d. Effect of Excluding Okanogan and Ferry/Stevens Geostrata  
   P.5.e. Analysis of Diffuse Thyroid UDAs in Relation to Alternative Dose 
Estimates ………………………………………………………..474 
   P.5.f. Scoping Analysis Regarding Out-of-Area Participants …………474 
   P.5.g. Analysis of Diffuse Thyroid UDAs in Relation to Alternative 
Representations of Exposure …………………………………….474 
    P.5.g.1. Analysis by Geostratum …………………………………….475 
    P.5.g.2. Analysis by Dichotomous Exposure Variable …………………..475 
   P.5.h. Confounding and Effect Modification …………………………...476 
   P.5.i. Uncertainty ………………………………………………………479 
 Q. Laboratory Values ………………………………………………………………481 
  Q.1. Thyroid Stimulating Hormone (TSH) …………………………………….481 
   Q.1.a. Uncertainty …………………………………………….……….484 
  Q.2. Total Thyroxine (T4) ………………………………………………….…486 
   Q.2.a. Uncertainty ………………………………………………..…….487 
  Q.3. Triiodothyronine Resin Uptake (T3RU) …………………………...…….488 
   Q.3.a. Uncertainty ………………………………………………………490 
  Q.4. Free Thyroxine Index (FTI) ……………………………………………..491 
   Q.4.a. Uncertainty ………………………………………………………493 
  Q.5. Anti-Thyroid Autoimmune Response ……………………………….……493 
   Q.5.a. Uncertainty ………………………………………………………496 
  Q.6. Anti-Thyroglobulin Antibody (anti-TG) ………………………………….498 
   Q.6.a. Uncertainty ………………………………………………………499 
  Q.7. Serum Calcium …………………………………………………………..500 
   Q.7.a. Uncertainty ………………………………………………………502 
  Q.8. Thyroid Mass …………………………………………………………….503 
    Q.8.a. Uncertainty ………………………………………………………504 
 R. Summary of Dose-Response Results …………………………………………….505 
 
X. DISCUSSION …………………………………………………………………………518
 A. Summary of Study Design and Execution ……………………………………….518 
 B. Summary of Dose-Response Results …………………………………………….520 
C. Consideration of Factors Related to Study Design and Execution ………………521 
  C.1. Factors Related to Cohort Definition and Selection …………………….521 
  C.2. Factors Related to Outcome Definition ………………………………….525 
  C.3. Factors Related to the Estimation of Thyroid Radiation Dose ……….…525 
  C.4. Potential for Confounding or Effect Modification ……………………….530 
  C.5. Statistical Power of the Study ………………………………………..….530 
D. Comparison of Results with Findings in Other Populations Exposed to  
Radiation. ………………………………………………………………………...531 
HTDS Final Report: June 21, 2002 – Table of Contents                                                                                                             xvii 
 E. Comparison of the Occurrence of Thyroid Disease Outcomes With Other  
Findings in the Literature ……………………………………………………..…534 
  E.1. Prevalence of Thyroid Cancer ………………………………………..…534 
  E.2. Prevalence of Thyroid Nodules …………………………………….……536 
  E.3. Prevalence of Hypothyroidism ………………………………………..…537 
  E.4. Prevalence of Autoimmune Thyroiditis ………………………………….539 
  E.5. Prevalence of Hyperparathyroidism …………………………….………540 
  E.6. Prevalence of Thyroid Ultrasound-Detected Abnormalities of the  
Thyroid (Thyroid UDAs) …………………………………………………541 
 F. Summary and Conclusions ………………………………………………………542 
 
X.I. REFERENCES …………………………………………………………………….…545 
 
 
 
 
 
 
HTDS Final Report: June 21, 2002 – Table of Contents                                                                                                             xviii 
HTDS Final Report: June 21, 2002 – List of Figures
LIST OF FIGURES
II. BACKGROUND
II.A-1. HEDR Study Area
IV. STUDY DESIGN
IV.A-1. Iodine-131 Thyroid Dose from All Exposure Pathways (Milk Cows on Fresh Pasture)
IV.A-2. Monthly 131I Releases from the Hanford Nuclear Site, 1944-1951
V. FIELD PROCEDURES AND METHODS, RESULTS OF DATA
COLLECTION PROCESS
V.A-1. Projected Power Function: Thyroid Neoplasia Plans 1, 2 and 3
V.A-2. Projected Power Function: Thyroid Malignancy Plans 1, 2, and 3
V.A-3. Projected Power Function: Ultrasound Detected Abnormalities of the Thyroid
Plans 1, 2 and 3
V.B-1. Locating and Tracing Potential Participants
V.B-2. Tracing Outcome for Pilot Study Sample 
V.B-3. Tracing Outcome for HTDS Pilot Study Sample, by Sex 
V.B-4. Tracing Outcome for Pilot Study Sample by Year of Birth 
V.B-5. Tracing Outcome for Pilot Study Sample, by Geostratum 
V.B-6. Tracing Outcome for the Transition Sample 
V.B-7. Tracing Outcome for Transition Sample, by Sex 
V.B-8. Tracing Outcome for Transition Sample, by Year of Birth 
V.B-9. Tracing Outcome for Transition Sample, by Geostratum 
V.B-10. Tracing Outcome for the Full Study Sample 
V.B-11. Tracing Outcome for the Full Study Sample, by Sex 
V.B-12. Tracing Outcome for the Full Study Sample, by Year of Birth
V.B-13. Tracing Outcome for the Full Study Sample, by Geostratum
V.B-14. Final Tracing Outcomes – Entire Study  
V.B-15. Final Tracing Outcome for Entire Study, by Sex  
V.B-16. Final Tracing Outcome for Entire Study, by Year of Birth  
V.B-17. Final Tracing Outcome for Entire Study by Geostratum 
V.B-18. Current Residences of Located Potential Participants
V.C-1. Agreement to Participate for the Pilot Study Sample 
V.C-2. Agreement to Participate for the Pilot Study Sample, by Geostatum  
V.C-3. Agreement to Participate for the Pilot Study Sample, by Sex
V.C-4. Agreement to Participate for the Pilot Study Sample, by Year of Birth
V.C-5. Agreement to Participate for the Transition Sample 
V.C-6. Agreement to Participate for the Transition Sample, by Geostratum  
V.C-7. Agreement to Participate for the Transition Sample, by Sex
V.C-8. Agreement to Participate for the Transition Sample, by Year of Birth 
V.C-9. Agreement to Participate for the Full Study Sample
HTDS Final Report: June 21, 2002 – List of Figures
V.C-10. Agreement to Participate for the Full Study Sample, by Geostratum
V.C-11. Agreement to Participate for the Full Study Sample, by Sex
V.C-12. Agreement to Participate for the Full Study Sample, By Year of Birth
V.C-13. Final Agreement to Participate for the Entire Study
V.C-14. Final Agreement to Participate for the Entire Study, by Geostratum 
V.C-15. Final Agreement to Participate for the Entire Study, by Sex
V.C-16. Final Agreement to Participate for the Entire Study, by Year of Birth 
V.C-17. Final Agreement to Participate for the Entire Study, by Geographic Region of 
Current Residence
V.C-18. Type of Illness/Impairment Precluding Participation for the Entire Study
V.E-1. Subjects Unable to Schedule, by Geographic Area of Current Residence
V.I-1. Outcome of Historical Medical Record Requests
V.I-2. Success Obtaining Historical Slides
VIII. STATISTICAL METHODS
VIII.C-1. Profile Log-likelihood Function for Any Thyroid UDA
VIII.C-2. Profile Log-likelihood Function for Thyroid Cancer
VIII.C-3. Profile Log-likelihood Function for Graves Disease
IX. RESULTS
IX.A-1. Raw Cow’s Milk Consumption, by Sex and Age
IX.A-2. Processed Cow’s Milk Consumption, by Sex and Age
IX.A-3. Goat’s Milk Consumption, by Sex and Age
IX.A-4. Total Milk Consumption, by Sex and Age
IX.A-5. Fruit Consumption, by Sex and Age
IX.A-6. Vegetable Consumption, by Sex and Age
IX.A-7. Free Range Chicken Egg Consumption, by Sex and Age
IX.B-1. Scatterplots of Geometric Mean and Mean Doses versus Median Dose
IX.B-2. Cumulative Distribution of Median Dose Estimates for 3191 In-Area Living
Evaluable Participants
IX.B-3. Cumulative Distribution of 100 Dose Estimates for Five Selected Participants
IX.B-4. Scatterplot of Ratio of 95th Percentile to Median versus Median Dose
IX.B-5. Mean of Estimated Median Thyroid Radiation Dose (in mGy) from 
Hanford 131I by Sex, Year of Birth, and Geostratum
IX.B-6. Estimated Dose in Relation to Reported Consumption of Cow’s and Goat’s
Milk and Milk Products During 1945, by Geostratum
IX.B-7. Effect of Dose Uncertainty on Statistical Power: Any Benign Thyroid Nodule
IX.B-8. Effect of Dose Uncertainty on Statistical Power: Thyroid Cancer
IX.B-9. Effect of Dose Uncertainty on Statistical Power: Ultrasound Detected
Abnormalities
IX.C-1. Plot of Estimated Slope by Dose Realization
HTDS Final Report: June 21, 2002 – List of Figures
IX.C-2. Distribution of Simulation Estimates of Logistic Regression Coefficient
IX.D-1. Plot of Estimated Slope and 95% CI by Dose Realization: Benign Thyroid
Nodule
IX.D-2. Distribution of Simulation Estimates of Logistic Regression Coefficient: Benign 
Thyroid Nodule
IX.E.1 Plot of Estimated Slope and 95% CI by Dose Realization: Total Thyroid
Neoplasia
IX.E-2. Distribution of Simulation Estimates of Logistic Regression Coefficient: Total 
Thyroid Neoplasia
IX.F-1. Plot of Estimated Slope and 95% CI by Dose Realization: Any Thyroid 
Nodule
IX.F-2. Distribution of Simulation Estimates of Logistic Regression Coefficient: 
Any Thyroid Nodule
IX.G-1. Plot of Estimated Slope and 95% CI by Dose Realization: Hypothyroidism
IX.G-2. Distribution of Simulation Estimates of Logistic Regression Coefficient: 
Hypothyroidism
IX.H-1. Plot of Estimated Slope and 95% CI by Dose Realization: Autoimmune
Thyroiditis
IX.H-2. Distribution of Simulation Estimates of Logistic Regression Coefficient: 
Autoimmune Thyroiditis
IX.I-1. Plot of estimated Slope and 95% CI by Dose Realization: Graves Disease
IX.I-2. Distribution of Simulation Estimates of Logistic Regression Coefficient: 
Graves Disease
IX.J-1. Plot of Estimated Slope and 95% CI by Dose Realization: Autoimmune
Thyroid Disease
IX.J-2. Distribution of Simulation Estimates of Logistic Regression Coefficient: 
Autoimmune Thyroid Disease
IX.K-1. Plot of estimated Slope and 95% CI by Dose Realization: Hyperthyroidism
IX.K-2. Distribution of Simulation Estimates of Logistic Regression Coefficient:
Hyperthyroidism
IX.L-1. Plot of Estimated Slope and 95% CI by Dose Realization: Multinodular 
Thyroid Gland
IX.L-2. Distribution of Simulation Estimates of Logistic Regression Coefficient: 
Multinodular Thyroid Gland
IX.M-1. Plot of Estimated Slope and 95% CI by Dose Realization: Simple Goiter
IX.M-2. Distribution of Simulation Estimates of Logistic Regression Coefficient: 
Simple Goiter
IX.O-1. Plot of Estimated Slope and 95% CI by Dose Realization:
Hyperparathyroidism
IX.O-2. Distribution of Simulation Estimates of Logistic Regression Coefficient:
Hyperparathyroidism
IX.P-1. Plot of Estimated Slope and 95% CI by Dose Realization: Any Ultrasound-
Detected Abnormality 
HTDS Final Report: June 21, 2002 – List of Figures
IX.P-2. Distribution of Simulation Estimates of Logistic Regression Coefficient: 
Any Ultrasound-Detected Abnormality
IX.P-3. Average Number of Thyroid UDAs per Person, by Sex, Dose Category, and UDA Size
IX.P-4. Plot of Estimated Slope and 95% CI by Dose Realization: Palpable Thyroid
UDAs
IX.P-5. Distribution of Simulation Estimates of Logistic Regression Coefficient:
Palpable Thyroid UDAs
IX.P-6. Plot of Estimated Slope and 95% CI by Dose Realization: Nonpalpable 
Focal Ultrasound-Detected Abnormalities
IX.P-7. Distribution of Simulation Estimates of Logistic Regression Coefficient: 
Nonpalpable Focal Ultrasound-Detected Abnormalities
IX.P-8. Plot of Estimated Slope and 95% CI by Dose Realization: Diffuse 
Ultrasound-Detected Abnormalities
IX.P-9. Distribution of Simulation Estimates of Logistic Regression Coefficient: 
Diffuse Ultrasound-Detected Abnormalities
IX.Q-1. Scatter Plot of TSH by RIA and Estimated Dose
IX.Q-2. Scatter Plot of TSH by EIA-1 and Estimated Dose
IX.Q-3. Scatter Plot of TSH by EIA-2 and Estimated Dose
IX.Q-4. Estimated Dose-Response for TSH by RIA, by Dose Realization
IX.Q-5. Estimated Dose-Response for TSH by EIA-1, by Dose Realization
IX.Q-6. Estimated Dose-Response for TSH by EIA-2, by Dose Realization
IX.Q-7. Scatter Plot of T4 and Estimated Dose
IX.Q-8. Estimated Dose-Response for T4, by Dose Realization
IX.Q-9. Scatter Plot of T3RU and Estimated Dose
IX.Q-10. Estimated Dose-Response for T3RU, by Dose Realization
IX.Q-11. Scatter Plot of FTI and Estimated Dose
IX.Q-12. Estimated Dose-Response for FTI, by Dose Realization
IX.Q-13. Scatter Plot of Anti-TPO and Estimated Dose
IX.Q-14. Scatter Plot of AMA and Estimated Dose
IX.Q-15. Estimated Dose-Response for Anti-TPO, by Dose Realization
IX.Q-16. Estimated Dose-Response for AMA, by Dose Realization
IX.Q-17. Scatter Plot of Anti-TG and Estimated Dose
IX.Q-18. Estimated Dose-Response for Anti-TG, by Dose Realization
IX.Q-19. Scatter Plot of Serum Calcium and Estimated Dose
IX.Q-20. Estimated Dose-Response for Serum Calcium, by Dose Realization
IX.Q-21. Scatter Plot of Estimated Thyroid Mass and Estimated Dose
IX.Q-22. Estimated Dose-Response for Thyroid Mass, by Dose Realization
HTDS Final Report: June 21, 2002 – List of Tables
LIST OF TABLES
II.  BACKGROUND
II.A-1. Estimates of Atmospheric Emissions of Radioactive Iodine from the Separations
Plants Stacks
V. FIELD PROCEDURES AND METHODS, RESULTS OF DATA COLLECTION
PROCESS
V.A-1. Birth Years Included in Each Phase of Participant Selection
V.A-2 Distribution of Birth Year, Sex, and Geostratum for the Full Study Cohort
V.A-3. Projected Dose Means and Variances (rad), and Sample Sizes of Full Study 
Dose Distribution for the Three Additional Sampling Plans
V.B-1. Tracing Sources Used, All Potential Participants – Pilot Study Sample
V.B-2. Tracing Sources Used, All Potential Participants – Transition and Full Study Sample
V.B-3. Usefulness of Tracing Sources in Locating Study Potential Participants – Pilot Study
Only 
V.B-4. Tracing Efforts for Those Not Located – Pilot Study Sample
V.B-5. Tracing Efforts for Those Not Located – Transition and Full Study Samples
V.B-6. Number of Sources Used to Trace Located and Unlocated Individuals – Pilot Study
Sample
V.B-7. Number of Sources Used to Trace Located and Unlocated Individuals – Transition
and Full Study Samples
V.B-8. Percentage of Pilot Study Potential Participants Located in each of the 76 Sampling
Strata -Pilot Study Sample 
V.B-9. Summary of Death Certificates Obtained for Deceased Study Potential Participants
V.C-1. Summary of Agreement and Refusal for the Pilot Study Sample
V.C-2. Reason for Refusal/Withdrawal for the Pilot Study Sample by Geographic Area of
Current Residence  
V.C-3. Summary of Agreement and Refusal for theTransition Sample  
V.C-4. Reason for Refusal/Withdrawal for the Transition Sample, by Geographic Area of
Residence  
V.C-5. Summary of Agreement and Refusal for the Full Study Sample  
V.C-6. Reason for Refusal/Withdrawal for the Full Study Sample, by Geographic Area of
Current Residence  
V.C-7. Summary of Agreement or Refusal for the Entire Study  
V.C-8. Reasons for Refusal or Withdrawal for the Entire Study, by Geographic Area of
Current 
Residence
V.C-9. Conversion to Agreement to Participate by Reason for Refusal for the Entire Study
V.C-10. Conversion to Agreement to Participate by Strength of Refusal for the Entire Study
HTDS Final Report: June 21, 2002 – List of Tables
V.D-1. Final Outcome of CATI by Participant’s Year of Birth for the Entire Study 
V.D-2. Interviewer’s Assessment of Quality of Responses to CATI (CATIs Used for Dose
Estimation Only) for the Entire Study  
V.D-3. Main Reasons for Unreliable or Questionable Responses to CATI (CATIs Used for
Dose Estimation Only) for the Entire Study 
V.D-4. CATI Interviewer’s Assessment of Respondent’s Cooperation (CATIs Used for Dose
Estimation Only) for the Entire Study 
V.D-5. Relationship of CATI Respondent to Participant for the Entire Study
V.D-6. Quality of CATI Data by Respondent’s Relationship to Participant for the Entire
Study 
V.E-1. Success in Scheduling Potential Participants - Pilot Study Sample  
V.E-2. Success in Scheduling Potential Participants - Transition Sample  
V.E-3. Success in Scheduling Potential Participants - Full Study Sample  
V.E-4. Final Success in Scheduling Potential Participants - Entire Study 
V.E-5. Location and Number of Clinic Days and Participants Seen at each Site – Entire
Study 
V.E-6. Current Residence of Participants by Clinic Site – Entire Study 
V.F-1. Agreement between AMA and Anti-TPO Assay Results 
V.F-2. Pairings of Physicians for Clinical Examinations
V.F-3. Results of Quality Control Ultrasound Studies
V.F-4. Radiologist Agreement on Presence of Any Nodule
V.F-5. Radiologist Agreement on Number of Nodules Less Than 5mm Average Dimension
V.F-6. Radiologist Agreement on Presence of Diffuse Abnormalities
V.F-7. Radiologist Agreement on Number of Nodules >5mm Average Dimensions
V.F-8. Summary of Clinic Participation - Pilot Study Sample
V.F-9. Summary of Clinic Participation - Transition Sample
V.F-10. Summary of Clinic Participation - Full Study Sample
V.F-11. Final Summary of Clinic Participation - Entire Study
V.G-1. Summary of Standard and Expanded Interviews by Phase of Study
V.G-2. In-Person Interviewers’ Assessments of Reliability of Responses
V.G-3. In-Person Interviewer’s Assessment of Reason for Questionable or Unreliable
Information
V.G-4. Interviewers’ Assessments of Respondent’s Cooperation
V-I-1. Systems Used for Cause of Death Coding
V.J-1. Tracking System Databases
V.J-3. Number of Records in Each Tracking System Database
V.J-3. Numbers of Records in the Clinic Database, Refusal Questionnaires, Cause of Death
Forms, and Dating of Diagnoses
V.K-1. Differences in Assumptions Used by CDC and HTDS
V.K-2. Comparison of Dose Estimates by CDC and HTDS
VIII.  STATISTICAL METHODS
VIII-B-1. Schematic Illustration of Dose Realizations
VIII.C-1. Illustration of Positive, Zero, and Negative Dose-responses
VIII.C-2. Description of Log True Doses for Subgroups 1– 3
HTDS Final Report: June 21, 2002 – List of Tables
IX. RESULTS
IX.A-1. Characteristics of Living Evaluable Participants
IX.A-2. History of Diagnostic X-Rays, Fluoroscopy, Thyroid Nuclear Scans, and other
Nuclear Medicine Procedures
IX.A-3. History of Radiation Treatment
IX.A-4. History of Dental X-rays
IX.A-5. Occupational History
IX.A-6. Smoking:  History of Ever Smoking
IX.A-7. Smoking:  Level of Use
IX.A-8. Age at HTDS Examination by Geostratum
IX.A-9. Age at HTDS Examination by Dichotomous Exposure Variable
IX.B-1. Summary of Dosimetry Interview Types and In-Area Status of 3440 Living Evaluable
Participants
IX.B-2. Characteristics of Primary and Alternative Sets of Radiation Dose Estimates
IX.B-3. Frequency Distribution of Estimated Thyroid Radiation Dose, by Sex
IX.B-4. Summary of Estimated Radiation Doses (in mGy) to the Thyroid from Hanford 131I,
by Geostratum
IX.B-5. Summary of Estimated Radiation Doses (in mGy) to the Thyroid from Hanford 131I,
by Sex and Year of Birth
IX.B-6. Summary of Radiation Doses (in mGy) to the Thyroid from Hanford 131I by Sex and
Age at HTDS Examination
IX.B-7. Summary of Estimated Radiation Doses (in mGy) to the Thyroid from Hanford 131I,
by Type of Dosimetry Interview and Year of Birth
IX.B-8. Summary of Estimated Radiation Doses (in mGy) to the Thyroid from Hanford 131I,
by Age at Exposure and HTDS Examination, Estimated Thyroid Dose from NTS and
History of Any Cancer Other Than Thyroid
IX.B-9. Summary of Estimated Radiation Doses (in mGy) to the Thyroid from Hanford 131I,
by Medical and Dental Radiation History
IX.B-10. Summary of Estimated Radiation Doses (in mGy) to the Thyroid from Hanford 131I,
by Occupational History
IX.B-11. Summary of Estimated Radiation Doses (in mGy) to the Thyroid from Hanford 131I,
by Smoking History
IX.B-12. Milk and Milk Product Consumption Levels Reported by CATI Respondents:
Distributions and Correlation with Estimated Dose
IX.B-13. Summary of Estimated Radiation Doses (in mGy) to the Thyroid, by Dichotomous
Exposure Variable
IX.B-14. Comparison of Projected and Obtained Statistical Power
IX.B-15. Effect of Dose Uncertainty on Statistical Power: Any Benign Thyroid Nodule
IX.B-16. Effect of Dose Uncertainty on Statistical Power: Thyroid Carcinoma
IX.B-17. Effect of Dose Uncertainty on Statistical Power: Ultrasound Detected Abnormalities
IX.B-18. Summary of Effect of Dose Uncertainties on Statistical Power (one-sided tests at
critical level α=.05) 
IX.B-19. Proportions of Out-of-Area Participants, by Sex, Birth Year, and Geostratum
IX.C-1. Diagnoses of Thyroid Cancer, by Basis for Diagnosis and Sex
IX.C-2. Frequency Distribution of Histologic Types of Thyroid Cancer, by Sex
IX.C-3. Pathways to Diagnosis of Thyroid Cancer
HTDS Final Report: June 21, 2002 – List of Tables
IX.C-4. Diagnoses of Thyroid Cancer by Sex, Dose Category, and Basis for Diagnosis
IX.C-5. Dose-Response Results for Diagnoses of Thyroid Cancer Based on HTDS or Prior
Histologic Evidence
IX.C-6. Diagnoses of Thyroid Cancer Based on HTDS or Prior Histologic Evidence, by
Geostratum and Sex
IX.C-7. Diagnoses of Thyroid Cancer based on HTDS or prior histologic evidence, by
exposure group and sex
IX.D-1. Diagnoses of Benign Thyroid Nodule, by Basis for Diagnosis and Sex
IX.D-2. Frequency Distribution of Histologic/Cytologic Types of Benign Thyroid Nodule, by
Sex
IX.D-3. Frequency Distribution of Other Histologic/Cytologic Types of Benign Thyroid
Nodule, by Sex
IX.D-4. Benign Thyroid Nodule and Nodules Suspicious for Follicular Neoplasm, by Sex
IX.D-5. Benign Thyroid Nodule Excluding Non-neoplastic Disease, by Sex
IX.D-6. Solitary Benign Thyroid Nodule Detected without Ultrasound, by Sex
IX.D-7. Benign Thyroid Nodule Excluding Colloid-Only Nodules, by Sex
IX.D-8. Benign Colloid Nodules, by Sex
IX.D-9. Pathways to Diagnosis of Benign Thyroid Nodules and Thyroid Nodules Suspicious
for Follicular Neoplasm
IX.D-10. Diagnoses of Benign Thyroid Nodule by Sex, Dose Category, and Basis for
Diagnosis
IX.D-11. Additional Disease Outcomes Related to Benign Thyroid Nodule by Sex and
Estimated Dose (cases based on primary definition of benign thyroid nodule, i.e.,
HTDS or prior histologic or cytologic diagnoses only)
IX.D-12. Summary of Dose-Response Results for Diagnoses of Benign Thyroid Nodule
IX.D-13. Diagnoses of Benign Thyroid Nodule Based on HTDS or Prior Histologic or
Cytologic Evidence, by Geostratum and Sex
IX.D-14. Diagnoses of Benign Thyroid Nodule based on HTDS or Prior Histologic or
Cytologic Evidence, by Exposure Group and Sex
IX.D-15. Confounding and Effect Modification by Sex, Age at Exposure or HTDS
Examination, Estimated Thyroid Dose from NTS, History of Any Cancer Other Than
Thyroid and Interview Type: Benign Thyroid Nodule
IX.D-16. Confounding and Effect Modification by History of Medical and Dental Radiation
Exposures: Benign Thyroid Nodule
IX.D-17. Confounding and Effect Modification by Occupational History: Benign Thyroid
Nodule
IX.D-18. Confounding and Effect Modification by Smoking: Benign Thyroid Nodule
IX.E-1. Total Thyroid Neoplasia, by Sex
IX.E-2. Diagnoses of Total Thyroid Neoplasia by Sex and Dose Category
IX.E-3 Dose-Response Results for Diagnoses of Total Thyroid Neoplasia
IX.E-4. Diagnoses of Total Thyroid Neoplasia Based On Histologic or Cytologic Evidence
from or Prior to the HTDS, by Geostratum and Sex
IX.E-5. Diagnoses of Total Thyroid Neoplasia Based on HTDS or Prior Histologic or
Cytologic Evidence, by Exposure Group and Sex
IX.F-1. Basis for Diagnosis of Any Thyroid Nodule Disease, by Sex
IX.F-2. Any Solitary Thyroid Nodule Detected without Ultrasound, by Sex
HTDS Final Report: June 21, 2002 – List of Tables
IX.F-3. Diagnoses of Any Thyroid Nodule by Sex, Estimated Dose, and Basis for Diagnosis
IX.F-4. Dose-Response Results for Diagnoses of Any Thyroid Nodule
IX.F-5. Diagnoses of Any Thyroid Nodule with at Least One Outcome Based On Histologic
or Cytologic Evidence from or Prior to the HTDS
IX.F-6. Diagnoses of Any Thyroid Nodule Based on HTDS or Prior Histologic or Cytologic
Evidence, by Exposure Group and Sex
IX.F-7. Confounding and Effect Modification by Sex, Age at Exposure or HTDS
Examination, Estimated Thyroid Dose from NTS, History of Any Cancer Other Than
Thyroid and Interview Type: Any Thyroid Nodule
IX.F-8. Confounding and Effect Modification by History of Medical and Dental Radiation
Exposures: Any Thyroid Nodule
IX.F-9. Confounding and Effect Modification by Occupational History: Any Thyroid Nodule
IX.F-10. Confounding and Effect Modification by Smoking: Any Thyroid Nodule
IX.G-1. Basis for Diagnosis of Hypothyroidism, by Sex
IX.G-2. Frequency Distribution of Possible Contributing Causes of Hypothyroidism, by Sex
IX.G-3. Permanent Hypothyroidism, by Sex
IX.G-4. Diagnoses of Hypothyroidism by Sex, Dose Category, and Basis for Diagnosis
IX.G-5. Additional Disease Outcomes Related to Hypothyroidism by Sex and Estimated Dose
(cases based on HTDS examination or medical records with supporting
documentation only)
IX.G-6. Dose-Response Results for Diagnoses of Hypothyroidism
IX.G-7. Diagnoses of Hypothyroidism Based on the HTDS Evaluation or on Medical Records
with Supporting Documentation
IX.G-8. Diagnoses of Hypothyroidism Based on the HTDS Evaluation or Medical Records
with or without Supporting Documentation (1st Alternative Definition), by
Geostratum and Sex
IX.G-9. Diagnoses of Hypothyroidism Based on the HTDS Evaluation, or on Medical
Records with or without Supporting Documentation (2nd Alternative Definition), or
Inferred from Past/Current Therapy, by Geostratum and Sex
IX.G-10. Diagnoses of Hypothyroidism Based on Any Source (3rd Alternative Definition), by
Geostratum and Sex
IX.G-11. Diagnoses of Hypothyroidism Based on HTDS or Medical Record with Supporting
Documentation, by Exposure Group and Sex
IX.G-12. Confounding and Effect Modification by Sex, Age at Exposure or HTDS
Examination, Estimated Thyroid Dose from NTS, History of Any Cancer Other Than
Thyroid, and Interview Type: Hypothyroidism
IX.G-13. Confounding and Effect Modification by History of Medical and Dental Radiation
Exposures: Hypothyroidism
IX.G-14. Confounding and Effect Modification by Occupational History: Hypothyroidism
IX.G-15. Confounding and Effect Modification by Smoking: Hypothyroidism
IX.H-1. Basis for Diagnosis of Autoimmune Thyroiditis, by Sex
IX.H-2. Diagnosis of Autoimmune Thyroiditis Based on AMA/anti-TPO and/or anti-TG, or
Medical Records with Supporting Documentation, by Sex
IX.H-3. Diagnosis of Autoimmune Thyroiditis Based on anti-TG, or Medical Records with
Supporting Documentation, by Sex
HTDS Final Report: June 21, 2002 – List of Tables
IX.H-4. Cross-tabulation of Disease Status with Respect to Diagnosis of Autoimmune
Thyroiditis in combination with Hypothyroidism, by Sex
IX.H-5. Autoimmune Thyroiditis in Combination with Non-Iatrogenic, Permanent
Hypothyroidism, by Sex
IX.H-6. Diagnoses of Autoimmune (Hashimoto’s) Thyroiditis by Sex, Estimated Dose, and
Basis for Diagnosis
IX.H-7. Additional Disease Outcomes Related to Autoimmune Thyroiditis
by Sex and Estimated Dose (cases based on HTDS examination or medical records
with supporting documentation only)
IX.H-8. Disease Outcomes Related to Autoimmune Thyroiditis with Hypothyroidism by Sex
and Estimated Dose (cases based on HTDS examination or medical records with
supporting documentation only)
IX.H-9. Summary of Dose-Response Results for Diagnoses of Autoimmune Thyroiditis
IX.H-10. Diagnoses of Autoimmune Thyroiditis Based on the HTDS Evaluation or on Medical
Records with Supporting Documentation, by Geostratum and Sex
IX.H-11. Diagnoses of Autoimmune Thyroiditis Based on HTDS or Medical Record with
Supporting Documentation, by Exposure Group and Sex
IX.H-12. Confounding and Effect Modification by Sex, Age at Exposure or HTDS
Examination, Estimated Thyroid Dose from NTS, History of Any Cancer Other than
Thyroid, and Interview Type: Autoimmune Thyroiditis
IX.H-13. Confounding and Effect Modification by History of Medical and Dental Radiation
Exposures: Autoimmune Thyroiditis
IX.H-14. Confounding and Effect Modification by Occupational History: Autoimmune
Thyroiditis
IX.H-15. Confounding and Effect Modification by Smoking: Autoimmune Thyroiditis
IX.I-1. Basis for Diagnosis of Graves Disease, by Sex
IX.I-2. Diagnoses of Graves Disease by Sex, Estimated Dose, and Basis for Diagnosis
IX.I-3. Summary of Dose-Response Results for Diagnoses of Graves Disease
IX.I-4. Diagnoses of Graves Disease Based on the HTDS Evaluation or on Medical Records
with Supporting Documentation, by Geostratum and Sex
IX.I-5. Diagnoses of Graves Disease based on HTDS or Medical Record with Supporting
Documentation, by Exposure Group and Sex
IX.I-6. Confounding and Effect Modification by Sex, Age at Exposure or HTDS
Examination, Estimated Thyroid Dose from NTS, History of Any Cancer Other than
Thyroid, and Interview Type: Graves Disease
IX.I-7. Confounding and Effect Modification by History of Medical and Dental Radiation
Exposures: Graves Disease
IX.I-8. Confounding and Effect Modification by Occupational History: Graves Disease
IX.I-9. Confounding and Effect Modification by Smoking: Graves Disease
IX.J-1. Basis for Diagnosis of Autoimmune Thyroid Disease, by Sex
IX.J-2. Diagnoses of Autoimmune Thyroid Disease by Sex, Estimated Dose, and Basis for
Diagnosis
IX.J-3. Summary of Dose-Response Results for Diagnoses of Autoimmune Thyroid Disease
IX.J-4. Diagnoses of Autoimmune Thyroid Disease based on the HTDS Evaluation or on
Medical Records with Supporting Documentation, by Geostratum and Sex
IX.J-5. Diagnoses of Autoimmune Thyroid Disease based on the HTDS evaluation or on
Medical Records with Supporting Documentation, by Exposure Group and Sex
HTDS Final Report: June 21, 2002 – List of Tables
IX.J-6. Confounding and Effect Modification by Sex, Age at Exposure or HTDS
Examination, Estimated Thyroid Dose from NTS, History of Any Cancer Other than
Thyroid, and Interview Type: Autoimmune Thyroid Disease
IX.J-7. Confounding and Effect Modification by History of Medical and Dental Radiation
Exposures: Autoimmune Thyroid Disease
IX.J-8. Confounding and Effect Modification by Occupational History: Autoimmune Thyroid
Disease
IX.J-9. Confounding and Effect Modification by Smoking: Autoimmune Thyroid Disease
IX.K-1. Basis for Diagnosis of Hyperthyroidism, by Sex
IX.K-2. Etiologies of Hyperthyroidism, by Sex
IX.K-3. Non-Iatrogenic Hyperthyroidism, by Sex
IX.K-4. Diagnoses of Hyperthyroidism by Sex, Estimated Dose, and Basis for Diagnosis
IX.K-5. Summary of Dose-Response Results for Diagnoses of Hyperthyroidism
IX.K-6. Diagnoses of Hyperthyroidism Based on the HTDS Evaluation or on Medical
Records with Supporting Documentation, by Geostratum and Sex
IX.K-7. Diagnoses of Hyperthyroidism Based on HTDS or Medical Record with Supporting
Documentation, by Exposure Group and Sex
IX.K-8. Confounding and Effect Modification by Sex, Age at Exposure or HTDS
Examination, Estimated Thyroid Dose from NTS, History of Any Cancer Other than
Thyroid, and Interview Type: Hyperthyroidism
IX.K-9. Confounding and Effect Modification by History of Medical and Dental Radiation
Exposures: Hyperthyroidism
IX.K-10. Confounding and Effect Modification by Occupational History: Hyperthyroidism
IX.K-11. Confounding and Effect Modification by Smoking: Hyperthyroidism
IX.L-1. Basis for Diagnosis of Multinodular Thyroid Gland, by Sex
IX.L-2. Etiologies of Multinodular Thyroid Gland, by Sex
IX.L-3. “Other” Etiologies of Multinodular Thyroid Gland, by Sex
IX.L-4. Diagnoses of Multinodular Thyroid Gland by Sex, Estimated Dose, and Basis for
Diagnosis
IX.L-5. Summary of Dose-Response Results for Diagnoses of Multinodular Thyroid Gland
IX.L-6. Diagnoses of Multinodular Thyroid Gland Based on the HTDS Evaluation,
by Geostratum and Sex
IX.L-7. Diagnoses of Multinodular Thyroid Gland Based on HTDS Examination, by
Exposure Group and Sex
IX.L-8. Confounding and Effect Modification by Sex, Age at Exposure or HTDS
Examination, Estimated Thyroid Dose from NTS, History of Any Cancer Other than
Thyroid, and Interview Type: Multinodular Thyroid Gland
IX.L-9. Confounding and Effect Modification by History of Medical and Dental Radiation
Exposures: Multinodular Thyroid Gland
IX.L-10. Confounding and Effect Modification by Occupational History: Multinodular Thyroid
Gland
IX.L-11. Confounding and Effect Modification by Smoking: Multinodular Thyroid Gland
IX.M-1. Basis for Diagnosis of Simple Goiter, by Sex
IX.M-2. Etiologies of Simple Goiter, by Sex
IX.M-3. “Other” Etiologies of Simple Goiter, by Sex
IX.M-4. Diagnoses of Simple Goiter by Sex, Estimated Dose, and Basis for Diagnosis
HTDS Final Report: June 21, 2002 – List of Tables
IX.M-5. Summary of Dose-Response Results for Diagnoses of Simple Goiter
IX.M-6. Diagnoses of Simple Goiter Based on the HTDS Evaluation, by Geostratum and Sex
IX.M-7. Diagnoses of Simple Goiter Based on Any Source, by Geostratum and Sex
IX.M-8. Diagnoses of Simple Goiter Based on HTDS Examination, by Exposure Group and
Sex
IX.M-9. Diagnoses of Simple Goiter Based on Any Source, by Exposure Group and Sex
IX.N-1. Diagnoses of Other Thyroid Disease by Sex, Dose Category, and Basis for Diagnosis
IX.N-2. Dose-Response Results for Diagnoses of Other Thyroid Disease
IX.O-1. Basis for Diagnosis of Hyperparathyroidism, by Sex
IX.O-2. Diagnoses of Hyperparathyroidism by Sex, Estimated Dose, and Basis for Diagnosis
IX.O-3. Summary of Dose-Response Results for Diagnoses of Hyperparathyroidism
IX.O-4. Diagnoses of Hyperparathyroidism Based on the HTDS Evaluation or on Medical
Records with Supporting Documentation, by Geostratum and Sex
IX.O-5. Diagnoses of Hyperparathyroidism Based on HTDS Any Diagnosis or
Participant/CATI Respondent Report, by Exposure Group and Sex
IX.P-1. Ultrasound-Detected Abnormalities, by Sex and Type of Abnormality
IX.P-2. Ultrasound-Detected Abnormalities, by Sex and Size of Abnormality
IX.P-3. Any Ultrasound-Detected Abnormality by Sex and Dose Category
IX.P-4. Dose-Response Results for Diagnoses of Any Thyroid UDA
IX.P-5. Any Ultrasound-Detected Abnormality, by Geostratum and Sex
IX.P-6. Any Ultrasound-Detected Abnormality, by Exposure Group and Sex
IX.P-7. Confounding and Effect Modification by Sex, Age at Exposure or HTDS
Examination, Estimated Thyroid Dose from NTS, History of Any Cancer Other than
Thyroid, and Interview Type: Any Ultrasound-Detected Abnormality
IX.P-8. Confounding and Effect Modification by History of Medical and Dental Radiation
Exposures: Any Ultrasound-Detected Abnormality
IX.P-9. Confounding and Effect Modification by Occupational History: Any Ultrasound-
Detected Abnormality
IX.P-10. Confounding and Effect Modification by Smoking: Any Ultrasound-Detected
Abnormality
IX.P-11. Number of Ultrasound-Detected Abnormalities of the Thyroid with Maximum
Dimension ≥ 5 mm, by Sex and Dose Category
IX.P-12. Number of Ultrasound-Detected Abnormalities of the Thyroid with Maximum
Dimension ≥ 10 mm, by Sex and Dose Category
IX.P-13. Number of Ultrasound-Detected Abnormalities of the Thyroid with Average
Dimension ≥ 15 mm, by Sex and Dose Category
IX.P-14. Poisson Regression Analyses of Numbers of Thyroid UDAs
IX.P-15. Proportion of Participants with HTDS Ultrasound Findings of Palpable Thyroid
UDAs, by Sex
IX.P-16. Palpable Ultrasound-Detected Abnormalities by Sex and Estimated Dose
IX.P-17. Dose-Response Results for Diagnoses of Palpable Thyroid UDA
IX.P-18. Palpable Ultrasound-Detected Abnormalities, by Geostratum and Sex
IX.P-19. Palpable Ultrasound-Detected Abnormalities, by Exposure Group and Sex
IX.P-20. Confounding and Effect Modification by Sex, Age at Exposure or HTDS
Examination, Estimated Thyroid Dose from NTS, History of Any Cancer Other Than
Thyroid, and Interview Type: Palpable Thyroid UDAs
HTDS Final Report: June 21, 2002 – List of Tables
IX.P-21. Confounding and Effect Modification by History of Medical and Dental Radiation
Exposures: Palpable Thyroid UDAs
IX.P-22. Confounding and Effect Modification by Occupational History: Palpable Thyroid
UDAs
IX.P-23. Confounding and Effect Modification by Smoking: Palpable Thyroid UDAs
IX.P-24. Proportion of Participants with HTDS Ultrasound Findings of Nonpalpable Focal
Thyroid UDAs, by Sex
IX.P-25. Nonpalpable Ultrasound-Detected Abnormalities by Sex, and Estimated Dose:
Participants with Ultrasound Only
IX.P-26. Dose-Response Results for Diagnoses of Nonpalpable Focal Thyroid UDAs
IX.P-27. Nonpalpable Focal Ultrasound-Detected Abnormalities, by Geostratum and Sex
IX.P-28. Nonpalpable Focal Ultrasound-Detected Abnormalities, by Exposure Group and Sex
IX.P-29. Confounding and Effect Modification by Sex, Age at Exposure or HTDS
Examination, Estimated Thyroid Dose from NTS, History of Any Cancer Other Than
Thyroid, and Interview Type: Nonpalpable Focal Ultrasound-Detected Abnormalities
IX.P-30. Confounding and Effect Modification by History of Medical and Dental Radiation
Exposures: Nonpalpable Focal Ultrasound-Detected Abnormalities
IX.P-31. Confounding and Effect Modification by Occupational History: Nonpalpable Focal
Ultrasound-Detected Abnormalities
IX.P-32. Confounding and Effect Modification by Smoking: Nonpalpable Focal Ultrasound-
Detected Abnormalities
IX.P-33. Proportion of Participants with HTDS Ultrasound Findings of Diffuse Thyroid
UDAs, by Sex
IX.P-34. Diffuse Ultrasound-Detected Abnormalities by Sex, and Estimated Dose:
Participants with Ultrasound Only
IX.P-35. Dose-Response Results for Diagnoses of Diffuse Ultrasound Abnormalities
IX.P-36. Diffuse Ultrasound-Detected Abnormalities, by Geostratum and Sex
IX.P-37. Diffuse Ultrasound-Detected Abnormalities, by Exposure Group and Sex
IX.P-38. Confounding and Effect Modification by Sex, Age at Exposure or HTDS
Examination, Estimated Thyroid Dose from NTS, History of Any Cancer Other than
Thyroid, and Interview Type: Diffuse Ultrasound-Detected Abnormalities
IX.P-39. Confounding and Effect Modification by History of Medical and Dental Radiation
Exposures: Diffuse Ultrasound-Detected Abnormalities
IX.P-40. Confounding and Effect Modification by Occupational History: Diffuse Ultrasound-
Detected Abnormalities
IX.P-41. Confounding and Effect Modification by Smoking: Diffuse Ultrasound-Detected
Abnormalities
IX.Q-1. Distributions of TSH Levels Measured by RIA, by Sex
IX.Q-2. Distributions of TSH Levels Measured by EIA-1, by Sex
IX.Q-3. Distributions of TSH Levels Measured by EIA-2, by Sex
IX.Q-4. Parameter Estimates for Linear Dose-Response Models: TS
IX.Q-5. Distributions of Total Thyroxine (T4) Levels, by Sex
IX.Q-6. Parameter Estimates for Linear Dose-Response Models: T4
IX.Q-7. Distributions of T3 Resin Uptake (T3RU), by Sex
IX.Q-8. Parameter Estimates for Linear Dose-Response Models: T3RU
IX.Q-9. Distributions of Free Thyroxine Index (FTI), by Sex
HTDS Final Report: June 21, 2002 – List of Tables
IX.Q-10. Parameter Estimates for Linear Dose-Response Models: FTI
IX.Q-11. Distributions of Anti-TPO, by Sex
IX.Q-12. Distributions of AMA, by Sex
IX.Q-13. Parameter Estimates for Linear Dose-Response Models: Anti-TPO and AMA
IX.Q-14. Distributions of Anti-TG, by Sex
IX-Q.15. Parameter Estimates for Linear Dose-Response Models: Anti-TG
IX.Q-16. Distributions of Serum Calcium, by Sex
IX.Q-17. Parameter Estimates for Linear Dose-Response Models: Serum Calcium
IX.Q-18. Distributions of Estimated Thyroid Mass, by Sex
IX.Q-19. Parameter Estimates for Linear Dose-Response Models: Thyroid Mass
IX.R-1. Summary of Dose-Response Results for Thyroid Disease Outcomes
IX.R-2. Summary of Dose-Response Results for Laboratory Values and Thyroid Mass
Executive Summary 
 
 
 
I. Background 
 
 The Hanford Thyroid Disease Study (HTDS) was mandated by an act of Congress in 1988.  The 
Centers for Disease Control and Prevention (CDC) was directed by Senate Bill 2889 to conduct a study of 
thyroid morbidity among persons who lived near the Hanford Nuclear Site between 1944 and 1957. A team 
of investigators at the Fred Hutchinson Cancer Research Center (FHCRC) and the University of 
Washington in Seattle was selected by the CDC to conduct the study, and a contract was awarded to the 
FHCRC on September 19, 1989.  
 
 The primary purpose of the study was to determine whether thyroid morbidity is increased among 
persons exposed to releases of radioactive iodine from the Hanford Nuclear Site between 1944 and 1957. 
The study was also designed to further determine in what way any increase in thyroid morbidity was related 
to the dose of radiation received (i.e., the characteristics of any dose-response relationship). Secondary 
objectives of the study included the following: 1) to determine whether hyperparathyroidism is increased 
among persons exposed to the Hanford radiation and, if so, to determine in what way the increase is related 
to the dose of radiation received; 2) to provide information to residents of the communities surrounding the 
Hanford Site regarding the objectives, design, and conduct of the study, as well as the findings and results 
of the research; and 3) to assess the appropriateness of the methods employed and the degree to which such 
an investigation could be successfully planned and executed, given the long interval since exposure and the 
uncertainties regarding radiation dose.  
 
 This study was conducted as a follow-up prevalence study. That is, a group of individuals (a 
“cohort”) was selected on the basis of presumed past exposure to varying levels of radioactive iodine (131I 
in particular) released into the atmosphere from Hanford, based on place and year of birth.  Individuals in 
the cohort were located and those who participated had a dose estimate calculated from answers to a 
dosimetry questionnaire, and were examined for the presence or history of thyroid disease. The primary 
analyses focused on living participants who received medical examinations to detect thyroid disease, and 
for whom thyroid radiation doses were estimated using the dosimetry system developed by the Hanford 
Environmental Dose Reconstruction (HEDR) Project. All forms of thyroid disease were investigated as part 
of the study and were included in the analysis, as were abnormalities of the thyroid gland seen on 
ultrasound examinations. In addition, primary hyperparathyroidism was evaluated by screening individuals 
for hypercalcemia.   
 
 The work was conducted in two stages. The first was a Pilot Study, the primary purpose of which 
was to evaluate the feasibility of the methods proposed, and to develop the specific operational procedures 
and data collection instruments needed for a full study.  The second stage was to implement the remaining 
fieldwork to complete such a study. This approach allowed the accumulation of information and experience 
prior to initiation of the more costly full-scale study.  
 
 The Pilot Study was completed in December 1994, with a report issued January 24, 1995.  
Reviews of the Pilot Study by the National Research Council’s Board of Radiation Effects Research of the 
Commission on Life Sciences and the federal Advisory Committee for the HTDS concluded that a full-
scale epidemiologic study should be undertaken.  The fieldwork for the Full Study was completed in 
December 1997.  This document summarizes the Final Report of the Hanford Thyroid Disease Study.  
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II. Fieldwork 
 
A. Cohort Definition and Participant Selection 
 
 To achieve the primary objective of the study, it was important to identify a cohort that would 
provide the greatest likelihood of detecting an association between Hanford radiation exposure and thyroid 
disease, if such a relationship exists.  This was accomplished by defining a cohort that would include 
adequate numbers of people with the highest possible radiation doses to the thyroid from Hanford, as well 
as people with very low radiation doses to the thyroid from Hanford.  
 
 Extensive efforts were made to investigate different sources of information that could be used to 
construct a cohort of people who might have been exposed.  Ideally, such a list would include everyone in a 
relatively large population living in the region around the Hanford site during the time period that 
atmospheric releases of radioactive iodine occurred, and would contain enough identifying information on 
each person to allow them to be located for the study (several decades after exposure).  Only birth records 
provided a viable unbiased source for identifying a cohort.  
 
 For the purposes of participant selection only, residence at time of birth was considered a 
surrogate for the anticipated radiation dose to the thyroid from Hanford, since doses could only be 
estimated from data collected during the study.  To select study participants for the Pilot Study, a birth 
roster was constructed based on all births to mothers resident in the Washington State counties of Benton, 
Franklin, Walla Walla, Okanogan, Ferry, and Stevens.  Following the Pilot Study, and based on the dose 
estimates for Pilot Study participants, Adams County was added for the Full Study selections, in order to 
maximize the numbers of participants with high doses.  Adequate numbers of participants with no or very 
low dose were obtained in the Pilot Study selections from Stevens, Ferry, and Okanogan counties, and no 
further selections were made from these areas.   
 
 Preliminary estimates from the HEDR project suggested that the highest thyroid doses were likely 
to be in people exposed as infants or children during the first years of Hanford operations.  This is because 
infants and children receive higher thyroid doses per unit exposure, due primarily to the small size of their 
thyroid glands.  Existing literature also suggests that the risks radiation-induced thyroid disease (and 
possibly hyperparathyroidism) are greatest among those exposed at youngest ages.  For these reasons, the 
Pilot Study included people born from 1942-46, since the large majority of atmospheric releases of 
radioactive iodine from the Hanford facility occurred in 1944-46. For the Full Study, additional selections 
from the years 1940 and 1941 in Benton, Franklin, and Adams counties were included to maximize the 
number of potentially high dose participants.  Thus, the cohort contained people with exposure beginning 
as early as the prenatal period, and as late as age three.  An additional benefit of choosing a young group 
was that mothers and close relatives of participants born during 1940-46 were more likely be alive and 
available for interview, compared to those of persons born earlier. 
 
 Selection of potential participants from the Birth Roster was stratified by geographical area, year 
of birth, and sex.  The purpose of stratification by geographical area and birth year was to assure that 
adequate numbers of high dose and low dose participants were identified, so that as wide a range of doses 
as possible was obtained.  Stratification by sex also reduced the possibility of confounding by sex that 
could reduce the efficiency of the study.  Geographical areas were defined to distinguish predominantly 
rural areas from those that are predominantly urban, because residents of predominantly rural areas may 
have been more likely to consume fresh raw milk than their more urban counterparts.  A total of 5199 
individuals were selected to form the cohort. 
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B. Tracing and Locating Study Participants 
 
 Because members of the study cohort were identified solely on the basis of birth records from the 
mid-1940s, extensive effort was required to locate them as adults nearly fifty years later. Thus, the primary 
objective of the tracing component of the study was to identify a current address and telephone number for 
all living cohort members, so they could be recruited to participate in the study.  A second objective was to 
obtain confirmation of death, as well as date and cause of death, for all those who were deceased. 
 
 Several approaches were used to trace potential participants.  Initially, relatively easy to use and 
readily accessible sources were used.  Subsequently, more resource-intensive and costly resources were 
employed to find the more difficult to locate individuals.  A final attempt to locate the most difficult to find 
potential participants was made by using established professional locating services and military locating 
services.  
 
 Of the 5199 cohort members, 4350 living individuals were located and 527 individuals were 
confirmed deceased.  Thus, nearly 94% of the cohort was located, with their identities confirmed.  Only 
322 potential participants (6.2%) remained "unable to locate” at the end of the study.  Notably, the ability 
to locate well over 90% of all potential participants did not vary substantially by sex, or geographic region 
of birth, or year of birth.  Almost 84% of all potential participants were located as living, and their 
identities (whether they agreed to participate or not) were confirmed directly by contact with the potential 
participants themselves or with close relatives who could verify their identities and current addresses.  
 
 Five hundred twenty-seven (10.1%) of the cohort members were confirmed to be deceased by a 
close relative and/or other reliable source (such as death certificate).  The proportion confirmed deceased 
was higher among males (12.7%) than females (7.5%). Sixteen potential participants (0.3%) were located 
as living, but died during the study prior to completing a clinic.  Death certificates were obtained for 93% 
of the total 543 deceased. 
 
 At least one living cohort member was located in every state in the U.S. except for Rhode Island.  
Fifty-four percent of those located resided in Washington State, 9.4% in California, 9.1% in Oregon and 
2.7% in Idaho.  The only other state where more than 2% of the living cohort members resided was Texas 
(2.2%).  Thirty-six participants (0.8% of those located) lived in countries outside of the U.S., including 
Canada, Dubai, Ecuador, Germany, Mexico, Saudi Arabia, South Africa, South Korea, England, Guam, 
Australia, Japan, France, Saipan, Hungary, Columbia, and Taiwan. 
 
 
C. Recruiting Study Participants 
 
 The objectives of the recruiting effort were to contact living cohort members, obtain their 
agreement to participate in the study, and to identify an appropriate respondent to complete the Computer 
Assisted Telephone Interview (CATI). Once a potential participant was located through the tracing 
procedure, initial contact was made by mail.  In some instances a preliminary letter or phone call was 
necessary to confirm the potential participant's identity. Each living potential participant located received 
an initial contact letter, fact sheet, and a description of what participation in the study would entail.  
 
 A recruiter called each located potential participant five to seven days after the first contact letter 
was mailed.  A minimum of 10-15 evening attempts were made at various weeknight and weekend time 
periods, and a minimum of three daytime (weekend and weekday) calls were attempted.  If the potential 
participant could not be contacted by phone after 20-25 attempts, a second letter was sent explaining that 
the study had been unable to reach them at the phone number on file, and asking them to call the toll-free 
HTDS number. After 40-45 attempts resulting in no contact with either the potential participant or a 
household member, the potential participant was considered “unable to contact” and no further attempts 
were made. 
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 If a potential participant refused, the recruiter asked him/her to complete a Refusal/Demographic 
Questionnaire.  Twelve demographic questions relating to race, ethnic origin, income, religion, and 
education level were asked in order to obtain a general profile of those who refused to participate, or who 
withdrew after initially agreeing to participate.  The recruiter also completed a Refusal Assessment after the 
call to record the nature and strength of the refusal from the recruiter’s perspective.  
 
 A total of 4239 potential participants (97.4% of all living, located cohort members) were contacted 
by telephone and invited to participate in the study.  An additional 93 (2.1% of all living, located cohort 
members) were located to an address, and were sent one or more letters, but could not be contacted by 
telephone.  Of those contacted by telephone, 3564 (84.1%, or 81.9% of all located, living cohort members) 
agreed to participate in the study.  Of those located alive, 634 (14.6%) refused to participate.   
 
 Willingness to participate did not differ substantially by sex, year of birth, or geographic region of 
birth. “Not interested” and/or “no time” were by far the most commonly given reasons given refusals, 
accounting for 64.8% of all refusals.  The second most commonly cited reasons were “illness” and 
“impairment” (7.6%). An additional 41 potential participants were determined to be unable to fully 
participate during the recruiting process and were consequently not included in the study regardless of 
willingness to participate.    
 
 
D. Computer Assisted Telephone Interview 
 
 The primary objective of the Computer-Assisted Telephone Interview (CATI) was to collect 
information that would be used as input for calculating an estimated radiation dose to the thyroid gland for 
each study participant.  A CATI was conducted by an interviewer who read the interview text and questions 
from a computer screen, and recorded the responses as they were given.  
 
 The CATI was designed to collect information from the early years of the participants’ lives, 
including time in utero if necessary, from 1944 to 1957. The interview was “location-driven” so that the 
information collected was specific to locations and periods of time directly relevant to the atmospheric 
releases of 131I from Hanford. The following topic areas were included in the CATI interview:  1) general 
demographic characteristics of the participant and his or her family; 2) a residential history of the 
participant from birth through 1957, and for the mother while pregnant with or breastfeeding the 
participant; 3) sources of the milk consumed by the participant from birth through 1957, and by the 
participant’s mother while pregnant and breastfeeding the participant; 4) milk consumption patterns of the 
participant from birth through 1957, and of the mother during pregnancy and breastfeeding; and 5) other 
patterns of food consumption, including green and leafy vegetables, fruit, and free range chicken eggs by 
the participant from birth through 1957, and by the mother while pregnant and breastfeeding.  In addition, 
medical history information was obtained for both the mother and the participant, including the following:  
1) thyroid diseases and selected other medical conditions diagnosed and treated in the participant; and 2) 
history of medical radiation exposures, either diagnostic or therapeutic, for the participant, and for the 
mother during pregnancy and breastfeeding. 
 
 To help the CATI respondents accurately report detailed information about their child (or sibling) 
from very long ago, several elements of the cognitive approach to interviewing were incorporated into the 
design of the CATI. The key element to this approach is to mentally take the respondent back to the time 
period in question, and have them remember as much about that time as possible.  As more memories of the 
time in question are recalled by the respondent, the likelihood of remembering answers to specific 
questions increases.  
 
 Memory materials were developed to help the respondent prepare for answering the interview 
questions.  Background information was provided to encourage memory about specific topics. The memory 
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materials were organized into a booklet that was sent with a Residence History Questionnaire to 
respondents in advance of the interview.  In addition, the text of the interview was refined to include 
references to specific parts of the memory materials at key points during the interview. 
 
Of the 2712 participants who identified a CATI respondent, interviews were completed for 2266 
(83.6%).  Of the 3447 eligible study participants who completed the clinic, 2133 (61.9%) had a CATI 
interview.  In 29 instances, CATI interviewers determined the quality of the data provided by respondents 
was too poor to be considered reliable.  Expanded interviews were performed at the clinic for these 29 
participants. 
 
 
E. Scheduling 
 
 The primary objective of the scheduling activity was to provide each participant with at least three 
options for clinic attendance, with the least possible inconvenience to the participant.  A schedule of clinic 
dates and locations was developed based on the current residences of participants.  Clinics were held in 
Seattle, Pasco, Spokane, Walla Walla, Yakima, Wenatchee, Colville, Omak, Portland Oregon and 
Vancouver Washington.  Most participants from outside Washington State attended clinics in Seattle. 
 
 Multiple attempts were made to contact all participants, and every participant was offered several 
options for clinic dates. Each scheduled participant was sent a letter that included: 1) the date and time of 
clinic appointment; 2) location of clinic and directions; 3) travel arrangements summary and/or tickets (if 
applicable); and 4) Interview Preparation Worksheet.  If a participant canceled a clinic appointment, an 
attempt was made to reschedule the participant.  A participant who canceled a clinic appointment would be 
rescheduled an unlimited number of times.  If a participant decided not to participate in the study during the 
scheduling process, the scheduler assessed the reason for the withdrawal and addressed the participant’s 
concerns in an attempt to retain participation.  If the participant persisted in the withdrawal, she or he was 
asked to complete a Refusal Questionnaire.   
 
 Approximately 90% of those who initially agreed to participate completed a clinic.  The number of 
participants who withdrew after initially agreeing to participate was 298 (7.7%).  
 
 
F. Clinical Evaluation 
 
 The objective of the clinical component of the study was to provide a thorough clinical 
examination of each study participant to determine the presence of thyroid disease, or primary 
hyperparathyroidism. Each participant was administered an In-Person Interview prior to the clinic 
examinations; this is described in more detail below. Following the interview, each participant underwent a 
full complement of examinations to determine the presence or absence of any thyroid disease or primary 
hyperparathyroidism.  The examinations included thyroid ultrasound, independent thyroid palpation by two 
study physicians, and blood tests for thyroid and parathyroid function, and anti-thyroid immune response.  
Additional studies were requested if indicated by the presence of palpable thyroid nodules.   
 
 The physical examination was conducted separately by two study physicians.  The results of their 
examinations were reviewed, and if there was any disagreement, the two examiners conferred and re-
examined the participant together to reach a consensus.  The findings of each physician were recorded 
separately, as were the findings of any consensus examination, prior to review of the ultrasound scan.  If 
abnormalities were found on the ultrasound which were not found on physical exam, the two physicians 
performed a final consensus examination.  The physical examination and ultrasound findings were then 
discussed with the participant. 
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 Participants found to have discrete, palpable, solitary thyroid nodules or dominant nodules within 
a multinodular gland upon examination were asked to undergo fine-needle aspiration (FNA) biopsy of the 
nodule. Participants who wanted to delay the procedure could either return to the HTDS clinic site on 
another clinic date, or have the FNA performed by a local physician in their community.  Thyroid nuclear 
scans were recommended for participants whose examination and laboratory results were suspicious for the 
presence of autonomously functioning thyroid nodules, Graves Disease, or toxic thyroid nodules. 
 
 A total of 3447 eligible participants were examined in the HTDS clinics.  Of the 3447 participants, 
3439 (99.8%) had blood drawn for thyroid function studies, and 3446 had thyroid ultrasound.  Of the 272 
participants for whom FNA was recommended, 259 (95.2%) underwent the procedure, while 28 of the 29 
(96.6%) participants recommended to have a nuclear scan complied.  
 
 
G. In-Person Interview 
 
 The purpose of the In-Person Interview was to obtain information directly from the study 
participant about his/her past exposures to occupational and/or medical irradiation, history of thyroid 
disease, and general demographic information.   In addition, for those participants who could not identify a 
respondent for the dosimetry interview, an expanded version of the In-Person Interview provided details 
regarding residence history and limited information on the type of milk consumed, for use in estimating 
their thyroid radiation doses from Hanford’s atmospheric releases of 131I.  The In-Person Interview was 
conducted before the participant began the medical components of the clinic (ultrasound, blood draw, and 
physical examination). This was done to ensure that the participant’s responses could not be influenced by 
knowledge of examination results.  All interviews were conducted in person by trained, experienced 
interviewers.    
 
 The In-Person Interview included questions about the participant from age 15 to the present, in the 
following topic areas:  1) general demographic characteristics; 2) residential history, including dates and 
locations of residences, 3) occupational history, focusing on occupations and industries with potential of 
exposure to any form of ionizing radiation; 4) military history as obtained in both the residential and 
occupational sections, especially regarding possible exposures to nuclear weapons tests (e.g., in Nevada or 
the Marshall Islands);  5) medical history, including dates and places for all thyroid-related diseases and 
symptoms;  6) history of medical and dental X-ray exposures;  7) history of nuclear medicine procedures;  
8) history of radiation therapy;  9) selected lifestyle factors, such as patterns of tobacco use; and 10) 
familiarity/bias questions to assess knowledge of the Hanford releases and any strongly-held beliefs about 
their possible health effects. 
 
 All 3447 eligible participants attending a HTDS clinic completed an In-Person Interview.  Six 
interviews were judged to have insufficient residence history information to calculate a dose estimate. One 
participant was unable to complete the interview because of developmental disabilities, however the 
participant’s father (who was unable due to illness to participate in a CATI dosimetry interview) was 
mailed a modified version of the expanded In-Person Interview questionnaire and provided the information 
in this manner. Overall, 61% of participants completed the Standard In-Person Interview, while 39% 
completed the Expanded version.   
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H. Clinic Medical Review and Final Diagnosis Determination 
 
 The objectives of the Clinic Medical Review and Final Diagnosis Determination processes were 
to:  1) evaluate each participant’s clinical thyroid examination results from the HTDS clinic visit; 2) 
communicate clinic results to participants in a timely manner and, when indicated, to the participant’s 
health care provider; and 3) assign the final diagnoses for each case, according to the format developed 
using all information available prior to and including the HTDS clinic. 
 
 Following each clinic, results of the laboratory tests performed on blood specimens, of 
radiologists’ reviews of ultrasound examinations, and of the study pathologist’s evaluation of any FNA 
specimens were received in the HTDS office within 5-6 days.  Physicians reviewed each participant’s clinic 
results, and a letter informing the participant of the results was sent. A Final Diagnosis Determination Form 
was completed for all remaining participants. All participants received their clinic results within 3-4 weeks 
following their clinic appointment. Letters were also sent to each participant’s health care provider, if the 
participant indicated this was to be done.   
 
 If follow-up tests were recommended to a participant, that participant’s clinic and follow-up 
results were reviewed at another Clinic Medical Review once the results were received in the HTDS office.  
A second results letter was mailed to the participant and their health care provider, describing the results of 
the follow-up tests.  The Final Diagnosis Determination Form was then completed. 
 
 All 3447 eligible participants who attended a study clinic received a Clinic Medical Review.  
Eighty percent of participants had a Final Diagnosis Determination Form completed at the time of their 
Clinic Medical Review.   The remaining 20% had either historical medical records or post-clinic 
recommendations for further diagnostic procedures, and had a Final Diagnosis Determination Form 
completed following compilation and review of the records from those providers. 
 
 A total of 259 participants had FNA procedures performed at the clinic or on the recommendation 
of the HTDS physicians.  Of these, 47 were recommended at Clinic Medical Review to have further biopsy 
or surgical procedures to rule out a diagnosis of thyroid neoplasm. In addition, 29 participants with thyroid 
nodules or suppressed TSH were recommended to undergo thyroid nuclear scan.  Twenty participants had 
an abnormal calcium level and were recommended to have additional blood drawn for parathyroid hormone 
(PTH) studies to confirm or rule out a diagnosis of hyperparathyroidism.  Thirty participants were 
requested to have additional blood drawn due to abnormal or borderline thyroid function. 
 
 
I. Historical and Post-Clinic Medical Records Review 
 
 The primary objectives of the medical record component were to: 1) document thyroid problems 
reported by study participants and CATI respondents; 2) obtain any cytological or histological specimens 
from previous biopsies or surgeries for review by the study’s pathologist; and 3) obtain the results 
(including histological specimens) of any further diagnostic or surgical procedures recommended by the 
HTDS as a result of a finding at the HTDS clinic. A secondary objective of the medical record component 
was to obtain cause of death information on all deceased cohort members, in order to assign cause of death 
codes and perform a mortality analysis.   
 
 During the CATI interview, respondents were asked to provide the names (and addresses, if 
known) of any physician who saw the participant for diagnosis or treatment of thyroid disease. At the time 
of the In-Person Interview, the participant was asked to provide the names and addresses of physicians or 
institutions where they had been diagnosed or treated for thyroid or parathyroid disease, and to sign a 
consent form for the release of information from each of these providers. 
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 For each deceased cohort member, the death certificate or informant information was used to 
complete a Cause of Death Form.  In addition, the primary cause of death was coded using the ICD9-CM 
system.  For those whose date of death preceded the use of the ICD9-CM system, the primary cause of 
death was also back-coded using the system in use at the time of death.  
 
 Reports of historical medical records were obtained for 694 participants, with a total of 1259 
consent forms completed to obtain medical records from different providers.  While the majority of reports 
were made during the In-Person Interview, CATI Interviews yielded 30 of these reports. 
 
 Of the 1259 Medical Record Consents obtained, a total of 795 (63.1%) separate medical records 
were received by the HTDS. No records were received for 464 requests (36.9%). In 102 (8.1%) cases, 
records could not be requested because the physician was deceased or retired, or a current address could not 
be identified.   For 128 (10.2%) requests, records were unavailable due to the destruction of records, the 
inability of the provider to identify the patient, or an inability to locate the records.  In 232 (18.4%) cases, 
records were not received after several contacts, without explanation as to why they were not available.  
 
 Of the 694 participants identifying historical medical records to be requested, pathology or 
cytology slides were requested for 52 (7.5%).  In a few cases, more than one set of slides was requested, for 
a total of 58 separate requests.   A total of 42 sets of historical pathology or cytology slides were received 
for 42 (80.8% of slides requested) participants.  
 
 One potential concern is that diagnoses of disease outcomes might be missed when requested 
medical records or slides could not be obtained: none or only part of the requested records or slides were 
received for 199 (29%) and 160 (23%), respectively, of the 694 participants for whom such requests were 
made.  However, even if a medical record or slide could not be obtained, the likelihood of a missed 
diagnosis was generally low because in most such situations the HTDS evaluation provided a definitive 
assessment of whether the diagnosis for which the medical record was sought was confirmed or not 
confirmed. 
 
 Medical records documenting further diagnostic studies recommended as a result of the HTDS 
clinic findings were requested for 35 participants, with a total of 72 separate requests.  All but one of these 
records were obtained, with at least one record obtained for each of the 35 participants.  Thirty-three of 
these participants also had histology or cytology slides requested, for a total of 35 separate requests.   All 
35  of these specimens were obtained. 
 
 Death certificates were received for 504 of the 543 deceased cohort members.  Cause of death was 
coded for 543 deceased cohort members.   
 
 
J. Dose Estimation  
 
The primary analyses of dose-response relationships were based on individual estimates of 
radiation dose to the thyroid from Hanford’s atmospheric releases of 131I, specifically organ doses to the 
thyroid that were estimated from data collected during the CATI and/or the Expanded In-Person Interview. 
The CIDER program developed by the HEDR Project was used to calculate estimated doses.  In particular 
the CIDER output for an individual consisted of 100 realizations of the estimated cumulative total organ 
dose to the thyroid from 131I.   
 
 Each of the 100 realizations of dose was calculated for a fixed set of conditions regarding the 
source term, environmental transport, and uptake of 131I, and these conditions for a given realization were 
the same for every participant.  The 100 realizations were obtained by randomly varying the conditions, 
i.e., the uncertain parameters in the HEDR models for source term, transport, etc., in order to characterize 
the uncertainty in the resulting dose estimates. Thus it is useful to view each realization as consisting of a 
set of doses, one for each in-area participant. For many purposes it was useful to have a single number or 
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“point estimate” to represent each participant’s dose.  For each living evaluable in-area participant, the 
median of the 100 realizations of dose, di = median(Di,1, … , Di,100) for participant i, was used as a summary 
measure of that participant’s dose.  .   
 
 Of the 3447 eligible participants who attended a study clinic, 3440 were considered evaluable for 
the study, i.e., had sufficient information for dose estimation and could be adequately examined for thyroid 
disease. The CIDER program calculated estimates of doses accumulated by people while living within a 
75,000 square mile geographical domain around Hanford.  Dose estimates could therefore be calculated by 
the CIDER program for 3191 of the evaluable participants who lived within that domain at least some time 
from the start of Hanford operations in 1944 through the end of 1957; these 3191 are designated “in area” 
participants.  The remaining 249 “out-of-area” participants did not, according to their CATI or Expanded 
In-Person Interview data, live within the domain during that time period.  Although the CIDER could not 
calculate dose estimates for the out-of-area participants, they were included in the study. 
 
 
K. Data Management 
 
 The primary objective of the Data Management Plan was to specify the procedures to develop and 
maintain the study databases, and the procedures that would be used to ensure data quality.  Principal 
components of the plan included duplicate entry for all data forms, range checks encoded in the data entry 
programs, and consistency check programs run on the data after entry.  A second objective of the Data 
Management Plan was to maintain the confidentiality of the data.  This included data in computerized form 
through the use of passwords and control of limited access to directories and data files, and to paper 
records, which were stored in locked files in locked offices or in a file room which had limited access via 
keycard. 
 
 In order to ensure high data quality, all data entered from paper forms were subject to double-entry 
verification.  Additional computer programs were written to check and crosscheck all of the data, both 
within a data form and across data forms.  For example, the diagnoses coded on the Final Diagnosis 
Determination Forms were compared to all the other data collected (i.e., examination forms, ultrasound 
forms, CATI data, In-Person Interview data, and the tracking system) to ensure that all appropriate 
diagnoses were included.  All inconsistencies were investigated by review of the participant’s records, 
including audiotapes of CATI interviews when necessary.  Once any changes were made to a database, 
check programs were run to ensure all changes had been made correctly.  
 
 
L. Data Quality Control 
  
 In addition to the data management plans and procedures outlined above, additional steps were 
taken after data collection to ensure a high degree of data quality.  These efforts included 1) more extensive 
between-table consistency checks of the In-Person Interview data and the CATI data, 2) hand calculation of 
the participant’s diet portion of the CIDER input data files (“scenario files”) for 10% of those with a CATI, 
3) comparison of the mother’s diet portion of the scenario file for all those with a CATI based on a separate 
computer program written by a programmer other than the one who created the scenario file program, 4) 
comparison of dose estimates produced by a CDC programmer versus those produced by HTDS, and 5) 
review by a second programmer of complex analysis programs that included code other than standard SAS 
procedures.   
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III. Special Considerations 
 
A. Coordination with the Advisory Committee 
 
 In June of 1990, an Advisory Committee was appointed by the Secretary of the Department of 
Health and Human Services to advise and consult with the CDC regarding the design and conduct of the 
study.  The committee was established pursuant to the Federal Advisory Committee Act, (5 U.S.C. 
Appendix 12).  The role of the committee was to review the development of the study protocol and conduct 
of the Pilot Study, assist in determining the feasibility and design of a full-scale epidemiologic study, and 
advise CDC on the analysis of the study results. 
 
 Initially, meetings of the committee were to be held on a quarterly basis in Atlanta, Georgia.  In 
recognition of the interest in the Pacific Northwest in such proceedings, however, the committee asked that 
at least one meeting per year be held in Washington State.  Following completion of the Pilot Study, 
meeting frequency was reduced to approximately once per year, with the majority of these held in Seattle, 
Washington.   
 
 Meetings of the Advisory Committee were open to the public.  All materials presented to the 
committee became public record, with copies available for members of the public at the meetings.  
Meetings held in Washington State were nearly always accompanied by an evening Public Meeting to 
allow members of the public to attend and to ask questions or make comments regarding the study. 
 
 Each meeting of the Advisory Committee began with an update on the progress of the study since 
the previous meeting.  These presentations included the status of preparations for the study field work, or 
later, the numbers of study participants completing each phase of the study.   Updates on the separate work 
concerning Native American populations were also included.  Requests for further information from the 
committee were documented, and information provided by study staff and investigators, as necessary.  
  
 
B. Public  Involvement 
 
 An important aspect of the HTDS was the provision of prompt, accurate, and complete 
information to the public.  In this context it was crucial that contacts be established with members of the 
populations most interested in the work.  Interested parties included representatives of the States of 
Washington, Oregon, and Idaho; the Native American Tribes and Nations in the study areas, and local area 
residents.  
 
 The public information activities of the study were designed to accomplish the following goals:  1) 
to assure that residents of the region understood the issues that led to the initiation of the study, the purpose 
and objectives of the study, its basic epidemiologic design, and the time schedule within which it was to be 
conducted; 2) to provide opportunities for the public to express concerns and comments regarding the 
design and conduct of the study, and to answer public questions regarding all aspects of the project; 3) to 
create public interest and support for the study, particularly in ways that such support might enhance 
participation by persons selected to be study participants; and 4) to assure broad dissemination and proper 
interpretation of final study results. 
 
 Throughout the study, and particularly in the early phases, the study investigators participated in 
public meetings held during the bi-monthly meetings of the HEDR Technical Steering Panel (TSP), and 
contributed to the planning activities of the Communications subcommittee of the TSP.  The HTDS also 
supplied the TSP with a fact sheet that was included with TSP fact sheet mailings.  This written material 
was updated periodically as the study progressed.  
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 Several separate approaches were also taken to provide information to the public regarding the 
HTDS.  Initially, the study protocol was made available for public review and comment prior to its 
submission to the CDC and the Advisory Committee.  In conjunction with this activity, a series of public  
meetings were held throughout the Northwest to discuss the protocol with the public and to answer specific 
questions.   
 
 In addition to the study fact sheet mentioned above, several study brochures were developed and a 
newsletter describing the progress and status of the study was initiated.  The brochures included the 
following: 1) HTDS Fact Sheet; 2) Questions and Answers about the Study; 3) Questions and Answers 
about Radiation and Thyroid Disease; and 4) Review of Thyroid Disease and Approach to Diagnosis.  A 
master mailing list, which included the lists previously maintained by the FHCRC, the CDC, and the 
HEDR Project, was assembled to mail the newsletter and brochures to interested individuals.  By the later 
stages of the HTDS,  the mailing list contained nearly 9700 names.  Early in the study, the newsletter was 
published on a quarterly basis.  Following the Pilot Study, however, yearly updates were used to inform 
interested parties of the study’s progress.  A total of 15 issues were published.  A special issue summarizing 
the findings in the Draft Final Report was distributed in January 1999.  
 
 Finally, study investigators and staff have been available to answer questions on a regular basis.  
A phone line was designated in the Seattle study office for public inquiries, and a toll-free telephone 
number was established at the Fred Hutchinson Cancer Research Center for the Hanford Thyroid Disease 
Study (1-800-638-HTDS).  People selected as study participants, and members of the general public, were 
encouraged to use the toll-free number to contact the study office if they had questions or scheduling 
conflicts.  As access to the World Wide Web became more common, a web site for the study was 
established at the FHCRC.  All study brochures and newsletters have been available at that site since 
January 1997, and are updated as necessary.  
 
 
C.  Native American Component 
 
 Nine Native American tribes and nations have reservations and ceded lands in the region around 
Hanford: Colville, Couer d’Alene, Kalispell, Kootenai, Nez Perce, Spokane, Umatilla, Warm Springs, and 
Yakama. Members of these tribes and nations were exposed to 131I from Hanford, and the original 
congressional mandate that led to the HTDS called specifically for the inclusion of “Indian tribes and tribal 
organizations.” The approach taken in the HTDS regarding the Native American populations was 
determined by two important characteristics of those populations. First, the lifestyles of many Native 
Americans were quite different in many respects from those of the non-Native population.  In particular, 
many Native Americans followed traditional cultural practices, especially regarding diet and sources of 
foods, which might influence the doses they received from Hanford’s 131I, but which were not explicitly 
modeled in the CIDER program.  Moreover many Native Americans maintained a seasonal migratory 
pattern of residence. Second, because the tribes and nations have sovereign rights recognized by the United 
States, conduct of a research project such as HTDS would require the approval and active cooperation of 
each tribal government. Thus, the objective of the HTDS with respect to the Native American populations 
was to assess the feasibility of conducting a study to determine whether thyroid disease has increased 
among Native Americans exposed to atmospheric releases of 131I from Hanford.   
 
 Sample size and power calculations were carried out to determine whether it would be feasible to 
conduct a retrospective cohort study using individual dose estimates, similar to that being conducted for the 
HTDS Full Study. These calculations were based on data provided by eight of the nine tribes regarding 
tribal-specific lifestyle and dietary practices. These data are likely to more accurately account for lifestyle 
patterns and practices specific to each tribe than using assumptions derived from the non-Native American 
population, and therefore the representative dose estimates are likely to more accurately approximate the 
doses members of each tribe would have likely received from Hanford. Similarly, the demographic data 
provided by each tribe are likely to more accurately reflect the size and demographic makeup of each tribe 
around the time of the Hanford releases.  
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 Even under very liberal assumptions regarding the number of tribal members who might be 
available to participate in a study, and the thyroid radiation doses Native Americans received from 
Hanford’s atmospheric releases of 131I, a study nearly twice the size of the HTDS Full Study (6426 living 
evaluable participants) would have only 50% power to detect an effect of the magnitude targeted by the 
Full Study, i.e., a 5% increase in total thyroid neoplasia per Gray. Even under a more extreme assumption 
that the baseline probabilities for thyroid neoplasia are only half of those assumed in the HTDS Full Study, 
a study of 6426 living evaluable participants would only have 71% power to detect the same magnitude of 
effect. Thus, it was recommended that a study of the design of the HTDS full study would not be feasible in 
the Native American population encompassed by the nine tribes in the Hanford region.  
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IV. Statistical Methods 
 
In the primary dose-response analyses, the exposure for each living evaluable in-area participant 
was represented by the estimated radiation dose to the thyroid from Hanford’s atmospheric releases of 131I, 
as calculated using the CIDER program created by the HEDR Project.  The primary dose-response analyses 
for disease outcomes and ultrasound-detected abnormalities (UDAs) of the thyroid were based on 
regression models in which the probability of having the outcome of interest varies as a linear function of 
estimated thyroid dose, specifically the median dose as mentioned above.  The model for this primary 
analysis permitted the background probability of the outcome to depend on sex, but assumed a common 
regression coefficient (slope) for the dose-response.  The regression coefficient can be interpreted as the 
change in the probability of the disease outcome, per unit change in dose. Since the purpose of the study 
was to determine whether thyroid disease has been increased, significance testing focused on the null 
hypothesis that the probability of having the outcome of interest does not vary with dose (i.e., that the 
regression parameter has value zero) and the one-sided alternative hypothesis that the probability increases 
with increasing dose (i.e., that the regression parameter is greater than zero).  Alternative sex-stratified 
dose-response models were also considered, specifically linear-quadratic and logistic models. 
 
 Identification and analysis of confounding and effect modifying factors was accomplished through 
the analysis of generalizations of the logistic exposure-response models.  For disease outcomes, these 
generalizations allowed the background probabilities of the outcome of interest (i.e., the intercept 
parameters) and/or the regression parameters to vary as functions of a number of factors that might 
potentially confound the relationship between thyroid radiation dose and the outcome of interest.  The 
influence of uncertainty of the dose estimates on the dose-response relationships was examined by 1) fitting 
the linear dose-response model using each of the 100 realizations of dose separately, and 2) using a 
Bayesian approach to calculate deattenuated estimates of the regression slope parameter in the sex-stratified 
logistic model. 
 
It was not assumed that the out-of-area participants were unexposed to 131I from Hanford.  Indeed, 
results of the HTDS Pilot Study suggested that many out-of-area participants lived in locations near the 
HEDR domain at various times during 1945-1957.  Alternative methods of assigning a dose estimate for 
out-of-area participants were developed, and these dose estimates were used to assess the sensitivity of 
dose-response results to assumptions about the doses for out-of-area participants.  
 
The distribution of doses was quite skewed, with large numbers of comparatively low doses and 
small numbers of quite high doses.  Therefore analyses were performed to assess whether the dose-
response results might be inordinately influenced by the high dose participants.  In particular, two empirical 
checks were made to assess whether the estimated regression coefficient adequately represents the dose-
response relationship over the lower dose range.   
 
Information released by the U.S. National Cancer Institute (NCI) shortly before and during 
October 1997, indicated that people living in the contiguous 48 states during the 1950s and 1960s were 
exposed to various levels of 131I released from the Nevada Test Site (NTS).  The material released by NCI 
included estimates of dose for representative individuals in all counties in the 48 states, as well as more 
detailed data regarding estimated dose by individual test detonation, county, and age.  Limited preliminary 
comparisons for HTDS participants suggested that in many cases the reported NTS dose estimates were 
comparable to or even greater than the estimated Hanford doses.  Therefore it was judged necessary to 
evaluate exposure to 131I from the NTS as a potential confounding factor.  For each participant in the 
HTDS, the “estimated NTS dose” was defined specifically as the thyroid dose from 131I entering the 
atmosphere from tests conducted at NTS between 1951 and 1957, inclusive, as estimated from data made 
publicly available by NCI.  A categorical variable representing each living evaluable participant’s relative 
level of exposure to 131I from the NTS was calculated for use in the analyses of potential confounding.   
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V. Summary of Dose-Response Results 
 
The primary evaluation of dose-response relationships focused on twelve categories of thyroid 
disease, hyperparathyroidism, and ultrasound-detected abnormalities of the thyroid. For each of these 14 
outcome categories a primary case definition was specified based on the most definitive diagnostic criteria 
available. Diagnostic information obtained from the HTDS evaluation and diagnostic information which 
was well documented in medical records and met criteria for HTDS diagnoses was considered to be the 
most definitive and of the highest quality. The primary analysis for each outcome was therefore restricted 
to cases defined according to these two sources. The principal dose-response analysis used this primary 
definition of outcome, individual radiation dose estimates (the median of CIDER’s 100 realizations for 
each individual) based on individual residence history, dietary consumption data from the CATI when 
available, and HEDR default values when such data were not available. The results from these analyses 
using the primary outcome definition constitute the principal findings of the HTDS. 
 
Additional criteria were also defined for each outcome category, to identify cases using less 
definitive diagnostic criteria, e.g., information obtained from prior medical records that did not meet HTDS 
criteria, or reports of a diagnosis by a participant or CATI respondent which could not be confirmed by the 
HTDS evaluation or medical records.  Although the principal findings of the HTDS are based on the 
primary outcome definition, dose-response analyses were also conducted for each of these alternative 
definitions with less definitive diagnostic criteria. In addition, dose-response analyses were conducted for 
six outcome categories based on the results of laboratory assays, and for thyroid mass estimated from the 
ultrasound scan. Dose-response analyses for all disease and thyroid UDA outcomes were repeated using 
two alternative sets of individual dose estimates, and two alternative representations of exposure that did 
not use the CIDER program to estimate individual radiation doses. Efforts were also made to evaluate the 
influence of uncertainties in individual dose estimates on the fitted dose-response relationships for the 
primary case definition in each outcome category. 
 
 In overall summary of the dose-response results, there was no evidence of a statistically significant 
association between estimated thyroid radiation dose from Hanford and the cumulative incidence of any of 
the 14 primary outcomes. There was also no evidence of any statistically significant dose-response 
relationship for any of the alternative definitions of outcome. The findings were essentially unchanged for 
analyses based on either of the two alternative sets of individual dose estimates. The results remained the 
same after taking into account several factors that might confound the relationship between radiation dose 
and the outcome of interest. There was no evidence of any statistically significant dose-response for any 
outcome that might be different from the linear model used in the primary analyses (e.g., a linear-quadratic 
or logistic relationship). Incorporation of uncertainty in the dose estimates did not significantly change the 
primary results for any of the outcomes or change the overall conclusions of the study. Summarized below 
are the main findings for each of the primary outcomes investigated.  
Thyroid Cancer  
 
 Twenty (0.6%) of the 3440 living evaluable participants were diagnosed with thyroid cancer; 13 
women (0.7%) and 7 men (0.4%). In all but one case, the diagnosis was based on histologic evidence from 
the HTDS examination (12) or prior histologic evidence (7). Using the primary definition (19 total cases; 
14 in-area) and maximum likelihood analysis of the sex-stratified linear probability model, the cumulative 
incidence of thyroid cancer did not increase significantly with estimated dose (p = 0.25), with an estimated 
slope of 0.002 per Gy, and Bonferroni-adjusted 95% confidence interval (CI) ranging from less than −0.001 
to 0.017 per Gy.  Analyses that considered less definitive criteria to identify cases and alternative dose 
estimates or representations of exposure revealed no statistically significant dose-response relationships. 
Incorporation of uncertainty in the dose estimates did not significantly change the primary results.  
 
Benign Thyroid Nodule 
 
Two hundred and forty-nine (7.2%) of the 3440 living evaluable participants had a diagnosis of 
benign thyroid nodule based on histologic or cytologic evidence arising from the HTDS examination or 
from a prior diagnosis which met HTDS diagnostic criteria; 170 (9.7%) women and 79 (4.7%) men. An 
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additional 38 participants (1.1%) had HTDS or prior diagnoses classified as clinical (i.e., palpable nodule 
with no cytology or histology available), and another 10 (0.3%) had diagnoses based solely on a report by 
the participant or his/her CATI respondent. Using the primary definition (249 total cases; 235 in-area), and 
maximum likelihood analysis of the sex-stratified linear probability model, the cumulative incidence of 
benign thyroid nodule did not increase significantly with estimated dose (p = 0.68), with an estimated slope 
of −0.008 per Gy, and Bonferroni-adjusted 95% CI ranging from less than −0.022 to 0.041 per Gy.  
Analyses that considered less definitive criteria to identify cases, as well as other disease outcomes related 
to benign nodules (e.g., benign nodules and nodules suspicious for follicular neoplasm, benign nodule 
excluding non-neoplastic disease, solitary nodule detected without ultrasound, benign nodule excluding 
colloid-only nodules, and benign colloid nodules), and analyses which considered alternative dose 
estimates or representations of exposure, revealed no statistically significant dose-response relationships. 
Accounting for potential confounding or effect modification, and incorporation of uncertainty in the dose 
estimates, did not significantly change the primary results.  
 
Total Thyroid Neoplasia 
 
 This outcome was defined to include participants with thyroid cancer based on HTDS or prior 
histology, or benign thyroid nodule with a histologic type of follicular adenoma, based on HTDS or prior 
histology. A total of 33 (1.0%) of the 3440 living evaluable participants were included in this category; 20 
(1.1%) women and 13 (0.8%) men.  Using the primary definition (33 total cases; 28 in-area), and maximum 
likelihood analysis of the sex-stratified linear probability model, the cumulative incidence of total thyroid 
neoplasia did not increase significantly with estimated dose (p = 0.42), with an estimated slope of 0.001 per 
Gy, and Bonferroni-adjusted 95% CI ranging from less than −0.003 to 0.022 per Gy. Analyses using 
alternative dose estimates or representations of exposure revealed no statistically significant dose-response 
relationships. Incorporation of uncertainty in the dose estimates did not significantly change the primary 
results. 
 
Any Thyroid Nodule 
 
This outcome was defined by the diagnosis of one or more of the following: benign thyroid 
nodule, thyroid cancer, or nodule suspicious for follicular neoplasm.  A total of 281 (8.2%) of the 3440 
living evaluable participants had this outcome based on histologic or cytologic evidence arising from the 
HTDS examination or from a prior diagnosis; 193 (11.0%) women and 88 (5.2%) men. Another 39 (1.1%) 
were based on HTDS or prior clinical diagnoses (i.e., palpable nodule with no available cytology or 
histology), and 10 living evaluable participants had diagnoses of any thyroid nodule based solely on reports 
from the participant or his/her CATI respondent. 
 
Using the primary definition (281 total cases; 261 in-area), and maximum likelihood analysis of 
the sex-stratified linear probability model, the cumulative incidence of any thyroid nodule did not increase 
significantly with estimated dose (p = 0.65), with an estimated slope of −0.007 per Gy, and  Bonferroni-
adjusted 95% CI ranging from less than −0.023 to 0.043 per Gy.  Analyses that considered less definitive 
criteria to identify cases and alternative dose estimates or representations of exposure revealed no 
statistically significant dose-response relationships. Accounting for potential confounding or effect 
modification, and incorporation of uncertainty in the dose estimates, did not significantly change the 
primary results. 
 
Hypothyroidism 
 
Two hundred and sixty-seven (7.8%) of the 3440 living evaluable participants had a diagnosis of 
hypothyroidism based on the HTDS evaluation or on medical records with supporting documentation; 204 
(11.7%) women and 63 (3.7%) men.  An additional 105 (3.1%) living evaluable participants had a 
diagnosis of hypothyroidism based on medical records but without supporting documentation, and 30 
(0.9%) were inferred from past or current thyroxine therapy. This latter group consisted of participants who 
were taking thyroid hormone replacement, but in whom no medical records were available to confirm the 
original diagnosis of hypothyroidism.  There were also 193 (5.6%) cases based solely on reports of 
hypothyroidism from the participant or his/her CATI respondent.  
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Using the primary definition (267 total cases; 246 in-area), and maximum likelihood analysis of 
the sex-stratified linear probability model, the cumulative incidence of hypothyroidism did not increase 
significantly with estimated dose (p = 0.61), with an estimated slope of –0.006 per Gy, and  Bonferroni-
adjusted 95% CI ranging from less than −0.016 to 0.047 per Gy. Analyses which considered less definitive 
criteria to identify cases, as well as permanent hypothyroidism, and analyses which considered alternative 
dose estimates or representations of exposure, revealed no statistically significant dose-response 
relationships, although the estimated regression coefficients from logistic regression analyses using less 
definitive criteria to identify cases were somewhat larger. Accounting for potential confounding or effect 
modification, and incorporation of uncertainty in the dose estimates, did not significantly change the 
primary results. 
 
Autoimmune (Hashimoto's) Thyroiditis 
 
 A total of 625 (18.2%) of the 3440 living evaluable participants had a diagnosis of autoimmune 
thyroiditis based on the HTDS evaluation or medical records with supporting documentation; 403 (23.1%) 
women and 222 (13.1%) men. Another three cases were based on medical records without supporting 
documentation, and one case was based solely on a report by the participant or his/her CATI respondent.  
 
Using the primary definition (625 total cases; 582 in-area), and maximum likelihood analysis of 
the sex-stratified linear probability model, the cumulative incidence of autoimmune thyroiditis did not 
increase significantly with estimated dose (p = 0.82), with an estimated slope of −0.026 per Gy, and 
Bonferroni-adjusted 95% CI ranging from less than −0.057 to 0.044 per Gy.  Analyses which considered 
less definitive criteria to identify cases, additional outcomes related to the assay for antithyroid immune 
response, and autoimmune thyroiditis in combination with non-iatrogenic, permanent hypothyroidism, as 
well as analyses which considered alternative dose estimates or representations of exposure, revealed no 
statistically significant dose-response relationships. Accounting for potential confounding or effect 
modification, and incorporation of uncertainty in the dose estimates, did not significantly change the 
primary results. 
 
Graves Disease 
 
A total of thirty-four (1.0%) of the 3440 living evaluable participants had a diagnosis of Graves 
Disease based on the HTDS evaluation or on medical records with supporting documentation; 28 (1.6%) 
women and 6 (0.4%) men.  Three (0.1%) living evaluable participants had a diagnosis of Graves Disease 
based on medical records without supporting documentation, and an additional thirteen (0.4%) were based 
solely on a report from the participant or his/her CATI respondent.   
 
Using the primary definition (34 total cases; 32 in-area), and maximum likelihood analysis of the 
sex-stratified linear probability model, the cumulative incidence of Graves Disease did not increase 
significantly with estimated dose (p = 0.56), with an estimated slope of −0.001 per Gy, and Bonferroni-
adjusted 95% CI ranging from less than −0.002 to 0.024 per Gy.  Analyses that considered less definitive 
criteria to identify cases and alternative dose estimates or representations of exposure revealed no 
statistically significant dose-response relationships. Accounting for potential confounding or effect 
modification, and incorporation of uncertainty in the dose estimates, did not significantly change the 
primary results. 
 
Autoimmune Thyroid Disease 
 
Autoimmune thyroid disease was defined by a diagnosis of autoimmune (Hashimoto’s) thyroiditis 
or Graves disease based on the HTDS evaluation or medical records with supporting documentation.  A 
total of 659 (19.2%) of the 3440 living evaluable participants were included in this category; 431 (24.7%) 
women and 228 (13.5%) men. These included 625 with autoimmune (Hashimoto’s) thyroiditis and 34 
others with diagnoses of Graves disease.  An additional 4 (0.1%) living evaluable participants had a 
diagnosis of autoimmune thyroid disease based on medical records without supporting documentation 
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(three with autoimmune thyroiditis, one with Graves disease).  Eleven others (0.3%) were based solely on a 
report by the participant or his/her CATI respondent (one with autoimmune thyroiditis, 10 with Graves 
disease). 
 
Using the primary definition (659 total cases; 614 in-area), and maximum likelihood analysis of 
the sex-stratified linear probability model, the cumulative incidence of autoimmune thyroid disease did not 
increase significantly with estimated dose (p = 0.80), with an estimated slope of −0.024, and Bonferroni-
adjusted 95% CI ranging from less than −0.058 to 0.048 per Gy.  Analyses that considered less definitive 
criteria to identify cases and alternative dose estimates or representations of exposure revealed no 
statistically significant dose-response relationships. Accounting for potential confounding or effect 
modification, and incorporation of uncertainty in the dose estimates, did not significantly change the 
primary results. 
 
Hyperthyroidism 
 
A total of 161 (4.7%) of the 3440 living evaluable participants were diagnosed with 
hyperthyroidism based on the HTDS evaluation or medical records with supporting documentation; 134 
(7.7%) women and 27 (1.6%) men.  An additional 14 (0.4%) living evaluable participants had a diagnosis 
of hyperthyroidism based on medical records without supporting documentation, and 21 (0.6%) were based 
solely on a report from the participant or his/her CATI respondent.  It is important to note that these 196 
cases included a substantial number of iatrogenic cases caused by excess thyroid hormone replacement.  
Since endogenous hyperthyroidism (hyperthyroidism not caused by thyroid hormone over-replacement) 
was of particular importance, analyses that focused on cases of non-iatrogenic hyperthyroidism were 
emphasized in this study. 
 
 Using the primary definition (161 total cases; 155 in-area), and maximum likelihood analysis of 
the sex-stratified linear probability model, the cumulative incidence of hyperthyroidism did not increase 
significantly with estimated dose (p = 0.22), with an estimated slope of 0.011 per Gy, and Bonferroni-
adjusted 95% CI ranging from less than −0.008 to 0.052 per Gy.  Analyses that considered less definitive 
criteria to identify cases, as well as non-iatrogenic hyperthyroidism, and analyses which considered 
alternative dose estimates or representations of exposure, revealed no statistically significant dose-response 
relationships. Accounting for potential confounding or effect modification, and incorporation of uncertainty 
in the dose estimates, did not significantly change the primary results. 
 
Multinodular Thyroid Gland  
 
A total of 95 (2.8%) of the 3440 living evaluable participants had a diagnosis of multinodular 
thyroid gland based on the HTDS evaluation; 73 (4.2 %) women and 22 (1.3 %) men.  An additional 
nineteen (0.6%) living evaluable participants had a diagnosis of multinodular thyroid gland based on 
medical records, and one diagnosis was based solely on a report from the participant or his/her CATI 
respondent.  
 
Using the primary definition (95 total cases; 85 in-area), and maximum likelihood analysis of the 
sex-stratified linear probability model, the cumulative incidence of multinodular thyroid gland did not 
increase significantly with estimated dose (p = 0.88), with an estimated slope of −0.006 per Gy. The lower 
limit of the Bonferroni-adjusted 95% confidence interval was not estimated, but the upper limit was 0.014 
per Gy. Analyses that considered less definitive criteria to identify cases and alternative dose estimates or 
representations of exposure revealed no statistically significant dose-response relationships. Accounting for 
potential confounding or effect modification, and incorporation of uncertainty in the dose estimates, did not 
significantly change the primary results. 
 
Simple Goiter 
 
The diagnosis of simple goiter was uncommon, with only 14 (0.4%) of the 3440 living evaluable 
participants having this diagnosis based on HTDS evaluation; 9 (0.5%) women and 5 (0.3%) men. Another 
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28 (0.8%) had diagnoses based on medical records, and for an additional 28 (0.8%) the diagnosis was based 
solely on a report by the participant or his/her CATI respondent.  
 
Using the primary definition (14 total cases; all in-area), and maximum likelihood analysis of the 
sex-stratified linear probability model, the cumulative incidence of simple goiter did not increase 
significantly with estimated dose (p = 0.74), with an estimated slope of −0.001 per Gy. The lower limit of 
the Bonferroni-adjusted 95% confidence interval was not estimated, but the upper limit was 0.012 per Gy. 
Analyses that considered less definitive criteria to identify cases and alternative dose estimates or 
representations of exposure revealed no statistically significant dose-response relationships. Incorporation 
of uncertainty in the dose estimates did not significantly change the primary results. 
 
Other Thyroid Disease 
 
Four living evaluable participants, all in the in-area group, had diagnoses of other thyroid disease 
based on their HTDS examinations or medical records with supporting documentation.  These included two 
cases of subacute thyroiditis, one case of familial thyroglobulin binding deficiency, and one case of 
secondary hypothyroidism. The first alternative definition added only two cases of subacute thyroiditis with 
diagnoses based on medical records without supporting documentation. For both the primary and first 
alternative definition of other thyroid disease, there were too few cases for meaningful estimation of the 
radiation dose-response. 
 
The second alternative definition added 20 participants, primarily with participant or CATI 
respondent reports of past thyroid disease of unknown type.  This brought the total number of cases to 26, 
of whom four were out-of-area participants.  Based on maximum likelihood analysis of the sex-stratified 
linear probability model using this case definition, the estimated slope was slightly greater than zero (0.002 
per Gy), with Bonferroni-adjusted 95% confidence interval ranging from less than –0.002 to 0.024 per Gy, 
providing no evidence that the cumulative incidence increased significantly with increasing dose (one-
tailed p = 0.39).  Because the number of cases in this category was small, and the diagnoses were 
heterogeneous and mostly unknown, further analyses of this outcome were not performed. 
 
Hyperparathyroidism 
 
A total of 12 (0.3%) living evaluable participants had a diagnosis of hyperparathyroidism based on 
the HTDS evaluation or on medical records with supporting documentation; 10 (0.6 %) women and 2 
(0.1%) men. Another two diagnoses were based on a report from the participant or his/her CATI 
respondent. One additional living evaluable participant who did not meet the study’s criteria for 
hyperparathyroidism nevertheless had an elevated calcium level in the presence of a high normal PTH 
level, when the PTH should have been suppressed, highly suggestive of hyperparathyroidism.  This 
participant was included as a case in an additional analysis. 
 
Using the primary definition (12 total cases; 11 in-area), the cumulative incidence of 
hyperparathyroidism did not increase significantly with estimated dose (p = 0.61), with an estimated slope 
of –0.0001 per Gy.  The lower limit of the Bonferroni-adjusted 95% confidence interval was not estimated, 
but the upper limit was 0.013 per Gy.  Analyses that considered less definitive criteria to identify cases and 
alternative dose estimates or representations of exposure revealed no statistically significant dose-response 
relationships. Incorporation of uncertainty in the dose estimates did not significantly change the primary 
results. 
  
Ultrasound-Detected Abnormalities of the Thyroid (Thyroid UDAs) 
 
The thyroid gland was visible in the ultrasound examinations of 3429 of the 3440 living evaluable 
participants.  For 11 participants the thyroid was not visible, 10 because of thyroid surgery and one because 
the sonographer couldn’t adequately visualize the thyroid.   Among the 3429 whose thyroids were visible, 
1596 (46.5%) had one or more thyroid UDAs; 964 (55.5 %) women and 632 (37.4 %) men. Ultrasound 
findings were categorized as palpable thyroid UDAs (224 or 6.5%), nonpalpable focal thyroid UDAs (1309 
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or 38.2%), and diffuse thyroid UDAs (458 or 13.4%).  All three types of UDA were more frequent among 
women than men.  Ultrasound-detected thyroid abnormalities were based only on the HTDS evaluation, not 
on any prior ultrasound scans.   
 
Based on maximum likelihood analysis of the sex-stratified linear probability model, the 
prevalence of any UDA (1596 total cases; 1481 in-area) did not increase significantly with estimated dose 
(p = 0.21), with an estimated slope of 0.031 per Gy, and Bonferroni-adjusted 95% CI ranging from −0.059 
to 0.116 per Gy. Similarly, the prevalence of palpable UDA (224 total cases; 204 in-area) did not increase 
significantly with estimated dose (p = 0.95), with an estimated slope of −0.018 per Gy.  The Bonferroni-
adjusted lower 95% confidence limit was not estimated due to the magnitude of the negative slope estimate, 
however the upper confidence limit was 0.015 per Gy. The prevalence of nonpalpable focal UDA (1309 
total cases; 1217 in-area) also did not increase significantly with estimated dose (p = 0.23), with an 
estimated slope of 0.027 per Gy and Bonferroni-adjusted 95% CI ranging from −0.061 to 0.115 per Gy. 
Analyses of all three types of ultrasound abnormalities in relation to alternative dose estimates or 
representations of exposure revealed no statistically significant dose-response relationships. Accounting for 
potential confounding or effect modification, and incorporation of uncertainty in the dose estimates, did not 
significantly change the primary results. 
 
Additional analyses were performed to assess whether ultrasound abnormalities might be 
precursors to radiation-induced clinical disease.  These analyses evaluated whether increasing dose was 
associated with increasing prevalence of large thyroid UDAs, increasing number of thyroid UDAs, or the 
presence of diffuse thyroid UDAs. To assess whether the dose-response results might be affected by the 
size of focal thyroid UDAs, three additional outcomes were analyzed.  These included the presence of a 
focal UDA with maximum dimension at least 5 mm, the presence of a focal UDA with maximum 
dimension at least 10 mm, and the presence of a focal UDA with average dimension at least 15 mm.  These 
additional analyses applied only to palpable and nonpalpable focal thyroid UDAs, since diffuse UDAs were 
not defined by any size criterion.  In none of these additional analyses was there any evidence that the risk 
of having a focal UDA of a particular size increased with increasing dose (p=0.64, 0.88 and 0.53 for the 
presence of focal UDA with maximum dimension of 5 mm, maximum dimension of 10 mm and average 
dimension of 15 mm, respectively). 
 
To assess whether the number of thyroid UDAs detected in individual participants might increase 
in relation to estimated thyroid radiation dose, the numbers of focal thyroid UDAs with maximum 
dimension ≥ 5 mm, maximum dimension ≥ 10 mm, and average dimension ≥ 15 mm were counted for each 
living evaluable participant with an HTDS ultrasound examination. No statistically significant dose-
response was found between estimated thyroid radiation dose and the average number of focal thyroid 
UDAs (p = 0.80, 0.48 and 0.43 for the number of thyroid UDAs meeting the three size criteria, 
respectively). 
 
The prevalence of diffuse thyroid UDA (458 total cases; 428 in-area) did not increase significantly 
with estimated dose (p = 0.14), with an estimated slope of 0.029 per Gy, and Bonferroni-adjusted 95% CI 
ranging from −0.029 to 0.100 per Gy.  Analyses that considered alternative dose estimates or 
representations of exposure revealed no statistically significant dose-response relationships. Accounting for 
potential confounding or effect modification, and incorporation of uncertainty in the dose estimates, did not 
significantly change the primary results. 
 
Laboratory Tests and Thyroid Mass 
 
Of the 3191 living evaluable in-area participants, 3183 (99.7%) provided a blood specimen at the 
HTDS clinic. Several laboratory assays were conducted to evaluate thyroid function, anti-thyroid antibody 
response, and serum calcium level. In addition to the dose-response analyses conducted of specific thyroid 
disease outcomes, which incorporated information from these tests in the determination of the diagnosis, 
dose-response analyses were also conducted to investigate whether there were associations between the 
laboratory values from these tests and estimated thyroid radiation dose from Hanford (i.e., regardless of 
thyroid disease diagnosis). 
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 Thyroid stimulating hormone (TSH) levels were measured for all participants who provided a 
blood specimen. Of the 3183 living evaluable in-area participants who provided blood samples, 222 were 
receiving exogenous thyroid hormone at the time of their HTDS clinic and were excluded from the 
analyses of TSH.  Among the remaining 2961 living evaluable in-area participants, three different TSH 
assays were used during the study.  There was no statistically significant trend of average TSH level in 
relation to estimated radiation dose for any of the three assays considered either separately or in a combined 
analysis. Free thyroxine index (FTI) was analyzed, also excluding the 222 participants who were receiving 
exogenous thyroid hormone at the time of their HTDS clinic. There was no significant trend of FTI in 
relation to estimated radiation dose (two tailed p = 0.23).  Three different tests for antithyroid antibody 
response (anti-TPO, AMA, and anti-TG) were used over the course of the study. There was no significant 
trend of any assay result in relation to estimated radiation dose (p = 0.66 for anti-TPO, 0.52 for AMA, and  
0.20 for anti-TG). 
 
 Serum calcium levels were measured in an effort to identify participants with hypercalcemia that 
might be secondary to hyperparathyroidism. Of the 3183 living evaluable in-area participants who provided 
blood samples, 227 with diagnoses of hypothyroidism or hyperthyroidism based on the HTDS examination 
were excluded from the primary analysis of serum calcium levels.  Two additional participants did not have 
serum calcium data due to insufficient volumes of collected blood. There was a statistically significant 
trend of decreasing serum calcium level in relation to increasing radiation dose (p = 0.0074), with an 
estimated slope of −0.09 per Gy, and Bonferroni-adjusted 95% CI ranging from −0.16 to −0.01 per Gy. 
Although there is no readily apparent explanation for this result, this finding deserves further comment. 
First, the outcome for which calcium was being measured, hyperparathyroidism, was not found to be 
associated with radiation dose. Second, the dose effect occurred within the normal range of calcium values. 
For both women and men, the estimated background means were about 9.2 ± .01, consistent with the 
normal range of the test (8.4 to 10.2). Only 0.9% of the cohort had low calcium levels less than 8.4 
(hypocalcemia).  There was no statistically significant relationship between hypocalcemia and radiation 
dose.  Third, even at a dose of 3000 mGy to the thyroid, which is larger than the maximum estimated dose 
for any study participant, the mean serum calcium levels predicted by the regression model were well 
within the normal range. Therefore, despite the statistically significant decrease in calcium levels with 
increasing dose, the resulting effect or clinical impact does not appear to be clinically significant. 
 
Estimates of thyroid mass were available for 3400 living evaluable participants for whom both 
lobes of the thyroid were visible on ultrasound; 3153 were in-area participants. There was no statistically 
significant trend of thyroid mass in relation to estimated radiation dose (p = 0.98). 
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VI. Summary Comments and Conclusions 
 
The HTDS was conducted to determine whether exposure to atmospheric releases of radioactive 
iodine, in particular 131I, from the Hanford Nuclear Site between 1944 and 1957 resulted in increased 
thyroid disease among those exposed.  The study evaluated twelve categories of thyroid disease, 
hyperparathyroidism, ultrasound-detected abnormalities of the thyroid, the results of several laboratory 
tests for thyroid function, anti-thyroid antibody and serum calcium level, and thyroid mass. The primary 
analysis (based on HTDS diagnostic criteria of the highest level of certainty) utilized an estimate of thyroid 
radiation dose for each individual based on information about their residence history and dietary 
consumption patterns during the times of the Hanford releases. Additional analyses were conducted using 
several alternative methods for estimating dose, both quantitative and qualitative, including methods that 
were independent of the HEDR models. The primary analyses were based on a linear dose-response model, 
adjusting for the effects of differences in response by sex, although alternative models for the shape of the 
dose-response were also investigated. The potential confounding or dose-response modifying effects of a 
number of lifestyle factors and indicators of other radiation exposure were evaluated. All primary dose-
response analyses were repeated to include adjustments for uncertainty in the individual radiation dose 
estimates.  
 
 This study found no statistically significant association between dose to the thyroid from Hanford 
radiation and 1) cumulative incidence of any of the disease outcomes; 2) prevalence of ultrasound-detected 
thyroid abnormalities; or 3) thyroid laboratory tests or thyroid mass. There was also no statistically 
significant dose-response for hyperparathyroidism, although increasing thyroid dose was significantly 
associated with a decrease in average serum calcium level. Although the explanation for this result is not 
clearly apparent, the finding does not appear to be of clinical significance. These results remained the same 
when alternative methods of assessing radiation dose were used, and after accounting for uncertainty in 
dose estimation. Based on data available regarding the tracing and enrollment of study participants, there is 
no evidence that the absence of a dose-response relationship is due to bias in selection of the cohort, loss to 
follow-up, or enrollment and participation.  
 
 Although no statistically significant dose-response was found for any of the disease outcomes in 
this study, many study participants had thyroid disease.  A considerable effort was made to assess the world 
literature on the prevalence of the major thyroid and parathyroid disease outcomes evaluated in the HTDS. 
Studies selected for review were those conducted in other locations and most comparable to the HTDS for 
the outcomes of thyroid nodules, thyroid cancer, hypothyroidism, autoimmune thyroiditis, 
hyperparathyroidism, and thyroid UDAs. This was done in order to compare the disease experience of the 
HTDS cohort to what might reasonably be expected based on the experience in other populations not 
exposed to Hanford radiation. As discussed in the Section X.E of the Report, comparisons of this type are 
imperfect and must be interpreted with great caution. Differences in prevalence estimates between the 
HTDS cohort and other populations may well reflect differences in any of a number of factors other than 
exposure to radiation from Hanford. Nevertheless, from review of these studies, it appears that estimates of 
cumulative incidence derived from the HTDS are well within the range and are consistent with published 
estimates. There is no indication that the levels of thyroid or parathyroid disease occurrence in the HTDS 
cohort are systematically different, or higher, than what has been reported around the world in a variety of 
different circumstances.  
 
 Given the differences between the radiation exposure circumstances at Hanford and those of other 
populations in which radiation-related risks of thyroid disease have been studied, the findings of this study 
are not inconsistent with the current published literature regarding the effect of exposure to 131I and the risk 
of thyroid and parathyroid disease. This is particularly so given the relatively small magnitude of the 
estimated thyroid radiation doses in HTDS study participants (mean = 174 mGy) and the relatively 
protracted nature of the exposure over time. There is little evidence in the literature to suggest that people 
exposed to 131I at the levels found in this study over a period of months or years would experience higher 
rates of thyroid or parathyroid disease as a result of their exposure.  
 
 Nevertheless, a lingering question for many may be whether the uncertain nature of the dose 
estimation used in the primary analyses is so great that it renders the quantitative dose-response results 
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inconclusive. The study has attempted to address this possibility in three ways. First, alternative qualitative 
methods of assigning exposure were used. Results from these analyses were consistent with those from the 
quantitative dose-response analyses. Second, two different approaches were employed to evaluate the 
impact of dose uncertainty on the primary risk estimates. Neither resulted in findings that were significantly 
different from those ignoring such uncertainty. Third, the impact of dose uncertainty on study power was 
assessed using simulation methods. These analyses revealed that the reduction in statistical power due to 
uncertainty in dose estimation was modest, and that even after accounting for such uncertainty the study 
had adequate statistical power to detect effects as small or smaller than those in the existing published 
literature. Although any epidemiologic study is limited to some extent by uncertainty in the assessment of 
exposure, the impact of such uncertainty on the power of the study and the estimation of risk is seldom 
addressed to the extent attempted here. Further, the fact that epidemiologic investigations are inherently 
“uncertain” does not imply complete randomness or unpredictability, nor does it mean that reasonable 
conclusions cannot be drawn from such studies.  
 
In conclusion, the results of the HTDS provide no evidence of a statistically significant association 
between increasing thyroid radiation dose from Hanford and the cumulative incidence of any of the primary 
outcomes studied. These findings do not definitively rule out the possibility that Hanford radiation 
exposures are associated with an increase in one or more of the outcomes under investigation. However, it 
does mean that if such associations exist, they were likely too small to detect using the best epidemiologic 
methods available.  
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I. INTRODUCTION
The Hanford Thyroid Disease Study  (HTDS) was conducted by a team of investigators at the
Fred Hutchinson Cancer Research Center (FHCRC) under contract to the Centers for Disease Control and
Prevention (CDC) Radiation Studies Branch.  The Study Management Team (SMT) which had primary
responsibility for the design and conduct of the investigation, consisted of Scott Davis, Ph.D.
(epidemiology), Kenneth Kopecky, Ph.D. (biostatistics), and Thomas Hamilton, M.D., Ph.D.
(endocrinology).  Bruce Amundson, M.D. (family medicine) was a member of the SMT through August
1998.  Ms. Peggy Adams Myers served as Project Manager through the release of the Draft Final Report.
Ms. Beth King assumed responsibility for project management thereafter.  In addition to the FHCRC team,
the study employed Dr. Robert Griep as an expert consultant on thyroid disease.  Dr. Bruce Kulander
served as the pathologist who reviewed all pathological specimens.  Four radiologists at Seattle Nuclear
Medicine/Ultrasound Associates interpreted the thyroid ultrasound scans.  Administrative, statistical, and
technical staff reported directly to the Project Manager and the SMT.  The clinical component of the HTDS
was directed by Dr. Hamilton, with the assistance of the HTDS study physicians in conducting thyroid
examinations.  Study operations were based at the FHCRC in Seattle, with a field office in the Tri-Cities
for the Subject Tracing component.
The CDC was kept informed on a monthly basis of progress in the design and conduct of the
study, and provided technical support as needed by the FHCRC.  Mr. Michael Sage and Mr. Michael
Donnelly served as the Project Officers.  Dr. Paul Garbe was the primary scientific liaison.  In addition, an
Advisory Committee was appointed for this study by the Secretary of the Department of Health and
Human Services to provide advice and consultation to the CDC and the SMT.
The technical approach to this research project was divided into three phases.  The first phase
involved the development of the study protocol and preparation for the Pilot Study.  These preparations
included the appointment and convening of the Advisory Committee and approval of the protocol by the
federal Office of Management and Budget (OMB) and the Institutional Review Board (IRB) of the
FHCRC.  This phase began upon award of the contract in September 1989, and was concluded in late
1992.  The other two phases of the study, the Pilot Study and the Full Study, are discussed further below. 
 
The study was conducted as a follow-up prevalence study.  That is, potential participants were
selected on the basis of presumed past level of exposure to radioactive iodine from Hanford, based on place
and year of birth.  Participants were located and evaluated for the presence or history of thyroid disease.
Information was also collected regarding each participant’s residence and dietary history in order to
estimate his or her thyroid radiation dose from Hanford.  The primary analyses focused on living
participants who received medical examinations to detect thyroid disease, and for whom individual thyroid
radiation doses could be estimated using the dosimetry system developed by the Hanford Environmental
Dose Reconstruction (HEDR) Project and the information collected by the HTDS.  Although the effects of
primary interest are defined by three categories of thyroid disease (hypothyroidism, benign thyroid
nodules, and thyroid cancer), information regarding all forms of thyroid disease were recorded as part of
the study and are included in the overall analysis.  In addition, hyperparathyroidism was evaluated by
screening individuals for hypercalcemia.  Since the aim of the study was to investigate whether risks of the
thyroid diseases were increased by exposure to Hanford’s 131I, the analysis examined whether the
cumulative incidence of these diseases increased with increasing dose to the thyroid.
 The methods of the study can be summarized as follows.  Potential study participants were
selected from birth records to form a cohort for follow-upPeople likely to have lived in a seven-county
geographic area surrounding the Hanford Site were selected to ensure as much as possible that the cohort
contained people with a wide range of radiation doses to the thyroid (e.g., from the highest doses to very
low doses).  Attempts were made to trace and locate each individual in the cohort.  Once located, each
person was invited to a medical clinic for a thorough diagnostic evaluation for thyroid disease.  At the
clinic, each study participant: 1) underwent a personal interview regarding details of his/her residential,
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medical, and personal histories; 2) provided a blood sample for thyroid function tests, antibody markers for
autoimmune thyroiditis, and serum calcium determination; 3) received a thyroid ultrasound examination;
and 4) received a physical examination of the thyroid by two physicians independently of one another.  For
those found to have palpable thyroid nodules or nonpalpable ultrasound detected thyroid nodules ≥ 1.5 cm
(average of three dimensions), permission was sought to conduct a fine needle aspiration to provide more
complete diagnostic information.  To verify reports of thyroid diseases that occurred in the past, medical
records and pathology specimens were sought and reviewed in a uniform manner.
Prior to the participant’s clinic visit, an attempt was made to interview the mother, or other close
relative knowledgeable about aspects of the participant’s childhood that influenced the radiation dose he or
she received from Hanford.  The information collected in this interview was used to estimate radiation dose
to the thyroid using algorithms developed by Battelle Pacific Northwest Laboratory as part of the Hanford
Environmental Dose Reconstruction (HEDR) Project.  Detailed descriptions of each component of the
study fieldwork are found in section V of this report.
Following the development and approval of the study protocol, the research was conducted in two
subsequent phases. The first was a Pilot Study.  The primary purpose of this phase was to evaluate the
feasibility of the methods proposed and to develop the specific operational procedures and data collection
instruments needed for a Full Study. Once the results of the Pilot Study indicated that it was feasible to
conduct a successful full-scale epidemiologic study, the second stage was implemented to complete the
remaining fieldwork for the Full Study. This approach allowed the accumulation of information and
experience prior to initiation of the more costly full-scale study. This also allowed for the possibility that
the design and procedures for the Full Study could be modified if necessary to account for the realities of
the field environment. 
Eleven Pilot Study objectives were specified in the original HTDS protocol (1). These objectives
dealt with both logistical and statistical issues.  Logistical issues to be evaluated included: 1) the efficacy
and success rates of the fieldwork procedures, including the use of birth certificates to identify potential
study participants; 2) the ability to trace and locate persons identified; 3) the ability to collect information
for use in estimating thyroid radiation dose; 4) the success in bringing participants to clinics for thyroid
examinations and 5) the costs of these activities.  Statistical issues to be evaluated included: 1) estimating
the distributions of radiation dose to the thyroid among groups of individuals defined by place of birth; 2)
evaluating the suitability of the areas from which participants were selected to ensure a cohort of
individuals with a full range of doses; and 3) calculation of the statistical power that could be reasonably
achieved in a Full Study and the sample size required to do so.  A detailed report of the results of the Pilot
Study was submitted to the CDC on January 24, 1995.  A summary of the findings of that report is
included here as Appendix 1 (Executive Summary of the Pilot Study Report).
It should be emphasized that in testing the feasibility of the study design, it was important to
evaluate procedures and instruments for participants who were likely to have received high doses from
Hanford radiation releases, as well as for those who were not likely to have received such doses.  There
was concern that the degree to which individuals could be identified, traced, located, and recruited into the
study might be influenced to a large extent by their physical proximity to the Hanford Site and their
perception of any direct threat to their own health from Hanford.  Thus, a very important aspect of the Pilot
Study was to evaluate the success of including people who lived in varying proximity to the Hanford Site.
It is also important to emphasize that the Pilot Study was not designed to assess health outcomes
in relation to radiation dose.  Instead, the Pilot Study was designed to: 1) test the feasibility of the proposed
field logistics; 2) estimate the radiation doses likely to have been received among study participants and,
therefore, to determine the distribution of doses according to factors such as geographical area (e.g., urban
vs. rural), age, and sex; and 3) derive the information necessary to adequately plan a Full Study that would
be capable of determining whether radiation releases from Hanford resulted in an increased risk of thyroid
disease or hyperparathyroidism. The number of participants included in the Pilot Study was too small and
the individual radiation dose estimates available from the HEDR Project were too preliminary to enable
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any formal evaluation of adverse health effects in the pilot phase of the HTDS.  Thus, no estimates of
thyroid disease or hyperparathyroidism risk associated with exposure to radioactive iodine were reported at
the conclusion of the Pilot Study.  However, all data obtained from individuals who participated in the
Pilot Study were included in the Full Study. 
The Pilot Study was completed in late 1994.  To maintain study operations in anticipation of
conducting the Full Study, it was necessary to define a “transition phase” between the Pilot Study and Full
Study.  In the fall of 1993 the Federal Advisory Committee and the CDC gave approval to select an
additional sample of 1000 potential participants to serve as a Transition Sample.  Based on the information
available at that time from the Pilot Study, it was decided that the Full Study would likely be implemented.
Thus, the Transition Sample was selected to enable field operations to continue while the Pilot Study was
completed and its results evaluated.  This approach also shortened the time to complete the Full Study. 
A report of the results of the Pilot Study was prepared and submitted to the CDC and the Advisory
Committee in January 1995. Each of the objectives outlined for the Pilot Study in the study protocol was
evaluated.  The report’s major conclusions were that:
1. The thyroid dose distributions obtained in the Pilot Study, which were the basis for the sample size
and power calculations, were reasonably representative of what the overall dose distribution would be
at the completion of the Full Study.
 
2. To achieve sufficient statistical power to detect an increase of 5% in thyroid neoplasia per Gray, it
would be necessary to enroll a minimum of approximately 3200 living evaluable participants.
 
3. The basic design and data collection methods would remain the same.
 
4. Estimation of doses study participants would be conducted by HTDS staff by remote access to the
HEDR computer programs at the CDC in Atlanta.
5. All births from the following years to mothers living in the indicated counties should be added to the
cohort:
a) 1942-1944:  Remaining Richland, Pasco/Kennewick and Benton County 
b) 1940-1941:  All of Benton and Franklin Counties
c) 1940-1944:  All of Adams County
The primary criterion for continuing with the Full Study was the ability to identify and recruit
adequate numbers of people with a sufficient range of radiation doses. Specifically, the aim was to design
the Full Study to have statistical power of at least 90% to detect a linear dose-response for the probability
of having thyroid neoplasia (malignant or benign) with a slope of 0.0001 per rad (10% per Gy).  If the
results of the Pilot Study had indicated that it would not be possible to obtain at least 80% power to detect
an effect of this magnitude, then consideration would have been given to terminating the study.  However,
the results of the Pilot Study (2) revealed that, not only did the procedures and plans work well for all
aspects of the study, a conservative projection of statistical power of 80% to detect an increased risk of
thyroid neoplasia of 5.0% per Gray was possible with some revisions to geographic areas and years of birth
sampled.  Section V.A. of this report discusses in detail the sampling utilized in the Full Study to achieve
this level of power.  
Thus, in February 1995, the Advisory Committee recommended to the CDC that the Full Study be
done.  The data collection phase of the Full Study was completed in late 1997, and was followed by a
period of data analysis and the reporting of results.  The purpose of this report is to document in detail the
conduct of each phase of the HTDS, and the results of the analyses that were done. 
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II. BACKGROUND
A. Historical Perspective
The Hanford Nuclear Site occupies an area of approximately 560 square miles in southeastern
Washington adjacent to the towns of Pasco, Kennewick, and Richland (Figure II.A-1).  The facility was
established in 1943 as part of the Manhattan Project to produce plutonium-239 for the development of the
first nuclear weapons.  The initial Hanford production reactor (B) became operational in September of
1944, and was followed by a second (D) in December.  Two chemical separations plants, which constituted
the second phase of plutonium production, began to operate in 1944 and 1945.  By 1957 there were six
additional production reactors and two fuel reprocessing plants on the Site.
Figure II.A-1 HEDR Study Area
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The creation of the Hanford Nuclear Site caused the regional population in the Columbia Basin to
expand rapidly.  Although the original construction force was large (approximately 50,000 persons), most
had left the area by the end of 1945.  However, major Hanford expansions in the late 1940s resulted in
substantial population growth in the Tri-Cities area of Richland, Pasco, and Kennewick.  Between 1945
and 1960, the population increased from approximately 40,000 to over 100,000 (3).  In addition, Army
anti-aircraft units numbering about 5000 troops per year served at Hanford beginning in 1950.  Army
personnel and construction workers and their families lived in a trailer-barracks enclave about five miles
north of Richland.  The counties surrounding the Hanford site, traditionally ranching and agricultural areas,
continued to be populated by small, family farms.  With the establishment of the Columbia Basin Irrigation
Project and subsequent agricultural development, large numbers of new families moved into the region in
the late 1950s.
In February 1986, largely as the result of repeated public requests from the Hanford Education
Action League (Spokane, Washington) and the Environmental Policy Institute (Washington, D.C.), as well
as requests from the Centers for Disease Control and Prevention and the State of Washington, the
Department of Energy made available over 19,000 pages of documents (many of which were previously
classified) describing radiation releases and environmental monitoring during the early years of plutonium
production at Hanford.  Based on information found in these documents and a subsequent Freedom of
Information Act (FOIA) request, an additional 20,000 pages were made public in April 1987.
Approximately 25,000 more pages have been released since late 1987.
Data contained in this material indicate that during the initial years of plutonium production at
Hanford substantial quantities of radionuclides were released into the atmosphere, particularly during the
first few years of production.  In attempting to produce plutonium rapidly in 1944 and 1945, irradiated
uranium was allowed to decay approximately 45 days before being treated for reprocessing.  As a result,
the subsequent chemical treatment of the irradiated uranium produced large atmospheric releases of
gaseous radionuclides.  A primary component of these releases was a radioactive isotope of iodine, iodine-
131 (131I).
Although it was uncertain exactly how much material was released from the Hanford site, it was
apparent that hundreds of thousands of Curies (Ci) of 131I were released into the atmosphere around
Hanford between 1944 and 1956.  Table II.A-1 displays two sets of estimates of annual emissions of 131I
from the fuels separation processing activities between 1944 and 1957. The largest releases occurred from
1944 through 1947, and in 1949 and 1951.  Radiation monitoring data recently made available indicate that
these atmospheric releases of 131I were carried by prevailing winds and deposited in areas surrounding the
Site.  During the period of largest releases, Hanford scientists gradually discovered that 131I deposited
readily on sagebrush and sand (4).  When the soil was disturbed by wind, construction, or agriculture, this
material was subsequently re-circulated and re-deposited.  Thus, attempts were made to establish tolerable
limits for 131I on vegetation (5) and to monitor 131I levels in range animals (cattle and sheep) and
jackrabbits (6).  Results of such studies indicate that animals were heavily exposed in areas downwind of
the Site (7), and that vegetation contamination levels on-site, particularly in the 200-area, were seldom
below what were considered to be tolerable at that time (.20 µCi/kg) (8).  In fact, an experiment conducted
in December of 1949 deliberately released a cloud of 131I into the atmosphere which drifted southeastward
and northeastward from the Site causing vegetation readings as high as 107.3 µCi/kg in Kennewick (9).
Releases from this so-called "Green Run" have been estimated to have been as high as 7780 Ci (10) or
even 11,000 Ci (10635).
Based on the data that initially became available, preliminary estimates were made of maximum
doses to the thyroid that could have been received by persons living in close proximity to the Hanford Site
during the years of atmospheric releases (11,12).  Using environmental monitoring data for 131I
concentrations in vegetation, a variety of assumptions regarding agricultural production and dietary
practices, and a U.S. Nuclear Regulatory Commission model to estimate thyroid doses, maximum doses
were estimated (12) for residents of Richland and Pasco for four age groups: infants (0-1 yr), children (2-
12 yr), teenagers (13-19 yr), and adults (20 and older).  During the year of peak releases (1945), it is
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estimated that the maximum annual thyroid dose to an infant may have been as high as approximately 2000
rad (11).  Through 1947, maximum annual infant thyroid doses may have remained quite high (above 100
rad) with even higher periodic doses corresponding to larger atmospheric releases in the late 1940s and
early 1950s.  Similar estimates for infants have been proposed (11,13), with maximum annual thyroid
doses decreasing to about one half these levels for children, about one quarter for teenagers, and about one-
fifth for adults (9). 
Table II.A-1. Estimates of Atmospheric Emissions of Radioactive Iodine from the Separations
Plants Stacks
131I Ci (annual)
Year
Anderson and
Roberts Estimates* Conklin Estimates**
1944 1700 54,000
1945 340,000 340,000
1946 76,000 76,000
1947 24,000 24,000
1948 1200 1200
1949 4670 7026 +
1950 2150 2734
1951 18,700 18,798
1952 967 996
1953 720 726
1954 540 544
1955 1200 1167
1956 370 NE++
1957 380 NE++
1944-1957 472,597 527,191
* Anderson JD.  Emitted and Decayed Values of Radionuclides in Gaseous Wastes Discharged to the Atmosphere.  ARH-3026,
Atlantic Richfield Hanford Company, Richland Washington, 3/1/74.
* Roberts RE.  History of Airborne Contamination and Control-200 Areas.  HW-55569 RD, Hanford Atomic Products Operations,
Richland Washington, 4/1/58, pg. 6.
** Conklin AW. Releases of Radioactivity from Hanford, 1944-1956.  Memorandum dated July 1, 1987.  Department of Social and
Health Services, Office of Radiation Protection, Olympia, Washington, 1989.
+ Includes releases from the “Green Run”.  Recent estimates indicate these releases may have been higher (7789 Ci) than those shown
(8).
++ NE – Not Estimated.
The disclosure of information in 1986 prompted widespread concern among people living near the
Hanford Nuclear Site.  Residents questioned whether such releases in the past may have increased their
risk for developing disease, particularly cancer.  Partially in response to their concerns, a panel of experts
(the Hanford Health Effects Review Panel) was convened by the Centers for Disease Control in August
1986 to evaluate the data contained in the first 19,000 pages of documents.  The Panel concluded that
substantial quantities of radionuclides, particularly 131I, had been released between 1944 and 1956 and that
off-site radiation exposures, particularly to the thyroid, were probably high enough to warrant further study
of health effects.  Since 131I concentrates in the thyroid, it was felt reasonable to expect that potential
adverse health effects associated with the Hanford radiation releases would most likely be diseases of the
thyroid.  Thus, the Panel recommended: 1) a study of 131I releases to estimate radiation doses that could
have been received by area residents, and 2) a study of thyroid morbidity among persons known or
suspected to have been exposed.
A second group was also formed during this time period (March 1986), the Hanford Historical
Documents Review (HHDR) Committee, which consisted of representatives from the states of Oregon and
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Washington as well as several Native American tribes.  A Peer Review Panel of experts was appointed as
an advisory group to the committee.  The HHDR focused their activities on further review of the
declassified documents, and worked to consider specific approaches to implementing the two principal
recommendations of the Hanford Health Effects Review Panel. 
As a result of these collective efforts, a comprehensive study of potential radiation doses began in
1987, initially funded by the United States Department of Energy.  The objective of the Hanford
Environmental Dose Reconstruction (HEDR) Project was to develop estimates of radiation doses that
people may have received from Hanford operations.  A primary focus of this effort was to estimate doses to
the thyroid resulting from 131I exposures.  Preliminary evidence from the HEDR Project indicated that the
contributions to thyroid dose from the shorter-lived isotopes of iodine (132I, 133I, 135I) were probably
negligible.  
Directed by an independent Technical Steering Panel (TSP) of eighteen scientists and community
representatives, Battelle Pacific Northwest Laboratories in Richland performed the technical work for
HEDR.  While originally performed under contract to the Department of Energy, in 1993 funding
responsibility was transferred to the Centers for Disease Control and Prevention.
In July 1990, the TSP made public draft reports of Phase 1 of the HEDR Project.  The objective of
that phase was to establish, in terms of data availability and modeling capability, the feasibility of
developing a system for estimating individual radiation doses and the uncertainties of those dose estimates.
For radionuclides released to the atmosphere, this was accomplished by developing preliminary estimates
of doses to the thyroid from 131I (14).  Although external exposure (immersion and groundshine),
inhalation, and vegetable consumption pathways were considered, the primary emphasis was on the cow's
milk pathway for 131I, since this was anticipated to be the dominant source of exposure for many people.
The Phase 1 region consisted of ten counties surrounding the Hanford Site. The population of that ten-
county area was approximately 270,000 during the late 1940s.  For this entire population, the median dose
to the thyroid from 131I ingestion of contaminated cow's milk during the period 1944-1947 was estimated to
be 1.7 rad, and the 90th percentile was 15 rad.  It was estimated that between 1.5% and 2% of the doses for
this population exceeded 100 rad.
The preliminary results from HEDR Phase 1 also identified subpopulations that received generally
higher exposures.  In particular, infants and young children who drank milk from family cows that grazed
on pasture in areas to the east, southeast, and south of Hanford may have received substantially higher
exposures.  Among such children, the median and 95th percentile doses were about 70 and 650 rad,
respectively.  Similar children living in this area who drank commercially produced milk had a distribution
of doses nearly as high.
These preliminary estimates were refined in the later phases of the HEDR Project.  The total
amount of 131I released into the air from Hanford between 1944 and 1972 was estimated in the HEDR
model to be about 740,000 Ci (2.73 x 107 gigabecquerels), with 99.8% released through 1957 (15). The
HEDR results, released in April 1994, contained thyroid radiation dose estimates for representative
individuals who lived in areas surrounding the Hanford facility during the times of the radiation releases,
and revealed that the deposition of radioactive 131I was carried further from the Site than estimated in the
Phase I results. Thus, relatively less radioactive 131I was deposited in areas closest to the Site, while larger
amounts were deposited further away than previously anticipated.  This effectively decreased the highest
dose estimates, while increasing the number of people with doses in the mid- and lower ranges.  Thus,
while the Phase II estimates indicated lower doses than those estimated in Phase I, the results continued to
provide strong evidence that large numbers of people, particularly children, may have been exposed to
thyroid doses in the range of 3 to 10 rad.  
One of the major products of the HEDR Project was a collection of computer programs and
databases that implemented the final HEDR models for calculating doses from radionuclides released into
the environment from Hanford (16).  One integrated set of these programs provided estimates of thyroid
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radiation doses from Hanford’s atmospheric releases of 131I.  This included models for the amounts of 131I
released into the atmosphere, for the transport of that 131I through the air and its deposition onto vegetation
and the ground, for its uptake into food and milk products and the distribution of those products, and for
the calculation of thyroid dose from exposure to 131I in environmental media (air, ground, and milk and
other foods).  In particular, a computer program called CIDER (“Calculation of Individual Doses from
Environmental Radionuclides”) combined data regarding estimated concentrations of 131I in environmental
media with information regarding characteristics of exposed individuals (e.g., location, diet, milk and food
sources) to calculate individualized estimates of thyroid dose.  The HEDR Project used the CIDER model
to estimate thyroid doses for hypothetical representative individuals (17,18).  As described elsewhere in
this report, the HTDS also used the CIDER program to calculate dose estimates for the study participants.
The second principal recommendation of the Hanford Health Effects Review Panel, the initiation
of a comprehensive thyroid morbidity study, was enabled by an act of Congress in 1988.  Mandated by
Senate Bill 2889, the CDC was directed to conduct a study of thyroid morbidity among persons who lived
near the Hanford Nuclear Site between 1944 and 1957 (Appendix 2).  Thyroid diseases were selected as
the primary focus for a health outcome study based on the information described above regarding radiation
releases, which suggested that 131I was the radionuclide most likely to pose a risk to human health.  As
reviewed in more detail in the section below, such exposures would be most likely to result in thyroid
morbidity as opposed to other forms of illness or disability. 
On March 27, 1989, the CDC issued a Request For Proposals (RFP) (Number 200-89-0716 P) to
solicit applications from organizations wishing to conduct such an investigation.  The proposal submitted
by a team of investigators at the Fred Hutchinson Cancer Research Center and the University of
Washington in Seattle was selected by the CDC, and a contract was awarded to the FHCRC on September
19, 1989.  
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B. Ionizing Radiation and Thyroid Disease  
Radiation-induced thyroid disease in humans has generally been considered in two broad
categories: thyroid neoplasia (benign and malignant neoplasms) and hypothyroidism.  More recently, it has
been suggested that the risk of autoimmune thyroid disease may also be increased by radiation exposure
(13).   In addition, acute thyroiditis can occur after high doses of radiation from orally administered 131I in
the treatment of certain thyroid disorders, such as thyroid cancer and hyperthyroidism (14).  The degree to
which the thyroid is ablated by radiation exposure, and the degree to which thyroid neoplasms or
hypothyroidism result, is dependent upon several factors:  type of radiation, dose, dose rate, age at
exposure, sex, and current age.  The type of radiation causing such disorders may be classified as either
external (primarily gamma or x-radiation) or internal radiation (primarily beta) from radioiodine.
B.1. Thyroid Neoplasia: Exposure to External Photon Radiation
The evidence linking ionizing radiation with the development of thyroid neoplasms in humans has
arisen largely from two sources: 1) studies of people who were previously exposed to external radiation in
childhood for treatment of benign diseases of the head and neck (15-26); and 2) studies of Japanese
survivors of the bombings of Hiroshima and Nagasaki who were exposed primarily to external radiation
(27-28). The first category of exposures includes children treated with external radiation for acne, tonsilar
hypertrophy, cervical adenitis, fungal infections of the scalp, suspected thymic enlargement (chest), and
pertussis (chest).  Although the first article describing the use of external radiation as therapy for such
problems was published in 1907 (29), it was not until the 1950s that increased rates of thyroid neoplasia in
exposed individuals began to be recognized (15-17).
Current evidence suggests that there is a dose level above which radiation-induced carcinogenesis
occurs less frequently than at lower doses (30).  Animal data and limited human studies collectively
suggest that at external radiation doses over 20,000 milligray (mGy) or perhaps 15,000 mGy, cell killing
and sterilization reduce the risk of carcinogenesis (17, 18, 25, 26).  Thus, estimates of risk for thyroid
neoplasia from external radiation are based on doses to the thyroid of less than 15,000 mGy.
Several cohorts exposed in childhood to external gamma radiation have been followed and
evaluated for the subsequent development of thyroid neoplasia.  An overall summary of such studies is
difficult because important factors such as dose, age at exposure, and length of follow-up have differed.
Nevertheless, these studies collectively demonstrate a dose-response relationship between external
radiation dose and the development of benign thyroid adenomas and thyroid cancers (14).  There have been
six principal studies involving populations exposed to external radiation (20, 31-35). The range of median
doses evaluated has been between approximately 60 to 8080 mGy to the thyroid.  Estimates of absolute
excess risk of thyroid cancer range from 0 to approximately 4 cases per million person-year-rad (PYR),
averaging about 2.5 per million PYR.  Among people exposed in childhood to external radiation, the
absolute excess risk for total thyroid nodules has been reported to be 12.3 excess cases per million PYR
(which includes thyroid cancer).   A study of Israeli children irradiated for tinea capitis revealed higher
absolute risk estimates (14 per million PYR) resulting from lower thyroid doses (average 90 mGy; range
43-169 mGy) (20). 
Ron et al. analyzed the primary data from seven previously published studies of persons exposed
to external radiation  (36).  These data showed a linear dose-response for individuals developing thyroid
cancer if they were exposed before age 15.  This linearity was observed down to a dose of 100 mGy but
leveled at higher doses greater than 10,000 mGy.  For persons exposed in childhood the excess relative risk
per Gray (ERR per Gy) was 7.7 (95% confidence interval  [CI] 2.1, 28.7) whereas little risk was observed
for individuals exposed after age 20.
Studies of Japanese A-bomb survivors, who were exposed primarily to whole-body external
radiation, show a similar dose-response relationship for thyroid cancer based on T65DR dosimetry (27). 
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The latest follow-up of the Japanese cohort confirms a strong dose-response for thyroid cancer.  The crude
incidence rates (cases per 10,000 person-years) for three dose groups (<10 millisieverts [mSv], 10-990
mSv, and >1000 mSv) showed a marked increase with increasing dose:  1.08 for the comparison group,
1.49 for the low dose group, and 3.71 for the high dose group (28). In addition, a strong linear dose-
response was shown with an estimated excess RR at 1000 mSv of 1.15 (95% CI 0.48, 2.14).  Age at
exposure was a significant modifier of thyroid cancer risk.  The excess RR at 1000 mSv was 9.46 (95% CI
4.11, 18.86) for persons exposed under age 10, compared to 3.02 for persons exposed between the ages of
10-19.  These results at young ages of exposure contrasted with those for exposure after age 20, for whom
the excess RR was 0.10 (95% CI -0.23, 0.75), consistent with no increased risk of thyroid cancer. 
B.2. Thyroid Neoplasia: Exposure to Radioactive Iodine
B.2.a. Medical Exposures to Radioiodine
Although animal studies clearly indicate that 131I can induce thyroid cancer (37-39), much less
information is available in relation to the induction of thyroid neoplasia in humans from doses due to 131I.
Evidence from human populations arises from two principal sources: persons receiving therapeutic
(moderately high) doses of 131I for Graves disease or thyrotoxicosis, and persons who received diagnostic
(lower) doses for thyroid nuclear 131I scans to evaluate suspected thyroid disease. The early studies of
persons receiving therapeutic 131I for hyperthyroidism have shown no convincing evidence that the risk of
thyroid cancer is increased among persons receiving 131I (40-44).  Most of the participants in those studies
were adults at the time of exposure, were followed for very short periods, had existing thyroid disease at
the time of treatment, and were treated with radiation doses that were quite high (generally 20,000 -
100,000 mGy).
A long-term follow-up of one of these studies (40) was recently published (45).  This study
compared cancer mortality rates in patients previously treated with 131I, usually for Graves disease, to
expected mortality rates for the general US population.  Although no increase in total cancer mortality was
found for patients treated with 131I, an increase in the risk of death from thyroid cancer was demonstrated.
The standardized mortality ratio (SMR) for thyroid cancer was 3.94 (95% CI 2.52, 5.86).  While this
increased risk was statistically significant, the absolute numbers of excess deaths were small and the
authors suspected that underlying thyroid disease at the time of 131I treatment might have contributed to
these results.
Similar results were obtained from another recent study which evaluated cancer incidence and
mortality in 7400 patients who were treated with radioiodine from 1950 to 1991 in England (#10138).  The
mean age of the cohort was 56 and the mean 131I administered activity was 308 MBq (8.316 millicuries).
The incidence and mortality rates were compared to registry data for England and Wales.  Overall cancer
incidence in the patient cohort was decreased (standardized incidence ratio [SIR] 0.83, 95% CI .77, .90) as
was overall cancer mortality (SMR 0.90, 95% CI .82, .98).  In contrast, the incidence and mortality of
thyroid cancer were increased approximately 3-fold (SIR 3.25, 95% CI 1.69, 6.25 and SMR 2.78 95% CI
1.16, 6.67).  However, the absolute numbers of thyroid cancer cases and deaths were quite small and the
authors could not distinguish between underlying thyrotoxicosis versus radioiodine as the cause of the
increased thyroid cancer incidence and mortality.
A number of studies have evaluated persons exposed to much lower doses (generally 500-1000
mGy) through diagnostic procedures (46-50).  Hall et al. (49) reported in 1996 a 40-year follow-up
experience of 34,000 patients who had received 131I for diagnostic purposes.  The mean dose for this cohort
was 1100 mGy.  The SIR for thyroid cancer was 1.35 (95% CI 1.05, 1.71).  Excess thyroid cancers were
apparent only among patients who were originally suspected of having a thyroid tumor, whereas no
increased risk was noted for those referred for other reasons (49).  In the group referred for suspected
thyroid tumors, the increased risk was not related to thyroid dose, age at exposure, or time since exposure.
The mean age at exposure of this cohort was 43; although 2408 members of the cohort (7%) were less than
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age 20, stratification of risk by very young age was not reported.  The authors of this study concluded that
the small increase in thyroid cancer was likely due to the underlying thyroid condition and not radiation
exposure.  The data also suggested that protraction of dose (lower dose rate) might result in lower risk than
an acute exposure of x-rays of the same total dose.
In 1989, the Food and Drug Administration’s Center for Devices and Radiological Health
reported the risk of thyroid disease from diagnostic 131I in a cohort comprised exclusively of children and
adolescents (50).  Of 3483 children in the exposed group, 48% were less than 10 years and 24% were less
than 5 years at time of entry into the cohort.  The average length of follow-up was 27 years; the mean and
median thyroid radiation dose were both less than 500 mGy.   The exposed group and two separate control
groups were sent questionnaires inquiring about subsequent thyroid surgery.  Of 34 patients with thyroid
surgery, 20 were included in the analysis.  Among these 20, the proportions with malignant tumors or with
benign thyroid conditions were higher in the exposed group than in either control group, however none of
these differences was statistically significant (50).
B.2.b. Environmental Exposures to Radioiodine
Until 1990, the principal sources of information regarding the risk of radiation-induced thyroid
disease from environmental exposures were limited to studies of Utah schoolchildren and Marshall
Islanders exposed to fallout from atmospheric nuclear testing.  Since then, a dramatic increase in childhood
thyroid cancer has been documented from radiation exposure from the Chernobyl accident in 1986, and
additional follow-up data have been published for the Utah cohort exposed to fallout from the Nevada Test
Site.  In contrast to the medical exposures described above, which were due exclusively to 131I, most of
these environmental exposures contained a mixture of 131I, external radiation, and short-lived radioiodines.
The following section is a brief summary of studies that have investigated the risk of thyroid neoplasia
from environmental exposures to radioiodine.
B.2.b.1. Utah
Over 100 atmospheric nuclear tests were conducted at the Nevada Test Site between 1951 and
1958.  Initial studies of thyroid disease incidence in Utah schoolchildren appeared to show no difference in
thyroid disease outcomes compared to children from unexposed areas (51, 52).  However, a follow-up
study of this cohort, published by Kerber, et al. in 1993, reported an excess risk of thyroid neoplasms that
was associated with exposure to radioiodine from the Nevada Test Site (53).
In that study, a relative risk of 3.4 (95% CI 0.5, 26.9) for the period prevalence of thyroid
neoplasms (benign and malignant) during 1965-1986 was observed participants with estimated thyroid
doses >400 mGy.  A statistically significant excess relative risk of 0.7% per mGy (with 95% lower
confidence bound 0.074%) was observed for total neoplasms (benign and malignant).  Although positive
dose-response trends were noted for total nodules and thyroid cancer (when analyzed separately), these
were not statistically significant.  Among 3545 study participants for whom thyroid doses could be
estimated, the mean dose was 98 mGy, although for those who were children in the most heavily
contaminated study county (Washington County, Utah), the mean dose was about 170 mGy.  Although the
dose was reported to be primarily from 131I, the contribution of external radiation or short-lived
radioiodines is uncertain.  The authors report that the study conclusions were limited by small numbers of
exposed individuals and a low incidence of thyroid neoplasms.
B.2.b.2. Marshall Islands
Of the 66 atomic tests conducted in the Marshall Islands between 1946 and 1958, the BRAVO
thermonuclear test on March 1, 1954 produced the largest single radiation exposure to the Marshallese
people.  Extensive evaluation of this population by Brookhaven National Laboratory has shown an increase
in benign and malignant thyroid nodules in residents of the northern atolls of Rongelap and Utirik (54,55). 
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Thyroid doses have been estimated to be primarily from a mixture of the short-lived radioiodines  (132I, 133I,
135I) and to a lesser extent, 131I and external gamma radiation (56,57).  For thyroid nodules, the absolute
excess risk coefficient for Marshallese people from Rongelap and Utrik was reported to be 830 cases per
Gy per million persons per year, or 8.3 cases per million PYR (57).
A more recent update by the Brookhaven group showed little change in prevalence of thyroid
nodularity among Rongelap and Utrik residents (58).  These authors also reviewed prior estimated thyroid
doses in the exposed persons.  For the Rongelap group, the estimated mean dose was 25,630 mGy for those
with benign nodules and 16,300 mGy for those with malignant disease.  For the less exposed Utrik group,
the estimated mean dose was 3710 mGy for benign nodularity and 2780 mGy for malignant disease.
Although the Brookhaven studies have maintained that fallout exposure from the BRAVO test
affected only the atolls Rongelap and Utrik, additional dosimetry studies have suggested a much wider area
of fallout exposure (59-62).  In addition, a retrospective cohort study of over 7000 Marshall Islanders
showed that the prevalence of palpable thyroid nodularity (≥ 1.0 cm) decreased linearly with increased
distance from the Bikini test site (63).  These results were highly statistically significant and strongly
suggested that fallout radiation affected a much wider region of northern and central atolls, including those
with populations used by Brookhaven as controls.   A new absolute risk coefficient of 1100 excess cases of
thyroid nodules per Gy per million persons per year (11 cases per million PYR) was calculated using a
revised estimate of the prevalence for unexposed Marshall Islanders (63).  These authors also concurred
with others that the exposure to the BRAVO test fallout (reported to be primarily short-lived radioiodines)
appeared to be nearly as effective as external radiation in producing both benign and malignant thyroid
neoplasms (54, 57, 63).
The authors of a recent report (60) attempted to independently assess the prevalence of thyroid
nodularity in the Marshall Islanders, and to compare their results to the 1987 study described above.  They
reported a much higher prevalence of thyroid nodules in the population and a relationship between thyroid
nodules prevalence and distance to Bikini atoll which was only of borderline statistical significance.
However, the apparently increased prevalence can be explained in part by the inclusion of ultrasound
abnormalities along with palpable nodules in their criteria for thyroid nodules.  Also, since they screened
very small numbers of persons from each atoll in the Marshall Islands, their study had little statistical
power to detect a relationship between thyroid nodule prevalence and distance from the Bikini test site.
Therefore their results cannot be viewed as inconsistent with the earlier reports.
B.2.b.3 Chernobyl 
Beginning in 1992, articles began to appear reporting increased rates of thyroid cancer in children
who were exposed to radiation from the Chernobyl accident in April of 1986 (64, 65).  Marked increases in
childhood thyroid cancer have since been reported for areas surrounding the Chernobyl reactor especially
in Belarus and Ukraine (66-68).  Pacini et al. evaluated thyroid cancer cases reported from registries in
Belarus since 1986 and compared them with presumably unexposed cases reported from registries in
France and Italy (66).  Of 472 cases of thyroid cancer from six regions in Belarus, 52% were from Gomel,
the most heavily contaminated region of Belarus; the numbers of cancer cases throughout Belarus roughly
correlated to the degree of radioactive contamination. In addition, the Belarussian cases, when compared to
the French and Italian cases, were younger and more likely to have cancers that were aggressive at initial
presentation and papillary in histology.   Correlations of population rates with population measures of
radiation dose (e.g. collective dose) have been reported in Ukraine and Russia as well (11465).  Increased
rates of thyroid cancer among those who were young at exposure have also been reported in Ukraine (69)
and Russia (11466).
Despite considerable efforts to assess the occurrence of thyroid cancer after the Chernobyl
accident, and to determine to what extent changes in occurrence since the accident are due to radiation
exposure, there is very little published information assessing a dose-response relationship between
Chernobyl radiation exposure and thyroid cancer based on individual estimates of radiation dose to the
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thyroid.  A recent report by Astakhova et al. (11464) is probably the best attempt to date, but individual
doses to children were nevertheless inferred from village Cs-137 measurements.  Based on 107 cases under
age 15 at the time of the accident, a strong relationship was found between estimated thyroid dose and the
risk of thyroid cancer. 
The radiation exposure received by people living near Chernobyl was in large part due to 131I,
although external radiation as well as short-lived radioiodines also contributed to the dose.  Several dose
reconstruction efforts have published representative thyroid dose estimates that span a wide range.
Stepanenko et al. reported thyroid doses for the heavily contaminated regions of Bryansk Oblast ranging
from 1600 to 2800 mGy for infants less than 1 year, and 1000 to 1800 mGy for children age 3-6 years (70).
Gavrilin et al. reported estimated average thyroid doses for 14 exposed territories in Gomel and Mogilev
which ranged from 220 mGy to 4700 mGy for children up to 7 years and 150 mGy to 3100 mGy in
children up to 18 years (71).  Likhtarev and colleagues reported estimated thyroid dose distributions in
persons from five oblasts in Ukraine which showed that almost 90% of the doses in children up to age 7
were between 5 and 1000 mGy (72).
Thus, although there is now compelling evidence that the radiation exposures from Chernobyl
have increased the risk of thyroid cancer in children in contaminated areas, and it is possible to estimate the
range of thyroid doses received by populations in those areas, at present there is little quantitative
information based on individual dose estimates regarding the risk of radiation-induced thyroid cancer after
the Chernobyl accident. Furthermore, few studies have adequately addressed the potential for other factors
such as iodine deficiency to modify the risk of radiation-induced thyroid cancer from Chernobyl. 
B.2.c. Relative Biological Effectiveness of 131I in the Induction of Thyroid Cancer
The lack of clear human evidence regarding 131I induced thyroid neoplasia makes it particularly
difficult to estimate the relative biological effectiveness of 131I compared to external radiation in the
induction of thyroid cancer.  The National Council on Radiation Protection (NCRP) has reviewed data
from many animal studies which have suggested that 131I is from 1/2 to less than 1/20th as effective as
external radiation in inducing thyroid cancer (30).  One study showed that 131I was equally effective to
external radiation in causing thyroid cancer in Long Island rats although the effect was dependent on the
presence of increased TSH stimulation (39).  Based on human experience, the relative biological
effectiveness was thought to be between zero and one-half.  In reviewing the results of both animal and
human studies, the NCRP suggested in its 1985 report that 131I is one-third as effective as external radiation
in producing thyroid cancer in the general population (30).  It should be noted that this was intended by
NCRP as a conservative value for radiation protection standards as opposed to risk estimation.  The BEIR
V report suggested that the radiation dose from internally deposited 131I may be two-thirds as effective as
external photon irradiation (73).  A new NCRP report on this issue is expected but is not published at the
time of this writing.
Several factors may be important in explaining a differential effect of 131I as a carcinogen relative
to external radiation.  These factors include dose rate and the relative heterogeneity of the distribution
within the thyroid gland of the dose from 131I, compared to the more homogeneous dose from external
radiation.  Although information is limited, several studies suggest that protraction of the exposure with
reduction of the dose rate may decrease the risk of developing thyroid cancer.   As noted above, Hall et al.
(49) suggested that the lack of radiation effect they observed in persons receiving diagnostic doses of 131I
may be related to the lower dose rate of 131I, since the dose from a single administration of 131I is delivered
over a 6 week period.  They speculated that this may be sufficient time for DNA repair to occur.  Ron et al.
also examined the effect of external radiation dose fractionation on the risk of developing thyroid neoplasia
(10137).   They pooled the results of three studies that included fractionated exposures and found a 30%
reduction in excess relative risk (ERR) per Gy for persons whose total dose was accumulated over 2 or
more exposures.  
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One additional study has specifically examined the effect of dose rate in children who were given
external radiation for skin hemangiomas.  A total of 396 children were examined at a mean of 22 years
after receiving radiation in infancy (mean total dose 86 mGy) for either a short duration (seconds to a few
minutes) or longer duration (30 minutes to several hours).   The risk of developing a thyroid nodule
increased with total dose and appeared to be linked to doses that were delivered in short duration.
Although no correlation with dose was found for children exposed for only long duration, the correlation
with dose for short duration approached, but did not achieve, statistical significance (ERR per Gy=10,
p<0.2) (74).  These authors suggested that dose rate may play a role in the risk of developing thyroid
neoplasia from external radiation exposure.
B.3. Hypothyroidism
External ionizing radiation to the thyroid has been documented to induce hypothyroidism,
although generally at high doses.  Maxon reviewed a number of studies which found no clinical
hypothyroidism in people who were followed up to 24 years after exposure to doses up to 10,000 mGy to
the head and neck (10062).  This review also included data on people receiving high doses of external
radiation who developed hypothyroidism.  These were typically case reports or series of patients receiving
radiation therapy for malignancies such as lymphoma.  Although the data are limited, the authors
concluded that the induction of hypothyroidism from external radiation was likely only at doses above
10,000 mGy.   
More information is available regarding the risk of hypothyroidism following radioiodine
exposure.  Maxon reported the risk of hypothyroidism in 6000 patients given a single dose of 131I for the
treatment of hyperthyroidism (10062).  A strong linear dose-response between thyroid dose and the
probability of hypothyroidism at five years after treatment was observed.  The dose range was 25,000 mGy
(minimum dose) to 200,000 mGy.  The probability of hypothyroidism was 50% at five years for persons
treated with 200,000 mGy of 131I.  These data suggested that at the minimum treatment dose of 25,000
mGy, the probability of hypothyroidism was approximately 15% at five years.  It should be noted that the
risk of hypothyroidism from 131I in patients with Graves disease may not be generalizable to the general
population.
Hypothyroidism was among the disease outcomes investigated in the Utah Study (10418).  The
period prevalence of hypothyroidism during 1965 through 1986 tended to decrease with increasing
estimated dose.  The relative risk for those with estimated doses > 400 mGy was 0.3 (95% confidence
interval 0.0, 2.2), thus providing no evidence that exposure to fallout from the Nevada Test Site was
associated with in increased risk of hypothyroidism. 
B.4 Autoimmune Thyroiditis
Two recent studies have suggested that exposure to ionizing radiation may be associated with an
increased risk of autoimmune thyroiditis.   In a follow up of the Nagasaki Adult Health Study cohort of
Japanese A-bomb survivors, the dose-response relationship between the prevalence of autoimmune
hypothyroidism and radiation exposure was evaluated.  Autoimmune hypothyroidism was defined as any
TSH elevation with positive thyroid autoantibodies.  Either a positive anti-microsomal antibody or positive
anti-thyroglobulin antibody was considered a positive result.    A dose-response was reported for
antithyroid antibody positivity in persons with spontaneous hypothyroidism (13).  This result suggested
that exposure to external radiation might be a risk factor for developing autoimmune thyroiditis with
hypothyroidism.  However, the published report provided very limited information, showing only a linear-
quadratic dose-response that was described as significant at the 5% critical level.
A similar result was observed in children exposed to Chernobyl fallout radiation (66).  Of 171
Belarussian children, 46% had positive anti-TPO levels compared to 23% of 103 children from Italy. 
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Higher levels of anti-thyroglobulin were also seen in the Belarussian children compared to the Italian
children.  The authors postulated that thyroid autoimmune reactions may be related to radiation exposure.
Although additional data are needed to confirm an association of autoimmune thyroiditis with
radiation exposure, one can speculate about potential mechanisms.  One question would be whether
radiation might be triggering an autoimmune response having the same natural history as spontaneous
autoimmune thyroiditis with the propensity toward developing hypothyroidism. Alternatively, radiation
might be causing a secondary, nonspecific autoimmune reaction resulting from damage to thyroid tissue.
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C. Ionizing Radiation and Parathyroid Disease
Although the primary purpose of the HTDS was to determine whether thyroid disease is increased
among persons exposed to radioactive iodine released from Hanford, a secondary objective was to
determine whether persons exposed to radioactive iodine from Hanford are at an increased risk of
developing hyperparathyroidism.  Because the parathyroid glands are located close to the thyroid, it is
possible that they may receive a radiation dose from beta-emitting 131I taken up by adjacent thyroid cells.
In considering potential health effects associated with thyroid radiation exposure, it may therefore be
important to include effects on the parathyroid glands.
C.1. Hyperparathyroidism:  Exposure to External Photon Radiation
There is considerable evidence to support the association between hyperparathyroidism and prior
head and neck exposure to external beam photon radiation.  Since the first case report of
hyperparathyroidism in an individual exposed to head and neck radiation by Rosen, et al. in 1975 (75),
there has been increasing evidence to indicate that ionizing radiation is a risk factor for the development of
hyperparathyroidism.
In addition to several retrospective studies, Tisell et al. (76) reported that 14% of 444 persons who
were previously treated with x-rays for tuberculous neck adenitis subsequently developed
hyperparathyroidism (HPT) at least 24 years after treatment. A statistically significant dose response was
found for developing HPT (dose range 0.6-45.7 Gy).  For persons with doses greater than 14 Gy, 29%
developed HPT with a relative risk in women twice that of men.  
Cohen et al. (77) have extended their investigation of hyperparathyroidism in individuals exposed
to head and neck radiation in childhood.  In such persons, who had received a mean dose of approximately
8000 mGy to the tonsilar region before the age of 16, the incidence of clinical hyperparathyroidism was
18.7 per 100,000 person-years below the age of 40 and 171 per 100,000 person-years in the age range of
40 to 60 years.  This represented a 2.9-fold and a 2.5-fold increase, respectively, in the incidence of
hyperparathyroidism compared with that in the general population.  Of interest, the above authors also
found that in those persons developing hyperparathyroidism, 31% also developed thyroid cancer,
compared to only 11.2% of individuals who had received prior radiation therapy but did not develop
parathyroid tumors.  The mean latency was 34.7 years with a maximum latency of 46 years.  In addition,
90% of the cases of hyperparathyroidism were secondary to single parathyroid adenomas.  In the latter
study the authors recommended screening calcium measurements in the routine evaluation of persons with
a prior history of childhood radiation treatments to the head and neck.
In an extension of the above study which compared prevalence rates with general population
rates, Schneider et al. have more recently examined the dose-response relationship for their cohort.  They
report an excess relative risk of hyperparathyroidism of 0.11 per centigray in a dose range up to 100 cGy
(1000 mGy) (78).   The authors used dose estimates established for the thyroid; these were used as
estimates of the average dose to the parathyroids.
A study of hyperparathyroidism among atomic bomb survivors in Japan corroborates the above
results (79).  The prevalence of hyperparathyroidism was found to be increased in individuals exposed to
500-1000 mGy when compared to unexposed control persons.  A dose-response with a linear trend was
observed as well as an age effect, with younger persons having higher risk.
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C.2. Hyperparathyroidism:  Exposure to Radioactive Iodine
Although the relationship between external beam radiation and the risk of hyperparathyroidism is
reasonably well established, there is little evidence to support the existence of a relationship between
radioactive iodine exposure and risk of parathyroid tumors.  Animal studies have indicated that parathyroid
hyperplasia or adenomas develop more frequently in rats given 131I than in control animals.  In addition,
such studies have also suggested an age effect in rats.  A higher frequency of parathyroid tumors has been
observed if 131I was given in the first two days of life compared to131I given at 2-4 months of age (80,81).  
In a retrospective report, Bondeson et al. (82) reported 600 consecutive cases of primary
hyperparathyroidism of whom 10 had documented histories of prior 131I treatment.  Such treatment had
been given for either Graves Disease or for ablation of thyroid remnants.  Age at the time of 131I therapy
ranged from 21 to 72 years with the interval to detection of hypercalcemia ranging between 3 and 27 years.
These authors also indicate that parathyroid adenomas developed at the sites of thyroid remnants in cases
with 131I ablation after thyroid tumor operations.
While the mechanism of parathyroid tumor induction in individuals exposed to external beam
radiation is almost certainly due to direct photon beam exposure, the mechanism of postulated parathyroid
tumor induction from radioactive iodine is less certain.  The parathyroid glands are not known to take up
iodine.  However it is plausible that parathyroid cells can be exposed to beta radiation from 131I taken up in
thyroid cells adjacent to the parathyroid glands.  This mechanism of exposure is consistent with the results
summarized above since the parathyroid glands in rats are imbedded within the thyroid tissue whereas in
humans they exist as separate organs.  Although the number of cases is quite small in the study by
Bondeson et al. (82), the development of parathyroid adenomas near the site of thyroid remnants treated
with 131I supports this hypothesis.
   
Estimated doses to the parathyroid glands can be calculated if the thyroid dose from radioactive
iodine is known.  For example, a 5.0 mCi administration of 131I would be expected to give a thyroid dose of
approximately 45,000 mGy and a parathyroid dose of approximately 16,500 mGy (83).  Therefore, the
parathyroid dose from 131I is approximately 30% of the thyroid dose for a given amount of 131I.
Thus, while it seems clear that external radiation is a risk factor for the development of
parathyroid tumors and subsequent hyperparathyroidism, the association of parathyroid disease with
radioactive iodine exposure is less certain.  Nevertheless, the available data are suggestive and warrant
further investigation.
HTDS Final Report: June 21, 2002 – Section II.D page 18
D. Ultrasound-Detected Abnormalities of the Thyroid (Thyroid UDAs)
Since the mid-1980s, high-frequency ultrasound has increasingly been used in the evaluation of
thyroid nodules.  Although the traditional definition of a thyroid “nodule” is based on clinical palpation, the
greater sensitivity of ultrasonography has led to its greater use, since it can detect nonpalpable, millimeter
size abnormalities.  Several important issues, however, have arisen with the use of this technology: 1)
thyroid UDAs have been shown to occur frequently in the general population without good understanding
of their risk of malignancy or biologic significance; 2) thyroid UDAs have often been classified as
“nodules” regardless of size; 3) the use of ultrasound in defining criteria for thyroid nodules has made it
difficult to compare clinical thyroid outcomes among epidemiological studies using different criteria for
thyroid nodularity and; 4) although ultrasound has exceptional sensitivity, recent data regarding specificity
(the ability to distinguish benign from malignant nodules) suggest that the increased specificity of
ultrasonography is associated with a significant decrease in sensitivity.  
As described further below, a few published studies have examined the possibility of association
between radiation exposure and thyroid UDAs.  However, to interpret those studies properly, careful
attention must be paid to the issues mentioned above. The following section summarizes the published
literature regarding the prevalence, clinical significance, and possible radiogenesis of thyroid UDAs.
D.1 Prevalence of Thyroid UDAs
A number of studies have shown a high prevalence of thyroid UDAs in the general population.
Tan et al. recently reviewed the literature and reported a range of prevalence of 17-67% (10269).   In 1000
persons referred for evaluation of hypercalcemia (of whom 8% had a nodular goiter), 46% had discrete
thyroid lesions on ultrasound and 38% were reported to have thyroid nodules (10446).  While these patients
are unlikely to be representative of the general population, they were not referred for suspicion of thyroid
disease. The highest prevalence of thyroid UDAs was reported in a prospective study of 100 female
employees responding to a notice on a bulletin board: 67% of these women, mean age 43, had abnormal
thyroid ultrasound scans (10114).  The results of this study are limited by small numbers.  Thyroid UDAs
in populations without apparent thyroid disease have also been documented outside the US with prevalence
figures ranging 17-27% (10777, 10229, 10444).   Most of these studies have been consistent in showing
that nonpalpable thyroid UDAs are generally small and that solitary nodules on clinical examination are
often associated with multiple other thyroid UDAs. Both Tan (10831) and Brander (10777) have
demonstrated that 48% of patients with known palpable thyroid nodules greater than 1 cm harbored
additional thyroid nodules found on ultrasound.
Brander and colleagues have published two important studies.  In the first study, 253 persons
randomly selected from a Finnish city council registry were screened for thyroid UDAs (10683).  The
sample was distributed evenly among four age brackets from 20 through 50.  The community was not
thought to have endemic goiter.  Thyroid UDAs were detected in 69 persons (27%).  These abnormalities
were solitary in 57%, multiple in 22%, and diffuse in 22%. The mean age for persons with normal
ultrasound scans was 35, the mean age for the group with abnormal ultrasound findings was 37.  The
frequency of these abnormalities was higher in women than men and increased with age for both sexes.
For women, the prevalence of thyroid UDAs was 30% in the 20-29 age group, 32% in the 30-39 age group,
and 41% in the 40-50 age group.  All participants underwent thyroid palpation prior to ultrasound
examination.  Palpable abnormalities were detected in 13 persons (5.1%): three with a solitary nodule, five
with multiple nodules, and five with abnormal consistency.  Fine needle aspirations were done in 30
individuals.   All were negative for malignancy with one intermediate probability of neoplasm; that person
underwent surgery and had a follicular adenoma.  The authors commented that thyroid UDAs were
common in an unselected population, and that the likelihood of malignancy was low. They recommended a
conservative approach to these lesions.
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In the second study (10209), Brander and colleagues performed follow-up ultrasound scans in
persons who initially had thyroid UDAs in the previous study. Of the 69 persons with initial thyroid UDAs,
57 (83%) were located and re-evaluated 5 years later. Of these 57 persons, 28 had thyroid UDAs that were
defined as macrofollicles (lesions less than or equal to 5mm).  After 5 years, 14 macrofollicles were
unchanged, 5 increased in size, 5 decreased in size, and 4 had no follow-up.
The remaining 29 persons had a total of 34 nodules which had been detected during the initial
ultrasound screening.  Of these, 12 had grown over 5 years, 8 had either disappeared or diminished in size,
and in seven persons a new lesion developed.  Of the 12 that had grown, biopsy was performed in 10 with 9
benign results and 1 which was a benign adenomatous nodule after surgical excision.  Of the 7 new lesions,
biopsy was performed in 5 and all were benign.  At the end of the 5-year follow-up, there were no
individuals with thyroid cancer who previously had thyroid UDAs at the initial screening.  The authors
acknowledged the small size of their study but concluded that in contrast to persons with nodules selected
for surgery,  “most lesions randomly detected at ultrasound of the thyroid are benign.”
Bruneton evaluated 1000 healthy volunteers without history of thyroid disease and performed high
frequency thyroid ultrasound examinations (10517). Although selection criteria or mean age were not
provided, 57% of participants were over 50 years.  Ultrasonography was performed with 13 MHz
transducers and all ultrasound nodules greater or equal to 3 mm were counted.  One or more nodules were
detected in 34.7% of participants. For persons less than age 50 (n=431), the prevalence was 25%.  For
persons greater than age 50 (n=569), prevalence was 42%.  For all ages, the prevalence in women was 44%
and the prevalence in men was 17.7%.
A Belgian study assessed thyroid UDAs in 300 patients who were referred for abdominal
ultrasound examinations (10444).  Although this study sample is not a random representation of the general
population, there were extensive exclusion criteria for those with symptoms or signs of thyroid disease. The
mean age was 47 (1-88) and 55% of participants were males.  Small echoic nodules were found in 19% of
patients.  In patients in their 7th decade, the prevalence increased to over 40%. 
These ultrasound prevalence studies can be compared to the autopsy study by Mortensen in 1955
which showed that approximately 50% of 1000 consecutive autopsies had single or multiple thyroid
nodules in glands which appeared “clinically normal” (10046). 
D.2. Specificity of Thyroid Ultrasonography in Predicting Thyroid Cancer
There has been significant controversy regarding whether there are ultrasound characteristics that
can independently predict malignancy in thyroid lesions. Rago and colleagues assessed 104 consecutive
patients by conventional ultrasound and color flow doppler prior to thyroid surgery (10240).  The
characteristics of the halo sign, hypoechogenicity, and microcalcifications were assessed by conventional
ultrasound while Type I, II, and III color flow patterns were assessed by color doppler. The combination of
absent halo, the presence of microcalcifications, and a Type III color flow pattern increased specificity for
thyroid cancer to 97%.  However, the sensitivity decreased to only 16%. Thus, while ultrasound and color
flow doppler increased the specificity for thyroid cancer it did so at the expense of sensitivity for predicting
thyroid cancer.
Takashima studied the sonographic and pathologic correlation in 69 of 99 surgically removed
nodules (10020).  Microcalcification showed the highest specificity of 93% with a positive predictive value
of 70% for thyroid cancer.  However, the sensitivity was only 36%.  They discussed the distinction between
dense calcifications, which are found in both thyroid cancer and benign lesions, and microcalcifications
which are much more specific for thyroid cancer.  However these are not always seen on ultrasound but
may be found on pathology review.  The authors conclude that “none of the various sonographic features,
such as multiplicity of nodules, presence or absence of halo or cystic areas, lesion echogenicity, or margin
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characteristics help to reliably distinguish between benign and malignant thyroid nodules.”  They state that
“microcalcifications were useful however sonographic microcalcification is not a sensitive nor sufficiently
accurate indicator of malignancy because pathologic microcalcifications are found, at most, in only 60% of
thyroid cancers.”
Tominori evaluated the combination of ultrasonographic and cytologic characteristics in predicting
thyroid cancer and developed an index which prepared patients better for selection for thyroid surgery.  He
acknowledged that “clearly sonographic features alone do not reliably separate benign from malignant
thyroid nodules” (10229).
In a similar statement, Sakaguchi reported that studies indicate that several ultrasound
characteristics are “suggestive” of thyroid cancer such as solid and hypoechoic lesions, irregular margin,
and fine microcalcifications (10231).  However, the authors stated that, “There is no single sonographic
criterion that distinguishes benign from malignant thyroid nodules.”  In a recent commentary, Hegedus and
Karstrup state, “A general finding – has been that there is no US [ultrasound] pattern, alone or in
combination with other techniques, that may be considered specific for thyroid cancer” (10218).
D.3. Ionizing Radiation and Thyroid UDAs
The increased sensitivity and the development of portable ultrasound equipment have made
ultrasonography particularly attractive in evaluating abnormalities of the thyroid gland in persons exposed
to environmental radiation.  In contrast to the increasing volume of literature regarding thyroid UDAs in the
general population, much less is known about whether ionizing radiation causes an increase in thyroid
UDAs prior to the development of clinical disease.
 
Schneider and coworkers evaluated a subgroup of their Michael Reese cohort who had been
exposed to head and neck radiation therapy during childhood for benign conditions.  They selected 54
individuals who had previously had normal thyroid exams and normal thyroid nuclear scans in the 1974-76
time period.  Of these 54 persons in this follow-up study many years after exposure, 47 (87%) had one or
more discrete thyroid UDAs (10111). In this cohort, external radiation exposure was clearly associated with
increased thyroid UDAs.  The authors concluded that: 1) thyroid nodules continued to develop in radiation-
exposed individuals many years after exposure and 2) although thyroid UDAs were quite common in the
general population, they were more prevalent in radiation-exposed populations. 
Other studies have also suggested that thyroid UDAs are more common in exposed populations.
Antonelli, et al. compared ultrasound scans of two groups: 50 hospital workers with occupational radiation
exposure (external radiation) in a hospital setting and 100 controls without such exposure (10154).  Thyroid
UDAs were detected in 38% of the exposed persons and only 13% of the controls.  Similarly, Sugenoya
and colleagues (11126) compared 299 children who were exposed to Chernobyl radiation to 323 children
who were unexposed.  Although none of the children in either group had palpable abnormalities, 34 of the
exposed (11.4%) had thyroid UDAs compared to 4 unexposed children (1.2%).
There is very limited information regarding the dose-response relationship between radiation
exposure to the thyroid and thyroid UDAs.  While such abnormalities might be expected to correlate with
clinical thyroid disease, the question of whether thyroid UDAs might represent an early marker of radiation
injury prior to the development of clinical disease is unknown.  There are currently no studies in the
literature to answer this question.
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III. STUDY OBJECTIVES
The primary objective of the HTDS was to determine whether thyroid morbidity (including, but
not limited to hypothyroidism, benign neoplasia, and malignant neoplasia) is increased among persons
exposed to atmospheric releases of radioactive iodine from the Hanford Nuclear Site between 1944 and
1957.  If an effect was detected, the study was designed to further determine in what way the increase in
thyroid morbidity is related to the dose of radiation received (i.e., the characteristics of any dose-response
relationship). 
In addition to these primary objectives, the HTDS had three specific secondary objectives: 1) to
determine whether hyperparathyroidism is increased among persons exposed to the Hanford radiation
releases and who received radiation doses to the thyroid and, if so, to determine in what way the increase in
hyperparathyroidism is related to the dose of radiation received; 2) to provide information to residents of
the communities surrounding the Hanford Site regarding the objectives, design, and conduct of the study,
as well as the findings and results of the research; and  3) to assess the appropriateness of the methods
employed and the degree to which such an investigation could be successfully planned and executed, given
the long interval since exposure and the uncertainties regarding radiation dose. 
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IV. STUDY DESIGN
A. Eligibility Criteria
The HTDS was based on a cohort of people defined by the following eligibility criteria:
• Mother’s residence at the time of the participant’s birth: Benton, Franklin, Walla Walla,
Okanogan, Ferry, Stevens, or Adams County in Washington State
• Year of birth: 1940 – 1946.
The rationale for this choice of counties and years is described in sections IV.A.1 and IV.A.2
below.  The mother’s usual residence at the time of the participant’s birth, which can be determined from
birth records, was used as a criterion since it was likely to indicate the participant’s place of residence
during the first years of Hanford’s operations, when the largest releases of 131I occurred (see section V.A.2
below).  The cohort included the majority of the possible combinations of the seven counties and seven
birth years.  However, birth year subcohorts for certain counties were not included since they were unlikely
to include many participants with relatively high thyroid radiation doses (see sections V.A.2 and V.A.3
below).
A.1 Mother's Residence at the Time of the Participant's Birth
Geographical proximity to the Hanford Nuclear Site is clearly a determinant of radiation doses
received by area residents.  The atmospheric transport and deposition of radioactive materials depend on
the location of the source of the release, the surrounding topography, and meteorological conditions at the
time of the release (i.e., wind speed, wind direction, precipitation and atmospheric stability).  The HEDR
Project considered such factors to estimate the atmospheric dispersion of radioactive iodine from Hanford.
Preliminary HEDR results were used to define the geographical boundaries for selection of the HTDS Pilot
Study Sample, and final HEDR estimates used to refine the boundaries for the selection for the Transition
and Full Study Samples.  The 75,000 square mile geographical domain within which the final HEDR
model applies is shown in Figure II.A-1 above.
The prevailing winds in the vicinity of the Hanford Site blow primarily from the North,
Northwest, and West across the Site to the East and Southeast.  Although there were some seasonal
variations according to month of the year, this pattern was generally consistent throughout the year during
the 1940s (92).  Wind direction determines the directions in which airborne plumes of radioactive material
most likely traveled, and thus the geographical areas most likely to have received deposits of radionuclides.
For the most part, atmospheric releases traveled to areas East and Southeast of the Hanford Site.
Utilizing meteorological data from the 1980s, information regarding the amount of material
released, and limited off-site monitoring data, the HEDR Project calculated 131I concentrations in
vegetation surrounding the Site. Later calculations conducted by Battelle Pacific Northwest Laboratories
using 1944-1947 meteorological data generally confirmed this geographical pattern of 131I concentration in
sagebrush.  These data suggested that the areas of highest concentration were primarily those closest to the
Site to the East and Southeast (e.g., in Benton, Franklin, and Walla Walla counties).  Final estimates from
the HEDR Project revealed a wider dispersion of 131I, with decreased concentrations in the areas nearest the
site and increased concentrations in areas somewhat more removed especially northeast of Hanford.  This
finding prompted the inclusion of Adams County in the Transition and Full Study Samples.
An important pathway of radioactive iodine exposure in humans is the ingestion of milk produced
by animals grazing on radioactive iodine-contaminated vegetation.  Therefore, milk distribution routes and
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milksheds are also important in defining a geographic area in which people were exposed to radioactive
iodine.  In an effort to describe such components of a milk pathway for radioactive iodine, the HEDR
Project attempted to reconstruct the following types of information for the period of highest releases (94):
1) types, quantities, and sources of feed for dairy cows in the area; and 2) location, relative size, and
distribution routes of all fresh milk processors/distributors in the area. 
For purposes of planning the Pilot Study, it was important to know the sources and distribution
patterns of the milk consumed in the areas of interest during the time period under study.  The HEDR
Project developed a summary measure for each of the ten counties surrounding the Site, based upon
production and consumption data, to indicate whether the county recorded a milk surplus, a milk deficit, or
was in relative balance regarding milk production and consumption.
Several important findings were reported (94).  Overall, the 10-county area surrounding Hanford
was self-sufficient in milk production and, in fact, recorded a surplus of almost 20% in 1945.  There is
considerable variability by county, however, which is largely explained by different amounts of irrigated
pasture available for raising dairy herds.  For example, Yakima, Kittitas, and Klickitat counties were milk
surplus counties, particularly Yakima and Kittitas.  Essentially all of the milk consumed by residents of
these counties was produced locally.  Similarly, all of the milk consumed in the Walla Walla area was
locally produced.  In contrast, Benton and Franklin counties imported milk.  Two of the primary sources of
commercial milk for residents of these counties were the Carnation Dairy in Sunnyside and the Twin City
Creamery in Kennewick.  Although the Twin City Creamery itself was located in Benton County, it
received milk from a number of dairies outside the county.
In addition, two special circumstances with regard to milk supply needed to be considered in
selecting potential study participants.  First, much of the commercial milk consumed by Richland residents
is thought to have come from the Carnation Plant in Sunnyside.  In fact, the Atomic Energy Commission
had a contract with Carnation in Sunnyside to supply the town of Richland with their milk during this time
period (95).  Second, a substantial amount of the milk consumed by people living in rural areas (which
constituted much of the area during the 1940s) was supplied by backyard cows.  It is estimated that
between 40% and 90% of the milk consumed by rural families came from this source. 
Thus, based upon these preliminary findings regarding meteorological conditions, the deposition
and concentration of radioactive iodine in vegetation, and the patterns of milk production and consumption
by county, the area encompassed by Benton, Franklin, and Walla Walla counties was defined in the Pilot
Study as the area within which people with the highest thyroid doses were most likely to be identified.
Adams County replaced Walla Walla County in the Full Study selections, as noted in section V.A.3.b, due
to the findings of the HEDR Project’s final report.
On July 12, 1990, the HEDR Project released its preliminary or ‘Phase I’ estimates of thyroid
doses potentially received by residents in a 10-county area surrounding the Hanford Site (12).  These
estimates were based upon computer models that included information regarding the amount of radioactive
material released, the dispersion and deposition of the material, the uptake of the material into the food
chain, the geographical distribution of food products (especially milk and dairy products), and the
consumption of contaminated food products by humans.  These preliminary estimates confirmed that
people who lived closest to the Hanford Site, particularly to the East and Southeast, were likely to have
received the highest radiation doses to the thyroid. 
To determine whether thyroid disease is increased among people who received a radiation dose to
the thyroid from Hanford radioactive iodine releases, it is necessary to compare rates of thyroid disease
among people with different levels of exposure, including very low exposures or no exposure.  The
considerations described above guided the definition of a group likely to have received the highest doses.
However, the selection of groups likely to have little or no exposure, or intermediate levels of exposure, is
equally important in properly evaluating whether the radiation exposure is associated with an increase in
the risk of thyroid disease.  The most important considerations in defining these groups are: 1) that the
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groups are comparable to the high-dose group with respect to other factors which could confound any
relationship between radioactive iodine exposure and thyroid disease (e.g., geography, urban/rural
composition, occupational factors, socioeconomic factors, age, ethnicity, sex); and 2) that the same
opportunities and resources exist to identify and trace people in low- and intermediate-dose groups as in
the high-dose group.
With these requirements in mind, three types of comparisons can be considered for use in a cohort
study of this type.  First, rates of thyroid disease in a general population (e.g., the entire United States)
could be used to evaluate whether the rates of thyroid disease observed in the cohort receiving a dose are
higher than would be expected based upon general population experience.  In the present context, however,
this approach is problematic primarily because, with the exception of thyroid cancer, incidence rates for the
thyroid diseases under study are generally not available for other populations (e.g., the United States or
Europe).  Estimates could be obtained from other study cohorts that have been followed subsequent to
exposure to ionizing radiation (e.g., the New York tinea capitis study), but such rates do not reflect general
population experience and the degree to which they can or should be generalized to the eastern Washington
experience is questionable. 
A second approach would be to include people who received zero or very low thyroid dose in the
cohort selected from the geographical areas most likely exposed to the Hanford releases as a comparison
group, and to compare disease rates in people with higher dose levels to the rates among those in this
"baseline" category.  An "internal" comparison group such as this has a number of advantages.  Most
importantly, concerns regarding comparability of other factors that might influence the risk of thyroid
disease are largely resolved.  Second, it is more efficient to enroll and study a single cohort, rather than two
geographically separate sub-cohorts (one from areas most likely exposed and one from areas most likely
unexposed).  Third, this approach allows for a very flexible analysis based on both a simple dichotomy of
exposure (dose vs. zero or very low dose) as well as a quantitative estimate of dose (i.e., a dose-response).
For this approach to succeed, however, relatively accurate individual doses need to be available, a full
range of doses needs to be represented in the cohort (or at least a sufficient number of people with
relatively high doses), and an adequate number of people with zero dose need to be included. 
In this study, particularly for its pilot phase, it could not be assured that the dose distribution in the
sub-cohort selected from Benton, Franklin, and Walla Walla counties would allow for such an approach
(e.g., that there would be an adequate number of people with very low doses, as well as a full range of
higher doses) because the selection of potential study participants could not be based on estimates of an
individual's radiation dose.  In fact, it could not even be assured at the time the Pilot Study was initiated
(1992) that an adequate individual-level dose estimation system would be available from the HEDR Project
for this study.  Finally, among people born in Benton, Franklin, and Walla Walla counties during 1942-
1946, those who received very low doses could not be presumed to be comparable, with respect to their
natural risk of thyroid disease, to those who received higher doses.  Those with little or no dose would
likely have drunk little or no milk, moved to locations more distant from Hanford before accumulating
more dose, and drunk milk imported from a less-exposed area.  These characteristics may be related to
health or socioeconomic status, and while none of them is known to influence the risk of thyroid disease,
the possibility that they may could not be ignored.
Consequently, a third approach for identifying comparison participants was to select people who
were not likely to have been exposed to the Hanford radiation releases and who were, therefore, not likely
to have received a radiation dose to the thyroid, on the basis of geographic proximity to the Hanford Site.
The primary purpose of such an approach was to be able to identify potential study participants with a high
degree of certainty that they received a very low or no radiation dose from radioactive iodine from
Hanford.  The two principal concerns with this approach, however, were: 1) to establish that such people
were truly unexposed (and, therefore, received very low or zero dose) and 2) to assure that such people are
comparable to those who did receive a dose regarding other characteristics that might influence the risk of
developing thyroid disease. 
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Thus, for the Pilot Study, some of the participants were identified from areas that are
geographically removed from the three-county area considered most likely exposed.  This design served
two important purposes.  First, it enabled the evaluation of radiation doses to the thyroid for a group of
people anticipated to be relatively unexposed to the atmospheric releases of radioactive iodine from the
Hanford Site in a manner identical to that used for people anticipated to be highly exposed.  Second, this
approach provided information regarding the success rates of the different data collection aspects of the
project among people born in areas removed from the Hanford Site relative to people born in areas in close
proximity.  It was recognized that, to the extent substantial differences in the success of participant
enrollment and data collection efforts were identified, revisions in the overall study design would have
been necessary. 
For a separate geographical area to be suitable as a source of study participants, two conditions
must be met: 1) the area must have received little or no exposure to the radioactive iodine from Hanford
either directly through atmospheric transport of the iodine or from importation of agricultural products
(principally milk) from contaminated areas; and 2) the participants from that area must be as comparable as
possible to those from the more exposed area regarding other factors that might influence the risk of
thyroid disease.  In practice, it may be difficult to define an area that satisfactorily meets the conditions
specified by both of these criteria.  With increasing distance from the Hanford Site (and, therefore, less
likelihood of exposure), there was concern that comparability of other factors would be more difficult to
achieve.
Regarding exposure to the atmospheric releases of 131I, initial information available from the
HEDR Project about prevailing wind patterns, 131I deposition, and commercial milk distribution suggested
that counties to the west and northwest of the Hanford Site might be possible sources of study participants
with relatively low doses.  Sagebrush concentrations of 131I in the northwestern-most sections of the 10-
County HEDR Phase I region were two or three orders of magnitude less than those in areas immediately
surrounding the Hanford Site, and these same counties were generally milk surplus areas, meaning that
they received little or no milk from cattle in areas likely to be more heavily contaminated by 131I.
Nevertheless, a careful review of the preliminary HEDR Phase I thyroid dose estimates released in
July, 1990, indicated that even in these counties some people may have received considerable radiation
doses to the thyroid; for example, infants in the eastern Census Divisions of Kittitas County (KI1, KI7,
KI8, KI9, KI10, KI11)  (see Figure 2.5 in reference (12)).  Furthermore, as continuing efforts were made
by the HEDR Project to improve the quality and completeness of the basic data regarding meteorology and
milk distribution used to calculate radiation doses, it became apparent that appreciable doses possibly
occurred in some of the counties outside the 10-County Phase I region (Figure IV.A-1, used with
permission, 93).
Thus, based upon the information available at the time about possible thyroid doses, it seemed
most prudent to attempt to locate subjects with little or no dose from areas at least one additional county
"layer" distant from the Phase I boundary, and more directly to the north of the Hanford Site.
Consequently, in the Pilot Study, selection of cohort members was extended to the three counties most
directly north of the Hanford Site (Okanogan, Ferry, and Stevens) which are separated from the Phase I 10-
county HEDR boundary by one "layer" of counties.  
The criterion of comparability of factors other than radiation exposure that might cause thyroid
disease was also a concern.  Relatively little is well established regarding the causes of thyroid disease.
Factors known to be of most potential concern were: 1) selected demographic factors, most notably age,
sex, and race; 2) socioeconomic status, most importantly as it relates to access to medical and dental care
and resulting exposures to medical and dental sources of ionizing radiation; and 3) dietary iodine intake.
In selecting Okanogan, Ferry, and Stevens counties for inclusion in the Pilot Study, it was
important to assess the degree to which the populations of these counties were similar to those of Benton,
Franklin, and Walla Walla counties in the 1940s regarding at least the factors listed above.  Age and sex
distributions for 13 counties in central and eastern Washington and north-central Oregon that might have
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been considered sources of people exposed to little or no radioactive iodine from Hanford showed little
variability among the counties in the ratio of males to females.  Okanogan, Ferry, and Stevens counties
were shown to have slightly higher proportions of children under the age of five than do Benton, Franklin,
and Walla Walla, but the difference was relatively small.
Figure IV.A-1. Iodine-131 Thyroid Dose from All Exposure Pathways (Milk Cows on Fresh 
Pasture)HTDS Final Report: June 21, 2002 – Section IV.A page 27
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Figure IV.A-1. Legend
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Comparisons of data from the 1940 Census showed that the populations of the counties to be
included in the Pilot Study were overwhelmingly classified as rural and white.  The median number of
years of school completed, and the proportion of the population 14 years of age and older employed in five
major occupational groups were also similar.  Thus, it was concluded that the composition of the six
counties included in the Pilot Study in terms of age, sex, race, education, percent rural, and major
occupational category were reasonably similar, and not greatly different from other counties in the larger
surrounding region.
It was also important to assess the degree to which iodine availability and/or intake might vary
among study counties.  Geographical differences in the distribution of iodine intake could result in
geographic differences in the rates of one or more of the thyroid diseases under study (e.g., endemic goiter
belts).  To the extent that such differences might be related to radiation dose from Hanford, they could
potentially confound an association between radiation exposure and thyroid disease.
Preferable to estimates of soil iodine concentrations would be estimates of iodine intake.
Although little work had been conducted in this regard on a geographic basis, in 1970 Oddie et al. (96)
reported estimates of average dietary iodine intake derived from thyroidal radioiodine uptakes in
approximately 30,000 euthyroid subjects in 133 locations throughout the United States.  Although average
daily iodine intake varied considerably throughout the United States (from 240 to 740 micrograms per
day), the Pacific Northwest was relatively uniform in the distribution of daily intake estimates.  Mean
values were reported for fifteen areas in the Northwest centered by two degrees latitude and longitude
(approximately 140 by 120 miles).  All values in the six Pilot Study counties were between 345 and 379
micrograms per day (a very narrow range compared to the overall distribution of values).  Thus, within the
confines of most of central and eastern Washington and north central Oregon, there is some evidence to
suggest that iodine intake was adequate and relatively uniform in the past.
The inclusion of Okanogan, Ferry, and Stevens counties in the Pilot Study was intended to
provide a convenient mechanism for identifying an adequate number of potential study participants who
received little or no radiation dose to the thyroid from Hanford.  It was not intended to serve as a means of
defining a "comparison area" or "control group."  Although potential study participants were selected
based, approximately, on the county in which they were born (see section V.A., below), the fact that a
person was born in one area or another was not relied upon to determine whether he or she was actually
exposed to radioactive iodine from Hanford and, more importantly, actually received a radiation dose to the
thyroid.  Exposure, and the estimate of the resulting radiation dose to the thyroid, was determined from a
detailed residential history and exposure information collected whenever possible from the mother or other
close relative of each study participant (discussed more fully in section V.D. below).  For example, a
person born in Benton County between 1942 and 1944 may have moved to a residence away from Hanford
before any exposure could occur.  Similarly, a person born in Stevens county may have lived or visited for
a prolonged time (e.g., a summer) within the "exposed area" and received a substantial thyroid dose.
Nevertheless, it was assumed that most of the study participants with the highest thyroid doses
would come from Benton, Franklin, or Walla Walla County, and that most of the participants from
Okanogan, Ferry, or Stevens counties would have very low thyroid doses.  The use of separate geographic
areas was simply a device that would allow a degree of control over participant selection to assure adequate
numbers of participants in the Pilot Study who would have thyroid doses at the highest and lowest
extremes of the dose distribution.
Based on the results from the HTDS Pilot Study, it was determined that the inclusion of
geographically removed populations in the selections for the Transition and Full Study samples was
unnecessary.  In fact, maximizing the number of participants with the highest doses proved to be of much
greater concern.  Thus, no additional selections were made from Stevens, Ferry, and Okanogan counties
following the Pilot Study selection.  In addition, due to the HEDR Project’s findings that people in Adams
County could be expected to have received higher doses than those in Walla Walla County, the HTDS
cohort was completed by selecting people from the Richland, Pasco/Kennewick, Benton County, Franklin
County, and Adams County geostrata.
If it was learned during any part of the study that a potential participant was adopted, the potential
participant was considered eligible if verification could be obtained that the birth mother's place of
residence at the time of the potential participant's birth was within one of the seven counties included in the
study.
A.2. Year of Birth
The radioactivity of 131I decays exponentially with a half-life of 8.4 days.  This implies that nearly
all of the thyroid dose produced by 131I released into the environment will be accumulated within a few
months after its release.  Therefore the time period of most interest for identifying potential participants
who could have received the highest thyroid doses is that which corresponds to the largest atmospheric
releases of radioactive iodine from the Hanford facility.  As shown in Figure IV.A-2, the large majority of
the releases occurred from the last two weeks of 1944 through 1946.  Beginning in 1947, monthly releases
were considerably lower, averaging between 100 and 2000 Ci (11).  The exceptions to this pattern were the
substantial release associated with the "Green Run" in December 1949 and the releases during 1951.  Thus,
the time during which area residents would likely have received the highest exposure to radioactive iodine
would have been the years 1944-1946. 
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Figure IV.A-2. Monthly 131I Releases from the Hanford Nuclear Site, 1944-1951
D
e
c
-
4
4
M
a
r
-
4
5
J
u
n
-
4
5
S
e
p
-
4
5
D
e
c
-
4
5
M
a
r
-
4
6
J
u
n
-
4
6
S
e
p
-
4
6
D
e
c
-
4
6
M
a
r
-
4
7
J
u
n
-
4
7
S
e
p
-
4
7
D
e
c
-
4
7
M
a
r
-
4
8
J
u
n
-
4
8
S
e
p
-
4
8
D
e
c
-
4
8
M
a
r
-
4
9
J
u
n
-
4
9
S
e
p
-
4
9
D
e
c
-
4
9
M
a
r
-
5
0
J
u
n
-
5
0
S
e
p
-
5
0
D
e
c
-
5
0
M
a
r
-
5
1
J
u
n
-
5
1
S
e
p
-
5
1
D
e
c
-
5
1
HTDS Final Report: June 21, 2002 – Section IV.A page 32
Existing literature suggests that age at exposure is an important factor in radiation-induced thyroid
disease.  In particular, risks among those who are very young at exposure may be higher than for those who
are adults at exposure for one or both of the following reasons: 1) higher radiation doses to the thyroid
result per unit exposure; or 2) there is an increased sensitivity in the young (i.e., an increased risk per unit
dose in the young).  It is known that iodine is metabolized differently in children than in adults.  The
concentration of radioactive iodine in the smaller thyroids of children (the infant thyroid is only about 1/10
the size of an adult thyroid) is greater per unit exposure (30).  Book (97) has shown that the thyroid dose to
infants resulting from the inhalation of a fixed concentration of radioactive iodine in air is twice that of
adults.  The dose in near-term infants is ten times that of adults.  By the ingestion pathway, six-month-olds
could receive thirty times the dose of an adult, largely as the result of smaller thyroids and a higher intake
of milk (30). 
A number of epidemiological studies have given rise to more indirect evidence regarding the issue
of increased sensitivity in the young.  Dobyns et al. (40) reported an increased risk of thyroid adenoma
among the youngest quartile of a cohort treated with 131I for Graves disease, although risks by specific
years of age were not investigated.  The incidence of thyroid cancer among atomic bomb survivors in
Japan exposed primarily to external gamma radiation has been shown to be higher among those exposed at
young ages.  A strong dose-response was seen in this cohort, with a three-fold increase in the excess
relative risk of children exposed less than 10 years of age compared to those exposed at ages 10-19.
Marshall Islanders exposed to nuclear fallout (external gamma and radioactive iodine) had increased rates
of thyroid neoplasia at earlier ages of exposure.  Compared to people exposed at age 18 and over, those
exposed under age 18 had 2.5 times the risk of developing benign nodules and those exposed in utero had a
five-fold risk of developing a benign thyroid nodule (55).  Results from a study of people treated with
radiation for tinea capitis in Israel (external gamma exposure) indicate that children exposed under the age
of five had 3.1 times the number of excess thyroid cancers at age 40 than those children exposed over age
five (51).  Although accurate dosimetry has hampered risk assessment of thyroid cancer from the
Chernobyl exposure, it is well documented that a dramatic increase in childhood thyroid cancer has
occurred in regions where significant exposure occurred.  One recent report showed that since the
Chernobyl accident, the incidence of thyroid cancer in 9-year-olds increased 50-fold in the “high exposure
area” compared to an increase of 6-fold among 17-year-old children (69).  Thus, although none of these
results are specific to individual years of age, collectively they indicate a pattern of higher risk for
radiation-induced thyroid disease at younger ages relative to adult ages. 
Although there are few human studies of exposure to 131I which can adequately evaluate the effect
of age at exposure, animal studies have suggested greater carcinogenic risk at younger ages.  In 131I uptake
experiments in rats, Sikov (98) demonstrated that fetal thyroids were 20 times more sensitive to functional
damage than adult thyroids.  Corresponding estimates for neonates and weanlings were 3 times and 1.5
times the sensitivity of adult thyroids, respectively.  Similar results have been observed in guinea pigs (99).
Christov (100) has reported similar findings using external radiation (x-rays) in Wistar rats.  Among those
irradiated at ten days of age, 40% developed thyroid adenomas whereas only 15% developed these tumors
when irradiated at 60 days of age.  None of the control rats developed tumors. 
Although there are no human data to support age at exposure as an important factor in
hyperparathyroidism after 131I exposure, animal studies do provide some evidence that there is an increased
frequency of parathyroid tumors in rats exposed to 131I at young ages relative to older ages (80,81).
Based on these data from animal and epidemiological studies, it seems reasonable to expect that
the risk of radiation-induced thyroid disease (and possibly hyperparathyroidism) would be greater among
those exposed at the youngest ages.  Therefore, the Pilot Study was limited to people who were children
(ages 0-5) during the periods of greatest atmospheric releases from Hanford (i.e., 1945-1946).  Thus,
people born from 1942-1946 were eligible for inclusion in the Pilot Study. 
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This approach was also advantageous regarding important aspects of the fieldwork.  Since the
primary information to be used in the dosimetry calculations was to be derived from interviews with
mothers (or other close relatives or individuals knowledgeable of the participant's childhood), it was
important to maximize the probability that such information could be successfully collected and that it
would be reasonably accurate.  Younger study participants would, in general, have younger parents.  Given
an average follow-up of about 40 years, the 0-5 year age range at the time of exposure would reasonably
assure that most parents of study participants would still be living and able to participate in an interview.
Following the Pilot Study, in order to include greater numbers of participants with thyroid doses
in the higher range, it was also necessary to change the years of birth from which potential participants
were selected (see section V.A.3 below).   Given that the largest exposures would have occurred in 1945, it
was thought more advantageous to select births from earlier years, 1940 and 1941, than from years later
than those already included in the study.  Thus, births from 1940 through 1944 were included in the Full
Study selections.  While there was some concern that including earlier births would decrease the numbers
of participants for whom a CATI respondent could be found, this was not felt to outweigh the need to
include as many higher dose participants as possible.
A.3. Other Possible Criteria
It is well established that thyroid neoplasia occurs more frequently in women (30), and there is
evidence to suggest an increased risk among the Jewish (30,101).  However, no attempt to further restrict
eligibility in the Pilot Study based upon sex or ethnicity was made.
Although there are no Reservations in Benton, Franklin, or Walla Walla counties, Native
American populations from the region were to be considered in the Pilot Study in an attempt to better
define the radiation doses these populations may have received.  Most Native Americans did not live in the
areas around the Hanford Site where the highest thyroid doses were likely to have occurred.  However
dietary and/or lifestyle practices specific to one or more of the Tribes and Nations in the region may have
been important in contributing to a radiation dose to the thyroid from Hanford's 131I.  Thus, as part of the
Pilot Study, it was planned to attempt to determine whether the Native American populations in the region
experienced exposures to radioactive iodine that could have resulted in significant thyroid doses.  Section
VII.A. specifies in more detail the conduct of this portion of the study.  No attempt was made, however, to
exclude people of Native American heritage from participation in the study.
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B. Definition of Evaluable Participant
An evaluable participant was defined as one who could be located, who agreed to participate in
the study, and for whom sufficient information could be obtained concerning both radiation exposure and
thyroid outcomes.  For each located participant, every attempt was made to obtain information from all
possible sources regarding radiation exposure from Hanford.  However, all information of possible use to
this study was often not available, especially in view of the length of time that had elapsed since the years
of peak exposure.  Therefore, for living participants, sufficient information was defined as the following:
In-Person Interview and physical examination.  Although participants were asked to provide a blood
sample and to receive an ultrasound examination (see section V.F, below), those who refused either or both
were not deemed non-evaluable.  Each participant's final assessment of thyroid or parathyroid disease
status was based on the best historical and current information available (as described more fully in
sections V.H-V.I).
For deceased subjects, sufficient information was defined as a residence history collected through
a surrogate respondent, medical history from a surrogate, and medical record confirmation of thyroid
disease reported by a surrogate.  It was planned that persons who could serve as surrogate respondents for
deceased subjects could include (but were not limited to): a parent, sibling, aunt or uncle of the subject.
During the course of the study, it was determined that the plan for conducting CATIs with surrogates for
the deceased subjects was not feasible.  A discussion of the results of field tests of this portion of the study
is contained in section V.D.4 below.
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C. Outcome Criteria
This section describes the diagnostic criteria for the thyroid and parathyroid outcomes that are
used in this study.  Each outcome had two components: 1) the criteria established by the HTDS Study
Management Team for the diagnosis of each outcome and 2) an indication of the basis for each diagnosis
which serves as a measure of the quality of that diagnosis.  The final diagnosis for each outcome included
both the presence or absence of the diagnosis and if present, information about the basis of the diagnostic
information.  For example, information about the basis of the diagnosis included whether the diagnosis was
made from the HTDS clinic evaluation, obtained from prior medical records with supporting
documentation, obtained from prior medical records without supporting documentation, or obtained from a
report by the participant or his or her Computer Assisted Telephone Interview (CATI) respondent, without
documentation from either the HTDS evaluation or any prior medical records.  Diagnostic information
obtained from the HTDS evaluation and diagnostic information which was well documented in medical
records and met criteria for HTDS diagnoses was considered to be the most definitive and of the highest
quality.  The primary analysis for each disease outcome was therefore restricted to cases defined according
to these two sources.  However, additional analyses were performed for each disease outcome using
alternative definitions that were more inclusive and less definitive.  These alternative definitions are
provided in sections IX.C through IX.O below.  If a participant had multiple sources of diagnostic
information for a particular thyroid disease, with more than one basis for diagnosis, then he or she was
classified according to the basis providing the most definitive diagnosis.
C.1. Thyroid Cancer  
Diagnostic criteria:  Thyroid malignancy according to histopathology reports from a surgical
specimen.  Original pathology slides were reviewed by the HTDS pathologist, whether the diagnosis
was made by HTDS physicians or whether the participant had already had prior thyroid surgery.
Basis for diagnosis.  The following categories indicate the basis for the diagnosis of  thyroid cancer:
1. Diagnosis originating from HTDS evaluation based on subsequent histology
2. Diagnosis from prior medical record with documentation of histology
3. Clinical diagnosis from HTDS evaluation (no histology available)
4. Clinical diagnosis from prior medical record (no histology available)
5.    Participant/respondent report only
 
 
C.2. Benign Thyroid Nodule
Diagnostic criteria: Any confirmed documentation of benign histology or cytology as interpreted by a
pathologist.
    
Basis for diagnosis.  The following categories indicate the basis for the diagnosis of benign thyroid
nodule:
1. Histologic or cytologic diagnosis based on HTDS clinic evaluation
2. Histologic or cytologic diagnosis based on prior medical record documentation
3. Clinical diagnosis from either HTDS evaluation or medical records (clinical impression without
cytology)
4. Participant/respondent report only
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C.3. Any Thyroid Nodule
Diagnostic criteria:  Any thyroid nodule which has been classified as thyroid cancer, a benign thyroid
nodule, or a nodule which is suspicious for malignancy or neoplasm.  The latter category represents
nodules that have cytology suspicious for either malignancy or follicular neoplasm for which no
surgery was performed and therefore no histology was available.
Basis for diagnosis.  The following categories indicate the basis for the diagnosis of any thyroid
nodule:
1. Histologic or cytologic diagnosis based on HTDS clinic evaluation
2. Histologic or cytologic diagnosis based on prior medical record documentation
3. Clinical diagnosis from either HTDS evaluation or medical records (clinical impression without
cytology)
4. Participant/respondent report only
C.4. Hypothyroidism
Diagnostic criteria:  Elevation of TSH above the upper limit of normal (5.0 µIu/ml) with either low
or normal thyroid hormone levels.
Basis for diagnosis.  The following categories indicate the basis for the diagnosis of hypothyroidism:
1. HTDS laboratory evaluation
2. Medical records with supporting documentation (elevated TSH)
3. Medical records without supporting documentation
4. Inferred from past or current thyroid hormone therapy
5. Participant/respondent report only
C.5. Autoimmune (Hashimoto’s) Thyroiditis
Diagnostic criteria:  Positive antithyroid antibody result on either antimicrosomal antibody (AMA) or
anti-thyroperoxidase antibody (anti-TPO).  Levels above the normal limits for these antibodies (AMA,
greater or equal to 25 u/ml; anti-TPO, greater or equal to 2.0 Iu/ml) were considered positive.
Participants with positive antibodies but with documentation of Graves disease were not included in
this outcome category.  Anti-thyroglobulin antibody was also used as an additional antibody marker
for an alternative diagnosis of autoimmune thyroiditis (positive result: greater or equal to 1.0 Iu/ml).
Basis for diagnosis.  The following categories indicate the basis for the diagnosis of autoimmune
thyroiditis:
1. HTDS laboratory evaluation
2. Medical records with supporting documentation (positive anti-thyroid antibodies)
3. Medical records without supporting documentation
4. Participant/respondent report only
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C.6. Graves Disease
Diagnostic criteria:  Hyperthyroidism present (see # 8 below) with the following additional criteria:  
1. Elevated radioiodine uptake and/or thyroid nuclear scan consistent with Graves disease; and/or
2. Exophthalmos
Basis for diagnosis.  The following categories indicate the basis for the diagnosis of Graves disease:
1. HTDS laboratory and nuclear medicine evaluation
2. Medical records with supporting documentation
3. Medical records without supporting documentation
4. Participant/respondent report only
C.7. Autoimmune Thyroid Disease
Diagnostic criteria:  Defined as having the diagnosis of either autoimmune thyroiditis or Graves
disease.  See above for diagnostic criteria and basis of diagnostic information for each of these
outcomes.
8. Basis for diagnosis.  In general, a diagnosis of autoimmune thyroid disease was simply assigned
on the basis for diagnosis of the autoimmune thyroiditis or Graves disease that the participant had.
In a small number of instances, participants had diagnoses of both autoimmune thyroiditis based
on the HTDS laboratory evaluation or medical records with supporting documentation, and of
Graves disease based on medical records without supporting documentation or on
participant/respondent report only.  In all of these instances, the basis for the diagnosis of
autoimmune thyroid disease was taken to be the more definitive, i.e. HTDS laboratory evaluation
or medical records with supporting documentation.
C.8. Hyperthyroidism
Diagnostic criteria:  Suppressed TSH (less than 0.32 µIu/ml) in the presence of normal or high
thyroid hormone levels.  The following additional information was collected to further assess the
etiology of hyperthyroidism:
1. To evaluate Graves disease or a toxic thyroid nodule as an etiology of a suppressed TSH, repeat
thyroid function tests  (TSH, T3 and T4 levels), a thyroid nuclear scan and radioiodine uptake
were requested (see #6 above).
2. History of current medical treatment with thyroid hormone was obtained to assess exogenous
thyroid hormone therapy as a cause of hyperthyroidism.  For participants having a suppressed
TSH while taking thyroid hormone medication, their hyperthyroidism was presumed to be caused
by exogenous thyroid hormone.
Basis for diagnosis.  The following categories indicate the basis for the diagnosis of hyperthyroidism:
1. HTDS laboratory evaluation
2. Medical records with supporting documentation
3. Medical records without supporting documentation
4. Participant/respondent report only
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C.9. Multinodular Thyroid Gland
Diagnostic criteria:   A thyroid gland with abnormal firm consistency with two or more discrete
nodules, or multiple firm lobular and/or nodular areas throughout the gland.  The definition of
thyromegaly in this study is a two-fold enlargement of the thyroid gland based on physical
examination.  Therefore, the above characteristics of a multinodular gland occurring in a gland
enlarged two-fold or more is classified as multinodular goiter whereas these characteristics occurring
in a gland of normal size (less than two-fold enlarged) is classified as multinodular gland.  The
definition of thyromegaly as a two-fold increase in thyroid gland size was chosen as a conservative
definition to avoid classifying normal variations as clinical disease. Dominant palpable nodules or
those which were nonpalpaple and greater than 1.5 cm in three dimensions underwent FNA biopsy.
Such nodules would then be classified as either benign or malignant depending on the results of the
biopsy or further thyroid surgery.
Basis for diagnosis.  The following categories indicate the basis for the diagnosis of multinodular
gland:
1. HTDS physical examination
2. Medical records with documentation of multinodular gland or goiter
3. Participant/respondent report only
C.10. Simple Goiter
Diagnostic criteria:  Diffuse thyromegaly (two-fold enlargement) with normal consistency and
without palpable nodules or lobulations. The definition of thyromegaly as a two-fold increase in
thyroid gland size was chosen as a conservative definition to avoid classifying normal variations as
clinical disease. This classification was intended primarily to reflect physiologic thyroid gland
enlargement.
Basis for diagnosis.  The following categories indicate the basis for the diagnosis of simple goiter:
1. HTDS physical examination
2. Medical records with documentation of diffuse goiter without nodularity or abnormalities in
consistency
3. Participant/respondent report only
C.11. Other Thyroid Disease
Diagnostic criteria:  This category was designated for any diagnoses of thyroid disease that are not
included in the HTDS diagnostic outcomes above.  It was primarily a category for participant reports
of unknown thyroid disease, diagnosed generally many years ago, and treated with unknown therapy
for which no medical records were available.
Basis for diagnosis.  The following categories indicate the basis for the diagnosis of other thyroid
disease:
1. HTDS evaluation
2. Participant/respondent report only
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C.12. Ultrasound-Detected Abnormalities of the Thyroid (Thyroid UDAs)
Diagnostic criteria:  The following categories of ultrasound abnormalities were defined:
1. Palpable ultrasound-detected thyroid abnormalities
2. Nonpalpable focal ultrasound-detected thyroid abnormalities
3. Diffuse (nonpalpable) ultrasound-detected abnormalities of the thyroid
4. Any ultrasound-detected abnormality of the thyroid (any of the above categories)
Basis for diagnosis.  All of these definitions were based on only one source of information: HTDS
ultrasound examination.
C.13. Hyperparathyroidism
Diagnostic criteria:  Defined as hypercalcemia (calcium greater than 10.2 mg/dl) with an
elevated PTH level (greater than 65pg/ml).
Basis for diagnosis.  The following categories indicate the basis for the diagnosis of
hyperparathyroidism:
1. HTDS laboratory evaluation
2. Medical records with supporting documentation
3. Medical records without supporting documentation
4. Participant/respondent report only
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V. FIELD PROCEDURES AND METHODS, RESULTS OF DATA
COLLECTION PROCESS
A. Cohort Definition, Subject Identification and Selection
A.1. Background
A.1.a. Objectives
The objective of this component of the study was to define and identify a group of people (a
cohort) who were exposed to atmospheric releases of radioactive iodine (131I) from the Hanford Nuclear
Site between 1944 and 1957.  Since the primary objective of the overall study was to determine whether
exposure to such radiation resulted in an increased risk of thyroid disease, it was important to identify a
cohort within which there would be the greatest likelihood of detecting an association between exposure to
131I from Hanford and thyroid disease, if such a relationship exists.  This was to be accomplished by
defining a cohort that would contain adequate numbers of people with the highest possible radiation doses
to the thyroid from Hanford, as well as people with very low radiation doses to the thyroid from Hanford.
A.1.b. Definition of the Cohort 
In seeking to define a cohort that would contain individuals with a full range of exposures to 131I
from Hanford, extensive attempts were made to investigate different sources of information that would
enable one to construct a comprehensive list of people who might have been exposed.  Ideally, such a list
would consist of all people in a relatively large population surrounding the Hanford site who were resident
during the time period that the largest atmospheric releases occurred, and would contain enough
identifying information to ensure that a sufficient number of people could be located nearly five decades
after exposure.  The following sources of information were investigated in the Hanford region: 1) school
enrollment records; 2) school health records; 3) school reunion lists; 4) health department clinic and
immunization records; 5) church membership lists; 6) town lists and voter registration records; 7) Census
Bureau records; 8) Internal Revenue Service records; 9) property tax and public utility records; and 10)
birth records. 
Most of these sources of information proved to be inadequate for constructing a sufficiently
comprehensive listing of individuals who might have been exposed to Hanford releases. School health
records, reunion lists, health department records, church lists, town and voter lists, and property and utility
records were all too incomplete. School enrollment records were complete and potentially very useful
where they existed, but unfortunately many school districts in the region had destroyed old records and a
few denied us access. Census Bureau and IRS records would have been ideal sources for enumerating a
population, but access to such information was prohibited by law.  Thus, only birth records provided an
acceptable source for identifying a cohort. 
Birth records provide a complete listing of all people born in a defined geographic area during
defined time periods. The records were available at no cost to the study and could be easily accessed by
staff. Thus, by abstracting information directly from birth certificates, it was possible to construct a roster
of individuals corresponding to specific geographic areas and time periods most relevant to the Hanford
releases. 
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A.2. Plan
A.2.a. Protocol Plan
For the Pilot Study, a birth roster was constructed based on all birth certificates from the counties
of Benton, Franklin, Walla Walla, Okanogan, Ferry, and Stevens for the years 1942-1946.  As indicated
above, complete birth records existed for these counties and were available from the State of Washington
Vital Records Division.  The following data were abstracted from each birth certificate and entered into a
computerized database to form the roster for selection of potential participants: birth certificate number,
mother’s usual residence, child’s name, sex, and birthdate, father’s name, mother’s name, mother’s mailing
address, and county of birth.
The field “Mother’s Mailing Address” was judged to best indicate the mother’s actual residence
when the subject was born. However, the birth certificates for births in Benton, Franklin, and Walla Walla
counties had been computerized previously for the CDC by the State of Washington, and “Mother’s
Mailing Address” was not included in this database.  Thus only “Mother’s Usual Residence” was available
and it was felt this might not reflect the mother’s actual residence when the subject was born.  Therefore,
HTDS staff computerized the mailing addresses for those mothers who gave birth in Benton, Franklin, and
Walla Walla Counties but whose usual residences were outside the six study counties in order to include
those whose “Mother’s Mailing Address” lay within the six Pilot Study counties in the roster for subject
selection. 
For purposes of geographical stratification, “Mother’s Residence at the Subject’s Birth” was
defined for the counties of Benton, Franklin and Walla Walla as follows:
• For births with “Mother’s Usual Residence” (birth certificate item 2) in one of the six Pilot Study
counties (Benton, Franklin, Walla Walla, Okanogan, Ferry and Stevens), “Mother’s Residence at
Subject’s Birth” was defined as the “Mother’s Usual Residence”
• For births with “Mother’s Usual Residence” outside the six study counties, “Mother’s Residence at the
Subject’s Birth” was defined to be the “Mother’s Mailing Address”.
For Okanogan, Ferry and Stevens counties, “Mother’s Residence at the Subject’s Birth” was
defined as the “Mother’s Mailing Address.”
In addition, birth records for Spokane and Yakima counties were reviewed to ascertain births that
occurred in those counties to residents of Benton, Franklin, and Walla Walla counties.  “Mother's
Residence at the Subject’s Birth” for these certificates was also assigned to be the “Mother’s Mailing
Address.”  People for whom the “Mother’s Residence at the Subject’s Birth” was outside the selected
counties were excluded from the roster.
Eligibility for the study was limited to people whose “Mother’s Residence at the Subject’s Birth”
was in one of the selected counties.
A.2.a.1. Rationale
As noted in section IV-A above, preliminary findings from the HEDR project regarding
meteorological conditions affecting the deposition and concentration of radioactive iodine in vegetation,
and the patterns of milk production and consumption by county, indicated that people with the highest
thyroid doses were most likely to have lived in the area encompassed by Benton, Franklin, and Walla
Walla counties. Thus, in the Pilot Study for the purposes of subject selection only, residence at time of
birth acted as a surrogate for the anticipated radiation dose to the thyroid from Hanford. Individual thyroid
radiation dose could only be estimated from data collected during the study.  The selection of cohort
members was also extended to include three counties on the Canadian border north of the Hanford site
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(Okanogan, Ferry and Stevens).  These counties were selected because, based upon the information
available at the time regarding possible radiation doses to the thyroid, they could be expected to contribute
some cohort members with very low radiation doses to the thyroid from Hanford.  In addition, people
living in these counties would likely be comparable to those who receive higher thyroid doses in terms of
other factors which could potentially influence the risk of thyroid disease (e.g., geography, urban/rural
composition, occupational factors, socioeconomic factors, age, ethnicity, sex).   Furthermore, similar
opportunities and resources existed to identify and trace people in this group as in the group that received a
thyroid dose.  Thus, a cohort was selected which was expected to contain people whose dose estimates
would range from the highest doses received to the lowest.
Preliminary estimates of the HEDR project suggested that the highest thyroid doses were probably
in people exposed as infants or children during the first years of Hanford operations.  This is because
infants and children receive higher thyroid doses per unit exposure due primarily to the small size of their
thyroid glands.  In addition, existing literature suggests that the risk of radiation-induced thyroid disease
(and possibly hyperparathyroidism) is greatest among those exposed at youngest ages (see section II.B. for
a more detailed description).  For these reasons, the Pilot Study was limited to people born from 1942-46,
since the large majority of releases of radioactive iodine from the Hanford facility occurred in 1944-46
(with the exceptions of the “Green Run” in December 1949 and the releases during 1951). Thus, the cohort
would contain people whose exposures began as early as the prenatal period, and as late as age three.  An
additional benefit of choosing this group was that mothers and close relatives of people born during 1942-
46 would more likely be alive and available for interview compared to those of people born earlier.
Selection of potential participants from the Birth Roster was stratified by geographical area, year
of birth, and sex.  The purpose of stratification by geographical area and birth year was to assure that
adequate numbers of high dose and low dose participants were identified, and a wide range of doses was
obtained.  Stratification by sex also reduced the possibility of confounding by sex that could reduce the
efficiency of the study. 
For purposes of stratified selection of subjects from the Birth Roster, geographical areas were
defined to distinguish predominantly rural areas from predominantly urban areas.  The reason for such
distinction was that it was reasonable to expect that people from predominantly rural areas may have been
more likely to consume fresh raw milk than their more urbanized counterparts.  If true, and if such
consumption patterns were an important determinant of higher dose, it might be important in the Full Study
to concentrate potential participant selection from rural areas.  At the time of protocol development, HEDR
Phase I results indicated that the distinction between fresh raw and commercial milk consumption did not
have a substantial effect on the magnitude of estimated thyroid dose (125).
Each person on the Birth Roster was assigned to the area which contained his or her “Mother's
Residence at the Subject’s Birth,” as outlined in section V.A.2.a.  Eight geographical areas, called
“geostrata” in this report, were defined:
1. Richland
2. Pasco/Kennewick
3. Walla Walla City
4. Benton County outside Richland and Kennewick
5. Franklin County outside Pasco
6. Walla Walla County outside Walla Walla City
7. Okanogan County
8. Ferry and Stevens Counties
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A.2.a.2. Completeness Required for Success
For each of the eight geostrata defined above, a target of ten living evaluable participants was
sought for the Pilot Study for each sex and year of birth.  For geostrata 2-6, there were ten strata (five years
of birth x two sexes) for a total target of 100 living evaluable participants in each area.  For geostratum 1
(Richland), there were six strata (three years x two sexes, as Richland was not defined as a geostratum
prior to 1944) for a total target of 60 living evaluable participants.  A target of five living evaluable
participants was sought in each of the ten year/sex strata for geostrata 7 and 8 (for a total of 100), however
during the Pilot Study sample selection the target of 10 living evaluable participants was actually used, for
a total of 200).  Thus, the Pilot Study attempted to enroll no less than 560 participants from geostrata 1-6,
and 200 participants from geostrata 7-8.  As a first approximation, twice this number of subjects was to be
selected from the Birth Roster to obtain the overall goal of 760 living evaluable participants.  The plan was
that if this goal was not achieved (i.e., less than a 50% success rate in locating and enrolling participants),
additional subjects would be selected in the same manner.
A.2.b. Plans for Assessing the Need for Change in the Full Study
The feasibility of basing the Full Study on a cohort identified solely from birth certificates
depended in part on whether adequate information could be obtained for a sufficiently large proportion of
cohort members, and whether the range of thyroid radiation doses obtained was sufficiently wide.
However, any decision regarding the roster of subjects for the Full Study (e.g., whether to include
additional birth year cohorts or participants identified from other sources, such as school records) would be
based on all pertinent information, and not just the data obtained and used to evaluate the above criteria.
It was anticipated that the birth cohort criteria for defining cohort members in the areas most
heavily exposed would be expanded for the Full Study.  Thus, assuming the same methods for identifying
cohort members (i.e., birth certificates), it was expected that additional birth year cohorts might be
included.  Such an expansion would likely be achieved by including people born before 1942, as this
would continue to provide the best opportunity to include people who received relatively high doses during
childhood.  It would also serve to include a larger range of ages at exposure.  However, it might also be
possible to expand the range of birth years slightly forward in time as well.
Decisions about whether and how to expand the cohort were to be based largely upon the sample
size calculations conducted at the conclusion of the Pilot Study and the resources available to the study.  If
insufficient numbers of births were available under the current criteria to satisfy the sample size
requirements of the Full Study, then clearly it would almost certainly be necessary to expand the cohort to
include additional births from other years.  If, however, it was not necessary to expand the cohort to meet
sample size requirements, such expansion, to the extent that resources allowed, would nevertheless be
proposed to increase the generalizability of the results by including a wider population representation in the
study.  Secondarily, such an expansion would serve to increase the power of the study.  
At the time the protocol was written, it was unclear whether the geographical boundaries of the
study area would change.  It was considered unlikely that the boundaries of the area exposed would be
significantly expanded.  More likely, it was thought that it might be possible (and advantageous) to restrict
the definition of “exposed” areas somewhat, based on the distribution of preliminary doses observed in the
Pilot Study.
To determine whether a geographically separate area should be identified, it was planned to
evaluate: 1) the dose distributions for participants born in the northern three counties (Okanogan, Ferry,
and Stevens); and 2) the degree to which all aspects of data collection among people geographically
removed from the Hanford site (and presumed to be less likely to be highly exposed) relative to those in
closer proximity was successfully conducted.  As described in section III-J.1 of the protocol, collectively,
these evaluations would allow a better determination of whether the geographically separate areas chosen
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for the Pilot Study would be suitable regarding doses (i.e., that most participants in those geostrata would
have relatively low doses) and logistics.  It could be, for example, that it would not be necessary to include
all of these counties in the Full Study.  In contrast, it was also recognized that the results of the Pilot Study
could indicate that none of the separate counties would be suitable for use in a Full Study.  If such a
determination was made based upon dose distributions (and not issues of feasibility of data collection), it
would be necessary to explore and define another geographical region or regions more removed from the
Hanford Site to maintain the capability of being able to conduct analyses that were not solely dependent on
HEDR individual dose estimates.  The evaluation of other potential regions would be based primarily on
the following factors: 1) meteorological data, 2) milk distribution patterns, and 3) socioeconomic and
lifestyle factors.
A.3. Revisions
A.3.a. Rationale for Revisions made in the Transition Sample
Prior to completion of the Pilot Study and before a final determination had been made regarding
the conduct of a Full Study, another selection of cohort members was made from the Birth Roster.  This
was done after consultation with the CDC and the HTDS Federal Advisory Committee, in anticipation of
continuing with a Full Study, to maintain continuity in field operations and study personnel.  This group,
called the Transition Sample, was selected prior to any analyses of the dose data from the Pilot Study.  The
Transition Sample was selected from each birth year and sex stratum in each of the following geostrata:
Richland, Pasco/Kennewick, Walla Walla City, Benton County, and Walla Walla County (further selection
from the Franklin County geostratum was not possible since all subjects in that geostratum had already
been selected for the Pilot Study sample). The Transition Sample was selected from these geostrata because
they were the most likely to have relatively high doses, and it was felt there were already sufficient
numbers of low dose participants.
A.3.b. Rationale for Revisions made in the Full Study
The power calculations described in detail in the Pilot Study Report outline the rationale for the
revisions made in the Full Study selection (see section V.A-5 below for a brief summary of these
calculations).  In short, it was determined that the cohort defined for the Pilot Study was likely to be
inadequate in size, and that greater numbers of participants in the higher dose range would be needed to
ensure sufficient statistical power for the primary dose-response analyses.  Therefore, in order to include
greater numbers of participants with thyroid doses in the higher range, it was necessary to change the years
of birth from which cohort members were selected.  Given that the largest exposures would have occurred
in 1945, it was thought more advantageous to select births from earlier years, 1940 and 1941, than from
years later than those already included in the study.  Thus, births from 1940 through 1944 were included in
the Full Study selections.  While there was some concern that including earlier births would decrease the
numbers of participants for whom a CATI respondent could be found, this was not felt to outweigh the
need to include as many higher dose participants as possible.
Essentially final results of the HEDR project became available while the HTDS Pilot Study was in
progress.  These results suggested that the geographical region defining the HTDS cohort should be revised
to meet the objective of including as many people with the highest thyroid doses as possible.  In particular,
the final HEDR results suggested that people born in Adams County might be more likely to have higher
thyroid doses from Hanford than those in the Walla Walla geostrata.
The Full Study cohort was therefore defined initially to include the Pilot Study and Transition
Samples along with (1) all remaining 1942-44 births in the Richland, Pasco/Kennewick, Benton County
and Franklin County geostrata; (2) all 1940-41 births with mother’s residence at subject’s birth in Benton
or Franklin County (which include the Pasco/Kennewick strata); and (3) all 1940-44 births with mother’s
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residence at subject’s birth in Adams County.  These birth years and geostrata were selected to ensure the
inclusion of more high dose participants, based on the dose estimates for hypothetical representative
individuals in the HEDR final report of April 21, 1994.  
The definition of the cohort was expanded one time, after it was determined that the number of
birth certificates obtained was lower than had been projected.  Originally it had been projected that 3427
living evaluable participants would be found in the Full Study cohort.  However, after obtaining the birth
certificates, because there were fewer births than anticipated and the Pilot Study showed there would be
fewer living evaluable participants than originally estimated, this projection was reduced to 3006.
Therefore, the cohort was expanded to include all remaining births between 12/31/44 and 6/30/45 in the
Richland, Pasco/Kennewick, Benton, and Adams County geostrata (no births in the Franklin County
geostratum remained unselected).  This increased the projected number of living evaluable participants
from 3006 to 3277, thereby maintaining essentially the same levels of power as originally projected.  
A.4. Outcome and Final Results
The final definition of the cohort was as follows:
1. All births from 01/01/40 to 06/30/45 (in the study counties searched for occurrence births) with
mother’s residence at subject’s birth in Benton, Franklin, or Adams counties (including the Richland
and Pasco/Kennewick geostrata).
2. A randomly selected subset of births from 07/01/45 to 12/31/46 in the same counties with mother’s
residence at subject’s birth in Benton or Franklin counties (including the Richland and
Pasco/Kennewick geostrata).
3. A randomly selected subset of births from 01/01/42 to 12/31/46 with mother’s residence at subject’s
birth in Walla Walla County (including the Walla Walla geostratum) or Okanogan, Ferry, or Stevens
counties.
Table V.A-1, below, shows the birth years within each geostratum from which subjects were
selected, by each phase of selection. Three separate selections were conducted to complete the Full Study
Sample, after the Pilot Study and Transition Samples were selected.  Table V.A-2 shows the numbers of
participants selected in each of the 100 strata for the Full Study.  Note that all people in the 1940-1944
birth cohorts for Benton, Franklin and Adams Counties (including the Richland and Pasco/Kennewick
geostrata) were selected.
Table V.A-1. Birth Years Included in Each Phase of Participant Selection
Phase of Selection
Geographic Area Pilot Transition Full 1 Full 2 Full 3
Richland 1944-46* 1944-46 1944 1/45-6/45
Pasco/Kennewick 1942-46 1942-46 1942-44 1940-41 1/45-6/45
Walla Walla City 1942-46 1942-46
Benton County 1942-46* 1942-46 1942-44 1940-41 1/45-6/45
Franklin County 1942-46 1940-41 1/45-6/45
Walla Walla County 1942-46 1942-46
Okanogan County 1942-46
Ferry/Stevens Counties 1942-46
Adams County 1940-44 1/45-6/45
* The city of Richland was defined as a geostratum separate from Benton County beginning in 1944.
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Table V.A-2 Distribution of Birth Year, Sex, and Geostratum for the Full Study Cohort
Birth Year
1940 1941 1942 1943 1944 1945 1946
Geostratum F M F M F M F M F M F M F M Total
Richland* Births 92 93 234 230 237 197 1083
Selected 92 93 142 128 43 44 542
% Selected 100 100 60.7 55.7 18.1 22.3 50.0
Pasco/
Kennewick
Births
Selected
63
63
77
77
84
84
82
82
84
84
83
83
140
140
162
162
216
216
228
228
209
131
209
127
243
41
204
40
2084
1558
% Selected 100 100 100 100 100 100 100 100 100 100 62.7 60.8 16.9 19.6 74.8
Walla Walla Births 179 205 184 182 260 255 300 336 307 322 2530
(city) Selected 44 41 41 40 40 42 40 42 41 41 412
% Selected 24.6 20.0 22.3 22.0 15.4 16.5 13.3 12.5 13.4 12.7 16.3
Benton Births 75 47 69 71 52 71 85 86 176 187 60 67 72 75 1193
County* Selected 75 47 69 71 52 71 85 86 176 187 51 57 48 50 1125
% Selected 100 100 100 100 100 100 100 100 100 100 85.0 85.1 66.7 66.7 94.3
Franklin Births 19 19 7 20 22 17 12 13 23 20 11 14 15 22 234
County Selected 19 19 7 20 22 17 12 13 23 20 11 14 15 22 234
% Selected 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
Walla Walla Births 47 53 46 66 66 71 71 58 84 80 642
County Selected 47 53 46 44 44 48 48 54 42 40 466
% Selected 100 100 100 66.7 66.7 67.6 67.6 93.1 50.0 50.0 72.6
Okanogan Births 217 236 255 280 222 237 227 253 317 306 2550
County Selected 21 22 21 20 21 22 21 21 21 21 211
% Selected 9.7 9.3 8.2 7.1 9.5 9.3 9.3 8.3 6.6 6.9 8.3
Ferry/ Births 231 233 215 234 178 197 125 117 198 227 1955
Stevens Selected 21 21 22 21 22 22 21 24 22 20 216
Counties % Selected 9.1 9.0 10.2 9.0 12.4 11.2 16.8 20.5 11.1 8.8 11.0
Adams** Births 30 31 37 36 37 44 45 44 48 45 17 21 435
County Selected 30 31 37 36 37 44 45 44 48 45 17 21 435
% Selected 100 100 100 100 100 100 100 100 100 100 100 100 100
Total Births 187 174 197 209 869 942 982 1067 1281 1333 1254 1305 1473 1433 12706
Selected 187 174 197 209 328 352 412 430 682 707 482 488 273 278 5199
* The city of Richland was defined as a geostratum separate from Benton County beginning in 1944.
** 1945 Adams County number of births is for January-June only (all other geostrata include some July-December 1945 births).
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A.5. Summary of Full Study Power Calculations, as Presented in HTDS Pilot Study
Report
Two primary objectives of the Pilot Study were to assess the suitability of areas chosen for the
selection of study participants, and to utilize Pilot Study dose information and response rates to estimate
sample sizes required to achieve adequate statistical power for a Full Study. As is often the case with
observational studies such as the HTDS, sample size and dose distribution cannot be chosen independently.
In particular, as the sample size increases, the relatively small groups of subjects likely to have the highest
doses are all selected, and further selections must be made from the relatively larger groups of people
likely to have smaller doses.  As a result, beyond a certain number, the effect of increasing sample size is to
a certain extent offset by the effect of decreasing mean and variance of the resulting dose distribution.
As described in Appendix H of the HTDS Protocol (1), the primary power calculations focused on
tests of the dose-response for the endpoint of thyroid neoplasia (malignant and benign).  Calculations were
also performed for two additional endpoints: thyroid malignancy and ultrasound-detected abnormality of
the thyroid (thyroid UDA).  These three outcomes were selected since they provided a range of baseline
outcome percentages: low (malignancy), intermediate (thyroid neoplasia), and high (UDA).  Sample sizes
were calculated for the χ2 test for linear trend in the cumulative incidence of disease with stratification by
sex.  In particular the sample size N required for the one-sided test with critical level α to achieve statistical
power 1-β to detect a dose-response coefficient B is given by the formula:
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where
zp = Φ-1(p) denotes the 100p-th percentile of the standard normal distribution,
i = 1,2 indexes the I=2 sexes,
πi =  proportion of the N participants of sex denoted by i,σ2 = variance of the dose distribution, and
Pi = Pi(µ) = Ai + Bµ is the probability of disease for sex denoted by i and dose equal to the mean dose µ.
This formula indicates that, as is typically the case, the required sample size is largely determined by the
variance σ2: in particular the required sample size is roughly inversely proportional to σ2. The effect of the
mean dose is much more limited. For a given sample size N, the equation above can be solved for the
power 1-β.  This approach was used under various assumptions about sample size, and power was
displayed in figures as a function of the dose-response coefficient B.   The resulting plot indicates in a
comprehensive way the power of the planned analyses to detect radiation effects of various magnitudes.
The approach taken in the analysis of the Pilot Study results was to project the mean and variance
of doses that might be obtained under various plans for selecting subjects to complete the sample for a Full
Study.  Consideration focused on three such plans: 
Plan 1: 
Remaining sampling would be restricted to birth records from 1942-44 for the Richland,
Pasco/Kennewick, Benton County, and Franklin County regions.  All remaining subjects from these
strata would be included in the Full Study.
Plan 2:
In addition to Plan 1, the definition of eligibility would be expanded to include births during
1940-41 to mothers whose residence at time of birth was in Benton and Franklin Counties, and all such
births would be included in the Full Study.  Note that these two counties include Pasco and Kennewick,
which do not need to be distinguished as a separate geographical region.
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Plan 3:
In addition to Plan 2, the definition of eligibility would be expanded to include births during
1940-44 to mothers with residence at the time of birth in Adams County, and all such births would be
included in the Full Study.
Note that Plan 1 required only projections based on dose data available from the Pilot Study,
while Plans 2 and 3 required projections of dose distributions for years and/or regions not included in the
Pilot Study.  The methods for calculating projected means and variances for both types of projections were
described in Appendix B of the Pilot Study Final Report. 
The projected sample sizes, means and variances for these three plans, based on all dose data
available from either the Pilot Study sample or the combined Pilot Study and transition sample, are shown
in Table V.A-3. 
Table V.A-3. Sample Size (N) and Projected Dose Mean and Variance (rad) of Full Study Dose
Distribution for the Three Additional Sampling Plans
Pilot Only (n=869) Pilot and Transition (n=1139)
Plan N Mean Variance Mean Variance
1 2619 13.7 361.1 14.5 372.9
2 3081 13.5 353.6 14.4 367.3
3 3427 14.6 393.8 15.4 404.3
The HTDS was based on a cohort of people defined by the following eligibility criteria:
• Mother’s residence at the time of the participant’s birth: Benton, Franklin, Walla Walla, Okanogan,
Ferry, Stevens, or Adams County in Washington State
• Year of birth: 1940 – 1946.
The rationale for this choice of counties and years is described in sections IV.A.1 and IV.A.2 below.
The mother’s usual residence at the time of the participant’s birth, which can be determined from birth
records, was used as a criterion since it was likely to indicate the participant’s place of residence during the
first years of Hanford’s operations, when the largest releases of 131I occurred (see section V.A.2 below).
The cohort included the majority of the possible combinations of the seven counties and seven birth years.
However birth year subcohorts for certain counties were not included since they were unlikely to include
many participants with relatively high thyroid radiation doses (see sections V.A.2 and V.A.3 below).
Power functions of tests for dose-response based on the projections derived from the Pilot Study
only are shown in Figures V.A-1 through V.A-3 for the endpoints of thyroid neoplasia (benign and
malignant combined), thyroid cancer, and thyroid UDAs.  In each figure, the lowest curve is based on Plan
1, and the highest on Plan 3.
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Figure V.A-1. Projected Power Function: Thyroid Neoplasia Plans 1, 2 and 3
0
0.2
0.4
0.6
0.8
1
0 1 2 3 4 5 6 7 8 9 10
Excess Risk (%) per Gy
P
o
w
e
r
Plan 1
Plan 2
Plan 3
Figure V.A-2. Projected Power Function: Thyroid Malignancy Plans 1, 2, and 3
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Figure V.A-3. Projected Power Function: Ultrasound Detected Abnormalities of the Thyroid
Plans 1, 2 and 3
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For the analysis of thyroid neoplasia (defined in the Protocol and Pilot Study as “all thyroid
nodules)," the baseline percentages of patients with disease were taken as 5% for women and 2% for men
(see Appendix H of the HTDS protocol for the derivation of these percentages).  Based on data from the
869 Pilot Study participants, Plan 1 was projected to provide power of 0.83 to detect a dose-response
coefficient of 5% per Gy.  Under Plans 2 and 3 this increased to 0.87 and 0.92, respectively (Figure V.A-
1).  Thus with Plan 3 there would be adequate power to detect about a doubling (tripling) of risk among
women (men) at 1 Gy (1000 mGy).  This magnitude of effect is similar to that projected from the relative
risk model of BEIR V as described in Appendix H of the HTDS protocol.  It is also comparable to that
recently reported for the Utah Study.  Kerber et al. (53) reported a significant radiation dose-response for
thyroid neoplasia during 1965-86 (p=0.019), with an estimated relative risk of 8.0 at 1 Gy (95% lower
confidence bound 1.7).
The baseline percentages of participants with thyroid malignancy were taken to be 0.7% for
women and 0.3% for men (see Appendix H of the protocol).  Plans 1, 2, and 3 were projected to provide
power of 0.80, 0.90, and 0.94, respectively, to detect a dose-response of 2.5% per Gy (Figure V.A-2).
For an analysis of thyroid UDAs, the baseline percentage of participants with such findings was
taken as 40% for both sexes, based on information available from reports of thyroid ultrasound screening
in unselected populations and the experience in the Pilot Study.  Plans 1, 2, and 3 were projected to provide
power of 0.90, 0.94, and 0.97 to detect a dose-response of 15% per Gy (Figure V.A-3).
A number of assumptions were made in the projections of statistical power described above.  To
assess the sensitivity of the projections to these assumptions, i.e., to assess whether deviations from any of
these assumptions might lead to significant changes in the projected levels of power, additional power
calculations were performed with these assumptions modified.  The following assumptions were examined
in these sensitivity calculations: 1) baseline rates of disease, 2) projected sample size, 3) doses from
expanded In-Person Interviews, 4) doses for participants born during 1940-41, and 5) Adams County
doses. In addition, the combined effects of deviations in more than one of these assumptions were
investigated. The detailed results of these sensitivity calculations were provided in the Pilot Study Final
Report (pages 55-74). Based on the results, the following conclusions were reached: 
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1. Cohorts identified from birth records were likely to provide a sufficiently wide distribution of
doses for successful completion of a Full Study.
2. The cohorts defined for the Pilot Study were likely to be inadequate for completing a Full Study,
and they should be augmented by the additions of 1940-41 Benton and Franklin Counties and
1940-44 Adams County births.
As described above, the modification proposed in the second conclusion was adopted.  However,
following the collection of the birth certificate data for the additional birth years and Adams County, and
the analysis of more complete data regarding participation rates, it was apparent that further expansion of
the cohort was needed.  This was accomplished by extending the range of birth dates for Benton, Franklin,
and Adams Counties to June 30, 1945.
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B. Tracing Potential Participants
B.1. Background
The HTDS was conducted as a follow-up cohort study.  Members of the study cohort were
identified based on location of birth in the early to mid-1940’s from birth certificates.  Consequently,
extensive effort would be required to locate cohort members, who were young children at the time of
exposure, as adults nearly fifty years later.  In addition, to identify all past and present thyroid disease in
cohort members, participation in the study could not be limited to telephone contact, but would require in-
person attendance for medical evaluation regardless of the participant’s current area of residence.
B.1.a. Objectives of Tracing
The primary objective of the tracing was to identify a current address and telephone number for all
living potential participants, so they could be recruited to participate in the study.  A second objective was
to obtain confirmation of death, as well as date and cause of death for all those deceased.
B.1.b. History of Tracing Efforts Around Hanford
Prior to the HTDS, a separately funded study had been conducted by investigators at the FHCRC
to determine if former residents of the Hanford area could be traced to their current residences for the
purposes of an epidemiologic study of radiation releases from the Hanford site.  The primary objectives of
this preliminary study were: 1) to design and test field procedures for identifying a group of potentially
exposed persons; 2) to attempt to trace each person forward in time to the present or until death; 3) to
obtain a current address and/or telephone number for each person; 4) to explore the feasibility of
interviewing people identified; and 5) to explore the feasibility of obtaining medical records to verify self-
reported illness histories.
The population selected for this preliminary study was defined by the rural area directly east of the
Hanford Nuclear Site in Franklin County, containing 37 farm blocks subdivided into approximately 1897
farm units.  Four farm blocks were randomly selected from the area, two being in the area of the two
research interviewers’ homes, and two being remote from these areas.  In this manner, it was hoped that
each interviewer would be working within an area that was very familiar and within which she would
personally know the residents, as well as in one area which was quite unfamiliar.  
Each interviewer was to obtain as much information as possible about anyone who resided in the
assigned farm blocks from the time they were first inhabited until the present.  Most farm blocks were first
inhabited in the early 1950’s due to the Columbia Basin Land Reclamation Project.  However, some farm
blocks were inhabited as early as 1909.
The principle sources of information the interviewers used to initially identify the population
living in the selected farm blocks was a title company in Pasco, Washington which recorded a complete
record of ownership for each farm unit.  Because ownership records do not include family members or
other residents, additional information was obtained through library references, telephone books, personal
visits, and telephone calls.  Thus, a chronology of persons who resided in each farm unit was constructed.  
A total of 126 persons were found to have resided on the 14 occupied farm units within the four
farm blocks.  This number includes primary owners/residents, their children, employed farm workers and
their families.  For all but four residents (3%), actual years of residency were ascertained.  Sixty-four (51%)
residents lived on the farm units for some period between 1949 and 1965, a time period that encompassed
much of the radioactive releases from Hanford. 
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Of the 126 persons identified, ten (8%) were documented to be deceased.  An additional eight
persons (6%) could not be located.  Slightly more than half of those identified and located were currently
still living on the farm units.  Another 15% were resident in the immediate area, and 5% were within
Washington or a neighboring state.  The remainder of those located resided in the Western U.S.  
The results suggested that identifying, tracing, and locating residents of this region during the time
period of interest regarding Hanford radiation releases was feasible, at least for the more rural segment of
the population.
B.1.c. Overview of Tracing Efforts
At the time the HTDS protocol was written, tracing and locating large numbers of people who
were born in the areas of interest up to 50 years ago presented significant logistical challenges.  It was
presumed this would be particularly true for women, many of whose surnames would have changed at least
once in the intervening years because of marriage.
The initial approach to locating and tracing individuals is depicted graphically in Figure V.B-1.
As shown in the diagram, searches were initiated based on the cohort member's name, the father's name and
the mother's name.  At the start of the search, efforts were concentrated on locating any one of these three
individuals until enough information was obtained to focus on the location of the potential participant. The
tracing process was to be undertaken as an investigative process, using different sources, as they needed to
be pursued.   The sources depicted were generally pursued in the order shown, beginning with the most
readily available, least costly and least labor intensive, and progressing toward the most costly and most
labor intensive until the potential participant was located or until all reasonable effort had been expended.
See below for a more detailed description of the tracing effort.
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Figure V.B-1. Locating and Tracing Potential Participants
FATHER’S NAME
POTENTIAL
PARTICIPANT’S NAME
MOTHER’S NAME
AVAILABLE FROM COMPUTER
MATCHING OF STATE RECORDS
• Birth records
• Department of motor vehicles
• Death records
READILY AVAILABLE, MINIMAL
INFORMATION REQUIRED
• Telephone directories
• Post Office forwarding
• City and reverse directories
• Existing high school reunion lists
• Voters records
• Utility Records
READILY AVAILABLE, MINIMAL
INFORMATION REQUIRED, LABOR
INTENSIVE
• Neighborhood searches
• Former school teachers
• Old newspaper searches for death,
birth and marriage announcements
• Other historical records
LIMITED AVAILABILITY, LABOR
INTENSIVE
• Agricultural, civic, religious and
veterans organizations
• Labor unions
• Additional high school reunion lists
AVAILABLE, COSTLY
• Locating service
• Public appeal
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Initially, two approaches were utilized to trace potential participants.  The first was a series of
computer matches of the study cohort to databases maintained by the State of Washington. These included: 1)
death certificates; 2) recent birth certificates (second generation births), linking through both the father's and
mother's name (i.e., the potential participant's name); and 3) Department of Licensing (Driver’s License and
Motor Vehicle Registration) information.  The second approach was to use readily available and relatively
inexpensive sources. These included primarily searches of telephone books, city directories, and Cole's reverse
directories.  In addition, several school reunion lists had already been obtained, and additional lists were
sought as sources of potential participant follow-up.  Field staff also searched for information using the Social
Security Death Index kept by the Genealogical Library of the Church of Jesus Christ of Latter Day Saints.
This source was particularly useful in locating family members through the deceased parent’s Social Security
payments. 
Persons not located with the computer matches or through the use of readily available sources were
sought using more intensive search methods including the use of county records of marriage records, and using
local libraries to search old newspapers for obituaries, wedding and birth announcements.  An attempt to locate
individuals not found using any of the above sources was made through contacts in the communities.   
To minimize the potential for bias in locating cohort members that might be related to either exposure
or disease status, it was decided that several possible sources of information would not be used.  These
included population-based tumor registries, unsolicited self-report by members of the public, and mailing lists
related to Hanford issues.  Because each of these sources could be the only means of locating some persons,
and inclusion in these sources might be related both to exposure status and/or thyroid disease status, they were
specifically avoided for tracing purposes.
When contacting people who may have had information on the potential participant’s location, such
as the potential participant’s mother or father, they were told that we were attempting to locate people who had
been selected from birth certificates to participate in a medical research study.  If the contact requested
additional information, they were told that the study was the Hanford Thyroid Disease Study and were given
basic information about the study.  If the person requested additional information before disclosing the location
of the potential participant, he or she was advised to contact the Seattle office toll-free telephone line. When
contacting potential study participants a script was used to provide basic information about the HTDS and to
inform them that a letter would be sent explaining the study in detail.  If more information about the study was
needed, the potential participant was advised to call the Seattle office toll-free telephone number and speak
with the Participation Coordinator.  
B.1.d. Staffing and Logistics
The tracing field staff consisted of several employees located in eastern Washington. A procedure
manual was used to prioritize steps to be taken in locating potential participants.  Records of each step in the
search for each potential participant were kept to learn more about the most efficient methods for locating
potential participants.   Regular meetings were held in the Tri-Cities with the Project Manager and Principal
Investigator to assess the success of this component throughout the fieldwork phase of the study.
B.2. Revisions to the Original Protocol Plan
B.2.a. Deletion of Ineffective Sources of Information and Addition of New Sources
During the Pilot Study, it was determined that some of the more difficult to use and often most
expensive sources were less effective and these were not actively pursued in the Full Study.  For example, high
school reunion lists were moderately helpful in the Pilot Study (useful information was obtained in 41% of the
cases in which such lists were used), but required rather extensive efforts to obtain. Overall, school records
were not a major source of tracing information.  The use of a locator service toward the end of the Pilot Study
proved to be very expensive per potential participant located, and the results varied considerably.  This source
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was not routinely used beyond the Pilot Study, but was replaced by sources mentioned below, provided by the
newly developed FHCRC Tracking Resource Center (TRC).
The use of more intensive contacts in small communities in the region was explored in the last few
months of the Pilot Study Tracing process.  Study staff made several trips during the Pilot Study to small
towns to talk to local citizens and "old-timers" and to look through local records (e.g., marriage, utilities,
property records). In general, these trips were moderately successful but labor intensive. Local postmasters,
teachers, and community leaders were able to provide some guidance, and often helped to gain access to local
records that might otherwise have been difficult to obtain.   Such sources were used for only a very few
potential participants, but when it was appropriate to pursue such sources, they were generally very successful
in locating that potential participant. 
In summary, the experience gained in the Pilot Study tracing effort identified a number of key
approaches and sources of information that proved to be useful in locating potential participants. These
approaches and sources defined the primary methodology used in locating the remaining potential participants
needed for a Full Study.  Those methods and sources that did not prove to be as useful were reserved for the
most difficult to locate, when other resources had been exhausted.
B.2.b. Addition of Computer On-line Database Information
Late in the tracing process for the Full Study, a Tracking Resource Center (TRC) was developed by
the FHCRC.  This resource was designed to provide tracing, locating, and tracking services to a number of
Center projects needing to identify and locate study participants or former patients.  The TRC was utilized by
the HTDS to locate potential participants who could not be located by other means.  Additional new resources
available through the TRC were: 1) a national, on-line database resource providing matches by name and
previous address; and 2) a national, on-line database providing matches by name and date-of-birth, linking
multiple public records available at that time.  While the use of these resources tended to be more expensive,
they were less labor intensive and frequently provided leads to assist in locating individuals who were the most
difficult to locate.
B.3. Final Tracing Process
Tracing of potential participants was conducted in three stages, in the following chronological order
for most potential participants.  The first stage consisted of a series of linkages with publicly available data
sources.  The second stage, which constituted the majority of the tracing effort, utilized a variety of resources
to look for potential participants on an individual basis.  The third stage, undertaken only for those individuals
most difficult to locate, was to enlist the services of the newly created FHCRC Tracking Resource Center
and/or a professional locating company.
B.3.a. Linkages with Publicly Available Data Sources
Five types of linkages to publicly available data sources were performed on either the entire study
sample or the appropriate subgroup, based on type of linkage.  First, the study sample was manually matched
to Washington State infant death certificates for the years 1942-1950 for the six original Pilot Study Counties 
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(not including Adams).1   Second, the study sample was matched by computer to the Washington State Death
Index (WSDI) for the years 1965-1990.2  This included some records for Washington State residents who died
outside of Washington, which were obtained through interstate exchange agreements.  For females, matching
to the death index was based on the potential participant’s birth name from the birth certificate and the Father’s
surname as reported on the death certificate.  Third, the Pilot Study sample was manually matched to a list of
Washington State Vietnam War deaths.  Because of the low return from searching the Vietnam War Deaths list
(only one match was found for the entire Pilot Study sample), routine searching of this list was not continued
for all potential participants in the Full Study samples, but was referred to as appropriate for more difficult to
locate individuals. 
The fourth step was perhaps the most unusual linkage undertaken in this series of linkages.
Washington State birth certificates list mother’s maiden (or birth) and current name, father’s name, mother’s
and father’s ages, and the child’s name.  To use this information to find study participants, female potential
participant birth names were matched to mother’s maiden name on Washington State birth certificates for the
period 1956-1990 (second generation births), primarily to identify possible married names. For matches found
in this way, the child's last name was assigned as a potential married name for the mother.  
Fifth, the names of the entire study sample (including possible married names obtained in step four,
above) were matched to the Washington State Department of Licensing (WSDOL) Driver’s License Records
by name and date of birth.  This match was periodically re-run during the course of the study as the WSDOL
records were updated.  Matches were also conducted individually as new possible married names, children’s
names, and spouse names were identified.
After the final linkages for the entire group were performed and some potential participants located,
three additional linkages were performed only on potential participants not yet located.  For the Pilot Study,
potential participant parents’ names were matched by computer to the WSDI (1965-1990), using father’s
name, mother’s maiden name and mother’s potential married name from the potential participant’s birth
certificate.  The purpose of this link was to provide dates and place of death for parents for whom an obituary
could then be found.  Because most obituaries list the survivors (including current names and place of
residence), this information was sometimes used to locate the potential participant or a relative of the potential
participant.  Since the parents’ dates of birth were not available on birth certificates (only age was listed), this
linkage resulted in many possible matches and was not repeated for the Full Study Sample. 
The second additional linkage performed for potential participants not located initially was to match
males to father’s name on Washington State birth certificates from 1956-1990 (second generation births) to
identify possible children, through whom the potential participant may be located.   Children identified this
way were then matched to the WSDOL records.
The final computer linkage, completed only for the Pilot Study, was to match female potential
participants’ names (both birth and potential married names) to centralized Washington State marriage records,
stored on microfiche, from 1970-present.  New potential married names identified through this linkage were
then matched to the WSDOL records.  For the Full Study, this search was done on an individual basis, mainly
at the county level, as the same access to these files was not possible at the time of the Full Study.
During the Full Study, matching against the National Death Index (NDI) files became available.  The
NDI is a central computerized index of death record information since 1979, compiled by the National Center
of Health Statistics from information submitted by state vital statistics offices.  Each record contains a standard
set of identifying data for each decedent.  Matches were performed for all potential participants not already
located.  In addition, parent names from the potential participant’s birth certificate were matched for some
potential participants.  In this way, the informant listed on the parental death certificate could be used as a
source for locating the potential participant.
                                                          
1 Infant death certificates were not routinely reviewed for 1940 and 1941 due to access problems.
2 The WSDI was reviewed for all subjects classified as unable to locate throughout the tracing process, the most current issue of the WSDI
was periodically reviewed for individuals not located in initial attempts.
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Several scenarios were possible for information on a given potential participant from the data
linkages.  These included:
1. Data linkage shows potential participant deceased: For all potential participants linked to a
Washington State Death Record, a death certificate (DC) was requested from the state. While
these linkages were performed as "exact matches" (highest possible likelihood that this is the
right person), great care was taken to check the death certificate against the birth certificate for
any indication that this may be a mismatch.
2. Data linkage shows potential participant linked to subsequent birth: For female potential
participants linked to subsequent births, the data from the match were checked against all
information entered on the potential participant birth certificate and tracing sheet.  If this
appeared to be a likely match and a potential married name was elicited, tracing efforts were then
directed toward this name until such time that it was confirmed this was indeed the right person.
3. Data linkage shows new address based on WSDOL: Linkage to this source was performed using
birth certificate names as well as possible new names generated from the subsequent births
listing.  The new address information represented the current address held by the WSDOL for
that person.  The date the information was given to WSDOL as valid was included in the listing.
B.3.b. Manual Tracing Resources
Following the data linkages performed on the potential participant roster database, information was
transferred to the eastern Washington staff to conduct tracing efforts manually for each individual.  A copy of
each potential participant’s birth certificate was included in a file created for each potential participant which
also included the tracing forms specifically designed for use in this study for documentation of tracing efforts
undertaken (See Appendix 3).
The second stage of tracing activity utilized numerous sources identified and pursued by HTDS study
staff.  In general, after the initial linkages were complete and the matches provided, the tracing staff first
undertook the process of locating those potential participants with the most promising information available.
This approach was taken to ensure a steady supply of potential participants to be recruited and scheduled for
clinics and to keep the study progressing as efficiently as possible.  For example, potential participants (or their
parents) with exact matches to the WSDOL data (providing addresses) were next searched through telephone
directories, city/reverse directories and/or CD-ROM directories and other available resources.  
Following the Pilot Study, several changes were made to the databases used to record tracing
information.  Information on the usefulness of sources was no longer collected.  In addition, some sources,
such as newspapers, were split into two or more categories to better capture the purpose of their use, such as
locating obituary information.  For this reason, separate tables are shown here for the Pilot Study Sample, and
Transition and Full Study Samples.  Tables V.B-1 and V.B-2 display the number of potential participants for
whom each manual source was ever used for those in the Pilot Study Sample, and those in the Transition and
Full Study Samples. 
Overwhelmingly, the primary sources of information for tracing potential participants were telephone
directories, family members, and various public records.  Initially, phone book searches were conducted by
hand, utilizing current and historical phone books obtained by the study and those available in local and
regional libraries.  Consequently, nearly all (97%) cohort members selected during the Pilot Study were sought
in phone books (Table V.B-1).  Early in the Pilot Study, however, CD-ROM products listing published phone
numbers throughout the United States were acquired for this purpose and used extensively, but did not replace
telephone directory use.  About half of cohort members in the Transition and Full Study samples were sought
in phone books, and 89% on CD-Rom directories (Table V.B-2).  Directory assistance throughout the United
States was also used extensively.  Of the other types of sources used, the Social Security death rosters, City
and County records (e.g., marriage records), and obituary information from newspapers and funeral homes
were used the most.  The category "Other Sources" in the following tables includes numerous other approaches
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utilized by tracing staff that were limited to a very few potential participants for any given source.  Table V.B-
3 depicts the usefulness of sources in locating potential participants, based on the Pilot Study experience.
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Table V.B-1. Tracing Sources Used, All Potential Participants – Pilot Study Sample
Source*
Source Was Ever Used (N=1587) †
Percent of Potential
No. of Potential Participants Participants (%)
Directories
• Telephone directories (hard copy)
• CD-ROM telephone directories
• Directory assistance
• City/Reverse directories
• CA People Finder/Western Gold
School Records
• High school reunion lists
• Other school records
• Alumni organizations
• School registration records
• Former school teachers
Other Specific Sources
• Relatives
• Social Security roster
• City/county records (includes
marriage records)
• Locating service
• Online services*
• Death certificates
• Newspapers
• Funeral home/cemetery
• Neighborhood searches
• HTDS-ID letters
• Employers
• Libraries
• Postal service
• Veterans organizations
• Letter to Social Security
Administration
• Native American sources (tribes and
IHS)
• Other HTDS participants
• Birth certificates
• Religious organizations
• Civic organizations
• Agricultural organizations
• Utility records
• Labor unions
• Voter registration
• Military reunion lists
• Historical documents
Other sources
1546
769
691
542
8
187
13
8
4
2
850
689
307
189
130
80
63
56
51
36
35
28
17
14
12
9
9
8
6
6
4
2
2
2
1
1
56
97.4
48.5
43.5
34.2
0.5
11.8
0.8
0.5
0.3
0.1
53.6
43.4
19.3
11.9
8.2
5.0
4.0
3.5
3.2
2.3
2.2
1.8
1.1
0.9
0.8
0.6
0.6
0.5
0.4
0.4
0.3
0.1
0.1
0.1
0.1
0.1
3.5
* The sources listed in this table do not include record linkages performed prior to entry of potential participants into the tracing system.
† Excludes 3 potential participants for whom no tracing data were entered due to a clerical error.
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Table V.B-2. Tracing Sources Used, All Potential Participants – Transition and Full Study Samples
Source*
Source Was Ever Used (N=3475)†
Percent of Potential
No. of Potential Participants Participants (%)
Directories
• CD-ROM telephone directories
• Telephone directories (hard copy)
• Directory assistance
• City/reverse directories
• CA People Finder/Western Gold
School records
• High school reunion lists
• School registration records
• Former school teachers
Other specific sources
• Relatives
• Social Security roster
• Obituaries/funeral homes
• Death index/death records
• Online services
• Marriage licenses
• Response to HTDS-ID letter
• Tax assessors
• Neighborhood searches
• Postal service
• Employers
• Locating service
• Letter to Social Security
Administration
• List of Vietnam veterans
• Military locator service
• Voter registration
• Labor unions
• Other city/county records
• Civic organizations
• Agricultural organizations
• Religious organizations
• Veterans organizations
• Utility records
Other sources
3106
1750
1014
919
28
121
9
1
1440
1410
1070
565
491
289
166
76
45
33
32
22
16
10
10
9
3
3
2
2
2
1
1
90
89.4
50.4
29.2
26.4
0.8
3.5
0.3
< 0.1
41.4
40.6
30.8
16.3
14.1
8.3
4.8
2.2
1.3
0.9
0.9
0.6
0.5
0.3
0.3
0.3
0.1
0.1
0.1
0.1
0.1
< 0.1
< 0.1
2.6
* The sources listed in this table do not include record linkages performed prior to entry of potential participants into the tracing system.
† Table excludes n=134 potential participants who were not entered into the HTDS tracing system.  All but one of these potential
participants (n=133) were located with information obtained from record linkages with the Washington state Department of Licensing,
prior to the implementation of the revised tracing system for transition and full study potential participants.  As a result of clerical error,
the remaining potential participant was never entered into the tracing system and, therefore, was not traced.
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Table V.B-3. Usefulness of Tracing Sources in Locating Study Potential Participants – Pilot Study 
Only (N=1587)†
   Source was Ever Source Lead to or Resulted in
Used** Locating Potential Participant
Source*        No.          %          No.            % ††
Directories
• Telephone directories (hard copy) 1543 97.2 1165 75.5
• CD-ROM telephone directories 762 48.0 744 97.6
• Directory assistance 664 41.8 523 78.8
• City/reverse directories 535 33.7 240 44.9
School records
• High school reunion lists 184 11.6 75 40.8
• Other school records 13 0.8 12 92.3
• Alumni organizations 8 0.5 7 87.5
• School registration records 4 0.3 2 50.0
• Former school teachers 2 0.1 0 --
Other specific sources
• Relatives 820 51.7 812 99.0
• Social Security roster 672 42.3 312 46.4
• City/county records (includes marriage
records)
304 19.2 154 50.7
• Locating service 187 11.8 85 45.5
• Newspapers 63 4.0 56 88.9
• Death certificates 51 3.2 44 86.3
• Neighborhood searches 50 3.2 32 64.0
• Funeral home/cemetery 35 2.2 28 80.0
• Employers 33 2.1 28 84.8
• Libraries 28 1.8 27 96.4
• Postal service 16 1.0 14 87.5
• Veterans organizations 14 0.9 7 50.0
• HTDS-ID letters 13 0.8 13 100.0
• Letter to Social Security Administration 12 0.8 12 100.0
• Native American sources (tribes and IHS) 9 0.6 7 77.8
• Other HTDS participants 9 0.6 9 100.0
• Birth certificates 8 0.5 8 100.0
• Religious organizations 6 0.4 6 100.0
• Civic organizations 6 0.4 5 83.3
• Agricultural organizations 4 0.3 4 100.0
• Utility records 2 0.1 1 50.0
• Labor unions 2 0.1 0 --
• Voter registration 1 0.1 1 100.0
• Military reunion lists 1 0.1 1 100.0
• Historical documents 1 0.1 1 100.0
Other sources 56 3.5 49 87.5
* The sources listed in this table do not include record linkages performed prior to entry of potential participants into the tracing system.
** These numbers differ from those in Table V.B-2 as this table contains only tracing performed prior to the end of the Pilot Study, after 
which information on usefulness of sources was no longer collected.
† Excludes 3 potential participants for whom no tracing data were entered due to a clerical error
†† Percent of those for who source was ever used.
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B.3.c. Unlocated Potential Participants
Extensive efforts were made to locate each potential participant identified through birth certificates.
While the tracing effort was extremely successful, not all potential participants could be located from the
minimal information provided by a birth certificate from 50 years ago.  Tables V.B-4 and V.B-5 show efforts
expended on potential participants not located.  Before efforts were closed out on any individual potential
participant, an extensive amount of effort was required.  This effort included all of the linkages performed in
the initial tracing phase, along with four primary sources that would be tried for everyone.  These sources
included telephone directories, CD-ROM telephone directories, the Social Security death roster or WSDI, and
one on-line service as mentioned above.  These represented the only manual sources that were appropriate to
try for all potential participants. 
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Table V.B-4. Tracing Efforts for Those Not Located – Pilot Study Sample
Source Was Ever Used (N=78)
Source        No. Percent of Unlocated (%)
Directories
• Telephone directories (hard copy) 77 98.7
• CD-ROM telephone directories 77 98.7
• City/reverse directories 62 79.5
• Directory assistance 61 78.2
• CA People Finder/Western Gold** 5 6.4
School records
• High school reunion lists 11 14.1
• School registration records 2 2.6
• Other school records 1 1.3
• Alumni organizations 1 1.3
Other specific sources
• Social security roster 75 96.2
• Online services** 70 89.7
• Locating service 48 61.5
• City/county records (includes
marriage records)
45 57.7
• Death certificates 21 26.9
• Relatives 11 14.1
• Neighborhood searches 5 6.4
• Funeral home/cemetery 5 6.4
• HTDS-ID letters 5 6.4
• Letter to Social Security
Administration
4 5.1
• Newspapers 3 3.8
• Libraries 2 2.6
• Postal service 2 2.6
• Employers 1 1.3
• Native American sources (tribes and
IHS)
1 1.3
• Other HTDS participants 1 1.3
• Birth certificates 1 1.3
• Agricultural organizations 1 1.3
• Labor unions 1 1.3
• Voter registration 1 1.3
Other sources 3 3.8
* The sources listed in this table do not include record linkages performed prior to entry of potential participants into the tracing system.
** Sources initiated during the transition/full study
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Table V.B-5. Tracing Efforts for Those Not Located – Transition and Full Study Samples
Source Was Ever Used (N=242)
Source No. Percent of Unlocated (%)
Directories
• CD-ROM telephone directories 240 99.2
• Telephone directories (hard copy) 218 90.1
• City/reverse directories 155 64.0
• Directory assistance 122 50.4
• CA People Finder/Western Gold 26 10.7
School records
• High school reunion lists 20 8.3
• School registration records 2 0.8
Other specific sources
• Social security roster 232 95.9
• Online services 225 93.0
• Obituaries/funeral homes 158 65.3
• Death index/death records 139 57.4
• Marriage licenses 48 19.8
• Relatives 25 10.3
• Response to HTDS-ID letter 20 8.3
• Tax assessors 11 4.5
• Postal service 6 2.5
• Neighborhood searches 5 2.1
• List of Vietnam veterans 4 1.7
• Locating service 3 1.2
• Letter to Social Security
Administration
3 1.2
• Military locator service 3 1.2
• Employers 2 0.8
• Voter registration 2 0.8
• Civic organizations 2 0.8
Other sources 13 5.4
* The sources listed in this table do not include record linkages performed prior to entry of potential participants into the tracing system.
Tracing potential participants based on birth certificates from the 1940s required the use of multiple
sources of information in most cases. After the initial linkages were performed, more than one source of
information was used for virtually all of the potential participants being traced. This is because even when a
computer linkage was made (e.g., with WSDOL files), at least one additional step was almost always required
to obtain information sufficiently detailed to contact the potential participant (e.g., a telephone number).  For
those most difficult to locate, many sources may have been used before the potential participant was located or
determined to be unlocatable. Tables V.B-6 and V.B-7 summarize the extent to which multiple sources were
used in the Pilot Study Phase and the Transition and Full Study Phases, by tracing outcome.  The number of
sources used after the initial linkages ranged from 1 - 16, with a mean of 4.8 sources per potential participant
for the Transition and Full Study Phases. 
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Table V.B-6. Number of Sources Used to Trace Located and Unlocated Individuals – 
Pilot Study Sample
         Located         Unlocated         Total
Number of
Sources Used No. % No. % No. %
1 13 0.9 0 -- 13 0.8
2 264 17.5 0 -- 264 16.6
3 242 16.0 0 -- 242 15.2
4 214 14.2 1 1.3 215 13.5
5 206 13.7 3 3.8 209 13.2
6 188 12.5 8 10.3 196 12.4
7 135 8.9 16 20.5 151 9.5
8 111 7.4 13 16.7 124 7.8
9 50 3.3 13 16.7 63 4.0
10 37 2.5 10 12.8 47 3.0
11 28 1.9 6 7.7 34 2.1
12 9 0.6 5 6.4 14 0.9
13 4 0.3 2 2.6 6 0.4
14 3 0.2 1 1.3 4 0.3
15 3 0.2 0 -- 3 0.2
16 0 -- 0 -- 0 --
17 2 0.1 0 -- 2 0.1
Total 1509 100.0 78 00.0 1587† 100.0
Mean no. of
4.99 8.54 5.16
sources
* The sources listed in this table do not include record linkages performed prior to entry of potential participants into the tracing system.
† Table excludes 3 potential participants for whom no tracing data were entered due to a clerical error.
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Table V.B-7. Number of Sources Used to Trace Located and Unlocated Individuals – 
Transition and Full Study Samples
         Located         Unlocated           Total
No. of
Sources Used No.            % No. % No.             %
1 108 3.3 0 -- 108 3.1
2 474 14.7 2 0.8 476 13.7
3 664 20.5 1 0.4 665 19.1
4 563 17.4 0 -- 563 16.2
5 334 10.3 11 4.5 345 9.9
6 307 9.5 19 7.9 326 9.4
7 240 7.4 38 15.7 278 8.0
8 210 6.5 46 19.0 256 7.4
9 149 4.6 48 19.8 197 5.7
10 93 2.9 30 12.4 123 3.5
11 50 1.5 23 9.5 73 2.1
12 22 0.7 12 5.0 34 1.0
13 9 0.3 5 2.1 14 0.4
14 7 0.2 5 2.1 12 0.3
15 2 0.1 2 0.8 4 0.1
16 1 < 0.1 0 -- 1 < 0.1
Total 3233 100.0 242 100.0 3475† 100.0
Mean no. of
4.80 8.69 5.07
sources
* The sources listed in this table do not include record linkages performed prior to entry of potential participants into the tracing system.
† Table excludes n=134 potential participants who were not entered into the HTDS tracing system.  All but one of these potential
participants (n=133) were located with information obtained from record linkages with the Washington state Department of Licensing,
prior to the implementation of the revised tracing system for transition and full study potential participants.  As a result of clerical error,
the remaining potential participant was never entered into the tracing system and, therefore, was not traced.
The effort expended toward the location of each potential participant was reviewed by the Data
Collection Specialist (DCS) responsible for the case and by the Lead Data Collection Specialist or the
Participation Supervisor to assure that all reasonable effort had been made and that all appropriate resources
had been used to locate the individual.  Only after this review was any potential participant “retired” as unable
to locate.  At least five sources were used for 316 of the 320 unlocated participants, and an average of more
than eight sources were used before potential participants were “retired.”
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B.4. Outcome and Final Results
B.4.a. Results from the Pilot Study Sample
Figure V.B-2 displays the results of the tracing of individuals selected for the Pilot Study Sample.  It
should be noted that these numbers vary slightly from the Pilot Study Report of January 24, 1995, as additional
potential participants from the Pilot Study selection were included in the Full Study.  Of the 1590 individuals
selected for the Pilot Study Sample, 1360 living individuals were located and 149 individuals were confirmed
deceased.  For 136 of the deceased individuals, a surrogate (ie. someone who might be able to provide study
information about the deceased individual) was located.  Thus, 94.9% of the original sample were located.
Only 81 (5.1%) potential participants were listed as "unable to locate." 
Figure V.B-2. Tracing Outcome for Pilot Study Sample (N = 1590)
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Located Alive
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B.4.a.1. Results by Strata
Figure V.B-3 presents tracing outcomes separately for the 791 females and the 799 males in the Pilot
Study Sample.  Success in locating living individuals was approximately the same for both sexes (87.2% for
females and 83.9% for males).  However, a larger proportion of Pilot Study Sample males were confirmed
deceased (11.8%) than females (7.0%). Thus, after combining the living potential participants with the
confirmed deceased, 95.6% of the Pilot Study Sample males and 94.2% of the females were located. This
finding was somewhat unexpected, as it was anticipated that females would be much more difficult to locate
after such a long period of time, due to name changes with marriage, particularly among this age group.
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Figure V.B-3. Tracing Outcome for HTDS Pilot Study Sample, by Sex (N = 1590)
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Figure V.B-4 displays the percent of the Pilot Study Sample located according to year of birth, from
1942-1946. There was relatively little difference in the proportion located in each birth year (range = 92.8% to
97.4%). Persons born in 1942 were slightly more frequently located than those born in the other years, but not
substantially so.
Figure V.B-4. Tracing Outcome for Pilot Study Sample, by Year of Birth (N = 1590)
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Figure V.B-5 displays the percent of the Pilot Study Sample located according to the eight regions
that defined the geographic sampling strata (geostrata). These are arranged in the figure to correspond in an
approximate manner to more urbanized areas (Richland, Pasco/Kennewick, and Walla Walla city) and
predominately rural areas (counties, outside city).  Although there is relatively little difference in the
proportion located across the eight regions, there was a tendency for the more rural areas to have higher
success rates.  Such a pattern might be expected given that it is likely that the temporary workers who came to
the area for construction jobs at the Hanford facility lived in more urban areas.  In four of the five rural
geostrata, 95% or more of the potential participants were located. Location rates for the three urban geostrata
areas ranged from 89.3% to 93.6%. 
Figure V.B-5. Tracing Outcome for Pilot Study Sample, by Geostratum (N = 1590)
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Table V.B-8 shows the proportion of Pilot Study Sample members located within each of the 76 strata
(defined by gender, year of birth, and geostrata). More than half the sample was located in all 76 strata. At
least 90% of the potential participants were located in 69 (90.8%) of the strata and at least 80% were located in
75 (98.7%) of the strata.  In one stratum, 1944 Richland females, only 18 of 23 (78.3%) were located. 
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Table V.B-8. Percentage of Pilot Study Potential Participants Located in Each of the 76 Sampling
Strata -Pilot Study Sample (N= 1590)
Year of Birth
Geostratum 1942 1943 1944 1945 1946
and Sex** No. % No. % No. % No. % No. %
Richland
Female See* See* 18 78 19 90 18 86
Male Footnote* Footnote* 21 91 21 100 20 91
Pasco/Kennewick
Female 21 100 18 90 21 95 16 80 18 90
Male 20 95 19 90 18 90 22 100 19 95
Walla Walla (city)
Female 22 100 18 90 18 90 17 85 19 95
Male 19 95 20 100 19 90 20 95 20 95
Benton County
Female 26 100 19 90 18 82 17 85 24 100 
Male 22 92 19 90 20 95 22 100 24 96
Franklin County
Female 21 95 12 100 22 96 7 88 16 100
Male 16 94 13 100 17 94 9 90 19 90
Walla Walla County
Female 24 100 23 100 22 100 24 100 19 90
Male 26 96 22 100 23 96 26 96 19 95
Okanogan County
Female 20 95 21 100 20 95 19 90 21 100
Male 22 100 19 95 21 95 20 95 21 100
Ferry/Stevens
Counties
Female 21 100 22 100 22 100 21 100 21 95
Male 21 100 20 95 21 95 24 100 20 100
* Richland was defined as a geostratum separate from Benton County only for births in 1944-1946.
** Sex is defined as actual sex, not sex strata, as 2 potential participants were misclassified: one potential participant in the 1945
Pasco/Kennewick stratum was misclasssified as female and another potential participant in the 1946 Franklin County stratum was
misclassified as male. 
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In summary, the Pilot Study demonstrated the feasibility of locating cohort members identified from
birth certificate records from the early to mid-1940s. Overall, 91% of the 1590 Pilot Study Sample members
identified from birth certificates were located by the end of the Pilot Study in December 1995.  By the end of
the Full Study, this percentage rose to 94.9%.   Success in locating people did not differ substantially
according to sex, year of birth, or geographic area of birth.  This indicated that the methods used throughout
the Pilot Study were effective at locating a substantial percentage of all selected potential participants.
B.4.b. Results from Transition Sample
The Transition Sample selection included potential participants from five of the eight geostrata used
during the Pilot Study (Richland, Pasco/Kennewick, Walla Walla City, Benton County outside of Pasco, Walla
Walla County outside of Walla Walla City).  No further selections were made from the Okanogan or
Ferry/Stevens geostrata because it was anticipated that the design of the Full Study would limit further
selections to only geostrata near Hanford.  No further selection from the Franklin County geostratum was
possible, since all its members were selected for the Pilot Study.  Figure V.B-6 shows the tracing outcomes for
potential participants in the Transition Sample.  A slightly lower percentage of potential participants were
located in the Transition Sample (93.3%) than the Pilot Study Sample (94.9%).  (Note that the category,
“Deceased, Surrogate Located” was used only in the Pilot Study, as it was initially intended that deceased
potential participants would be represented in the study by a surrogate, when available.  Please see section V.D
for a complete discussion of this issue.)
Figure V.B-6. Tracing Outcome for the Transition Sample (N = 1005)
Located Deceased
8 .9%  (N=89) 
Unable to   Locate
6 .7%  (N=67)
Located Alive
84 .5%  (N=849)
HTDS Final Report: June 21, 2002 – Section V.B page 74
B.4.b.1. Results by Strata
Figure V.B-7 shows tracing outcomes by sex for the Transition Sample.  Tracing efforts were slightly
more successful in locating males than females.  This difference was more evident in the Transition Sample
(95.0% vs. 91.6% of males and females respectively) than in the Pilot Study Sample (95.6% vs. 94.2%).
However, the overall success rate for tracing both males and females remained consistently high.
Figure V.B-7. Tracing Outcome for Transition Sample, by Sex (N = 1005)
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Figure V.B-8 shows tracing outcome by year of birth for the Transition Sample.  Ability to locate
potential participants in the Transition Sample ranged from 90.8% for those born in 1945 to 97% for those
born in 1943.
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Figure V.B-8. Tracing Outcome for Transition Sample, by Year of Birth (N = 1005)
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Figure V.B-9 shows tracing outcomes by geostrata for the Transition Sample.  The success rate for
locating Transition Sample members ranged from 87.1% in the Richland geostratum to 97.8% in the Walla
Walla County geostratum.  As in the Pilot Study Sample, efforts were slightly more effective in locating those
born in rural areas, presumably due to a less mobile population.
HTDS Final Report: June 21, 2002 – Section V.B page 76
Figure V.B-9. Tracing Outcome for Transition Sample, by Geostratum (N = 1005)
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B.4.c. Results for the Full Study Sample
The HTDS Full Study included all potential participants selected for the Pilot Study and Transition
Samples, along with those selected later.  For convenience, however, those selected after the Pilot Study and
Transition Sample selections are designated the Full Study Sample.  A total of 2604 potential participants were
included in the Full Study Sample.  The Full Study Sample was selected from five of the nine geostrata used in
the entire study (Richland, Pasco/Kennewick, Benton County outside of Pasco, Franklin County outside of
Kennewick, and Adams County).  In addition, the Full Study Sample included people born in 1940-41.  Figure
V.B-10 shows tracing outcomes for the Full Study Sample.  A larger percentage of Full Study Sample
members were located deceased (11.1%, compared to 9.4% and 8.9% for the Pilot Study and Transition
Samples), presumably due to the inclusion of potential participants born in 1940 and 1941.  Nevertheless, the
percentage located (93.3%) was similar to those for the Pilot Study and Transition Samples.
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Figure V.B-10. Tracing Outcome for the Full Study Sample (N = 2604)
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B.4.c.1. Results by Strata
Figure V.B-11 shows tracing outcomes by sex for the Full Study Sample.  The percentage of female
potential participants located in the Full Study Sample (91.3%) was again slightly lower when compared to the
percentage of males located (95.2%).  While the difference was slightly larger than for the Pilot and Transition
samples, it was not substantially different.  
Figure V.B-11. Tracing Outcome for the Full Study Sample, by Sex (N = 2604)
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Figure V.B-12 shows tracing outcome by year of birth for the Full Study Sample.  Ability to locate
potential participants by year of birth in the Full Study Sample varied from 90.0% for those born in 1945 to
98.9% for those born in 1942.  This is consistent with the location rates for the Pilot and Transition Samples.
Figure V.B-12. Tracing Outcome for the Full Study Sample, by Year of Birth
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Figure V.B-13 shows tracing outcome by geostratum for the Full Study Sample. Success in locating
potential participants ranged from 91.4% in the Richland geostratum to 98.6% in the Franklin County
geostratum.   The highest success was achieved in locating potential participants born in the relatively rural
Franklin County and Adams County geostrata.
Figure V.B-13. Tracing Outcome for the Full Study Sample, by Geostratum
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B.4.d. Overall Results for the Full Study
B.4.d.1. Success in Locating Study Potential Participants
Figure V.B-14 shows the final tracing outcomes for the entire study.  Of the 5199 individuals sought,
4350 (83.7%) living individuals were located and 527 (10.1%) individuals were confirmed deceased.   Thus,
93.8% of the sample were located and their identities confirmed.  Only 322 potential participants (6.2%)
remained unlocated at the end of the study.  In addition, the ability to locate well over 90% of all potential
participants did not vary substantially by sex, geographic region at birth, or year of birth.  Figures V.B-15 to
V.B-17 show the final tracing outcomes for the study by sex, by year of birth, and by geostrata.
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Figure V.B-14. Final Tracing Outcomes for Entire Study  (N=5199)
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Figure V.B-15. Final Tracing Outcome for Entire Study, by Sex  (N=5199)
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Figure V.B-16. Final Tracing Outcome for Entire Study, by Year of Birth  (N=5199)
0
10
20
30
40
50
60
70
80
90
100
1940 1941 1942 1943 1944 1945 1946
P
er
ce
n
t
Located Alive
Located Deceased
Unable to  Locate
Year of Birth
Figure V.B-17. Final Tracing Outcome for Entire Study, by Geostratum (N = 5199)
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Almost 84% of all potential participants were located as living and potentially evaluable (whether
they agreed to participate or not).  For most (83.4%) this was confirmed directly by contact with the potential
participant or with a close relative who could verify the potential participant’s identity and provide a current
address.  An additional 12 potential participants (0.2%) were located to a current address using other reliable
urces providing enough information to verify their identity as the selected potential participant.  ThesesoHTDS Final Report: June 21, 2002 – Section V.B page 82
potential participants were sent a letter asking them to participate, but no direct contact was made, as no
telephone number was available.
Five hundred twenty-seven (10.1%) of all selected potential participants were confirmed as deceased
by a close relative and/or other reliable source (e.g., death certificate).  A larger proportion of males was
confirmed deceased (12.7%) than females (7.5%). Sixteen potential participants  (0.3%) were located as living,
but died during the study before agreeing to participate or prior to attending a clinic.  An additional 22  (0.4%)
potential participants were located as living but required a surrogate due to mental or physical conditions.
Twenty-one of these potential participants were unable to participate in clinics, but were positively identified,
while one attended a clinic with the assistance of a family member and an assistant. Two potential participants
were determined to be ineligible, one because he was adopted and actually had been born in Spokane, which
was his birth mother’s usual residence, and the other due to a mistake on the birth certificate regarding the
“Mother’s Mailing Address,” which indicated the mother lived in Walla Walla when the potential participant
was born, when it should have been Columbia County as reflected in the “Mother’s Usual Residence.” 
B.4.d.2. Current Residence of Living Potential Participants
At least one potential participant was located in every state in the U.S. except for Rhode Island (see
Figure V.B-18).  Fifty-four percent of the located potential participants resided in Washington State, 9.4% in
California, 9.1% in Oregon and 2.7% in Idaho.  The only other state where more than 2% of the located
potential participants resided was Texas (2.2%).  Thirty-six potential participants (0.8% of those located)
resided outside of the U.S.  Potential participants were located in Canada, Dubai, Ecuador, Germany, Mexico,
Saudi Arabia, South Africa, England, Guam, Australia, Japan, France, Saipan, Hungary, Columbia, Taiwan
and South Korea.  Many of these (26) participated in the study.  Although excessive travel costs associated
with foreign travel prohibited the study from flying participants to the U.S. from outside North America, those
participants who had plans to be in the U.S. during the study were brought to Seattle whenever possible to
attend a clinic during that time.
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Figure V.B-18. Current Residences of Located Potential Participants
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B.4.d.3. Death Certificates Obtained for Deceased Potential Participants
As noted above, 527 cohort members were deceased when located, and another 16 located individuals
died before agreeing to participate or attending a study clinic.  For these 543 potential participants, an attempt
was made to obtain a death certificate to verify the death and collect information about the cause of death.  In
504 cases (92.8%), the death certificate was obtained.  However, in 7.2% of cases, no death certificate could be
located in the state in which the potential participant was reported to have died, or no state of death was known
by the respondent, and could not be ascertained from the National Death Index.  Consistent with the tracing
results for living potential participants, the majority of those deceased had died in Washington State, with
Oregon and California having the second and third largest proportions of deceased potential participants.
Table V.B-9 shows the success in obtaining death certificates in the states where the 543 potential participants
were reported to be deceased.
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Table V.B-9. Summary of Death Certificates Obtained for Deceased Study Potential Participants
Death Death Certificate Not Death Certificate
Reported Residence Certificates Requested Due to Lack of Requested But Not
at Death Obtained Information Found          Total
Washington 372 3 14 389
Oregon 30 0 1 31
California 22 0 5 27
Idaho 7 0 3 10
Montana 7 0 1 8
Texas 7 0 0 7
Colorado 6 0 0 6
Minnesota 6 0 0 6
Utah 5 0 0 5
Alaska 4 0 0 4
Nebraska 3 0 1 4
New York 3 0 1 4
Wyoming 2 0 2 4
Arizona 2 0 2 4
Nevada 3 0 0 3
Arkansas 2 0 0 2
Delaware 1 0 1 2
Florida 2 0 0 2
Georgia 2 0 0 2
Hawaii 2 0 0 2
Pennsylvania 2 0 0 2
South Carolina 2 0 0 2
Tennessee 1 0 1 2
Alabama 1 0 0 1
Illinois 1 0 0 1
Kentucky 1 0 0 1
Missouri 1 0 0 1
Mississippi 1 0 0 1
North Carolina 1 0 0 1
New Hampshire 1 0 0 1
Ohio 1 0 0 1
Oklahoma 1 0 0 1
Virginia 1 0 0 1
Out of U.S. 1 0 1 2
Unknown 0 3 0 3
Total 504 6 33 543
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C. Recruiting
C.1. Background
The design of the HTDS posed significant challenges for recruiting study participants. It required
that each participant be asked to identify an older relative (preferably the mother) to complete an extensive
telephone interview.  In addition, the participant was asked to travel to a clinic for a complete medical
evaluation to determine the presence of thyroid disease and to complete an In-Person Interview. 
C.1.a. Objectives of Recruiting
The objectives of the recruiting activities were to contact and obtain agreement of living potential
participants to participate in the study, and to identify an appropriate Computer Assisted Telephone
Interview (CATI) respondent.  It was necessary to do this within a time frame that would provide
sufficiently large pools of participants to schedule regional clinics, while also allowing participants ample
opportunity to attend a clinic.
C.2. Recruiting Procedures
C.2.a. Initial Written Contact and Attempt to Contact by Phone
Each potential participant who was located was sent an introduction/participation letter, a study
Fact Sheet and Description of Study Participation.  Calls to potential participants began approximately 5-7
days after the letters were sent.  Since potential participants would be in their late 40s and early 50s at the
time of recruitment, they were assumed to be working.  Therefore, the majority of recruitment calls were
made during the evenings, taking into consideration the time zone in which the potential participant
resided.  A minimum of 10-15 evening attempts were made at various weeknight and weekend (generally
Sunday evening) time periods, and a minimum of three daytime (weekend and weekday) calls were
attempted. 
 
If the potential participant could not be contacted by phone after 20-25 attempts, a second letter
was sent explaining that the Recruiter had been unable to reach them at that phone number, and asking
them to contact the Recruiter or Participation Coordinator at the toll-free HTDS number1.  Further attempts
to contact these people were postponed for approximately one month, after which both day and evening
attempts would begin again until the participant was reached or until 40 attempts had been made.  After 40-
45 attempts resulting in no contact with either the potential participant or a household member, another
letter was sent.  This letter included the toll-free number and card for the potential participant to complete
and return in a self-addressed stamped envelope confirming that he or she was the identified person, and
asking for a phone number and time at which he or she would most likely be available. 
If there was no response to this letter, and the letter was not returned with an address correction or
as unable to deliver within one month, the potential participant was considered “unable to contact” and no
further attempts were made.  If the potential participant or household member had been reached at least
once, additional attempts beyond the 40-45 calls were sometimes made, dependent on the nature of the
contact.
If at any point in the process of attempting to contact a potential participant the phone number was
disconnected or proved to be a wrong number, efforts were made to obtain a correct phone number through
directory assistance, the original informant, or another available source.  When necessary, potential
                                                          
1 If all or most calls up to this point resulted in an answering machine, a general message was left on up to three occasions explaining
that we were calling from the HTDS and leaving the toll-free number for the potential participant to contact the Recruiter.
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participants were returned to the tracing staff for additional tracing effort.  Later in the recruitment phase,
the FHCRC Tracking Resource Center assisted in locating updated address and telephone information.  If a
new telephone number could not be obtained, a second letter (as described above for those not contacted
after 20-25 attempts) was sent asking the potential participant to contact HTDS at the toll-free number.  If
no response was received and no telephone contact was ever made, a letter was sent, asking him or her to
contact the study or return the enclosed card to confirm identity as the study potential participant and/or
providing contact information.
C.2.b. Telephone Contact with the Potential Participant
Once the potential participant was reached by phone, the Recruiter explained the reason for the
call, confirmed the person’s identity (full name, date and county of birth) and attempted to obtain
agreement to participate by explaining the purpose and nature of the study and responding to any concerns
as appropriate.  A script was developed and used to ensure that each potential participant received the same
basic information about the study.  However, the nature of the recruitment call required that Recruiters be
flexible enough to respond to individual questions and concerns.  Recruiters were trained to be able to
address a variety of questions and concerns in order to obtain the highest participation rate possible.
Every effort was made to recruit and provide interpreters or other assistance as necessary for non-
English speakers, illiterate, hearing and vision impaired, or otherwise impaired persons to achieve
maximum participation in the study.  If a potential participant was reluctant to participate, the Recruiter
would encourage him or her to contact the Participation Coordinator or Project Manager so that specific
concerns could be addressed.  If the potential participant still refused, in most cases, a second contact by
letter was sent in approximately three to six months to allow for the possibility that he or she would have
reconsidered the decision.  This letter was followed by a telephone call, as with the first attempt, to try
again to gain participation and to respond to any questions or concerns.
If the potential participant agreed to participate in the study, the Recruiter requested that the
participant name a respondent for the CATI.   Whenever possible, the CATI respondent was the potential
participant's mother, who was assumed to be best able to answer the CATI questions.  The next choices, in
order of preference were: father, older sibling (at least six years older), or other family member who lived
with the potential participant for a large part of his/her early childhood since birth. 
The Recruiter described the dosimetry materials and interview to ensure that the participant felt
that the respondent would be willing and able to complete the CATI process.  A CATI Respondent
Assessment (Appendix 4) was then completed with the participant.  Questions were asked about the
respondent’s abilities, such as sight, hearing and special needs.  This information was then provided to the
CATI Interviewer.
If no CATI respondent was available, the potential participant was informed that he or she was
still eligible for participation and was assured that his or her participation was valuable even without a
CATI respondent.  Participants without a CATI respondent were interviewed at the clinic using an
expanded version of the In-Person Interview (IPI). 
During the recruitment call, the Recruiter assessed whether travel arrangements were required and
which clinic site would be the most accessible for the participant.  In most cases, the clinic site selected was
the one closest to the participant’s usual residence.  Seattle was selected as the clinic location for most
participants living outside of the Pacific Northwest, for both participant convenience and typically lower
airfare cost. 
If a CATI respondent was named, the participant was called back after the CATI was completed to
schedule the clinic visit.  If no CATI respondent was named, attempts to schedule could begin immediately,
depending on availability at the clinic location selected. 
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C.2.c. Confirmation of Agreement to Participate and Six Month Letter
In the Pilot Study, letters were sent to participants soon after they had agreed to participate,
thanking them for agreeing to participate and explaining that they would be contacted to schedule a clinic
appointment.  During the Full Study, when the volume of letters to participants was extremely high and lag
time between recruiting and scheduling could be six months or longer, the confirmation letter was replaced
by a letter sent to all participants who had not yet been scheduled for a clinic within six months after the
recruitment call.  The purpose of the “six month letter” was two-fold.   First, it served to assure participants
that they would be contacted and that their participation was still very important to the study.  Second, it
enabled the study to be advised of address changes through the United States Postal Service change of
address service.
C.2.d. Refusals and Second Attempts
While every reasonable effort was made to persuade each potential participant to participate, it
was inevitable that some would refuse or be unable to participate.  When a potential participant refused, the
Recruiter asked them to complete a Refusal/Demographic Questionnaire (Appendix 5). Twelve
demographic questions relating to race, ethnic origin, income, religion, and education level were asked to
obtain a general profile of those who refused to participate or later withdrew from the study.
The Recruiter also completed a Refusal Assessment (Appendix 6) after the call to record the
nature and strength of the refusal from the Recruiter’s perspective.  This information was used to determine
if, and when, to re-contact the potential participant to have the best opportunity to convert the refusal to an
agreement to participate.  A second attempt to recruit was generally made unless the participant specifically
requested that the HTDS not re-contact them, was hostile, or if it was clearly not possible for this person to
participate in the study for reasons such as long term illness or disability.  The default date for making
second attempts was set at approximately three months after the first attempt.
C.2.e. Second Request for Participation
A second attempt letter, requesting participation and explaining the study, was sent within three to
six months following the first recruitment contact, or after an appropriate amount of time based on
information provided by the potential participant and the Recruiter.  As with the initial contact, each letter
also included a description of study participation and fact sheets.   A Recruiter began attempts to call
approximately 5-7 days after the second letter was sent.  As with the first attempt call, a script was used as
a guideline to ensure that all potential participants received the same information about the study.
However, as with the initial attempt, the Recruiter’s approach and responses were individualized to respond
to the potential participant’s questions and concerns. 
If the potential participant agreed to participate on the second attempt, the same steps were
followed as for an agreement on the first attempt in requesting CATI respondent information and
determining clinic location.  If he or she refused, the Recruiter asked him or her to complete a Refusal
Demographic Questionnaire (unless this had been completed during the first attempt call).  The Recruiter
also completed a Refusal Assessment after the call to record the reason for and strength of the refusal.  No
further recruitment attempts were made if a potential participant refused on the second attempt.
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C.3. Outcome and Results
C.3.a. Results for the Pilot Study Sample
Figure V.C-1 summarizes the willingness of individuals in the Pilot Study Sample to agree to
participate in the study.  It should be noted that these numbers may vary slightly from those found in the
Pilot Study Final Report of January 24, 1995, as some additional participants from the Pilot Study Sample
were recruited after that time.
Figure V.C-1. Agreement to Participate for the Pilot Study Sample (N = 1360)
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* Other: Unable to participate, Ineligible, Died prior to participation
Of the 1360 potential participants located alive, 1354 (99.6%) were sent letters requesting
participation, and 1320 (97.1%) were contacted by telephone. One thousand ninety-four (80.4%) of those
located alive agreed to participate (82.9% of those contacted by telephone).  Eleven of those located alive
were judged physically incapable of participating by a close relative or guardian, or were found to be
otherwise unable to participate. Two hundred fifteen (15.8%) of the living located potential participants
refused to participate in the study.  Of those agreeing to participate, 49 (3.6%) refused on the initial
attempt, but were re-contacted a second time and the refusal was converted to agreement.  The participation
rate remained remarkably constant over the course of the Pilot Study, fluctuating less than 3% in either
direction over the last year of this phase of the study. Table V.C-1 summarizes the recruiting experience for
the Pilot Study Sample.
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Table V.C-1. Summary of Agreement and Refusal for the Pilot Study Sample (N=1360)
Contact Status No.
    % of
Contacted
by Phone
% of
Letter
Sent % of Total
Letter sent 1354 -- 100.0 99.6
Unable to contact 34 -- 2.5 2.5
Contacted by phone 1320 100.0 97.5 97.1
Agreed, final 1094 82.9 80.8 80.4
- on first attempt 1045 79.2 77.2 76.8
- on second attempt 49 3.7 3.6 3.6
Refused, final 215 16.3 15.9 15.8
Unable to participate 11 0.8 0.8 0.8
Died prior to participation 4 -- -- 0.3
Ineligible 2 -- -- 0.1
Located with no contact 0 -- -- 0.0
In summary, the Pilot Study demonstrated that, once located and contacted by telephone, a large
proportion of individuals would agree to participate in the study.  Approximately 83% of those in the Pilot
Study Sample who were contacted by telephone agreed to participate during the course of the study.
Figure V.C-2 shows the proportion of the Pilot Study Sample located alive who agreed to
participate, by the eight geostrata used in the Pilot Study.  The participation rate was uniformly high and
relatively similar across the eight geostrata.  The lowest percentage was among those born in Ferry and
Stevens counties, located furthest from the Hanford Site (74.5%), and the highest was in Franklin County
(84.9%), the area closest to the site.
Figure V.C-2. Agreement to Participate for the Pilot Study Sample, by Geostratum  (N=1360)
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Figures V.C-3 and V.C-4 show that willingness to participate also did not differ substantially
according to sex (82.8% for females vs. 78.1% for males) or year of birth (78.8% to 82.4%).  
Figure V.C-3. Agreement to Participate for the Pilot Study Sample, by Sex (N = 1360)
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Figure V.C-4. Agreement to Participate for the Pilot Study Sample, by Year of Birth  (N = 1360)
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Similarly, the area of current residence did not significantly influence the willingness to
participate. The most common reasons for non-participation were “Not Interested” and “No Time,” with
64.7% (139) of refusals and withdrawals falling into these two categories.  The next most common reason
for non-participation was illness or medical impairment/disability.  Eighteen (8.4%) Pilot Study non-
participants or their family member/guardian cited a medical condition, illness, disability, or impairment as
the reason for not participating.  Surprisingly, unwillingness to travel was only cited as the reason for non-
participation by four potential participants outside the Northwest in the Pilot Study Sample.  Other reasons
given were opposition to the study, concern about the effect of participation on insurance coverage, advice
from an attorney, and not having thyroid disease.  Table V.C-2 shows the reasons for refusal or withdrawal
from the study by geographic area of current residence for the Pilot Study Sample.
Table V.C-2. Reason for Refusal/Withdrawal for the Pilot Study Sample by Geographic Area of
Current Residence  (N=215)
Reason for Refusal or Withdrawal
Not
Interested
or No Time
Illness or
Impairment
Unwilling
to Travel
Opposed
to Study
Legal or
Insurance
Concerns
No
Thyroid
Disease Other* Total
Area of
Current
Residence No. % No. % No. % No. % No. % No. % No. % No.
All WA 82 66.1 9 7.3 1 0.8 8 6.5 3 2.4 1 0.8 20 16.1 124
Seattle 12 75.0 1 6.2 0 -- 0 -- 0 -- 0 -- 3 18.8 16
Everett 1 33.3 0 -- 0 -- 1 33.3 0 -- 0 -- 1 33.3 3
Tacoma 3 60.0 0 -- 0 -- 0 -- 0 -- 0 -- 2 40 5
Olympia 3 75.0 0 -- 0 -- 0 -- 0 -- 0 -- 1 25.0 4
SW WA 5 83.3 0 -- 0 -- 1 16.7 0 -- 0 -- 0 -- 6
Wenatchee 9 69.2 3 23.1 0 -- 0 -- 0 -- 0 -- 1 7.7 13
Yakima 2 25.0 1 12.5 1 12.5 0 -- 1 12.5 0 -- 3 37.5 8
Spokane 22 75.9 0 -- 0 -- 3 10.3 0 -- 1 3.4 3 10.3 29
Tri-Cities 24 61.5 4 10.3 0 -- 3 7.7 2 5.1 0 -- 6 15.4 39
SE WA 1 100 0 -- 0 -- 0 -- 0 -- 0 -- 0 -- 1
Other NW 21 60.0 3 8.6 1 2.9 2 5.7 2 5.7 1 2.9 5 14.3 35
CA/HI 9 52.9 5 29.4 0 -- 1 5.9 1 5.9 0  -- 1 5.9 17
Southwest 11 91.7 0 -- 0 -- 0 -- 0 -- 0 -- 1 8.3 12
Midwest 7 58.3 1 8.3 4 33.3 0 -- 0 -- 0 -- 0 -- 12
South 7 70.0 0 -- 0 -- 0 -- 0 -- 0 -- 3 30.0 10
East 2 40.0 0 -- 0 -- 1 20.0 0 -- 1 20.0 1 20.0 5
Other 0 -- 0 -- 0 -- 0 -- 0 -- 0 -- 0 -- 0
Total 139 64.7 18 8.4 6 2.8 12 5.6 6 2.8 3 1.4 31 14.4 215
* Other: Includes family problems, personal reasons, distrust, lack of personal benefit, scheduling problems, refusal by a household
member on the potential participant’s behalf, and no reason given. 
 Overall, these results indicate that the methods developed for recruiting participants for the study
were feasible and would result in relatively high levels of participation. 
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C.3.b. Results from the Transition Sample
Figure V.C-5 summarizes the willingness of individuals in the Transition Sample to agree to
participate during the course of the study. 
Figure V.C-5. Agreement to Participate for the Transition Sample (N = 849)
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Of the 849 potential participants located alive, 847 (99.8%) were sent letters requesting
participation, and 831 (97.9%) were contacted by telephone. Six hundred ninety-two (81.5%) of those
located alive agreed to participate.  Eleven located potential participants were judged medically incapable
of participating by a close relative or guardian contacted during the process, or were found to be otherwise
unable to participate.  One hundred twenty-eight of those located alive (15.1%) refused to participate in the
study.  Of those agreeing to participate, 33 (3.9%) potential participants refused on the initial attempt, but
were re-contacted a second time and agreed to participate on the second recruiting attempt.   Sixteen (1.9%)
of those located to an address were unreachable by telephone and could not be recruited. Table V.C-3
summarizes the recruiting experience for the Transition Sample.
Table V.C-3. Summary of Agreement and Refusal for theTransition Sample  (N=849)
Contact Status No.
  % of
Contacted
by Phone
% of
Letter
Sent
% of
Total
Letter sent 847 -- 100.0 99.8
Unable to contact 16 -- 1.9 1.9
Contacted by phone 831 100.0 98.1 97.9
Agreed, final 692 83.3 81.7 81.5
- on first attempt 659 79.3 77.8 77.6
- on second attempt 33 4.0 3.9 3.9
Refused, final 128 15.4 15.1 15.1
Unable to participate 11 1.3 1.3 1.3
Died prior to participation 1 -- -- 0.1
Ineligible 0 -- -- 0.0
Located with no contact 1 -- -- 0.1
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In summary, the results in the Transition Sample did not differ appreciably from those in the Pilot
Study.  Of those individuals contacted by telephone, 83.3% agreed to participate in the study.  A total of
2.0% (17) of those located to an address were not reachable by telephone.  
Figure V.C-6 shows the proportion of Transition Sample potential participants located alive who
agreed to participate, according to the five geostrata used in the Transition Sample.  The participation rate
was uniformly high and relatively similar across the five areas. The lowest percentage was among those
born in Richland (77.6%), and the highest among those born in Pasco/Kennewick (86.7%).
Figure V.C-6. Agreement to Participate for the Transition Sample, by Geostratum  (N=849)
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Willingness to participate did not differ substantially according to sex  (80.6% of females vs.
82.4% of males) or year of birth (78.7% to 86.3%) (Figures V.C-7 and V.C-8).   Similarly, the area of
current residence did not significantly influence the willingness to participate.  Table V.C-4 summarizes the
reasons for refusal by geographic area of current residence for the Transition Sample.  Reasons for refusal
did not vary substantially from the Pilot Study Sample experience.
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Figure V.C-7. Agreement to Participate for the Transition Sample, by Sex (N=849)
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Figure V.C-8. Agreement to Participate for the Transition Sample, by Year of Birth  (N=849)
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Table V.C-4. Reason for Refusal/Withdrawal for the Transition Sample, by Geographic Area of 
Current Residence (N=128)
Reason for Refusal or Withdrawal
Not
Interested
or No Time
Illness or
Impairment
Unwilling
to Travel
Opposed to
Study
Legal
Concerns
No Thyroid
Disease Other* Total
Area of
Current
Residence No. % No. % No. % No. % No. % No. % No. % No.
All WA 48 69.6 3 4.3 0 -- 4 5.8 1 1.4 1 1.4 12 17.4 69
Seattle 6 60.0 0 -- 0 -- 0 0 -- 0 -- 4 40.0 10
Everett 2 100 0 -- 0 -- 0 -- 0 -- 0 -- 0 -- 2
Tacoma 2 100 0 -- 0 -- 0 -- 0 -- 0 -- 0 -- 2
Olympia 4 80.0 1 20.0 0 -- 0 -- 0 -- 0 -- 0 -- 5
SW WA 1 33.3 0 -- 0 -- 1 33.3 0 -- 0 -- 1 33.3 3
Wenatchee 2 100 0 -- 0 -- 0 -- 0 -- 0 -- 0 -- 2
Yakima 4 57.1 1 14.3 0 -- 1 14.3 1 14.3 0 -- 0 -- 7
Spokane 5 71.4 0 -- 0 -- 1 14.3 0 -- 0 -- 1 14.3 7
Tri-Cities 22 71.0 1 3.2 0 -- 1 3.2 0 -- 1 3.2 6 19.4 31
SE WA 0 -- 0 -- 0 -- 0 -- 0 -- 0 -- 0 -- 0
Other NW 9 56.2 1 6.2 1 6.2 0 -- 0 -- 0 -- 5 31.2 16
CA/HI 6 66.7 1 11.1 1 11.1 0 -- 0 -- 0 -- 1 11.1 9
Southwest 2 50.0 0 -- 1 25.0 1 25.0 0 -- 0 -- 0 -- 4
Midwest 8 66.7 1 8.3 0 -- 0 -- 0 -- 1 8.3 2 16.7 12
South 6 75.0 0 -- 1 12.5 0 -- 0 -- 0 -- 1 12.5 8
East 6 66.7 0 -- 0 -- 0 -- 0 -- 0 -- 3 33.3 9
Other 0 -- 0 -- 0 -- 0 -- 0 -- 0 -- 1 100 1
Total 85 66.4 6 4.7 4 3.1 5 3.9 1 0.8 2 1.6 25 19.5 128
* Other: Includes family problems, personal reasons, distrust, lack of personal benefit, scheduling problems, refusal by a household
member on the potential participant’s behalf, and no reason given. 
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C.3.c. Results for the Full Study Sample
Figure V.C-9 summarizes the willingness of those located alive in the Full Study Sample to agree
to participate during the course of the study.
Figure V.C-9. Agreement to Participate for the Full Study Sample (N = 2141)
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Of the 2141 Full Study Sample potential participants located alive, 2128 (99.4%) were sent letters
requesting participation, and 2088 (97.5%) were contacted by telephone.  A total of 1778 (83.0%) of those
located alive agreed to participate.  Nineteen (0.9%) of those located alive were judged medically incapable
of participating by a close family member or guardian, or were found to be otherwise unable to participate.
Two hundred ninety-one of those located alive (13.6%) refused to participate in the study.  Of those
agreeing to participate, 36 (1.7%) refused on the initial attempt, but were re-contacted a second time, and
agreed to participate on the second recruiting attempt.  Forty-two (2.0%) of those located to an address
were unreachable by telephone.  Table V.C-5 summarizes the recruiting experience for the Full Study
Sample.
HTDS Fin
Table V.C-5. Summary of Agreement and Refusal for the Full Study Sample  (N=2141)
Contact Status No.
% of
Contacted
by Phone
% of
Letter
Sent % of Total
Letter Sent 2128 -- 100.0 99.4
Unable to contact     40 --     1.9   1.9
Contacted by phone 2088 100.0   98.1 97.5
     Agreed, final 1778  85.2  83.6 83.0
     - on first attempt 1742   83.4  81.9 81.4
     - on second attempt     36     1.7    1.7   1.7
     Refused, final    291   13.9  13.7 13.6
     Unable to participate     19    0.9    0.9   0.9
Died prior to participation     11 -- --   0.5
Ineligible       0 -- --   0.0
Located with no contact       2 -- --   0.1
Figure V.C-10 shows the proportion of Full Study Sample members located alive who agreed to
participate in the study, according to the five geostrata used in the Full Study Sample.  The participation
rate was uniformly high and relatively similar across the areas. The lowest percentage was among those 
born in Franklin County (80.0%), while the highest was among those born in Benton County (84.4%).
Figure V.C-10. Agreement to Participate for the Full Study Sample, by Geostratum  (N=2141)
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illingness to participate also did not differ substantially according to sex  (85.1% for females vs.
 males) or year of birth (77.5% to 89.6%) (Figures V.C-11 and V.C-12).  Similarly, the area of
idence did not significantly influence the willingness to participate.  Table V.C-6 shows the
r non-participation by geographic area of current residence.  Reasons given were similar to those
e Pilot and Transition Samples.
HFigure V.C-11. Agreement to Participate for the Full Study Sample, by Sex (N = 2141)
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Table V.C-6. Reason for Refusal/Withdrawal for the Full Study Sample, by Geographic Area of
Current Residence   (N=291)
Reason for Refusal or Withdrawal
Not
Interested
or No Time
Illness or
Impairment
Unwilling
to Travel
Opposed to
Study
Insurance
Concerns
No
Thyroid
Disease Other* Total
Area of
Current
Residence No. % No. % No. % No. % No. % No. % No. % No.
All WA 86 64.2 9 6.7 2 1.5 5 3.7 1 0.7 0 -- 31 23.1 134
Seattle 10 55.6 1 5.6 0 -- 1 5.6 1 5.6 0 -- 5 27.8 18
Everett 4 57.1 1 14.3 0 -- 0 -- 0 -- 0 -- 2 28.6 7
Tacoma 6 75.0 0 -- 0 -- 0 -- 0 -- 0 -- 2 25.0 8
Olympia 3 50.0 1 16.7 1 16.7 0 -- 0 -- 0 -- 1 16.7 6
SW WA 6 66.7 0 -- 0 -- 1 11.1 0 -- 0 -- 2 22.2 9
Wenatchee 8 88.9 0 -- 0 -- 0 -- 0 -- 0 -- 1 11.1 9
Yakima 8 72.7 1 9.1 0 -- 0 -- 0 -- 0 -- 2 18.2 11
Spokane 12 60.0 3 15.0 0 -- 0 -- 0 -- 0 -- 5 25.0 20
Tri-Cities 29 63.0 2 4.3 1 2.2 3 6.5 0 -- 0 -- 11 23.9 46
SE WA 0 -- 0 -- 0 -- 0 -- 0 -- 0 -- 0 -- 0
Other NW 21 55.3 5 13.2 3 7.9 0 -- 0 -- 1 2.6 8 21.1 38
CA/HI 20 71.4 2 7.1 3 10.7 1 3.6 0 -- 0 -- 2 7.1 28
Southwest 17 63.0 5 18.5 1 3.7 2 7.4 0 0 0 0 2 7.4 27
Midwest 19 70.4 2 7.4 3 11.1 0 -- 0 -- 0 -- 3 11.1 27
South 13 56.5 0 -- 7 30.4 0 -- 0 -- 0 -- 3 13.0 23
East 10 83.3 1 8.3 0 -- 0 -- 0 -- 0 -- 1 8.3 12
Other 1 50.0 0 -- 1 50.0 0 -- 0 -- 0 -- 0 -- 2
Total 187 64.3 24 8.2 20 6.9 8 2.7 1 0.3 1 0.3 50 17.2 291
* Other: Includes family problems, personal reasons, distrust, lack of personal benefit, scheduling problems, refusal by a household
member on the potential participant’s behalf, and no reason given. 
C.3.d. Results for the Entire Study
A summary of the agreement to participate for the entire study is provided in Table V.C-7 and
shown in Figure V.C-13.  In all, 4239 potential participants (97.4% of all living, located) were contacted by
telephone to request participation.  An additional 93 (2.1% of all living, located) were located to an address,
and were sent one or more letters, but could not be contacted by telephone2. A total of 3564 potential
participants (84.1% of those who were contacted by telephone, 81.9% of all located, living) agreed on
either a first or a second attempt.  Of those located alive, 634  (14.6%) refused to participate in the study. 
Forty-one living located potential participants (0.9%) were determined to be unable to fully
participate and were consequently not included in the study regardless of willingness to participate.
Twenty-five were reported by others (parents, guardians or caregivers) to be incapable of participating due
to mental or physical/medical disability.  In these cases, contact with the person directly was not possible
and could not be considered a refusal.  Of the remaining 16, six were incarcerated out of state for the
duration of the study; three were not opposed to participating, but were living outside of the U.S. and had
no plans to return to the U.S. during the study; the remaining seven were either adopted, and/or did not
have sufficient information regarding residence history of the birth mother or their early childhood to
accurately assess residence/dose, and therefore would not have been evaluable (see section IV.B above for
definition of evaluable participant).
   
2
                                                       
Either no phone number was available or multiple attempts to reach by phone resulted in no contact.
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Figure V.C-13. Final Agreement to Participate for the Entire Study (N = 4350)
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Table V.C-7. Summary of Agreement or Refusal for the Entire Study  (N=4350)
Contact Status No.
% of
Contacted
by Phone
% of Letter
Sent % of Total
Letter Sent 4329 -- 100.0 99.5
Unable to contact 90 -- 2.1 2.1
Contacted by phone 4239 100.0 97.9 97.4
     Agreed, final 3564 84.1 82.3 81.9
     - on first attempt 3446 81.3 79.6 79.2
     - on second attempt 118 2.8 2.7 2.7
     Refused, final 634 15.0 14.6 14.6
     Unable to participate 41 1.0 0.9 0.9
Died prior to participation 16 -- -- 0.4
Ineligible 2 -- -- 0.0
Located with no contact 3 -- -- 0.1
Agreement to participate is shown by geostrata in Figure V.C-14.  While those born in Ferry and
Stevens Counties had the lowest agreement rate at 74.5%, willingness to participate did not otherwise differ
substantially by geographic region of birth.   Agreement rates from all other geographic strata ranged from
77.7-84.3%.
HTDS 
Agreement to participate is shown by sex for the entire study in Figure V.C-15.  Women were
slightly more likely to agree than men, 83.5% and 80.4% respectively.
Figure V.C-15. Final Agreement to Participate for the Entire Study, by Sex (N = 4350)
Figure V.C-14. Final Agreement to Participate for the Entire Study, by Geostratum  (N=4350)
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Willingness to participate did not vary appreciably by birth year, as shown in Figure V.C-16.
Agreement rates range from 78.8% to 86.6% for the seven years of birth (1940-1946), with no apparent
pattern.
Figure V.C-16. Final Agreement to Participate for the Entire Study, by Year of Birth (N=4350)
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Agreement to participate by area of current residence is shown in Figure V.C-17.  A slight
variation was evident by region of the country.  Agreement rates in the Midwest, Southern and Eastern
portions of the US ranged from 77.0-78.4%, whereas in the western U.S. they ranged from 82.1-83.1%.
Those living outside the U.S. had an agreement rate of 80.6%.
Figure V.C-17. Final Agreement to Participate for the Entire Study, by Geographic Region of
Current Residence (N=4350)
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The Regions in Figure V.C-17 were defined as follows:
Washington State
Cal/Hawaii: - California, Hawaii
Other Northwest: - Alaska, Idaho, Montana, Oregon, and Wyoming
Southwest: - Arizona, Colorado, Nevada, New Mexico, Texas, Utah
Midwest: - Illinois, Indiana, Iowa, Kansas, Kentucky, Michigan, Minnesota,
Missouri, Nebraska, North Dakota, Ohio, South Dakota, Wisconsin
South: - Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, North
Carolina, Oklahoma, South Carolina, Tennessee
East:  - Connecticut, Delaware, Maine, Maryland, Massachusetts, New
Hampshire, New Jersey, New York, Pennsylvania, Rhode Island,
Vermont, Virginia, Washington D.C., West Virginia
C.3.d.1. Agreement on First Attempt vs. Second Attempt (conversions)
Of those who “ever agreed” (3862), 95.9% (3704) agreed on the first attempt while 4.4% (172)
agreed on the second attempt refusal conversion.  Of all potential participants who “ever agreed,” those
agreeing on the second attempt were more likely to withdraw and/or never attend a clinic (39.5%),
compared to those who agreed on the first attempt, but withdrew or never attended a clinic (9.6%).
Nonetheless, it is still noteworthy that of the 172 potential participants whose initial refusal was converted
to an agreement on a second attempt, 104 (60.5%) did eventually attend clinics, making up 3% of all
participants attending clinics.  
Table V.C-8 shows the reasons given for refusal or withdrawal, by geographic area of current
residence.  Overwhelmingly, “Not Interested” and “No Time” were the main reasons cited for non-
participation, with 64.8% of all refusals falling into this category.  The next highest category, at 7.6% (48
cohort members) was illness or impairment.   In general, the reasons given did not vary significantly by
area of current residence, although fewer Washington State residences cited unwillingness to travel as
compared to those outside the state.  Still, this reason accounted for only 30 (4.7%) refusals to participate. 
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Table V.C-8. Reasons for Refusal or Withdrawal for the Entire Study, by Geographic Area of 
Current Residence (N=634) 
Reason for Refusal or Withdrawal
Not
Interested
or No Time
Illness or
Impairment
Unwilling
to Travel
Opposed to
Study
Legal or
Insurance
Concerns
No
Thyroid
Disease Other* Total
Area of
Current
Residence No. % No. % No. % No. % No. % No. % No. % No.
All WA 216 66.1 21 6.4 3 0.9 17 5.2 5 1.5 2 0.6 63 19.3 327
Seattle 28 63.6 2 4.5 0 -- 1 2.3 1 2.3 0 -- 12 27.3 44
Everett 7 58.3 1 8.3 0 -- 1 8.3 0 -- 0 -- 3 25.0 12
Tacoma 11 73.3 0 -- 0 -- 0 -- 0 -- 0 -- 4 26.7 15
Olympia 10 66.7 2 13.3 1 6.7 0 -- 0 -- 0 -- 2 13.3 15
SW WA 12 66.7 0 -- 0 -- 3 16.7 0 -- 0 -- 3 16.7 18
Wenatchee 19 79.2 3 12.5 0 -- 0 -- 0 -- 0 -- 2 8.3 24
Yakima 14 53.8 3 11.5 1 3.8 1 3.8 2 7.7 0 0 5 19.2 26
Spokane 39 69.6 3 5.4 0 0 4 7.1 0 -- 1 1.8 9 16.1 56
Tri-Cities 75 64.7 7 6.0 1 0.9 7 6.0 2 1.7 1 0.9 23 19.8 116
SE WA 1 100 0 -- 0 -- 0 -- 0 -- 0 -- 0 -- 1
Other NW 51 57.3 9 10.1 5 5.6 2 2.2 2 2.2 2 2.2 18 20.2 89
CA/HI 35 64.8 8 14.8 4 7.4 2 3.7 1 1.9 0 -- 4 7.4 54
Southwest 30 69.8 5 11.6 2 4.7 3 7.0 0 -- 0 -- 3 7.0 43
Midwest 34 66.7 4 7.8 7 13.7 0 -- 0 -- 1 2.0 5 9.8 51
South 26 63.4 0 -- 8 19.5 0 -- 0 -- 0 -- 7 17.1 41
East 18 69.2 1 3.8 0 -- 1 3.8 0 -- 1 3.8 5 19.2 26
Other 1 33.3 0 -- 1 33.3 0 -- 0 -- 0 -- 1 33.3 3
Total 411 64.8 48 7.6 30 4.7 25 3.9 8 1.3 6 0.9 106 16.7 634
* Other: Includes family problems, personal reasons, distrust, lack of personal benefit, scheduling problems, refusal by a household
member on the potential participant’s behalf, and no reason given. 
C.3.d.2. Refusals
Among the final refusals (those either not recontacted or if recontacted, not converted to
agreement), overwhelmingly, “not interested” and/or “no time” were the reasons given for most refusals,
making up 31.9% and 33.0%, respectively.  Other frequently cited reasons were “illness” (5.5%),
“unwilling to travel” (4.7%), and “opposed to study” (3.9%).  Particular efforts were made to accommodate
potential participants who cited illness as a reason for being unable to participate, including repeated
contacts, covering the cost of travel companion, special food, lodging and local travel accommodations.
Nineteen (3.0%) responses indicated that a person other than the potential participant refused for the
potential participant or discouraged them from participating.  These were often spouses who were opposed
to participation or who claimed to be responding on their spouse’s behalf.  While every effort was made to
talk to the potential participant directly, the policy was not to pursue cases in which a family member
would refuse for or not allow contact with the potential participant.  In such cases, no further contact was
attempted.  This situation was thus considered a refusal to participate.
In eleven cases, the reason for non-participation was that the potential participant and Scheduler
could not agree upon an acceptable clinic appointment.  In most cases, this was simply due to the potential
participant’s extremely busy schedule at work and/or home, which precluded a genuinely interested
participant from attending the clinic.
For those who refused or withdrew from the study due to illness, or were judged unable to
participate due to impairment, the reason for their non-participation was recorded at the time of the refusal
or withdrawal.  The type of illness or impairment was recorded in the Recruiter’s notes on the Refusal
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Assessment Form.  Figure V.C-18 summarizes the types of illnesses and impairments that precluded
participation in the study.  For those potential participants in the “Other” category reasons ranged from
wanting the study to pay for their spouse to travel to the clinic with them for a vacation, to feeling that
participation in a study with a politically controversial topic would conflict with their religious beliefs.  In
no case was current thyroid disease given as a reason for non-participation, however, one potential
participant did state he/she did not wish to participate because he/she had already undergone a
thyroidectomy for cancer and did not wish to have additional studies for this condition.  
Figure V.C-18. Type of Illness/Impairment Precluding Participation for the Entire Study (N=48) 
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C.3.d.3. Success in Converting Refusals/Withdrawals by Reason for Refusal
With the exception of those who cited illness or gave no reason, there was relatively little variation
in the success rate for converting initial refusals (shown in Table V.C-9, below).  Success rates were higher
for those who gave a reason of “no time” or “not interested” initially, and were highest for those who cited
illness as the reason for initial refusal.  The percent of conversions of those contacted a second time ranged
from 0% for those reporting impairment as the reason for their refusal to 81% who refused for “other
reasons”.
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Table V.C-9. Conversion to Agreement to Participate by Reason for Refusal for the Entire Study
               Recontacted                 Converted to Agreement
Reasons Refused Total                 No. % No.
% of
Recontacted     % of Total
No time 250 147 58.8 41 27.9 16.4
Not interested 242 156 64.5 40 25.6 16.5
Illness 40 9 22.5 5 55.6 12.5
No reason given 34 9 26.5 4 44.4 11.8
Unwilling to travel 33 14 42.4 3 21.4 9.1
Opposed to study 29 15 51.7 4 26.7 13.8
Other person refused 22 12 54.6 3 25.0 13.6
Family problems 15 8 53.3 3 37.5 20.0
Impaired 13 3 23.1 0 0.0 0.0
Scheduling problems 11 0 0.0 0 0.0 0.0
No thyroid disease 6 2 33.3 0 0.0 0.0
Distrustful/suspicious 6 3 50.0 0 0.0 0.0
Advice of attorney 5 4 80.0 1 25.0 20.0
Insurance concerns 5 3 60.0 1 33.3 20.0
No personal benefit 5 0 0.0 0 0.0 0.0
Personal reasons 5 1 20.0 0 0.0 0.0
CATI upset respondent 3 2 66.7 0 0.0 0.0
Other reason 28 16 57.1 13 81.2 46.4
Total 752 404 53.7 118 29.2 15.7
* All who “ever agreed” on second attempt, including those who later withdrew
C.3.d.4. Success in Converting Refusals/Withdrawals by “Strength” of Refusal
It should be noted that whether or not a potential participant was re-contacted for a second attempt
at recruitment was based on the Recruiter’s or Participation Coordinator’s discretion, potentially producing
an inherently biased, “pre-selected” group of participants who were contacted for a second attempt.  This
may, in turn, affect the ability to accurately compare success in converting refusals by strength of refusal or
other variables.  With this in mind, it is still of interest to consider the success rates of refusal conversion by
strength of initial refusal and by reason for refusal.  
Fifty-six percent (245) of those classified as “firm” in their refusal on first attempt were re-
contacted, while 60.9% (143) of those whose refusal was categorized as “mild” were contacted for a second
attempt.  Of those whose response was considered “hostile” on the first attempt, a total of 16 (20%) were
designated for re-contact.  These few potential participants were felt eligible for re-contact based on the
point at which the refusal occurred (generally in the first seconds of the recruitment call).
 
Success in converting refusals to agreement to participate, when potential participants were re-
contacted for a second attempt, did appear related to the strength of the initial refusal or withdrawal
(classified by the Recruiter as mild, firm, or hostile).  When contacted for a second attempt, 36.4% of
participants whose refusal was categorized as “mild” agreed on a second attempt.  In comparison, 24.5% of
the participants who had been reported as “firm” in their refusal on the first attempt agreed on the second
attempt.  Interestingly, of those judged “hostile” on initial contact who were re-contacted, 37.5% agreed on
the second attempt.  This was, however, a small and highly select group, which would not represent
“hostile” refusers as a whole.
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The variation in success rates for conversion of refusals when comparing all potential participants
(whether re-contacted or not) by strength of refusal was similar between the “mild” and “firm” refusals,
22.1% and 13.7%, respectively.  Table V.C-10 shows conversion to agreement by strength of refusal.
Table V.C-10. Conversion to Agreement to Participate by Strength of Refusal for the Entire Study
Strength of % Converted of % Converted of
Refusal         No. Re-contacted       % Converted Re-contacted Total Refused
Mild 235 143 60.9 52 36.4 22.1
Firm 437 245 56.1 60 24.5 13.7
Hostile 80 16 20.0 6 37.5 7.5
Total 752 404 53.7 118 29.2 15.7
While the attempts to convert initial refusals or withdrawals appear to be more successful when re-
contacting those whose refusals were classified as mild, with 13.7% of all  “firm” refusals/withdrawals
agreeing to participate on the second attempt, it also seemed worthwhile to attempt to convert most
potential participants regardless of perceived strength of first refusal (with the exception of truly hostile
potential participants who were generally not re-contacted).
C.3.e. Conclusions
Efforts to recruit participants for this study were successful and met or exceeded initial
expectations.  Although participation required a substantial effort on the part of the participant and his/her
family, these rates of success indicate a substantial degree of general willingness of those selected to
participate in this study.
An important part of this success can be attributed to highly trained recruiting staff who was able
to respond appropriately to potential participants’ concerns.  The approach of sending detailed study
information prior to contacting potential participants seemed to work well for the purposes of recruiting.  In
addition, re-contacting many potential participants who refused on the first attempt (or withdrew), resulted
in substantial refusal conversions and a 3% increase in those ultimately attending a clinic.
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D. Computer Assisted Telephone Interview
D.1. Background
Two basic approaches were considered for collecting information about study participants’ early
years of life: 1) a personal interview with one respondent and other members of the family present; and 2) a
telephone interview with a respondent and other family members connected by a conference call.  The
approach of conducting a personal interview was deemed not to be feasible due to the logistical
complexities of organizing such interviews all over the country and the very high costs that would be
associated with such a process.  A decision was made to proceed with the development of a Computer
Assisted Telephone Interview (CATI).  The idea of involving more than one person was later incorporated,
to a limited degree, when special circumstances dictated that an additional person (or persons) would
enhance the recall of specific information (e.g., cow feeding patterns).
D.1.a. Objectives of the Interview
The primary objective of the CATI was to collect information that would be used as input for
calculating a radiation dose to the thyroid gland from Hanford’s 131I for each study participant, as well as
information about other radiation exposures and diagnoses of thyroid disease experienced by the
participant.  Secondary objectives of the CATI component of the study were to: 1) interview a person
knowledgeable about each participant’s early life (e.g., someone who could answer questions about the
whereabouts, circumstances, and habits that an individual could not be expected to know about his/her very
early years); and 2) assure that the accuracy and integrity of the data collected were of acceptable quality.
D.1.b. Historical Perspective and Special Challenges
Prior to the time that the HTDS began developing a CATI for dose determination purposes, the
CATI technique had been used extensively for several years by many organizations, primarily to conduct
telephone surveys for health and opinion research.  A CATI is conducted by an interviewer who reads the
survey text and questions from a computer screen.  As the respondent provides each answer, the
interviewer enters the response into the computer, and the response immediately becomes part of the
permanent database.  The computer program is designed to show the next question on the screen that
should be asked, based on the previous answer(s).
Surveys conducted with CATI are generally quite straightforward, and they are usually structured
in such a way that the questions are formatted for multiple choice, true/false - agree/disagree, and short
answer responses.  The total interview time is seldom greater than twenty minutes, and the respondent does
not prepare in advance for the interview.  CATI is often used in conjunction with “cold calling” to identify
respondents willing to spend a few minutes on the telephone participating in a survey.
In the initial stages of planning the HTDS CATI, it became apparent that the interview would be
far more complex than is typical of the CATI format.  It appeared that the “state of the art” for CATI
methodology did not incorporate many of the key features that would be required for the HTDS CATI.
Several characteristics of the HTDS posed special challenges to developing a workable CATI.
First, much of the information required pertains to events that happened between forty and fifty
years before the interview.  Furthermore, much of the information in the interview could be considered
rather mundane in that the questions would need to refer to events and circumstances of daily life.  Clearly,
asking people to recall such detailed information from so long ago would present very special challenges.  
Second, a large volume of information would need to be collected during the interview.  It would
be necessary to develop a structure that would organize the various types of data collected, while
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accommodating a wide range of life circumstances among the study participants.  For example, some
participants were born in the study area while their parents resided there only temporarily, perhaps for only
a few weeks, before moving out of the Northwest.  Such an interview would yield a relatively small amount
of data.  Other participants were born and lived their entire lives in the area, perhaps at multiple residences.
An interview about such an individual could produce a much larger amount of data.  It would be important
to have computer software that could adequately adjust to the very different circumstances that would
likely arise, and the variations in the amount of data collected.  Third, and related, it would be critically
important that the system be capable of managing complex skip patterns, and allow for on-line consistency
checks and the ability to correct entries on-line.
D.2. Content and Design of the CATI
The plan for CATI described in the HTDS Protocol provided the rationale for the content of the
interview and identified its components.  It was designed to collect information from the early years of the
participants’ lives, including time in utero, from 1944 to 1957.  The period of greatest interest, with regard
to exposure to radioactive iodine, was each participant’s early childhood.  The interview was “location-
driven” so that the information collected was specific to locations and periods of time directly relevant to
the radiation releases from Hanford.
The following topic areas were included in the CATI: 1) a residential history of the participant
from birth through 1957, and for the mother while pregnant with and breastfeeding the participant; 2)
sources of milk consumed by the participant from birth through 1957, and for the participant’s mother
while pregnant and breastfeeding (including commercial milk producers and private sources, for both
cow’s and goat’s milk; 3) milk consumption patterns for the participant from birth through 1957, and for
the mother during pregnancy and breastfeeding; 4) other patterns of food consumption, including green and
leafy vegetables, fresh fruit and free-range chicken eggs, for the participant from birth through 1957, and
for the mother while pregnant and breastfeeding.  In addition, medical history information was obtained for
both the mother and the participant, including the following: 1) thyroid diseases and selected other medical
conditions diagnosed and treated in the participant; 2) history of radiation exposures, either diagnostic or
therapeutic, for the participant, and for the mother during pregnancy and breastfeeding.  The name of the
treating physician for these conditions and treatments was obtained when possible.
The CATI was developed in cooperation with a number of individuals and groups, including the
Technical Steering Panel of the Hanford Environmental Dose Reconstruction Project and Battelle Pacific
Northwest Laboratories, staff at the CDC, scientists who had conducted similar studies (e.g., Dr. Lynn
Lyon at the University of Utah), and experts in survey and cognitive research. 
After extensive investigation of available software options, the INGRES software package was
selected as the basis for developing the CATI.  INGRES provided a relational database structure, which
was judged to be essential for the type of system envisioned, and contained many of the technical features
needed to accommodate a complex interview with on-line quality control.
The CATI was administered to the participant’s mother, or other person knowledgeable about the
participant’s early years, by specially trained interviewers.  The interview was recorded on audiotape with
the respondent’s permission, so that a permanent record, independent of the computer system, would be
created.  The recording could be used for back-up to the computer system, for training and quality control
monitoring of interviewers, and for clarification of information provided during the interview.
D.2.a. Development of a Cognitive Approach to Enhance Long-term Recall
From the initial stage of questionnaire development it was apparent that making the interview
successful would depend largely on the ability of respondents to accurately report detailed information
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about their child (or sibling) from very long ago.  In July 1990 a workshop was held to consider how the
questionnaire and the process of conducting the CATI interview could be modified to include as many
characteristics of a cognitive interview as possible.  Participants in the workshop included Dr. Donald
Dillman, a sociologist and leading national authority on survey research from the Washington State
University at Pullman; Dr. Ronald Fisher, a cognitive psychologist from Florida International University;
and Dr. David Price, an agricultural economist and member of the Hanford Environmental Dose
Reconstruction Project Technical Steering Panel from Washington State University, the four HTDS
investigators, and key HTDS staff (Project Manager, Programmer, Field Operations Supervisor).  Dr.
Dillman’s expertise in interview data collection has been utilized by the U.S. Department of the Census,
while Dr. Fisher’s work has been used extensively to assist in both criminal investigation and investigations
of food-borne illness.
The cognitive interview is a technique developed to enhance recall.  It is based on principles of
cognition and memory retrieval theory.  In the cognitive interview, it is important to mentally take the
respondent back to the time period in question, and have them remember as much about that time as
possible.  As more memories of the time in question are recalled by the respondent, the likelihood of
remembering answers to specific questions increases.  Thus, for an interview regarding food consumption
patterns such as the HTDS CATI, one would want to guide the respondent to remember not only major
events or favorite songs of the time, but what the kitchen where the food was prepared looked like, and
where food was purchased.  These principals of the cognitive interview, with extensive preparation by the
respondent, differ greatly from the standard epidemiologic interview.  In most epidemiologic studies, great
care is taken to ensure that the respondent does not prepare in advance to answer questions.  Such
preparation, it is felt, could produce bias in that those who are ill may be more likely to prepare and report
exposure than those who are not.  However, these studies also generally do not ask such specific questions
about daily life events so many years after the fact.  
D.2.b. Development and Testing of the CATI
During the spring of 1991 the first field testing of a paper version of the questionnaire took place
in the Tri-Cities area.  Individuals who had offered to help the study in some way were asked to participate
in the testing.  Three interviews were conducted with people in their homes.  These individuals closely fit
the profile of a CATI respondent.  Generally, they were in the same age range as the parents of study
participants, and they had children who were born during nearly the same years as study participants.  Care
was taken not to include individuals who could possibly be asked later to participate in the actual study.
Major conclusions drawn from this field test included the following: 1) it was too difficult for
respondents to look at maps and determine the exact locations of residences; 2) the memory prompts
previously developed were helpful, but needed to be expanded to encourage advance preparation by the
respondent; 3) asking respondents to identify all residences during the interview without preparing
beforehand was too difficult; and 4) giving the respondent the opportunity to prepare ahead of time for the
interview was very important, and would be a major determinant in obtaining a successful interview.  
During the early summer of 1992, Dr. John Tarnai, a sociologist from Washington State
University and colleague of Dr. Don Dillman, began working with the HTDS staff on expanding and
refining the memory materials that would be provided to respondents in preparation for the interview.  As a
result of the field testing concluded in 1991, it was decided to ask respondents to provide a written
residence history to be mailed to the study office prior to conducting the interview.  One goal of the
memory materials was to encourage recall for completion of the residence history by providing information
about events that happened during each year of interest.  World, national, and local events, as well as
popular songs, movies, and trends from each year were included to help provide a frame of reference that
would help direct memory to many years ago.
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Additional memory materials were developed to help the respondent prepare for answering the
interview questions.  Background information was provided to encourage memory about specific topics.
For example, the dates of VE Day and the death of President Roosevelt were provided as general reference
dates, while the beginning of war rationing and the Tri-Cites Memorial Day flood of 1948 were added to
focus on local events which might have impacted food consumption practices.  The memory materials were
organized into a booklet that was to be sent with the residence history questionnaire.  In addition, the text of
the interview was refined to include references to specific parts of the memory materials at key points
during the interview.
A second and more extensive field test was conducted during July and August of 1992.  Telephone
interviews were conducted with parents, friends, relatives of HTDS and other FHCRC staff members, and a
few individuals recruited from local senior citizens centers.  All respondents were similar in age to the
parents of study participants.  Precautions were taken to ensure that none of the individuals involved could
later be asked to participate in the study.  Fifteen individuals participated as respondents in this effort.
This round of field testing consisted of two parts.  Interviews were completed with about half the
individuals, and they were then asked to provide feedback about the interview experience.  The primary
finding was that the volume of materials provided for memory recall purposes was overwhelming.  As a
result, the materials were divided into two parts.  The first booklet, titled the Calendar of Events (Appendix
7), would accompany the Residence History Questionnaire (Appendix 8) that respondents would complete
and mail back prior to the interview.  The second, titled the Interview Booklet (Appendix 9), was designed
to contain information that would help prepare for answering the interview questions.  The Interview
Booklet was to be mailed a few days after the Calendar of Events and Residence History Questionnaire
were sent.
The revised materials, sent out in two separate mailings, were used during the second part of field
testing.  These later interviews confirmed that dividing the materials was easier for the respondents, as the
volume of information was not so intimidating.  In response to comments from the second group that it was
difficult to foresee what the questions in the interview would be like, a sheet of sample questions was
developed.  An additional page of materials entitled “Meet the Johnsons,” presented a profile of a typical
family, then gave examples of questions from the interview with the appropriate responses, based on
information provided in the profile.  This sheet was enclosed with the Interview Booklet, and is included
here as Appendix 10.
Additional smaller refinements to the questionnaire text were made during the early fall of 1992,
as a result of the CATI training and practice interviews (Appendix 11).
D.2.c. Final Process and Procedures 
D.2.c.1. Conducting the Interview
Each participant recruited for the study was asked to identify a respondent for the CATI as
described in section V.C.2.b above.  This person was to be knowledgeable regarding the participant’s early
life and eating habits, able to perform the required preparation for the interview, and able to respond to the
questions over the phone during a conversation that could be over an hour in length.
Once the respondent was identified, a letter was sent informing her or him that the participant had
asked that they complete this portion of the study.  This letter was followed by a phone call from the
Interviewer to explain the process and obtain consent to do the CATI.  If the respondent declined to do the
interview, the participant was recontacted to determine if another respondent was available.  If the
respondent consented to the interview, the Residence History Questionnaire and Calendar of Events were
sent to them to complete.  The Residence History Questionnaire was to be sent back to the Interviewer, and
once received, the Interviewer called the respondent to review the information and schedule the actual
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interview. With the respondent’s consent, interviews were recorded on audiotape for quality control and
interviewer training purposes.   
Once the interview was completed, the Interviewer updated the tracking system, so the participant
could be scheduled for a clinic appointment.  A thank-you letter was sent to each respondent in
appreciation of his or her participation in the study.
D.2.c.2. Quality Control
Quality control for the CATI was first addressed in the thorough training given to each interviewer
prior to performing actual interviews.  Each interviewer was provided extensive training on both the
interview instrument as well as the computer system required to administer the CATI.  Over the course of
the study, seven interviewers were trained to conduct the CATI.  Each interviewer received written
materials including a flow diagram of the entire interview, a question-by-question training manual, and a
manual covering interviewing techniques such as appropriate probing and responses to respondent
questions.  In addition, they received documentation of the CATI program, special training on making data
corrections during the interview (when respondents changed their minds regarding a previous answer), and
a procedure manual outlining the CATI process from initial contact to completion of the interview.
When the study first began, the original three interviewers traveled to Washington State University
in Pullman for training in the cognitive interview technique.  Two additional interviewers underwent this
training later in the study, while the final two interviewers hired received this portion of the training from
experienced HTDS interviewers.
Interviewers continued their training by conducting the interview with HTDS staff, family and
friends.  This was followed by practice interviews with volunteers (often the parents of HTDS staff
members) who had children in the age range of study participants.  Tapes of these “practice” interviews
were reviewed with the CATI Supervisor and experienced interviewers for feedback on technique and
accuracy.  Later in the study, new interviewers began their training by listening to previous interviews with
an experienced interviewer.
Throughout the study, the CATI supervisor listened to tapes of the interviews as part of the quality
control plan.  Checks of the data entered during the interview were compared to the answers given on the
tape. Any necessary data corrections were performed by the systems analyst/programmer.  Feedback on
any errors found was given to individual interviewers by the CATI Supervisor.  In addition, early in the
study, tapes were copied and forwarded to Dr. John Tarnai and Ms. Ellen Lammiman of Washington State
University, Pullman.  These recordings were reviewed for interviewer technique in assisting recall of
participants, appropriate probing questions, and consistency.  Feedback from Dr. Tarnai and Ms.
Lammiman was forwarded to the interviewers as part of the ongoing assessment of their work.  Sampling
of tapes was performed on a random basis for two interviews per week during the first six months of the
study.  Additional tapes were monitored following the training of new interviewers, or when specific issues
were found.  Random checks continued throughout the study at a rate of approximately one interview per
week.
Quality assessment of the respondent’s ability to answer the interview questions was also
performed.  Following each section of the interview, interviewers recorded their assessment of how reliable
the responses were for those questions using the categories of High, Generally Reliable, Questionable, or
Unreliable.  These assessments were based on whether the respondent seemed fairly certain of the
responses, appeared to be guessing or asking the interviewer for help in making the “correct” response, and
whether the responses were consistent or contradictory.  At the end of the interview, the interviewer also
recorded her or his overall assessment of the reliability of the responses, and of the respondent’s level of
cooperation (Very Good, Good Fair, or Poor).
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D.3. Outcome and Results
D.3.a. Pilot Study Results
CATIs were completed for 797 (85.1%) of the 937 participants in the Pilot Study Sample who
identified a CATI respondent.  Of the 1063 Pilot Study participants who completed the clinic, 756 (71.1%)
had a complete CATI interview.  Forty-one participants withdrew from participation after the CATI was
completed.  In 14 instances, CATI Interviewers deemed the quality of the data provided by respondents too
poor to be considered reliable.  Expanded interviews were performed at the clinic for these participants.
D.3.b. Transition Sample Results
Of the 536 participants in the Transition Sample who identified a CATI respondent, interviews
were completed for 458 (85.4%).  Of the 664 Transition Sample participants who completed the clinic, 429
(64.6%) had a CATI.  Twenty-nine participants withdrew from the study after a CATI was completed. In
two instances, CATI Interviewers determined that the quality of the data provided by respondents was too
poor to be considered reliable.  Expanded interviews were performed at the clinic for these participants.
D.3.c. Results for the Full Study Sample
CATIs were completed for 1011 (81.6%) of the 1239 participants in the Full Study Sample who
identified a CATI respondent.  Of the 1720 Full Study Sample participants who completed the clinic, 948
(55.1%) had a CATI.  Sixty-three participants withdrew from the study after a CATI was completed. In 13
instances, CATI Interviewers determined that the quality of the data provided by respondents was too poor
to be considered reliable.  Expanded interviews were performed at the clinic for these participants.
D.3.d. Overall Results for the Entire Study
Of the 2712 participants who identified a CATI respondent in the entire study, interviews were
completed for 2266 (83.6%).  Of the 3447 eligible participants who completed the clinic, 2133 (61.9%) had
a CATI.  One hundred-thirty-three participants withdrew from the study after a CATI was completed.  In
29 of the 2133 instances, CATI Interviewers determined the quality of the data provided by respondents
was too poor to be considered reliable.  Expanded interviews were performed at the clinic for these
participants. 
D.3.e.  Conclusions
The percentage of CATIs completed for participants declined with each successive phase of the
study.  This can probably be attributed to the fact that respondents were somewhat older as the study
progressed, especially following the Full Study Sample.  Participants born in 1940 and 1941 were included
at this time, and this small difference in birth years may have contributed to the decrease in the overall
percentage of CATIs completed.  Table V.D-1 shows the number of CATIs completed by year of
participant’s birth.
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Table V.D-1. Final Outcome of CATI by Participant’s Year of Birth for the Entire Study
(N =2712*)
CATI Completed*
Year of Birth
Respondent
Identified No.
% of those
w/Respondent
Identified
CATI
Completed for
those
Attending a
Clinic
% of those
Attending a
Clinic with
CATI
1940 164 135 82.3 128 52.0
1941 170 136 80.0 129 45.3
1942 366 317 86.6 299 63.2
1943 438 348 79.5 326 58.2
1944 742 608 81.9 569 62.7
1945 504 436 86.5 412 67.4
1946 328 286 87.2 270 74.0
* Includes all CATIs completed, whether acceptable for dose determination or not.
D.3.e.1. Quality of the Data
Overall data quality was very high as reported by the interviewers.  Tables V.D-2 through V.D-4
show the assessment of data reliability as reported by the CATI interviewers. Responses were judged to be
of high quality or generally reliable for most interviews for most sections. Responses in the section related
to the participant’s milk and dietary consumption history were judged by the interviewers to be
questionable in approximately 9% of the interviews.  Not surprisingly, the main reason cited for
questionable or unreliable responses was unclear memory.  The interviewer judged the respondent’s
cooperation to be good or very good in over 94% of the interviews.
Table V.D-2. Interviewer’s Overall Assessment of Reliability of Responses to CATI (CATIs Used 
for Dose Estimation Only) for the Entire Study  (N=2123)
Overall
Milk Source
Data
Mother’s Milk
Consumption
and Dietary
Data
Participant’s
Milk
Consumption
and Dietary
Data
Mother’s
Medical
History
Participant’s
Medical
History
Response Quality No. % No. % No. % No. % No. % No. %
High 410 19.3 387 18.2 377 17.8 297 14.0 1178 55.5 951 44.8
Generally reliable 1523 71.7 1570 74.0 1552 73.1 1483 69.9 910 42.9 1118 52.7
Questionable 170 8.0 39 1.8 53 2.5 193 9.1 23 1.1 44 2.1
Unreliable 11 0.5 0 0 1 0 10 0.5 3 0.1 4 0.2
Unknown 9 0.4 127 6.0 140 6.6 140 6.6 9 0.4 6 0.3
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Table V.D-3. Main Reasons for Unreliable or Questionable Responses to CATI (CATIs Used for
Dose Estimation Only) for the Entire Study  (N=2123)
Overall
Milk Source
Data
Mother’s Milk
Consumption
Participant’s
Milk
Consumption
and Dietary
Data
Mother’s
Medical
History
Participant’s
Medical
History
Response Quality No. % No. % No. % No. % No. % No. %
Unclear memory
of events
136 6.4 34 1.6 41 1.9 141 6.6 21 1.0 35 1.6
Uncertain
understanding of
questions
9 0.4 1 0 2 0.1 17 0.8 0 0 1 0
Hurried responses 8 0.4 1 0 2 0.1 11 0.5 0 0 1 0
Other 28 1.3 3 0.1 8 0.4 33 1.6 5 0.2 9 0.4
Don’t know 0 0 0 0 1 0 1 0 0 0 2 0.1
Not applicable* 1942 91.5 2084 98.2 2069 97.5 1920 90.4 2097 98.8 2075 97.7
* Response quality High, Generally Reliable or Unknown
Table V.D-4. CATI Interviewer’s Assessment of Respondent’s Cooperation (CATIs Used for Dose
Estimation Only) for the Entire Study  (N = 2123)
Respondent’s Cooperation No. %
Very good 1511 71.2
Good 496 23.4
Fair 99 4.7
Poor 8 0.4
Not answered 9 0.4
It was anticipated from the beginning of the study that participants’ mothers would be the most
reliable respondents for the majority of the interview questions, as mothers would be most familiar with the
participant’s dietary habits and medical histories.  This was generally the case. Table V.D-5 shows the
relationship of the respondent to the study participant, while Table V.D-6 shows the quality of the CATI
data by the respondent’s relationship to the participant.
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Table V.D-5. Relationship of CATI Respondent to Participant for the Entire Study
All Persons Who
Agreed
To Participate Living Evaluable Participants
All
Interviews
(N=2268)
All
Interviews
(N=2133)
Interviews Used as Source
of Dosimetry Data
(N=2123)
Relationship to Respondent      No. %           No. %        No.            %
Birth mother 1674 73.8 1577 73.9 1568 73.9
Adopted mother 8 0.4 6 0.3 6 0.3
Father 167 7.4 158 7.4 158 7.4
Sister 289 12.7 270 12.7 270 12.7
Brother 89 3.9 82 3.8 81 3.8
Aunt 29 1.3 28 1.3 28 1.3
Uncle 4 0.2 4 0.2 4 0.2
Other relative 3 0.1 3 0.1 3 0.1
Family friend 5 0.2 5 0.2 5 0.2
Table V.D-6. Quality of CATI Data by Respondent’s Relationship to Participant for the Entire
Study (N =2268)
Birth
Mother
Adopted
Mother Father
Older
Sister
Older
Brother
Other
Family
Member
Family
Friend
Overall
Response
Quality No. % No. % No. % No. % No. % No. % No. %
High 328 19.6 0 0 28 16.8 59 20.4 23 25.8 1 2.8 1 20.0
Generally
reliable
1203 71.9 7 87.5 121 72.5 208 72.0 54 60.7 23 63.9 1 20.0
Questionable 125 7.5 1 12.5 14 8.4 18 6.2 12 13.5 12 33.3 3 60.0
Unreliable 7 0.4 0 0.0 3 1.8 4 1.4 0 0.0 0 0.0 0 0.0
Unknown 11 0.7 0 0.0 1 0.6 0 0.0 0 0.0 0 0.0 0 0.0
Total 1674 8 167 289 89 36 5
D.4. Attempts to Administer the CATI to Respondents for Deceased Potential
Participants
D.4.a. Development of a Revised CATI for Deceased Potential Participants
The HTDS Protocol stated that CATIs would be conducted for deceased potential participants,
using the CATI respondent as a surrogate for the potential participants in collecting information contained
in the In-Person Interview as well.  A separate CATI instrument was developed for this purpose in the late
summer of 1994.  The questionnaire was an expansion of the original CATI, adding questions that were
part of the In-Person Interview administered to living participants.  These included questions about
occupational history, smoking history, and demographics.  It was recognized that, depending on the age of
the potential participant at death, some questions would not be pertinent.  Only those germane to the
participant’s life circumstances would be asked during the interview.
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Special memory materials and interview preparation materials were developed for use with the
revised CATI for deceased potential participants.  Although similar to those for the interviews conducted
for living participants, there were some differences in content: 1) the residence history information was
collected from birth to death instead of through 1957 only; 2) a cause of death information questionnaire
was added for the respondent to complete; and 3) sections about occupational history and smoking history
were added to the Interview Booklet.
D.4.b. Conducting a CATI for Deceased Potential Participants
Thirty-three potential participants known to be deceased were selected from HTDS tracing records
during the fall of 1994 to test the revised CATI process and instruments.  Those selected included a large
number of potential participants who died in infancy.  The objective was to select cases for whom the
interview would be comparatively uncomplicated.  Letters of approach were sent to the respondents, and
recruiting of the respondents was begun after about one week, as with living study participants.  The CATI
Interviewers found that the respondents had difficulties discussing the deceased potential participants and
their lives.
The overall refusal rate among respondents for deceased potential participants was about 55% (18
of 33) at the end of this short pilot project.  Although some respondents initially agreed to participate, as the
process unfolded they found they could not proceed.  They reported that the experience was just too painful
for them to continue.  Interviews were eventually completed for 15 of the 33 (45%) deceased potential
participants.
Based on this pilot experience, it was decided that pursuing such an approach would be difficult
for respondents and staff, and would not be likely to produce data of sufficient quality to be useful in
estimating doses for deceased potential participants.  Thus, in March of 1995, the decision was made not to
attempt a CATI interview for deceased potential participants.  The reasons for this decision were presented
to the CDC and the HTDS Advisory Committee, who agreed that further attempts to perform CATIs for
deceased potential participants were not warranted.
D.5. Success of the CATI Component
Despite significant obstacles, the CATI component of the study was quite successful, not only in
terms of completion of interviews, but in the success of the programming and logistical aspects of the
CATI.  Because no existing CATI software was available which would accommodate the needs of the
dosimetry system, it was necessary to identify software that would be suitable for creating a custom
interview to satisfy the requirements of the HTDS.  This task was undertaken by Mr. Mark Saporito,
Systems Analyst and Programmer for the HTDS, using the INGRES relational database program.  While
developing such a program required extensive lead-time and testing, it also allowed for a system which
could be completely matched to the needs of the study, both in terms of the type of information gathered
and the use of the cognitive interview.
The idea of using a cognitive approach added significantly to the development time of the CATI as
well.  Because the data being sought were from such a distant time period and revolved around fairly
mundane activities of daily living, the cognitive approach was extremely important in eliciting accurate
information from respondents.  There was, however, an equally important need to refrain from prompting
the respondents’ answers too much.  Thus, careful and extensive planning, and advice from multiple
consultants was used to ensure that the cognitive materials provided would not “lead” the respondents to
give certain answers merely because they felt that was what the Interviewer expected.
The CATI dosimetry system developed for use in the HTDS was quite successful in providing a
relatively smooth process for the interviews.  The staff was successful in identifying appropriate
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respondents, and completing interviews when a respondent was available.  While there is no way to check
the accuracy of the data elicited, the interviewers felt confident that most respondents were able to give
responses which accurately reflected their recollections of the experience of the study participants.
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E. Scheduling
E.1. Background
Prior to the initiation of the study it was believed that study participants would be widely
distributed, with those who had moved away from eastern Washington living primarily in major urban
centers in the West and throughout the country.  The clinic location sites proposed in the study protocol,
therefore, included sites throughout the Pacific Northwest as well as thirteen urban areas across the United
States. Once the tracing component of the study began, however, it quickly became apparent that the
majority of potential study participants lived in the Pacific Northwest.  This made it possible to plan to hold
almost all of the clinics within Washington State, with many participants driving to the clinic nearest their
home.  Those living outside the state could then be flown to Seattle to the clinics held at the FHCRC.
Thus, three primary clinic sites were selected to accommodate the majority of study participants: Seattle,
Pasco, and Spokane.  Additional clinic sites in Walla Walla, Yakima, Wenatchee, and Omak were planned
so participants living in these areas would not have to travel as far to attend a clinic.  Although one two-
day clinic was held in Portland, Oregon early in the study, subsequent clinics for Oregon residents were
held in nearby Vancouver, Washington. 
There were several advantages to being able to hold nearly all of the clinics within Washington
State.  First, HTDS could offer all participants a number of different clinic locations in the Northwest.  If
one location was not convenient, there were others, also relatively close.  Second, clinic directions and
maps to participants did not have to be constantly re-developed, and there was less potential for error in
communicating directions to the participants. Third, many participants located outside the Northwest found
the city of Seattle to be an excellent choice for a vacation, and planned their clinic visit to coincide with
their vacation plans.  Scheduling participants from out of state was also easier.  Rather than waiting for all
out-of-state participants to be located before scheduling clinics in other regions, they could be brought to
Seattle throughout the study, or to other clinic sites, if that was desirable.  In addition, holding all clinics in
Washington State assisted the blinding of HTDS physicians to residence histories of participants, as it
could not be assumed that those living in other states had been less exposed.
The timing and distribution of clinics was determined jointly by the Participation Coordinator and
Field Operations Supervisor.  As cohort members were located by the Tracing staff, recruiting and CATI
efforts were focused so that pools of potential participants for a clinic would be large enough to support
full clinic operations.  In this way, the clinics could be scheduled at or close to capacity, and more clinics
could be scheduled in areas with larger numbers of participants recruited.
A policy was established to provide reimbursement and offer assistance with arrangements for a
number of special needs: 1) foreign language interpreters for non-English speaking participants; 2) sign
language interpreters for the hearing impaired; 3) personal assistant or companion for participants with a
physical or cognitive impairment; and 4) security assistance for participants incarcerated within
Washington State.  Other special needs were assessed as necessary, and decisions made on a case-by-case
basis.
E.2. Objectives of Scheduling
The primary objective of the scheduling activity was to provide each participant with at least three
options for clinic attendance, with the least possible inconvenience to the participant.  For those
participants within driving distance of a clinic, this included providing mileage and meal reimbursement
allowances, as well as hotel allowances in the case of overnight trips.  For those requiring air travel, all
travel arrangements were prepaid by the study and made through FHCRC travel staff, or later, the study’s
Travel Coordinator, to minimize the inconvenience to participants who had to travel to attend a study
clinic.
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E.3. Final Process and Procedures 
The Clinic Field Operations Supervisor and the Participation Coordinator developed a schedule of
clinic dates and locations based on the current residences of participants. The clinic appointment was
scheduled after the CATI, or after recruiting, if no CATI respondent was available. 
Multiple attempts were made to contact all participants and each participant was offered several
options for clinic dates.  The Schedulers made calls to participants at varying times of the day and week.
All participants, including those scheduled in the final few months of the study, were offered at least three
options for clinics. Participants requiring air travel or overnight accommodations were called between 12
and four weeks in advance of the clinic date.  Participants not requiring air travel or hotel accommodations
could be scheduled up to two weeks before the clinic date.  
 
A computerized tracking system was utilized for tracking the progress of participants through the
scheduling process and for creating reports used to generate appointment confirmation letters.  Each
scheduled participant was sent a letter that included 1) the date and time of clinic appointment; 2) the
location of the clinic and directions; 3) travel arrangements summary and/or tickets (if applicable) and 4)
the Interview Preparation Worksheet. 
If a participant canceled a clinic appointment, the Schedulers attempted to reschedule the
participant as soon as possible.  A participant who canceled a clinic appointment would be rescheduled an
unlimited number of times.  If a participant did not show up for a clinic appointment, without notifying the
HTDS, the Schedulers attempted to reschedule an appointment.  After a participant did not show up for
three separate appointment times, no additional attempts were made to schedule the participant. Reminder
calls were instituted to reduce the number of “no-shows” at the clinics.  These calls were made one to three
days prior to the clinic appointment.  Based on previous experience with similar epidemiological studies,
these reminder calls helped to reduce the number of participants who failed to show for their clinic
appointment.
Despite concerted efforts, it was not possible to re-contact some participants after they had agreed
to participate (either due to disconnected phone numbers or repeated attempts resulting in no answer or
answering machines).  In each case, attempts were made to obtain updated information from the CATI
respondent (if one was available), through the initial tracing source, or by returning to the tracing staff for
further tracing work.  If these efforts did not obtain a current telephone number, a letter was sent to the
participant requesting they contact us.  If attempts to obtain updated information were unsuccessful, or if
the participant did not respond to the letters or telephone messages, the participant was classified as
“unable to schedule.”
The Schedulers assessed the need for travel arrangements and, when necessary, would make the
transportation, hotel and other arrangements for the participant.  Schedulers followed specific guidelines
for allowable travel expenses and reimbursements for participants.  The Schedulers completed travel
information forms for documenting travel plans.
If a participant decided not to participate in the study during the scheduling process, the Scheduler
assessed the reason for the withdrawal and addressed the participant’s concerns in an attempt to retain
participation.  If the participant persisted in the withdrawal, they were asked to complete a Refusal
Questionnaire.  
If a participant withdrew after agreeing on the first attempt, the decision to re-contact for a second
attempt was made by the Scheduler and/or Participation Coordinator, based on the nature of the
withdrawal. Second attempts following a withdrawal were handled in the same way regardless of the point
at which the withdrawal took place.
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E.4. Outcome
E.4.a. Results for the Pilot Study Sample
A total of 1174 Pilot Study Sample participants agreed to participate in the study, and 1063
(90.5%) attended clinics.  These figures may differ slightly from those in the Pilot Study Final Report,
since efforts to locate, recruit and schedule remaining Pilot Study participants continued throughout the
Full Study.
Results in section V.C above, Recruiting, refer to the final agreement status of each participant at
the end of the study.  It should be noted, however, that some participants actually agreed to participate at
the time of recruitment and withdrew from the study at the time of scheduling a clinic appointment.  Table
V.E-1 shows numbers of those who “Ever Agreed” to participate, those who “Withdrew” from the study
prior to being scheduled to attend a clinic, and those who actually attended a clinic, for the Pilot Study
Sample.
Table V.E-1. Success in Scheduling Potential Participants - Pilot Study Sample  (N=1590)
Scheduling Status No.
% of
Ever Agreed
(N=1174)
% of
Agreed
Excluding
Withdrawals
(N=1094)
% of
Living/Located
Pilot Subjects
(N=1360)
% of
Selected
Pilot Subjects
(N=1590)
Ever agreed to participate 1174 -- -- 86.3 73.8
Withdrew 80 6.8 -- 5.9 5.0
Agreed (did not withdraw) 1094 93.2 -- 80.4 68.8
Attended clinic 1063 90.5 97.2 78.2 66.9
Unable to schedule* 31 2.6 2.8 2.3 1.9
* Those categorized as “Unable to schedule” are those participants who agreed to participate but attempts to re-contact the participant
were unsuccessful.  A few additional participants, although offered at least three clinic appointment choices, could not be scheduled
before the end of clinics.
E.4.b. Results for the Transition Sample
Table V.E-2 shows numbers of those who “Ever Agreed” to participate, those who “Withdrew”
from the study prior to being scheduled to attend a clinic, and those who actually attended a clinic, for the
Transition Sample.
Table V.E-2. Success in Scheduling Potential Participants - Transition Sample  (N=1005)
Scheduling Status      No.
% of
Ever Agreed
(N=749)
% of Agreed
Excluding Withdrawals
(N=692)
% of
Living/Located
Transition Sample
(N=849)
% of Selected
Transition Sample
(N=1005)
Ever agreed to participate 749 -- -- 88.2 74.5
Withdrew 57 7.6 -- 6.7 5.7
Agreed (did not withdraw) 692 92.4 -- 81.5 68.9
Attended clinic 664 88.7 96.0 78.2 66.1
Unable to schedule* 28 3.7 4.0 3.3 2.8
* Those categorized as “Unable to schedule” are those participants who agreed to participate but attempts to re-contact the participant
were unsuccessful.  A few additional participants, although offered at least three clinic appointment choices, could not be scheduled
before the end of clinics.
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E.4.c. Results for the Full Study Sample
Table V.E-3 shows numbers of those who “Ever Agreed” to participate, those who “Withdrew”
from the study prior to being scheduled to attend a clinic, and those who actually attended a clinic, for the
Full Study Sample.
Table V.E-3. Success in Scheduling Potential Participants - Full Study Sample  (N=2604)
Scheduling Status     No.
% of 
Ever 
Agreed
(N=1939)
% of
 Agreed 
Excluding
Withdrawals
(N=1778)
% of 
Living/Located
Full Subjects
(N=2141)
% of 
Selected
Full Subjects
(N=2604)
Ever agreed to participate 1939 -- -- 90.6 74.5
Withdrew 161 8.3 -- 7.5 6.2
Agreed (did not withdraw) 1778 91.7 -- 83.0 68.3
Attended clinic 1720 88.7 96.7 80.3 66.1
Unable to schedule* 58 3.0 3.3 2.7 2.2
* Those categorized as “Unable to schedule” are those participants who agreed to participate but attempts to re-contact the participant
were unsuccessful.  A few additional participants, although offered at least three clinic appointment choices, could not be scheduled
before the end of clinics.
E.4.d. Overall Results for the Entire Study
Table V.E-4 shows the final status of scheduling efforts for all those who agreed to participate in
the study.  Of those who agreed to participate, and did not withdraw from the study at a later time, 96.7%
(3447 of 3564) attended a clinic.  The rates for withdrawal (7.7%) and for those who did not withdraw but
never attended a clinic (3.0%) remained fairly constant throughout the study. 
Table V.E-4. Final Success in Scheduling Potential Participants - Entire Study (N=5199)
Scheduling Status      No.
% of
Ever Agreed
(N=3862)
% of
Agreed
Excluding
Withdrawals
(N=3564)
% of
Living/Located
All Subjects
(N=4350)
% of
Selected
All Subjects
(N=5199)
Ever agreed to participate 3862 -- -- 88.8 74.3
Withdrew 298 7.7 -- 6.9 5.7
Agreed (did not withdraw) 3564 92.3 -- 81.9 68.6
Attended clinic 3447 89.3 96.7 79.2 66.3
Unable to schedule* 117 3.0 3.3 2.7 2.3
* Those categorized as “Unable to schedule” are those participants who agreed to participate but attempts to re-contact the participant
were unsuccessful.  A few additional participants, although offered at least three clinic appointment choices, could not be scheduled
before the end of clinics.
HWhile it might be anticipated that those who declined to participate or could not be scheduled
would most likely be those participants traveling the longest distances, this did not prove to be the case.  It
is likely that the popularity of the city of Seattle as a vacation destination and the diligent efforts of the
Schedulers to coordinate participant’s clinic appointments with their vacation plans, greatly reduced the
number who would not attend a clinic due to travel requirements.  Figure V.E-1 shows those who agreed to
participate but never attended a clinic, by current area of residence. 
Figure V.E-1. Subjects Unable to Schedule, by Geographic Area of Current Residence 
N
e
S
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ote: Southwest, Midwest, South and East regions are defined in section V.C.3.d.
The clinic sites used during the study, number of days at each clinic, and number of participants at
ach clinic are summarized in Table V.E-5.   Approximately 50% of participants attended a clinic in
eattle.  Pasco and Spokane were the next most commonly used clinic sites with 21.8% and 13.6% of
articipants, respectively.
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Table V.E-5. Location and Number of Clinic Days and Participants Seen at each Site – 
Entire Study  (N=3447)
Clinic Location No. of Days at Clinic Site
No. of Participants Seen at
Clinic Site % of Participants
Seattle 133 1719 49.9
Pasco 60 753 21.8
Spokane 37 469 13.6
Vancouver, WA 22 295 8.6
Yakima 7 84 2.4
Walla Walla 4 46 1.3
Portland, OR 2 33 1.0
Wenatchee 1 17 0.5
Omak 1 16 0.5
Colville 2 15 0.4
Total 269 3447 100
The current residences of participants and the clinics they attended are shown in Table V.E-6.
While most participants attended the clinic nearest their home, a number of participants attended a clinic in
other areas.  This occurred either as an incentive to participation (e.g., the participant wanted to travel to
visit family) or due to difficulty scheduling the participant at a clinic in their area.  The latter reason was
most common in the smaller, more rural communities, where fewer clinics were held.
Table V.E-6. Current Residence of Participants by Clinic Site – Entire Study (N=3447)
Clinic Site Attended
Current Residence Seattle Pasco Spokane
Vancouver,
WA Portland,
OR Yakima
Walla
Walla Colville Wenatchee Omak
Greater Seattle 583 3 1 6 1 1 0 0 0
SW Washington 3 3 1 78 0 0 0 0 0
Wenatchee 11 19 23 0 6 0 1 16 15
Yakima 8 50 0 0 76 1 0 1 0
Spokane* 5 6 329 1 0 1 14 0 1
Tri-Cities 6 559 7 1 1 38 0 0 0
SE Washington 0 1 6 0 0 0 0 0 0
Other Northwest 117 80 79 220 0 5 0 0 0
California/Hawaii 318 10 3 10 0 0 0 0 0
Southwest US 237 12 7 3 0 0 0 0 0
Midwest US 164 4 6 4 0 0 0 0 0
Southern US 146 3 2 3 0 0 0 0 0
Eastern US 99 1 3 2 0 0 0 0 0
Out of US 22 2 2 0 0 0 0 0 0
* Includes the Colville area.
Note: Southwest, Midwest, South and East regions are defined in section V.C.3.d.
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E.4.e. Conclusions
The process developed for scheduling participants proved to be extremely effective with nearly
90% of those who ever agreed to participate completing a clinic.  The number of participants who
withdrew after initially agreeing (298) was not unexpectedly high, considering the requirements of the
clinical thyroid exam and interview, as well as the amount of travel required by many participants.   The
Schedulers arranged travel, including airline and/or hotel arrangements, for 1288 (37.4%) of the 3447
participants attending a clinic.   
The participants who did not officially withdraw from the study, but who could not be scheduled
into a clinic, were offered a minimum of three clinic options, and most were offered many more
opportunities.  In many cases, those in the category of “unable to schedule” and/or withdrew had multiple
reasons for being unable to attend.  These reasons included illness, unpredictable work schedules, and
family responsibilities.  Although some participants withdrew from the study during the scheduling process
or were unable to be scheduled because of scheduling conflicts, many initially reluctant participants were
persuaded by the scheduling staff to attend a clinic.
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F. Clinical Evaluation
F.1. Background
F.1.a. Objectives for Clinical Evaluations
The objective of the clinical evaluation was to provide a thorough clinical examination of each
study participant to identify the presence of thyroid disease or primary hyperparathyroidism.  The
evaluation provided data to determine the current presence or absence of disease for each disease endpoint.
In addition, the clinic visit provided an opportunity for participants to ask questions and receive
information about radiation and thyroid disease.
F.1.b. Rationale
The clinical evaluation provided information on each participant’s current thyroid and parathyroid
disease status.  Prior to the examinations, each participant was asked to respond to an In-Person Interview
(see section V.G.) which included questions pertaining to history of thyroid disease or
hyperparathyroidism.  The clinical evaluation included a thyroid ultrasound scan, independent thyroid
examinations (palpation) by two physicians specializing in thyroid disease, and blood collection for thyroid
function, parathyroid function, and anti-thyroid immune response tests.  Additional studies were requested
if indicated by the presence of palpable thyroid nodules.  All costs associated with the clinical work-up, as
well as travel to and from the clinic sites, were paid by the study.
F.2. Clinic Procedures
F.2.a Clinic Locations and Schedules
 All clinics were held in Washington State, except for one 2-day clinic in Portland, Oregon.
Conducting clinics in Washington provided efficiencies in equipment transport, planning, set-up, and staff
travel.   The clinics at the Fred Hutchinson Cancer Research Center in Seattle were primarily held on
Friday and Saturday.  Suitable clinic space was usually not available on Friday in other locations so clinics
were most often held on Saturday and Sunday in locations other than Seattle.   
F.2.b. Clinical Evaluation Process  
Specific procedures for clinic operations were developed to optimize efficiency, assure all steps
were completed, minimize waiting and maintain confidentiality.  A packet was prepared for each scheduled
participant containing consent forms and the data forms to be completed at the clinic. Participant names
were written on index cards that were removed from the packets and transported separately for purposes of
confidentiality and then re-attached to the packet at the clinic site.  A clinic flow sheet was attached to the
front of the packet.  The clinic flow sheet provided an outline of each step or station to be visited and
included a list of all data forms. The clinic staff person performing each clinic activity would check-off the
completed activity.  
Participants would first check in with the clinic coordinator and sign the study consent form
(Appendix 12).  The participant was then escorted to the In-Person Interview.  After the interview, he or
she was taken to the blood draw station.  Following the blood collection, the nurse or phlebotomist
answered any participant questions.  
The next step was the ultrasound scan.  The ultrasound scan was recorded on videotape, prints
were made of key findings in the exam, and the sonographer completed a Thyroid Ultrasound Form
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(Appendix 13).  Following the ultrasound scan, thyroid exams were conducted separately by each of the
two physicians at the clinic and the results recorded on Thyroid Examination Forms (Appendix 14).  After
the two independent exams, the physicians would confer.  If there was disagreement between the
examiners, they would perform another thyroid exam together to reach a consensus and complete a
Consensus Examination Form (Appendix 15).   After the two physicians reached an agreement on the
exam findings and recorded the results, they reviewed the ultrasound scan results and the ultrasound scan
prints.  If there was any disagreement between the ultrasound scan and the physical exam results, a post-
ultrasound consensus exam was done together by the two physicians and a Post-Ultrasound Consensus
Examination Form completed.  The physicians then conferred privately and discussed the results of the
exams and the ultrasound scan.   The physicians returned to the exam room to discuss the exam and
ultrasound findings with the participant.   A Thyroid Ultrasound Fact Sheet was given to all participants
(Appendix 16).
If a fine needle aspiration (FNA) was indicated as a result of the exam or ultrasound scan, the
physicians would discuss this recommendation with the participant and request consent to perform the
procedure.  FNA procedures were performed at any time throughout the day according to the participant’s
schedule or request. 
The final step was a check-out with the Clinic Coordinator.  The coordinator reviewed the clinic
flow sheet to be certain that all steps were completed and checked that all data forms were completed.
Travel reimbursement paperwork was completed at check-out.
At the end of the last clinic day, staff packed up all clinic supplies and equipment. Participant
names were removed from the individual packets and the packets were transported to the HTDS office in a
locked suitcase. Clinic staff transported serum specimens to the Pacific Medical Center Laboratory in
Seattle and transported FNA specimens to the Laboratory of Pathology at Swedish Hospital in Seattle.
Ultrasound videotapes were sent by messenger to Seattle Nuclear Medicine Associates.
F.2.c. Clinic Staffing
Clinic staff consisted of two physicians, one nurse or phlebotomist, one ultrasonographer, two or
three interviewers, and a Field Operations Coordinator or Supervisor.  Approximately fifteen potential
participants were evaluated on each day.  The dates and locations of clinics and staffing assignments were
finalized 3-4 months in advance.   To improve efficiency at clinics, various members of the clinic staff
were trained and capable of performing multiple tasks. The Field Operation Supervisor was a certified
phlebotomist and was trained to assist with FNA procedures.  Both Field Operation Coordinators were
trained in the In-Person Interview and one was also able to assist with FNA procedures.  In addition, one
interviewer was a certified phlebotomist, allowing her to assist the nurse or phelbotomist at peak times, or
move to this position if needed.  
F.2.d. Efforts to Reduce Physician and Ultrasonographer Bias
To ensure that the clinical decisions by the physicians and sonographers were not influenced by
knowledge of the participants’ possible exposures to Hanford 131I, several precautions were taken during
the clinical evaluation.  The nurse or the phlebotomist asked participants not to speak with the physicians
and sonographers about where they had lived, or about the possibility of their exposure to radiation from
Hanford.  Signs were also posted throughout the clinic requesting that participants not discuss these issues
with physicians and sonographers.  In addition, some participants who lived in towns where clinics were
held were asked to attend clinics in other areas, so that physicians and sonographers would not associate
participants at one clinic site with exposure and those at another clinic site with non-exposure.  Finally,
physicans were required to record at the end of their evaluation of each participant whether he had any
indication fo possible radiation exposure for that individual.  Of a total of 3440 evaluable participants,
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there were only 15 instances where the physician had some suspicion that the participant might have had
prior radiation exposure.
F.3. Serum Sample  
F.3.a. Laboratory Studies
The Research Nurse collected a blood sample for thyroid function and other laboratory studies.  A
small number of persons refused to provide a blood sample.  Such refusal did not affect the participant’s
eligibility for participation in the study or evaluability (see section IV.B above).  Three 10 cc tubes of
blood were drawn and centrifuged on site.  The serum was transported within 72 hours to Seattle where
one tube was frozen at -70 degrees Centigrade and stored as a reserve.  The remaining two tubes were
transported to the clinical laboratory at Pacific Medical Center in Seattle for the following studies:
♦ TSH (Thyroid Stimulating Hormone)
♦ FTI (Free Thyroxine Index)
♦ Antithyroid Antibodies
♦ Calcium
F.3.b. Changes in Laboratory Assays
F.3.b.1. AMA to Anti-TPO
Specific tests and assays changed throughout the course of the study, prompted by changes in the
industry standard and on the recommendations from the laboratories.
The antimicrosomal antibody (AMA) assay was used initially to screen for autoimmune thyroid
disease.  Due to improvements in laboratory assays, the anti-thryroperoxidase  (Anti-TPO) assay was
available from Pacific Medical Center Laboratory in September 1995.  At the request of the HTDS, the two
assays were run in tandem until more than 500 assays had been performed using both methods.  An
analysis was performed to ensure the two methods were comparable, after which, the AMA was
discontinued.  The results of this analysis are shown in Table V.F-1 below.
Table V.F-1. Agreement between AMA and Anti-TPO Assay Results (N=677)
Anti-TPO
   Negative   Positive      Total
Negative 480 19 499  (73.7%)
Positive 49 129 178  (26.3%)AMA
Total 529 148 677
These results indicate a high level of agreement (90%) between the two assay methods.
F.3.b.2. TSH Methods - RIA, EIA-1, EIA-2
The TSH test methods performed on HTDS serum specimens were done initially by radioimmune
assay (RIA).  The RIA method was used from November 1992 through January 1994.  The RIA TSH
method was changed to an ELISA immunometric assay (designated EIA-1) method starting February 1994.
The EIA-1 method was used from February 1994 through August 1995.  The EIA-1 method was modified
to the EIA-2 method in September 1995.  The EIA-2 method was used from September 1995 until the end
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of the study in September 1997. In addition, the TSH normal range from the EIA-2 method was changed
from a range of 0.47-5.01 units to 0.32-5.01 units as of Jan. 10, 1997.
F.3.b.3. Parathyroid Hormone Methods
Measurement of Intact PTH was done for all participants with an elevated serum calcium level.
From the first clinic in November 1992 through October 1994, the Intact PTH test was done by the
immunoradiometric assay.  From November 1994 through the last clinic in September 1997, PTH was
done by two methods, the IRMA and the Chemiluminescence methods.  Separate calcium levels
accompanied each method.
F.3.b.4. Anti-TG
In 1998 after the clinics were completed, anti-thyroglobulin antibody (anti-TG) assays were
performed on serum samples that had been frozen and stored from the blood samples provided by HTDS
participants at the study clinics. Although the anti-TPO antibody served as the highest quality assay for
autoimmune thyroid disease, recent improvements in the anti-TG assay were available through Dr. Carole
Spencer, an international expert in the measurement of antithyroid antibodies.  These assays, which were
performed in Dr. Spencer's laboratory, provided an opportunity to assess more fully the cumulative
incidence of autoimmune thyroiditis in the HTDS cohort.
F.4. Inclusion of an Ultrasound Exam
The clinical evaluation included a thyroid ultrasound scan to detect thyroid nodularity.  The
decision to include an ultrasound scan in the clinical evaluation was based on three primary benefits: 1)
there would likely be a small increase in the ability of the study to detect a radiation effect associated with
clinical thyroid disease as currently defined; 2) nonpalpable thyroid UDAs abnormalities of the thyroid
could be included as a study outcome variable and 3) the recorded ultrasound scan provided an objective
record of the presence, location, and characteristics of thyroid growth abnormalities.
A certified ultrasound technologist performed the scan and was blinded to the participants’
exposure status. The entire thyroid ultrasound scan was recorded on videotape.  Physicians examined the
participant without any knowledge of the ultrasound findings, then again after viewing printouts from the
scan.  Following the clinic, the videotaped scans were transported to Seattle for review by an off-site
radiologist.
F.5. Ultrasound Follow-up Program
F.5.a. Purpose of the Ultrasound Follow-up Program
Participants at clinics who were found to have nonpalpable thyroid abnormalities seen only on the
ultrasound scans were given a Thyroid Ultrasound Fact Sheet.  This fact sheet explained the unknown
clinical significance of the abnormal findings.  In addition, these participants were invited to participate in
the HTDS Ultrasound Follow-Up Program. 
The Ultrasound Follow-Up Program was offered as a service to participants, and was not intended
as a substitute for treatment or follow-up by participants’ health care providers.  The primary purpose of
the program was to: 1) identify early nonpalpable, rapidly growing, thyroid cancers, and 2) provide referral
assistance to facilitate appropriate management of participants’ medical care.
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Initially, there were two possible follow-up appointments for eligible participants.  The first
appointment was at 9 months after the initial clinic appointment and, if a change was detected on physical
exam or ultrasound scan, a second follow-up appointment was recommended 6 months after that date.
This second exam was a total of 15 months after the participant’s initial clinic appointment.  This design
was modified in January 1994 to become a one-time follow-up appointment done 9-15 months after the
participant’s initial clinic appointment.
The original design of the follow-up program also included an examination by an HTDS
physician.  In February 1994, the physician examination was discontinued as part of the follow-up
program.    The purpose of the follow-up program was to detect changes in nonpalpable thyroid cancers.
Since it was very unlikely that small changes in size could be detected by physical examination, it was
decided that little useful information was provided by the follow-up physical exam.    If a new or larger
nodule was found on follow-up ultrasound exam, the participant was examined by a physician.  A total of
260 participants were evaluated during the Ultrasound Follow-Up Program. 
F.5.b. Discontinuation of the Ultrasound Follow-up Program
The Ultrasound Follow-Up Program was discontinued in June of 1995 for several reasons.  In
May 1995, a physician review of the data collected from the follow-up program revealed that no significant
changes were found between the initial and follow-up ultrasound scans that would change the diagnosis or
the recommended treatment or follow-up.  Consequently, very little new diagnostic information had been
collected from the follow-up program and no fast-growing cancers had been identified.  The Ultrasound
Follow-Up Program was not one of the HTDS research objectives and data from the follow-up exams and
scan were not entered into the primary database.  Therefore, discontinuation of the follow-up program did
not affect the study’s objectives.
The follow-up program became difficult to integrate into the busy HTDS clinic schedule.   The
follow-up program utilized the same ultrasound equipment and personnel as the HTDS clinics.  An
assessment of the clinic schedules indicated that the follow-up program would cause a significant delay in
the completion of the HTDS clinical evaluations.  Also, scheduling of the follow-up clinics was
determining the dates and locations of HTDS clinics rather than consideration of new participants’
residences. 
An additional operational concern was the volume of work generated by the follow-up program.
The Ultrasound Follow-up Program demanded substantial staff time and effort at clinics, and in the study
office for follow-up appointment calls and letters, entry of tracking data, and physician review of the
results and preparation of follow-up outcome letters to participants and their personal physicians.
Continuation of the follow-up program would have required hiring additional staff and purchasing
additional equipment.   
In June of 1995, after consultation with the CDC and the HTDS Advisory Committee, the
ultrasound follow-up program was discontinued. A special fact sheet was developed for health care
providers and participants that provided information on the significance and management of patients with
nonpalpable thyroid ultrasound detected abnormalities (UDAs).
F.6. Physicians
 The study began with two HTDS physicians.  In April 1993, four physicians were added to meet
the demands of the full clinic schedule.  All physicians were thyroid specialists.  Physician pairings and
clinic locations were rotated among physicians to reduce the potential for bias that might occur if the same
physicians worked only at certain clinic locations.
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A total of 3447 eligible participants attended a clinic, however, one participant did not have a
thyroid exam due to a tracheotomy.  Three of the 3446 participants who had a thyroid exam were examined
by one physician, rather than two because of a scheduling problem.  The numbers of participants examined
by each pair of physicians is shown in Table V.F-2.  Physicians #1 and #2 participated from the beginning
of the clinical activity and continued throughout the study. As a result, 746 (21.6%) of the participants
were examined by physicians #1 and #2, and 2822 (81.9%) were examined by a physician pair that
included physician #1 and/or #2.  The three participants examined by a single physician were all seen by
physician #1 or #2.
Table V.F-2. Pairings of Physicians for Clinical Examinations*
Second Physician
First
Physician
No
Second
Physician #2 #3 #4 #5  #6
#1         1 746 285 322 367 198
0.03% 21.6% 8.3% 9.3% 10.7% 5.7%
#2          2 -- 332 423 66 82
0.06% -- 9.6% 12.3% 1.9% 2.4%
#3 -- -- -- 117 67 233
-- -- -- 3.4% 1.9% 6.8%
#4 -- -- -- -- 26 141
-- -- -- -- 0.8% 4.1%
#5 -- -- -- -- -- 38
-- -- -- -- -- 1.1%
* Entries in the table are the number (upper) and percentage of participants who attended the clinic and were examined by the
indicated pair of physicians.
F.7. FNA Criteria
The original study protocol called for FNA procedures to be performed on study participants
whose exams indicated the presence of discrete, palpable, solitary thyroid nodules or discrete, dominant
nodules in a multinodular thyroid gland.
In February 1994 the criteria for conducting FNA procedures at clinics were expanded.  In
addition to nodules palpated on exam, the HTDS physicians also requested consent to perform FNA on
participants who were found to have nonpalpable ultrasound detected nodules of 1.5 cm or greater (average
of three dimensions) in a palpable thyroid gland.  This modification was made after several participants
were found to have quite large abnormalities detected by ultrasound that neither of the two experienced
thyroidologists could palpate.  The decision to attempt to perform an FNA on these large, ultrasound
detected thyroid abnormalities was based on: 1) consideration of the HTDS physician’s confidence of
biopsying the nodule(s) detected by the ultrasound; 2) the physician’s concern that the abnormality may
represent a thyroid neoplasm; and 3) technical and safety aspects of performing a biopsy on a nonpalpable
abnormality. 
In some cases, the HTDS physicians recommended an FNA to a study participant after his/her
clinic appointment.  This recommendation was made as a result of the radiologist’s review of a
participant’s ultrasound scan results. 
In a very few cases, participants were recommended to undergo ultrasound-guided FNA as a
safety precaution due to a nodule’s close proximity to the carotid artery.  In these rare instances, the
participant was referred to a medical facility near their place of residence that had the capability for
ultrasound-guided FNA.   The data collected from these procedures were used in the data analysis.
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After review of the FNA biopsy results, each participant was assigned a diagnosis from the FNA
or was recommended to have further evaluation.  If the FNA was consistent with thyroid cancer (papillary
carcinoma), the participant was recommended to see his/her physician for consideration of thyroid surgery.
As discussed in section V.I below, all histology slides from such surgery were requested for review by the
HTDS study pathologist and the diagnosis of either thyroid cancer or benign thyroid nodule was assigned
depending on the pathology review.  If the HTDS FNA result was adequate and consistent with a benign
thyroid nodule, no further evaluation of the nodule was recommended, and the participant was
recommended to follow-up with their personal physician.  In these cases, the HTDS diagnosis was benign
thyroid nodule.
If the initial FNA biopsy result indicated an intermediate or high probability of a follicular
neoplasm (either benign or malignant), the participant was recommended to have further evaluation by
his/her physician team, usually with consideration of thyroid surgery.  These recommendations were made
since FNA cytology cannot reliably distinguish between a benign follicular neoplasm (adenoma) and a
follicular carcinoma.  In these participants, no HTDS diagnosis was initially assigned but rather the
participant was followed until the end of the study to await further diagnostic information, usually from
surgery.  When such information became available, the participant was then given an HTDS diagnosis of
either thyroid cancer or a benign thyroid nodule depending on the outcome of the surgical diagnosis.  For
participants who (for whatever reason) did not go on to have thyroid surgery by the end of the HTDS field
component (1997), definitive information to make a diagnosis on the nodule that was biopsied was not
available.  For the HTDS analysis, these individuals were classified as having a nodule “suspicious for
follicular neoplasm”.  It is important to emphasize that none of the participants with this diagnosis had a
nodule that was suspicious for papillary thyroid cancer but rather a nodule that had some probability of a
follicular neoplasm.  Since the majority of such lesions represent benign follicular adenomas, this category
largely would be expected to represent benign nodular lesions.  The following data from the HTDS
illustrate this further.
Of the 259 evaluable participants who underwent FNA, 47 (18.1%)  were recommended to have
further biopsy or surgery.  Of these 47, 12 were subsequently found to have thyroid cancer, five to have
follicular adenoma, and 13 to have benign nodule other than follicular adenoma.  The remaining 17
participants (6.6% of the original 259) were classified as suspicious for follicular neoplasm.  All of these
17 cases were so classified because they did not go on to have further biopsy or surgery.  For none of these
17 participants was there an actual clinical suspicion of papillary cancer.  In fact all 17 had intermediate or
high probability of follicular neoplasm based on their FNA results.  Thus, for the 6.6% of the 259 persons
who had FNA and were recommended to have further biopsy or surgery, we were not able to obtain further
cytological or histological diagnoses.  While the absence of such diagnoses makes it impossible to rule out
the possibility of thyroid cancer, the probability of a benign lesion would be quite high given that all the 17
cases were suspicious for follicular neoplasm rather than for papillary carcinoma.
F.8. Thyroid Nuclear Scan Criteria
A thyroid nuclear scan and radioiodine uptake was recommended for three situations: 1) the
results of an FNA indicated suspicious cytology which could be an indicator of an autonomously
functioning nodule; 2) a neck mass was felt in the physical exam which was suggestive of an abnormality,
but because of a technically difficult exam (e.g., a very obese neck), a consensus between examiners could
not be reached at the clinic; and 3) for participants who had a suppressed TSH blood value and a normal or
elevated FTI blood value to rule out a diagnosis of Graves Disease or a toxic thyroid nodule.
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F.9. Training and Quality Control
F.9.a. Training
Two months prior to the first HTDS clinic, a “mock” clinic was held for staff training.  HTDS
staff assumed the roles of study participants and went through each clinic activity including the interview,
blood draw, thyroid ultrasound scan and physical exam.  Blood specimens were sent to the laboratory and
analyzed to test specimen processing, transport, and other clinic procedures.  
The mock clinic accomplished three primary objectives.  First, the anticipated amount of time a
participant would spend at each activity, and the total time at the HTDS clinic were verified to be
consistent with the predicted total of two hours.  The second objective was to test the designed clinic flow.
The goal was to ensure the smooth and orderly transfer of participants through the various steps of the
clinics, to avoid long waits, and to assure that each activity would be completed. The third objective was to
give HTDS staff firsthand experience of the clinic activities to raise their awareness and ability to respond
to participant questions and concerns about any part of the clinic experience.
The study ultrasonographers underwent additional training with Dr. Keith Wang of Seattle
Nuclear Medicine Associates to standardize their technique of performing thyroid ultrasound scans.  New
sonographers were accompanied by the experienced HTDS sonographers for a minimum of two full days
or until agreement in technique was obtained.  During this training period, one sonographer performed the
exam and recorded the results while the second sonographer recorded the findings on a second Thyroid
Ultrasound form.  The sonographers then switched places for the next participant.  At the end of the clinic,
the Field Operation Supervisor compared the findings for each participant, reviewed any discrepancies
with both sonographers, and instituted further training as necessary.
F.9.b. Ultrasonographer Quality Control   
A total of four certified sonographers worked on the study at various times but only one or two
sonographers were on staff at any given time.  An attempt was made to divide the clinical schedule evenly
between the two sonographers on staff.  In addition to the initial training, ongoing quality control
procedures were undertaken to monitor inter-operator reliability.  Approximately every two months, both
sonographers would perform independent scans on each of five participants.  The results of the scans were
recorded on separate videotapes, the findings were compared and discrepancies were noted and discussed.
Quality of sonography outcomes was monitored for each pair of sonographers that were currently sharing
clinics.  Results of the ultrasound quality control comparisons, based on a total of 103 participants, are
summarized in Table V.F-3.
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Table V.F-3. Results of Quality Control Ultrasound Studies
A B No. of Participants
Ultrasound
Tech Pair
No. of
Participants
No. of
Nodules
(>5 mm)
Identified
by Either
Tech
No. of
Nodules
(>5 mm)
Identified
by Both
Techs
B, as a
Percent
of A
With No
Nodules
(>5 mm)
by Both
Techs
With No
Nodules
(>5 mm) by
Tech 1 but >1
Such Nodules
by Other Tech
With >1 Nodule
(5 mm) by Tech
1, but No Such
Nodules by
Other Tech
1 + 2 30 33 20 61%      16    1 1
1 + 3 25 27 12 44%      16    1 2
1 + 4 48 79 44 55%       23    1 4
F.9.c. Radiology Quality Control Program
A radiology quality control program was designed to monitor agreement rates among the
radiologists interpreting the videotaped ultrasound scans.  Six radiologists were initially identified to
review and interpret the ultrasound videotapes for the HTDS.  The radiologist assigned to read ultrasound
scans for a particular clinic was determined solely by the radiologists’ work schedules and availability. No
effort was made to equalize the numbers of scans read by each radiologist.  One radiologist interpreted the
scans from the first clinic only, and one radiologist read scans only through the second month of the study.
From early 1993 until the end of the study, four radiologists were involved in interpreting the HTDS
ultrasound scans.
For purposes of quality control, approximately ten scans per month were sent back to the
radiologists to be reviewed and interpreted a second time.  These tapes were submitted along with scans
from the most recent clinic.  Comparisons between the two forms of abstracted findings by the radiologists
were made to determine if significant changes could be identified between the first and second reading.  A
total of 343 ultrasound exams were interpreted twice.  In most cases the second review was performed by a
radiologist other than the one who originally reviewed the case.  However, in a few cases, the quality
control review was done by the radiologist who first reviewed the case due to the radiologists’ scheduling.
As shown in Tables V.F-4 through V.F-7, there were very high levels of concordance between the results
of the original reviews and second review.
Table V.F-4. Radiologist Agreement on Presence of Any Nodule
QC Radiologist
Clinic Radiologist Yes No Uncertain Total
Yes 132     6 2 140
No     4 195 2 201
Uncertain     1     0 1     2
Total 137 201 5 343
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Table V.F-5. Radiologist Agreement on Number of Nodules Less Than 5mm Average 
Dimension
QC Radiologist
Clinic Radiologist 0 <10 ˜10 Total
0 289   4 0 293
<10     7 40 0   47
˜10     2   0 1     3
Total 298 44 1 343
Table V.F-6. Radiologist Agreement on Presence of Diffuse Abnormalities
QC Radiologist
Clinic Radiologist   Yes      No   Total
Yes 30     8   38
No 7 298 305
Total 37 306 343
Table V.F-7. Radiologist Agreement on Number of Nodules >5mm Average Dimensions
QC Radiologist
0 1 2 3 ˜3 Total
0 220 - - - - 220
1 - 69 - - - 69
2 - 1 25 - - 26
3 - - - 9 1 10
˜3 - - - - 18 18
Clinic
Radiologist
Total 220 70 25 9 19 343
F.10. Outcome and Results
F.10.a. Results for the Pilot Study Sample
Table V.F-8. shows the number of Pilot Study participants completing each component of the
clinic.  A total of 1063 Pilot Study participants attended a clinic.  All except four participants (99.6%) had
blood drawn for thyroid function and other studies.  Seventy-six of the 79 participants for whom fine-
needle aspiration was recommended had the procedure performed.  This represents a 96.2% consent rate
for FNA, significantly higher than had been anticipated.
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Table V.F-8. Summary of Clinic Participation - Pilot Study Sample
Clinic Components Completed
       No.        % A
Agreed to participate 1094 --
Attended clinic 1063 100
In-Person Interview 1063 100
Ultrasound examination 1063 100
Radiologist review of ultrasound 1063 100
Blood sample drawn 1059 99.6
All thyroid function tests performed and
results obtained
1058 99.5
Thyroid examination by two physicians 1061 99.8
Thyroid examination by one physician 2 0.2
A Percentage calculated in relation to number who attended clinic.
F.10.b. Results for the Transition Sample
Table V.F-9 shows the number of Transition participants completing each component of the
clinic.  A total of 664 participants from the Transition Sample attended a clinic.  All except one (99.8%)
had blood drawn for thyroid function studies.  Forty-three  (97.7%) of the 44 for whom FNA was
recommended had the procedure performed.
Table V.F-9. Summary of Clinic Participation - Transition Sample
Clinic Components Completed
No.            % A
Agreed to participate 692 --
Attended clinic 664 100
In-Person Interview 664 100
Ultrasound examination 664 100
Radiologist review of ultrasound 664 100
Blood sample drawn 663 99.8
All thyroid function tests performed and
results obtained
661 99.5
Thyroid examination by two physicians 663 99.8
Thyroid examination by one physician 1 0.2
A Percentage calculated in relation to number who attended clinic.
F.10.c. Results for the Full Study Sample 
Table V.F-10 shows the number of Full Study participants completing each component of the
clinic.  A total of 1720 participants from the Full Study sample attended a clinic.  All except four (99.8%)
had blood drawn for thyroid function studies.  Of the 149 for whom FNA was recommended, 140 (94.0%)
had the procedure performed.
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Table V.F-10. Summary of Clinic Participation - Full Study Sample
Clinic Components Completed
     No.        % A
Agreed to participate 1778 --
Attended clinic 1720 100
In-Person Interview 1720 100
Ultrasound examination 1719 99.9
Radiologist review of ultrasound 1719 99.9
Blood sample drawn 1717 99.8
All thyroid function tests performed and
results obtained
1713 99.6
Thyroid examination by two physicians 1719 99.9
Thyroid examination by one physician 0 0
A Percentage calculated in relation to number who attended clinic.
F.10.d. Overall Results for the Entire Study 
Table V.F-11 shows the number of participants from the entire study completing each component
of the clinic.  A total of 3447 eligible participants attended an HTDS clinic.  Seven of these participants
were judged non-evaluable (see section IV-B for definition of evaluable participant) following their clinic
participation, one due to inability to perform a thyroid exam due to a tracheotomy, and six because of
incomplete residence histories.  Of the 3447 participants, 3439 (99.8%) had blood drawn for thyroid
function studies, and 3446 had a thyroid ultrasound scan.  Three participants were examined by only one
physician due to scheduling difficulties.  Of the 272 participants for whom FNA was recommended, 259
(95.2%) underwent the procedure, while 28 (96.6%) of the 29 participants recommended to have a nuclear
scan complied. 
Table V.F-11. Final Summary of Clinic Participation - Entire Study
Clinic Components Completed
    No.         % A
Agreed to participate 3564 --
Attended clinic 3447 100
In-Person Interview 3447 100
Ultrasound examination 3446 99.97
Radiologist review of ultrasound 3446 99.97
Blood sample drawn 3439 99.8
All thyroid function tests performed and
results obtained
3432 99.6
Thyroid examination by two physicians 3443 99.9
Thyroid examination by one physician 3 0.1
A Percentage calculated in relation to number who attended clinic.
F.10.e. Conclusions
One indication of the success of the HTDS clinics is the excellent overall completion rates for
each component of the clinical evaluation, particularly the FNA procedures.  An emphasis was placed on
establishing a caring and supportive environment for participants and reducing the level of stress to
participants during the medical examinations. 
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G. In-Person Interview
G.1. Background
The standard In-Person Interview (IPI) consisted of questions designed to collect information
about the following areas: 1) residences after age 15 to identify participants who may have received
radiation exposure living near other nuclear facilities; 2) occupational history, to account for possible on-
the-job radiation exposure; 3) smoking history; 4) medical and dental radiological procedures or radiation
therapy after age 15 to complete the identification of radiation exposure to the thyroid from these sources
begun in the CATI; 5) thyroid disorders after age 15 to complete the medical history begun in the CATI; 6)
prescription drug history, to identify those persons whose thyroid disease may be a side effect of certain
prescription medications, or who are now taking medications which could impact the results of thyroid
assays performed at the clinic; 7) standard demographic questions; and 8) familiarity/bias questions  to
determine if a relationship exists between the answers given in the questionnaire, and the participant’s
knowledge or beliefs about the Hanford radiation releases.
The questions on the standard IPI (Appendix 17) covered the time period beginning after age 15
and extending to the present because detailed information about the subject from birth through age 15 was
obtained in the CATI.  However, since it was anticipated that a CATI respondent might not be available for
all potential participants, an expanded version of the IPI (Appendix 18) was designed to also collect
information from birth through age 15 that would have been provided by the CATI (see section V-D for
more information regarding CATI).   
G.2. Objectives of the In-Person Interview
The primary purpose of the IPI was to obtain information directly from the study participant about
past occupational or medical radiation exposures, history of thyroid disease, and general demographic
information.  Most questions in the standard IPI pertained to the period after age 15 to the present because
the CATI provided information about the period from birth through age 15.   Participants who did not have
a CATI were given an expanded version of the IPI for collecting key data for the period from birth to age
15. This expanded version of the IPI provided details about residence history and types of milk consumed
which were necessary to estimate a Hanford radiation dose.  The IPI was conducted before the participant
completed the medical components of the thyroid clinical evaluation (ultrasound, blood draw, and physical
examination) to ensure that the participant’s responses would not be influenced by knowledge of exam
results.
G.3. Development and Revision of the Questionnaire
A total of six versions of the standard and expanded In-Person Interviews were used in the three
phases of the study.  With the exception of a modification of the residence history questions following the
Pilot Study, the differences between versions consisted of minor wording changes made for clarification
purposes and deletion of questions determined to be unnecessary.  Listed below is a summary of the
revisions:
November 4, 1992 Original version
January 6, 1993 Wording changes for clarification; income categories in demographics section
adjusted; change in the order of questions in the prescription drug section
December 20, 1994 Pilot Study Revisions:
Information about residences asked after 1957 only for geographic areas near other
nuclear production facilities or test sites; mother’s residence history while pregnant
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was added to the expanded version for participants born after December 1944;
questions on whether the participant had ever been diagnosed with
hyperparathyroidism were added
June 28, 1995 Deleted questions about other names used by the participant, except those for whom
historical medical records were being sought; deleted question on reasons why the
participant thought they didn’t know more about Hanford; minor wording changes in
two areas of participant directions
December 11, 1995 Revised wording from “x-ray treatment” to “radiation treatment” in medical history
section; modified the explanation of fluoroscopy for clarification
G.4. Procedures for the In-Person Interview
All interviews were conducted by trained and experienced Interviewers at the time of the
participant’s visit to the HTDS clinic. The interview was always completed before the thyroid examination
to eliminate the possibility that the participant’s answers to the interview questions may be influenced by
the results of the thyroid exam.  Prior to the initiation of the interview, each participant was required to
read and sign a consent form agreeing to participate in the study.  
An In-Person Interview Preparation Worksheet (Appendix 19) was sent to the participant two
weeks before the clinic appointment.  Participants were asked to complete the worksheet prior to attending
the HTDS clinic, and to refer to this form during the interview.  At the end of the interview, the worksheet
was collected from the participant to be filed with the questionnaire.
Following each In-Person Interview, the interviewer recorded his or her subjective impression of
the reliability of the data collected (High, Generally Reliable, Questionable, Unreliable) and the
participant’s level of cooperation (Very Good, Good, Fair, Poor).
Interviewers were not assigned to any particular clinics or counties, thereby reducing the potential
for bias that might occur if area-specific assignments were made.  
G.5. Training and Quality Control
Interviewers were initially trained by the same Field Operations Coordinator and experienced
FHCRC interviewing personnel to assure uniformity and quality in the interviewing procedures.  Training
consisted of instruction in general interviewing skills, proper methods and timing of probing, detailed
question-by-question instruction, and instruction on editing and callbacks.  Training sessions included role-
playing exercises.  Interviewers pilot tested the questionnaires and worksheets and refined their skills by
interviewing a small sample of volunteers.  Training was supplemented by two manuals: 1) a general
Interviewing Manual and 2) a Question-by-Question Manual for the standard and expanded versions of the
In-Person Interview.    
The Interviewers edited (reviewed) each questionnaire at the clinic site immediately after the
interview was completed to assure all information was completely filled out and to identify discrepancies.
The Field Operations Coordinator edited the interview a second time (over-edited) within 14 days of the
date the interview was conducted.  Re-contacting of study participants by the Field Operations Coordinator
for clarification or missed questions was usually done within two weeks of the date of the original
interview.  The Field Operations Coordinator coded the questionnaires for data entry at the time of over-
editing.  A manual for coding of interviews was developed and documents the coding procedures utilized.
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Call-backs to participants for clarification or additional information were limited to those
instances where the HTDS Interviewer made an error, either by omitting a question or not adequately
probing a question.  Most decisions on whether to call back a participant for additional information relating
to the residence history were discussed with a study investigator before contacting a participant to
determine whether information obtained after the thyroid examination could be used.
G.6. Outcome and Results
At the conclusion of the study, a total of 3447 eligible participants had attended the HTDS clinic.
No participants declined to complete an In-Person Interview.  Review of the interviews resulted in
identifying six questionnaires judged to have insufficient residence history information to calculate a dose
estimate.  These six participants were determined to be non-evaluable (see section IV.B for definition of
evaluable participant).  One participant was unable to complete the interview because of developmental
disabilities, however the participant’s father (who was unable due to illness to participate in a CATI) was
mailed a modified version of the expanded interview and provided the dosimetry and In-Person Interview
information in this manner.  Some participants with developmental or other disabilities were accompanied
during the interview by a family member or guardian, who aided in the interview process.  
Table V.G-1 is a summary of standard and expanded interviews completed during each phase of
the study.  The passage of time and selection of participants from earlier birth years later in the study
increased the use of the Expanded In-Person Interview in the Transition and Full Study Samples.  Overall,
61% of participants completed the Standard In-Person Interview, while 39% completed the expanded
version.  The 2112 with a Standard In-Person Interview included eight participants who should have
received the expanded version, as they had no CATI respondent.  These eight participants were called back
after the clinic to collect the additional residence history information that would have been collected in the
Expanded IPI, in order to estimate their dose.
Table V.G-1. Summary of Standard and Expanded Interviews by Phase of Study
       Pilot Study        Transition        Full Study TotalVersion of
Questionnaire No. % No. % No. % No. %
Standard 750 70.6 427 64.3 935 54.4 2112 61.3
Expanded 313 29.4 237 35.7 785 45.6 1335 38.7
Total 1063 664 1720 3447
G.7. Quality of In-Person Interview and Expanded In-Person Interview Data
Overall, the quality of the information obtained in the interview was judged by the Interviewers to
be high. If the Interviewer assessed the quality of the data to be questionable or unreliable, then he or she
recorded the reason for this determination and identified specific sections affected.  Table V.G-2 shows the
Interviewer’s assessment of the reliability of the participant’s responses to the standard and expanded
versions of the questionnaire, as well as those Expanded In-Person Interviews used for dose estimation,
i.e., excluding the interviews with insufficient residence history to calculate a dose estimate.  Responses to
the standard questionnaire were judged to be of high quality somewhat more frequently than those to the
expanded questionnaire, but both versions were judged to provide high or generally reliable data in more
than 95% of the interviews.  Table V.G-3 shows the reasons for questionable or unreliable data.  The most
common reason was that the participant did not have a clear memory of the events in question.  This reason
was cited more often for the expanded version than the standard version.  Approximately a quarter of the
questionable or unreliable responses to both versions were due to an uncertain understanding of the
questions by the respondent.  All but a few participants were judged to have a very good or good level of
cooperation (Table V.G-4).
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Only 120 of the 3447 In-Person Interviews (both Standard and Expanded) were judged to have
data of questionable, unreliable, or unknown reliability.  Of these, 65 were used for dose estimation
purposes.  Note that in Tables V.G-2, V.G-3 and V.G-4, the third column, Expanded IPI Used for Dose
Estimation, includes the eight participants mentioned above who had a Standard IPI at the clinic but should
have received an Expanded IPI.
Table V.G-2. In-Person Interviewers’ Assessments of Reliability of Responses 
Standard IPI All Expanded IPI
Expanded IPI Used for
Dose Estimation
Reliability of Responses No. % No. % No. %
High 949 44.9 411 30.8 407 30.9
Generally reliable 1110 52.6 851 63.7 845 64.2
Questionable 49 2.3 61 4.6 59 4.5
Unreliable 1 0.0 2 0.1 2 0.2
Unknown 3 0.1 4 0.3 4 0.3
Expanded IPI done, data
not used
-- -- 6 0.4 --
Total 2112 100 1335 100 1317 100
Table V.G-3. In-Person Interviewer’s Assessments of Reasons for Questionable or Unreliable
Information 
Standard IPI All Expanded IPI
Expanded IPI Used for
Dose Estimation
Reason No. % No. % No. %
Unclear memory
of events 16 0.8 34 2.5 34 2.6
Uncertain understanding
of questions 15 0.7 15 1.1 15 1.1
Hurried responses 3 0.1 2 0.1 2 0.2
Other 16 0.8 12 0.9 10 0.8
Not applicable* 2062 97.6 1272 95.3 1256 95.4
Total 2112 100 1335 100 1317 100
* Reliability of Responses was High, Generally reliable, Unknown, or Expanded IPI done, data not used
Table V.G-4. Interviewers’ Assessments of Respondent’s Cooperation 
Standard IP All Expanded IPI
Expanded IPI Used for
Dose EstimationRespondent’s
Cooperation No. % No. % No. %
Very good 1703 80.6 1021 76.5 1011 76.8
Good 382 18.1 278 20.8 277 21.0
Fair 22 1.0 26 1.9 25 1.9
Poor 3 0.1 0 0.0 0 0.0
Not answered 2 0.1 4 0.3 4 0.3
Expanded IPI done, data
not used
-- -- 6 0.4 -- --
Total 2112 100 1335 100 1317 100
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More than 90% of participants at least partially completed an Interview Preparation Worksheet
prior to the interview.
The residence history in the Expanded IPI presented the most recall difficulty since participants
were quite young at the time.  Codes referred to as “fuzzy date codes” were assigned to each residence in
the birth through 1957 section of the interview.  The codes indicate the precision with which the participant
was able to specify the date of a residence change (i.e. within two months, within three months, plus or
minus 6 months, a year or more).   This allowed coding of inexact responses to date questions to standard
mm/yy codes.   For example, responses such as “in the fall of 1947” and “1952 or 1953” would be coded
as 10/47 and 1/53, respectively.  These and other coding rules were contained in a written Coding Manual.
G.8. Conclusions
A complete In-Person Interview was obtained from all except six of the 3447 eligible study
participants attending an HTDS clinic.  These six non-evaluable participants were judged to have
insufficient information in the residence history section of the expanded interview to calculate a dose
estimate. The interview data were obtained easily and few modifications of the questionnaire were needed
throughout the study.  The Interviewers judged the responses to be Highly or Generally Reliable in over
95% of the interviews.
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H. Medical Review and Final Diagnosis Determination
H.1. Background
H.1.a. Objectives of Medical Review and Final Diagnosis Determination
The objectives of the medical review and final diagnosis determination processes were: 1) to
evaluate each participant’s HTDS clinical thyroid evaluation results; 2) to communicate results of the
clinical evaluation to participants in a timely manner and, with permission, to communicate the results to
the participant’s health care provider; 3) to assign the final diagnoses for each case according to the format
developed (see Appendix 20) using all information available prior to and including the HTDS clinical
evaluation.
H.1.b. Rationale
A large amount of information was collected for each study participant from the interview and
clinical evaluation. This information included serum laboratory results; ultrasound exam, physical
examination and for some participants, FNA results, thyroid nuclear scans and medical records.  Members
of the HTDS clinic team met in regular sessions to review the clinical information for study participants.
The purposes of these reviews were to determine final diagnoses and to plan the letters and telephone calls
for communicating the results to the participants and their health care providers.  After all diagnostic
information was assembled and the Medical Review was completed, Dr. Hamilton completed a Final
Diagnosis Determination Form. This data form was used to record all of the final thyroid, parathyroid, or
ultrasound outcomes of the HTDS diagnostic evaluation. 
H.2. Medical Review and Final Diagnosis Determination
H.2.a. Medical Review Process
The results from the laboratory assays, cytology interpretations and radiologists’ reviews of
ultrasound tapes were received in the HTDS office within 5-6 days after the HTDS clinic.  Results and
review forms were assembled for each clinic participant for the weekly Medical Review session.  The staff
participating in the Medical Review included Drs. Hamilton and Griep, the Research Nurse, and the Field
Operations Supervisor (FOS).  During the review, the FOS completed tracking data forms for the Medical
Review.  Dr. Hamilton reviewed participants with no abnormal findings, while both Drs. Hamilton and
Griep reviewed those with abnormalities.  
All participants underwent a post-clinic Medical Review of the HTDS clinical evaluation results
within two weeks of the clinic appointment.  During the review session a letter to report the results of the
evaluation was developed for each participant, plans were outlined for communicating abnormal results to
participants, and a determination was made as to whether further diagnostic procedures or treatment should
be recommended.  If the participant did not report any history of thyroid disease during the In-Person
Interview, a final diagnosis assessment was made and a Final Diagnosis Determination Form was
completed as part of the Medical Review process.  If a participant reported a past history of thyroid disease
during the In-Person Interview, medical records were requested and the final diagnosis determination was
deferred until after those records were obtained, abstracted, and reviewed.
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H.2.b. Additional Tests
The first step in each participant’s review was to determine whether any recommendations for
further testing were necessary to confirm or rule out a diagnosis.  Additional tests may have included: 1)
thyroid nuclear scan (e.g. for Graves Disease or toxic thyroid nodule diagnosis); 2) repeat blood draw for
additional tests such as parathyroid hormone in the case of elevated calcium; 3) repeat analysis of existing
serum due to equivocal results; and 4) repeat thyroid FNA due to inadequate specimen.
An HTDS physician or the Research Nurse contacted participants needing additional tests by
telephone to discuss the abnormal results, to answer questions, and to recommend the appropriate follow-
up procedures.  If consent had been given to contact the participant’s health care provider, that person was
also contacted to discuss the recommendations.  Following this initial contact, the Research Nurse re-
contacted each of these participants on a regular basis to determine if the recommendations had been
followed, and to obtain consent for receiving results reports.  If consent was obtained, medical records,
cytology and pathology slides and reports were requested and reviewed in the same manner as historical
records and slides.  The tracking system was used to track the progress of recommendations for further
procedures and the acquisition of outcome information.  
Nuclear scans were arranged by the Research Nurse to be done at a medical facility most
convenient for the participant.  For additional blood tests, the participant’s blood was collected at a local
health care provider’s office or the nearest medical laboratory and shipped to Pacific Medical Center
Clinical Laboratory in Seattle for processing.  The Research Nurse handled all arrangements for follow-up
tests, shipping of specimens and payment of services.  
H.2.c. Communication of Medical Review Results to Participants and Their Health Care
Providers
After evaluating each participant’s clinical information, the physicians drafted a letter to the
participant outlining the results of the evaluation.  The Data Control Technicians printed the letters and
attached the laboratory results pages and appropriate fact sheets for each participant.  If the participant’s
results were all normal, the results letter was mailed out immediately.  The Research Nurse entered
information about all cases with abnormal findings into a follow-up system for contacting by telephone and
further follow-up as indicated.  The results letters for the participants with abnormal findings were mailed
after telephone contact by the Research Nurse.  All participants received their results within 3-4 weeks
after their clinic appointment.
Letters were also sent to each participant’s health care provider if the participant indicated this
was to be done and supplied the provider’s name and address.  The letters to health care providers included
recommendations for follow-up monitoring and tests.  The health care providers were also sent copies of
the results letter and the fact sheets sent to the participant.
All participants who had an FNA recommended by the HTDS physicians were called by the
Research Nurse or Dr. Griep on the day of the Medical Review.  If the participant gave consent, the health
care provider was also contacted by telephone to discuss biopsy results and to answer any questions.  On
the rare occasion when a repeat FNA was recommended, participants were called by Dr. Griep to discuss
the results of the procedure.  
If additional tests were recommended after the Medical Review, the results of these tests were
reviewed at the next Medical Review session and a second results letter was mailed to the participant and
his/her health care provider, describing the results of the follow-up tests. 
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H.2.d. Fact Sheets
Fact Sheets on various topics related to the HTDS clinical evaluation and results were developed
and distributed to provide information to study participants.  One fact sheet described the purpose and
explained the results of the blood tests conducted as part of the clinical evaluation.   A Physician Referral
Resources handout was developed to help participants locate a health care provider for follow-up on
conditions identified in the HTDS evaluation.  A fact sheet explaining autoimmune thyroiditis, and a series
of fact sheets about nonpalpable ultrasound-detected abnormalities of the thyroid were provided only to
participants with these results.  An Ultrasound Follow-up fact sheet was distributed to explain the follow-
up program for persons with ultrasound-detected abnormalities of the thyroid.  Following discontinuation
of the Ultrasound Follow-Up Program in April 1995 (see section V.F.5 above), the Ultrasound Follow-up
fact sheet was discontinued and an additional paragraph of information was added to the results letter to
discuss the significance of nonpalpable ultrasound detected thyroid abnormalities.  Later, a new fact sheet
describing what was known about nonpalpable ultrasound-detected thyroid abnormalities was added to
provide additional information for participants (and their health care providers) who had no other thyroid
disease identified.  
H.2.e. Final Diagnosis Determination
Findings from the HTDS clinical evaluation, and in some cases, historical medical records
identified during the interview process (see section V.G), were reviewed to determine the participant’s
final diagnoses. The final diagnoses included information about thyroid and parathyroid outcomes
(including basis for diagnosis) and ultrasound findings.  Diagnoses for cases with no indication of thyroid
abnormalities were made by Dr. Hamilton.  Diagnoses for cases with any indication of an abnormality were
made by consensus of Drs. Hamilton and Griep.  The final diagnosis data were recorded on the Final
Diagnosis Determination Form (see section IV.C above).  Final diagnoses or disease outcomes were further
defined by variables to indicate the quality and source of documentation on which the diagnosis was based.
 
Final diagnosis determinations were made based on the following information: 1) HTDS blood
test results; 2) HTDS ultrasound results; 3) HTDS examination results; 4) previous thyroid disease or
treatment with thyroid medication reported in the HTDS In-Person Interview or CATI; 5) current use of
thyroid prescription medication reported in the HTDS In-Person Interview; 6) HTDS FNA results, if any;
7) HTDS-recommended diagnostic or surgical procedures, if any; and 8) historical medical records
obtained by HTDS, if any. 
The Final Diagnosis Determination Form underwent minor revisions during the first two years of
the study.  In July 1995 the following three significant changes were made: 1) the two outcomes for
multinodular goiter based on being on thyroid medication or not, were consolidated into one category
designated multinodular thyroid gland; 2) Graves Disease was added as a separate diagnostic outcome; and
3) the “basis for diagnosis” and “Histologic/Cytologic Type” sections for each diagnosis were expanded
and standardized.  
After these revisions, it was necessary to review and revise the Final Diagnosis Determination
Forms for approximately 1376 participants whose diagnoses had been assigned on earlier versions of the
form.  Six staff members reviewed the original Final Diagnosis Determination Forms and transferred data
to the new forms.  Laboratory results from the clinical evaluation were reviewed and ultrasound findings
documented for each case.  If no diagnoses had been indicated (i.e., findings were normal) the revised form
was considered complete after verification by a second staff person.  Dr. Hamilton thoroughly reviewed the
diagnosis determination for cases with findings varying from those originally documented and cases where
at least one diagnosis had previously been identified.   
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H.2.f.  Dating of Diagnoses
To perform analyses accounting for the potential effects of the Nevada Test Site exposure,
diagnoses made before 1957 had to be distinguished from later diagnoses.  Therefore a date was assigned
for every diagnosis recorded on the Final Diagnosis Determination Form, corresponding to the date or age
of that diagnosis.  If there were medical records, or a prior mention of thyroid disease during the CATI or
In-Person Interview, the subject’s chart was reviewed to determine the date or age of diagnosis.
Otherwise, if the diagnosis was based on findings at or as a result of the HTDS examination, the clinic
appointment date was assigned as the date of diagnosis.  When dates/ages were not specific, the midpoint
of the range was assigned as the date/age of diagnosis.
H.3. Outcome and Results
H.3.a. Number of Cases Reviewed and Follow-up Procedures Recommended
The total of 3447 eligible participants underwent medical review.  For 79.3% of these participants,
the Final Diagnosis Determination Form was completed at the time of their Clinic Medical Review.   The
remaining 20.7% had either requests for historical medical records or post-clinic recommendations for
further diagnostic procedures.  For these cases, the Final Diagnosis Determination Form was completed
after all the additional results or records had been received.  
A total of 259 participants had FNA procedures performed at the HTDS clinic or on the
recommendation of the HTDS physicians after the Medical Review.  Of these 259 participants, the HTDS
physicians recommended that 47 participants have further biopsy or surgical procedures to rule out a
diagnosis of thyroid neoplasm, or were recommended to undergo close follow-up by their health care
provider to monitor progression of a thyroid disorder.  Another fifteen were followed for further diagnostic
tests such as blood redraws or nuclear scans.  In addition, 29 participants with thyroid nodules or
suppressed TSH were recommended to undergo thyroid nuclear scan.  Twenty participants had an
abnormal calcium level and were recommended to have additional blood drawn and analyzed for
parathyroid hormone (PTH) studies to confirm or rule out a diagnosis of hyperparathyroidism.  Thirty
participants were requested to have additional blood drawn due to abnormal or borderline thyroid function.
H.3.b. Conclusions
The Medical Review and final diagnosis determination processes were conducted efficiently and
all participants received a thorough evaluation of the clinical results to determine the presence or absence
of thyroid disease.  Study participants were provided with their results in a timely and considerate manner
and they were provided with recommendations for follow-up if a condition was identified.   
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I. Historical and Post-Clinic Medical Records and Specimens
I.1. Background
I.1.a. Objectives of Obtaining Medical Records
The primary objectives of the medical record component were to: 1) document thyroid problems
reported by study participants and CATI respondents; 2) obtain any cytological or histological specimens
from previous thyroid biopsies or surgeries for review by the study’s pathologist; and 3) obtain the results
(including histological specimens) of any further diagnostic or surgical procedures recommended by HTDS
as a result of findings at the HTDS clinic.  A secondary objective of the medical record component was to
obtain cause of death information on all cohort members located deceased, and assign cause of death codes
according to a standardized rubric.
I.2. Process and Procedures Used
I.2.a. Historical Medical Records
Information was obtained from both the participant and the CATI respondent for the purpose of
obtaining historical medical records.  During the CATI, respondents were asked to provide the names (and
addresses, if known) of any physician who saw the participant for diagnosis or treatment of thyroid disease.
Prior to the clinic appointment, the participant was sent a work sheet on which to list the names and
addresses of their current physician and any previous physicians seen for diagnosis or treatment of thyroid
disease.  At the time of the In-Person Interview, the participant was asked to provide the names and
addresses of physicians or institutions where they had been diagnosed or treated for thyroid or parathyroid
disease, and to sign a consent form for the release of information from each of these providers.  Information
from the CATI was provided to the In-Person Interviewer in the clinic packet so that consent for any
records identified only by the CATI respondent could also be obtained from the participant during the
clinic visit.
All completed consent forms were returned to the office, where a Data Technician reviewed them
for completeness.  If the provider’s address was unknown to the participant, attempts were made to locate a
current address so the consent could be delivered.  A letter requesting the pertinent records was generated
to accompany each consent form.  Copies of the consent forms were filed in the participant’s medical
record.  If a current address for a provider could not be obtained, the original consent signed by the
participant was filed in the record with a notation that the provider could not be located.  A log of medical
record requests was kept so that requests could be followed and further action taken if records were not
received.  Information regarding the request of medical records was updated in the study Tracking System.
Once records were received, they were given to the Medical Records Abstractor for review,
organization, and abstracting of laboratory values.  If specific records were found to be missing, the
Abstractor relayed this information to the Data Technician, who re-contacted the provider for the
information.  Once the record was deemed complete for HTDS purposes, the abstract and records were
filed in the HTDS medical record, and the study Tracking System was updated to indicate the case was
ready for Medical Review.  
During the Medical Review sessions  (for cases with medical records), the Medical Records
Supervisor and Dr. Hamilton reviewed each case and Dr. Hamilton assigned the proper final diagnoses.
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I.2.b. Post-Clinic Medical Records
For those participants where HTDS physicians recommended further work-up or treatment based
on the HTDS clinic findings, medical records documenting these procedures were also requested.  At the
time the recommendation was made, the Research Nurse asked the participant to give consent for the
HTDS to obtain these records.  Once signed consent forms were received (either at the clinic or through the
mail, if the recommendation was made based on the results of clinic cytology or blood tests), they were
handled in the same manner as those for historical medical records.  Tracking of requests, however, was
handled by the Research Nurse, who kept in contact with the participants throughout any further evaluation,
to ensure that recommendations were adequately carried out, or that the participant fully understood the
ramifications to their health if they chose not to do so.  Once records were received, this information was
entered into the study tracking system, and the records were flagged as ready for medical review.
I.2.c. Blinding the Reviewer to Radiation Exposure
References to areas in which the participant had lived were blocked out of any records prior to
review by Dr. Hamilton so no inference of radiation dose could be made based on past residences.  This
blinding of radiation exposure was accomplished in the following manner.  When a record was found to
state that the participant was a “downwinder,” had lived in the Hanford area (or an area away from
Hanford), or had been exposed to radiation from Hanford, a copy of those records was made.  The original
was filed in a section of the HTDS medical record marked “Unused Information,” and stapled with a cover
sheet so it would not be read inadvertently.  The exposure information on the copy was then deleted, and
the blinded copy used in the Medical Review process by Dr. Hamilton.  The participant’s name was
recorded in a logbook along with information identifying the records that mentioned exposure status.  
A similar procedure was used for records that indicated the participant had undergone radiation
therapy for malignancies other than thyroid.  In cases where the participant or respondent reported thyroid
disease in the participant, only radiation therapy for disseminated malignancies such as leukemia was
blinded.  For participants without any report of thyroid disease, only radiation therapy to the upper body
was blinded, including any radiation for disseminated malignancies such as leukemia.  Again, details on the
blinded records were recorded in a logbook.  
Upon instituting these procedures, it immediately became apparent that by only blocking out such
references to radiation exposure, Dr. Hamilton might infer that all cases with sections censored had
references to radiation exposure.  Thus it was decided that some random blinding of records would need to
be performed as well.  For this reason, every seventh case with medical records was selected for random
blinding.  The information blinded in these cases was always completely unrelated to radiation exposure
status or radiation therapy.  For example, references to previous gallbladder surgery might be censored in
one case; while in another, documentation of a motor vehicle accident might be censored.  Again, the
original records were placed in the “Unused Information” section, with the blinded copies used for medical
record review.   
I.2.d. Cause of Death Coding
For each potential participant located deceased, the death certificate or informant information was
used to complete a Cause of Death Form (Appendix 21).  In addition, the primary cause of death was coded
using the ICD9-CM system.  For those whose date of death preceded the use of the ICD9-CM system, the
primary cause of death was also back-coded using the system in use at the time of death (Table V.I-1).  See
section V.B.4.d.3 above, for detail on the success in obtaining death certificates.
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Table V.I-1. Systems Used for Cause of Death Coding
Coding System Date Published Dates of Use
International List of Causes of Death 1939 1940-1948
International Select Causes of Death 1948 1949-1955
International Classification of Diseases, Sixth Revision 1955 1956-1961
International Classification of Diseases, Seventh Revision 1962 1962-1967
International Classification of Diseases, Eighth Revision 1968 1968-1978
International Classification of Diseases, Ninth Revision 1979 1979-1997
I.3. Outcome and Results
I.3.a. Historical Records 
Reports of historical medical records were obtained for 694 participants, with a total of 1259
consent forms completed to obtain medical records from different providers.   While the vast majority of
reports were made during the In-Person Interview, CATIs yielded 30 of these reports.
Of the 1259 Medical Record Consents obtained, a total of 795 (63.1%) separate medical records
were received by the HTDS. No records were received for 464 requests (36.9%).  Figure V.I-1 shows the
reasons for non-receipt of records.  In 102 (8.1%) cases, records could not be requested because the
physician was deceased, retired or a current address could not be identified.   For 128 (10.2%) requests,
records were unavailable due to the destruction of records, the inability of the provider to identify the
patient, or an inability to locate the records.  In 232 (18.4%) cases, records were not received after several
contacts, without explanation as to why they were not available. 
Figure V.I-1. Outcome of Historical Medical Record Requests  (N = 1259)
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I.3.b. Historical Pathology and Cytology Slides
Of the 694 participants identifying historical medical records to be requested, pathology or
cytology slides were requested for 52 (7.5%).  In a few cases, more than one set of slides was requested, for
a total of 58 separate requests.   A total of 42 sets of historical pathology or cytology slides were received
for 42 participants (80.8% of those for whom slides were requested).  Of the requests not resulting in
receipt of slides, 11 were related to procedures performed prior to 1985 and the slides had been discarded,
and three were not available.  In the other two cases, cytology slides were not provided, as there would be
no additional slides on file if they were lost or not returned.  In these two cases, copies of the cytology
reports were provided, and it was determined that the cytology appeared to be from the same nodules on
which FNA had been performed at the HTDS clinics.  Figure V.I-2 shows the success in obtaining
historical cytology and pathology slides for review.
Figure V.I-2. Success Obtaining Historical Slides  (N=58)
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edical records documenting further diagnostic studies recommended as a result of the HTDS
ings were requested for 35 participants, with a total of 72 separate requests.  All but one of these
s obtained, with at least one record obtained for each of the 35 participants.  Thirty-three of these
ts also had histology or cytology slides requested, for a total of 35 separate requests.   All thirty-
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ause of death was coded for 527 potential participants who were located deceased and 16
articipants who were located alive but died prior to participation in the HTDS.  Death certificates
ved for 504 of the 543 total deceased potential participants. 
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In no case was thyroid disease listed as a primary or contributing cause of death on any death
certificate obtained.  In one case, the family member informant stated that the potential participant’s cause
of death may have been thyroid disease.  However, the death certificate was obtained for this potential
participant and the primary cause found to be malignant lymphoma.
I.4. Potential Impact of Medical Records and Slides That Were Not Obtained
One potential concern is that diagnoses of disease outcomes might be missed if requested medical
records or slides could not be obtained: none or only part of the requested records or slides were received
for 199 (29%) and 160 (23%), respectively, of the 694 participants for whom such requests were made.
However, even if a medical record or slide could not be obtained, the likelihood of a missed diagnosis was
generally low because in most such situations the HTDS evaluation provided a definitive assessment of
whether the diagnosis for which the medical record or slide was sought was confirmed or not confirmed.
For example, if a participant or CATI respondent reported a diagnosis of a thyroid nodule 30 years ago, that
diagnosis would almost certainly be confirmed by HTDS physicians based on current physical exam and
ultrasound scans.  An exception would be for a participant reporting thyroid cancer, who then had thyroid
surgery, and then had missing medical records.  However, this occurred in only one individual. 
To further clarify this issue, all of the diagnoses for participants with at least one missing medical
record or slide were reviewed to determine which did not have a confirmed HTDS diagnosis and therefore
might have been missed based on not receiving that medical record or slide.  Of the 556 diagnoses for the
359 participants with at least one requested medical record or slide not obtained, 318 (57%) were
confirmed by the HTDS evaluation.  Of the remaining 238 diagnoses, 109 were diagnoses of
hypothyroidism for which at least one requested medical record or slide was not obtained.  Each of these
109 participants had normal thyroid function during the HTDS evaluation, thereby eliminating the
possibility of permanent hypothyroidism.  Of the remaining 129 diagnoses, 54 (16 with hyperthyroidism,
28 with simple goiter or multinodular gland, and 10 with “other” thyroid disease) were reported by or for
participants who had completely normal HTDS thyroid evaluations.  In addition, there were four
miscellaneous reports of thyroid disease for which the HTDS evaluation was normal.  For these 58
diagnoses the normal HTDS evaluation eliminates the possibility that these participants had permanent
thyroid disease in these categories.  Consequently, there were 71 diagnoses (13% of the 556 diagnoses) for
which a missing record might have contributed to a diagnosis that was not confirmed by the HTDS
evaluation.  It must be emphasized however, that given the completeness of the HTDS clinical evaluation,
this figure of 13% is likely an upper bound for the possibility of missed diagnoses related to any missing
medical records.
Finally, it should be noted that the analysis of each thyroid disease outcome and of
hyperparathyroidism included estimation of the dose-response not only for the definitive diagnoses based
on HTDS evaluation or medical records with documentation supporting the diagnosis, but also for those
based on less definitive criteria.  In particular, these alternative analyses included diagnoses based on CATI
respondent or participant reports only, which by definition had no confirmation from either the HTDS
examination or from any medical records.
I.5. Conclusions
Attempting to obtain medical records and slides from as long ago as fifty years prior was expected
to be one of the most difficult aspects of the HTDS.  Many medical records are destroyed after only seven
to ten years; physicians retire, sell their practices, or die, leaving little hope of locating historical records
and slides.  While no estimates of success in locating such records or slides was made in the HTDS
Protocol, it was generally felt that records and slides would be obtained in no more than 50-60% of cases.
While the experience of the HTDS was only slightly better at 63.6% of consents resulting in records or
slides, it should be noted that of 694 participants with historical records or slides requested, 495 (71.3%) of
participants identifying one or more records or slides had at least one record or slide retrieved.  More recent
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records and slides were retrieved more easily and, in many cases, these referred to earlier diagnoses for
which the original records or slides could not be located.  This enabled the study to confirm historical
diagnoses in a greater percent of cases, despite the lack of older records.
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J. Data Management
J.1. Objectives of Data Management
The primary data management objective was to establish procedures that would be used to develop
and maintain the study databases, and the procedures that would be used to ensure data quality.  These
procedures included manual review (editing) of data recorded on paper forms, duplicate entry for all data
forms, validity checks encoded in the data entry programs, and consistency check programs run on the data
after entry.  
The second data management objective was to define procedures to maintain the security and
confidentiality of the data.  This included data in computerized form, through the use of passwords and
control of limited access to directories and data files, as well as hard copies of data, i.e., paper records,
which were stored securely in locked files in locked offices or in a file room which had limited access via
keycard.
The data collected for this study were classified into six main categories for purposes of data
management:
1. Tracking system
2. CATI
3. In-Person Interview
4. Clinic Data Forms, Final Diagnosis Determination Forms, Refusal Questionnaires, Cause of Death
Forms and Dating of Diagnoses
5. ICD9 Coding of Cause of Death
6. Problems Forms
The general principles guiding the development of data management procedures were the same for
all six categories of data.  These general principles included the use where appropriate of manual reviews
(editing) of data originating on paper forms, duplicate data entry, automatic validity checks at data entry,
additional computerized checks of data validity, frequent backups of computerized databases, password
control of access to databases and of authority to update databases, and restricted access to physical
repositories of data and specimens.  The specific implementation of these general principles varied
according to the nature of the data in each category, as described below. 
At the beginning of the study, transfer of data between computers or from computers to back-up
storage media was accomplished by means of removable media such as diskettes or tapes.  Subsequently all
of the study computers were connected to a local area network (LAN), and thereafter transfers and back up
of data were managed through the LAN.  The descriptions that follow describe the procedures that were
adopted following availability of the LAN.
J.2. Data Management Procedures
J.2.a. General Procedures
Data were entered on personal computers which were linked via a LAN. Some data entry
programs were stored on this network, in a directory with limited access.  The LAN was backed up each
business day by the network administrator.  
To maintain confidentiality of the data, multiple levels of security were employed.  First, the
HTDS staff worked in a secure building with access to the floor limited to those with a security key card.
The actual computers used for data entry were kept in locked offices and only authorized study personnel
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had access to them.  Most of the study computers were linked via a Novell local area network (LAN) and
access to the data entry programs located on the local area network was limited via user names.  The data
files stored on the network were backed up daily Monday through Friday by the network administrator.  All
other data entry files were backed up daily when in use on floppy diskettes. 
Apassword program was installed on all study computers.  The password was changed whenever
an employee left the HTDS or periodically during times when there were no staffing changes.  As an
additional security measure when an employee left the study, the network administrator revoked access to
the local area network.  A final security measure utilized was to keep all completed study forms in locked
files or in a fileroom with limited key card access.
Preprinted labels with the participant’s unique identification (ID) number were attached to each of
the participant’s forms to prevent transcription errors. 
J.2.b. Tracking System
The tracking system contained data regarding the progress of participants through the study.
These data were used by study staff to ensure the prompt and complete progress of potential participants
through the various components of study participation: recruitment, identification of a CATI respondent
and completion of the CATI, clinic scheduling, completion of clinic activities and recommended follow-up
procedures, medical records requests, and completion of medical review and participant contacting.  The
tracking system database was written using dBase IV software as a menu driven program consisting of
eight databases linked by the participant's ID number and last name.  Table V.J-1 gives a brief description
of the eight databases in the Tracking System:
Table V.J-1. Tracking System Databases
Database Description
Overall Summary of each potential participant’s status.
Tracing Tracing outcome, vital status, and death information.
Participation Agreement/refusal/withdrawal information.
Dosimetry Information regarding the CATI respondent and agreement
and completion status of the CATI.  Contains more than
one record for some participants.
Clinic Clinic appointment information and completion of
individual clinic items.
Miscellaneous Information regarding blood re-analyses, nuclear scans and
repeat FNAs.  Contains more than one record for some
participants.
Medical Records Information regarding medical records requests.  Contains
one record per medical record request, and thus has more
than one record for some participants. 
Participants Participant’s name and identification number.
Data entry programs for the tracking system were written to be user friendly, with all appropriate
instructions on the screens as needed to enhance ease and accuracy of use.
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Entry of data into the tracking system was not done in duplicate.  Duplicate entry turned out to be
impractical, and was deemed unnecessary in part because these were not outcome data.  However, a
program was run on these data periodically to check for invalid or inconsistent data.
Information about located potential participants was initially entered into the Tracking System on
a weekly basis by a Data Technician, using data received from the Tracing staff in the Tri-Cities.  Once the
data for the week were entered, an electronic mail message was sent to key HTDS staff alerting them that
the Tracking system had been updated, and noting any special circumstances for the new potential
participants, who were identified only by ID number.  As the various steps involved in contacting,
recruiting, identifying a CATI respondent and completing the CATI, and clinic scheduling of a potential
participant were accomplished, study staff created and updated records in the appropriate Tracking System
data bases.
Following each clinic, the list of participants attending, and the steps of the clinic process
completed by each participant were entered into the system by the Data Technicians. For participants who
identified historical medical records, or for whom additional post-clinic studies were recommended,
records were created in the Tracking System to track the request and receipt of these data, and to flag cases
as ready for Medical Review.
J.2.c. CATI
A Computer Assisted Telephone Interview (CATI) was used for data entry of the dosimetry
questionnaire on a real-time basis during the interview.  The data entry program for this interview was
written by the study programmer using the INGRES database software.  Since the responses received
during the CATI were entered directly into the database, they were not verified by duplicate data entry.
One section that was handled somewhat differently was the residence history section, which was sent to the
CATI respondent prior to the telephone interview.  In most cases, the residence history was returned and
data entered prior to the actual telephone interview, and then reviewed in the course of the interview.
The CATI database was programmed with automatic range checks, as well as skip patterns, where
appropriate.  (In the process of creating the scenario files used for dose calculations, additional consistency
checks were run on the CATI data.)
At the end of each day during which they performed CATIs, each Interviewer copied the CATI
database from his or her data entry computer to the network. This computer was equipped with a tape
backup unit and software capable of making unattended backups at pre-selected times.   See section VI
Dose Determination, for more details regarding the CATI data.
J.2.d. Clinic In-Person Interview
The In-Person Interviews were completed and reviewed (edited) by the Interviewers at each clinic.
After each clinic, the Field Operations Coordinator again reviewed (over-edited) the interviews and coded
all items except the grid locations in the residence history section.  A data technician, using a map provided
by Battelle PNL for this purpose, coded locations of residences from the Residence History.  Once the
locations were coded, the interviews were data entered and verified in an INGRES database by a data
technician on a separate personal computer.  The verification database included programmed range checks
and appropriate skip patterns.  Upon completion of verification, the interview data were copied onto the
local area network.  These data were then converted into SAS databases using the software package
DBMSCOPY.  Programs were written in SAS to perform additional consistency and edit checks. 
There were two types of the in-person interviews: the Standard In-Person Interview (designed for
participants for whom a CATI had been completed) and the Expanded In-Person Interview (designed for
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participants for whom a CATI had not been completed).  A total of six versions of the Standard and
Expanded In-Person Interviews were used during the study.  The differences between versions consisted
primarily of minor wording changes, and when revisions to the questionnaire were made, the appropriate
changes were made to the data entry program.  After the Pilot Study, however, there was a major revision
to the way the residence history questions were asked.  See section V.G above for details of the revisions
made to the questionnaire.  Due to the major revision after the Pilot Study, new versions of the In-Person
Interview database and data entry programs were created.  When the data technician copied the files onto
the local area network after this revision was in place, two new directories were used, one for the Standard
and one for the Expanded version of the questionnaire.
J.2.e. Clinic Data Forms, Final Diagnosis Determination Form, Refusal Questionnaire,
Cause of Death Form and Dating of Diagnoses
Eight data forms were completed as part of the clinic component of the study.  These forms
included: 1) Clinic Flow Sheet, 2) Thyroid Exam Form, 3) Consensus Exam Form, 4) Post Ultrasound
Consensus Exam Form, 5) Ultrasound Form, 6) FNA Form (as needed), 7) Blood Test Results Form, and 8)
Final Diagnosis Determination Form.  The Refusal Questionnaire, completed for those who refused
participation but agreed to answer demographic questions, the Cause of Death Form, and Dating of
Diagnoses were processed in the same manner as the clinic component data forms and are therefore
included in the following descriptions.
The data forms were entered and verified in SPSS data entry files.  The data entry programs
contained range checks as well as skip and fill rules.  A data entry manual was written for each data form,
and included step-by-step instructions for entering the data.  These manuals also contained detailed
information regarding the variable names, types, length, description, and valid codes, and outlined the skip
patterns.  At the back of each manual was a Decision Log, where the Data Entry Operator identified cases
that required a decision regarding how to enter the data.  The Data Supervisor or the Statistical Research
Associate reviewed all entries in the decision log.  The data entry manuals were stored in the Data
Supervisor’s office.
At the end of each month, the SPSS data entry files were converted to SAS data files via
DBMSCOPY software that was available on the local area network.  The converted files were then checked
for duplicate records and unverified records, and any problems found were corrected.  These files were then
appended to the master files, which contained all previously cleaned data.  As these files were appended,
they were also compared to the master files for duplicates, and any found were deleted.  The master files
were stored in a directory with limited access, so that only the Data Supervisor and Statistical Research
Associate could make changes to the files. 
After the files were appended to the master files, a series of SAS programs were run to check for
any inconsistencies in the data files, such as skip patterns, invalid values, etc.  When an inconsistency was
found, the original clinic data forms were visually checked and a SAS program was written which made
the appropriate corrections.  Hard copies of all such programs were stored in a locked file cabinet in the
Statistical Research Associate’s office.
Most of the clinic forms underwent minor revisions during the course of the study, and when
necessary, the data entry programs were revised accordingly after careful investigation to ensure
consistency of pre- and post-revision data.  More significant modifications are described below: 
Clinic Flow Sheets:  The clinic flow sheet was used to track the progress of participants through the clinic,
and did not contain substantive information regarding participant characteristics, radiation exposure, or
outcomes.  Data entry of the clinic flow sheet was discontinued after the 5/20/95 clinic.
FNA Form:  The FNA form was not originally planned to be data entered.  However, it was determined that
it would be of interest to know how many FNA procedures were performed by each physician and
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consequently the FNA forms were data entered.  In addition, an FNA form abstract was developed and used
for the few FNA procedures that were performed at the request of HTDS but by an outside physician. This
form indicated the number of nodules aspirated by the outside physician.  The ID number, date of FNA and
number of nodules aspirated was entered, in order to count how many nodules were aspirated.
Blood Results Form:  The blood test results were reported from the laboratory on their own standard form.
The database and data entry programs were revised when necessary to accommodate changes in the
laboratory’s form or in the assays they performed.  Additional data were entered by study staff to further
characterize the laboratory results, including identifiers of reassays (initial result, or reassay of original
specimen), TSH assay type (RIA, EIA-1, or EIA-2), and PTH and calcium assay types (IRMA or
chemiluminescence).  See section V.F.3 Clinics, for further information on the laboratory assays used.
Final Diagnosis Determination Form:  This Form underwent significant revisions during the course of the
study, and the last version was adopted on July 28, 1995.  To ensure consistency of the data from this key
form, a copy of the final version was completed for all participants, including those whose medical review
results had been recorded on an earlier version of the form.  Please refer to section V.H.2.e above for a
description of the changes made to the Final Diagnosis Determination Form.
J.2.f. ICD9 Cause of Death Coding
The ICD9 Cause of Death Coding was entered into an Excel spreadsheet by the staff member who
performed the coding and then verified and resolved any discrepancies. This spreadsheet was then
converted into a SAS datafile using the software package DBMSCOPY.
J.2.g. Problems Forms 
Throughout the study, staff were encouraged to bring any procedural problems to the attention of
the supervisors and the Study Management Team.  To formalize this process, a Problems Form was
created.  This form was completed by the person(s) who identified the problem and given to the
Administrative Coordinator, who was responsible for bringing it to the attention of the appropriate people
to be involved in determining and carrying out the resolution.    The Administrative Coordinator was
responsible for tracking progress toward resolution of items on Problems Forms, and prepared a weekly
summary of the status of the outstanding forms.  This summary was reviewed by the supervisors at weekly
meetings and was also given to the Study Management Team for review.  As resolutions to each problem
were decided upon, these were logged by the Administrative Coordinator and the resolution of the problem
was recorded on the Problems Form.
 J.3. Outcome and Results
J.3.a. Tracking System
Table V.J-2 displays the number of records in each of the tracking system databases.
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Table V.J-2. Number of Records in Each Tracking System Database
Database No. of Records
Overall 4346
Tracing 4883
Participation 4348
Dosimetry 4447
Clinic 4346
Miscellaneous     69
Medical records 1443
Participants 4385
J.3.b. CATI
A total of 2133 participants who attended the HTDS clinic had a CATI.  Of these 2133
participants, 29 also had an Expanded In-Person Interview.  An additional 135 potential participants had a
CATI, but withdrew from the study before attending an HTDS clinic.
J.3.c. Clinic In-Person Interview
A total of 2112 participants had a Standard In-Person Interview at the clinic. In addition, 1335
participants had an Expanded In-Person Interview at the clinic.  One of these participants had help from
his/her father as well as a caregiver during the Expanded In-Person Interview. 
J.3.d. Clinic Data Forms, Refusal Questionnaires, Cause of Death Form, and Dating of
Diagnoses 
Table V.J-3 indicates the number of each of the clinic data forms, Refusal Questionnaires, Cause
of Death Forms and Dating of Diagnoses that were data entered and the number of people with at least one
of these forms entered for the 3447 eligible participants who attended a clinic.
HTDS Final Report: June 21, 2002 – Section V.J page 158
Table V.J-3. Numbers of Records in the Clinic Database, Refusal Questionnaires, Cause of Death
Forms, and Dating of Diagnoses
Data Entered and Verified
No. of Forms No. of Participants
Clinic Data Forms
Clinic Flow Sheet 1192 1192
Initial Blood Test Results 3439 3439
Thyroid Examination Form 6899 3447
Consensus Examination Form 3447 3447
Ultrasound Form
 Ultrasonographer 3447 3447
 Radiologist 3447 3447
 Ultrasonographer QC 103 103
 Radiologist QC 343 329
Post Ultrasound Consensus Exam Form 3448* 3447
FNA Form 263 259
Final Diagnosis Determination Form 3447 3447
Additional Blood Test Results 
Thyroid Function Redraws 27 27
Calcium Function Redraws 20 20
Reanalysis of Clinic Panel 37 37
Reanalysis of Thyroid Redraw 0 0
Reanalysis of Calcium Redraw 1 1
Refusal Questionnaire 365 365
Cause of Death Form 543 543
Dating of Diagnoses 1258** 667
* Includes one participant with a second Post-Ultrasound Consensus Exam Form following review by the radiologist, 
which indicated a new nodule.
** Number represents total number of diagnoses assigned a date prior to the clinic appointment date.
J.3.e. Problems Forms
A total of 147 Problems Forms were completed during the study.  Problems ranged from clerical
scheduling issues to final diagnosis determination.  Each problem was reviewed and possible solutions
discussed by the appropriate staff. All problems on the forms were ultimately resolved.
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K. Data Quality Control
In addition to the data management plans and procedures outlined in the previous section,
additional steps were taken after data collection to ensure a high degree of data quality.  These efforts
included more extensive examination of the In-Person Questionnaire data, the CATI data, scenario file
Construction, dose estimation, and computer programming.  More detailed descriptions of these efforts
follow. 
K.1. In-Person Interview Questionnaire Data
Data from the In-Person Interviews were entered into four INGRES databases, one each for the
original and the revised versions of the Standard and Expanded In-Person Interviews.  Each database
consisted of approximately 25 tables.  The frequency distribution of each variable was examined to check
for invalid codes or values.  Data from questions involved in skip patterns, i.e., questions that that might or
not be asked, depending on the response to another question, were also reviewed.  If any problems were
found, such as invalid codes or inconsistent skip patterns, the participant’s questionnaire was reviewed and
the correct code was entered into the database.  The background table, which includes the participant’s ID,
date of birth, and date of interview, was compared to the tracking system database to assure that each study
participant who completed an In-Person Interview was present in the background table. Participant ID
number then linked all of the tables.  The background table was used as a reference to confirm that
participants had information in each table.  Once all of the within-table and between-table checks were
completed, the four databases were compared to check for duplicate ID numbers between databases.  
The most frequent problems found as a result of reviewing the In-Person Interview databases
included the following:  (1) residence histories having multiple addresses with the same move-in and/or
move-out dates, and (2) medical histories reporting an age at first medical procedure less than 15 years of
age in the Standard In-Person Interview, which only asked about procedures after the age of 15.  The
questionnaires of participants with either of these data problems were reviewed and the database revised as
needed.  In addition, several database tables contained exactly duplicated records due to a programming
error in the INGRES database structure.  Finally, many extraneous records had been created when previous
attempts to correct records in the databases resulted in the creation of new records, rather than overwriting
of records.  These duplicate and extraneous records were identified and deleted.  
K.2. CATI Data
The CATI data were stored in INGRES databases, each consisting of approximately 65 tables.
Quality control began within each table by reviewing the frequency distribution of each variable.  If any
invalid codes were found, the audiotapes of the pertinent interviews were reviewed and the database was
corrected accordingly.  Data from questions involved in skip patterns were checked for consistency.  Once
these within-table checks were completed, the log table, which contains the participant’s ID number, date
of birth and date of interview, was compared against the tracking system to assure that all participants for
whom a CATI had been completed appeared in the CATI databases.  This table was then used as a
reference in the between-table checks.  When possible errors or inconsistencies were detected, the
audiotape of the pertinent CATI was reviewed and the CATI database was updated as needed.  Once all of
the within-table and between-table checks were completed, the two databases were merged to search for
any duplicate participant ID numbers.
 After the two CATI databases were merged into one database, a series of more in-depth
computerized consistency checks were conducted.  These included the identification of definite
inconsistencies as well as suspicious data that weren’t necessarily inconsistent.  All definite and possible
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inconsistencies were investigated by reviewing the audiotapes of the CATIs, and correcting the CATI
database as needed.  Below is a more detailed description of the additional checks that were performed.
• A comparison was made between the table indicating the types of milk consumed at each residence to
the tables containing the actual milk consumption values, to ensure that only the types of milk
specified for a particular residence were reported as having been consumed at that residence.  Note that
data from the table indicating milk types is not used in the dose calculation, since this information is
implicit in the information about quantities consumed.  It was known that CATI respondents
sometimes changed their responses during the interview, and it was believed that when they did, the
tables of actual consumption values of the various types of milk would be the most accurate.  Many of
the discrepancies detected resulted in revision in the table of milk types.  However, this comparison
also identified occurrences of a particular data entry error that occurred when the Interview sometimes
neglected to zero out of the consumption of a given type of milk, when the discontinuation of that type
of milk occurred at the time of a residence change.  For example, a participant may have consumed
raw cow’s milk only at his or her first residence, but only processed cow’s milk thereafter.  In such a
case the Interview should have changed the raw cow’s milk consumption to zero at the time of the
residence change, but didn’t always do so.  All of these data entry errors were corrected in the table of
milk consumption values.
• The food and milk consumption tables, which contained information about quantities consumed during
different time periods for each participant, were searched for overlapping time periods or duplicate
change dates.  This check was made for each type of consumption (milk, fruit, vegetable, and eggs), as
well as for the brands of milk.
• Large changes in consumption of specific food and milk products were examined.  A large change was
defined to include any increase or decrease by more that a factor of ten in the consumption rate.  In
addition, to test check for errors that might have arisen from changes in the way a CATI respondent
reported consumption rates, e.g., from units per day to units per week, the following additional criteria
were defined: (1) a decrease (increase) by more than a factor of 6 in conjunction with a change in
reported consumption from units per day to units per week (or from units per week to units per day,
respectively), and (2) a decrease (increase) by more than a factor of 4 in conjunction with a change in
reported consumption from units per week to units per month (or from units per month to units per
week, respectively).  Review of CATI audiotapes confirmed that many of these large changes were
indeed reported by the CATI respondent.   Consumption values that were erroneous due to mistaken
entry of the consumption rate were corrected in the table of consumption values. 
• Extremely large consumption values were checked for both participant’s and mother’s diets, for each
type of food and milk product category separately, i.e., for glasses, other servings and products of milk
for all types of milk consumed, and for raw vegetables, cooked vegetables, raw tree fruit, cooked tree
fruit, raw vine fruit, cooked vine fruit, and free range chicken eggs. In addition, the totals for a
particular type of consumption, i.e. processed cow’s milk, raw cow’s milk, total milk consumed, total
fruit, and total vegetables were also checked for extremely large values.  Descriptive statistics were
calculated for each of these separate and combined categories, and records indicating very high
consumption levels were identified. The pertinent CATI audiotapes reviewed, and the data were
verified or corrected, as appropriate.
• Because consumption of contaminated goat’s milk was expected to cause relatively large doses, the
audio recordings of all CATIs with an indication of consumption of goat’s milk were reviewed and the
data verified or corrected as appropriate. 
• The CATI allowed the respondent to report that consumption of a given food or milk product changed
gradually over a defined time period, for example, from one glass of milk per day at age 6 months to 3
glasses per day at age 3 years.  Such “gradual changes” were coded a particular way.  All records that
were coded to indicate a gradual change, but for which the consumption value did not in fact change,
were investigated.  Most of these were determined to be correct because the CATI respondent initially
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indicated that a gradual change had occurred, but subsequently reported that the quantity consumed
had remained constant.  In the remaining instances the database was corrected as appropriate, after
review of the CATI audiotape is necessary.
• To code a gradual change in consumption of a food or milk product that ended at the end of 1957 (the
end of the period for which doses were estimated), the CATI interviewers entered data indicating a
change in consumption on 12/31/57 or 12/30/57.  (Since dietary data were not collected after that date,
this served as a convention to indicate the end of a gradual change.)  All other changes of consumption
in the year 1957 were investigated to ensure that they weren’t meant to indicate gradual changes, and
to search for errors in the year of the change date.  The CATI audiotapes were reviewed and the table
of consumption values corrected as necessary.  One CATI Interviewer was found to have consistently
recorded gradual changes ending at the end of 1957 incorrectly, using a date other than 12/31/57 or
12/30/57.  All the consumption change dates in 1957 in this Interviewer’s CATIs that were revised to
reflect gradual changes ending at the end of 1957, with the exception of those for which consumption
changed either to or from zero, which were considered reliable indicators of nongradual changes.  
K.3. Scenario File Construction 
To examine the accuracy of scenario file creation, portions of selected scenario files, including the
participant’s diet and residence history and the mother’s diet, were recreated by hand or by a computer
program written by someone other than the programmer who created the original scenario files.  The
participant’s diet portion of the scenario file was recreated by hand for approximately 10% of those with
CATIs.  Two-thirds of those chosen were among the participants with more than the median number of
records in the diet portion of the scenario file, and one third from those with fewer than the median number
of records.  Also included in this group were all participants with a diagnosis of thyroid cancer who had a
CATI.
 The residence portion of the scenario file was also recreated by hand but for a smaller number of
subjects, as this was much less complex than the diet portion.  The mapping of residences was also checked
for 26 participants (110 places of residence) and no errors were found.  In addition, the encoding places of
residence within the HEDR domain was tested by checking whether the encoded locations were within the
state and county recorded from the CATI or Expanded In-Person Interview.  Only 4 errors were found and
corrected.  There was an error found in the map book, which was prepared by Battelle Pacific Northwest
Laboratories for use in determining residence codes.  The residence codes in Kittitas county were incorrect
as written and subsequently revised.  This affected 11 HTDS potential participants, whose residence codes
were revised accordingly.
The mother’s diet portion of the scenario file was recreated via SAS programming by a different
programmer than the one who created the original diet portion of the scenario file.  These two files were
then compared.  
When the recreations of scenario file data described above identified any discrepancies, the
computer programs used to create scenario files were examined for errors of logic or coding, and modified
as appropriate.
K.4. Dose Calculation
In order to check the process of scenario file creation and dose estimation, raw dosimetry data for
10 participants whose doses were based on CATI data were provided to an investigator at the CDC.  Using
that raw data, the CDC investigator created scenario files from those data, and used those scenario files as
input to the CIDER program to calculate a set of dose estimates which were then compared to the original
estimates calculated by HTDS.  Initially, the CDC was not informed of any assumptions made by the
HTDS in creating the scenario files, in order to test whether the assumptions she made were similar to those
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of HTDS.  After a preliminary comparison of the CDC and HTDS dose estimates, it was determined that
the CDC used the library of reference diets defined in the HEDR model for persons who consumed
commercial (“grocery”) milk, while the HTDS used the reference diets for persons who consumed milk
from family cows (see section VI.A.3.a below for further description of reference diets).  Although the
selection of reference diet library had relatively little impact on the estimated doses of participants whose
diets were largely if not entirely specified in their CATI data, the grocery milk reference diet library was
used by both CDC and HTDS in the subsequent comparisons.
There were several other issues, primarily concerning the handling of unknown or incompletely
specified data, for which the CDC and HTDS made different assumptions.  These are described in Table
V.K-1 below.  
Table V.K-1. Differences in Assumptions Used by CDC and HTDS
Issue CDC HTDS
Gradual change in
consumption of a food, milk,
or milk product
The time interval of the gradual
change was divided into thirds.
Consumption in the 3 resulting
subintervals was as follows:
   First: C(begin),
   Middle: [C(begin)+C(end)] / 2, and
   Last: C(end), 
where C(begin) and C(end) denote the
consumption levels at the beginning
and end of the interval, respectively.
The time interval was split by year
and the consumption in each interval
was calculated by successively adding
the quantity 
   [C(end) −C(begin)] / (#intervals−1),
where C(begin) and C(end) denote the
consumption levels at the beginning
and end of the interval, respectively.
Unknown food, milk, or
milk product consumption
quantity
If the quantity was known for some
portion of the time, that amount was
used to estimate the amount during the
time when it was unknown.
Left as unknown (i.e. used CIDER
defaults) with the exceptions of 1)
other servings of milk or milk
products was unknown, or 2) one
component of fruit was unknown.
For the former, an HTDS default was
used, based on tables of median
amounts consumed by age, sex, and
types of milk consumed.  For the
latter, the unknown component was
set to 0.  If more than one component
of fruit was unknown, the total was
set to unknown.
Combination of milk
products and fresh milk
Sum of fresh milk and milk product
quantities
Sum of fresh milk quantity plus half
of milk product quantity
% Local for vegetables
when known for both raw
and cooked vegetables
The higher of % local for raw
vegetables and % local for cooked
vegetables was used
The weighted average of % local for
raw vegetables and % local for
cooked vegetables was used
% Local for vegetables
when unknown for at least
one of raw and cooked
vegetables
Used 50% Used 100%
Milk Brands – Brand
unrecognized by CIDER
Used brand code Set to grocer milk
Milk Brands – When brand
records start after the milk
start date
Assumed first reported milk brands
applied from milk start date
Used CIDER default milk brand from
milk start date until start of reported
milk brands
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Despite the differences listed in the table above, the CDC dose estimates were relatively close to
those of HTDS, differing by less than 5% for half of the ten, and by less than 20% for eight of the ten; see
Table V.K-2 below.
Table V.K-2. Comparison of Dose Estimates by CDC and HTDS
Estimated Dose
(Median of 100 Realizations, in mGy)
Case CDC HTDS % Difference
  1 9.9 10.4 −5.1
  2 9.1 9.2 −0.8
  3 5.4 10.1 −46.2
  4 35.8 25.0 43.1
  5 2.5 2.7 −6.6
  6 57.7 55.7 3.6
  7 94.4 85.0 11.2
  8 8.6 8.4 2.9
  9 95.9 95.4 0.6
10 12.5 12.2 2.7
The difference in dose estimates for case #3 in Table V.K-2 (5.4 versus 10.1 mGy) was due to a
misspecification of the participant’s milk consumption in the HTDS estimate; this misspecification was
corrected before the participant’s final dose estimates were calculated.  The difference for case #3 arose
from a misspecification of the participant’s wean date in the CDC dose estimate.  The difference for case
#7 resulted from the different methods of combining milk products and fresh milk (see Table V.K-1
above).  In summary, this comparison indicated a high level of agreement between dose estimates
calculated by HTDS and those calculated by investigators external to the HTDS who were left to devise
their own assumptions regarding missing or incompletely specified information.
K.5.  Computer Programming
The computer programs that involved major manipulations of the data or complex code other than
standard SAS procedures were reviewed or tested in various ways to ensure they were accurately doing
what was intended.  The computer programs that created files of outcome data, as well as those that created
the files of data regarding the factors analyzed as possible confounding or effect modifying factors were
reviewed by a second person.  The dose-response programming was checked as follows.  First, the Newton-
Raphson algorithm used in these programs was written in Pascal.  Using small test data files, the output
was compared to hand calculations.  In addition, a “fixed” data file, with doses and outcomes that would
yield a known intercept and dose-response slope, was used to ensure the output was correct.  When the
HTDS data was used, the fitted values were examined to ensure they were reasonable.  The program was
first used for simple cases (e.g., one dose realization with one outcome) and then built upon to handle all
100 dose realizations plus three average doses (media, mean, and geometric mean) with multiple outcomes.
Once this was completed, the program was written again using SAS IML, and the output of the two
versions compared.  Throughout the process, matrix manipulations were performed to ensure they had the
properties required of the Newton-Raphson algorithm.
The program to compute an estimated dose from Nevada Test Site exposures for each participant
was written by the HTDS Programmer, using Fortran.  Output from this program was compared to
estimates obtained using the web-based tool provided on the NCI’s website
(http://rex.nci.nih.gov/INTRFCE_GIFS/radiation_fallout/radiation_131.html) for a small number of
participants, to verify that the program and web tool provided the same results.
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K.6 Mortality Data
 
Encoding of causes of death is described in sections V.I.2.d and V.I.3.d above.  As a quality
control check, text descriptions of causes of death from the death certificates or informant information were
compared to the assigned cause of death code for the 543 potential participants for whom cause of death
information was obtained.  In 13 of 543 (2.4%) cases, the code was revised as a result of this review.  In
seven (1.3%) of the cases, the code was revised to 410 - Acute Myocardial Infarction from Another, Non-
acute Cardiac Condition, in keeping with the coding rules regarding acute cardiovascular disease.  In three
(0.6%) of the cases, the code was revised from E995 – Injury due to War Operations by Other and
Unspecified Forms of Conventional Warfare, to a more specific cause, due to identification of an additional
information source on the exact cause of Vietnam war deaths.  In one case (0.2%), the cause of death was
changed from 770 – Other Respiratory Conditions of Fetus and Newborn to 760 – Fetus or Newborn
Affected by Maternal Conditions Which May be Unrelated to Present Pregnancy.  The remaining two
revisions were due to data entry errors.
The programs written for the mortality analysis were also reviewed.  Person-years at risk were
calculated by hand and compared to the results of the computer program for selected participants.  The
numbers of living people in Washington State used in the mortality analysis program for the various sex,
age group and calendar year categories were double checked by hand to ensure their accuracy.  Similarly,
the numbers of deaths in Washington State for specific causes of death and by sex, age group and year of
death were also double checked by hand to ensure their accuracy.  
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VI. Radiation Dose Estimation
A. Background
A.1. Objectives of Dose Estimation
In an epidemiological study concerning a quantitative exposure such as the thyroid dose from
Hanford’s 131I, the most informative analyses are likely to be those that examine the dose-response
relationship in terms of individual measurements or estimates of exposure.  When the initial planning of
HTDS began, it was anticipated that the Hanford Dose Reconstruction (HEDR) Project, which was then
well on its way to completion, would produce a system that could be used to estimate each study
participant’s thyroid radiation dose.  The study design for HTDS was therefore built in part on the
assumption that individual dose estimates would be available, although the design was intended to allow
the study to succeed in the unlikely event that individual dose estimation was not possible.  This
assumption had several implications for the study.  For example, it implied the need to collect information
from which individual dose estimates could be calculated, which led in turn to the CATI component of
HTDS.  It also implied the need for the HTDS to establish a system that would process such information
into a form suitable for use in dose estimation, accomplish the dose calculations, and make the results
available for analysis.
The primary objective of this component of the study was to calculate individual estimates of
radiation doses to the thyroid for HTDS participants.  Specifically the estimates referred to doses to the
thyroid from 131I released into the atmosphere from the Hanford site, as calculated by the dosimetry system
created by the HEDR Project.  Secondary objectives included testing and verifying the accuracy of data that
were used for calculation of dose estimates, and the production of data files concerning dose-related
characteristics of the study participants, for use by the study statisticians.  These data files would include
both descriptive data regarding the participants, particularly concerning dose-determining characteristics, as
well as data that might be used for alternative characterizations of exposure to Hanford’s 131I.  An
additional secondary objective was added late in the study: to calculate estimates of doses that study
participants received from the Nevada Test Site.
A.2. History of the HEDR Project
In 1987 the U.S. Department of Energy directed Battelle’s Pacific Northwest Laboratories to
conduct the HEDR Project, following the 1986 recommendation of the Hanford Health Effects Review
Panel (16).  In 1988 a Technical Steering Panel was selected to direct the HEDR project.  One of the main
objectives of the HEDR Project was to evaluate the feasibility of developing a system to estimate
individual radiation doses to the thyroid from Hanford’s 131I and if feasibility was demonstrated, to develop
such a system.  The evaluation of feasibility, often referred to as HEDR Phase I, was completed in 1991.  It
was concluded that the available data regarding source terms, atmospheric conditions, deposition rates, and
environmental and food chain transport were adequate to support the development of a system to estimate
radiation doses.  It was also concluded that existing models and computer codes could be adapted for
estimating doses and analyzing the uncertainty of the estimates.  As part of the demonstration of feasibility,
a preliminary set of dose estimates was calculated for hypothetical representative individuals in a 10-county
area around the Hanford site.  These were the dose estimates available at the inception of HTDS and during
the development of the HTDS protocol.
Based on the Phase I results, the HEDR project proceeded to develop a dosimetry system that
included the capability of estimating radiation doses to the thyroid from Hanford’s atmospheric releases of
131I.  These dose estimates included contributions from dietary pathways, i.e., the consumption of
contaminated milk and food products, from inhalation of contaminated air, and from external exposure.  In
particular these estimates could be calculated for individuals using specific data regarding residence and
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dietary history and other factors.  One important part of this phase of the HEDR work was establishing the
geographical domain within which doses could be calculated.  The resulting domain, roughly 250 miles
east to west and 300 miles from north to south, was substantially larger than the 10-county Phase I area.  A
working version of the dosimetry system was in place by early 1994, and the main HEDR final reports
were published in April 1994.  Thus an essentially final dosimetry system was available in time for use in
calculating doses for the HTDS Pilot Study.  This was particularly significant to HTDS, since the final
HEDR results differed from the HEDR Phase I results in ways that impacted the design of the HTDS Full
Study.
In 1999 and 2000, based on recommendations arising from the National Academy of Sciences
review of the HTDS draft Final Report (78) and discussion with HTDS investigators, investigators are
Battelle Pacific Northwest Laboratories made a number of modifications in the HEDR model’s computer
program and data files (see Appendix 22).  The resulting version of the HEDR system for dose estimation
was used to calculate the dose estimates used for the analyses described in this report.
A.3. Special Challenges of Dose Estimation for HTDS
A.3.a. HEDR Dose Models
The central challenge for HTDS arose from the need to complete a version of the questionnaire
and program the CATI before the HEDR model was complete.  Thus the data items to be included, and the
specific definitions of those items, were not completely known.  The most difficult areas in this regard were
selection of feeding regimes for family cows, delay times before consumption of certain milk products,
milk delivery to homes, identification of dairies inconsistent with HEDR information, definitions of leafy
vegetables, and the handling of reference diets.
• Cow feeding regimes were undefined when the CATI was first developed.  HEDR investigators
initially recommended that the interview ask whether the cows were fed fresh grass or green chop.
However in the final dosimetry system, cow feeding regimes were defined by whether or not the cows
were grazed on irrigated pastureland.  Fortunately the CATI included questions about the source of
water for the cows, since it was unknown initially whether water would be a significant source of 131I.
The information about water source was used to impute whether the pasture was irrigated.
• The final HEDR model did not allow the specification of milk products other than fresh milk and
“stored milk.”  The difficulty with the stored milk component was that it did not distinguish between
relatively fresh milk products such as cottage cheese and ice cream, and products with long intervals to
consumption such as aged cheese and canned or powdered milk.  HTDS collected information only for
milk products that were relatively fresh.  To allow for the time lag for consumption of milk products, a
conversion factor of 0.5 was applied to these products, after consultation with Battelle investigators.
Thus the quantity of fresh milk products was multiplied by 0.5 and then added to the amount of fresh
milk to obtain the total amount of fresh milk for use as input data by the CIDER program.
• At the recommendation of HEDR investigators, the CATI included questions asking whether
commercially produced milk was purchased at a store or delivered to the home.  Since milk purchased
in a store might sit a few days on the shelf before being purchased, the difference in "holdup times"
could affect dose contributions from the fresh milk pathway by about 20-30%.  The design
specifications for CIDER included definitions of 22 media containing 131I contamination, including
milk categories for grocery milk (purchased) and creamery milk (delivered).  However in the final
version of CIDER the creamery milk category was not implemented.  It was therefore necessary to
treat milk that CATI respondents described as delivered to their homes as though it was purchased in
stores.
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• One important challenge facing HEDR was the reconstruction of the commercial milk distribution
system within the HEDR geographical domain.  When the HTDS CATI was initially designed, HEDR
was able to provide a preliminary list of 55 dairies that operated in the Benton, Franklin and Walla
Walla counties.  These 55 were included in the HTDS interview materials.  The final version of the
HEDR system included many more dairies.  In October 1995 HTDS received from HEDR
investigators a list of 163 dairies that were included in the dosimetry system.  Occasionally, of course,
CATI respondents identified as a milk source a dairy that was inconsistent with the HEDR data, i.e.,
that did not serve the area in question at the time in question according to the HEDR data.  In 12
instances such inconsistencies were observed in the data from 2 or more CATI respondents.  In eight of
these 12, the dairy in question was mentioned by only 2 CATI respondents.   Information about these
inconsistencies was sent to the HEDR Task Completion Working Group and to former HEDR
investigators in April 1996.  Since the reported discrepancies did not provide definitive evidence of
inadequacies in the HEDR commercial milk distribution model, that model was not revised in response
to these discrepancies.  Therefore HTDS adopted the following approach.  Whenever a CATI
respondent indicated that the participant consumed milk or milk products from a dairy that did not,
according to the HEDR data, serve the area in question during the period in question, the dairy was
assumed to be unknown for the participant’s dose calculation.  This had the effect of assigning the
HEDR location- and time-specific default as the source of commercial milk and milk products.  If the
HEDR model specified that only a single dairy served the location at that time, then that dairy was
assumed to be the source of dairy products.  If the HEDR model identified two or more dairies that
served a region during the time period of interest, then the default was defined as a mixture of milk and
milk products from those dairies.
• The definitions of “leafy vegetables” differed somewhat between the HTDS CATI and the HEDR
dosimetry system.  For example the final HEDR definition of leafy vegetables included string beans,
while the HTDS definition did not.  Another problem with leafy greens was conversion of servings
(the unit used in the CATI) to kilograms (the unit required for input into the CIDER program).  The
HEDR system did not define how this conversion should be calculated.  Therefore, after conferring
with HEDR investigators and dieticians, HTDS developed conversion factors based on the weights of
servings of individual leafy vegetables.
• Reference diets were built into the HEDR dosimetry system to provide default information about
dietary factors.  Such default information could be used when all or only part of a participant’s dietary
history was unknown.  In HTDS this occurred whenever the CATI respondent was unable to provide
the specific information.  The Expanded In-Person Interview given to HTDS participants without
CATI respondents included no questions regarding quantities of milk and food products consumed
during childhood.  Therefore the calculation of dose estimates for those with dosimetry data from the
Expanded In-Person was necessarily based entirely on default dietary data.  The final HEDR system
was limited to a total of four sets of reference diets, each containing 120 combinations of age, sex,
lifestyle and season for each of nine categories of food and milk products.  The reference diets are
defined for four different circumstances: milk from backyard cows, milk from commercial sources,
goat milk only and cows fed stored feed only.  Nearly every HTDS case fell into one of the first two
categories (backyard cow's milk or commercial milk).  However the HEDR model did not include
reference diets for people who were reported to have consumed unknown quantities of both
commercial and family cow’s milk.  Also the CIDER program allowed for the specification of only a
single reference diet in each set of input data.  Therefore it was impractical to allow a participant’s
reference diet category to change over time, and HTDS used the backyard cow’s milk reference diet
for dose estimation.
A.3.b. Technical Issues
When HTDS began, it was clear that the dosimetry data would be complex, and it was therefore
unclear whether a CATI would be feasible.  In 1990, the fastest PC had a 386 chip and many on the HTDS
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staff were still using 286 IBM-AT computers.  The complexity of the data implied that a relational or
hierarchical data base structure would be required.  Three candidate database management systems were
given the most serious consideration.  The first, SIR (Scientific Information Retrieval) was originally
developed on mainframe computers, but had become available for desktop personal computers.  SIR is a
hierarchical database that allows more than one record per case all indexed by an ID number.  However
SIR was relatively inflexible and had very poor data entry features to make it unsuitable for CATI.  Two
relational database management systems, ORACLE and INGRES, originally developed for mainframe
environments, were also available on personal computers.  Of these two, INGRES was selected on the basis
of its flexibility, superior data entry capabilities, substantially lower cost, availability of a local office with
technical support, and ability to run on relatively modest personal computers.  The flexibility, stability and
features of INGRES allowed it to meet all of the study’s needs.  A copy of the SIR product was also
required by the study for use in processing dosimetry data through several steps required to create input
files for the CIDER program.
Flexibility of the dosimetry data base management system was important since the CATI was
modified several times after data collection began.  Moreover the INGRES-based system allowed the
capability for interviewers to revise responses in real time during the CATI.  Designing the system to
permit interviewers to return to and modify previous responses during the interview presented many
challenges.  However it was considered important since it would minimize the need to temporarily
discontinue interviews to permit entry of revisions that would impact the appropriateness of subsequent
questions.  Since the CATI was expected to be a significant imposition on the time and altruism of the
respondent, every effort was made to minimize the number of temporary discontinuations.
The ability to correct data after the interview was also an essential component of the dosimetry
data base management system.  A separate set of data entry programs were written exclusively for data
correction.  Initially, the Systems Analyst was the only person allowed to make data corrections.  After
about one year much of this responsibility was shifted to the CATI Interviewers, who by then had enough
experience with the data to make many kinds of corrections, and to judge when a correction was so
complex or unclear that it had to be performed by the Systems Analyst.  In such instances the Interviewer
completed a data correction form and the Systems Analyst made the corrections.
A.3.c. Logistics
HTDS had three computers available for CATIs, each with its own copy of the CATI database.
Each CATI database contained only data from the interviews conducted on that computer.  After the CATI
was completed and any necessary corrections made to the data, the Interviewer copied the data to the local
area network maintained by the Epidemiology Program of the Fred Hutchinson Cancer Research Center.
Data from the three CATI databases were then captured from the network and combined into a single
database on the Systems Analyst's computer.  
Creating scenario files (i.e., input data files required by the HEDR dosimetry system) from the
CATI databases was a complex process performed by the Systems Analyst.  It involved merging records
for 18 components of the participant’s diet that could vary independently over time into a single set of
sequential records.  Each diet component existed as a separate table in the INGRES CATI database.  They
were combined into a single table in the SIR database using INGRES’s report writer, programs written in
FORTRAN, and the SIR programming language.  These were then merged with data regarding the
participant’s residence history, birth date, and mother's diet if necessary to create the scenario file using a
FORTRAN program.  For participants whose doses were based on data from the Expanded In-Person
Interview, the procedure for creating scenario files was similar but somewhat simpler, because that
interview did not collect information about quantities of food and milk products consumed by the
participant.
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B. Dose Estimation Procedures
When the HTDS protocol was developed in 1993, plans regarding the methods for calculating
doses to the thyroid from Hanford’s atmospheric releases of 131I could not be specified, since relatively
little was known about the dosimetry system that would be available.  It was assumed that a dosimetry
system would be available, and that it would be capable of calculating doses for HTDS participants using
the data collected in the CATI or Expanded In-Person Interview.  It was highly likely, though not certain,
that dose calculations would be performed by some agency other than HTDS. 
B.1. Staffing and Logistics
The study’s Systems Analyst/Programmer had primary responsibility for the calculation and
management of dose estimates.  This included the following tasks: developing procedures for capturing and
processing CATI and Expanded Interview data into a format suitable for dose calculations (scenario files),
transferring data to the custodian of the dosimetry system to have the calculations performed, receiving the
dose estimates back from the custodian of the dosimetry, and making the dose estimate data available to
HTDS investigators for statistical analysis.
The HEDR model originally used by HTDS for was installed on a Sun workstation administered
by the CDC in Atlanta.  Scenario files were created in Seattle and transmitted to Atlanta via the Internet.
This version of the model was used to calculate doses used in the analyses for draft HTDS Final Report.
Scenario files typically contained data for between 40 and 45 participants, and the Sun installation
of CIDER typically required about 70 minutes to calculate doses for those participants.  After the doses
were calculated by CIDER, HTDS transmitted the results to Seattle, again via the Internet.  CIDER
computed 100 realizations of dose for each year from 1944 to 1957 (14 years), and for each of the 10
pathways (inhalation, external exposure, and ingestion pathways for eight food and milk categories).  This
resulted in at least 14,000 realizations of dose for each participant. If the participant moved during a year,
100 realizations for each of the 10 pathways were computed for each location during the year.  HTDS
wrote a program to combine the 14,000 realizations into 100 realizations of total dose.  
B.2. Revisions of the HEDR Model and Computer Programs
The HEDR model, and more specifically the CIDER program, were revised a number of times
during the course of HTDS.  A number of HTDS suggestions were incorporated in the final version of
CIDER:
1. The maximum number of sources of fresh milk was increased from 3 to 5.  Many households had
multiple sources of milk such as a backyard cow, commercial milk delivered to the home or purchased
at a store, and milk served at school.
2. Goat's milk was retained in the final HEDR model.  HEDR investigators considered dropping goat's
milk, however HTDS CATI data showed that about 1 % of households drank goat's milk.
3. Cow feeding regime #4 (cow fed mostly stored feed) was retained in the final HEDR model.  CATI
data showed there were cows fed entirely with hay and stored feed.  
4. The maximum number of diet specifications was increased (to 860).  This was necessary to
accommodate the multiple changes in diet that were typical of HTDS participants.  HEDR initially set
this limit much lower, based on an assumption that many individuals would share common diets.  Even
with this increased limit, however, only 40-45 CATI cases could be processed at one time.
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5. In the summer of 1997 HTDS detected an error in how the CIDER program handled breast-feeding of
participants and helped identify and test the correction
In response to suggestions made in the National Research Council’s (NRC’s) review of the draft
Final Report of the HTDS (78), a number of further revisions were made in the CIDER program by
investigators at Battelle Pacific Northwest Laboratories.  These are described in detail in Appendix 22,
which reproduces a letter report produced by investigators at Battelle Pacific Northwest Laboratories (126).
One of the most important revisions was to provide HTDS a version of the CIDER program and the related
data libraries that could be run on a desktop personal computer with relatively modest memory (see section
7.1 of Appendix 22).  This eliminated the need for a cumbersome procedure described above for passing
scenario files and dose estimation output between the HTDS offices in Seattle and the CDC in Atlanta.  The
HEDR model used by HTDS to estimate the doses used in this report was run on an IBM compatible PC
located in the HTDS office.  The doses were calculated by the HTDS programmer in much the same
manner as described above, although the time CIDER typically required to calculate doses for 40-45
participants decreased to about 7 minutes.
The Battelle investigators made two other significant revisions in the CIDER program.  As
described in section 7.2 of Appendix 22, the handling of uncertainty in dose conversion factors (DCFs) was
revised.  The HEDR model accounted for these uncertainties by generating 100 realizations of each age-
and sex-specific DCF according to defined uncertainty distributions (127).  In the original implementation
of CIDER, the order of these realizations was fixed.  That is, for every participant, the first dose realization
was calculated using the first realizations of the DCFs, the second dose using the second DCF realizations,
and so on.  This created an artificial correlation between dose estimates of different participants, since they
all shared common values of the DCFs in each realization.  The revised version of CIDER therefore
included an option to randomly permute the order in which the 100 DCFs are selected for each participant,
thereby eliminating the artificial correlation.  This option was employed for all dose estimates used in the
analyses described in this report.
The second significant revision in the CIDER program provided options to assign uncertainties to
participant-specific dietary consumption data obtained from CATIs (see section 7.3 of Appendix 22).  In
the original implementation of CIDER, quantities of food and milk products consumed by a person were
treated as uncertain only if they were specified as unknown in the scenario file of input data.  If the amount
of a food or milk product that a person consumed could be specified in a scenario file, then CIDER treated
that amount as fixed, with no uncertainty, in estimating the resulting dose.  For most HTDS participants
with doses based on CATI data, age-specific quantities of foods, milk, and milk products consumed were
reported by the CATI respondent.  While it was recognized from the beginning of HTDS that it is
unrealistic to ignore the uncertainties in dietary data collected from interviews several decades after the
exposure period of interest, the original version of the CIDER program provided no practical means to
incorporate that uncertainty.  The final version of CIDER includes options to assign uncertainties to
reported dietary intakes.  These options are described in detail in section 7.3 of Appendix 22
The final version of CIDER and the related data libraries included two other revisions that had
only limited impact on the dose estimates.  These included correction of source terms beginning August
1951 (see section 3.1 of Appendix 22), and of the uncertainty distribution of fetal dose conversion factors
(section 6 of Appendix 22).
C. Doses from the Nevada Test Site
Information released by the U.S. National Cancer Institute (NCI) shortly before and during
October, 1997, indicated that persons living in the contiguous 48 states during the 1950s and 1960s were
exposed to various levels of 131I released from the Nevada Test Site (NTS).  The material released by NCI
included estimates of dose for various representative individuals for all counties in the 48 states, as well as
more detailed data regarding estimated dose by shot (i.e., by individual test detonation), county, and age.
Limited preliminary comparisons for HTDS participants suggested that in many cases the reported NTS
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dose estimates were comparable to or even greater than the estimated Hanford doses.  Therefore it was
judged necessary to add exposure to 131I from the NTS to the list of potential confounding factors.
The CATI and In-Person Interviews included complete residence histories for all participants for
the period from December 1944 through 1957.  For periods when a participant lived outside the HEDR
geographical domain, the county and state of residence were recorded, although details regarding diet and
sources of food and milk were not obtained.  This was fortuitous, since it provided a means to calculate
estimates of NTS-derived dose.  Using data regarding representative doses by age and county available
from the NCI’s website, the HTDS Systems Analyst/Programmer created a program that calculated
estimated NTS doses for study participants, based on their residence histories through 1957.
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VII. SPECIAL CONSIDERATIONS
A. Assessment of the Feasibility of a Health Study in Native American Populations
A.1. Background
Nine Native American tribes and nations have reservations and ceded lands in the region around
Hanford: Colville, Couer d’Alene, Kalispell, Kootenai, Nez Perce, Spokane, Umatilla, Warm Springs, and
Yakama. Members of these tribes and nations were exposed to 131I from Hanford, and the original
Congressional mandate that led to the HTDS called specifically for the inclusion of “Indian tribes and
tribal organizations.”
The approach taken in the HTDS regarding the Native American communities was determined by
two important characteristics of those populations.  First, the lifestyles of many Native Americans were
quite different in many respects from those of the non-Native population.  In particular, many Native
Americans followed traditional cultural practices, especially regarding diet and sources of foods, which
might influence the doses they received from Hanford’s 131I but which were not explicitly modeled in the
HEDR calculational programs.  Moreover, many Native Americans maintained a seasonal migratory
pattern of residence.  Second, because the tribes and nations have sovereign rights recognized by the
United States, conduct of a research project such as HTDS would require the approval of each tribal
government and active cooperation of tribal members to obtain culturally sensitive data. 
As stated in the HTDS protocol (1), the objective of the HTDS with respect to the Native
American populations was to assess the feasibility of conducting a study to determine whether thyroid
disease was increased among Native Americans exposed to 131I from Hanford.  The approach taken to meet
this objective involved the following steps:
1. Identifying study designs that could meet the main objective, i.e., to determine whether thyroid
disease has increased among Native Americans exposed to 131I from Hanford.
 
2. Establishing guidelines for assessing whether any of the proposed designs had adequate
probability of providing a definitive conclusion regarding the main objective. These guidelines
were to be established in collaboration with CDC staff and representatives of the tribes involved.
 
3. Analyzing demographic data and estimates of thyroid doses from 131I, using dietary and lifestyle
information provided by the tribes, in relation to the established guidelines to reach a conclusion
about feasibility of a study in the Native American population.
These activities were undertaken in parallel with those of the Full Study. The sections below
briefly describe the progression of this component of the HTDS. Demographic data and information about
lifestyle practices collected by each tribe, as well as radiation dose estimates specific to each tribe, are
considered proprietary and belong to the tribes. These data were made available to the HTDS investigators
for purposes of assessing the feasibility of a study in the Native American population with the
understanding that they would not be disclosed. Therefore, no data specific to individual tribes are included
in this report. 
A.2. Initially Recommended Study Design and Guidelines for Assessing Feasibility
Since the main objective of a study in the Native American population is the same as that for the
HTDS Full Study, the choice of possible study designs was subject to the same constraints as the HTDS
Full Study (see section IV.A.1 above for a discussion of study design considerations).  Therefore, the
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HTDS investigators initially recommended that a retrospective cohort design using individual dose
estimates, similar to that used for the HTDS Full Study, would be most appropriate for a study in the
Native American population.
To begin the feasibility assessment of conducting such a study, it was necessary first to obtain
information from each tribe about the number of persons who might be available and willing to participate
in a study  It was necessary to obtain information to estimate thyroid radiation doses that members of the
tribe would have likely received from Hanford. When the HTDS was initiated, work was already underway
in conjunction with the Hanford Environmental Dose Reconstruction Project to begin to collect such
information within the tribes.  A working group was formed to facilitate this effort, and to provide
technical assistance.  This working group was composed of representatives of each tribe, the Technical
Steering Panel of the HEDR project, Battelle, Pacific Northwest Laboratory, the CDC, and the health
departments of the states of Washington, Oregon, and Idaho. The HTDS joined this group (the Native
American Working or NAWG), and was represented by one of the study investigators at each meeting.
This provided a close link between the HTDS and each tribe throughout the entire process of data
collection and dose estimation for the Native American population. 
As the data collection effort proceeded, it became clear that guidelines for assessing the feasibility
of an epidemiologic study should be developed and agreed upon prior to examination of any tribal-specific
data. At a meeting of the Native American Working Group in January 1994, HTDS investigators proposed
the following guidelines for assessing whether an epidemiological study of the recommended
(retrospective cohort) design should be conducted in the Native American population.
• Justification of such a study would require pilot data indicating the feasibility of identifying and
recruiting adequate numbers of people with a range of radiation doses sufficient to ensure that a
one-sided test at the 5% critical level has at least 80% power to detect a linear dose-response for
the probability of thyroid neoplasia with a slope of 10−5 per mGy.
 
• If pilot data indicated that such a study would have substantially less power, e.g., below 70%, to
detect an effect of this magnitude, then a study in the Native American population would not be
recommended on scientific grounds.
 
 This criterion was analogous to that initially proposed for the decision about whether to proceed
with the HTDS Full Study.  In particular, the target of 80% power to detect an effect of 10−5 per mGy was
considered scientifically sound, providing a sufficiently high level of statistical power (80%) to detect a
relatively small effect (10−5 per mGy).  It was also considered achievable, based on the dose data available
at the time, i.e., the HEDR Phase I dose results. 
 
As a resul t of the HTDS presentation at the January 1994 meeting, the NAWG formed a
Subcommittee on HTDS Study Design to further evaluate the proposed guidelines.  In May 1994, this
Subcommittee of the NAWG requested the HTDS investigators provide a document regarding possible
study designs that might be considered for a thyroid study in the Native American population.  In June
1994 the requested document was submitted to the Subcommittee (128).  In that document, the HTDS
investigators concluded that, given the objective of determining conclusively whether thyroid disease was
increased among Native Americans exposed to Hanford’s 131I, the most appropriate study design remained
a retrospective cohort study with individual dose estimates, similar to that of the HTDS Full Study. 
 
 
A.3. Modified Guidelines for Assessing Feasibility
 
W hen the essentially final HEDR results became available in April 1994 (14, 118), it was
apparent that the range of dose estimates for HTDS participants would be substantially smaller than the
HEDR Phase I results had suggested.  Consequently, the preferred criterion of having 80% power to detect
an effect of 10−5 per mGy no longer appeared achievable.  Therefore, modification of the recommended
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criterion had to be considered to ensure adequate power (at least 80%) to detect a dose-response effect of
5×10−5/mGy for thyroid neoplasia.  Although this represents a substantial decrease in the power of the
study, it was still considered scientifically justifiable (see section V.A.5 above).  For example, based on
projected baseline probabilities for thyroid neoplasia of 5% and 2% for women and men, respectively, in
the HTDS cohort, an effect of 5×10−5/mGy corresponds to doubling the probability for women at a dose of
1000 mGy, and to approximately tripling the risk for men at that dose.  This is roughly the magnitude of
effect seen in the study of persons in Utah exposed to fallout from the Nevada Test Site (60).
 
At  an October 1994 meeting of the NAWG, representatives of the tribes and nations agreed to
provide demographic information and representative dose estimates that were calculated for them by staff
at Battelle Pacific Northwest Laboratory as part of the Phase I Native American component of the HEDR
project.  From 1994 through early 1996, six tribes provided the estimated dose data to HTDS.  Five of
these tribes also provided information about their numbers of members during the 1940s and 1950s.  Based
on these data, HTDS investigators calculated predictions of the dose distributions, cohort sizes, and
statistical power that might be available for a study in the Native American population.
 
In M ay 1996, at a meeting of the Intertribal Council on Hanford Health Projects or ICHHP (which
had by then taken the place of the NAWG), HTDS investigators made a presentation regarding the impact
of the final HEDR results.  For the reasons discussed above, they recommended that the guidelines for
assessing feasibility be relaxed.  They also presented the results of the power calculations based on the
preliminary dose data that had been provided by six tribes or nations.  These calculations showed that the
projected range of doses and cohort sizes were not large enough to meet the modified guideline of 80%
power to detect an effect of 5×10−5/mGy for thyroid neoplasia.  However it was also recognized that the
dose data available at that time were quite limited with respect to both the number of interviews conducted
with tribal members, and the number of tribes completing data collection.  Thus, these data would not
likely provide sufficiently accurate projections of the dose distributions that would actually be obtained if a
Native American study were performed.  Consequently, the HTDS investigators recommended that the
final determination regarding feasibility of a study be postponed until the second stage of data collection
and dose calculation for the tribes was complete.
 
 
 A.4. Final Assessment of Feasibility
 
The second stage of data coll ection took place during 1996 and 1997.  One tribe did not complete
this stage of data collection and dose estimation.  This data collection was intended to provide input data
for the calculation of estimated doses for hypothetical representative persons based on realistic assumptions
about diet, food sources, and seasonal changes in residence.  In 1997 and 1998 CDC staff communicated
with each tribe or nation to obtain approval of the assumptions used for calculation of these representative
dose estimates. Between late 1997 and mid 1998, CDC and HTDS staff calculated representative dose
estimates as data and approvals became available from the tribes.
 
 Dose estimates for each tribe were calculated using several scenarios for the hypothetical
representative persons.  These scenarios were defined by the following factors: 
 
• Sex.
• Year of birth, including at least 1940, 1942, 1944, 1945, 1946 for every tribe.  For three of the
tribes, earlier and later birth years were also included.  The date of birth was assumed to be
January 1 in each year.
• Age at weaning, including at least 0 months (indicating absence of breast-feeding) and 12 months.
Older ages at weaning were included for the calculations of some tribes.
• Diet, traditional diet as reported by the tribe versus reference diet as provided by the CIDER
program.
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Examination of the representative Native American doses revealed that the pattern of estimated
dose in relation to birth year was generally the same as that of the individual dose estimates of the HTDS
Full Study.  That is, estimated doses tended to be highest for representative persons born in 1945.  The
representative doses decreased with decreasing (earlier) birth year, and were also lower for the 1946 births.
One tribe’s dose estimates differed slightly from this pattern in that the highest representative dose estimate
was for a 1944 birth.  However doses for 1945 were similar to those for 1944, and doses still decreased as
one moved away from 1944 or 1945, toward either earlier or later birth years.
These representative dose estimates were used to perform statistical power calculations in
essentially the same way as those presented by HTDS investigators to the May, 1996, meeting of the
ICHHP.  Note that the new power calculations differed from the earlier calculations in the following
respects: 1) they were based on the representative dose estimates calculated in 1997 and 1998 and based on
presumably more accurate scenarios for tribe-specific dietary data and residence histories, and 2) they were
based on eight of the nine tribes, rather than the six tribes in the earlier calculations (five tribes provided
data for both sets of power calculations).
The statistical power of a study depends in part on the mean and variance of the distribution of
doses that would be estimated for the study participants (see Appendix H in HTDS Protocol [1]). These
quantities were estimated by 1) estimating the mean and variance of the dose distributions and number of
participants for birth year cohorts within each tribe, and then 2) calculating the mean and variance of the
overall dose distribution that would result. 
To assess the feasibility of a study in the Native American population, initial calculations of
statistical power were performed using nonconservative assumptions, i.e. assumptions that would tend to
produce an overestimate of the statistical power.  This was done as a scoping calculation: if the
overestimated statistical power was too low to justify conduct of a study, then the even lower projections of
power that would result from using more realistic assumptions would also be evidence against feasibility.
If, on the other hand, the initial scoping calculations indicated that adequate statistical power might be
obtained, then more careful evaluation of the projected statistical power would be pursued.  The non-
conservative assumptions that were made for the initial scoping calculations were as follows.
Assumption 1.  The projected mean of the dose distribution was calculated by assuming that, within each
tribe, the mean dose that would be obtained for each of the 1940, 1942, 1944, 1945, and 1946 birth cohorts
would equal the maximum representative dose calculated for that tribe and birth year.
Assumption 2.  For each tribe’s 1941 and 1943 birth cohorts, for which representative doses were not
calculated, the mean was assumed to equal the maximum representative dose calculated for that tribe’s
1942 and 1944 birth years, respectively.
Assumption 3.  All nine tribes and nations would participate in a proposed study of the Native American
population, even though one tribe did not participate in the second stage of data collection and
representative dose calculation.  Since representative dose estimates were not available for this tribe, it was
assumed that each of its birth cohorts would have the same mean dose as the tribe with the highest
representative dose estimates.  This assumption is quite non-conservative, since the mean doses for this
tribe would almost certainly be much smaller.
Assumption 4.  For each birth year cohort within each tribe, the variance (V) of the doses was assumed to
equal the square of the mean dose (M),
V = M2 .
The representative dose calculations provided estimated doses for certain types of individuals, but
did not provide estimates of the variance that might be observed in a population of real individuals.
Therefore, the relationship between mean and variance of doses for populations of real individuals was
estimated from the individual dose data available from the HTDS Full Study.  The 3191 living evaluable
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in-area participants in the Full Study were divided into 100 subgroups defined by sex, year of birth, and
geostratum, and the mean and variance of the dose estimates for each subgroup were calculated.
Regression analyses indicated that the relationship between variance and mean was approximately of the
form 
V = MB .
For dose estimates which used individual residence histories, individual information collected by
the CATI, and HEDR default values for items for which CATI data were not available or for individuals
without a CATI, the exponent B was estimated to be 1.8 ± 0.03 (S.E.).  For dose estimates which used
individual residence histories and HEDR default values exclusively (i.e., no individual CATI data), the
exponent B was estimated to be  1.7 ± 0.03.  Using an exponent of 2 results in larger estimates of variance,
and therefore higher projections of statistical power, than would be obtained with 1.7 or 1.8.
Assumption 5  Non-conservative assumptions were made regarding the numbers of participants who would
be available from the nine Native American populations.  In particular, for tribes that provided detailed
demographic data, it was assumed that all members of the included birth cohorts would be living evaluable
participants.  For all other tribes it was assumed that a total of 1000 living evaluable participants would be
available. This constitutes perhaps quite an overestimate of the number of participants, given the relatively
small size of several of the tribes. 
Based on these assumptions, sample sizes and dose distributions for a Native American study
based on the 1940 – 1946 birth year cohorts for all nine tribes were projected, and the resulting statistical
power was calculated.  For the initial scoping calculations, a sample size of 6426 living evaluable
participants was projected.  For thyroid neoplasia, assuming the same background rates as were assumed
for the planning of the Full Study, i.e., 5% for women and 2% for men, there would be only 50% power to
detect a dose-response effect of 5×10−5/mGy.  
In addition to sample size and the mean and variance of the dose distribution, power is also
influenced by the baseline probabilities of disease.  In particular, all other factors being equal, power
increases as the baseline probabilities decrease.  Therefore, the sensitivity of the estimated power to the
assumed background rates was investigated as part of the initial scoping calculations.  To provide a rather
extreme boundary for estimated power, calculations were repeated assuming that the baseline probabilities
of thyroid neoplasia in the Native American population are only half of those assumed for the Full Study
(2.5% rather than 5% for women, 1% rather than 2% for men).  Under this assumption there would still be
power of only 71% to detect an effect of 5×10−5/mGy.  Unfortunately, there are no good estimates
available of the baseline prevalence of thyroid neoplasia among the nine tribes in the Hanford region.
Thus, the assumption of one half used above is intended only to provide a wide boundary of what might be
achieved in study power.  It is not based on specific estimates of disease prevalence in the Native American
population.  
In summary, initial sample size and power calculations were carried out based on data provided by
eight of the nine tribes under consideration.  It is presumed that these data reflect lifestyle patterns and
practices specific to each tribe, and that therefore the representative dose estimates more accurately
approximate the dose members of each tribe would have likely received from Hanford than earlier
estimates.  Similarly, it is presumed the demographic data provide a reasonably accurate estimate of the
size and demographic makeup of each tribe around the time of the Hanford releases.  The five assumptions
described above that form the basis for the scoping calculations are deliberately non-conservative.  Within
a reasonable framework, they are intended to err in the direction of overestimating possible doses, variance
of doses, numbers of available participants, and members of participating tribes.  Even under such extreme
assumptions, a study nearly double in size as the HTDS Full Study (6426 living evaluable participants)
would have only 50% power to detect an effect of the magnitude considered scientifically sound.  Even
under the more extreme assumption that the baseline probabilities for thyroid neoplasia are only half of
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those assumed in the Full Study, a study of 6426 living evaluable participants would only have 71% power
to detect the same magnitude of effect. 
Based on these results, the HTDS investigators recommended that it was not feasible, nor
scientifically justified, to undertake a study of the same design as the Full Study (i.e., a retrospective cohort
study).  Such a study would require more than 6400 living evaluable Native American participants, and
would have at most 50% power to detect a dose-response effect of 5x10-5/mGy for thyroid neoplasia. 
B. Coordination with the Advisory Committee
In June of 1990, an Advisory Committee was appointed by the Secretary of the Department of
Health and Human Services to advise and consult with the CDC regarding the design and conduct of the
study.  The committee was established pursuant to the Federal Advisory Committee Act, 5 U.S.C.
(Appendix 2).  The role of the committee was to review the development of the study protocol and conduct
of the Pilot Study, assist in determining the feasibility and design of a full-scale epidemiologic study, and
advise the CDC on the analysis of the study data.
The committee was to be made up of seven scientific and lay members representing different areas
of expertise or knowledge.  The original members appointed to the committee were: 1) Mr. Lou Stone,
representing Native Americans; 2) Dr. Owen Hoffman, Ph.D., representing expertise in Radiation Science;
3) Dr. Genevieve Matanowski, M.D., Dr. P.H., representing expertise in Epidemiology; 4) Mr. Jim Thomas
of the Hanford Education Action League, representing environmental organizations in the Pacific
Northwest; 5) Dr. Arthur Schneider, M.D., representing expertise in thyroid disease; 6) Ms. Christine
Holmes, representing the people of Washington State; and 7) Dr. Larry Jecha, M.D., Health Officer for
Benton-Franklin Counties, ad hoc member.  The first meeting was held in Atlanta, Georgia in March 1991.
Dr. Jecha was appointed Chairman by the CDC.
Prior to the first meeting, Ms. Holmes notified the CDC that she would be unable to participate as
a member of the committee.  Her position was replaced with Ms. Kristine Gebbie, Secretary of Health for
the State of Washington.  Due to concern that the affected population might not be adequately represented
by a state official, the committee requested a consultant position be added to the committee.  This would be
a non-voting member familiar with the concerns of those who felt their health had been affected by
radiation from Hanford.  Ms. Pamela Hoefer, R.N., of the Hanford Downwinders Coalition was selected to
fill this position.  Ms. Hoefer attended meetings from March 1992 to February 1993.
Over the course of the study, several individuals were replaced as their term of service expired,
Dr. Maureen Hatch (epidemiology) replaced Dr. Matanowski in August 1995, Dr. Marlene McKetty
(dosimetry) replaced Dr. Hoffman in August 1995, and Ms. Elizabeth Ward (State of Washington)
replaced Secretary Gebbie in August 1995.  Ms. Judith Jurji replaced Ms. Hoefer in October 1993 as a
consultant to the Committee representing the Hanford Downwinders Coalition.
Initially, meetings of the committee were to be held on a quarterly basis in Atlanta.  In recognition
of the interest in the Pacific Northwest in such proceedings, however, the committee asked that at least one
meeting per year be held in Washington State.  Following completion of the Pilot Study, meeting
frequency was reduced to approximately once per year, with the majority of these held in Seattle,
Washington.
Meetings of the Advisory Committee were uniformly open to the public.  All materials presented
to the committee became public record, with copies available for members of the public at the meetings.
Time for public comment and questions was allowed in each meeting’s agenda.  In addition, meetings held
in Washington State were usually accompanied by an evening Public Meeting to allow members of the
public to attend and ask questions regarding the study.
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Each meeting of the Advisory Committee began with an update on the progress of the study since
the previous meeting.  These presentations included the status of preparations for the field work, or later,
the numbers of study participants completing each phase of the study.   Updates on the separate work
concerning Native American populations were also included.  In addition to monitoring ongoing
operations, the Committee focused most of its attention on the following items: 1) review and approval of
the initial study protocol; 2) review of the Pilot Study Final Report and recommendations to move forward
with a Full Study; 3) development of guidelines for assessing the feasibility of a study of Native American
populations; 4) review of the Analysis Plan for the Full Study; and 5) review of the Communications Plan
for the Full Study.
C. Public Information
An important aspect of this research was the provision of prompt, accurate, and complete
information to the public.  In this context it was crucial that contacts be established with members of the
populations most interested in (and potentially affected by) the work.  Interested parties included
representatives of the States of Washington, Oregon, and Idaho, the Native American Tribes and Nations
in the study areas, and local area residents. 
The public information activities of the study were designed to accomplish the following goals:
1. To assure that residents of the region understood the issues that led to the initiation of the study, the
purpose and objectives of the study, its basic epidemiologic design, and the time schedule within
which it was to be conducted.
 
2. To provide opportunities for the public to express concerns and comments regarding the design and
conduct of the study, and to answer public questions regarding all aspects of the project.
3. To create public interest and support for the study, particularly in ways that might enhance
participation by persons selected to be study participants.
 
4. To assure broad dissemination and proper interpretation of final study results.
Although all members of the Study Management Team fully expected to contribute in an effort to
keep the public informed and to answer questions, Dr. Scott Davis assumed primary responsibility for
coordinating such activities.  An important initial step in the overall approach was to establish contact with
counterparts on the TSP responsible for public information activities (the Communications Subcommittee,
chaired by Ms. Mary Lou Blazek).  Thus, while the HEDR Project was still underway, the two projects
coordinated their efforts to keep the public as well as agencies of the states and Native American Tribes
and Nations well informed regarding the planning and the progress of the study.   This process was greatly
facilitated by the fact that one of the HTDS investigators, Dr. Kenneth Kopecky, was also a member of the
TSP and served on the Communications Subcommittee.
Throughout the HTDS, and particularly in its early phases, the SMT participated in public
meetings held during the bimonthly meetings of the TSP, and contributed to the planning activities of the
Communications subcommittee of the TSP.  Members of the SMT, or the Project Manager, attended each
TSP meeting. In addition, a member of the HTDS staff attended all meetings of the Communications
Subcommittee.  In an effort to work more extensively with the TSP in the area of providing public
information, at least one member of the SMT was present whenever possible at all TSP-sponsored public
meetings and workshops.  The HTDS also supplied the TSP with a Fact Sheet that was included with TSP
fact sheet mailings.  This written material was updated periodically as the study progressed. 
Several separate approaches were also taken to provide information to the public regarding the
HTDS.  Initially, the study protocol was made available for public review and comment prior to its
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submission to the CDC and the Advisory Committee.  In conjunction with this activity, a series of public
(town) meetings were held throughout the Northwest to discuss the protocol with the public and to answer
specific questions.  Similar public meetings were held in conjunction with meetings of the Advisory
Committee held in the Pacific Northwest.
In addition to the study Fact Sheet mentioned above, several study brochures were developed and
a newsletter describing the progress and status of the study was initiated.  A master mailing list, which
included the lists previously maintained by the FHCRC, the CDC, and the HEDR Project was assembled to
mail the newsletter and brochures to interested individuals.  
Finally, study investigators and staff were available to answer questions on a regular basis.  A
phone line was designated in the Seattle study office for public inquiries, and a toll-free telephone number
was established at the Fred Hutchinson Cancer Research Center for the Hanford Thyroid Disease Study (1-
800-638-HTDS).  Persons selected as study participants were encouraged to use the toll-free number to
contact the study office if they had questions or scheduling conflicts.  The toll-free number was also made
available to the general public so that anyone with questions or comments could easily contact the study.
As access to the World Wide Web via the internet became more common, a web site for the study was
established at the FHCRC.  All study brochures and newsletters have been available at that site since
January 1997, and are updated as appropriate.  Links to the FHCRC, Centers for Disease Control and
Prevention, and Hanford Health Information Network sites have been established.  The HTDS web site can
be accessed at http://www.fhcrc.org/science/phs/htds.
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VIII. STATISTICAL METHODS
A. General Approach
A.1. Objectives of the Statistical Analysis
The primary objective of the HTDS was to determine whether thyroid disease has been increased
among persons exposed to radioactive iodine released from the Hanford Nuclear Site between 1944 and
1957 (see section III above).  To meet this overall objective, the statistical analysis had the following three
specific objectives:
1. To estimate, and test the statistical significance of, exposure-response relationships between various
thyroid disease outcomes (and other outcome and response variables) and measures of exposure (dose)
to radioactive iodine from Hanford.
2. To identify and analyze the effects on these dose-response relationships of any confounding or effect-
modifying factors.
3. To investigate, to the extent possible, the shapes of any dose-response relationships that are found.  
These specific objectives are discussed in more detail in the following three sections.
A.1.a. Estimation and Testing of Dose-Response Relationships
The primary analyses of this study examined dose-response relationships for the following
response variables:
1. Thyroid disease outcomes
• Thyroid cancer
• Benign thyroid nodule
• Thyroid neoplasia
• Any thyroid nodule (benign, malignant, or suspicious for follicular neoplasm)
• Hypothyroidism
• Autoimmune thyroiditis (Hashimoto’s thyroiditis)
• Graves disease
• Autoimmune thyroid disease (i.e., Hashimoto’s and/or Graves)
• Hyperthyroidism
• Multinodular thyroid gland
• Simple goiter
• Other thyroid disease
2. Other outcome variables
• Hyperparathyroidism
• Ultrasound-detected abnormalities of the thyroid (thyroid UDAs)
3. Other response variables
• Thyroid stimulating hormone (TSH)
• Total thyroxine (T4)
• Triiodothyronine resin uptake (T3RU)
• Free thyroxine index (FTI)
• Anti-thyroid anti-microsomal antibody (AMA) or anti-thyroid peroxidase antibody (anti-TPO)
• Anti-thyroglobulin antibody (anti-TG)
• Thyroid mass
• Serum calcium
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The list of thyroid disease outcomes was comprehensive since the objective (“to determine
whether thyroid disease is increased ...”) included all thyroid diseases.  Therefore it included thyroid
diseases for which associations with ionizing radiation have been reported in other settings (thyroid cancer,
any thyroid nodule, autoimmune thyroiditis, and hypothyroidism (see section II.B above), as well as other
diseases for which associations have not been reported.  In view of the public concern about possible
unanticipated effects of exposure to 131I from Hanford, and of the Congressional mandate that the study
address thyroid morbidity, the exposure-outcome relationship was analyzed and reported separately for
each of the outcomes listed above. While the various outcomes can be distinguished in terms of the
quantity and strength of the existing evidence for association with exposure to 131I, such distinction played
no role in determining how or how extensively the various outcomes were analyzed.  Similarly, while the
outcomes might be distinguished in terms of severity of impact on a person’s life, the same level of effort
was expended to assess each diagnostic outcome and its relationship to 131I exposure.
In the primary dose-response analyses, the exposure for each individual was represented by the
estimated radiation dose to the thyroid from 131I, as calculated using the CIDER program created by the
Hanford Environmental Dose Reconstruction Project.  CIDER calculates a dose estimate only if the
participant resided within the 246-by-306 mile HEDR geographical domain after December 25, 1944(129,
130). Therefore ad hoc estimates of the thyroid dose were used for study participants for whom CIDER did
not produce a dose estimate; see section VIII.C.1.a.3 below for further details.
The primary dose-response analyses for disease outcomes were based on regression models in
which the probability of having the outcome of interest varies as a linear function of thyroid dose.  In
particular, this primary model permitted background probability of the outcome (i.e., the intercept
parameter) to depend on sex, but assumed a common regression coefficient (slope) for dose.  The
regression coefficient can be interpreted as the change in the probability of the disease outcome, per unit
change in dose.  So, for example, a slope of 0.005 per Gy indicates that the probability increases by 0.005
(i.e., five per thousand or 0.5 percentage points) for each dose increase of 1 Gy and a slope of 0 per Gy
indicates that the probability does not change with dose.  Estimation of the dose-response relationship was
accomplished by estimating the slope of this stratified linear dose-response model.  Since the purpose of
the study was to determine whether thyroid disease has been increased, significance testing focused on the
null hypothesis that the probability of having the outcome of interest does not vary with dose (i.e., that the
slope has value zero) and the one-sided alternative hypothesis that the probability increases with increasing
dose (i.e., that the slope is greater than zero).  Analogous approaches were taken for the other response
variables (TSH, etc.).  See section VIII.C.2 below for more details.
One problem that arises in using a linear probability model is the following: if the slope is greater
than 0 (or less than 0), then for sufficiently large doses the model will yield probabilities greater than 1 (or
less than 0), which are not permissible values.  This could present a practical problem for disease outcomes
with low background rates, since slightly negative slopes might imply disease probabilities less than 0 for
doses with the range that occurred among study participants.  As discussed further below, other models for
the dose-response relationship were examined as alternatives to the linear model.  One of these, the logistic
model (described in section VIII.C.2), has the practical advantage that the probabilities derived from it are
always greater than 0 and less than 1, regardless of the values of the intercepts, regression coefficient or
dose.  Therefore the logistic model was employed not only as an alternative to the primary linear model,
but also for more detailed investigation of the influences of other factors on the radiation dose-response.
A.1.b. Confounding and Effect Modification
The relationship between disease risk and a possible risk factor such as radiation exposure is said
to be “confounded” if both the risk of disease and exposure are correlated with some other factor, called a
confounding factor or simply a confounder.  If the presence of confounding is ignored, an epidemiological
study can produce erroneous results.  Suppose, for purposes of illustration, that smokers received higher
doses from Hanford’s 131I than nonsmokers, and that smoking itself increases the risk of thyroid disease. 
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Finally suppose, also for this example, that disease risk is unrelated to radiation exposure.  Then if a study
simply examined the relationship between thyroid disease and radiation dose without accounting for
smoking, it might erroneously conclude that disease risk is higher among people more heavily exposed to
radiation compared to those with less exposure, because the former group included more smokers.
Confounding can also cause a study to conclude erroneously that there is no association between an
outcome and an exposure that in fact increases risk of the outcome.  The potential problem of confounding
can be addressed in epidemiological studies by performing analyses that adjust for the effects of possible
confounders.
Effect modification occurs when the association between disease risk and the exposure of interest
differs according to a third factor, called the “effect modifier.”  For example, an association between risk of
a certain thyroid disease outcome and radiation exposure might occur only among women, but not among
men.  In that situation, sex would modify the radiation effect.
Identification and analysis of confounding and effect modifying factors was accomplished through
the analysis of generalizations of the logistic dose-response models mentioned above.  For disease
outcomes, these generalizations allowed the background probabilities of the outcome of interest (i.e., the
intercept parameters) and/or the regression parameters to vary as functions of factors in the following
categories:
• Sex
• Age at first exposure to 131I from Hanford
• Age at HTDS examination
• Ethnicity
• Smoking
• Other radiation exposure to the thyroid (occupational, medical, dental, fallout from the Nevada
Test Site)
In addition, the source of each participant's dosimetry data, i.e., the CATI or the Expanded In-
Person Interview, was included among the potential confounding or effect modifying factors.
A.1.c. Shape of Dose-Response Relationships
Investigation of the shapes of dose-response relationships was accomplished through the analysis
of generalizations of and alternatives to the primary linear dose-response model, including linear-quadratic
and logistic models.
A.2. Estimation and Significance Testing 
In drawing inferences about dose-response relationships, two general statistical approaches may
be considered: estimation and significance testing.  These two approaches are largely complementary, each
providing useful information that the other does not, and each is needed to meet the study’s overall
objective.  Therefore both approaches were employed in reporting results of the HTDS.  Regarding
Objective 1, for example, regression coefficients that represented how each response variable listed in
section VIII.A.1.a above changes in relationship to the 131I radiation dose to the thyroid were estimated.
These estimates included confidence intervals, which serve to characterize how precisely the true values of
the coefficients were likely to have been estimated.  In addition, however, significance tests were
performed.  The one-sided p-values produced by these tests indicated the degree to which the study results
were inconsistent with, and therefore evidence against, the null hypotheses that the outcomes are not
associated with dose.  Thus the two approaches together provided estimates of the magnitude of any
radiation effects, and measures of the strength of evidence against the null hypotheses of no association.
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B. Definitions of Variables
The kinds of data that were collected and the analyses that were performed for the study can be
divided into three categories:
1. Process information.  This includes descriptive analyses regarding the numbers of persons selected, the
success rates of the various steps in locating and recruiting those persons, and in completion of the
study’s various data collection activities.
2. Characteristics of living evaluable participants.  This includes descriptive analyses regarding
demographic variables, as well as characteristics used for the calculation of dose estimates, and
information about possible occupational and medical exposures to radiation.
3. Analyses of exposures and outcomes.  This includes descriptive analyses of the distributions of
radiation dose to the thyroid and of frequencies of disease outcomes and other response variables, as
well as the inferential analyses of the radiation dose-response relationships, including analyses of dose
effect modification and confounding, and of the effect of uncertainty in the dose estimates.
B.1. Process Information
HTDS used computerized tracing and tracking systems to monitor the progress of the 5199
selected persons through the study’s various steps of identification and location (tracing), and contacting,
recruitment, and study participation (tracking).  At the end of data collection, these systems contained
information about the outcomes of the various steps for each selected person.  This information was used to
describe the success rates of the various steps, and to search for possible sources of bias that might affect
the estimated dose-response relationships.  The following variables were obtained from the tracing and
tracking data:
B.1.a. Stratification Factors
Stratification factors included sex, year of birth, and mother’s usual place of residence
(“geostratum”), as recorded on the selected person’s birth certificate.  From the tracing, recruiting and
interviewing activities of this study, it was noted that the sex or birth year data were incorrect for a small
number of selected persons.  The resulting corrections were not made in the stratification data (since there
was less or no possibility of detecting such errors for persons who were not located or not interviewed);
corrected sex and year of birth data were recorded in separate data files.  All analyses involving sex and
birth year in this report are based on the corrected data, unless specifically indicated otherwise.
B.1.b. Tracing Outcome  
At the end of the tracing component of the study, each of the 5199 selected persons was
categorized as not located; located, deceased; or located, alive.
B.1.c. Cause of Death
For all selected persons who were found to be deceased when located, or who were located alive
but died prior to meeting the criteria that define a living evaluable participant, death certificates were
sought, and the causes of death abstracted.  The causes were categorized, taking into account the need to
identify conditions related to thyroid or parathyroid disease.  In addition, the primary cause of death for
each deceased cohort member for whom a cause of death was identified was coded using the International
Classification of Diseases, 9th Revision (ICD9-CM).  For deaths prior to 1979, (when ICD9-CM was
implemented) the primary cause of death was also coded to the system in use at that time.
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B.1.d. Contacting Outcomes
At the end of the recruiting component of the study, each person who was located alive was
categorized as to whether or not he or she could be contacted by telephone call from the HTDS recruiting
staff.
B.1.e. Recruiting Outcomes
At the end of the recruiting component of the study, each contacted person was categorized
according to the outcome of the recruiting effort, as either agreed to participate, refused to participate, or
lost to contact without agreeing or refusing.  Those who agreed or refused were also classified according to
whether they agreed or refused on the initial recruiting attempt or after recontacting.  Those who failed to
decide whether or not to participate by the end of the recruiting period or who initially agreed to participate
but subsequently withdrew that agreement were counted as having refused.
B.1.f. Dosimetry Data Collection
Data for dose estimation were collected from two sources.  The preferred source of data was the
Computer Assisted Telephone Interview (CATI); (see section V.D above, and HTDS Protocol, Appendix
1) of one or more persons with direct knowledge of the participant’s infancy and childhood and, for
participants born after mid-December, 1994, the participant’s mother’s pregnancy.  In some cases,
however, no suitable and willing CATI respondent could be identified, or the information from the CATI
was judged to be unreliable.  In such cases, the dosimetry information was collected from the participant by
means of an expanded version of the In-Person Interview (Exp-IPI) conducted during his or her clinic visit.
At the end of the CATI and clinic components of the study, each person who agreed to participate was
categorized according to:  1) whether or not a CATI was completed; and 2) whether or not an Exp-IPI was
performed.  Persons for whom a CATI was performed were also categorized according to the relationship
of the primary CATI respondent to the subject of the interview: birth mother, adoptive mother, father,
sister, brother, aunt, uncle, other relative, or other.  In some instances, CATI data were collected but not
used for dose estimation, or CATI and Exp-IPI data were combined (e.g., for participants for whom the
CATI was judged inadequate).  For purposes of analysis, the participants were classified according to the
source of their dosimetry data: CATI versus Exp-IPI.
The CATI included information about the Interviewer’s assessment of quality of responses.  This
information was collected at several points during the interview: following sections concerning sources of
milk, the mother’s milk consumption and dietary history (if applicable, i.e., if the participant was born after
December 15, 1944), the participant’s milk consumption and dietary history, the mother’s medical history,
and the participant’s medical history; and after completion of the entire interview.  At each of these points
the Interviewer recorded his or her subjective assessment of the quality of the responses (high, generally
reliable, questionable, or unreliable).  If the quality was rated unreliable or questionable, the Interviewer
also recorded his or her subjective assessment of the main reason (unclear memory of events, uncertain
understanding of questions, hurried responses, or other).  In addition, following the sections concerning the
participant’s milk consumption and dietary history and the participant’s medical history, the Interviewer
recorded his or her subjective assessment of how often explanatory text was repeated (very often, often,
not often).  At the end of the CATI the Interviewer recorded his or her subjective assessment of the
respondent’s cooperation (very good, good, fair, poor).
The Exp-IPI included much more limited information about the Interviewer’s assessment of
interview quality.  At the end of the interview, the Interviewer recorded his or her subjective assessments
of the respondent’s cooperation and the quality of responses (using the categories defined above).  In
addition, for interviews rated unreliable or questionable, the Interviewer recorded his or her subjective
assessment of the main reason for this rating in narrative form.  These narrative answers were classified
into the categories defined above for the CATI.
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B.1.g. Clinic Participation
Each person who agreed to participate was categorized according to whether or not he or she
attended a clinic.  Participants (i.e., persons who attended a clinic) were also classified according to
whether each of the clinical components was completed: In-Person Interview, ultrasound examination,
radiologist review of ultrasound examination, blood draw, thyroid function tests, and physical examination
of the thyroid.  For participants who received the physical examination of the thyroid, the number of
examining physicians, one or two, was recorded.  In addition, for participants recommended to have a fine
needle aspiration, thyroid scan, or other follow-up for diagnosis of thyroid or parathyroid disease, the
results of those procedures were also recorded.
B.1.h. Requests for Medical Records or Slides
Each request for medical records or slides was classified according to the type of request: past
medical records, past pathology slides, post-clinic medical records, and post-clinic pathology slides.  The
“post-clinic” requests refer to records or slides that were created after the participant’s clinic visit and as a
result of an HTDS recommendation for further evaluation.  In addition, each request was classified
according to outcome: requested materials received versus not received.  For each living evaluable
participant the number of requests of each of the four types was recorded, along with the corresponding
numbers of requests for which materials were received.
B.2. Characteristics of Living Evaluable Participants
B.2.a. Demographic Data
The following demographic variables were obtained from the tracking system and interview
results: sex (corrected), year of birth (corrected), age at HTDS examination, race/ethnicity, religious
preference.
B.2.b. Residence History
A residence history is a description of the places a person has lived, and of the dates he or she
lived at each place.  Residence histories for study participants ranged from the very simple (e.g., a single
residence throughout the entire period) to the very complex (e.g., dozens of residences during the period).
For each living evaluable participant, the number of residences in the HEDR domain and the duration of
residence in the HEDR domain during the period of interest (December 1944 through December 1957)
were determined from the CATI or Exp-IPI as appropriate.  Note that some living evaluable participants
who were born and moved away from the domain before December 15, 1944 had no residences within the
HEDR geographic domain during the time period of interest.  These participants, designated out-of-area
participants, were not excluded from the study.
B.2.c. Dosimetric Data
Dosimetric data includes the information (other than residence history) that is used to calculate an
individual’s estimated dose, such as the consumption levels and sources of milk and food products.  Most
of the data used for calculating dose estimates has the characteristic of varying over time.  Key
determinants of the radiation dose to the thyroid, such as sources of food products and quantities
consumed, are subject to change at unpredictable points in time and cannot be characterized by single
numerical or categorical variables.  
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For participants with CATIs as the source of dosimetry data, the participant’s consumption levels
of the following milk and food products were recorded: processed cow’s milk, raw cow’s milk, the total of
processed and raw cow’s milk, processed goat’s milk, raw goat’s milk, the total of processed and raw
goat’s milk, fresh fruit, fresh green and leafy vegetables, and eggs from free range chickens.  The milk
consumption values were reported in the units of grams and 8 ounce servings per day; fruit and vegetable
consumption were reported in grams per day; and egg consumption was recorded in grams per days and
eggs per week (0, 1, 2, 3, 4-6, 7, > 7).
For participants born or breast-fed after December 14, 1944, the CATI included questions about
the mother’s sources and consumption of milk and other food products.  These were used to record the
mother’s consumption levels of the following for the period from December 15, 1944 until the participant’s
birth or end of breast-feeding as appropriate: processed cow’s milk, raw cow’s milk, the total of processed
and raw cow’s milk, processed goat’s milk, raw goat’s milk, the total of processed and raw goat’s milk,
fresh fruit, fresh green and leafy vegetables, and eggs from free range chickens.
For descriptive purposes, consumption data for milk and food products from the CATI was
summarized in two ways.  The first way was used to show how consumption levels changed with age: each
participant’s consumption of a particular milk or food product was reported for any of the following dates
that fell within the period of interest (December, 1944 through December, 1957): the six-month
anniversary of the participant’s birth, and each of his or her first through 15th birthdays.  
 The second summary of consumption data was used to examine how overall milk and milk
product consumption levels were correlated with estimated thyroid radiation dose.  To calculate each
participant’s average consumption level, his or her reported total number of 8 oz. servings for a particular
type of milk was first calculated by integrating the reported consumption levels over the time periods for
which the CATI respondent reported consumption levels of that milk.  For example, if a CATI respondent
reported that a participant consumed three 8 oz. servings per day over a period of 2 years, the total
consumption was 3 × 2 × 365 = 2190 8 oz. servings for that period.  For these calculations participants
born in 1946 were assigned milk consumption values of 0 for 1945.  Also participants in the 1940-1945
birth strata who never lived inside the HEDR domain during 1945 were assigned consumption levels of 0
for 1945.  If the consumption level for a particular type of milk was unknown for any or all of the time
period in question (because the CATI respondent could not report the quantity of glasses consumed), the
total consumption was considered unknown for these calculations.  Two measures of average consumption
were calculated.  The first, designated “Average No. of 8 oz. servings per day,” was obtained by dividing
the reported total number of 8 oz. servings for a given time period by the duration of that period in days
(e.g., by 365 for average consumption during 1945).  The second measure of average consumption,
designated “Average No. of 8 oz. servings per in-area day,” used a different divisor: the number of days
during the period for which (1) the participant lived within the HEDR domain and (2) the level of milk
consumption was reported in the participant’s CATI.  Average consumption levels were calculated for two
time periods:  (1) 1945, the year in which by far the largest amount of 131I was released from Hanford (see
section IV.A.2 above), and (2) the entire period 1944-1957. 
 
 
 B.2.d. Age at Exposure 
 
 Age at exposure to 131I may be a particularly important effect-modifying factor: exposure at
younger ages may produce a greater increase in risk of subsequent thyroid neoplasia, and perhaps of other
outcomes, compared to exposure at older ages.  An assumption of such age dependence is built into the
NCRP risk estimates for thyroid carcinogenesis induced by exposure to radioiodine (36).  However this
assumption relies heavily on extrapolation from human studies of other kinds of radiation exposure, and on
animal studies.  Therefore particular attention was paid to analyzing the effect of age at exposure.
Unfortunately, age at exposure was not simply defined for this study, since most participants’ exposures to
131I from Hanford occurred over a protracted period of time, and therefore over a range of ages.  Therefore
age at first exposure was examined as the possible effect-modifying factor.
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For calculating age at first exposure to 131I from Hanford, the definition of age was generalized
from its usual definition to include negative values representing gestational ages, extending from birth back
to gestational age 90 days (about −0.5 years), the age at which thyroid function is assumed to begin in the
HEDR model (126).  Similarly, the definition of a participant’s residence was generalized to include the
participant’s mother’s residence during the participant’s gestation from age −0.75 to 0 (birth).  With these
conventions, age at first exposure was defined as the maximum of −0.75, age on December 15, 1944, and
age when the participant first resided in the HEDR geographical domain.
B.2.e. Medical and Dental Radiation Exposure History of Participant
For participants with CATIs as the source of dosimetry data, information about medical and dental
radiation exposures was obtained by combining data from the CATI and In-Person Interviews; otherwise
the information was obtained from the In-Person Interview alone.  For descriptive purposes, each living
evaluable participant was classified according to whether or not he or she had a history of each of a number
of diagnostic radiation procedures: CAT scan of the upper body, diagnostic x-ray of the head, diagnostic
x-ray of the neck, diagnostic x-ray of the chest or upper body (including mammograms), diagnostic x-ray
of the stomach or mid-back, barium enema, upper GI, intravenous pyelogram, fluoroscopy of the upper
body, thyroid nuclear scan, and other nuclear scan.  Participants were also classified according to whether
they had a history of the following types of radiation treatment: radiation treatment for any cancer other
than thyroid cancer, x-ray treatment to the upper body for acne, x-ray treatment for ringworm, x-ray
treatment for enlarged tonsils, x-ray treatment to the upper body for tuberculosis, x-ray treatment for scalp
infection, x-ray treatment for enlarged thymus, and x-ray treatment to the upper body for any other reason.
Finally, participants were classified according to whether they ever had routine dental x-rays, ever had
routine dental x-rays more than once per year, and ever had dental x-rays that did not usually include
shielding of the neck area.
B.2.f. Occupational History
The In-Person Interview included questions about employment in a number of industries or
occupations that might involve exposure to ionizing radiation.  For descriptive purposes, each living
evaluable participant was classified according to whether or not he or she had ever worked in each of the
following industries and occupations: geology; metallurgy; metal processing; ore refining; mining; nuclear
industry; on the premises of a nuclear facility; health care with exposure to radioactive materials or x-rays;
scientist, researcher or student with exposure to radioactive materials or x-rays; military working around
nuclear testing, nuclear submarines or other radiation exposure; any other industry or occupation that might
have caused exposure to radioactive materials or x-rays.
B.2.g. Smoking History
Information about smoking histories was obtained from the In-Person Interview.  Participants
were categorized according to history of ever smoking each of filtered cigarettes, nonfiltered cigarettes,
any cigarettes, cigars, or pipe.  In addition, for those who reported ever smoking a particular product, the
level of use of that product was quantified in terms of cigarette pack-years (average number of 20-cigarette
packs per day times number of years cigarettes smoked), cigar-years (average number of cigars per day
times number of years cigars smoked), and pipe-years (average number of bowls per day times number of
years pipes smoked) as appropriate.
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131 B.2.h. Exposure to I from the Nevada Test Site
 Information released by the U.S. National Cancer Institute (NCI) in 1997 (131), indicated that
persons living in the contiguous 48 states during the 1950s and 1960s were exposed to various levels of 131I
released from the Nevada Test Site (NTS).  The information released by NCI included estimates of dose
for representative individuals in all counties in the 48 states, as well as more detailed data regarding
estimated dose by shot (i.e., by individual test detonation), county, and age.  Limited preliminary
comparisons for HTDS participants suggested that in many cases the reported NTS dose estimates were
comparable to or even greater than the estimated Hanford doses.  Therefore it was judged necessary to add
exposure to 131I from the NTS to the list of potential confounding factors.
 
 For HTDS, the “estimated NTS dose” was defined as the thyroid dose from 131I entering the
atmosphere from tests conducted at NTS between 1951 and 1957, inclusive, as estimated from data made
publicly available by NCI.  The limitation to tests conducted through 1957 was based on two
considerations:  1) although NCI reported exposures through 1972, it was estimated that 99% of the 131I
was released from 90 tests conducted between 1952 and 1957, and 2) HTDS collected complete residence
histories for all living evaluable participants only through 1957, including residences outside the HEDR
domain.  Each living evaluable participant’s estimated NTS dose was calculated as the total of doses from
all 57 shots at the NTS between 1951 and 1957.  HTDS staff wrote computer code to accumulate for each
participant, the estimated thyroid dose from each shot taking into account the participant’s residence
history.
 
B.3. Analyses of Exposures and Outcomes
B.3.a. Exposure Data
The primary analyses of dose-response relationships were based on individual estimates of
radiation dose to the thyroid, specifically organ doses to the thyroid which were estimated from the
residence history and dosimetric data collected during the CATI and/or Exp-IPI.  The participants were
divided into two categories regarding dose estimates:
• The first category, and by far the largest, includes the participants who lived at some time between
December 15, 1944, and December 31, 1957, in the geographical domain defined by the Hanford
Environmental Dose Reconstruction Project.  Doses for these participants were calculated using the
CIDER program, which was created by the HEDR Project.  These are designated in-area
participants.
• The second category consists of persons who never resided within the HEDR domain between
December 15, 1944, and December 31, 1957.  The CIDER program does not provide dose estimates
for these participants.  These are designated out-of-area participants.
 
 The dose estimates produced by CIDER for the in-area participants were derived from
information collected during the CATI and/or Exp-IPI. After review and editing, these data were formatted
into scenario files that served as input to the CIDER program (132).  The CIDER output for each in-area
participant consisted of 100 realizations of the estimated cumulative total organ dose to the thyroid from
131I, as well as corresponding sets of realizations of dose by year and by pathway.  The CATI and Exp-IPI
also included a short series of questions meant to elicit the respondent’s level of knowledge and opinions
regarding thyroid disease, radiation, and Hanford, which were used to investigate the possibility of recall
bias.
 
It is im portant to recognize that in the CIDER program each of the 100 realizations of dose is
calculated for a fixed set of conditions regarding the source term and environmental transport, and that
these conditions for a given realization were the same for every participant.  The 100 realizations were
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obtained by randomly varying the conditions, i.e., the uncertain parameters in the HEDR models for source
term, transport, etc., in order to characterize the uncertainty in the resulting dose estimates (16).  Thus it is
useful to view each realization as consisting of a set of doses, one for each in-area participant.  This can be
illustrated by the following table, in which the k-th realization of dose for the i-th participant (i = 1, …, N)
is denoted Di,k, where N is the number of living evaluable in-area participants.
 
 Table VIII.B-1. Schematic Illustration of Dose Realizations
 
  Realization
 Participant  1  2  …  100
 1  D1,1  D1,2  …  D1,100
 2  D2,1  D2,2  …  D2,100
 …  …  …  …  …
 N  DN,1  DN,2  …  DN,100
 
 
 Each column in this table, i.e., each realization {D1,k, … , DN,k}, is a set of doses which are
consistent in the sense that they were all calculated under the same conditions.  For example, the amounts
of 131I released into the air (the “source term”) will be higher in some realizations and lower in others.  This
variability is likely to induce a corresponding variation in dose estimates: realizations with higher or lower
source terms may tend to produce higher or lower dose estimates, respectively, for many participants.  As a
result, the dose estimates of different participants may tend to be correlated across the 100 realizations.
Some components of the dosimetry model, for example those subject to the constraint of mass balancing,
may introduce negative correlations.  Consider the example of atmospheric transport.  For each realization
to be properly mass-balanced, if one region receives a particularly high deposition of 131I, then the
depositions in other regions may tend to be lower.  Thus estimated doses of participants exposed largely
from the depositions in the first region may tend to be negatively correlated with the doses of those
exposed to 131I deposited in other regions.
 
 In the original version of the CIDER program, the dose conversion factors (DCFs), which in
effect convert estimated amounts of 131I taken up by the thyroid (measured in Ci) into estimated dose (in
mGy or related units), were assumed to be the same for all participants in each realization.  This almost
certainly induced an unrealistically high level of positive correlation: every participants’ dose estimates
would tend to rise or fall together as the DCFs increased or decreased from realization to realization.
Therefore the CIDER program was modified to permit the realizations of DCFs to be randomly permuted
for each participant (see Appendix 22).  This was expected to greatly reduce the correlation of dose
realizations across participants.
 
 A further revision of the CIDER program allowed uncertainties to be applied to dietary input data
for CATI participants.  Incorporating this additional source of uncertainty would of course increase the
uncertainties of the resulting dose estimates.  Since the magnitudes of these uncertainties could not be
determined or estimated from the data collected for HTDS or from other sources, the revision of CIDER
allowed their magnitudes to be specified (see Appendix 22).  As described further below, this capability
was used to assess how estimates of radiation dose-response parameters were affected by the incorporation
of additional uncertainties of various plausible magnitudes.
 
For m any purposes it was useful to have a single number or “point estimate” to represent each
participant’s dose.  For each in-area participant, the median of the 100 realizations of dose, di =
median(Di,1, … , Di,100) for participant i, was used as a summary measure of that participant’s dose.  In
particular, the median doses were used for descriptive purposes that required categorization of participants
by dose.  Two other point estimates were also calculated for each in-area participant.  The first is the
geometric mean: 
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 GMi = exp(N
−1 Σkln Di,k).
 
Finally, for com parability with reported results of the Utah Thyroid Study (10479, 11425, 10139),
the arithmetic mean dose (called simply the mean dose) was also calculated:
 
 Mi = N
−1 Σk Di,k.
 For descriptive purposes, it as also useful to have summary measures of the uncertainty of dose
estimates for the in-area participants.  For use with the median doses, the ratio of the 95th percentile to the
median dose was calculated.  In addition, the geometric standard deviation (GSDi) and standard deviation
(SDi) were calculated for use with the geometric and arithmetic means, respectively:
 
 GSDi = exp([(N−1)−1 Σk(ln2 Di,k − N−1 [Σkln Di,k]2)]1/2)
 
 SDi = [(N−1)−1 Σk(D 2 −1 2 1/2i,k  − N  [Σk Di,k] )] .
 
Prelim inary analysis of doses indicated that the empirical distributions of the logarithms of the
individual participant’s doses, ln(Di,1), … , ln(Di,100), were roughly normally distributed, with variances
that changed relatively little from participant to participant.   As a result each participant’s median and
geometric mean were nearly equal.  Thus analyses of dose-response relationships were essentially
unchanged whether based on medians or geometric means.  Also, the arithmetic mean doses were roughly
a constant multiple, C, of the median or geometric mean where C > 1.  Preliminary results suggested that
the value of C will be about 1.35, i.e., that the mean doses were about 35% larger than the median or
geometric mean doses.  Since mean doses were expected to be consistently larger than geometric mean or
median doses, the estimated effects of exposure on outcomes were expected to be smaller in magnitude if
based on mean dose, compared to median or geometric mean dose. 
B.3.b. Alternative Representations of Exposure
 In addition to the individual estimates of thyroid radiation dose described above, alternative
representations of exposure to Hanford’s 131I were defined.  When the HTDS protocol was developed, the
consideration of such alternatives arose from the possibility that the HEDR project, which had not then
completed its feasibility phase, might not provide a system for calculating individual dose estimates.  Since
the HTDS did in fact develop a dosimetry system that could be adapted for HTDS use, this reason for
considering alternative characterizations of exposure became moot.  Nevertheless, alternative
characterizations remained of interest, since they could be used to assess whether there might be evidence
of a radiation effect that was not revealed in the primary dose-response analyses using individual dose
estimates from the CIDER program. Two alternative representations of exposure were considered:
geostratum and a dichotomous (high versus low) exposure variable.  Unlike the estimates of thyroid
radiation doses, which were available only for the in-area participants, both of these alternative
representations of exposure were defined for all living evaluable participants, including the out-of-area
group.  
 
B.3.b.1 Geostrata
 
 The first alternative was simply the participants’ geostrata, i.e., the nine geographical regions that
were defined for the selection of potential study participants (see section IV.A.1 above).  The rationale for
considering geostratum as an alternative representation of exposure was as follows.  The results of the
HEDR project strongly suggested that doses received by participants varied markedly according to their
places of residence, particularly during the period of highest 131I releases (130).  Since each participant’s
geostratum was his or her mother’s usual place of residence at the time of the participant’s birth, many
participants were likely to have resided in their respective geostrata for at least some of their infancy or
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childhood.  Therefore geostratum might be at least somewhat correlated with the doses study participants
received.  
 
 There are obvious limitations in using geostratum as an alternative representation of exposure.
Most importantly it fails to account for changes in residence or dietary factors that can strongly influence
the dose an individual actually received.  Therefore analyses of cumulative incidence of disease outcomes
or prevalence of thyroid UDAs in relation to geostrata were unlikely to provide conclusive evidence either
for or against an effect of 131I from Hanford.
B.3.b.2. Dichotomous Exposure Variable
 
 The second alternative was defined in such a way as to reduce the weaknesses inherent in using
geostratum as a characterization of exposure.  Specifically, an attempt was made to assign the living
evaluable participants into relatively high and low exposure groups using simple characterizations of the
residence and milk consumption histories.  The high exposure group was defined to include participants
who lived in the downwind counties closest to Hanford during 1945 and consumed appreciable quantities
of milk, while the low exposure group was defined to include participants who lived sufficiently far away
from Hanford and/or drank sufficiently small quantities of milk.  Specifically, the two groups were defined
as follows:
 
• High exposure group.  This group included all living evaluable participants born before July 2,
1945, who lived in Benton (excluding the city of Richland, but including Kennewick), Franklin
(including Pasco), or Adams County for at least 180 days during 1945, and who were reported to
consume an average of at least one 8 oz. serving of milk and milk products per day during 1945.
Since this criterion depends in part on the participant’s individual milk consumption history, only
participants with CATI data used for dose estimation could be included in this group.
 
• Low exposure group.  This group included living evaluable participants in the following
categories:
 
(i)  Out-of area participants.
 
 (ii)  In-area participants born before January 1, 1946 who lived in Ferry, Stevens, or Okanogan
County or outside the HEDR domain from December 15, 1944 or their birthdays (whichever
occurred first) through December 31, 1951.
 
 (iii) In-area participants born before January 1, 1946 who lived in Ferry, Stevens, or Okanogan
County or outside the HEDR domain from December 15, 1944 or their birthdays (whichever
occurred first) through December 31, 1945, and who lived outside Benton, Franklin and Adams
Counties from January 1, 1946 through December 31, 1951.
 
 (iv) In-area participants born before January 1, 1946 who are not in categories (i) or (ii), but who
lived outside Benton, Franklin and Adams Counties from December 15, 1944 or their birthdays
(whichever occurred first) through December 31, 1951, and who were reported to consume an
average of less than one 8 oz. serving of milk and milk products per day during 1945.  Note that
only participants with CATI data used for dose estimation could meet this criterion.
 
 (v) In-area participants born after December 31, 1945 who lived outside Benton, Franklin and
Adams Counties from birth through December 31, 1951.
 
W hile the exposure groups defined above were expected to provide a more reliable
characterization of exposure than geostratum, they could not be expected to provide a perfectly accurate
separation of high- and low-exposed participants.  For example, it could not be assured that every
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participant in the high exposure group had a higher dose from Hanford’s 131I than every participant in the
low exposure group.  The criteria above were defined to ensure a reasonable likelihood that the high and
low exposure groups consisted largely of participants with comparatively high and low doses, respectively.  
 
 The categories defined above did not include all possible circumstances, e.g., participants who
lived at least 180 days in Benton, Franklin or Adams Counties during 1945 but who were reported to
consume an average of less than one 8 oz. serving of milk and milk products per day during 1945.  Living
evaluable participants who did not meet any of the criteria above for either the high or low exposure group
were not assigned to either group, and were excluded from analyses involving the dichotomous exposure
variable.
 
 
 B.3.c. Outcome Data
 
 The outcome data for this study included the following:
 
• Diagnoses of thyroid disease and primary hyperparathyroidism
• Presence of ultrasound-detected abnormalities of the thyroid (UDAs)
• Results of thyroid function and antibody tests, thyroid volume, and serum calcium levels
 
 See section VIII.A.1 a. above for a more detailed list of outcomes, and IV.C for definitions of
outcomes.  Data for the first two categories (diagnoses of thyroid disease and hyperparathyroidism, and
ultrasound-detected abnormalities) were obtained from the Final Diagnosis Determination Form (FDDF;
Appendix 20).  Thyroid mass was obtained from the ultrasound measurements recorded by the HTDS
sonographer at the time of the clinical examination (LxWxHx.55 calculated separately for the right and left
lobes, then added together), unless revised by the radiologist.  Results of thyroid function and antibody
tests and serum calcium levels were obtained from reports provided by the laboratories performing the
analyses.
 
One di sease outcome category from the FDDF requires special comment: “thyroid nodule
suspicious for follicular neoplasm.”  This category was included on the FDDF to allow for the possibility
that diagnostic information would not permit a definitive determination of a nodule’s behavior (benign
versus malignant).  It was also used for participants who, on HTDS cytology review, were described as
having a nodule with an intermediate or high probability of being a follicular neoplasm, and who did not
have a subsequent surgery that could provide a definitive histologic diagnosis.  At the end of the data
collection period, all participants remaining in the “suspicious” category were in this latter group.  None of
these cases were suspicious for papillary carcinoma.  Most of the nodules in this group were likely to be
benign, however they could not be counted among the confirmed cases of benign nodules.   Therefore they
were included in the combined category of participants with any thyroid nodule.  In addition, they were
included along with the benign nodules in a secondary analysis to assess whether their omission might
disguise a dose-response.
 
For each participant with a di sease outcome, additional information about that outcome was
available from the FDDF, including the basis for the diagnosis and, for some outcomes, possible etiologies
or contributing causes (see Appendix 20).  Similarly, for participants with a thyroid UDA, the FDDF
included further information about the UDA.  Therefore it was important to identify a primary definition
for each outcome, as well as alternative definitions of outcome that would be considered.  The primary
definitions were intended to include cases with (1) a broad but meaningful range of specific outcome
subtypes (e.g., benign thyroid nodules of any histologic/cytologic type), and (2) an adequately definitive
basis for diagnosis (e.g., based on histologic or cytologic evidence confirmed by the HTDS evaluation).
The alternative definitions were intended to permit analysis of the effects of (1) restricting outcomes to
more specific subtypes (e.g., benign thyroid nodule excluding nonneoplastic disease, or non-iatrogenic
hyperthyroidism), and (2) changing the level of diagnostic certainty (e.g., including all diagnoses, ranging
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from those based on HTDS evaluation to those based only on participant/respondent report).  The primary
and alternative definitions of the various disease and ultrasound outcomes are given in section IV.C. 
 
 
 C. Analytic Methods
 
A variety of descriptive analyses were  performed to summarize process information,
characteristics of the living evaluable participants, and exposure and outcome data.  These analyses made
use of standard descriptive statistical techniques, primarily frequency tables and crosstabulations,
calculation of estimates of central tendency (e.g., means, medians) and dispersion (e.g., ranges, 5th and 95th
percentiles), and simple plots of standard types (e.g., bar plots, pie charts, scatter plots).
 
 
 C.1. Statistical Models for Analyses of Exposures and Outcomes
 
St andard statistical techniques were used to provide descriptions of radiation dose estimates and
outcomes.   These included the calculation of summary statistics (median, minimum, maximum, mean,
standard deviation) and cumulative distribution functions to describe distributions of estimated doses, for
presentation in tabular or graphical form.  Uncertainties of dose estimates for in-area participants were
illustrated graphically, including cumulative distribution functions of ratios of the 95th percentile to the
median dose, and of geometric standard deviations (GSD) of dose, and scatterplots of the 95th percentile-
to-median dose ratio (on the vertical axis) by median dose (horizontal axis, on logarithmic scale), and of
GSD by geometric mean dose.
 
 Summaries of outcome data were displayed in tables showing the numbers of cases and relative
frequencies for subcategories defined by, e.g., basis for diagnosis or disease subtype, for women and men
separately, and for both sexes combined.
 
 The relationships between outcomes and estimated dose were displayed in tables showing numbers of
cases within dose categories, for women and men separately and for both sexes combined.  The number of
cases in each category was also expressed as a percentage of the number of living evaluable participants in
the category.    
 
 
 C.1.a. Inferences About Dose-response Relationships: Models for Objective 1
 
As descri bed in the HTDS Protocol, Appendix H (1), the primary analysis of exposure-outcome
relationships for disease outcomes focused on the cumulative incidence of the outcome among living
evaluable participants at the time they are examined for the study.  “Cumulative incidence” referred
specifically to the proportion of participants with the outcome of interest diagnosed at any time up to and
including the HTDS examination. Thus it is most comparable to “period prevalence” as defined for the
Utah Thyroid Study (133), if it is understood that the beginning of the period of observation is the birth of
the participant.  However the term “cumulative incidence” was used for HTDS, since “period prevalence”
implies a risk period defined by uniform calendar dates for all study participants.  One basic model served
as the starting point for estimation and significance testing of the dose-response relationships for the
disease and ultrasound outcomes listed in paragraph II.B above.  This was the stratified linear probability
model:
 
 [1] Pj(d) = Aj  + B × d
 
 where 
 
j = 1, 2 i ndexes the strata defined by sex,
 d is the cumulative dose to the thyroid,
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 Pj(d) is the probability that a living evaluable participant in stratum j and with dose d has the
disease of interest,
 Aj is the background probability for participants in stratum j, i.e., the probability of the outcome in
the absence of the radiation exposure, and
 B is the regression coefficient that expresses the magnitude of the radiation effect.
 
Like disease outcom es, the presence or absence of thyroid UDA is also a binary outcome, and
model [1] is applicable.  However unlike the disease outcomes, for which diagnoses could have occurred
any time up to and including the HTDS examination, detection of thyroid UDAs was based entirely on the
HTDS examination.  Therefore for thyroid UDAs, the probability Pj(d) in model [1] refers to the
prevalence, rather than cumulative incidence. 
 
 
The regressi on coefficient B in [1] represents the slope of the dose-response.  According to the
model, the probability of disease increases with increasing dose, does not change with dose, or decreases
with increasing dose depending on whether B > 0, B = 0, or B < 0, respectively.  Suppose, for example,
that the background probability of thyroid cancer among women is A1  = 0.007.  Table VIII.C-1 illustrates
how the probability of thyroid cancer varies in relation to dose for three different values of the slope B.
 
 Table VIII.C-1. Illustration of Positive, Zero, and Negative Dose-responses
 
  Probability of Thyroid Cancer for Women (A1  = 0.007)
Dose (mGy) B = 0.025 per Gy B = 0.000 per Gy B = −0.005 per Gy
0 0.0070 0.0070 0.0070
100 0.0095 0.0070 0.0065
1000 0.0320 0.0070 0.0020
    
    
    
    
 
 
 Note that if B < 0, then for sufficiently large doses, the probability of disease will be less than or
equal to 0, especially for outcomes with low background rates.  For example, continuing the illustration
from the table above, if B = −0.005 per Gy, then for women with doses greater than 1400 mGy (1.4 Gy)
the linear probability model implies that the probability of disease is less than 0, which is impossible.
While it is almost certain that probabilities of disease outcomes do not decrease with increasing dose, the
estimate of B may be less than 0 due to the essentially random variability of disease occurrence, especially
if the true value of B is near 0.  Therefore the parameters of model [1] were estimated under the constraint
that every participant’s probability must be greater than 0.  (Estimation was similarly constrained to ensure
that every participant’s probability is less than 1, the maximum possible value for probabilities.  However
this constraint was rarely invoked since most outcomes had sufficiently low background rates.)
 
 Since the linear probability model could yield impermissible values for probabilities, e.g.,
cumulative incidence of disease or thyroid UDA prevalence less than 0 (see section VIII.A.1.a above), the
sex-stratified logistic regression model was also considered. 
 
 [2] Pj(d) = exp(Aj  + B × d) / [1 + exp(Aj  + B × d)].
 
 It should be noted that the parameters of the logistic model do not correspond directly to those of the linear
model [1].  For example, the values of the intercept parameters Aj are not the background probabilities.
Nevertheless the background probabilities can be calculated from the parameters of the logistic model:
 
 [3] Pj(0) = exp(Aj) / [1 + exp(Aj)] for j = 1, 2.
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 Although the regression coefficient B in the logistic model does not represent the slope of a linear
probability model, it can nevertheless be used in a similar way to assess the evidence for or against the
existence of a dose-response relationship.
 
 A stratified model analogous to [1] was used for laboratory values (thyroid function, antibody
tests, and serum calcium) and thyroid volume: 
 
 [4] Ej(d) = Aj  + B × d
 
 where
 
 Ej(d) is the mean of the (possibly transformed) value for living evaluable participants in stratum j
and with dose d, and
 Aj is the background mean for participants in stratum j, i.e., the mean in the absence of the
radiation exposure, and the other terms are defined as for [1].
 
 Transformation of some laboratory values (e.g., to logarithms) was expected to be appropriate
since they are bounded below by zero and likely to be right-skewed.  Analyses of TSH, T4, T3RU, and FTI
in relation to estimated thyroid radiation dose were limited to participants who were not on thyroid
hormone replacement at the time of their HTDS examination.
 
 As mentioned above, three different assays were used for TSH, and two assays for anti-thyroid
antibody.  The three TSH assays (RIA, EIA-1, and EIA-2) all measured the same quantity (serum
concentration of TSH).  Therefore for TSH model [4] was generalized to assess whether B and/or the Aj
differed among the three assays.  The situation was different for the two anti-thyroid antibody assays:
AMA and anti-TPO do not measure the same quantity.  Therefore their data were not combined, and model
[4] was fit separately to the AMA and anti-TPO data.
 
 
 C.1.a.1. Alternative Point Estimates of Dose to Thyroid from Hanford 131I 
 
 As noted above, two point estimates of each in-area participant’s dose were available in addition
to the median: the arithmetic and geometric means.  To assess the extent to which the results might be
influenced by the choice of the point estimate to represent dose, certain analyses were repeated using the
arithmetic and geometric means.  
 
 The use of arithmetic mean doses is similar to the approach taken in the analysis of the Utah
Thyroid Study (133, 134).  However it must be noted that the results of the HTDS and the Utah study are
not directly comparable, even for the analyses of neoplastic diseases, since their outcome variables differ:
the HTDS dealt with lifetime cumulative incidence through the early-to-mid 1990s, in a cohort born in the
early-to-mid 1940s; the Utah study dealt with incidence and prevalence in the late 1960s and mid 1980s, in
a cohort born from the mid-1940s to the mid-1950s. 
 
 
 C.1.a.2. Sensitivity of Results to Large Doses
 
 The distribution of doses was expected to be quite skewed, with large numbers of participants
having comparatively low doses, and small numbers having quite high doses.  Therefore, for the disease
outcomes and thyroid UDAs, analyses were performed to assess whether the regression coefficient B might
be inordinately influenced by the high dose participants.  In particular, two empirical checks were made to
assess whether the estimated regression coefficient adequately represents the dose-response relationship
over the lower dose range.  The first check consisted of fitting a linear-quadratic exposure-response model:
 
 [5] Pj(d) = Aj  + B1 × d + B2 × d2
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 If the quadratic term B2 was found to be significantly different from 0, then the estimated
regression coefficient B from the linear model [1] could be interpreted as underestimating or
overestimating the effect in the low dose range, depending on whether the estimate of B2 is negative or
positive, respectively. The second check consisted of fitting the linear model [1] with participants in high
dose categories excluded.
 
 
 C.1.a.3. Dose Estimates for Out-of-Area Participants
 
 It cannot be assumed that the out-of-area participants were unexposed to 131I from Hanford.
Indeed, results of the HTDS Pilot Study suggested that many out-of-area participants lived in locations
near the HEDR domain at various times during 1945-1957 (135).  Furthermore, results of the HEDR
project strongly imply that people living outside the domain could have received doses higher than those
for some people who lived inside the domain; see for example, Figures 6 through 8 of Farris, et al. (10493).
The following empirical approaches were taken to provide dose estimates for the out-of-area participants.
These dose estimates were used to assess the sensitivity of dose-response results to assumptions about the
doses.
 
• Out-of-area dose assumption 1: All out-of-area participants were assigned doses of 0 mGy.
• Out-of-area dose assumption 2: Each out-of-area participant who lived anywhere in Washington
State, Oregon, Idaho, Montana, British Columbia, or Alberta between December 15, 1944, and
December 31, 1957, was assigned the maximum dose for a representative child residing in the
grid square of the HEDR domain closest to any of the participant’s residences.  All other out-of-
area participants were assigned doses of 0 mGy.
The assignment of maximum doses required for assumption 2 was accomplished as follows.  The
region lying outside the HEDR domain but within Washington State, Oregon, Idaho, Montana, British
Columbia, or Alberta was divided into four subregions, each corresponding to part of the boundary of the
HEDR domain. 
• North/northeast subregion: British Columbia, Alberta, and counties in the northern halves of Idaho and
Montana, corresponding to the northern boundary and upper half of the eastern boundary of the HEDR
domain.
• Southeast subregion: The remaining counties of Montana and counties in Idaho lying north of a
boundary defined by county lines extending approximately southeast from the southeastern corner of
the HEDR domain, corresponding to the lower half of the boundary of the HEDR domain.
• South subregion: The remaining counties in Idaho, and counties in Oregon lying east of a boundary
defined by county lines extending approximately southwest from the southwestern corner of the
HEDR domain, corresponding to the southern boundary of the HEDR domain.
• West subregion: The remaining counties in Oregon, and all counties in Washington State,
corresponding to the western boundary of the HEDR domain.
The maximum estimated dose for a representative child was then calculated for each of four the
segments of the HEDR domain boundary to which the subregions correspond.  Based on a representative
child born in December 1944 with a diet of backyard cow’s milk and produce, the associated doses were
51 mGy for the north/northeast subregion, 12 mGy for the southeast subregion, 14 mGy for the south
subregion, and 8 mGy for the west subregion.
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The residence histories of the out-of-area living evaluable participants were then reviewed to
identify those who had ever lived in any of the four subregions between December 1944 and the end of
1957.  Those who had were assigned the highest dose for any subregion in which they had lived during that
period.  
 
 For each disease and thyroid UDA outcome, the sensitivity of the dose-response results to the
inclusion or exclusion of the out-of-area participants was assessed by comparing the results from the
primary analysis (which excluded the out-of-area participants) to those obtained from the following two
scoping analyses.  The linear probability model [1] was used for all of these analyses.
 
• Scoping Analysis #1: Out-of-area participants were assigned doses under assumption 1 (i.e., extremely
low doses) if they did not have the outcome of interest, and under assumption 2 (comparatively high
doses) if they did have the outcome of interest, i.e., imposing a strong positive dose-response
relationship among the out-of-area participants.
• 
• Scoping Analysis #2: Out-of-area participants were assigned doses under assumption 1 (i.e., extremely
low doses) if they had the outcome of interest, and under assumption 2 (comparatively high doses) if
they did not have the outcome of interest.  This imposed a strong negative dose-response relationship
among the out-of-area participants.
 These two scoping analyses were intended to represent a wide but plausible range of impact that
the out-of-area participants might have on the estimated dose-outcome relationships.  
 
 
 C.1.b. Inferences About Dose-response Relationships: Models for Objective 2
 
General izations of the logistic regression model [2] were examined to identify and account for
confounding and effect-modifying factors in the analyses of disease outcomes and thyroid UDAs.  These
generalizations permitted the background probabilities to depend on factors in addition to sex (e.g., year of
birth, age at HTDS examination, smoking, and other thyroid radiation exposure), and the regression
coefficient to depend on those factors as well as sex.  To model effects on the background probabilities, Aj
was replaced with an expression of the form a′x, where x is a vector with components representing the
stratification and the additional factors to be considered and a is a vector of corresponding regression
coefficients.  Similarly, to model effects on the regression coefficient (i.e., to identify effect-modifying
factors), the regression coefficient B was replaced by an expression of the form b′z, where z is a vector
with components representing the factors being considered.  
 
 
 C.1.c. Inferences About Dose-response Relationships: Models for Objective 3
 
Altern atives to model [1] were considered in order to investigate the shapes of any
exposure-response relationships that were found.  These included the logistic model [2] and the linear-
quadratic model [5] described above.
 
 
 C.1.d. Inferences About Dose-response Relationships for Numbers of UDAs
 
Additional analyses of ultrasound-detected th yroid abnormalities (thyroid UDAs) were performed
to investigate whether the average number of abnormalities above a given size might increase with
increasing radiation dose to the thyroid.  For these analyses, each participant’s number of such UDAs was
assumed to follow a Poisson distribution with mean value Mj(d) for participants in stratum j with dose d,
where
 
M j(d) = exp( Aj  + B × d ).
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 C.2. Calculational Methods for Inferential Analyses
 
No previ ous epidemiological studies have dealt with exposure data of the kind available for this
study, i.e., correlated sets of multiple realizations of estimated dose for the in-area participants; and no
specific dose estimates for an appreciable number of participants (the out-of-area group).  Two sets of
analyses were performed:
 
• The first set of analyses used single dose estimates for each living evaluable participant.  In
particular the median dose estimates (di as defined in section VIII.B.3.a above) were used as the
primary point estimate of each participant’s thyroid radiation dose from Hanford’s 131I. This
approach, which is generally analogous to that used for the main published analysis of results
from the Utah Study (134), ignored the uncertainty of the dose estimates and might therefore be
expected to introduce bias into estimation of dose-response relationships.  However this analysis
had several advantages: it corresponded to the manner in which dose-response relationships were
displayed in the tabular and graphical formats; it was analogous to analyses that have been
performed for other studies of the effects of radiation on thyroid disease; and it was expected to
provide reasonably accurate significance test results (as observed empirically [134]).
 
• The second set of analyses investigated the effects of uncertainty in the estimated doses from
Hanford’s 131I.  It was expected that this would have little impact on the results of significance
tests of dose-response relationships.
These two sets of analyses are described in more detail in the following section.
C.2.a. Analyses Ignoring Dose Uncertainties
For the analyses ignoring dose uncertainties, the primary method for calculating parameter
estimates was the method of maximum likelihood.  In addition, however, certain analyses were performed
using an alternative method, the method of least squares.  Maximum likelihood and least squares are two
generally applicable methods for estimating parameters of statistical models, including dose-response
models.  The specific implementations of these methods for HTDS are described in the following sections.
C.2.a.1. Maximum Likelihood Analyses of the Sex-stratified Linear Probability Model
Maximum likelihood estimates were calculated for the sex-stratified linear probability model [1]
for disease outcomes and thyroid UDAs.  As described in section VIII.C.1.a, the possible values of the sex-
specific background rates A1 and A2 and of the slope B are constrained by the requirement that
probabilities Pj(d) must lie between 0 and 1.  For example, if the background disease rates are low and
there are few or no cases at the high end of the dose range, the regression parameter B in [1] is likely to be
negative (e.g., B < 0).  If it is too negative, there will be some study participants whose estimated
probabilities are less than 0.  To reduce difficulties that could arise from attempting to maximize the
likelihood function under this constraint, estimation was based on the profile likelihood function.  Let
L(A1, A2, B) denote the log-likelihood function, i.e., the logarithm of the probability of the observed
outcome data given the doses and parameter values A1, A2, and B:
[7] L(A1, A2, B) = Σ i { Yi × ln[Pj(i)(d i)] + (1 − Yi ) × ln[1 − Pj(i)(d i)] }
where di denotes the estimated thyroid radiation dose of participant i, j(i) is the stratum of participant i, and
Yi is an indicator variable for the outcome of interest, i.e., Yi = 1 if the disease of thyroid UDA is detected
in participant i, and Yi = 0 otherwise.  In [7] the summation is taken over i = 1, …, N where N is the
number of living evaluable in-area participants.  Note that the parameters to be estimated enter [7] through
the sex-stratified linear model for Pj(i)(d ), i.e., equation [1].  For a given value of the slope parameter B, the
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log-likelihood [7] varies as a function the two background rates A1 and A2.  Let A1,max(B) and A2,max(B)
denote the values of A1 and A2 for which L(A1, A2, B) is maximized (again for the given value of B).  Then
the profile log-likelihood function can be written as
PL(B) = L[A1,max(B), A2,max(B), B] .
Note that the profile log-likelihood is simply a function of a single parameter, the slope B.
The maximum likelihood estimates of all three parameters of the sex-stratified linear probability
model can be obtained by finding BMLE, the value of B for which PL(B) is maximized.  The maximum
likelihood estimates of the background rates are then simply Aj,MLE = Aj,max(B MLE) for j = 1 and 2.  Figure
VIII.C-1 below illustrates the profile log-likelihood function for the outcome of any thyroid ultrasound-
detected abnormality (UDA; see section IX.P.2 below for the complete analysis of this outcome).
The vertical axis displays the value of the natural logarithm of the profile likelihood
function, PL(B), multiplied by 2, since this value is used for significance testing and 
confidence interval calculation as described below.  MLE = maximum likelihood 
estimate, UCL = upper confidence limit (see section VIII.C.2.b.1 below).
Note that since conversion to logarithms and multiplication by 2 are monotone increasing
transformations, the value of B which maximizes the curve in Figure VIII.C-1 also maximizes the profile
likelihood function itself, and is therefore the maximum likelihood estimate of the slope.  The example of
any thyroid UDA in Figure VIII.C-1 above is comparatively well-behaved.  That is, the maximum of the
profile likelihood function is clearly evident, with values decreasing sharply and fairly symmetrically for
either smaller or larger values of the slope B.   This occurred because the background prevalence of any
thyroid UDA was relatively high.  Therefore the requirement that probabilities lie between 0 and 1 imposed
no practical constraint.  The situation was somewhat different for disease outcomes with low background
probabilities.  Figure VIII.C-2 displays the profile log-likelihood function for the outcome of thyroid
cancer (see section IX.C below for the complete analysis of this outcome).
Figure VIII.C-1. Profile Log-likelihood Function for Any Thyroid UDA
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The vertical axis displays the value of the natural logarithm of the profile likelihood
function, PL(B), multiplied by 2, since this value is used for significance testing and
confidence interval calculation as described below.  MLE = maximum likelihood
estimate, UCL = upper confidence limit (see section VIII.C.2.b.1 below).
In contrast to the relatively high prevalence of thyroid UDAs, the background probabilities of
thyroid cancer are low: only 14 (0.4%) of the 3191 living evaluable in-area participants had diagnoses of
thyroid cancer based on the primary diagnostic definition (see section IX.C below).  Therefore, due to the
constraint described above, the profile likelihood function begins to decrease precipitously for increasingly
negative values of the slope B.  Nevertheless the value of B for which the profile likelihood is maximized
is clearly evident.
Figure VIII.C-3 below displays the profile log-likelihood function for the outcome of Graves
disease, which like thyroid cancer is relatively uncommon: 32 (1.0%) of the 3191 living evaluable in-area
participants had diagnoses of Graves disease based on the primary diagnostic definition (see section IX.I.
below).  In this case the maximum likelihood estimate of B was slightly negative, and the profile likelihood
function decreases very rapidly for even slightly more negative values of B. 
Figure VIII.C-2. Profile Log-likelihood Function for Thyroid Cancer
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The vertical axis displays the value of the natural logarithm of the profile likelihood
function, PL(B), multiplied by 2, since this value is used for significance testing and
confidence interval calculation as described below.  MLE = maximum likelihood
estimate, UCL = upper confidence limit (see section VIII.C.2.b.1 below).
Computer programs were written by HTDS staff to fit models of the sex-stratified linear
probability model [1] using the Newton-Raphson method to maximize the profile likelihood function.
Likelihood ratio tests based on the profile likelihood function were used to test the statistical significance
of the dose-response relationships in these analyses.  Specifically, the test statistic was
χ2 = 2 × { ln[ PL(0) ]) − ln[ PL(BMLE) ] } ,
which, under the null hypothesis that the slope is 0, has a chi-square distribution with 1 degree of freedom.
P-values for testing the one-sided alternative hypothesis that risk increases with increasing dose were
calculated as
P   = [ 1 – F1(χ2) ] / 2,  if BMLE ≥ 0
[ 1 + F1(χ2) ] / 2,  if BMLE < 0 ,
where F1(•) is the cumulative distribution function of the chi-square distribution with 1 degree of freedom.
Confidence intervals for the parameters of the sex-stratified linear probability model were calculated as
described in VIII.C.2.b.1 below.
C.2.a.2. Maximum Likelihood Analyses of Logistic Models
The parameters of logistic dose-response models of the form [2] and its generalizations for
analyses of possible confounding and effect modification (see section VIII.C.1.b above) were estimated
using SAS PROC LOGISTIC, a commercially available program for fitting logistic regression models.  
Logistic regression models were also used to analyze disease outcomes in relation to alternative
representations of exposure, i.e., by geostratum and by the dichotomous exposure variable described in
section VIII.B.3.b above.  For analyses by geostratum, each living evaluable participant was assigned a
vector of eight indicator variables:
Gi,1 = 1 if participant i had geostratum Pasco/Kennewick, = 0 otherwise,
Figure VIII.C-3. Profile Log-likelihood Function for Graves Disease
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Gi,2 = 1 if participant i had geostratum Walla Walla City, = 0 otherwise, etc.
Note that these eight indicator variables all had value 0 for participants in the Richland geostratum.  A
similar indicator variable was defined for participants in the high or low exposure groups:
Hi = 1 if participant i is in the high exposure group, = 0 otherwise.
In both of these analyses age at the time of HTDS examination was included in the regression model.  This
was done because the nine geostrata differed slightly in their participants’ average ages at examination, as
did the high and low exposure groups (see section IX.A.7).  Since cumulative incidence of thyroid diseases
and prevalence of thyroid UDA increase with age, age at HTDS examination was included in order to
adjust for its possible confounding effect.  The sex-stratified age adjusted logistic regression models that
allowed the cumulative incidence of disease outcomes or prevalence of thyroid UDA outcomes to vary
among the geostrata or between the high and low exposure groups were then
Pj(i)(di) = exp[ Aj(i)  + Bc × C i +  Σg (Bg × Gi,g) ] / {1 + exp[ Aj(i)  + Bc × C i + Σg (Bg × Gi,g) ] }
and 
Pj(i)(di) = exp( Aj(i)  + Bc × C i +  B × Hi ) / [1 + exp( Aj(i)  + Bc × C i +  B × Hi ) ] , 
respectively, where 
C i = age at HTDS examination for participant i.
C.2.a.3. Maximum Likelihood Analyses of Dose-Response Models for Laboratory Values, Thyroid Mass,
and Numbers of UDAs
Since laboratory values and thyroid mass are quantitative variables, some of which are subject to
censoring, their dose response models [4] were analyzed using SAS PROC LIFEREG, which calculates
maximum likelihood estimates of parameters for parametric models.  Maximum likelihood estimates were
also calculated for the Poisson regression model used to analyze numbers of thyroid UDAs as described in
section VIII.C.1.d above; the statistical program SPlus was used for these calculations.
 
C.2.a.4. Least Squares Analyses
The method of least squares is another general method for estimating parameters in statistical
models, an alternative to the method of maximum likelihood.  SAS PROC REG was used to perform
unweighted least squares analyses for three types of analysis of HTDS data.  The first was to estimate the
parameters of the sex-stratified linear probability model [1].  This analysis, designated the least squares
analysis of ungrouped data (“LSU”), used the same data as in the profile likelihood analyses described in
section VIII.C.2.a.1 above, i.e., the individual dose estimates and disease outcome data for each living
evaluable participant.  
For the second analysis, designated the least squares analysis of grouped data (“LSG”), the living
evaluable in-area participants were grouped into eight dose categories, with cutpoints at 10, 50, 100, 150,
200, 300, and 400 mGy.  The arithmetic means of the estimated thyroid doses of the participants in each
category were then calculated separately for women and men.  These average doses were then substituted
for the individual dose estimates in the sex-stratified linear probability model [1].
The third use of least squares was to estimate the parameters of the linear-quadratic dose-response
model [5].
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C.2.b. Confidence Intervals
Confidence intervals were calculated for all estimates of background rates and dose-response
slopes or regression coefficients.  The method used to calculate confidence limits depended on the model
and method of estimation, as described below.  In addition, since three or more parameters were estimated
for each model considered, confidence intervals were adjusted for the simultaneous estimation of multiple
parameters as described in section VIII.C.2.b.4 below.
C.2.b.1. Linear Probability Model
As described above in section VIII.C.2.a.1, the parameters of the sex-stratified linear probability
model [1] were estimated by maximizing the profile likelihood function.  The profile likelihood function
was also used to calculate confidence limits as follows:
BLCL = max{ B | B < BMLE and ln[ PL(B) ] ≤ ln[ PL(BMLE) ] − 0.5 × Q(cB , 1) } and
BUCL = min{ B | B > BMLE and ln[ PL(B) ] ≤ ln[ PL(BMLE) ] − 0.5 × Q(cB , 1) } ,
where
BLCL is the lower confidence limit for the slope,
BUCL is the upper confidence limit for the slope, 
BMLE is the maximum likelihood estimate of the slope,
cB is the confidence level (see VIII.C.2.b.4 below), and
Q(cB , 1) is the cB-th percentile of the chi-square distribution with 1 degree of freedom
Confidence limits for the two sex-specific intercepts were calculated as
[8] Aj,LCL = Aj,MLE − Z[(100 + cB)/2] × SE(Aj,MLE) and
Aj,UCL = Aj,MLE + Z[(100 + cB)/2] × SE(Aj,MLE), for j = 1, 2,
where
Aj,LCL is the lower confidence limit for the sex-specific intercept Aj,
Aj,UCL is the upper confidence limit for Aj, 
Aj,MLE is the maximum likelihood estimate of Aj,
SE(Aj,MLE) is the estimated standard error of Aj,MLE ,
cB is the confidence level (see VIII.C.2.b.4 below), and
Z[(100 + cB)/2] is the [(100 + cB)/2]-th percentile of the standard normal distribution.
C.2.b.2. Logistic Models
Confidence intervals for parameters of logistic dose-response model [2] and its generalizations for
analyses of confounding and effect modification were calculated from the parameters estimates and their
estimated standard errors.  For example, for the simple logistic dose-response model [2], confidence limits
for the regression coefficient were calculated as 
[9] BLCL = BMLE − Z[(100 + cB)/2] × SE(BMLE) and
BUCL = BMLE + Z[(100 + cB)/2] × SE(BMLE) ,
where
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BLCL is the lower confidence limit for the regression parameter,
BUCL is the upper confidence limit for the regression parameter, 
BMLE is the maximum likelihood estimate of the regression parameter,
SE(BMLE) is the estimated standard error of BMLE ,
cB is the confidence level (see VIII.C.2.b.4 below), and
Z[(100 + cB)/2] is the [(100 + cB)/2]-th percentile of the standard normal distribution.
Confidence limits for the intercept parameters A1 and A2 in logistic models were calculated using [8], and
converted into confidence limits for the background rates (see [3] above) as follows:
Pi ,LCL(0) = exp(Aj,LCL) / [ 1 + exp(Aj,LCL) ] and
 Pi ,UCL(0) = exp(Aj,UCL) / [ 1 + exp(Aj,UCL) ] for j = 1, 2.
C.2.b.3. Models Fit by Method of Least Squares
For parameters estimated by the method of least squares, confidence intervals were calculated
using [9] for the coefficients of dose terms and [8] for intercept terms.  For linear-quadratic models,
confidence intervals for the coefficients of the linear and quadratic terms were calculated as:
[9] Bt,LCL = Bt,MLE − Z[(100 + cB)/2] × SE(Bt,MLE) and
Bt,UCL = Bt,MLE + Z[(100 + cB)/2] × SE(Bt,MLE) ,
where
Bt,LCL is the lower confidence limit for the coefficient of the linear (t=1) or quadratic (t=2) term,
Bt,UCL is the upper confidence limit for the coefficient of the linear (t=1) or quadratic (t=2) term, 
Bt,MLE is the least sqaures estimate of the regression coefficient, for t = 1 or 2,
SE(Bt,MLE) is the estimated standard error of Bt,MLE ,
cB is the confidence level (see section VIII.C.2.b.4 below), and
Z[(100 + cB)/2] is the [(100 + cB)/2]-th percentile of the standard normal distribution.
C.2.b.4. Confidence Level and Bonferroni Adjustment
The goal in calculating confidence intervals was to achieve a nominal 95% confidence level.
However when confidence intervals with a given nominal confidence level are calculated simultaneously
for more than one parameter of a model, the probability that all of the intervals contain the true values of
their respective parameters is less than the nominal confidence level.  For example, if 95% confidence
intervals are to be calculated for each of the three parameters of the simple sex-stratified linear probability
model [1] (i.e., the slope and the two sex-specific background rates), the probability that all three intervals
will contain their true parameter values is less than 95%.  In order to adjust for this effect of estimating
multiple parameters, the Bonferroni method was used.  In this method confidence intervals are calculated at
a confidence level higher than the nominal level in order to ensure that the probability that all confidence
intervals for a given model contain their respective true parameter values is not less than the nominal
confidence level.  Specifically, if confidence intervals are calculated for k parameters, then to achieve an
overall confidence level no less than c, each confidence interval is calculated using confidence level
cB = 1 – ( 1 – c ) / k .
Thus for models with three parameters, in order to ensure overall confidence level no less than
c = 95%, the three confidence intervals are each calculated at level cB = 98.33%.  For models with four or
five parameters, cB = 98.75% or 99%, respectively.
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Since cB > c, each parameter’s Bonferroni-adjusted confidence interval is wider than its
unadjusted interval.  In particular, upper confidence limits for slopes and dose-response regression
parameters are higher with the Bonferroni adjustment than without.
C.2.c. Analyses of the Effect of Dose Uncertainties
It has long been recognized that the estimation of parameters in regression models such as the
linear probability model [1] or the logistic model [2] is subject to bias if an independent variable (thyroid
dose in this case) is observed with nonsystematic error, i.e., with an uncertainty that does not tend to
systematically reduce or increase the values of the independent variable.  In general, the effect of such
error is to “attenuate” the estimate of the regression coefficient.  That is, if the outcome variable tends to
increase as the true value of the independent variable increases, the regression coefficient will tend to be
underestimated.  This phenomenon was observed by Kerber et al. (134) in their analysis of the Utah
Thyroid Study.  Significance tests can also be affected by error in the independent variable, although this is
usually less of a problem.  
 A number of approaches have been devised over the years to deal with this problem, i.e., to
correct or “deattentuate” estimates of regression coefficients. An approach analogous to that taken in the
Utah Thyroid Study (133, 134) was used to calculate “deattentuated” estimates of the regression coefficient
B.
 
 
 C.2.c.1. General Approach
 
The general  approach of the Utah Thyroid Study (133) was followed in reporting the results of
dose-response analyses.  That is, the main results were based on analyses that used point estimates of dose
and ignored dose uncertainty.  The additional analyses that adjusted for dose uncertainties were performed
to illustrate how that adjustment affects the estimates and statistical significance of the dose-response
relationships.  Reporting results based on analyses that ignored uncertainties in the estimated thyroid doses
from Hanford’s 131I was important for two reasons.
 
• The results of the conventional analyses (e.g., fitted dose-response functions based on the
participants’ median or mean doses) will be useful if one attempts to generalize from HTDS
cohort to other persons with thyroid doses estimated by the CIDER program.  The median dose
estimate can then be applied to the corresponding HTDS estimates of dose-response functions
from the conventional analysis.  They cannot, however, be applied to the estimates based on the
extended analysis that adjusts for uncertainty.
 
• The results of the conventional analysis will be comparable to the main results of the Utah
Thyroid Study, which were reported in terms of mean doses (133).
 
 
 C.2.c.2. Descriptive Analysis of Effects of Dose Uncertainty
 
To illustrate how the uncertainty of estimated doses influenced the fitted dose-response
relationships, the linear dose-response models [1] were fit using each of the 100 realizations of dose
separately.  The point estimates of and Bonferroni-adjusted 95% confidence intervals for B, the slope
parameter representing the magnitude of the radiation effect, were displayed graphically to illustrate how
the estimate varied among the 100 realizations of dose, and how the estimates from the 100 realizations
compare to those based on the average doses.
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C.2.c.3. Estimation of B with Adjustment for Dose Uncertainty
A Bayesian approach was used to calculate “deattentuated” estimates of the regression coefficient
B in the sex-stratified logistic model [2].  This approach specifies the relationship among observed data
(outcomes and estimated thyroid doses), unobserved data (the participants’ true doses), and the parameters
of distributions governing the observed and unobserved data.  Specifically, let GMi and GSDi denote the
geometric mean and geometric standard deviation of the i-th participant’s 100 dose estimates, as defined in
section VIII.B.3. above, and let Ti denote the logarithm of the unobserved true dose (“true log dose”) of
participant i.  The analysis was performed under the following assumptions. 
(i) The logarithm of each participant’s geometric mean dose, i.e., the arithmetic mean of the logarithms of
his or her 100 dose estimates, is normally distributed with mean Ti and variance ln
2(GSDi): 
ln(GMi)  ~  N( Ti , ln
2(GSDi) ) for i = 1, …, N.
(ii)  The true log doses Ti are themselves normally distributed with means and variances that differ between
G subgroups of participants:
Ti  ~  N( Mg(i) , Vg(i) ) for i = 1, …, N,
where g(i) ⊂ {1, …, G} is the index of the subgroup containing participant i.  The parameters of the
underlying distributions of true log doses, i.e., Mg and Vg for g = 1, …, G, are of course unknown and must
be estimated.
(iii) Given the participant’s true dose, the probability of the disease outcome or thyroid UDA outcome of
interest is independent of his or her estimated dose, i.e., for each living evaluable in-area participant i= 1,
…, N, the probability of the outcome is given by
 
 Prob(Yi | GMi , Ti ) = exp(Aj(i)  + B × Ti) / [1 + exp(Aj(i)  + B × Ti)] ,
 
 where Yi is the indicator of the outcome (Yi = 1 if the participant has the outcome, otherwise Yi = 0).
 
(iv)  To complete the specifications necessary to implement the Bayesian approach, relatively
uninformative prior distributions were assigned for the regression parameters (A1, A2, and B) and the
means of the distributions of true log doses (M1, …, MG), i.e., normal distributions with mean 0 and
variance 106.  Since the variance V of the distributions of true log doses is required to be greater than 0, its
prior distribution was taken to be the gamma distribution with shape parameter 0.001 and scale parameter
106.
For assumption (ii), the subgroups of participants were defined so that they would be likely to
have different underlying distributions of true log doses.  In particular the subgroups were defined by
geostrata and year of birth strata as follows:
Subgroup 1 (relatively high doses):  Richland, Pasco/Kennewick, and Benton, Franklin, and
Adams County geostrata, and 1940-1945 birth year strata. 
Subgroup 2 (intermediate doses):  Richland, Pasco/Kennewick, and Benton, Franklin, and Adams
County geostrata, and 1946 birth year strata; or Walla Walla City or County geostrata, and 1940-
1945 birth year strata. 
Subgroup 3 (relatively low doses):  Walla Walla City or County geostrata, and 1946 birth year
strata; or Okanogan and Ferry/Stevens County geostrata (any birth year strata).
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In addition, the distributions of true doses in (ii) were assumed to have common variance V, i.e., Vg  = V
for g = 1, …, G.
The objective of the Bayesian approach was to estimate the posterior marginal distribution of the
regression parameters, conditional on the observed data, i.e., on the values of Yi, GMi, GSDi for i = 1, …,
N.  This was accomplished using the Gibbs sampling technique, as implemented by the freeware
WinBUGS package (available at http://www.mrc-bsu.cam.ac.uk/bugs).  
To begin the Gibbs sampling, initial values were specified as follows:
B = 0 ,
Aj = ln[ bj / (1 − bj) ]  for j = 1 or 2, where bj is the proportion of participants of sex j with the 
outcome, and
Ti = ln(GMi) for i = 1, …, N .
The initial values of the means of the distributions of log true doses for the three subgroups were simply
the means of ln(GMi), which are summarized in the following table:
Table VIII.C-2 Description of Log True Doses for Subgroups 1– 3
Subgroup
No. of Living Evaluable
In-Area Participants
Mean of
ln(GMi)
Variance of
ln(GMi)
1 2173 -2.27 3.33
2   646 -2.82 1.28
3   372 -4.41 2.51
Based on the variances of ln(GMi) in the three subgroups, the initial value of the common variance V was
defined as 2.5.
With these initial values, the Gibbs sampler was run for 2000 “burn-in” iterations, then for 5000
iterations to provide the estimated posterior marginal distribution of the regression parameters conditional
on the observed data.  In particular, the median of the 5000 values of B from its estimated marginal
distribution was used to provide a “de-attenuated” estimate of the dose-response coefficient.  In addition,
the percentiles of that marginal distribution were used to provide an empirical confidence interval for the
regression coefficient.  Specifically, in order to obtain empirical confidence limits adjusted by the
Bonferroni technique for the simultaneous estimation of three parameters (see section VIII.C.2.b.4 above),
the percentiles at the 0.83% and 99.17% levels, i.e., the 41st and 4959th largest values of B, were defined as
the confidence limits.  Finally, a one-tailed empirical p-value was calculated as the proportion of the 5000
realizations for which the simulated value of B was less than 0.
C.2.c.4. Out-of-Area Participants
The approach described above applies only to analyses limited to the in-area participants, i.e., to
those for whom the CIDER program provides 100 realizations of estimated dose.  No attempt was made to
calculate deattenuated estimates of the dose-response relationships using both the in-area and out-of-area
participants.
HTDS Final Report: June 21, 2002 – Section VIII page 208
D. Exposures from the Nevada Test Site
The ability to estimate thyroid doses caused by fallout 131I from the Nevada Test Site (NTS)
became available during the course of HTDS, as described in section VIII.B.2.h above.  This section
describes the way that information about exposures to fallout 131I from the NTS was used in the HTDS.
D.1. General Approach
The general approach was to treat exposure to 131I from the NTS as a potential confounding factor
or effect modifier.  Therefore the primary analyses of exposure-outcome relationships remained as
described above.  Moreover the analysis of potential confounding and effect modification by NTS
exposures was performed basically as described for other potential confounders.  However some special
steps were necessary for analyses involving the NTS exposures; these steps are described below.
The decision to treat NTS exposure as a potential confounding or effect-modifying factor meant
that certain other analyses that might be considered possible were not performed.  
• No attempt was made to estimate, or test the statistical significance of, dose-response relationships
between thyroid disease outcomes (or other response variables) and estimated NTS doses.  This
was because the HTDS cohort was defined to provide adequate statistical power for investigating
the effects of Hanford doses, not NTS doses.  Therefore it was very likely to be inadequate for the
latter purpose.
 
• No analyses were conducted in which estimates of Hanford and NTS doses were added together
or otherwise combined for use as the exposure variable.  There were two reasons for this:  1) the
objectives of HTDS refer specifically to the effects of doses from Hanford, and  2) it is not clear
that dose estimates from the two dosimetry systems are comparable, and is it not known how to
combine the estimates of uncertainty of the two doses.
 
 
 D.2. Handling of Disease Outcome Variables in Analyses Involving NTS Doses
 
 Exposures to 131I from Hanford and the NTS occurred over a prolonged period of time.  Therefore
careful consideration was given to the handling of outcomes that were determined while exposure was still
occurring.
 
No special handling was necessary to accom modate NTS exposures in the analyses of the
prevalence of thyroid UDAs, since these were based on the HTDS examination, long after the cessation of
Hanford and NTS exposures.  However, for disease outcomes the situation was different, since diagnoses
might have occurred before the end of 1957, i.e., before the end of the period for which estimated doses
from NTS fallout were calculated (see section VIII.B.2.h above).  As described in section VIII.C.1.a above,
the primary analysis of each disease outcome was based on the cumulative incidence of the outcome
among living evaluable participants.  “Cumulative incidence” referred specifically to the percentage of
living evaluable participants with the outcome of interest diagnosed at any time up to and including the
HTDS examination.
 
 One possible alternative to the use of cumulative incidence was to perform an “incidence study,”
i.e., to analyze incidence rates (cases per 100,000 person-years).  The use of incidence rates is a standard
epidemiological method that has been successfully applied in a number of studies of radiation effects.  It is
often particularly appropriate when exposure occurs over a prolonged period.  However when the HTDS
protocol and Analysis Plan were developed (i.e., prior to the availability of information about exposures to
131I from the NTS), two major reasons were identified that argued against trying to perform an incidence
study. 
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• Dates of many past diagnoses (i.e., diagnoses made prior to the participant’s HTDS examination)
were likely to be imprecisely known.  This was expected to be true to varying degrees for
diagnoses documented in medical records.  Reports of past diagnoses based solely on the In-
Person Interview of the participant or the CATI were likely to be especially imprecise.
 
• The age profiles of incidence rates were likely to be distorted by the occurrence of HTDS
examinations.  NCRP has noted that tumor registries may underestimate the true incidence of
thyroid cancer by a factor of three (36).  Thus it was expected that the highly sensitive HTDS
examinations would induce an apparent sharp jump in age-specific incidence rates of neoplastic
diseases.  This was anticipated for non-neoplastic diseases as well.
 In addition, a third enabling reason was identified.  While this reason did not argue against
analyzing incidence rates, it did provide a rationale for the use of cumulative incidence.
 
• The bulk of the Hanford exposure occurred before 1950, while the vast majority of diagnoses
likely occurred later.  Therefore an analysis of cumulative incidence, which in effect treats all
diagnoses as occurring after completion of exposure, was unlikely to be seriously biased.
 
 When the decision was made to include the NTS exposure as a potential confounding or effect
modifying factor, the applicability of these reasons was re-examined.  The first two reasons remained
strong arguments against conducting an incidence study.  However the third reason was more problematic:
since the NTS exposures occurred primarily between 1952 and 1957, the likelihood that some diagnoses
occurred before the end of exposure was increased (HTDS participants were 11 to 18 years old at the end
of 1957).  Therefore the decision was made to modify analyses that include NTS exposure by considering
cumulative incidence since January 1, 1958.  This was accomplished for each disease outcome by
excluding any participant with a diagnosis of that outcome before January 1, 1958.  Implications of this
decision included the following:
 
• Restricting the period of observation to begin on January 1, 1958, rather than at birth, might have
an impact on the estimates and/or statistical significance of the dose-response relationships of
interest, i.e., the associations between cumulative incidence of disease outcomes and Hanford
dose.  It was considered likely that any such impact would be small, since it is expected that few
diagnoses occurred before 1958.  For any disease outcome with no diagnoses before 1958, the
modification would have no effect.  For disease outcomes that included diagnoses before 1958,
the effect of restricting the period of observation was examined.  The age-stratified linear
probability model (equation [1] above) was fit using both the unrestricted and the restricted
periods of observation.  In addition the generalized linear probability model including the pooled
categorical variable for NTS exposure was also fit using both the unrestricted and the restricted
periods of observation.  The results of these four fits were compared to assess whether the choice
of observation period affects the estimated effect of Hanford doses. 
• To perform the modified analysis, each diagnosis had to be classified according to its date: before
1958 or after 1957.  As noted in Reason 1 above, dates of many past diagnoses were known only
imprecisely.  However many cases with imprecisely known diagnosis dates could be accurately
assigned between these two time intervals.  Only a few cases could not be accurately assigned
with a high degree of certainty.  Each such case was assigned a diagnosis date in the middle of the
range of plausible dates based on the available information, and then into one of the two time
intervals on the basis of that assigned date.
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IX. RESULTS
A. Characteristics of the Living Evaluable Participants
Of the 3447 eligible participants who attended an HTDS clinic, seven (0.2%) were determined to
be nonevaluable according to the criteria in section IV.B above.  Six did not have complete residence
histories for the period from the beginning of their possible exposure to 131I from Hanford through the end
of 1957, and the seventh had a tracheotomy tube in place which prevented palpation of her thyroid at her
HTDS clinical examination.  The remaining 3440, designated the living evaluable participants, are the basis
for most of the analyses reported here.  For each of these 3440 participants, sufficient data were available to
permit an evaluation of thyroid health and estimation of the radiation dose from Hanford’s 131I.  Several
characteristics of the living evaluable participants are summarized in Table IX.A-1.   About half (50.8%) of
the living evaluable participants were women.  About one-fourth (26.3%) were born in 1944, and another
third (34.0%) were born in 1943 or 1945.  Therefore a large proportion of the living evaluable participants
were infants or very young children during 1945, the years of the largest releases of 131I from Hanford.  At
the time of their HTDS examinations, the living evaluable participants ranged in age from 45 to 57 (median
51).  A large majority (97.5%) described themselves as white or Caucasian.  
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Table IX.A-1. Characteristics of Living Evaluable Participants
Characteristic        No.         %
Sex Female 1747 50.8
Male 1693 49.2
Total 3440 100.0
Year of birth 1940 243 7.1
1941 283 8.2
1942 472 13.7
1943 560 16.3
1944 906 26.3
1945 611 17.8
1946 365 10.6
Total 3440 100.0
Age at examination 45 1 --
46 58 1.7
47 194 5.6
48 264 7.7
49 323 9.4
50 388 11.3
51 741 21.5
52 561 16.3
53 278 8.1
54 229 6.7
55 273 7.9
56 118 3.4
57 12 0.3
Total 3440 100.0
Race/ethnic origin White/Caucasian 3354 97.5
Black/Negro 1 --
Asian or Pacific Islander 10 0.3
Native American 40 1.2
Spanish or Hispanic 5 0.1
Other 23 0.7
Don’t Know 2 0.1
Not Recorded 1 --
Refused 4 0.1
Total 3440 100.0
Religious preference Protestant 2176 63.3
Catholic 483 14.0
Jewish 4 0.1
Mormon 128 3.7
Seventh Day Adventist 108 3.1
Other 94 2.7
None 437 12.7
Not Recorded 1 --
Refused 6 0.2
Don’t Know 3 0.1
Total 3440 100.0
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One important purpose for collecting information about the characteristics described above (as
well as the other factors described below) was to use that information to test for possible confounding and
effect modification in the analyses of the radiation dose-responses (see section VIII.A.1.b above).  As noted
above, the living evaluable participants overwhelmingly identified themselves as white or Caucasian
(97.5%). Therefore, meaningful analyses of race or ethnic origin as a potential confounder or effect
modifier could not be performed.  In addition, Jewish religious preference was of particular interest as a
potential confounder or effect modifier, since there is some evidence suggesting increased risk of thyroid
cancer in Jewish populations (136).  However only four (0.1%) of the living evaluable participants stated
Jewish as their religious preference, so further analysis of this factor was not possible.
A.1. History of Diagnostic X-Rays, Fluoroscopy, Thyroid Nuclear Scans, and other
Nuclear Medicine Procedures
Of the 3440 living evaluable participants, 3318 (96.4%) had a report, either from the In-Person
Interview or the CATI, of one or more diagnostic x-rays or fluoroscopies of the upper body, thyroid nuclear
scans, or other nuclear medicine procedures.  The proportions with reports of specific procedures are
summarized in Table IX.A-2.
Table IX.A-2. History of Diagnostic X-Rays, Fluoroscopy, Thyroid Nuclear Scans, and other
Nuclear Medicine Procedures
In-Person Interview
Only
In-Person Interview and
CATI
Have You Ever Had: No. % No. %
CAT scan of the upper body?   832 24.2 *
Diagnostic x-rays of the head? 1183 34.4 1294 37.6
Diagnostic x-rays of the neck? 1026 29.8 1045 30.4
Diagnostic x-rays of the chest or upper body,
including mammograms?
3027 88.0 3045 88.5
Diagnostic x-rays of the stomach or mid-back?   745 21.7 *
Barium enema?   887 25.8 *
Upper GI? 1228 35.7 1236 35.9
Intravenous pyelogram or IVP?   420 12.2   425 12.4
Fluoroscopy of the upper body?   234   6.8   271    7.9
Other nuclear scan?   229   6.7   231    6.7
Any of the above? 3305 96.1 3317 96.4
* Question not asked in CATI
 Percent calculated in relation to number of living evaluable participants
By far the most common types of procedures were diagnostic x-rays of the chest or upper body,
including mammograms, which were reported for 3045 (88.5%) of the living evaluable participants.  Also
particularly common were diagnostic x-rays of the head or neck, which were reported for 37.6% and
30.4%, respectively, and upper GI examinations (35.9%).  Nearly one-fourth (24.2%) of the living
evaluable participants reported a history of upper body CAT scan (since the CATI covered the time period
ending in 1957, it did not include a question regarding CAT scans).  Upper body fluoroscopies were
reported for 271 (7.9%) living evaluable participants.  Histories of nuclear scans other than thyroid scans
were reported for 231 (6.7%) of the living evaluable participants.  In addition, histories of thyroid nuclear
scans, which are used to assist in the diagnosis of thyroid disorders, were reported for 142 (4.1%) of the
living evaluable participants.
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A.2. History of Radiation Treatment
Histories of x-ray treatment affecting the upper body for reasons other than cancer were reported
for 90 (2.6%) of the living evaluable participants (Table IX.A-3).  The most common reason stated was
treatment of acne, reported for 37 (1.1%).
Cancer other than thyroid cancer was reported on the In-Person Interview by 276 (8.0%) of the
living evaluable participants, with 42 of these 276 reporting having received radiation therapy for the
cancer.
Table IX.A-3. History of Radiation Treatment
In-Person Interview
Only
In-Person Interview and
CATI
Have You Ever Had: No. % No. %
X-ray treatment to the upper body for acne?   32 0.9 37 1.1
X-ray treatment to the upper body for ringworm?     1   0.03 10 0.3
X-ray treatment for enlarged tonsils?     2   0.06   4 0.1
X-ray treatment to the upper body for tuberculosis?     2   0.06   2   0.06
X-ray treatment for scalp infection?     1   0.03   1   0.03
X-ray treatment for enlarged thymus?     0 --   7 0.2
X-ray treatment to the upper body for any other
reason?
  15 0.4 31 0.9
Any of the above x-ray treatments?   52 1.5 90 2.6
History of any cancer other than thyroid? 276 8.0 *
Radiation treatment for any cancer other than
thyroid?
42 1.2
* Question not asked in CATI
  Percent calculated in relation to number of living evaluable participants
A.3. History of Dental X-rays
A history of dental x-ray exposure was reported for nearly all (99.2%) of the living evaluable
participants, although only 346 (10.1%) reported receiving dental x-rays more frequently than once per
year during their life (see Table IX.A-4).  About half (51.8%) of the living evaluable participants reported
on the In-Person Interview or CATI at least one time period when lead shielding of the neck was not used
in dental x-ray examinations. 
Table IX.A-4. History of Dental X-rays
In-Person Interview
Only
In-Person Interview and
CATI
Have You Ever Had: No. % No. %
Dental x-ray? 3406 99.0 3414 99.2
Dental x-ray more frequently than once a year?   324   9.4   346 10.1
Dental x-rays that did not usually include a lead
shield over the neck area?
1727 50.2 1781 51.8
  Percent calculated in relation to number of living evaluable participants
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A.4. Occupational History
Data regarding the participants’ occupational histories were obtained from the In-Person
Interview.  The intention was to identify persons who had worked in occupations that might involve
exposure to radiation.  Therefore, results are presented for occupations in the metals industry, employment
at nuclear facilities, and other occupations that might involve exposure to radioactive materials.  The results
are summarized in Table IX.A-5.
Table IX.A-5. Occupational History
Have You Ever Worked in Any of the Following Female Male Total
Industries or Occupations? No. % No. % No. %
Any Metal Industry   30   1.7 239 14.1 269   7.8
           Geology     5   0.3   19   1.1   24   0.7
           Metallurgy     7   0.4   45   2.7   52   1.5
           Metal processing   15   0.9 131   7.7 146   4.2
           Ore refining     2   0.1   29   1.7   31   0.9
           Mining     1   0.1   60   3.5   61   1.8
Any Nuclear Facility 110   6.3 273 16.1 383 11.1
          Nuclear Industry, as a civilian   84   4.8 168   9.9 252   7.3
          On the premises of a nuclear facility   85   4.9 224 13.2 309   9.0
Any Area Exposed to Radioactive Materials/X-Rays 203 11.6 274 16.2 477 13.9
           Health care 178 10.2   81   4.8 259   7.5
           Scientist, researcher, or student   34   1.9   56   3.3   90   2.6
           Military     2   0.1 123   7.3 125   3.6
           Any other industry or occupation   16   0.9   66   3.9   82   2.4
Any of the Above Industries 321 18.4 636 37.6 957 27.8
 Percent calculated in relation to number of living evaluable participants
 
Of the 3440 living evaluable participants, 957 (27.8%) reported a history of employment in one or
more of the occupations or facilities of interest.  The proportion was higher among the men (37.6%)
compared to the women (18.4%).  The higher proportion among the men was largely due to occupations in
the metals industry (14.1%) or employment at nuclear facilities (16.1%).  The proportions of women
reporting such histories were much smaller (1.7% and 6.3% respectively).  The proportions of men and
women reporting histories of working in areas with possible exposure to radioactive materials were more
similar: 16.2% for men, 11.6% for women.  Most of the women with such histories identified an occupation
in the health care industry (10.2%).
A.5. Smoking History
The In-Person Interview included a series of questions regarding smoking.  Of the 3440 living
evaluable participants, 2053 (59.7%) reported a history of ever smoking cigarettes, cigars, and/or pipes.
See Table IX.A-6.
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Table IX.A-6. Smoking:  History of Ever Smoking 
Have You Ever Smoked Female Male Total
Any of the Following: No. % No. % No. %
Non-filter cigarettes? 180 10.3   755 44.6   935 27.2
Filter cigarettes? 880 50.4 1013 59.8 1893 55.0
Any cigarettes? 897 51.3 1103 65.2 2000 58.1
Cigars?     4   0.2   121   7.1   125   3.6
Pipe?     2   0.1   221 13.0   223   6.5
Any of the above? 897 51.3 1156 68.3 2053 59.7
  Percent calculated in relation to number of living evaluable participants
The proportion that reported ever smoking was higher among men (68.3%) than women (51.3%).
As expected, cigarette smoking was by far the most common form, reported by all of the women who
reported any kind of smoking, and by 65.2% of the 1693 living evaluable male participants.  The amount of
cigarette smoking was quantified in terms of pack-years.  One pack-year is equivalent to smoking one pack
a day for one year.  When adequate data were available from the In-Person Interview, the total consumption
in pack-years was calculated by integrating the reported consumption in packs per day over the years of
smoking.  Similar calculations were performed to quantify cigar and pipe smoking based on cigars per day
and pipes (bowls) smoked per day.  The results are shown in Table IX.A-7.
Table IX.A-7. Smoking:  Level of Use
Female Male Total
Non-filter cigarettes Median 1.5 4 3
(pack-years) Range 0.01-70 .0003-98.9 .0003-98.9
Number 180 745 925
Filter cigarettes Median 18.54 19 18.75
(pack-years) Range 0.01-140 0.01-130 0.01-140
Number 874 1009 1883
Any cigarettes Median 19.5 24.1 21.25
(pack-years) Range 0.01-140 0.01-136 0.01-140
Number 891 1090 1981
Cigars Median 1 6 6
(cigar-years) Range 0.8-2 0.01-443 0.01-443
Number 4 119 123
Pipe Median 1.1 5.7 5.7
(pipe-years) Range 0.7-1.4 0.1-500 0.1-500
Number 2 217 219
Among 1981 living evaluable participants who ever smoked cigarettes and for whom adequate
consumption data were available, the median total pack-years was 21.25 (range 0.01 to 140).   The
consumption was higher among men who smoked cigarettes, with a median of 24.1 pack-years, compared
to 19.5 pack-years for women.  Cigar- and pipe-smoking men reported median consumption levels of 6
cigar-years and 5.7 pipe-years.  Very few women reported ever smoking cigars or pipes.
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A.6. Dietary Factors
Each participant’s thyroid radiation dose depends on several factors.  Of particular importance is
the dietary history, including the amounts of milk, milk products and other foods that the participant
consumed, and the sources of those foods.  Therefore, information about these dietary factors was collected
as part of the CATI for use by the CIDER program in calculating estimated radiation doses.  The following
sections present information about the quantities of various milk and food products consumed by the 1979
living evaluable in-area participants whose CATI data were used for dose estimation, as reported by their
CATI respondents.  Results are shown separately for women and men.  Since a participant’s consumption
of milk and food products typically changed over time, results are also shown by age.  Specifically,
descriptive statistics (mean, median, and 5th, 25th, 75th and 95th percentiles) were calculated for the reported
amounts consumed on the participant’s 6-month birthday and annual birthdays (first, second, etc.) through
age 15.  (Since CATI respondents often reported that dietary factors changed on birthdays, the values used
for these analyses were in fact those reported for 5 days after the participant’s birthday.)  If a participant
was out of area on one of these occasions, or his or her consumption was reported as unknown, then he or
she was excluded from the distribution for that birthday.  Similarly, if a participant’s birthday occurred
before December 1944 or after 1957, then he or she was excluded from the distribution for that birthday.  If
a participant was reported not to have consumed a given milk or food product on a given birthday, then the
consumption was taken to be zero.
A.6.a. Raw Cow’s Milk and Milk Products
Consumption of raw cow's milk or milk products was reported for 999 (50.5%) of the 1979 living
evaluable in-area participants whose CATI data were used for dose estimation (498 women, 501 men).  For
61 of these 975 participants (31 women, 30 men), the CATI respondent was unable to provide estimates of
the quantity consumed.  Figure IX.A-1 summarizes the distributions of raw cow’s milk and milk products
consumption by sex and age.  Each participant’s consumption, expressed as 8 oz. servings per day, was
calculated from that reported for glasses of milk, other servings of milk, and milk products.  At every age
shown in the figures, fewer than half of the participants were reported to consume raw cow’s milk or milk
products, and the 5th and 25th percentiles and medians were consequently all zero; therefore these three
statistics are omitted from the figure for clarity. 
As shown in Figure IX.A-1, consumption of raw cow’s milk and milk products increased sharply
for both sexes until age 2, then leveled off at averages of about 1.6 and 1.9 eight oz.servings per day for
women and men, respectively.  For both sexes, only about 12% were reported to consume raw cow’s milk
or milk products at 6 months of age, and only about 28% at one year of age.  At older ages the proportions
of nonconsumers ranged between 33% and 40%.
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Figure IX.A-1. Raw Cow’s Milk Consumption, by Sex and Age
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A.6.b. Processed Cow’s Milk and Milk Products
Consumption of processed cow's milk or milk products was reported for 1741 (88.0%) of the 1979
living evaluable in-area participants whose CATI data were used for dose estimation (871 women, 870
men).  For 86 of these 1746 (44 women, 42 men), the CATI respondent was unable to provide estimates of
the quantities consumed.  Figure IX.A-2 summarizes the distributions of processed cow’s milk and milk
products consumption by sex and age.  Each participant’s consumption, expressed as 8 oz. servings per
day, was calculated from that reported for glasses of milk, other servings of milk, and milk products.  At
every age shown in the figures, more than 10% of the participants were reported to be nonconsumers of
processed cow’s milk or milk products, and the 5th percentiles were consequently all zero; therefore the 5th
percentiles are omitted from the figure for clarity. 
As shown in Figure IX.A-2, consumption of processed cow’s milk and milk products increased to
about 2 eight oz. servings per day at one year of age.  For women, consumption remained fairly stable at
this level until about age 5 or 6, then increased to about three 8 oz. servings per day.  For men, consumption
increased fairly steadily until the teenage years, to just under four 8 oz. servings per day.  For both sexes,
the proportion of nonconsumers decreased from nearly 40% at age 1 to 20% at age 6; thereafter the
proportions remained fairly stable at 10 – 14%.
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Figure IX.A-2. Processed Cow’s Milk Consumption, by Sex and Age
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A.6.c. Goat’s Milk and Milk Products
Consumption of goat’s milk or milk products was reported for only 46 (2.3%) of the 1979 living
evaluable in area participants whose CATI data were used for dose estimation (23 women, 23 men).  For
five of these 46 (three women, two men), the CATI respondent was unable to provide estimates of the
quantities consumed.  The reported consumption levels for the remaining 41 participants, i.e., the 20
women and 21 men for whom quantities consumed were reported, are displayed in Figure IX.A-3.  Note
that this figure differs from figures IX.A-1 and IX.A-2 above, since it displays the levels reported for
individual participants rather than percentiles of the consumption levels.  
In figure IX.A-3 below, the consumption levels reported for an individual participant at various
ages are connected by lines.  This was done to illustrate changes of consumption levels over time, and does
not imply that every participant in the figure consumed goat’s milk or milk products continuously
throughout the ages indicated.  For ages at which a participant was reported to be a nonconsumer of goat’s
milk or milk products, points are omitted from the figure for clarity.   There were three participants for
whom consumption of goat’s milk or milk products was reported only for one or more periods of time that
did not include their six-month birthday or any of their first through 15th birthdays.  In order to include the
participants in the figure, their consumption levels were plotted for ages at which consumption occurred.
The reported consumption levels for these three participants are indicated in the figure by dashed lines and
and “x” symbols.  For example, one female participant was reported to have consumed about 4.5 servings
of goat’s milk or milk products per day between the ages of about 3.5 and 11.7 years, except during a
two-month period of each year, a period that happened to include her birthday.  Therefore her consumption
levels are shown in Figure IX.A-3 below for ages 3.5 years, 4.5 years, etc.
The levels of goat’s milk and milk product consumption reported by CATI respondents for these
46 participants ranged up to six 8 oz. servings per day for both women and men.
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Figure IX.A-3. Goat’s Milk Consumption, by Sex and Age
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 A.6.d. Total Milk and Milk Products
Figure IX.A-4 summarizes the distributions of total milk consumption (raw or processed cow’s or
goat’s milk and milk products) by sex and age.  Each participant’s consumption, expressed as 8 oz.
servings per day, was calculated from that reported for glasses of milk, other servings of milk, and milk
products. 
As shown in Figure IX.A-4, the reported consumption of milk and milk products increased to
about four 8 oz. servings per day at two years of age.  For women, consumption remained fairly stable,
increasing slightly and gradually until the teenage years.  For men, consumption increased steadily up to
about six 8 oz. servings per day by age 15.  For both sexes, the proportion for whom no milk consumption
was reported was 69% at age 6 months and 15% at one year of age.  For women, the proportion of
nonconsumers fell to 3% at age 2 years, and was 2% or less for all older ages.  For men, the proportion of
nonconsumers was about 1% at 2 and 3 years of age, and 0.3% or less for all older ages.
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Figure IX.A-4. Total Milk Consumption, by Sex and Age
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A.6.e. Fruit
Consumption of fruit was reported for 1786 (90.2%) of the 1979 living evaluable in-area
participants whose CATI data were used for dose estimation (895 women, 891 men).  For 144 of these
1786 (67 women, 77 men), the CATI respondent was unable to provide estimates of the quantities
consumed.  Figure IX.A-5 summarizes the distributions of fruit consumption by sex and age.  Each
participant’s consumption, expressed as grams per day, was calculated from the information reported by the
CATI respondent. 
As shown in Figure IX.A-5, the reported consumption of fruit increased steadily with age for both
sexes, to about 430 grams per day for women and over 535 grams per day for men by the teenage years.
For both sexes, the proportion who were reported not to consume fruit decreased from about 75% at 6
months of age to about 50% and 25% at one and two years of age, respectively.  The proportions continued
to decrease with increasing age, reaching plateaus of about 2% for women and 1% or less for men after
age 7.
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Figure IX.A-5. Fruit Consumption, by Sex and Age
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A.6.f. Vegetables
Consumption of green and leafy vegetables was reported for 1693 (85.6%) of the 1979 living
evaluable in-area participants whose CATI data were used for dose estimation (855 women, 838 men).  For
154 of these 1693 (74 women, 80 men), the CATI respondent was unable to provide estimates of the
quantities consumed.  Figure IX.A-6 summarizes the distributions of vegetable consumption by sex and
age.  Each participant’s consumption, expressed as grams per day, was calculated from the information
reported by the CATI respondent. 
As shown in Figure IX.A-6, the reported consumption of vegetables increased steadily with age
for both sexes, to about 130 grams per day for women and over 150 grams per day for men by the teenage
years.  For both sexes, the proportion who were reported not to consume vegetables decreased from over
90% at 6 months of age to 9% at 6 years of age.  The proportions of nonconsumers continued to decrease
slightly at older ages, ranging between 2% and 4% after age 9.
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Figure IX.A-6. Vegetable Consumption, by Sex and Age
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A.6.g. Free Range Chicken Eggs
Consumption of free range chickens was reported for 1057 (53.4%) of the 1979 living evaluable
in-area participants whose CATI data were used for dose estimation (552 women, 505 men).  For 64 of
these 1057 (34 women, 30 men), the CATI respondent was unable to provide estimates of the quantities
consumed.  Figure IX.A-7 summarizes the distributions of free range chicken egg consumption by sex and
age.  Each participant’s consumption, expressed as grams per day, was calculated from the information
reported by the CATI respondent.  At every age shown in the figures, fewer than half of the participants
were reported to consume free range chicken eggs, and the 5th and 25th percentiles and medians were
consequently all zero; therefore these three statistics are omitted from the figure for clarity. 
 
As shown in Figure IX.A-7, the reported consumption of free range chicken eggs increased
steadily with age for men, but less so for women.  For women, consumption increased to about 16 grams
per day by age 3, then increased only slowly to about 22 grams per day by the teenage years.  For men
consumption increased to about 15 grams per day by age 3, and then continued to increase to about 30
grams per day by the teenage years.  For both sexes, the proportion who were reported not to consume free
range chicken eggs decreased from over 85% at 6 months of age to just over 50% at 5 years of age, and
remained between 50% and 57% for all older ages.
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Figure IX.A-7. Free Range Chicken Egg Consumption, by Sex and Age
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A.7. Age Distribution for the Alternative Representations to Exposure
As described in section VIII.B.3.b, two alternative representations of exposure to Hanford’s 131I
were defined, in order to assess whether there might be evidence of a radiation effect that was not apparent
from the dose-response analyses using the individual dose estimates calculated by the CIDER program.
These alternative representations of exposure were categorical variables, specifically the geostratum and a
dichotomous variable defined to identify participants likely to have relatively high versus relatively low
exposures (see section VIII.B.3.b.2).  Since 1) the definitions of these alternative representations were
based entirely (geostratum) or partially (dichotomous exposure variable) on geostratum, and 2) both years
of birth and years during which HTDS examinations were performed varied by geostratum, it was of
interest to examine whether the participants’ ages at HTDS examination were correlated with either
alternative representation of dose.  Table IX.A-8 shows that the age at HTDS examination varies somewhat
by geostratum, with mean age ranging from 49 years for the Okanogan and Ferry/Stevens County geostrata,
to 53 years for the Adams County geostratum.  This reflects the fact that participants in the Okanogan and
Ferry/Stevens geostrata were selected only for the Pilot Study phase, while those from Adams County were
selected only during the Full Study phase.  In addition, the birth years from which participants were
selected were 1942-1946 for the Okanogan and Ferry/Stevens geostrata, while for Adams County they were
from 1940-1945.
Table IX.A-8. Age at HTDS Examination by Geostratum
Geostratum No. Median Minimum Maximum Mean St. Dev.
Richland 352 51 46 53 50 1.6
Pasco/Kennewick 1009 52 46 57 52 2.1
Walla Walla City 264 50 46 55 50 1.9
Benton Co. 734 52 46 57 52 2.4
Franklin Co. 149 50 45 57 51 3.1
Walla Walla Co. 334 50 46 55 50 1.9
Okanogan Co. 139 49 46 55 49 2.0
Ferry/Stevens Cos. 138 49 46 54 49 1.5
Adams Co. 321 53 50 57 53 1.6
As can be seen in Table IX.A-9, the age at HTDS examination also differed slightly by the
dichotomous exposure variable, with the mean age at HTDS examination 2 years higher in the high
exposure group compared to the low exposure group.
Table IX.A-9. Age at HTDS Examination by Dichotomous Exposure Variable
Exposure Group No. Median Minimum Maximum Mean St. Dev.
Low 677 50 46 57 50 2.7
High 580 52 47 57 52 2.0
Although the two tables above indicate that the geostrata, as well as the high and low exposure
groups, differed somewhat with respect to the distributions of age at HTDS examination, the differences are
rather small, with a maximum difference of 4 years in average age.  Although cumulative incidence of
disease outcomes or prevalence of thyroid UDAs is likely to increase with age, differences of only a few
years of age are unlikely to cause large increases.  Nevertheless, the analyses of disease outcomes and
thyroid UDAs in relation to these two alternative representations of exposure were adjusted for age at
HTDS examination.
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B. Estimated Radiation Doses to the Thyroid from Hanford 131I 
 
As described in section VI above, estimates of thyroid radiation doses from atmospheric releases 
of Hanford’s 131I were calculated using the computer program CIDER, which was developed by the HEDR 
Project (137).  Specifically, CIDER calculated estimates of doses received by an individual during any 
times from December 1944 to the end of 1957, that he or she reports being inside the 246-by-306 mile 
HEDR geographical domain (Figure II.A-1).   
 
It is important to understand that CIDER does not calculate any contribution to a person’s dose for 
periods he or she reports being outside the HEDR domain.  This does not reflect an assumption that persons 
were not exposed while outside the domain, but rather the difficulty of accurately estimating doses received 
at long distances from Hanford, and the likelihood that such doses were small.  A fundamental objective of 
the HEDR project in determining the domain’s boundaries was to ensure a high likelihood that individuals 
could not receive appreciable doses while outside the domain.  In particular, the domain was defined by the 
HEDR Project to include as much as possible of the region over which appreciable doses might have been 
received, while taking into account the decreasing reliability of 131I atmospheric transport modeling at 
longer and longer distances. 
 
Based on the residence histories obtained from the CATIs and Expanded In-Person Interviews, 
3191 (93%) of the 3440 living evaluable participants lived within the HEDR domain at least some time 
from December 1944 to the end of 1957.  These are the participants for whom CIDER can compute a dose 
estimate.  For convenience, these 3191 participants are designated as “in-area” participants in this report 
(see Table IX.B-1 below).  The residence histories of the remaining 249 living evaluable participants (7% 
of the 3440) included no residence within the HEDR domain from December 1944 to the end of 1957.  
These 249 individuals are designated as “out-of-area” participants.  
 
Dosimetric data were obtained from CATIs for 2123 (62%) of the 3440 living evaluable 
participants, and from Expanded-IPIs for the remaining 1317 (38%). 
 
Table IX.B-1.  Summary of Dosimetry Interview Types and In-Area Status of 3440 Living 
Evaluable Participants 
 
                  In-Area Status 
Type of Dosimetry Interview In-Area Out-of-Area Total
2123
1317 
3440
 
CATI 1979 144 
Expanded In-Person 1212 105 
Total 3191 249 
 
 
 
 
B.1. Calculation of Estimated Thyroid Radiation Doses for In-Area Participants 
 
Three sets of dose estimates were calculated for the 3191 in-area participants.  The sources of data 
used for these three sets of doses are summarized in Table IX.B-2.   
 
Table IX.B-2.  Characteristics of Primary and Alternative Sets of Radiation Dose Estimates 
 
 Primary Dose 
Estimates 
First Alternative 
Dose Estimates 
Second Alternative 
Dose Estimates 
Use CATI specifics regarding 
amounts and sources of food 
and milk? 
 
Yes 
 
No 
 
Yes 
Source of default values HEDR HEDR HTDS* 
* Note that for expanded IPIs HEDR defaults were used for consumption other than milk. 
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In the dose-response analyses reported below, the primary emphasis is given to results based on 
the primary set of dose estimates.  Analyses using the alternative sets of dose were performed primarily to 
assess the sensitivity of the dose-response results to the type of dose estimate.   
 
 
B.2. Point Estimates and Uncertainty of Doses 
 
As described in section VIII.B.3.a above, the CIDER program actually returns 100 estimates or 
“realizations” of each participant’s dose.  For many purposes, in particular for the conventional analyses of 
dose-responses described in section VIII.B.3.a above, it is important to have a single number or “point 
estimate” to serve as each participant’s estimated dose.  Three obvious candidates for the point estimate are 
the median, mean, and geometric mean of the 100 realizations.  These three point estimates were calculated 
for each of the 3191 in-area living evaluable participants.  It was expected that the three point estimates 
would be highly correlated with each other, and this is confirmed in Figure IX.B-1 below. 
 
 
HTDS Final Report: June 21, 2002 – Section IX.B  page 233 
Figure IX.B-1. Scatterplots of Geometric Mean and Mean Doses versus Median Dose 
 
A. Geometric Mean versus Median 
 
 
B. Mean versus Median 
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The distributions of each participant’s 100 dose estimates tended to be roughly lognormally 
distributed.  Therefore the medians and geometric means were nearly equal for most participants, as can be 
seen in Panel A of Figure IX.B-1.  Furthermore, due to the approximate lognormality of each participant’s 
100 realizations, the mean doses tended to be somewhat larger than the medians (Figure IX.B-1, Panel B). 
 
Because of the very high degree of correlation among the three possible point estimates, it can be 
expected that they will give very similar results in the analyses of radiation dose-responses, at least in terms 
of statistical significance.  Therefore the remainder of this report focuses primarily on the median as the 
point estimate of participants’ doses.  For simplicity, the terms “doses” or “estimated doses” will refer to 
the median dose estimates unless otherwise indicated. 
 
Figure IX.B-2 displays the cumulative frequency distribution (CDF) of the median doses.  The 
shape of the CDF indicates that the distribution of median doses is strongly skewed to the right.  The 
majority of participants have relatively low doses, while the rest have doses that are spread over a wide 
range of higher values. 
 
Figure IX.B-2. Cumulative Distribution of Median Dose Estimates for 3191 In-Area Living  
Evaluable Participants 
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The uncertainty in each participant’s dose estimate is represented by the variation among his or 
her 100 dose estimates provided by CIDER (see section VIII.B.3.a above).  This is illustrated in Figure 
IX.B-3.  Empirical cumulative distribution functions of the 100 dose realizations for each of five selected 
participants are shown in the figure. The five participants were chosen on the basis of their estimated doses 
(i.e., the medians of their 100 dose realizations) to cover the entire range of dose estimates.  Specifically, 
the participants in the figure are those with (from left to right) the smallest dose, the 25th, 50th, and 75th 
percentile doses, and the largest dose among all 3191 living evaluable in-area participants.  It is evident 
from Figure IX.B-3 that the distributions of 100 realizations are approximately normally distributed.  
Moreover, the fact that the curves are approximately parallel suggests that the variances of log-transformed 
dose realizations, or equivalently, the geometric standard deviations of the dose realizations, are roughly 
the same for each participant. 
 
 
HTDS Final Report: June 21, 2002 – Section IX.B  page 235 
HTDS Final Report: June 21, 2002 – Section IX.B  page 236 
Figure IX.B-3. Cumulative Distribution of 100 Dose Estimates for Five Selected Participants 
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One simple and useful characterization of the magnitude of the uncertainty is the ratio of an upper 
percentile of the 100 realizations, e.g., the 95th percentile, to the median.  Among the 3191 in-area living 
evaluable participants, these ratios had a median value of 3.8 and ranged from 1.8 to 13.7, although the 
ratio was less than 10.0 for all but three of the 3191 participants.  Only 10% of the ratios were less than 2.7, 
and only another 10% were greater than 5.3. Figure IX.B-4 displays these ratios in relation to the median 
dose estimates.  
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Figure IX.B-4. Scatterplot of Ratio of 95th Percentile to Median versus Median Dose 
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The clustering of the ratios around a value of about 4 is evident in Figure IX.B-4, and there is no 
indication that the magnitude of uncertainty varies in relation to the median dose. 
 
Another simple characterization of the magnitude of the uncertainties of the estimated doses is the 
geometric standard deviation or GSD (see section VIII.B.3.a above).  For the 3191 living evaluable in-area 
participants, i.e., the study participants for whom the CIDER program was able to calculate dose estimates, 
the GSDs ranged from 1.56 to 5.42, with a mean of 2.18. 
 
A total of 890 living evaluable in-area participants (28%) had dose estimates with GSDs less than 
2.0.  In its review of the HTDS Draft Final Report, the National Research Council (NRC) questioned how 
GSDs less than 2 could occur, reasoning as follows (138).  In CIDER’s dose calculations, dose conversion 
factors (DCFs) were treated as uncertain parameters.  For example, CIDER uses age-specific ingestion 
DCFs to convert total ingested Curies of 131I activity (from milk, food, etc.) into dose (measured in mGy).  
Similarly, CIDER uses age-specific inhalation DCFs to convert inhaled 131I activity to dose.  In CIDER, the 
DCFs for the ingestion and inhalation pathways, which accounted for most of the dose received by the 
majority of study participants, were assumed to be lognormally distributed with a GSD of 2.0 (10509).  
Since the GSD of the product of two uncertain variables is the product of their respective GSDs, the NRC 
reasoned, the GSDs of the doses should rarely if ever be less than 2.  The NRC further noted that only 
GSDs of 2 or greater were reported for representative dose calculations performed by the HEDR project 
[10493]. 
 
The NRC failed to recognize that dose estimates with GSDs less than 2.0 were a predictable 
consequence of the fact that CIDER’s calculation of doses involves addition of doses after activity levels 
are multiplied by DCFs.  Specifically, the last step of CIDER’s dose calculation is the addition of estimated 
doses from multiple pathways (ingestion, inhalation, and immersion) and time periods defined by age 
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and/or calendar year.  Each of the estimated dose components in this addition has its own uncertainty, with 
GSD 2 or greater for ingestion or inhalation components.  Now consider the addition of two lognormally 
distributed (or approximately lognormally distributed) variables with similar GSDs.  If the first variable has 
a much larger geometric mean than the second, the GSD of the sum will generally be close in value to the 
GSD of the first variable.  However if the two variables have similar geometric means, the GSD of their 
sum will be substantially less than either variable’s GSD.  Both of these situations occurred in the 
calculation of dose estimates for the various HTDS participants.  Many participants received a large 
majority of their accumulated dose from one pathway (e.g., ingestion) and one time period (e.g., all or part 
of 1945).  For such participants, the GSD of the total dose was therefore close to the GSD of that dominant 
component, i.e., 2 or greater.  However, for other participants there were two or more components of dose 
having roughly similar geometric means.  When added together, these produced total doses with GSDs less 
than 2.  The NRC also failed to recognize that the representative dose calculations reported by the HEDR 
project were not informative in this regard.  For example, consider the representative doses reported in 
Table 1 of the paper by Farris et al. [10493].  The estimated doses for the hypothetical people represented 
in that table were dominated by the component accumulated through ingestion during 1945.  Consequently 
the GSDs for all of the examples in the table were 2 or greater. 
 
  
B.3. Distributions of Primary Dose Estimates 
 
The primary estimates of radiation dose for the 3191 in-area living evaluable participants ranged 
from a minimum of 0.0029 mGy to a maximum of 2823 mGy, with a median of 97 mGy.  The mean and 
standard deviation of the distribution of estimated doses were 174 mGy and 224 mGy, respectively.  The 
distribution of dose estimates was quite heavily skewed, as shown in Figure IX.B-2 above.  As shown in 
Table IX.B-3 below, the distributions of median doses did not differ markedly between women and men. 
 
 
Table IX.B-3. Frequency Distribution of Estimated Thyroid Radiation Dose, by Sex 
 
Estimated 
Thyroid 
 
Living Evaluable Participants 
Radiation Female Male Total 
Dose (mGy)    No. % No. % No. % 
< 10   182 11.2   186 11.9   368 11.5 
10-49   320 19.7   314 20.0   634 19.9 
50-99   313 19.3   310 19.8   623 19.5 
100-149   220 13.6   171 10.9   391 12.3 
150-199   126   7.8   109   6.9   235   7.4 
200-299   139   8.6   148   9.4   287   9.0 
300-399   144   8.9   160 10.2   304   9.5 
400-999   171 10.5   154   9.8   325 10.2 
1000+       7   0.4     17   1.1     24   0.8 
Total In-Area 1622 100 1569  100 3191  100 
Out of Area   125   7.2   124   7.3   249   7.2 
Total 1747 100 1693  100 3440  100 
 
 
Twenty-four (0.8%) of the 3191 in-area living evaluable participants had dose estimates greater 
than 1000 mGy, and only seven (0.2%) had estimates over 2000 mGy.  Summary statistics for the 
distributions of estimated doses are shown by geostratum in Table IX.B-4.  As expected, the estimated 
doses tended to be higher for participants in the Richland, Pasco/Kennewick, and Benton, Franklin and 
Adams County geostrata.  They tended to be lowest for the Okanogan and Ferry/Stevens County geostrata, 
and intermediate for the two Walla Walla geostrata. 
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Table IX.B-4. Summary of Estimated Radiation Doses (in mGy) to the Thyroid from Hanford 131I,  
  by Geostratum 
 
Geostratum     No.   Median       Minimum      Maximum         Mean       St. Dev. 
Richland 348 101 0.1 2455 220 284 
Pasco/Kennewick 910 242 .003 1235 255 200 
Walla Walla City 250 64 .06 745 74 76 
Benton Co. 656 83 .05 2823 170 311 
Franklin Co. 141 173 .004 1028 234 215 
Walla Walla Co. 320 66 .1 1016 83 93 
Okanogan Co. 125 5 .003 158 11 19 
Ferry/Stevens Cos. 131 32 .02 128 36 28 
Adams Co. 310 161 .008 584 166 101 
Total 3191   97 .0029 2823 174 224 
 
 Summary statistics for the distributions of estimated doses are shown by sex and birth year in 
Table IX.B-5 below.  The distributions of estimated doses were similar for men and women.  The 
arithmetic mean doses are slightly larger for men (177 mGy) than women (171 mGy), but the medians are 
quite similar (96 mGy for men, 99 mGy for women).  Seventeen (1.1%) of the 1569 men and 7 (0.4%) of 
the 1622 women had doses above 1000 mGy.  Four of the seven participants with doses over 2000 were 
female.   
 
Table IX.B-5. Summary of Estimated Radiation Doses (in mGy) to the Thyroid from Hanford 131I, by  
  Sex and Year of Birth 
 
Sex Year No. Median Minimum Maximum Mean St. Dev. 
Female 1940 111 122 .04 547 160 132 
 1941 133 164 .003 935 202 170 
 1942 224 102 .003 952 166 175 
 1943 236 102 .007 652 152 146 
 1944 416 125 0.05 2823 230 329 
 1945 318 94 0.1 956 171 187 
 1946 184 29 0.3 373 50 58 
 1940-46 1622 99 .003 2823 171 220 
Male 1940 107 163 .05 1102 199 187 
 1941 122 165 0.3 782 204 163 
 1942 211 107 .005 1016 174 166 
 1943 248 118 0.2 1235 179 177 
 1944 413 114 .003 2455 228 324 
 1945 290 73 .08 975 166 208 
 1946 178 28 .006 717 48 78 
 1940-46 1569 96 .003 2455 177 228 
Total 1940-46 3191   97 .0029 2823 174 224 
 
 
 Doses tended to be higher for participants born in 1940 – 1941, to drop somewhat for those born 
in 1942 – 1943, then to increase again for those born in 1944 .  This pattern was largely an artifact of the 
way in which the study cohort was defined.  As described above, the 1940 and 1941 birth cohorts were 
limited to Benton, Franklin and Adams counties (including Pasco and Kennewick), since these counties 
were expected to provide participants with relatively high doses.  The other counties, from which 
participants would have been expected to have lower doses, were not included in the 1940 and 1941 
cohorts.  The effect of this exclusion is shown in Figure IX.B-5 below, which displays the mean estimated 
doses by sex, birth year, and geostratum. 
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Figure IX.B-5. Mean of Estimated Median Thyroid Radiation Dose (in mGy) from Hanford 131I by 
Sex, Year of Birth, and Geostratum 
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Twenty-three of the 24 participants with estimated doses greater than 1000 mGy were in the 
Richland, Pasco/Kennewick, Benton or Franklin County geostrata (one was in Walla Walla County).   All 
but three of the 24 were born in 1944, as were all of the seven with estimated doses over 2000 mGy. 
 
  Participants’ ages at the time of their HTDS examinations ranged from 45 to 57 years.  As shown 
in Table IX.B-6, the participants who were youngest when examined tended to have lower doses, since 
many of them were born too late to be exposed during the period of highest releases in early and mid 1945. 
 
Table IX.B-6. Summary of Radiation Doses (in mGy) to the Thyroid from Hanford 131I by Sex and 
Age at HTDS Examination 
 
 
Sex 
Age at  
Exam 
 
 No. 
 
    Median 
 
      Minimum 
 
Maximum 
 
Mean 
 
St. Dev. 
Female 45-46* 33 21 0.3 105 34 29 
 47 84 35 0.3 472 69 88 
 48 136 50 0.1 946 96 137 
 49 165 69 0.1 1028 114 147 
 50 182 103 0.06 2823 205 320 
 51 359 126 0.003 1349 210 220 
 52 256 110 0.1 2792 211 296 
 53 112 118 0.007 821 169 158 
 54 105 163 2.1 676 199 160 
 55 133 126 0.004 935 177 161 
 56 54 124 0.003 450 146 122 
 57 3 128 56 195 126 70 
Male 46 26 25 5 717 61 137 
 47 106 33 0.006 486 60 79 
 48 126 43 0.003 931 104 170 
 49 146 69 0.1 1083 138 198 
 50 186 80 0.07 1015 168 215 
 51 341 120 0.005 2455 220 294 
 52 253 120 0.1 1989 214 262 
 53 113 171 0.3 1337 216 198 
 54 111 168 0.005 782 191 145 
 55 107 163 1.4 793 205 179 
 56 47 123 0.3 1102 169 188 
 57 7 196 .05 368 193 144 
* Only one person was 45 years old at the time of examination. 
 
 
 There were two major differences in the dose calculations for participants with CATIs versus 
those with Expanded In-Person Interviews:   
 
• The first, and perhaps most obvious difference, was the potential availability from CATIs of specific, 
detailed information about quantities and sources of the milk and other food products consumed by the 
participant during 1944 – 1957.  The CIDER program provided default estimates of these 
characteristics whenever they were not specified by HTDS.  Thus the CIDER defaults were used for all 
participants with dose calculated from Expanded In-Person Interview.  For those with CATI dosimetry 
data, however, the CIDER defaults were used only when necessary, i.e., when the CATI respondent 
was unable to provide the information.  
 
• The second major difference between doses calculated from CATI and Expanded In-Person Interview 
data concerned the contributions to participants’ doses from breastfeeding.  The CATI included 
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questions regarding whether or not the participant was breastfed any time after the start of 131I releases 
from Hanford.  However, it was anticipated that many, if not most participants, without CATI 
respondents would be unable to answer such a question accurately.  Therefore the Expanded In-Person 
Interview did not include questions regarding breastfeeding of the participant.  Similarly, since 
participants without CATI respondents could not be expected to recall details of early life such as the 
age at which they began drinking cow’s milk, no such questions were included in the Expanded In-
Person Interview.  In the absence of data on these characteristics, the CIDER model assumed that 
cow’s milk consumption began at birth.  Therefore all 1212 in-area living evaluable participants with 
an Expanded In-Person Interview were effectively assumed to have begun drinking cow’s milk at 
birth.   
 
 The impact of interview type on the estimated doses is shown in Table IX.B-7. 
 
Table IX.B-7.  Summary of Estimated Radiation Doses (in mGy) to the Thyroid from Hanford 131I, 
by Type of Dosimetry Interview and Year of Birth 
 
Interview Birth Year No. Median Minimum Maximum Mean St. Dev. 
CATI 1940 116 150 0.05 1102 209 191 
 1941 115 139 1.7 935 208 204 
 1942 277 102 0.003 953 173 181 
 1943 284 106 0.007 1235 170 184 
 1944 511 91 0.003 1143 151 195 
 1945 408 59 0.08 943 105 134 
 1946 268 29 0.006 717 51 74 
 1940-46 1979 81 0.003 1235 140 174 
Expanded 1940 102 125 0.04 707 145 112 
IPI 1941 139 187 0.003 524 198 128 
 1942 158 104 0.06 1016 164 149 
 1943 200 106 0.1 498 160 129 
 1944 319 247 0.1 2823 355 436 
 1945 200 269 0.5 975 299 237 
 1946 94 28 1.2 236 46 48 
 1940-46 1212 154 0.003 2823 229 279 
 
 
 The average doses (i.e., the means or medians in Table IX.B-7) are generally similar for each year 
except 1944 and 1945.  In those two years, however, the doses based on Expanded In-Person Interviews are 
notably larger (arithmetic means 355 and 299 mGy, respectively) compared to those based on CATI input 
data (151 and 105 mGy).  This difference reflects the assumption that participants without CATI dosimetry 
data were assumed to drink cow’s milk from birth.  As described in the paragraphs above, this likely led to 
overestimation of the doses for some of the participants with doses based on Expanded In-Person 
Interviews who were in fact breastfed.  In addition, CATI respondents reported that the majority of 
participants did not consume fresh cow’s or goat’s milk or milk products in the first months of life (e.g., 
69% at 6 months of age; see section IX.A.6.d above).  
 
 Table IX.B-8 displays the dose distributions according to age at first exposure to 131I from 
Hanford, age at HTDS examination, and estimated thyroid dose from the Nevada Test Site (NTS).  
Participants with prenatal exposure have rather lower doses than other participants, in part since nearly all 
of the 1946 birth stratum, which missed the months of highest 131I releases from Hanford, were exposed in 
utero.  Participants who were first exposed to 131I from Hanford before 180 days of age also have somewhat 
lower doses for a similar reason.  Participants who were ≤50 years old at the time of their HTDS 
examinations also had somewhat lower doses, since they tended to be in the later birth year strata.  
Participants with relatively higher estimated thyroid doses from the NTS tended to have lower doses from 
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Hanford, in part due to residence.  There were no major differences in the doses of those who had a history 
of any cancer other than thyroid compared to those with no such history. 
 
Table IX.B-8. Summary of Estimated Radiation Doses (in mGy) to the Thyroid from Hanford 131I, 
by Age at Exposure and HTDS Examination, Estimated Thyroid Dose from NTS 
and History of Any Cancer Other Than Thyroid 
 
Covariate  No. Median Minimum Maximum Mean St. Dev.
Prenatal exposure? Yes   No 
1034 
2157 
  58 
118 
.038 
.003 
2206 
2823 
135 
193 
194 
235 
1st exposure before  
age 180 days? 
Yes 
  No 
1478 
1713 
75 
115 
.038 
.003 
2823 
1350 
172 
176 
269 
176 
Age at HTDS 
Examination > 50? 
Yes 
  No 
2001 
1190 
128 
  61 
.003 
.003 
2792 
2823 
203 
125 
233 
199 
NTS thyroid 
dose > 5.3 mGy? 
Yes 
  No 
1567 
1622 
  66 
145 
.003 
.003 
2792 
2823 
128 
218 
206 
232 
History of any cancer  
other than thyroid? 
Yes 
  No 
  248 
2938 
104 
  96 
.003 
.003 
2823 
2792 
194 
172 
310 
215 
 
 
 Table IX.B-9 displays distributions of estimated dose in relation to participants’ histories of 
various types of medical and dental radiation exposures. The thyroid doses from Hanford do not differ 
greatly according to the presence or absence of the various kinds of exposure. 
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Table IX.B-9.  Summary of Estimated Radiation Doses (in mGy) to the Thyroid from Hanford 131I, 
by Medical and Dental Radiation History 
 
 
Have You Ever Had: 
  
No. 
 
Median 
 
Minimum 
 
Maximum 
 
Mean 
St. 
Dev. 
CAT scan of the  
upper body? 
Yes 
  No 
  775 
2374 
  98 
  96 
.003 
.003 
2823 
  930 
174 
174 
188 
236 
Diagnostic x-rays of  
the head? 
Yes 
  No 
1191 
1964 
  90 
102 
.003 
.003 
2482 
2823 
164 
179 
215 
228 
Diagnostic x-rays of  
the neck? 
Yes 
  No 
  966 
2201 
112 
  90 
.003 
.003 
2823 
2455 
195 
164 
257 
207 
Diagnostic x-rays of 
the chest or upper?  
body, including 
mammograms? 
Yes 
  No 
2821 
  352 
  96 
  99 
.003 
.005 
2823 
1410 
176 
161 
228 
191 
Diag. x-rays of the  
stomach or mid-back? 
Yes 
  No 
  692 
2428 
  96 
  97 
.003 
.003 
2482 
2823 
165 
176 
211 
227 
Barium enema? Yes   No 
  825 
2334 
  94 
  99 
.003 
.004 
2823 
2792 
174 
174 
223 
225 
Upper GI? Yes   No 
1146 
2031 
  99 
  96 
.003 
.004 
2823 
2792 
181 
170 
226 
223 
Intravenous pyelogram  
or IVP? 
Yes 
  No 
  398 
2759 
100 
  97 
.003 
.003 
1337 
2823 
185 
172 
215 
225 
Fluoroscopy of the  
upper body? 
Yes 
  No 
  246 
2915 
105 
  96 
.210 
.003 
1028 
2823 
192 
172 
222 
224 
Other nuclear scan? Yes   No 
  217 
2945 
  92 
  97 
.122 
.003 
1337 
2823 
185 
173 
219 
225 
Radiation treatment for 
any cancer other than 
thyroid? 
Yes 
No 
    39 
3147 
119 
  97 
.413 
.003 
1349 
2823 
202 
174 
275 
223 
Dental x-rays that did 
not usually include a  
lead shield over the 
neck area? 
Yes 
  No 
1648 
1543 
  95 
  99 
.003 
.005 2482 
170 
178 
222 
226 
 
 
 Table IX.B-10 displays distributions of estimated dose in relation to participants’ occupational 
histories.  The 371 living evaluable in-area participants who reported ever working in a nuclear facility had 
somewhat higher estimated thyroid doses from Hanford (median 148 mGy).  
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Table IX.B-10.  Summary of Estimated Radiation Doses (in mGy) to the Thyroid from Hanford 131I, 
by Occupational History 
 
Have You Ever 
Worked in Any of the 
Following: 
  
 
No. 
 
 
Median 
 
 
Minimum 
 
 
Maximum 
 
 
Mean 
 
St. 
Dev. 
Any metal industry? Yes   No 
  238 
2953 
  85 
  98 
.003 
.003 
1016 
2823 
176 
174 
204 
226 
Any nuclear facility? Yes   No 
  371 
2820 
148 
  93 
.015 
.003 
2455 
2823 
248 
164 
280 
214 
Any other industry or 
occupation where you 
may have been 
exposed to radioactive 
materials or x-rays? 
Yes 
  No 
442 
2749 
  92 
  98 
.003 
.003 
2823 
2792 
172 
174 
258 
218 
Any of the above 
industries or 
occupations? 
Yes 
  No 
  892 
2299 
104 
  94 
.003 
.003 
2823 
2792 
196 
166 
250 
213 
 
 
As shown in Table IX.B-11, the distributions of estimated thyroid doses from Hanford did not differ 
appreciably between living evaluable in-area participants who reported any history of smoking cigarettes, 
or of any smoking, compared to those without such histories. 
 
Table IX.B-11.  Summary of Estimated Radiation Doses (in mGy) to the Thyroid from Hanford 131I, 
by Smoking History 
 
Have You Ever 
Smoked Any of the 
Following: 
  
 
No. 
 
 
Median 
 
 
Minimum 
 
 
Maximum 
 
 
Mean 
 
St. 
Dev. 
Cigarettes (unfiltered 
or filtered)? 
Yes 
  No 
1854 
1329 
  96 
  98 
.003 
.005 
2823 
2206 
177 
169 
238 
203 
Any of cigarettes, 
cigar or pipe? 
Yes 
  No 
1900 
1283 
  96 
  97 
.003 
.005 
2823 
2206 
177 
169 
237 
204 
 
 
Since the consumption of milk contaminated with 131I from Hanford was a key source of exposure 
for many study participants, the relationship between milk and milk product consumption and estimated 
radiation dose was investigated.  Average milk and milk product consumption levels (expressed as the 
reported average number of 8 oz. servings consumed per day) were calculated as described in section 
VIII.B.2.c above for each of the 1979 living evaluable participants whose CATI data were used for dose 
estimation.  To calculate each participant’s average consumption level, his or her reported total number of 8 
oz. servings for a particular type of milk was first calculated by integrating the reported consumption levels 
over the time periods for which the CATI respondent reported consumption levels of that milk.  For 
example, if a CATI respondent reported that a participant consumed three 8 oz. servings per day over a 
period of 2 years, the total consumption was 3 × 2 × 365 = 2190 8 oz. servings for that period.  For these 
calculations participants born in 1946 were assigned milk consumption values of 0 for 1945.  Also, 
participants in the 1940-1945 birth strata who never lived inside the HEDR domain during 1945 were 
assigned consumption levels of 0 for 1945.  If the consumption level for a particular type of milk was 
unknown for any or all of the time period in question (because the CATI respondent could not report the 
quantity of glasses consumed), the total consumption was considered unknown for these calculations. 
 
Two measures of average consumption were calculated.  The first measure of average 
consumption, designated “Average No. of 8 oz. Servings per Day,” was obtained by dividing the reported 
total number of 8 oz. servings for a given time period by the duration of that period in days (e.g., by 365 for 
average consumption during 1945).  The second measure, designated “Average No. of 8 oz. Servings per In 
Area Day,” used a different divisor: the number of days during the period for which (1) the participant lived 
within the HEDR domain and (2) the level of milk consumption was reported in the participant’s CATI.   
 
Average consumption levels were calculated for two time periods:  (1) 1945, the year in which by 
far the largest amount of  131I was released from Hanford (see section II above), and (2) the entire period 
1944-1957.  Table IX.B-12 summarizes milk consumption data reported for the 1979 participants whose 
CATI data were used for dose estimation are shown for three types of milk: raw (“backyard”) cow’s milk, 
processed cow’s milk, and goat’s milk, as well as for total cow’s milk and total milk (cow’s plus goat’s).  
Among the 1979 in-area participants whose CATI data were used for dose estimation, the proportions for 
whom reported average consumption levels were known exceeded 90% for all types of milk.  The 
proportion for whom the reported average consumption level was zero varied widely according to the type 
of milk or milk product and time period.  For example, the proportion with no consumption of cow’s milk 
(raw or processed) was 37% for 1945, but only 8% for all years.  This difference reflects the experience of 
children who were too young to consume cow’s milk in 1945, but did consume it at older ages, and the 
assignment of 0 consumption in 1945 for participants born in 1946.  Since very few participants were 
reported to have consumed goat’s milk or milk products, the median consumption levels for these were 
zero.  Similarly the median consumption levels of raw cow’s milk and milk products were all 0, since fewer 
than half of the participants were reported to have consumed these. 
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Table IX.B-12. Milk and Milk Product Consumption Levels Reported by CATI Respondents: Distributions and Correlation with Estimated Dose 
 
  
Participants with Milk and 
Milk Product Consumption 
Levels Reported in CATI 
 
Reported Average No. of 
8 oz. Servings per Day 
 
Reported Average No. of 
8 oz. Servings per In Area Day 
 
 
Period 
 
Type of Milk 
or Milk Product 
 
 
No. 
 
 
% 
 
Number (%) 
with 0 
 
 
Mean 
 
 
Median 
 
 
Range 
Corr. with 
Estimated 
Dose * 
 
 
Mean 
 
 
Median 
 
 
Range 
Corr. with 
Estimated 
Dose * 
1945 Raw cow’s 1927   97% 1351  (70%) 1.05 0 0 – 12.22 0.31 1.09 0 0 – 12.22 0.30 
Only Processed cow’s 1904   96% 1016  (53%) 1.07 0 0 – 12.38 0.37 1.19 0 0 – 12.38 0.34 
 Total cow’s 1866   94%   683  (37%) 2.13 1.37 0 – 12.38 0.57 2.30 1.86 0 – 13.29 0.53 
 Goat’s 1979 100% 1947  (98%) 0.03 0 0 –   5.69 0.09 0.03 0 0 –   6.00 0.09 
 Total 1866   94%   679  (36%) 2.16 1.40 0 – 12.38 0.57 2.33 2.00 0 – 13.29 0.53 
1944 Raw cow’s 1902   96%   980  (52%) 1.28 0 0 – 11.49 0.23 1.43 0 0 – 11.49 0.21 
– 1957 Processed cow’s 1854   94%   238  (13%) 2.12 1.66 0 – 12.08 0.31 2.64 2.58 0 – 12.38 0.21 
 Total cow’s 1807   91%   147  (  8%) 3.43 3.58 0 – 12.08 0.46 4.11 4.18 0 – 12.93 0.38 
 Goat’s 1979 100% 1933  (98%) 0.01 0 0 –   4.29 0.06 0.02 0 0 –   5.00 0.06 
 Total 1807   91%   147  (  8%) 3.44 3.59 0 – 15.87 0.46 4.12 4.18 0 – 15.87 0.39 
* Spearman rank order correlation coefficient 
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Table IX.B-12 above also shows the correlation between estimated radiation dose and the 
measures of average milk and milk product consumption.  The Spearman rank order correlation coefficients 
ranged from 0.21 to 0.57 for the various measures of cow’s milk and milk product consumption.  In 
contrast, the correlations were quite low for goat’s milk and milk products: since these were consumed by 
only a small minority of the participants, most of the variability of the estimated doses occurred among the 
nonconsumers of goat’s milk and milk products, resulting in the low correlation. 
 
In view of the large number of other factors that influenced the participants’ doses, the magnitude 
of the correlations between estimated dose and these aggregate measures of cow’s or total milk and milk 
product consumption is noteworthy.  The effect of milk and milk product consumption on estimated doses 
of course depends on other factors, in particular the participant’s residence history.  For example the HEDR 
model implies that consuming an average of one 8 oz. servings per day throughout 1945 resulted in a 
higher dose for residents of Franklin county (immediately east of the Hanford site) than for, say, Jefferson 
County, Oregon (in the southwest corner of the HEDR domain).  Figure IX.B-6 displays the relationship 
between estimated thyroid dose and one measure of milk and milk product consumption, the reported 
average number of 8 oz. servings per in area day of the total of cow’s and goat’s milk for 1945.  In order to 
display, at least approximately, the effect of residence location on the relationship between consumption 
and estimated dose, the participants were divided into three groups based on geostratum: Benton, Franklin 
and Adams counties (including Richland, Pasco and Kennewick); Walla Walla County (including Walla 
Walla City); and Okanogan, Ferry and Stevens Counties.  While a participant’s geostratum (i.e., county of 
mother’s usual residence at the participant’s birth) does not correspond perfectly to his or her residence 
history, it provides a reasonable approximation. 
 
Figure IX.B-6. Estimated Dose in Relation to Reported Consumption of Cow’s and Goat’s Milk  
and Milk Products During 1945, by Geostratum 
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Note: Richland and Pasco/Kennewick geostrata are included within “Benton, Franklin, Adams” and Walla Walla  city geostratum is 
included within “Walla Walla”. 
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The curves in Figure IX.B-6 show smoothed estimates of the average doses, as function of the 
consumption level, for the three groups.  A trend of increasing dose with increasing consumption is evident 
for the figure.  Moreover consumption had a stronger effect on dose for participants in the Benton, Franklin 
and Adams county geostrata, compared to the other two groups.  For example, based on the fitted curves in 
Figure IX.B-6, the average estimated dose for participants in the Benton, Franklin and Adams County 
geostrata increased from 85 mGy for those with no consumption of cow’s or goat’s milk or milk products, 
(i.e., zero 8 oz. servings per in area day) to 219 mGy for those with an average consumption of four 8 oz. 
servings per in area day.  In contrast, for the Walla Walla County geostrata, the mean estimated dose 
increased from 38 mGy to 119 mGy, while for the Okanogan, Ferry, and Stevens County geostrata, the 
mean estimated dose increased from 15 mGy for nonconsumers to 36 mGy for those with an average 
consumption of four 8 oz. servings per in area day. 
 
As described in Section VIII.B.3.b, two alternative representations of exposure to Hanford’s 131I 
were defined, to assess whether there might be evidence of a radiation effect that was not apparent from the 
dose-response analyses using the individual dose estimates calculated by the CIDER program.  These 
alternative representations of exposure were categorical variables, specifically the geostratum and a 
dichotomous variable defined to identify participants likely to have relatively high versus relatively low 
exposures (see section VIII.B.3.b.2).  The analyses of disease and thyroid UDA outcomes in relation to 
these alternative exposure variables did not make use of the estimated doses.  Nevertheless it was of 
interest to examine the distributions of estimated doses within the categories defined by these two 
variables. 
 
The distributions of estimated doses are shown by geostratum in Table IX.B-4 above, and by the 
dichotomous exposure variable in Table IX.B-13 below.  Note that the low exposure group included the 
249 out-of-area participants for whom the CIDER program does not calculate a dose estimate.  Therefore 
the description of the estimated dose distribution for the low exposure group in Table IX.B-13 refers only 
to the other 428 participants.  As expected, estimated doses of participants in the low exposure group were 
generally lower, with a mean of 23 mGy, compared to the high exposure group with mean 288 mGy.    
 
However there was substantial overlap in the distributions of estimated doses: the maximum 
estimated dose in the low exposure group was 160 mGy, while the minimum estimated dose in the high 
exposure group was 12 mGy.  This overlap is not surprising, since the dichotomous exposure variable uses 
only part of the detailed full set of information that enters into CIDER’s calculation of individual dose 
estimates. 
 
Table IX.B-13. Summary of Estimated Radiation Doses (in mGy) to the Thyroid, by Dichotomous  
  Exposure Variable 
 
Exposure Group     No. Median Minimum Maximum Mean St. Dev. 
Low – in area 428 15 .003 160 23 25 
Low – out of area 249 --- --- --- --- --- 
High 580 224 12 1235 288 214 
 
 
The remaining 2183 living evaluable participants, who could not be classified into either the low 
or the high exposure group, and all of whom were among the in-area group, had estimated doses ranging 
from 0.003 mGy to 2823 mGy, with mean 173 mGy.  
 
 
B.4 Implications for Statistical Power 
 
The study’s statistical power to detect an effect of 131I from Hanford was determined primarily by 
the number of living evaluable participants and by the mean and variance of their doses.  As described in 
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section V.A above, the final cohort definition was established in order to ensure a high likelihood that there 
would be a sufficient number of living evaluable participants and a dose distribution with a sufficiently 
large variance.  Since the power to detect a dose-response of a given magnitude depends on the background 
rates, power was calculated for three exemplary outcomes corresponding to a range of background rates: 
 
• Any Benign Thyroid Nodule, representing outcomes with intermediate background rates (assumed for 
power calculations to be 0.05 or 5% for women, 0.02 or 2% for men). 
 
• Thyroid Carcinoma, representing outcomes with low background rates (assumed to be 0.007 or 0.7% 
for women, 0.003 or 0.3% for men). 
 
• Ultrasound Detected Abnormalities, representing outcomes with high background rates (assumed to be 
0.40 or 40% for both sexes). 
 
Table IX.B-14 below summarizes the projections that were made for the Full Study cohort based 
on the results of the Pilot Study, assuming one-sided tests for a positive dose-response (i.e., slope > 0) at 
critical level α = 0.05, and ignoring dose uncertainties.  Also shown are the results that were actually 
obtained. 
 
Table IX.B-14. Comparison of Projected and Obtained Statistical Power 
 
 Projected Obtained
3277 3191 
152 174 
38619 50150
Number of in-area living evaluable participants 
Mean of dose distribution (mGy) 
Variance of dose distribution (mGy2)  
Any benign thyroid nodule (intermediate background rates): 
   power to detect 0.05 per Gy 0.91 0.95 
Thyroid carcinoma (low background rates): 
   power to detect 0.025 per Gy 0.93 0.96 
UDAs (high background rates): 
   power to detect 0.12 per Gy 0.86 0.92 
  
 
  
 
It should be noted that the projected results assumed that out-of-area participants would be 
included, while the “Obtained” results are limited to the in-area participants, who were the basis for the 
primary analyses of the radiation dose-responses.  Although the number of in-area living evaluable 
participants (3191) fell a bit short of the projection, the mean and variance of the dose distribution were 
larger than projected.  As a result, the statistical power exceeded the projections. 
 
As noted in the NRC’s review of the draft HTDS Final Report, the uncertainties of the estimated 
doses could be expected to reduce the study’s power from the levels summarized in Table IX.B-14 above 
(138).  While it would be desirable to calculate the study’s power with a direct adjustment for the dose 
uncertainties, this is impractical due to the complex nature of the correlations of the uncertainties between 
individual participants.  Therefore, in order to assess the impact of dose uncertainty on the study’s 
statistical power, a simulation analysis was performed.  Such simulation studies are often used to 
investigate statistical power when exact calculations are impractical.  The basic idea is to randomly 
generate (“simulate”) a large number of data sets that mimic the key characteristics of the study (e.g., 
background rates, variance of the dose estimates, magnitudes and correlations of the dose uncertainties) for 
a specific hypothesis (null or alternative).  Each simulated data set includes outcome data that are 
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themselves randomly generated under the hypothesis, and the significance of the resulting dose-response is 
tested.  The proportion of data sets for which the null hypothesis is rejected is then an estimate of the 
study’s power at the specific hypothesis.  
 
For the HTDS, the simulation study began by specifying, for a given exemplary outcome (e.g., 
any benign thyroid nodule, thyroid carcinoma, or UDA as in Table IX.B-14 above), the sex-specific 
background rates and the slope of the dose-response under a specific hypothesis of interest (e.g., for any 
benign thyroid nodule, background rates 0.05 for women and 0.02 for men, and slope 0.05 per Gy).  The 
simulation then proceeded through the following steps: 
 
• Step 1: Randomly select 100 dose realizations with replacement from the existing 100 realizations.  
(Selection with replacement means that some realizations might not be selected, while others 
might be selected more than once.)  Calculate each participant’s median dose from the 100 
randomly selected realizations. 
 
• Step 2: Randomly select one of the 100 dose realizations.  Treating this single set of doses as the 
“true” doses, calculate each participant’s “true” probability of having the disease outcome using 
the sex-stratified linear model (see section VIII.C.1.a above) and the specified parameter values.    
Then randomly generate each participant’s disease outcome (present or absent), with the 
probability of having the disease given by his or her “true” probability. 
• Step 3: Fit the sex-stratified linear probability model using the median doses from Step 1 and the 
outcomes from Step 2, and determine whether the estimated slope is significantly greater than 0 at a 
given critical level (e.g., α = 0.05 or 0.10). 
 
After repeating Steps 1 through 3 for a large number of iterations (e.g., 1000), the proportion of 
iterations for which the estimated slope was significantly greater than 0 was calculated.  This proportion is 
an estimate of the study’s statistical power, i.e., of the probability of rejecting the null hypothesis that the 
slope is 0. 
 
Note that the random selection with replacement in step 1 was used to ensure that this procedure 
accounted properly for not only the magnitude of the dose uncertainties, but for the between-participant 
correlations of dose uncertainties as well. 
 
The results of the simulation study for the outcome of any benign thyroid nodule are shown in 
Table IX.B-15 and Figure IX.B-7.  The power was evaluated for the following values of the slope 
parameter: 0 (i.e., the null hypothesis); 0.036 and 0.044 per Gy, for which the test at critical level α = 0.05 
has power 0.80 and 0.90, respectively, if dose uncertainty is ignored; and 0.05, 0.06, 0.07, and 0.75 per Gy.  
Background rates were assumed to be 0.05 for women and 0.02 for men.  As expected, the dose 
uncertainties had no evident effect on the size of the test, i.e., the power under the null hypothesis (slope = 
0).  In addition, for alternative hypotheses with the slope greater than zero, the simulation study indicated 
that there was a modest loss of power due to dose uncertainties.  For example, if the true slope of the linear 
dose-response is 0.05 per Gy (5% per Gy), then the estimated power of the test at critical level α = 0.05 
based on the simulation study (i.e., accounting for dose uncertainties) was 0.863, somewhat less than the 
value of 0.95 obtained if uncertainty was ignored. 
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Table IX.B-15. Effect of Dose Uncertainty on Statistical Power: Any Benign Thyroid Nodule 
 
 Power of Test at Critical Level α = 0.05 Power of Test at Critical Level α = 0.10 
Slope 
(per Gy) 
Ignoring 
Uncertainty 
Accounting for 
Uncertainty 
Ignoring 
Uncertainty 
Accounting for 
Uncertainty 
0 0.05 0.039 0.10 0.090 
.036 0.80 0.713 0.88 0.787 
.044 0.90 0.829 0.95 0.870 
.050 0.95 0.863 0.98 0.912 
.060 0.99 0.893 0.99 0.933 
.070 0.997 0.931 0.999 0.956 
.075 0.999 0.967 1.00 0.978 
 
 
Although the study was designed to ensure that tests at critical level α = 0.05 have adequate 
power, it should be recognized that dose-response parameters with p-values greater than 0.05 might also be 
considered evidence of a radiation effect.  Therefore results are also shown in Table IX.B-15 for tests at 
critical level α = 0.10.  For example, the study had an estimated power of 0.912 for finding a dose-response 
with p-value < 0.10 if the true dose-response in fact had slope 0.05 per Gy.
 Figure IX.B-7. Effect of Dose Uncertainty on Statistical Power: Any Benign Thyroid Nodule 
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Solid lines show power calculated ignoring dose uncertainties for tests at critical level α = 0.05 (lower curve) and 0.10 (upper curve).  
Circles show estimated power accounting for dose uncertainties, for tests at α = 0.05 (solid) and 0.10 (open). 
 
 
Table IX.B-16 and Figure IX.B-8 display similar results for the outcome of thyroid carcinoma, 
which represents outcomes with low background rates.  The power was evaluated for the following values 
of the slope parameter: 0 (i.e., the null hypothesis); 0.0169 and 0.0208 per Gy, for which the test at critical 
level α = 0.05 has power 0.80 and 0.90, respectively, if dose uncertainty is ignored; and 0.025, 0.0275, 
0.030, and 0.035 per Gy.  Background rates were assumed to be 0.007 for women and 0.003 for men.  
Accounting for dose uncertainties, the power of the test at critical level α = 0.05 to detect an effect of 0.025 
per Gy (2.5% per Gy) was estimated to be 0.855, compared to 0.96 if uncertainty was ignored. 
 
Table IX.B-16. Effect of Dose Uncertainty on Statistical Power: Thyroid Carcinoma 
 
 Power of Test at Critical Level α = 0.05 Power of Test at Critical Level α = 0.10 
Slope 
(per Gy) 
Ignoring 
Uncertainty 
Accounting for 
Uncertainty 
Ignoring 
Uncertainty 
Accounting for 
Uncertainty 
0 0.05  0.10  
0.0169 0.80 0.726 0.89 0.799 
0.0208 0.90 0.764 0.95 0.864 
0.025 0.96 0.855 0.98 0.904 
0.0275 0.98 0.848 0.99 0.911 
0.030 0.99 0.888 0.995 0.926 
0.035 0.996 0.922 0.999 0.952 
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Figure IX.B-8. Effect of Dose Uncertainty on Statistical Power: Thyroid Carcinoma 
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Solid lines show power calculated ignoring dose uncertainties for tests at critical level α = 0.05 (lower curve) and 0.10 (upper curve).  
Circles show estimated power accounting for dose uncertainties, for tests at α = 0.05 (solid) and 0.10 (open). 
 
 
 
 
 
 
 
 
 
Table IX.B-17 and Figure IX.B-9 display similar results for the outcome of ultrasound detected 
abnormality, which represents outcomes with high background rates.  The power was evaluated for the 
following values of the slope parameter: 0 (i.e., the null hypothesis); 0.097 and 0.114 per Gy, for which the 
test at critical level α = 0.05 has power 0.80 and 0.90, respectively, if dose uncertainty is ignored; and 0.12, 
0.13, and 0.14 per Gy.  Background rates were assumed to be 0.40 for both women and men.  Accounting 
for dose uncertainties, the power of the test at critical level α = 0.05 to detect an effect of 0.12 per Gy (12% 
per Gy) was estimated to be 0.847, compared to 0.92 if uncertainty was ignored. 
Table IX.B-17. Effect of Dose Uncertainty on Statistical Power: Ultrasound Detected Abnormalities 
 
 Power of Test at Critical Level α = 0.05 Power of Test at Critical Level α = 0.10 
Slope 
(per Gy) 
Ignoring 
Uncertainty 
Accounting for 
Uncertainty 
Ignoring 
Uncertainty 
Accounting for 
Uncertainty 
0 0.05 0.053 0.10 0.113 
0.097 0.80 0.782 0.89 0.852 
0.114 0.90 0.840 0.95 0.891 
0.12 0.92 0.847 0.98 0.909 
0.13 0.95 0.892 0.99 0.936 
0.14 0.97 0.894 0.995 0.937 
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Figure IX.B-9. Effect of Dose Uncertainty on Statistical Power: Ultrasound Detected Abnormalities 
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Solid lines show power calculated ignoring dose uncertainties for tests at critical level α = 0.05 (lower curve) and 0.10 (upper curve).  
Circles show estimated power accounting for dose uncertainties, for tests at α = 0.05 (solid) and 0.10 (open). 
In summary, the results of the simulation study showed that the effect of dose uncertainty was, as 
expected, to reduce the study’s statistical power somewhat below the levels calculated with the 
uncertainties ignored.  However, as summarized in Table IX.B-18 below, the reduction was modest, with 
about 85% power available for the alternative hypotheses to which the study’s design was originally 
targeted. 
 
Table IX.B-18. Summary of Effect of Dose Uncertainties on Statistical Power (one-sided tests at  
critical level α = 0.05) 
 
 Ignoring Uncertainty 
Accounting for 
Uncertainty 
Any benign thyroid nodule (intermediate background rates): 
   power to detect 5% per Gy 0.95 0.863 
Thyroid carcinoma (low background rates): 
   power to detect 2.5% per Gy 0.96 0.855 
UDAs (high background rates): 
   power to detect 12% per Gy 0.92 0.847 
 
 
To interpret the study’s power properly, it is important to consider not only the level of power, but 
also the size of the dose-response effect for which that power is obtained.  For example, for the exemplary 
outcome with low background rates, thyroid cancer, with assumed background probabilities of 0.7% and 
0.3% for women and men, respectively, a linear dose-response with slope 2.5% per Gy yields probabilities 
of 1.1% and 0.7%, respectively, at the study participants’ average dose of 174 mGy.  These can also be 
expressed as relative risks of 1.1/0.7 = 1.62 and 2.45 for women and men, respectively, for an overall 
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average of 2.04.  For the exemplary outcomes with intermediate (any benign thyroid nodule) or high 
(thyroid UDA) background rates, the corresponding relative risks (average over both sexes) are markedly 
smaller: 1.30 (5% per Gy) and 1.05 (12% per Gy), respectively.  These represent the magnitudes of the 
effects for which the study’s one-sided tests at critical level α = 0.05 had estimates of about 85% to 86% 
power after accounting for the effects of dose uncertainties (see Table IX.B-18 above). 
 
For comparison to results of other studies, the magnitudes of radiation effects can be expressed as 
the relative risks at 1000 mGy (1 Gy).  For the low background rate example of thyroid cancer, a slope of 
2.5% per Gy corresponds to probabilities of 3.2% and 2.8% for women and men at 1 Gy, respectively, i.e., 
to relative risks of 4.57 and 9.33, and an average of 6.95, at 1 Gy.  This is similar to the estimated relative 
risk of 8.9 at 1 Gy reported for the Utah Study in their analysis that did not account for the effects of dose 
uncertainties (10139).   However the appropriate comparison is to the estimated relative risk that is 
obtained after adjusting for the effect of dose uncertainties.  The authors of the Utah Study reported that 
their uncertainty-adjusted estimates were about three-fold greater than the unadjusted estimates, 
corresponding to a relative risk of 1 + 3 × (8.9 – 1), or about 25 at 1 Gy.  A recent analysis suggested that 
the adjustment should perhaps be smaller: Mallick and colleagues analyzed the Utah Study’s data 
concerning thyroid neoplasms and concluded that the estimated relative risk at 1 Gy should be 
approximately doubled, rather than tripled, to account for dose uncertainties (139).  Assuming this 
conclusion applies to thyroid cancer, the estimated relative risk would be about 17 at 1 Gy.  The HTDS 
clearly had adequate statistical power to detect an effect of this magnitude.  For example, after accounting 
for dose uncertainty there was an estimated 92% power to detect a linear dose-response with a slope of 
3.5% per Gy for thyroid cancer (Table IX.B-18 above), which corresponds to an average relative risk (both 
sexes combined) of 9.33 at 1 Gy, well below the estimated effect from the Utah Study. 
 
 
B.5. Out-of-Area Participants 
 
The numbers of out-of-area subjects are shown by sex, birth year, and geostratum in Table  
IX.B-19.  The percentage of out-of-area participants was 7.2% for women (125/1747) and 7.3% for men 
(124/1693), but varied widely among birth years and geostrata.   
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Table IX.B-19. Proportions of Out-of-Area Participants, by Sex, Birth Year, and Geostratum 
 
  Living Evaluable Out-of-Area 
  Participants No. % 
Sex Female 1747 125   7.2 
 Male 1693 124   7.3 
Birth Year 1940 243   25 10.3 
 1941 283   28   9.9 
 1942 472   37   7.8 
 1943 560   76 13.6 
 1944 906   77   8.5 
 1945 611     3   0.5 
 1946 365     3   0.8 
Geostratum Richland 352     4   1.1 
 Pasco/Kennewick 1009   99   9.8 
 Walla Walla City 264   14   5.3 
 Benton Co. 734   78 10.6 
 Franklin Co. 149     8   5.4 
 Walla Walla Co. 334   14   4.2 
 Okanogan Co. 139   14 10.1 
 Ferry/Stevens Cos. 138     7   5.1 
 Adams Co. 321   11   3.4 
Total  3440 249   7.2 
 
 
Only 6 (0.6%) of the 976 participants born in 1945 or 1946 were in the out-of-area group.  In the 
earlier years, however, the percentage ranged from 7.8% (37/472) for 1942 to 13.6% (76/560) for 1943.  
The sharp drop in 1945-46 reflects that fact that the nearly all participants lived at or near their mother’s 
“usual place of residence” for at least some time after their births.  Consequently most participants born in 
1945-46 first lived within the HEDR geographical domain.  Participants born before 1945 and therefore, for 
the most part, before the start of 131I releases from Hanford, had more time during which their families 
might move outside the HEDR domain. 
 
Regarding geostrata, only 4 (1.1%) of the 352 participants in the Richland geostratum were in the 
out-of-area group.  This occurred primarily because Richland was not defined as separate geostratum until 
1944.  Therefore it does not include participants born during 1940-1943 who, as explained above, had a 
greater likelihood of moving outside the HEDR domain before the start if Hanford’s 131I releases.  In the 
other eight geostrata the percentage of out-of-area participants ranged from 3.4% (11/321) in the Adams 
County geostratum to 10.6% (78/734) in the Benton County geostratum. 
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C. Thyroid Cancer
C.1. Occurrence of Thyroid Cancer
The primary and alternative definitions for thyroid cancer were as follows:
• Primary definition: HTDS or prior histologic diagnosis (19 cases)
• Alternative definition: HTDS or prior histologic or clinical diagnosis (20 cases)
Twenty participants (0.6%) were diagnosed with thyroid cancer (Table IX.C-1), including 13
women (0.7%) and 7 men (0.4%).  Of the twenty participants found to have thyroid cancer, all but one had
diagnoses based on histologic evidence from either the HTDS examination (12) or prior medical care (7).
Only one living evaluable participant’s diagnosis of thyroid cancer was based on a prior clinical diagnosis.
This participant’s histology records had been destroyed, but her medical records from 1966 included
mention of  “Thyroidectomy (cancer) 4/65”.  
Of the 20 cancer diagnoses, 12 (60%) resulted from the HTDS examination and 8 (40%) were
made prior to the participant’s HTDS examination.  
Table IX.C-1. Diagnoses of Thyroid Cancer, by Basis for Diagnosis and Sex
Female Male Total
Diagnosis of Thyroid Cancer No.     % No.     % No.      %
Yes     13     0.7       7     0.4     20     0.6
Histologic diagnosis:  HTDS       6     0.3       6     0.4     12     0.3
Prior histologic diagnosis       6     0.3       1     0.1       7     0.2
Prior clinical diagnosis       1     0.1       0        --       1     0.0
No 1732   99.1 1685   99.5 3417   99.3
Unknown       2     0.1       1     0.1       3     0.1
Total 1747 100.0 1693 100.0 3440 100.0
 
 
 
Three additional living evaluable participants were classified “unknown” with regard to diagnosis
of thyroid cancer.  One of these participants had a fine needle aspiration (FNA) prior to the HTDS clinic of
a mass outside of the thyroid.  This mass was not seen or felt at the HTDS clinic, and no surgery was ever
performed, thus thyroid cancer could not be ruled out.  The second participant did not have a fine needle
aspiration at the HTDS clinic due to a history of cardiac risk, and never had an FNA performed subsequent
to the clinic.  Again thyroid cancer could not be ruled out.  For the third participant the two doctors at the
HTDS clinic disagreed as to whether the subject had a lobulation or a small nodule and the ultrasound did
not identify any nodules.  These three participants were included as non-cases in analyses of the thyroid
cancer dose-response.
Three other participants or potential participants had evidence of thyroid cancers that were not
included in the primary analysis:
• Two living evaluable participants had thyroid cancers diagnosed after participating in HTDS.  In
one case the thyroid pathology was incidental to an HTDS recommendation for parathyroid
surgery.  In the other case the HTDS evaluation concluded that the two palpable nodules at the
clinic were most likely non-thyroid, based on a normal nuclear scan.  It was subsequently
conveyed via a phone call from the participant that she had thyroid cancer.  It was determined that
since our evaluation of this subject was concluded with no recommendation for surgery or follow-
up for definitive pathology, the information from the phone call could not be used or pursued.
Although these two diagnoses could not be used in the primary analysis of thyroid cancer, they
were included in an additional dose-response analysis (see section IX.C.2.c below).
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• One potential participant who refused to participate in HTDS gave as a reason that he/she had thyroid
cancer and had already seen too many doctors.  Since this person did not participate in the HTDS, this
case could not be included in any analyses.
Sixteen (80.0%) of the 20 cancer cases had papillary cancer, while three (15.0%) had follicular
cancer (Table IX.C-2).  The histologic type was unknown for the one participant with only a prior clinical
diagnosis.
Table IX.C-2. Frequency Distribution of Histologic Types of Thyroid Cancer, by Sex
Female Male Total
Histologic Type Cases % Cases % Cases %
Papillary Cancer 10   76.9 6   85.7 16   80.0
Follicular Cancer   2   15.4 1   14.3   3   15.0
Unknown   1     7.7 0        --   1     5.0
Total 13 100.0 7 100.0 20 100.0
C.1.a Pathways to Diagnosis of Thyroid Cancer
The section above described the sources of information for all diagnoses of thyroid cancer among
the living evaluable study participants. The diagnoses that resulted from the HTDS clinical examinations
can also be characterized according to the method of detection (or “pathway to diagnosis”).  As described
in section V.F above, the HTDS employed a comprehensive diagnostic design in which participants
received a thyroid ultrasound scan that was viewed only after two independent thyroid physical
examinations were conducted by thyroid specialists. Additional thyroid exams were then conducted only if
the ultrasound showed abnormalities that were not detected by the physicians. For the 12 diagnoses of
thyroid cancer that were made as a result of the HTDS examination, Table IX.C-3 shows which component
of the diagnostic process was instrumental in making the diagnosis.  The majority of the thyroid cancers
(10 or 83%) were detected because one or both of the physicians palpated a new thyroid mass before
viewing the videotaped recording of the ultrasound examination. However the other two thyroid cancers
were detected only when the physicians repeated the physical examination after reviewing the ultrasound
scan.  These descriptive results illustrate the contributions of multiple diagnostic methods in the evaluation
process. They also underscore the differences that can occur in the prevalence of thyroid disease from one
study to another depending on the diagnostic methods used.
Table IX.C–3. Pathways to Diagnosis of Thyroid Cancer
Thyroid Cancer
Pathway to Diagnosis No. %
Palpable prior to ultrasound  10 83.3
Palpable only after ultrasound   2 16.7
Palpable only (not detected on ultrasound)   0 --
Nonpalpable (detected only on ultrasound)   0 --
Total  12  100
C.2. Analysis of Thyroid Cancer Risk
C.2.a. Primary Analysis 
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Nineteen living evaluable participants had diagnoses of thyroid cancer based on HTDS or prior
histologic evidence.  Five of these cases were out-of-area participants, for whom the CIDER program
could not calculate dose estimates.  The numbers of cases and proportions with thyroid cancer are shown
by sex and dose category in Table IX.C-4.
Table IX.C-4. Diagnoses of Thyroid Cancer by Sex, Dose Category, and Basis for Diagnosis
A. Female
 
 
 Thyroid
Radiation
Dose
 
 Living
Evaluable
Female
 Primary Definition:
Cases Based on HTDS
or Prior Histologic
Diagnosis
 Alternative Definition:
 Cases Based on HTDS
or Prior Histologic or
Clinical Diagnosis
 (mGy)    No.  No.  %  No.  %
 Out of Area   125   2  1.6   3  2.4
 < 10   182   1  0.5   1  0.5
 10-49   320   3  0.9   3  0.9
 50-99   313   1  0.3   1  0.3
 100-149   220   1  0.5   1  0.5
 150-199   126   1  0.8   1  0.8
 200-299   139   1  0.7   1  0.7
 300-399   144   1  0.7   1  0.7
 400-999   171   1  0.6   1  0.6
 1000+       7   0    --   0   --
 Total  1747  12  0.7  13  0.7
 
B. Male
 
 
 Thyroid
Radiation
Dose
 
 Living
Evaluable
Male
 Primary Definition:
Cases Based on HTDS
or Prior Histologic
Diagnosis
 Alternative Definition:
 Cases Based on HTDS
or Prior Histologic or
Clinical Diagnosis
 (mGy)    No.  No.  %  No.  %
 Out of Area   124  3  2.4  3  2.4
 < 10   186  1  0.5  1  0.5
 10-49   314  2  0.6  2  0.6
 50-99   310  0    --  0    --
 100-149   171  0    --  0    --
 150-199   109  0    --  0    --
 200-299   148  0    --  0    --
 300-399   160  0    --  0    --
 400-999   154  0    --  0    --
 1000+     17  1  5.9  1  5.9
 Total  1693  7  0.4  7  0.4
 
The highest estimated dose among the 14 in-area cases was 1083 mGy.  Parameter estimates for
the linear dose-response model based on the 3191 living evaluable in-area participants are shown in Table
IX.C-5 below.  Based on maximum likelihood analysis of the sex-stratified linear probability model, and
using primary dose estimates (Table IX.C-5, row 1), the risk of thyroid cancer did not increase
significantly with estimated dose (p = 0.25), with an estimated slope B of 0.002 per Gy, and 95% CI
ranging from less than −0.001 to 0.017 per Gy.  The background thyroid cancer rates were estimated to be
0.006 with confidence interval (0.001, 0.011) for women, and 0.002 with confidence interval (0, 0.005) for
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men.  Results obtained by least squares analysis using ungrouped or grouped data were similar (rows 2 and
3 of Table IX.C-5).
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Dose-
Response Dose
Exclusions /
Additional
Method
of Estimated Background Rates 
Estimated
Slope of Dose-
Statistical Significance
of Dose-Response
Row Outcome Model Estimates Inclusions Analysis Female Male Response (per Gy) (one-tailed p-value)
1.
Primary definition
(HTDS or prior,
histologic diagnosis)
Linear Primary None MLE
.006 ± .002
(.001, .011)
.002 ± .001
(0*, .005)
.002 ± .004
 (< −.001, .017) 0.25
2. Primary definition Linear Primary None LSU
.005 ± .002
(.001, .010)
.002 ± .002
(0*, .006)
.005 ± .005
 (−.008, .017) 0.19
3. Primary definition Linear Primary None LSG
.006 ± .002
(.002, .011)
.003 ± .002
(0*, .007)
−.000 ± .006
 (−.015, .014) 0.51
4. Primary definition Linear Primary
+ 2 Incidental
cases
MLE
.007 ± .002
(.002, .012)
.002 ± .001
(0*, .005)
.002 ± .004
 (< −.001, .017) 0.28
5. Primary definition LQ Primary None LSU
.006 ± .002
(.001, .011)
.002 ± .002
(0*, .007)
Lin: .002 ± .009
(−.020, .024)
Quad: .002 ± .006
(−.012 .017)
Quad: 0.70
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, ">"
indicates that the upper confidence limit is greater than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are not
given for estimated background rates from logistic regression model.  “0*” indicates that the lower confidence limit for a background rate was less than 0.
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
Okanogan, F/S = Ferry/Stevens, OOA = out of area
Table continued on next page
Table IX.C-5. Dose-Response Results for Diagnoses of Thyroid Cancer Based on HTDS or Prior Histologic Evidence
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Dose-
Response Dose
Exclusions /
Additional
Method
of Estimated Background Rates 
Estimated
Slope of Dose-
Statistical Significance
of Dose-Response
Row Outcome Model Estimates Inclusions Analysis Female Male Response (per Gy) (one-tailed p-value)
Primary definition Logistic Primary None MLE
.005
(.002, .013)
.002
(.001, .008)
.71 ± .79
( -1.18, 2.61)
0.22
Primary definition Linear Primary
Exclude dose
> 1000 mGy
MLE
.007 ± .002
(.001, .013)
.002 ± .001
(0*, .005)
−.002 ± .006
(NE, >.011)
0.77
Primary definition Logistic Primary
Exclude dose
> 400 mGy
 MLE
.007 ± .003
(0*, .014)
.002 ± .001
(0*, .005)
−.006 ± .016
(NE, .015)
0.87
Primary definition Linear Primary
Exclude
OK and F/S
geostrata
MLE
.006 ± .002
(.0005, .011)
.002 ± .001
(0*, .006)
.002 ± .004
(<-.001,.018)
0.26
. Primary definition Linear Alt. #1 None MLE
.006 ± .002
(.001, .012)
.003 ± .002
(0*, .007)
−.001 ± .005
(NE, .015)
0.59
tries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, ">"
dicates that the upper confidence limit is greater than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are not
ven for estimated background rates from logistic regression model.  “0*” indicates that the lower confidence limit for a background rate was less than 0.
bbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
kanogan, F/S = Ferry/Stevens, OOA = out of area
able continued on next page
Table IX.C-5. Dose-Response Results for Diagnoses of Thyroid Cancer Based on HTDS or Prior Histologic Evidence (continued)H
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Dose-
Response Dose
Exclusions /
Additional
Method
of Estimated Background Rates 
Estimated
Slope of Dose-
Statistical Significance
of Dose-Response
Row Outcome Model Estimates Inclusions Analysis Female Male Response (per Gy) (one-tailed p-value)
11. Primary definition Linear Alt. #2 None MLE
006 ± .002
(.0005, .012)
.003 ± .001
(0*, .006)
−.001 ± .010
(NE, .008)
0.80
12. Primary definition Linear Primary
Include
OOA
(scoping
analysis #1)
MLE
.007 ± .002
(.002, .012)
.004 ± .002
(.0001, .008)
.0006 ± .004
(<-.002, >.015)
0.44
13. Primary definition Linear Primary
Include
OOA
(scoping
analysis #2)
MLE
.007 ± .002
(.002, .012)
.004 ± .002
(.0001, .008)
.0002 ± .004
(<-.002, >.014)
0.48
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, ">"
indicates that the upper confidence limit is greater than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are not
given for estimated background rates from logistic regression model.  “0*” indicates that the lower confidence limit for a background rate was less than 0.
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
Okanogan, F/S = Ferry/Stevens, OOA = out of area
Table IX.C-5. Dose-Response Results for Diagnoses of Thyroid Cancer Based on HTDS or Prior Histologic Evidence (continued)
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C.2.b. Alternative Definition for Diagnosis of Thyroid Cancer
As described in section IX.C.1 above, only one participant had a diagnosis of thyroid cancer based
on anything other than HTDS or prior histologic diagnosis.   This case was an out-of-area participant, and
therefore had no effect on the primary dose-response analysis.
C.2.c. Effect of Including Incidental Diagnoses of Thyroid Cancer  
As described in section IX.C.1 above, two living evaluable participants had thyroid cancers that
were determined to be incidental.  That is, each diagnosis was made after the participant’s HTDS
examination, and not as a result of a study recommendation for further evaluation of a possible thyroid
cancer.  These two cases were not included in the primary analysis of thyroid cancer to avoid introducing a
possible reporting bias.  However, in view of the importance of thyroid cancer as a disease outcome,
additional analyses that included these two incidental cases were performed.  These two participants were
both in the in-area group, and their estimated thyroid radiation doses were 169 and 62 mGy.  When these
two incidental cases were included along with the 14 in-area cases in the primary analysis, the results were
essentially unchanged, with estimated slope 0.002 per Gy with 95% CI ranging from less than −0.001 to
0.017 per Gy (Table IX.C-5, row 4).
C.2.d. Alternative Dose-Response Functions
Shown in row 5 of Table IX.C-5, the estimated regression coefficient for the dose-squared term in
the linear-quadratic dose-response model [5] was 0.002 with Bonferroni-adjusted 95% confidence interval
ranging from –0.012 to 0.017.  Thus the addition of a quadratic term did not significantly improve the fit of
the model (p = 0.70).
The regression parameter for the effect of dose in the sex-stratified logistic regression model [2]
was estimated as 0.71 with Bonferroni-adjusted 95% confidence interval ranging from –1.18 to 2.61.  Thus
there was no evidence from the logistic regression model that cumulative incidence of thyroid cancer
increased significantly with increasing dose (p = 0.22, Table IX.C-5, row 6).
C.2.e. Effect of Excluding Participants in High Dose Categories
  The proportions of in-area women with cancer varied little over the dose categories shown in
Table IX.C-4, ranging between 0.3% and 0.9%, with no cases among the seven women with doses over
1000 mGy.  One of the four male thyroid cancer cases in the in-area group had an estimated dose of 1083
mGy, while the other three had doses less than 50 mGy.  Consequently, when participants in the highest
dose categories (> 1000 mGy or > 400 mGy) were excluded, the estimated slope of the dose-response
decreased slightly, to −0.002 per Gy with Bonferroni-adjusted 95% upper confidence limit exceeding
0.011 per Gy among those with doses < 1000 mGy, and to −0.006 per Gy with upper confidence limit
0.015 per Gy among those with doses < 400 mGy (Table IX.C-5, rows 7 and 8).  Thus there was no
evidence that the dose-response results were inordinately influenced by the outcomes of participants in the
highest dose categories.
C.2.f. Effect of Excluding Okanogan and Ferry/Stevens Geostrata
When participants in the Okanogan and Ferry/Stevens geostrata were excluded, the estimated
slope of the dose-response changed only slightly, to 0.002 per Gy with 95% CI ranging from less than
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−0.001 to 0.018 per Gy (Table IX.C-5, row 9).  Thus there was no evidence that the dose-response results
were inordinately influenced by the outcomes of participants in these geostrata.
C.2.g. Analysis of Thyroid Cancer in Relation to Alternative Dose Estimates 
Parameter estimates for the linear dose-response model using the alternative dose estimates are
shown in rows 10 and 11 of Table IX.C-5 above.  For both alternative dose estimates the estimated slope B
decreased as compared to the primary dose set, from 0.002 to −0.001, and thus in neither case was there
evidence that the cumulative incidence of thyroid cancer increased with increasing dose.
C.2.h. Scoping Analyses Regarding Out-of-Area Participants
See section VIII.C.1.a.3  for a description of the scoping analyses that were performed to assess
the possible impact of including the 249 out-of-area participants.  As summarized in rows 12 and 13 of
Table IX.C-5, in both analyses the inclusion of the out-of-area participants slightly decreased the estimated
slope of the dose-response, but did not materially change the dose-response results.
C.2.i.  Analysis of Thyroid Cancer in Relation to Alternative Representations of
Exposure
In the analyses by geostratum and by dichotomous exposure variable, the sex and age-adjusted
comparisons of cumulative incidence were performed as described in section VIII.C.2.a.2.
C.2.i.1. Analysis by Geostratum
Since only 19 participants had thyroid cancer (see Table IX.C-6), the test for heterogeneity among
the nine geostrata had little statistical power.  Therefore the absence of significant heterogeneity (p = 0.73)
was not strong evidence against the possibility that the cumulative incidence of thyroid cancer might in fact
vary among the geostrata.  The percentages with cancer were somewhat higher in the Okanogan and
Ferry/Stevens geostrata (1.4% for women, 0.7% for men) than in the remaining geostrata (0.6% and 0.4%),
but this difference was also not statistically significant (p = 0.26).
Table IX.C-6. Diagnoses of Thyroid Cancer Based on HTDS or Prior Histologic Evidence, by
Geostratum and Sex
Female Male Total
Geostratum No. Cases % No. Cases % No. Cases %
Richland   179   1 0.6   173 1 0.6   352   2 0.6
Pasco/Kennewick   508   3 0.6   501 1 0.2 1009   4 0.4
Benton County   376   2 0.5   358 2 0.6   734   4 0.5
Franklin County     73   0 --     76 0 --   149   0 --
Adams County   165   1 0.6   156 0 --   321   1 0.3
Walla Walla (city)   133   1 0.8   131 1 0.8   264   2 0.8
Walla Walla County   170   2 1.2   164 1 0.6   334   3 0.9
Okanogan County     75   1 1.3     64 1 1.6   139   2 1.4
Ferry/Stevens Counties     68   1 1.5     70 0 0.0   138   1 0.7
Total 1747 12 0.7 1693 7 0.4 3440 19 0.6
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C.2.i.2. Analysis by Dichotomous Exposure Variable
See section VIII.B.3.b.2 above for a description of the high and low exposure categories.  Eleven
(0.9%) of the 1257 participants included in these analyses had thyroid cancer based on an HTDS or prior
histologic examination (see Table IX.C-7).  These included 3/580 (0.5%) in the high exposure group and
8/677 (1.2%) in the low exposure group.  Thus there was no evidence that cumulative incidence of thyroid
cancer was elevated in the high exposure group (p = 0.86). 
Table IX.C-7. Diagnoses of Thyroid Cancer based on HTDS or prior histologic evidence, by
exposure group and sex 
Exposure Female Male Total
Group No. Cases % No. Cases % No. Cases %
Low 351 4 1.1 326 4 1.2   677   8 1.2
High 298 2 0.7 282 1 0.4   580   3 0.5
Total 649 6 0.9 608 5 0.8 1257 11 0.9
C.2.j. Confounding and Effect Modification  
There were too few participants with diagnoses of thyroid cancer to warrant any analysis of
confounding or effect modification.
C.2.k. Uncertainty
The estimated slopes of the sex-stratified linear dose-response model for thyroid cancer are shown
in Figure IX.C-1 for each of the 100 dose realizations produced by the CIDER model.  The confidence
intervals in that figure are calculated at the 98.33% confidence interval, i.e., are adjusted by the Bonferroni
technique for the simultaneous estimation of the slope and two sex-specific background rates.  While the
point estimate of the slope is greater than 0 for 65 of the 100 realizations, the confidence interval includes 0
for all of the 100 realizations.  Also shown in Figure IX.C-1 (to the right of realization 100) are the
estimates and confidence intervals calculated using (from left to right) the median, geometric mean and
mean of each participant’s 100 dose realizations. In summary, for none of the 100 realizations of the
estimated doses was there a statistically significant dose-response.
Figure IX.C-1. Plot of Estimated Slope by Dose Realization
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Figure IX.C-2 displays the distribution of the 5000 estimates of the logistic coefficient obtained
by the simulation procedures described in section VIII.C.2.b.3 above. It is evident from the figure that most
of the estimates were between about –5.0 and 2.0. The estimate was less than or equal to 0 for 2574 of the
5000 replications, implying an empirical one-tailed p-value of 0.52. The median estimate was –0.06, and
the upper and lower percentiles corresponding to the Bonferroni-adjusted 95% confidence interval were
–8.29 and 2.11.  These may be compared to the estimate of 0.71 with confidence interval (-1.18, 2.61)
obtained using the median dose estimates without adjustment for uncertainty. Thus, this method of
adjusting the estimated logistic regression coefficient for the uncertainty in the dose estimates did not
provide evidence that the cumulative incidence of thyroid cancer increased with increasing dose. 
Figure IX.C-2. Distribution of Simulation Estimates of Logistic Regression Coefficient
slope sample: 5000
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D. Benign Thyroid Nodule 
D.1. Occurrence of Benign Thyroid Nodule
The primary and alternative definitions for benign thyroid nodule were as follows:
• Primary definition: HTDS or prior, histologic or cytologic diagnosis (249 cases)
• Alternative definition #1: HTDS or prior, histologic, cytologic or clinical diagnosis (287 cases)
• Alternative definition #2: Any diagnosis or participant/respondent report (297 cases).
Table IX.D-1 shows the numbers and percentages of living evaluable participants with diagnoses
of benign thyroid nodule, and the bases for those diagnoses, by sex.  Two hundred and forty-nine (7.2%)
living evaluable participants had a diagnosis of benign thyroid nodule based on histologic or cytologic
evidence arising from the HTDS examination or from a prior diagnosis, with 170 (9.7%) women  79 (4.7%)
men having this condition, respectively.  Thirty-eight (1.1%) participants had diagnoses classified as
clinical.  Additionally, for 10 (0.3%) the diagnosis was based solely on a report by the participant or his/her
CATI respondent.
Table IX.D-1. Diagnoses of Benign Thyroid Nodule, by Basis for Diagnosis and Sex
Female Male Total
Diagnosis of Benign Thyroid Nodule No. % No. % No. %
Yes   200   11.4     97     5.7   297     8.6
Histologic diagnosis:  HTDS       7     0.4       6     0.4     13     0.4
Cytologic diagnosis:  HTDS   142     8.1     65     3.8   207     6.0
Prior histologic diagnosis     19     1.1       7     0.4     26     0.8
Prior cytologic diagnosis       2     0.1       1     0.1       3     0.1
Clinical diagnosis:  HTDS     16     0.9     13     0.8     29     0.8
Prior clinical diagnosis       7     0.4       2     0.1       9     0.3
Participant/respondent report       7     0.4       3     0.2     10     0.3
No 1545   88.4 1595   94.2 3140   91.3
Unknown       2     0.1       1      0.1       3     0.1
Total 1747 100.0 1693 100.0 3440 100.0
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Three living evaluable participants were classified “unknown” with regard to diagnosis of benign
thyroid nodule.  One of these participants reported a history of having a thyroid “lump” removed, but had
no record of surgery or evidence of a surgical scar.  The second participant’s medical record included
mention of thyroid nodule by one physician. However a second physician disagreed, revising the diagnosis
to thyromegaly, with decrease in size after treatment.  For the third participant, the two doctors at the
HTDS clinic disagreed as to whether the subject had a lobulation or a small nodule and the ultrasound did
not identify any nodules (this participant was also classified as “unknown” for diagnosis of thyroid cancer).
These three participants were included as non-cases in analyses of the dose-response for benign thyroid
nodule.
As shown in Table IX.D-2, the majority of benign thyroid nodules were colloid nodules (69.7%).
Follicular adenomas accounted for only 4.7% of the diagnoses.  The remaining 33.0% included a variety of
types of nodules, which are described in Table IX.D-3.
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Table IX.D-2. Frequency Distribution of Histologic/Cytologic Types of Benign Thyroid Nodule, by
Sex
Female Male Total
Histologic/Cytologic Type Cases % Cases % Cases %
Colloid nodule 139   69.5 68   70.1 207   69.7
Follicular adenoma     8     4.0   6     6.2   14     4.7
Other   71   35.5 26   26.8   97   32.7
Total with benign thyroid nodule 200 100.0 97 100.0 297 100.0
Note:  A participant can have >1 histologic/cytologic type
Table IX.D-3. Frequency Distribution of Other Histologic/Cytologic Types of Benign Thyroid
Nodule, by Sex
Female Male Total
Other Histologic/Cytologic Type Cases % Cases % Cases %
Unknown/uncertain* 25   35.2   14   53.8 39   40.2
Hashimoto’s thyroiditis 23   32.4 6   23.1 29   29.9
Thyroglossal duct cyst   4     5.6 1     3.8   5     5.2
Adenomatous nodule/goiter   3     4.2 2     7.7   5     5.2
Benign follicular nodule   7     9.9 1     3.8   8     8.2
Benign nodular goiter   2     2.8 0       --   2     2.1
Chronic thyroiditis w/benign follicles
& Hurthle cells
  1     1.4 0       --   1     1.0
Colloid nodule vs follicular adenoma   1     1.4 0       --   1     1.0
Hashimoto’s & non-neoplastic
follicular nodule w/colloid
  1     1.4 0       --   1     1.0
Nodular hyperplasia   1     1.4 0       --   1     1.0
Possible thyroiditis   1     1.4 0       --   1     1.0
Simple cyst   1     1.4 0       --   1     1.0
Nondiagnostic, probable colloid
nodule
  1     1.4 0       --   1     1.0
Unknown due to
participant/respondent report
0       --   1     3.8   1     1.0
Probable neoplastic macrofollicular
nodule 
0       --   1     3.8   1     1.0
Total with other histologic/cytologic
type 71 100.0 26 100.0 97 100.0
* No cytology available
Of the 98 participants with histologic/cytologic type classified ‘Other’ (Table IX.D-3), 39 (39.8%)
were of unknown or uncertain type, meaning no cytology was available.  Another 29 (29.6%) were
associated with Hashimoto’s thyroiditis, 8 (8.2%) were due to a benign follicular nodule, 5 (5.1%) were
due to a thyroglossal duct cyst, 5 (5.1%) were due to an adenomatous nodule, 2 (2.0%) were due to a
benign nodular goiter, and the remaining 9 were due to varying individual specifications of the
histologic/cytologic type. 
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D.1.a. Additional Disease Outcomes Related to Benign Thyroid Nodule
The following additional disease outcomes related to benign thyroid nodule were considered.
These outcomes were defined based on the primary definition of benign thyroid nodule (i.e. HTDS or prior,
histologic or cytologic evidence).
D.1.a.1 Benign Thyroid Nodules and Nodules Suspicious for Thyroid Follicular Adenoma
Additional analyses were performed in which the participants with either benign thyroid nodules
or nodules coded as “suspicious for follicular neoplasm” were combined as cases.  The category of
suspicious for follicular neoplasm deserves some additional comment.  Participants having FNA biopsy for
a palpable nodule or a nonpalpable nodule larger than an average of 1.5 cm, were recommended to have
further evaluation or consideration of thyroid surgery if the FNA result was reported as either suspicious
for malignancy or suspicious for follicular neoplasm.  For those participants who did have surgery, the
HTDS final diagnosis was then designated as either cancer or benign thyroid nodule based on the surgical
pathology.  However, there were 16 participants with FNA results reported as suspicious for follicular
neoplasm who chose not to have surgery.  None of those individuals had FNA results that were suspicious
for cancer.  Their FNA results showed either intermediate or high probability of follicular neoplasm; none
were suspicious for papillary cancer. Although these 16 cases were most likely to represent a benign
thyroid nodule, the risk of thyroid cancer in such cases has been reported to be approximately 10-30%.  
Sixteen participants without other benign thyroid nodules (14 women, 2 men) had diagnoses of
nodules suspicious for follicular neoplasm, all based on cytology.  Consequently the 3440 living evaluable
participants included 265 (7.7%) with diagnoses of benign thyroid nodule or nodule suspicious for
follicular neoplasm (Table IX.D-4), with more than twice as many cases among women (10.5%) than men
(4.8%).
Table IX.D-4. Benign Thyroid Nodule and Nodules Suspicious for Follicular Neoplasm, by Sex
Female Male TotalBenign Thyroid Nodule or
Nodule Suspicious for
Follicular Neoplasm No. % No. % No. %
Yes   184   10.5     81     4.8   265     7.7
No 1563   89.5 1612   95.2 3175   92.3
Total 1747 100.0 1693 100.0 3440 100.0
D.1.a.2. Benign Thyroid Nodule Excluding Non-neoplastic Disease
The outcome of benign thyroid nodule excluding non-neoplastic etiology was defined in order to
exclude cases that might have a specific non-neoplastic etiology, as their inclusion might mask a dose-
response effect.  This outcome was defined to include participants with a diagnosis of benign thyroid
nodule based on histologic or cytologic evidence from the HTDS or prior examination, but excluding those
with any of the following:
• Autoimmune thyroiditis based on HTDS evaluation or medical records with supporting
documentation;
• Graves disease based on HTDS evaluation or medical records with supporting documentation; or
• Hyperthyroidism based on HTDS evaluation or medical records with supporting documentation with
an etiology of toxic nodular goiter or solitary toxic nodule.  
Among the 3440 living evaluable participants 175 (5.1%) had a diagnosis of benign thyroid
nodule excluding a non-neoplastic etiology, with the percentage of cases about twice as high for women
(6.7%) as for men (3.4%) (Table IX.D-5).
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Table IX.D-5. Benign Thyroid Nodule Excluding Non-neoplastic Disease, by Sex
      Female     Male TotalBenign Thyroid Nodule
Excluding Non-neoplastic
Disease No. % No. % No. %
Yes   117     6.7     58     3.4   175     5.1
No 1630   93.3 1635   96.6 3265   94.9
Total 1747 100.0 1693 100.0 3440 100.0
D.1.a.3. Solitary Benign Thyroid Nodule Detected without Ultrasound
The outcome of palpable, solitary, benign thyroid nodule detected without ultrasound was defined
in order to simulate the effect of screening for thyroid disease by palpation only, i.e., without ultrasound
examination.  A total of 88 living evaluable participants (64 women, 24 men) had diagnoses of such
nodules (Table IX.D-6).
Table IX.D-6. Solitary Benign Thyroid Nodule Detected without Ultrasound, by Sex
       Female    Male      Total
Solitary Benign Thyroid
Nodule Detected without
Ultrasound No. % No. % No. %
Yes     64     3.7     24     1.4     88     2.6
No 1683   96.3 1669   98.6 3352   97.4
Total 1747 100.0 1693 100.0 3440 100.0
For the majority of the 88 living evaluable participants with solitary benign thyroid nodules that
were detected without ultrasound, i.e., by palpation, those nodules were also observed on the ultrasound
examination.  However for 21 (24%) of the 88, those nodules were not detected by ultrasound.  Twelve
(57%) of these 21 participants each had 1-6 discrete focal ultrasound abnormalities in addition to the
palpable nodule which was not detected on ultrasound.  In addition, 15 of 21 (71%) had documented
Hashimoto’s thyroiditis.  Only 4 participants (0.1% of the 3429 living evaluable participants whose thyroid
glands were visible in their ultrasound examinations) had a palpable nodule with a completely normal
ultrasound scan.  These results suggest that the reason for the discordance between palpation and
ultrasound in this small group was the abnormal thyroid tissue that is present throughout the gland in
individuals with Hashimoto’s thyroiditis, a fact well known in clinical practice.  Since only 4 participants
had true palpable nodules that were not detected by ultrasound, a dose-response analysis of this specific
outcome was not feasible.
D.1.a.4. Benign Thyroid Nodule Excluding Colloid-Only Nodules
In the primary analysis, thyroid nodules with abundant colloid but insufficient follicular cells
(designated for this study as “colloid-only” nodules) were classified as benign thyroid nodules.  Since such
a cytology result is technically nondiagnostic, an additional analysis was performed in which the colloid-
only nodules were not counted among the benign thyroid nodules.  Of the 249 living evaluable participants
with diagnoses of benign thyroid nodules, 18 (12 women and six men) had diagnoses based solely on
colloid-only nodules.  Thus a total of 231 (6.7%) had benign thyroid nodules excluding colloid-only
nodules (Table IX.D-7).
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Table IX.D-7. Benign Thyroid Nodule Excluding Colloid-Only Nodules, by Sex
       Female Male TotalBenign Thyroid Nodule
Excluding Colloid-only
Nodules    No. %    No. % No. %
Yes   158     9.0     73     4.3   231     6.7
No 1589   91.0 1620   95.7 3209   93.3
Total 1747 100.0 1693 100.0 3440 100.0
D.1.a.5. Benign Colloid Nodules
Colloid nodules comprised the largest category of benign thyroid nodules.  Thus the outcome of
benign colloid nodules was defined to determine whether colloid nodules might be related to 131I exposure.
Participants were counted as cases for this outcome if they had colloid nodules, regardless of whether they
had any other benign thyroid nodules. As shown in Table IX.D-8 below, 201(5.8%) of the 3440 living
evaluable participants had benign colloid nodules.
Table IX.D-8. Benign Colloid Nodules, by Sex
       Female Male Total
Benign Colloid Nodules  No.      %    No.      %   No.       %
Yes 136 7.8     65 3.8 201 5.8
No 1611   92.2 1628 96.2 3239 94.2
Total 1747 100.0 1693 100.0 3440 100.0
D.1.b. Pathways to Diagnosis of Benign Thyroid Nodules and Thyroid Nodules Suspicious for
Follicular Neoplasm
The diagnoses described above were based primarily on diagnostic testing done at the HTDS
clinics as well as the participants’ prior medical records. As was done for thyroid cancer, the diagnoses that
resulted from the HTDS clinical examinations were characterized according to the method of detection (or
“pathway to diagnosis”).  As described in section V.F above, the HTDS employed a comprehensive
diagnostic design in which participants received a thyroid ultrasound scan that was viewed only after two
independent thyroid physical examinations were conducted by thyroid specialists. Additional thyroid
examinations were then conducted only if the ultrasound showed abnormalities that were not detected by
the physicians. 
Table IX.D-9. shows the method of detection for diagnoses of benign thyroid nodules, or nodules
suspicious for follicular neoplasm, that resulted from HTDS examinations.
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Table IX.D-9. Pathways to Diagnosis of Benign Thyroid Nodules and Thyroid Nodules Suspicious
for Follicular Neoplasm
Benign Thyroid
Nodule
Suspicious for
Follicular Neoplasm Total
Pathway To Diagnosis No. % No. % No. %
Palpable prior to ultrasound 104 47.3 7 41.2 110* 46.6
Palpable only after ultrasound 67 30.5 7 41.2 74 31.4
Palpable only (not detected on
ultrasound)
15 6.8 0 -- 15 6.4
Nonpalpable (detected only on
ultrasound)
28 12.7 2 11.8 30 12.7
Uncertain consensus on physician exam 0 -- 1 5.9 1 0.4
Complex cases:  FNA decision based on
combination of ultrasound and palpation
6 2.7 0 -- 6 2.5
Total 220 100 17 100 236 100
* Note that one participant with both a benign thyroid nodule and a nodule suspicious for follicular neoplasm, both of which were
palpable prior to ultrasound, is only counted once in the Total column.
The results in Table IX.D-9 show that about half of these diagnoses (125 or 51%) could have been
detected by palpation alone. However nearly a third of these diagnoses (74 or 31%) required ultrasound
review before they were detected by palpation.  For 30 (13%) of these diagnoses, ultrasound was the only
method that led to the diagnosis; these cases were relatively large, nonpalpable nodules (>1.5 cm in 3
dimensions) that were biopsied because of their size.  None of these cases showed thyroid cancer.  The
relative frequencies of the various pathways to diagnosis were about the same for nodules suspicious for
follicular neoplasm as for diagnoses of benign thyroid nodules.  As indicated previously for thyroid cancer,
these descriptive results illustrate the contributions of multiple diagnostic methods in the evaluation
process. They also underscore the fairly large differences that can occur in the prevalence of thyroid disease
from one study to another depending on the diagnostic methods used.
D.2. Analysis of Benign Thyroid Nodule Risk
D.2.a. Primary Analysis
Two hundred forty-nine living evaluable participants had diagnoses of benign thyroid nodule(s)
based on HTDS or prior histology or cytology.  Fourteen of these cases were out-of-area participants, for
whom the CIDER program could not calculate dose estimates.  The number of cases and proportion with
benign thyroid nodule(s) are shown by sex, dose category and basis for diagnosis in Table IX.D-10.  The
numbers and proportions of cases of additional disease outcomes related to benign thyroid nodule are
shown in Table IX.D-11.
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 Table IX.D-10. Diagnoses of Benign Thyroid Nodule by Sex, Dose Category, and Basis for Diagnosis
 
 A.  Female
 
 Thyroid
Radiation
Dose 
Living
Evaluable
Female
Primary Definition:
Cases Based on
HTDS or Prior
Histologic or
Cytologic Diagnosis
1st Alternative Definition:
Cases Based on HTDS or
Prior Histology,
Cytology, or Clinical
Diagnosis
2nd Alternative Definition:
Cases Based on Any
Diagnosis or Participant or
CATI Report
(mGy) No. No.   % No.   % No.   %
Out of Area   125   10   8.0   12   9.6   13 10.4
< 10   182   20 11.0   24 13.2   25 13.7
10-49   320   31   9.7   34 10.6   34 10.6
50-99   313   27   8.6   31   9.9   31   9.9
100-149   220   19   8.6   21   9.5   23 10.5
150-199   126   17 13.5   18 14.3   19 15.1
200-299   139   15 10.8   17 12.2   19 13.7
300-399   144   12   8.3   16 11.1   16 11.1
400-999   171   19 11.1   20 11.7   20 11.7
1000+       7     0      --     0      --     0      --
Total 1747 170   9.7 193 11.0 200 11.4
 
  
  
 
     
  
    
   
 
  
    
    
   
    
 
       
 
 
 B.  Male
 
 
 
 Thyroid
Radiation
Dose 
Living
Evaluable
Male
Primary Definition:
Cases Based on
HTDS or Prior
Histologic or
Cytologic Diagnosis
1st Alternative Definition:
Cases Based on HTDS or
Prior Histology,
Cytology, or Clinical
Diagnosis
2nd Alternative Definition:
Cases Based on Any
Diagnosis or Participant or
CATI Report
(mGy)    No. No. % No. % No. %
Out of Area   124   4 3.2   4 3.2   4 3.2
< 10   186   7 3.8   8 4.3   8 4.3
10-49   314 19 6.1 19 6.1 19 6.1
50-99   310 14 4.5 23 7.4 24 7.7
100-149   171   7 4.1   9 5.3   9 5.3
150-199   109   6 5.5   6 5.5   6 5.5
200-299   148 13 8.8 14 9.5 14 9.5
300-399   160   5 3.1   6 3.8   6 3.8
400-999   154   3 1.9   4 2.6   6 3.9
1000+     17   1 5.9   1 5.9   1 5.9
Total 1693 79 4.7 94 5.6 97 5.7
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 Table IX.D-11. Additional Disease Outcomes Related to Benign Thyroid Nodule by Sex and
Estimated Dose (cases based on primary definition of benign thyroid nodule, i.e.,
HTDS or prior histologic or cytologic diagnoses only)
 
 A.  Female
 
 Thyroid
Radiation
Dose
 Living
Evaluable
Female
 Benign Thyroid
Nodule
 or Nodule
Suspicious for
Follicular
Neoplasm
 Benign Thyroid
Nodule Excluding
Non-neoplastic
 Disease
 Solitary Benign
Thyroid Nodule
 Detected without
Ultrasound
 Benign Thyroid
Nodule Excluding
Colloid Only
Nodules  Colloid Nodules
 (mGy)     No.  No.   %   No.   %  No.  %  No.      %   No.      %
 OOA   125   11   8.8     8  6.4   5  4.0     9   7.2  7   5.6
 < 10   182   23  12.6   14  7.7   5  2.7   18   9.9  14   7.7
 10-49   320   32  10.0   24  7.5  15  4.7   27   8.4  25   7.8
 50-99   313   30   9.6   15  4.8  13  4.2   26   8.3  20   6.4
 100-149   220   21   9.5   15  6.8   3  1.4   18   8.2  17   7.7
 150-199   126   18  14.3   12  9.5   7  5.6   17  13.5  13  10.3
 200-299   139   15  10.8   11  7.9   4  2.9   14  10.1  10   7.2
 300-399   144   13   9.0     6  4.2   5  3.5   12   8.3  12   8.3
 400-999   171   21  12.3   12  7.0   7  4.1   17   9.9  18  10.5
 1000+       7     0     --     0    --   0       --     0      --   0      --
 Total  1747  184  10.5  117  6.7  64  3.7  158   9.0  136   7.8
 
 B.  Male
 
 Thyroid
Radiation
Dose
Living
Evaluable
Female
Benign Thyroid
Nodule or
Nodule
Suspicious for
follicular
neoplasm
Benign Thyroid
Nodule Excluding
Non-neoplastic
Disease
Solitary Benign
Nodule Detected
without
Ultrasound
Benign Thyroid
Nodule
Excluding Colloid
Only Nodules Colloid Nodules
(mGy) No. No.   %   No. % No.       %   No.      % No.   %
OOA   124   4 3.2   2 1.6   1 0.8   4 3.2 4 3.2
< 10   186   7 3.8   5 2.7   2 1.1   7 3.8 6 3.2
10-49   314 19 6.1 14 4.5   6 1.9 16 5.1 17 5.4
50-99   310 15 4.8   9 2.9   4 1.3 13 4.2 13 4.2
100-149   171   7 4.1   5 2.9   3 1.8   7 4.1 6 3.5
150-199   109   7 6.4   5 4.6   0   --   6 5.5      3 2.8
200-299   148 13 8.8 10 6.8   4 2.7 12 8.1 9 6.1
300-399   160   5 3.1   5 3.1   2 1.3   5 3.1 4 2.5
400-999   154   3 1.9   2 1.3   2 1.3   3 1.9 2 1.3
1000+     17   1 5.9   1 5.9   0    --   0    -- 1 5.9
Total 1693 81 4.8 58 3.4 24 1.4 73 4.3 65 3.8
 
 
  
 
 
 
 
 
 
      
       
       
          
         
       
     
          
       
       
     
            
 OOA = out of area participant
 
Parameter estimates for the linear dose-response model based on the 3191 in-area participants are
shown in row 1 of Table IX.D-12 below. Based on maximum likelihood analysis of the sex-stratified linear
probability model, and using the primary dose estimates, the estimated slope B was slightly less than zero
(–0.008 per Gy) with Bonferroni-adjusted 95% CI ranging from less than −0.022 to 0.041 per Gy,
providing no evidence that cumulative incidence increased with increasing dose (one-tailed p = 0.68).  The
corresponding estimated background rates for diagnosis of benign thyroid nodule were 0.100 with
confidence interval (0.081, 0.119) for women and 0.049 with confidence interval (0.034, 0.064) for men.
Very similar results were obtained when the model was fit by the method of least squares using ungrouped
or grouped data (Table IX.D-12, rows 2 and 3).
HTDS Final Report: June 21, 2002 – Section IX.D page 277
Table IX.D-12. Summary of Dose-Response Results for Diagnoses of Benign Thyroid Nodule
Dose-
Response Dose
Exclusions /
Additional
Method
of Estimated Background Rates 
Estimated
Slope of Dose-
Statistical Significance
of Dose-Response
Row Outcome Model Estimates Inclusions Analysis Female Male Response (per Gy) (one-tailed p-value)
1.
Primary definition
(HTDS or prior,
histologic or cytologic
diagnosis)
Linear Primary None MLE
.100 ± .008
(.081, .119)
.049 ± .006
(.034, .064)
−.008 ± .015
(< −.022, .041) 0.68
2. Primary definition Linear Primary None LSU
.100 ± .007
(.082, .117)
.049 ± .008
(.031, .067)
−.006 ± .021
(−.055, .043) 0.61
3. Primary definition Linear Primary None LSG
.101 ± .008
(.083, .119)
.050 ± .008
(.031, .069)
−.013 ± .024
(−.069, .044) 0.70
4.
Alternative def. #1
(HTDS or prior,
histologic, cytologic, 
or clinical diagnosis)
Linear Primary None MLE
.114 ± .008
(.094, .134)
.060 ± .007
(.044, .075)
−.013 ± .016
(< −.026, .037) 0.77
5.
Alternative def. #2 
(Any diagnosis or
participant/respondent
report)
Linear Primary None MLE
.117 ± .008
(.096, .137)
.061 ± .007
(.044, .077)
−.008 ± .018
(< −.027, .046) 0.67
6.
Benign thyroid nodule 
and nodules suspicious 
for follicular neoplasm
Linear Primary None MLE
.108 ± .008
(.089, .128)
.050 ± .006
(.036, .065)
−.008 ± .015
(< −.022, .041) 0.69
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, ">"
indicates that the upper confidence limit is greater than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are
not given for estimated background rates from logistic regression model.  
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
Okanogan, F/S = Ferry/Stevens, OOA = out of area
Table continued on next page
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Table IX.D-12. Summary of Dose-Response Results for Diagnoses of Benign Thyroid Nodule (continued)
Dose-
Response Dose
Exclusions /
Additional
Method
of Estimated Background Rates 
Estimated
Slope of Dose-
Statistical Significance
of Dose-Response
Row Outcome Model Estimates Inclusions Analysis Female Male Response (per Gy) (one-tailed p-value)
7.
Benign thyroid nodule
excluding non-
neoplastic disease
Linear Primary None MLE
.068 ± .007
(.052, .084)
.036 ± .005
(.024, .049)
−.003 ± .013
(< −.016, .039) 0.60
8.
Solitary benign thyroid
nodule detected without
ultrasound
Linear Primary None MLE
.037 ± .005
(.024, .050)
.015 ± .004
(.006, .025)
−.005 ± .014
(< −.006, .032) 0.63
9.
Benign thyroid nodule
excluding colloid 
only nodules
Linear Primary None MLE
.095 ± .009
(.075, .116)
.047 ± .006
(.031, .062)
−.019 ± .025
(NE, .026)
0.91
10. Benign colloid nodules Linear Primary None MLE
.080 ± .007
(.062, .097)
.039 ± .005
(.026, .052)
−.002 ± .015
(< −.018, .044) 0.56
11. Primary definition LQ Primary None LSU
.100 ± .008
(.080, .120)
.049 ± .008
(.029, .070)
Lin: −.009 ± .035
(−.096, .078)
Quad: .003 ± .023
(−.055, .060)
Quad: 0.90
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, ">"
indicates that the upper confidence limit is greater than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are
not given for estimated background rates from logistic regression model.  
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
Okanogan, F/S = Ferry/Stevens, OOA = out of area
Table continued on next page
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Table IX.D-12. Summary of Dose-Response Results for Diagnoses of Benign Thyroid Nodule (continued)
Dose-
Response Dose
Exclusions /
Additional
Method
of Estimated Background Rates 
Estimated
Slope of Dose-
Statistical Significance
of Dose-Response
Row Outcome Model Estimates Inclusions Analysis Female Male Response (per Gy) (one-tailed p-value)
12. Primary definition Logistic Primary None MLE
.100
(.081, .123)
.048
(.036, .065)
−.092 ± .316
(−.849, .666) 0.62
13. Primary definition Linear Primary
Exclude dose
> 1000 mGy
MLE
.103 ± .009
(.082, .124)
.051 ± .007
(.035, .067)
−.021 ± .026
(< −.058, >.045) 0.79
14. Primary definition Linear Primary
Exclude dose
> 400 mGy
MLE
.098 ± .009
(.075, .120)
.051 ± .008
(.032, .070)
.001 ± .045
(−.102, .113) 0.49
15. Primary definition Linear Primary
Exclude 
Ok and F/S
geostrata
MLE
.098 ± .008
(.078, .118)
.047 ± .006
(.032, .062)
−.004 ± .017
(<−.021, .047) 0.60
16. Primary definition Linear Alt. #1 None MLE
.100 ± .008
(.081, .119)
.049 ± .006
(.034, .064)
−.007 ± .015
(< −.022, .039) 0.68
17. Primary definition Linear Alt. #2 None MLE
.101 ± .008
(.083, .119)
.050 ± .006
(.036, .065)
−.013 ± .010
(−.026, .023) 0.86
18. Primary definition Linear Primary
Include OOA
(scoping
analysis #1)
MLE
.098 ± .008
(.080, .116)
.047 ± .006
(.034, .061)
−.004 ± .016
(< −.021, .045) 0.60
19. Primary definition Linear Primary
Include OOA
(scoping
analysis #2)
MLE
.098 ± .008
(.080, .116)
.047 ± .006
(.034, .061)
−.005 ± .016
(< −.021, .044) 0.62
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, ">"
indicates that the upper confidence limit is greater than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are
not given for estimated background rates from logistic regression model. 
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
Okanogan, F/S = Ferry/Stevens, OOA = out of area
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D.2.b. Alternative Definitions for Diagnosis of Benign Thyroid Nodule  
Two alternative definitions for cases of benign thyroid nodule were considered.  The first
alternative added the 38 participants with HTDS or prior clinical diagnoses of benign thyroid nodule(s), for
a total of 287 cases (271 in-area, and 16 out-of-area).  The second added another 10 participants based
solely on a report from the participant or his/her CATI respondent, for a total of 297 cases (280 in-area, and
17 out-of-area).  As shown in rows 4 and 5 of Table IX.D-12 above, the parameter estimates for the linear
dose-response model using either of these alternative definitions were essentially identical to those obtained
in the primary analysis.  In particular, the estimated slope of the linear dose-response model was less than
zero for all three definitions of benign thyroid nodule, providing no evidence for any definition that the
cumulative incidence of benign thyroid nodule increased with increasing dose (p = 0.68, 0.77, and 0.67 for
the primary and first and second alternative definitions, respectively).
D.2.c. Additional Disease Outcomes Related to Benign Thyroid Nodule
D.2.c.1. Benign Thyroid Nodules and Nodules Suspicious for Follicular Neoplasm
Since most of the thyroid nodules classified as suspicious for follicular neoplasm were likely to be
benign, the dose-response was also analyzed for the outcome of benign thyroid nodules and nodules
suspicious for follicular neoplasm (Table IX.D-12, row 6).  The estimated dose-response for this outcome
was slightly negative (−0.008 per Gy with Bonferroni-adjusted 95% CI ranging from less than −0.022 to
0.041 per Gy), and consequently there was no evidence that the cumulative incidence of such nodules
increased significantly with increasing dose (p = 0.69). 
D.2.c.2 Benign Thyroid Nodule Excluding Non-neoplastic Disease
In order to investigate the possibility that a radiation-related increase in risk of benign thyroid
nodules might be masked by the presence of nodules associated with other, nonradiogenic diseases, the
dose-response was also analyzed for the outcome of benign thyroid nodule excluding non-neoplastic
disease.  The estimated dose-response for this outcome was also slightly negative (−0.003 per Gy with
Bonferroni-adjusted 95% CI ranging from less than −0.016 to 0.039 per Gy, Table IX.D-12, row 7), and
consequently there was no evidence that the cumulative incidence of such nodules increased significantly
with increasing dose (p = 0.60).
D.2.c.3. Solitary Benign Thyroid Nodule Detected Without Ultrasound
As shown in row 8 of Table IX.D-12, the estimated slope of the dose-response for the outcome of
solitary benign thyroid nodule detected without ultrasound was not significantly greater than zero (-0.005
per Gy, with Bonferroni-adjusted 95% confidence limits ranging from less than –0.006 to 0.032).
Consequently there was no evidence that the cumulative incidence of such nodules increased significantly
with increasing dose (p = 0.63).
 
D.2.c.4. Benign Thyroid Nodule Excluding Colloid-Only Nodules
The estimated slope of the dose-response for benign thyroid nodules excluding colloid-only
nodules was slightly negative (−0.019 per Gy, Table IX.D-12, row 9).  The Bonferroni-adjusted 95% lower
confidence limit could not be estimated, and the upper confidence limit was 0.026 per Gy (p = 0.91).
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D.2.c.5 Benign Colloid Nodules  
The majority of participants with diagnoses of benign thyroid nodules had colloid nodules.
Among the 3191 in-area participants, the cumulative incidence of colloid nodules did not increase
significantly with increasing dose. As shown in row 10 of Table IX.D-12 above, the estimated slope was
-0.002 per Gy, with Bonferroni-adjusted 95% confidence interval ranging from less than -0.018 to 0.044
per Gy (p=0.56).
D.2.d. Alternative Dose-Response Functions 
As shown in row 11 of Table IX.D-12, the estimated regression coefficient for the dose-squared
term in the linear-quadratic dose-response model [5] was 0.003 with Bonferroni-adjusted 95% confidence
interval ranging from –0.055 to 0.060.  Thus the addition of a quadratic term did not significantly improve
the fit of the model (p = 0.90).
Parameter estimates for the sex-stratified logistic dose-response model [2] are shown in row 12 of
Table IX.D-12.  The estimated coefficient of radiation dose was less than zero ( −0.092 per Gy, with
Bonferroni-adjusted 95% confidence limits −0.849 and 0.666), providing no evidence that risk of benign
thyroid nodule increased significantly with increasing dose (p = 0.62).
D.2.e. Effect of Excluding Participants in High Dose Categories
As rows 13 and 14 of Table IX.D-12 show, when participants in high dose categories were
excluded, there was no evidence that the cumulative incidence of benign thyroid nodules increased with
increasing dose.
D.2.f. Effect of Excluding Okanogan and Ferry/Stevens Geostrata
When participants in the Okanogan and Ferry/Stevens geostrata were excluded, the estimated
slope B was not significantly greater than zero (-.004 per Gy, with Bonferroni-adjusted 95% CI ranging
from less than -0.021 to 0.047 per Gy; Table IX.D-12, row 15), providing no evidence that the cumulative
incidence of benign thyroid nodule increased with increasing dose (p=0.60).
D.2.g. Analysis of Benign Thyroid Nodules in Relation to Alternative Dose Estimates
As shown in rows 16 and 17 of Table IX.D-12, the cumulative incidence of benign thyroid nodule
did not increase significantly in relation to either of the alternative dose estimates.
D.2.h. Scoping Analysis Regarding Out-of-Area Participants
See section VIII.C.1.a.3 for a description of the scoping analyses that were performed to assess the
possible impact of including the 249 out-of-area participants.  As summarized in rows 18 and 19 of Table
IX.D-12, in both analyses the inclusion of the out-of-area participants had almost no effect on the estimated
slope of the dose-response.  In particular, the estimated slope of the dose-response was slightly negative in
both scoping analyses, providing no evidence that cumulative incidence increased with increasing dose (p =
0.60 and 0.62 for the first and second scoping analysis, respectively).
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D.2.i. Analysis of Benign Thyroid Nodule in Relation to Alternative Representations of
Exposure
In the analyses by geostratum and by dichotomous exposure variable, the sex and age-adjusted
comparisons of cumulative incidence were performed as described in section VIII.C.2.a.2.
D.2.i.1. Analysis by Geostratum
As shown in Table IX.D-13, among the entire 3440 living evaluable participants, the proportions
with benign thyroid nodules ranged from 10/75 (13.3% in the Okanogan County geostratum) to 11/179
(6.1%, Richland) for women, and from 14/156 (9.0%, Adams County) to 2/76 (2.6%, Franklin County) for
men (p = 0.028 for heterogeneity among the nine geostrata).  In particular the percentages with benign
thyroid nodules were somewhat higher in the Okanogan and Ferry/Stevens geostrata (11.9% for women,
6.0% for men) than in the remaining geostrata (9.5% and 4.6%, respectively; p = 0.048).  Since it was
likely that participants in the Okanogan and Ferry/Stevens geostrata tended to have lower thyroid doses
from Hanford’s 131I than those in other geostrata, it does not appear that these differences can be attributed
to an effect of Hanford’s 131I. 
Table IX.D-13. Diagnoses of Benign Thyroid Nodule Based on HTDS or Prior Histologic or
Cytologic Evidence, by Geostratum and Sex
Female Male Total
Geostratum No. Cases % No. Cases % No. Cases %
Richland 179 11 6.1 173 7 4.0 352 18 5.1
Pasco/Kennewick 508 42 8.3 501 13 2.6 1009 55 5.5
Benton County 376 43 11.4 358 23 6.4 734 66 9.0
Franklin County 73 7 9.6 76 2 2.6 149 9 6.0
Adams County 165 18 10.9 156 14 9.0 321 32 10.0
Walla Walla (city) 133 13 9.8 131 5 3.8 264 18 6.8
Walla Walla County 170 19 11.2 164 7 4.3 334 26 7.8
Okanogan County 75 10 13.3 64 4 6.3 139 14 10.1
Ferry/Stevens Counties 68 7 10.3 70 4 5.7 138 11 8.0
Total 1747 170 9.7 1693 79 4.7 3440 249 7.2
D.2.i.2. Analysis by Dichotomous Exposure Variable
Of the 1257 participants included in these analyses, 102 (8.1%) had a diagnosis of benign thyroid
nodule(s) based on an HTDS or prior histologic or cytologic examination (see Table IX.D-14).  These
included 53/580 (9.1%) in the high exposure group and 49/677 (7.2%) in the low exposure group.  After
adjusting for the effects of sex and age at HTDS clinic in the logistic regression analysis, there was no
statistically significant evidence that the cumulative incidence of benign thyroid nodule was elevated in the
high exposure group (p = 0.20).
Table IX.D-14. Diagnoses of Benign Thyroid Nodule based on HTDS or Prior Histologic or
Cytologic Evidence, by Exposure Group and Sex 
Female Male Total
Exposure Group No. Cases % No. Cases % No. Cases %
Low 351 34 9.7 326 15 4.6 677 49 7.2
High 298 36 12.1 282 17 6.0 580 53 9.1
Total 649 70 10.8 608 32 5.3 1257 102 8.1
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D.2.j. Confounding and Effect Modification
As described in section VIII above, additional sex-stratified logistic regression models were
investigated to examine the possibility that confounding might influence the primary dose-response results,
and to search for factors that might modify a radiation dose-response.  These analyses were based on the
primary definition of benign thyroid nodules, i.e., those with an HTDS or prior histologic or cytologic
diagnosis, and on the primary dose estimates.  Table IX.D-15 displays results for models including sex, age
at first exposure to Hanford 131I (prenatal, and < 180 days), age at HTDS examination, estimated dose from
the NTS, history of any other cancer other than thyroid, and HTDS interview type (CATI versus expanded
In-Person Interview).  
Note that sex was not analyzed as a possible confounder since its effect was already adjusted for in
the sex-stratified model.  Adjusting for the possibility of confounding by any of the other covariates in
Table IX.D-15 did not markedly change the estimated regression coefficient.  For example, adjusting for a
potential confounding effect of exposure to Hanford’s 131I in the HEDR domain before age 180 days
changed the estimated coefficient from −0.092 to −0.121, a small change when considered in relation to the
confidence intervals for these two estimates, (−0.849, 0.666) and (−0.966, 0.724), respectively.  Moreover
the adjusted estimate remained less than zero.  Consequently, there was no evidence that a confounding
effect of this age covariate obscured a positive dose-response for benign thyroid nodule.  This pattern is
evident for all of the covariates other than sex in Table IX.D-15.
The analyses of effect modification address the question of whether the dose-response might vary
according to other characteristics of the study participants.  This was tested by comparing the estimated
regression coefficients for the groups defined by each covariate.  As shown in Table IX.D-15, the
regression coefficients did not differ significantly between the groups defined by any of the covariates,
suggesting that none of them was a significant modifier of a radiation dose-response for benign thyroid
nodule.
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Table IX.D-15. Confounding and Effect Modification by Sex, Age at Exposure or HTDS
Examination, Estimated Thyroid Dose from NTS, History of Any Cancer Other
Than Thyroid and Interview Type: Benign Thyroid Nodule
Estimated Dose-Response Coefficient (per Gy)
Covariate Yes / Adjusted for Including Effect Modification
 (0=No, 1=Yes) Total Unadjusted Confounding Group 0 Group 1 P
Female?
1622 /
3191
−.092 ± .316
(−.849, .666)
Not
Applicable
−.454 ± .601
(−1.96, 1.05)
.070 ± .368
(−.849, .990) .45
Prenatal
exposure?
1034 /
3191
−.092 ± .316
(−.849, .666)
−.165 ± .324
(−1.00, .670)
−.147 ± .367
(−1.11, .821)
−.230 ± .687
(−2.04, 1.58) .91
1st exposure
before age 180
days?
1478 /
3191
−.092 ± .316
(−.849, .666)
−.113 ± .327
(−.954, .728)
−.161 ± .522
(−1.54, 1.22)
−.082 ± .414
(−1.18, 1.01) .91
Age at exam
>50?
2001 /
3191
−.092 ± .316
(−.849, .666)
−.222 ± .333
(−1.08, .634)
−.516 ± .737
(−2.46, 1.43)
−.135 ± .374
(−1.12, .853) .64
NTS 131I dose
> 5.3 mGy?
1566 /
3187
−.097 ± .318
(−.858, .665)
−.109 ± .326
(−.949, .731)
.153 ± .393
(−.884, 1.19)
−.588 ± .608
(−2.19, 1.02) .29
History of any
cancer other than
thyroid?
248 /
3186
−.091 ± .316
(−.848, .666)
−.091 ± .317
(−.909, .726)
−.263 ± .365
(−1.23, .700)
−.483 ± .560
(−.994, 1.96) .30
Expanded In-
Person Interview?
1212 /
3191
−.092 ± .316
(−.849, .666)
−.007 ± .319
(−.828, .814)
−.135 ± .497
(−1.45, 1.18)
−.083 ± .403
(−.980, 1.15) .73
Entries in the table are estimate ± standard error for the regression coefficient, with Bonferroni-adjusted 95% confidence interval in
parentheses, based on sex-stratified logistic regression models.  P-values indicate the statistical significance of two-tailed comparison
of estimated coefficients between Groups 0 and 1.
Tables IX.D-16 and IX.D-17 display similar results from analyses including history of medical or
dental x-ray exposure or occupational exposure as potential confounding or effect modifying factors.  The
estimates of the regression coefficient calculated with adjustment for confounding are all close to the
unadjusted estimates.  Moreover the adjusted estimates all remained less than zero.  Thus there was no
evidence that a confounding effect of any of these covariates obscured a positive dose-response for benign
thyroid nodule.
There is no evidence of any statistically significant effect modification by any of the covariates in
Tables IX.D-16 and IX.D-17, with two possible exceptions.  
• The estimated dose-response coefficient was markedly negative (−2.44) for the 398 participants with
histories of IVP, but not for the majority of participants without such histories (0.118 with confidence
interval ranging from −0.704 to 0.941; p=0.036).
• The estimated dose-response coefficient was markedly negative (−3.13) for the 442 participants with
histories of occupations that might have involved exposure to radioactive materials or x-rays, but not
for the majority of participants without such histories (0.112 with confidence interval ranging from
−0.738 to 0.963; p=0.023).
The statistical significance of these differences must be interpreted with caution due to the large
number of such comparisons that were performed.  Moreover, neither of these two covariates identified a
group of participants with a significantly positive dose-response.
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Table IX.D-16. Confounding and Effect Modification by History of Medical and Dental Radiation
Exposures: Benign Thyroid Nodule 
Estimated Dose-Response Coefficient (per Gy)
Ever Had: Yes / Adjusted for Including Effect Modification
 (0=No, 1=Yes) Total Unadjusted Confounding Group 0 Group 1 P
CAT scan of the
upper body?
775 /
3149
−.120 ± .320
(−.885, .646)
−.119 ± .319
(−.940, .701)
.057 ± .325
(−.800, .913)
−1.17± .88
(−3.51, 1.16) .18
Diagnostic x-rays
of the head?
1191 /
3155
−.063 ± .315
(−.816, .691)
−.057 ± .314
(−.866, .751)
.188 ± .353
(−.743, 1.12)
−.650 ± .626
(−2.30, 1.00) .23
Diagnostic x-rays
of the neck?
966 /
3167
−.085 ± .316
(−.842, .672)
−.109 ± .316
(−.924, .706)
−.051 ± .428
(−1.18, 1.08)
−.178 ± .477
(−1.44, 1.08) .84
Diagnostic x-rays
of chest or upper
body, including
mammograms?
2821 /
3173
−.095 ± .317
(−.854, .664)
−.087 ± .317
(−.904, .730)
−.014 ± 1.23
(−3.27, 3.24)
−.092 ± .328
(−.959, .774) .95
Diagnostic x-rays
of the stomach or
mid-back?
692 /
3120
−.118 ± .325
(−.896, .659)
−.123 ± .325
(−.960, .715)
−.260 ± .379
(−1.26, .739)
.348 ± .629
(−1.31, 2.01) .43
Barium enema?
825 /
3159
−.098 ± .317
(−.856, .660)
−.097 ± .317
(−.912, .719)
−.196 ± .382
(−1.20, .812)
.149 ± .562
(−1.33, 1.63) .62
Upper GI?
1146 /
3177
−.117 ± .320
(−.882, .648)
−.116 ± .320
(−.940, .708)
−.154 ± .364
(−.806, 1.11)
−.696 ± .607
(−2.30, .906) .22
Intravenous
pyelogram?
398 /
3157
−.095 ± .318
(−.856, .667)
−.084 ± .319
(−.904, .737)
.118 ± .312
(−.704, .941)
−2.44 ± 1.33
(−5.96, 1.07) .036
Fluoroscopy of 
the upper body?
246 /
3161
−.071 ± .316
(−.828, .686)
−.074 ± .317
(−.890, .742)
.022 ± .318
(−.818, .862)
−1.48 ± 1.42
(−5.21, 2.26) .26
Nuclear scan
(excluding thyroid
scan)?
217 /
3162
−.091 ± .317
(−.851, .668)
−.088 ± .317
(−.905, .729)
−.017 ± .319
(−.859, .824)
−1.46 ± 1.61
(−5.71, 2.79) .34
Dental x-rays that
did not usually
include a lead
shield over the
neck area?
1648 /
3191
−.092 ± .316
(−.849, .666)
−.095 ± .317
(−.911, .720)
.143 ± .414
(−.949, 1.24)
−.380 ± .495
(−1.69, .927) .41
Entries in the table are estimate ± standard error for the regression coefficient, with Bonferroni-adjusted 95% confidence interval in
parentheses, based on sex-stratified logistic regression models.  P-values indicate the statistical significance of two-tailed comparison
of estimated coefficients between Groups 0 and 1.
HTDS Final Report: June 21, 2002 – Section IX.D page 286
Table IX.D-17. Confounding and Effect Modification by Occupational History: Benign Thyroid
Nodule
Have You Ever
Worked in Any of
Estimated Dose-Response Coefficient (per Gy)
the Following: Yes / Adjusted for Including Effect Modification
 (0=No, 1=Yes) Total Unadjusted Confounding Group 0 Group 1 P
Any metal
industry?
238 /
3191
−.092 ± .316
(−.849, .666)
−.083 ± .316
(−.896, .730)
−.090 ± .321
(−.937, .757)
.144 ± 1.77
(−4.53, 4.82) .90
Any nuclear
facility?
371 /
3191
−.092 ± .316
(−.849, .666)
−.094 ± .320
(−.917, .729)
−.127 ± .351
(−1.05, .798)
.081 ± .783
(−1.98, 2.15) .81
Any other industry
or occupation
where you may
have been exposed
to radioactive
materials or x-
rays?
442 /
3191
−.092 ± .316
(−.849, .666)
−.114 ± .319
(−.936, .708)
.112 ± .322
(−.738, .963)
−3.13 ± 1.69
(−7.59, 1.33) .023
Any of the above
industries or
occupations?
892 /
3191
−.092 ± .316
(−.849, .666)
−.062 ± .316
(−.875, .751)
−.045 ± .366
(−1.01, .922)
−.108 ± .623
(−1.75, 1.54) .93
Entries in the table are estimate ± standard error for the regression coefficient, with Bonferroni-adjusted 95% confidence interval in
parentheses, based on sex-stratified logistic regression models.  P-values indicate the statistical significance of two-tailed comparison
of estimated coefficients between Groups 0 and 1.
Table IX.D-18 displays the results of analyses of possible confounding or effect modification by
smoking variables.  There was no evidence that the dose-response was significantly confounded by either
smoking variable, or that there was a dose-response that differed significantly according to smoking
history.
Table IX.D-18. Confounding and Effect Modification by Smoking: Benign Thyroid Nodule
Have You Ever
Smoked Any of
Estimated Dose-Response Coefficient (per Gy)
the Following: Yes / Adjusted for Including Effect Modification
(0=No, 1=Yes) Total Unadjusted Confounding Group 0 Group 1 P
Cigarettes
(unfiltered or
filtered)?
1854 /
3183
−.087 ± .316
(−.843, .668)
−.085 ± .316
(−.899, .729)
−.135 ± .533
(−1.54, 1.27)
−.057 ± .390
(−1.09, .972) .91
Any of cigarettes,
cigar or pipe?
1900 /
3183
−.087 ± .316
(−.843, .668)
−.085 ± .316
(−.898, .729)
−.034 ± .535
(−1.45, 1.38)
−.111 ± .394
(−1.15, .927) .91
Entries in the table are estimate ± standard error for the regression coefficient, with Bonferroni-adjusted 95% confidence interval in
parentheses, based on sex-stratified logistic regression models.  P-values indicate the statistical significance of two-tailed comparison
of estimated coefficients between Groups 0 and 1.
D.2.k. Uncertainty
The estimated slopes of the sex-stratified linear dose-response model for benign thyroid nodule are
shown in Figure IX.D-1 for each of the 100 dose realizations produced by the CIDER model.  The
confidence intervals in that figure are calculated at the 98.33% confidence level, i.e., are adjusted by the
Bonferroni technique for the simultaneous estimation of the slope and two sex-specific background rates. 
While the point estimate of the slope is greater than 0 for 30 of the 100 realizations, the confidence interval
includes 0 for all 100 realizations.  Also shown in Figure IX.D-1 (to the right of realization 100) are the
estimates and confidence intervals calculated using (from left to right) the median, geometric mean and
mean of each participant’s 100 dose realizations. In summary, for none of the 100 realizations of the
estimated doses was there a statistically significant dose-response, and for the majority of realizations the
estimated slope was less than 0.
Figure IX.D-1. Plot of Estimated Slope and 95% CI by Dose Realization: Benign Thyroid Nodule
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Figure IX.D-2 displays the distribution of the 5000 estimates of the logistic regression coefficient
obtained by the simulation procedures described in section VIII.C.2.b.3 above.  It is evident from the figure
that most of the estimates were between about –2.0 and 1.0.  The estimate was less than or equal to 0 for
3608 of the 5000 replications, implying an empirical one-tailed p-value of 0.72.  The median estimate was
–0.25, and the upper and lower percentiles corresponding to the Bonferroni-adjusted 95% confidence
interval were –1.60 and 0.70.  These may be compared to the estimate of −.092 with confidence interval
(−.849, .666) obtained using the median dose estimates without adjustment for uncertainty. Thus, this
method of adjusting the estimated logistic regression coefficient for the uncertainty in the dose estimates
did not provide evidence that the cumulative incidence of benign thyroid nodule increased with increasing
dose.
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Figure IX.D-2. Distribution of Simulation Estimates of Logistic Regression Coefficient: Benign 
Thyroid Nodule
slope sample: 5000
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E. Total Thyroid Neoplasia
E.1. Occurrence of Total Thyroid Neoplasia
The outcome of total thyroid neoplasia was defined to include participants with thyroid carcinoma
based on HTDS or prior histology or benign thyroid nodule with a histologic type of follicular adenoma,
based on HTDS or prior histology.
Among the 3440 living evaluable participants 33 (1.0%) had a diagnosis of total thyroid neoplasia,
with the percentage of cases slightly higher for women (1.1%) compared to men (0.8%) (Table IX.E-1). 
Table IX.E-1. Total Thyroid Neoplasia, by Sex
 
Diagnosis of Thyroid Cancer or Female Male Total
Follicular Adenoma No. % No. % No.        %
Yes     20     1.1     13     0.8     33     1.0
No 1727   98.9 1680   99.2 3407   99.0
Total 1747 100.0 1693 100.0 3440 100.0
E.2. Analysis of Total Thyroid Neoplasia Risk
E.2.a. Primary Analysis
The proportions of living evaluable participants with total thyroid neoplasia are shown by sex, in-
area status, and dose group in Table IX.E-2.
Table IX.E-2. Diagnoses of Total Thyroid Neoplasia by Sex and Dose Category
 
 
 
 
 Thyroid
Radiation
Dose (mGy)
Living
Evaluable
Female
Primary Definition:
Cases Based on
HTDS or Prior
Histologic Diagnosis
Living
Evaluable
Male
Primary Definition:  Cases
Based on HTDS or Prior
Histologic Diagnosis
No. No. % No. No. %
Out of Area 125 2 1.6 124 3 2.4
< 10 182 2 1.1 186 2 1.1
10-49 320 4 1.3 314 3 1.0
50-99 313 4 1.3 310 0   --
100-149 220 2 0.9 171 0   --
150-199 126 2 1.6 109 2 1.8
200-299 139 2 1.4 148 1 0.7
300-399 144 1 0.7 160 1 0.6
400-999 171 1 0.6 154 0   --
1000+     7 0 --   17 1 5.9
Total    1747      20 1.1        1693 13 0.8
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Parameter estimates for the linear dose-response model based on the 3191 in-area participants are
shown in row 1 of Table IX.E-3 below. Based on maximum likelihood analysis of the sex-stratified linear
probability model, the estimated slope B was 0.001 per Gy with Bonferroni-adjusted 95% CI ranging from
less than −0.003 to 0.022 per Gy, providing no evidence that cumulative incidence increased with
increasing dose (one-tailed p = 0.42).  The corresponding estimated background rates for diagnosis of total
thyroid neoplasia were 0.011 with confidence interval (0.004 , 0.018) for women and 0.006 with
confidence interval (0.001, 0.012) for men.  Very similar results were obtained when the model was fit by
the method of least squares using ungrouped or grouped data (Table IX.E-3, rows 2 and 3).
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Dose-
Response Dose
Exclusions /
Additional
Method of  
 Estimated Background Rates 
Estimated
Slope of Dose-
Statistical Significance
of Dose-Response
Row Outcome Model Estimates Inclusions Analysis Female Male Response (per Gy) (one-tailed p-value)
1.
Primary definition
(HTDS or prior,
histologic diagnosis)
Linear Primary None MLE
.011 ± .003
(.004, .018)
.006 ± .002
(.001, .012)
.001 ± .006
(< −.003, .022) 0.42
2. Primary definition Linear Primary None LSU
.011 ± .003
(.005, .017)
006 ± .003
(0*, .013)
.000 ± .007
(−.017, .018) 0.48
3. Primary definition Linear Primary None LSG
.012 ± .003
(.006, .019)
.007 ± .003
(.001, .014)
−.006 ± .009
(−.026, .015) 0.75
4. Primary definition LQ Primary None LSU
.011 ± .003
(.004, .019)
.007 ± .003
(0*, .014)
Lin: −.003 ± .013
(−.034, .028)
Quad: .003 ± .008
(−.018, .023)
Quad: 0.74
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, ">"
indicates that the upper confidence limit is greater than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are
not given for estimated background rates from logistic regression model.  “0*” indicates that the lower confidence limit for a background rate was less than 0.
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
Okanogan, F/S = Ferry/Stevens, OOA = out of area
Table continued on next page
Table IX.E-3 Dose-Response Results for Diagnoses of Total Thyroid Neoplasia
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Dose-
Response Dose
Exclusions /
Additional
Method
of
 
 Estimated Background Rates 
Estimated
Slope of Dose-
Statistical Significance
of Dose-Response
Row Outcome Model Estimates Inclusions
Analysi
s
Female Male Response (per Gy) (one-tailed p-value)
5. Primary definition Logistic Primary None MLE
.011
(.006, .021)
.006
(.003, .014)
.050 ± .833
(−1.94, 2.04) 0.48
6. Primary definition Linear Primary
Exclude dose
> 1000 mGy
MLE
.012 ± .003
(.005, .020)
.007 ± .002
(.001, .012)
-.006 ± .007
(< −.007, >.017) 0.77
7. Primary definition Linear Primary
Exclude dose
> 400 mGy
MLE
.012 ± .003
(.004, .020)
.007 ± .003
(0*, .013)
-.001 ± .015
(−.034, .040) 0.53
8. Primary definition Linear Primary
Exclude 
OK and F/S
geostrata
MLE
.010 ± .003
(.003, .016)
.006 ± .002
(.000, .012)
.002 ± .007
(<−.003, .023) 0.37
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, ">"
indicates that the upper confidence limit is greater than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are
not given for estimated background rates from logistic regression model.  “0*” indicates that the lower confidence limit for a background rate was less than 0.
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
Okanogan, F/S = Ferry/Stevens, OOA = out of area
Table continued on next page
Table IX.E-3 Dose-Response Results for Diagnoses of Total Thyroid Neoplasia (continued)
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Dose-
Response Dose
Exclusions /
Additional
Method
of Estimated Background Rates 
Estimated
Slope of Dose-
Statistical Significance
of Dose-Response
Row Outcome Model Estimates Inclusions Analysis Female Male Response (per Gy) (one-tailed p-value)
9. Primary definition Linear Alt. #1 None MLE
.012 ± .003
(.004, .019)
007 ± .003
(.000, .013)
-.003 ± .009
(NE, .015)
0.77
10. Primary definition Linear Alt. #2 None MLE
.011 ± .003
(.004, .018)
007 ± .003
(.001, .013)
-.003 ± .010
(NE, .010)
0.85
11. Primary definition Linear Primary
Include
OOA
(scoping
analysis #1)
MLE
.012 ± .003
(.005, .018)
.008 ± .002
(.002, .014)
-.001 ± .006
(<-.003, .019)
0.55
12. Primary definition Linear Primary
Include
OOA
(scoping
analysis #2)
MLE
.012 ± .003
(.005, .018
.008 ± .002
(.002, .014)
-.001 ± .006
(<-.003, >.018)
0.58
 
 
Table IX.E-3 Dose-Response Results for Diagnoses of Total Thyroid Neoplasia (continued)
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, ">"
indicates that the upper confidence limit is greater than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are
not given for estimated background rates from logistic regression model.  “0*” indicates that the lower confidence limit for a background rate was less than 0.
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, OK =
Okanogan, F/S = Ferry/Stevens, OOA = out of area
Table continued on next page
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E.2.b. Alternative Dose-Response Functions
As shown in row 4 of Table IX.E-3, the estimated regression coefficient for the dose-squared term
in the linear-quadratic dose-response model [5] was 0.003 with Bonferroni-adjusted 95% confidence
interval ranging from –0.018 to 0.023.  Thus the addition of a quadratic term did not significantly improve
the fit of the model (p = 0.74).
The regression parameter for the effect of dose in the sex-stratified logistic regression model [2]
was estimated as 0.050 with Bonferroni-adjusted 95% CI ranging from –1.94 to 2.04 (Table IX.E-3, row 5).
Thus there was no evidence from the logistic regression model that cumulative incidence of total thyroid
neoplasia increased significantly with increasing dose (p = 0.48).
E.2.c. Effect of Excluding Participants in High Dose Categories
As shown in rows 6 and 7 of Table IX.E-3, excluding participants with doses above 1000 mGy or
above 400 mGy resulted in slightly negative estimates for the slope of the dose-response, thus providing no
evidence that risk increased with increasing dose (p = 0.77 and 0.53 based on participants with doses ≤
1000 mGy and ≤ 400 mGy, respectively).
E.2.d. Effect of Excluding Okanogan and Ferry/Stevens Geostrata 
As shown in row 8 of Table IX.E-3, if participants from the Okanogan and Ferry/Stevens geostrata
are excluded, the estimated slope of the dose-response is 0.002 per Gy, with Bonferroni-adjusted 95%
confidence interval ranging from less than - 0.003 to 0.023 per Gy; p = 0.37).
E.2.e. Analysis of Total Thyroid Neoplasia in Relation to Alternative Dose Estimates
As shown in rows 9 and 10 of Table IX.E-3, the cumulative incidence of total thyroid neoplasia
did not increase significantly in relation to either of the alternative dose estimates.
E.2.f. Scoping Analysis Regarding Out-of-Area Participants
See section VIII.C.1.a.3 for a description of the scoping analyses that were performed to assess the
possible impact of including the 249 out-of-area participants.  As summarized in rows 11 and 12 of Table
IX.E-3, in both analyses the inclusion of the out-of-area participants slightly decreased the estimated slope
of the dose-response, but did not materially change the dose-response results.
E.2.g. Analysis of Total Thyroid Neoplasia in Relation to Alternative Representations of
Exposure
In the analyses by geostratum and by dichotomous exposure variable, the sex and age-adjusted
comparisons of cumulative incidence were performed as described in section VIII.C.2.a.2.
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E.2.g.1. Analysis by Geostratum
As shown in Table IX.E-4, among the entire 3440 living evaluable participants, the proportions
with thyroid neoplasia ranged from 0/73 (0% in the Franklin County geostratum) to 2/68 (2.9%,
Ferry/Stevens Counties) for women, and from 0/76 (0%, Franklin County) to 1/64 (1.6%, Okanogan
County) for men (p = 0.41 for heterogeneity among the nine geostrata).  In particular the percentages with
thyroid neoplasia were somewhat higher in the Okanogan and Ferry/Stevens geostrata (2.8% for women,
1.5% for men) than in the remaining geostrata (1.0% and 0.7%, respectively; p = 0.037).  Since it was
likely that participants in the Okanogan and Ferry/Stevens geostrata tended to have lower thyroid doses
from Hanford’s 131I than those in other geostrata, it does not appear that these differences can be attributed
to an effect of Hanford’s 131I. 
Table IX.E-4. Diagnoses of Total Thyroid Neoplasia Based On Histologic or Cytologic Evidence
from or Prior to the HTDS, by Geostratum and Sex
Female Male Total
Geostratum No. Cases % No. Cases % No. Cases %
Richland 179 2 1.1 173 1 0.6 352 3 0.9
Pasco/Kennewick 508 4 0.8 501 3 0.6 1009 7 0.7
Benton County 376 5 1.3 358 4 1.1 734 9 1.2
Franklin County 73 0 -- 76 0 -- 149 0 --
Adams County 165 2 1.2 156 1 0.6 321 3 0.9
Walla Walla (city) 133 1 0.8 131 1 0.8 264 2 0.8
Walla Walla County 170 2 1.2 164 1 0.6 334 3 0.9
Okanogan County 75 2 2.7 64 1 1.6 139 3 2.2
Ferry/Stevens Counties 68 2 2.9 70 1 1.4 138 3 2.2
Total 1747 20 1.1 1693 13 0.8 3440 33 1.0
E.2.g.2. Analysis by Dichotomous Exposure Variable
Of the 1257 participants included in these analyses, 16 (1.3%) had a diagnosis of total thyroid
neoplasia based on an HTDS or prior histologic or cytologic examination (see Table IX.E-5).  These
included 5/580 (0.9%) in the high exposure group and 11/677 (1.6%) in the low exposure group.  After
adjusting for the effects of sex and age at HTDS clinic in the logistic regression analysis, there was no
statistically significant evidence that the cumulative incidence of total thyroid neoplasia was elevated in the
high exposure group (p = 0.73).
Table IX.E-5. Diagnoses of Total Thyroid Neoplasia Based on HTDS or Prior Histologic or
Cytologic Evidence, by Exposure Group and Sex 
Female Male Total
Exposure Group No.   Cases % No. Cases % No. Cases %
Low 351 6 1.7 326 5 1.5 677 11 1.6
High 298 3 1.0 282 2 0.7 580 5 0.9
Total 649 9 1.4 608 7 1.2 1257 16 1.3
E.2.h. Confounding and Effect Modification
There were too few participants with diagnoses in the category of total thyroid neoplasia to
warrant any analysis of confounding or effect modification.
E.2.i. Uncertainty
The estimated slopes of the sex-stratified linear dose-response model for total thyroid neoplasia
are shown in Figure IX.E-1 for each of the 100 dose realizations produced by the CIDER model.  The
confidence intervals in that figure are calculated at the 98.33% confidence level, i.e., are adjusted by the
Bonferroni technique for the simultaneous estimation of the slope and two sex-specific background rates.
While the point estimate of the slope is greater than 0 for 47 of the 100 realizations, the confidence interval
includes 0 for all 100 realizations.  Also shown in Figure IX.E-1 (to the right of realization 100) are the
estimates and confidence intervals calculated using (from left to right) the median, geometric mean and
mean of each participant’s 100 dose realizations dose. In summary, for none of the 100 realizations of the
estimated doses was there a statistically significant dose-response, and for about half of the realizations the
estimated slope was less than 0.
Figure IX.E.1 Plot of Estimated Slope and 95% CI by Dose Realization: Total Thyroid Neoplasia
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Figure IX.E-2 displays the distribution of the 5000 estimates of the logistic regression coefficient
obtained by the simulation procedures described in section VIII.C.2.b.3 above. It is evident from the figure
that most of the estimates were between about –6.0 and 1.5. The estimate was less than or equal to 0 for
3640 of the 5000 replications, implying an empirical one-tailed p-value of 0.73.  The median estimate was
–0.73, and the upper and lower percentiles corresponding to the Bonferroni-adjusted 95% confidence
interval were –6.78 and 1.42.  These may be compared to the estimate of 0.050 with confidence interval
(−1.94, 2.04) obtained using the median dose estimates without adjustment for uncertainty. Thus this
method of adjusting the estimated logistic regression coefficient for the uncertainty in the dose estimates
did not provide evidence that the cumulative incidence of thyroid neoplasia increased with increasing dose.
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Figure IX.E-2. Distribution of Simulation Estimates of Logistic Regression Coefficient: Total 
Thyroid Neoplasia
slope sample: 5000
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F. Any Thyroid Nodule
F.1. Occurrence of Any Thyroid Nodule
The primary and alternative definitions for the outcome of any thyroid nodule were as follows:
• Primary definition: HTDS or prior, histologic or cytologic diagnosis (281 cases)
• Alternative definition #1: HTDS or prior, histologic, cytologic or clinical diagnosis (320 cases)
• Alternative definition #2: Any diagnosis or participant/respondent report (330 cases).
The outcome of any thyroid nodule was defined by the presence of a diagnosis of one or more of
benign thyroid nodule, thyroid carcinoma, or nodule suspicious for follicular neoplasm.  Table IX.F-1
shows that 281 (8.2%) living evaluable participants had a diagnosis of any thyroid nodule based on
histologic or cytologic evidence from the HTDS or prior, with the percentage about twice as high for
women (11.0%) as for men (5.2%).  Another 1.1% was based on clinical diagnoses by the HTDS or prior.
There were 10 living evaluable participants with a diagnosis of any thyroid nodule based on reports from
the participant or his/her CATI respondent.
Table IX.F-1. Basis for Diagnosis of Any Thyroid Nodule Disease, by Sex
Female Male Total
Diagnosis of Any Thyroid Nodule No. % No. % No. %
Yes 224 12.8 106 6.3 330 9.6
Histologic diagnosis:  HTDS 11 0.6 12 0.7 23 0.7
Cytologic diagnosis:  HTDS 156 8.9 67 4.0 223 6.5
Prior histologic diagnosis 24 1.4 8 0.5 32 0.9
Prior cytologic diagnosis 2 0.1 1 0.1 3 0.1
Clinical diagnosis:  HTDS 16 0.9 13 0.8 29 0.8
Clinical diagnosis:  prior 8 0.5 2 0.1 10 0.3
Participant/respondent report 7 0.4 3 0.2 10 0.3
No 1521 87.1 1586 93.7 3107 90.3
Unknown 2 0.1 1 0.1 3 0.1
Total 1747 100.0 1693 100.0 3440 100.0
•       
•       
•       
•       
•       
•       
• 
F.1.a. Additional Disease Outcomes Related to Any Thyroid Nodule
F.1.a.1. Any Solitary Thyroid Nodule Detected without Ultrasound
The outcome of any palpable solitary thyroid nodule detected without ultrasound was defined in
order to simulate the effect of screening for thyroid disease by palpation only, i.e., without ultrasound
examination.  This analysis allows us to compare the prevalence of thyroid nodularity with older studies
(e.g. The Framingham Study) that used only palpation to determine the prevalence of nodular thyroid
disease.  In HTDS a total of 117 living evaluable participants (83 women, 34 men) had diagnoses of such
nodules (Table IX.F-2).
Table IX.F-2. Any Solitary Thyroid Nodule Detected without Ultrasound, by Sex
Female Male TotalAny Solitary  Thyroid Nodule
Detected without Ultrasound No. % No. % No. %
Yes     83     4.8     34     2.0   117     3.4
No 1664   95.2 1659   98.0 3323   96.6
Total 1747 100.0 1693 100.0 3440 100.0
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For the majority of the 117 living evaluable participants with solitary thyroid nodules that were
detected without ultrasound, i.e., by palpation, those nodules were also observed on the ultrasound
examination.  However for 21 (18%) of the 117, those nodules were not detected by ultrasound.  Twelve
(57%) of these 21 participants each had 1-6 discrete focal ultrasound abnormalities in addition to the
palpable nodule which was not detected on ultrasound.  In addition, 15 of 21 (71%) had documented
Hashimoto’s thyroiditis.  Only 4 participants (0.1% of the 3429 living evaluable participants whose thyroid
glands were visible in their ultrasound examinations) had a palpable nodule with a completely normal
ultrasound scan.  These results suggest that the reason for the discordance between palpation and
ultrasound in this small group was the abnormal thyroid tissue that is present throughout the gland in
individuals with Hashimoto’s thyroiditis, a fact well known in clinical practice.  Since only 4 participants
had true palpable nodules that were not detected by ultrasound, a dose-response analysis of this specific
outcome was not feasible.
F.2. Analysis of Any Thyroid Nodule Risk
F.2.a. Primary Analysis
The proportions with any thyroid nodule are shown by sex, in-area status, and dose group in Table
IX.F-3 below.  The numbers and proportions with diagnoses of any solitary thyroid nodule detected without
ultrasound are also shown.
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37 
35 
26 
21 
19 
18 
22 
0 
24 
-- 
12.8 
  0 
83 
      
4.
nd Alternative
Definition:
ases Based on Any Solita
2
13.6 
15.9 
11.6 
11.2 
11.8 
16.7 
13.7 
12.5 
12.9 
  7 
  8 
18 
16 
  5 
  8 
  4 
  7 
10 
5.6
4.4
5.6
5.1
2.3
6.3
2.9
4.9
5.8
--
8
T
Radiation
Dose
(mGy)
Living
Evaluable
Male
ary Definition:
ses Based on
TDS or Prior
Histologic or
Cytologic
Diagnosis
1st Alternative
Definition:Cases
Based on HTDS or
Prior Histology,
Cytology, or
Clinical Diagnosis
2
C
Any Diagnosis or
Participant or
CATI Report
ry
Thyroid Nodule
Detected without
Ultrasound
No. No.         % No. No.         %       % No. %
OOA 124 7 5.6 7 5.6 7 5.6   3 2.4
< 10 186 8 4.3 9 4.8 9 4.8   3 1.6
10-49 314 21 6.7 21 6.7 21 6.7   7 2.2
50-99 310 15 4.8 24 7.7 25 8.1   6 1.9
100-149 171 7 4.1 9 5.3 9 5.3   3 1.8
150-199 109 7 6.4 7 6.4 7 6.4   1 0.9
200-299 148 13 8.8 14 9.5 14 9.5   6 4.1
300-399 160 5 3.1 6 3.8 6 3.8   2 1.3
400-999 154 3 1.9 4 2.6 6 3.9   3 1.9
1000+   17 2 11.8 2 11.8 2 11.8   0    --
Total    1693 88 5.2 103 6.1 106 6.3 34 2.0
         
         
         
         
         
         
         
         
         
         
         
         
OOA = out of area
Parameter estimates for the linear dose-response model based on the 3191 in-area participants are
shown in row 1 of Table IX.F-4 below. Based on maximum likelihood analysis of the sex-stratified linear
probability model, the estimated slope B was slightly less than zero (–0.007 per Gy) with Bonferroni-
adjusted 95% CI ranging from less than −0.023 to 0.043 per Gy, providing no evidence that cumulative
incidence increased with increasing dose (one-tailed p = 0.65).  The corresponding estimated background
rates for outcome of any thyroid nodule were 0.112 with confidence interval (0.092, 0.132) for women and
0.053 with confidence interval (0.038 to 0.068) for men.  Very similar results were obtained when the
model was fit by least squares using ungrouped or grouped data (Table IX.F-4, rows 2 and 3).
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Dose-
Response Dose
Exclusions /
Additional
Method
of Estimated Background Rates 
Estimated
Slope of Dose-
Statistical Significance
of Dose-Response
Row Outcome Model Estimates Inclusions Analysis Female Male Response (per Gy) (one-tailed p-value)
1.
Primary definition
(HTDS or prior,
histologic or cytologic
diagnosis)
Linear Primary None MLE
.112 ± .008
(.092, .132)
.053 ± .006
(.038, .068)
-.007 ± .016
(<-.023, .043)
0.65
2. Primary definition Linear Primary None LSU
.112 ± .008
(.094, .131)
.053 ± .008
(.034, .072)
−.006 ± .022
(−.058, .045) 0.61
3. Primary definition Linear Primary None LSG
.114 ± .008
(.095, .133)
.055 ± .008
(.035, .074)
−.017 ± .025
(−.078, .043) 0.75
4.
Alternative def. #1
(HTDS or prior,
histologic, cytologic, 
or clinical diagnosis)
Linear Primary None MLE
.126 ± .009
(.105, .147)
.063 ± .007
(.047, .080)
-.012 ± .017
(<-.028, .039)
0.75
5.
Alternative def. #2 
(Any diagnosis or
participant/respondent
report)
Linear Primary None MLE
.129 ± .009
(.108, .150)
.064 ± .007
(.048, .081)
-.007 ± .019
(<-.029, .047)
0.65
Table IX.F-4. Dose-Response Results for Diagnoses of Any Thyroid Nodule
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, “>”
indicates that the upper confidence limit is greater than the indicated value,“NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are not
given for estimated background rates from logistic regression model.
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
Okanogan, F/S = Ferry/Stevens, OOA = out of area
Table continued on next page
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Dose-
Response Dose
Exclusions /
Additional
Method
of Estimated Background Rates 
Estimated
Slope of Dose-
Statistical Significance
of Dose-Response
Row Outcome Model Estimates Inclusions Analysis Female Male Response (per Gy) (one-tailed p-value)
6.
Solitary thyroid nodule
detected without
ultrasound
Linear Primary None MLE
.047 ± .006
(.032, .061)
.020 ± .004
(.009, .030)
.001 ± .015
(<-.009, .042)
0.46
7. Primary definition LQ Primary None LSU
.113 ± .008
(.092, .134)
.054 ± .009
(.032, .075)
Lin: −.014 ± .037
(−.105, .078)
Quad: .006 ± .024
(−.054, .066)
Quad: 0.80
8. Primary definition Logistic Primary None MLE
.112
(.092, .137)
.052
(.039, .070)
-.09 ± .30
(-.81, .63)
0.62
9. Primary definition Linear Primary
Exclude dose
> 1000 mGy
MLE
.117 ± .009
(.095, .140)
.055 ± .007
(.039, .072)
-.032 ± .026
(<-.062, >.035
0.88
10. Primary definition Linear Primary
Exclude dose
> 400 mGy
MLE
.112 ± .010
(.089, .135)
.056 ± .008
(.037, .076)
-.017 ± .046
(-.122, .099)
0.64
11. Primary definition Linear Primary
Exclude 
Ok and F/S
geostrata
MLE
.108 ± .009
(.087, .129)
.051 ± .007
(.035, .067)
-.003 ± .018
(<-.023, .050)
0.56
12. Primary definition Linear Alt. #1 None MLE
.113 ± .008
(.093, .133)
.054 ± .006
(.038, .069)
-.010 ± .015
(<-.024, .036)
0.74
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, “>”
indicates that the upper confidence limit is greater than the indicated value,“NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are not
given for estimated background rates from logistic regression model.
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
Okanogan, F/S = Ferry/Stevens, OOA = out of area
Table IX.F-4. Dose-Response Results for Diagnoses of Any Thyroid Nodule (continued)
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Table continued on next page
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Table IX.F-4. Dose-Response Results for Diagnoses of Any Thyroid Nodule (continued)
Dose-
Response Dose
Exclusions /
Additional
Method
of Estimated Background Rates 
Estimated
Slope of Dose-
Statistical Significance
of Dose-Response
Row Outcome Model Estimates Inclusions Analysis Female Male Response (per Gy) (one-tailed p-value)
13. Primary definition Linear Alt. #2 None MLE
.114 ± .008
(.094, .133)
.055 ± .006
(.040, .069)
-.015 ± .010
(-.028, .021)
0.88
14. Primary definition Linear Primary
Include OOA
(scoping
analysis #1)
MLE
.111 ± .008
(.092, .131)
.053 ± .006
(.038, .067)
-.006 ± .016
(<-.023, .043)
0.64
15. Primary definition Linear Primary
Include OOA
(scoping
analysis #2)
MLE
.112 ± .008
(.093, .131)
.053 ± .006
(.039, .068)
-.007 ± .016
(<-.023, >.041)
0.66
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, “>”
indicates that the upper confidence limit is greater than the indicated value,“NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are not
given for estimated background rates from logistic regression model.
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
Okanogan, F/S = Ferry/Stevens, OOA = out of area
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F.2.b. Alternative Definitions for Diagnosis of Any Thyroid Nodule
Two alternative definitions for cases of any thyroid nodule were considered.  The first alternative
added the 39 participants with HTDS or prior clinical diagnoses of any thyroid nodule, for a total of 320
(297 in-area, 23 out-of-area) cases.  The second alternative criterion for defining cases of nodular disease
added another 10 participants based solely on a report from the participant or his/her CATI respondent, for
a total of 330 (306 in-area, 24 out-of-area) cases.  As shown in rows 4 and 5 of Table IX.F-4 above, there
was no evidence that the cumulative incidence of any thyroid nodule increased with increasing dose for
either of these alternative definitions.
F.2.c. Additional Disease Outcomes Related to Any Thyroid Nodule
F.2.c.1. Any Solitary Thyroid Nodule Detected Without Ultrasound
As shown in row 6 of Table IX.F-4, the estimated slope of the dose-response for the outcome of
any solitary thyroid nodule detected without ultrasound was not significantly greater than zero (0.001 per
Gy with Bonferroni-adjusted 95% CI ranging from less than −0.009 to 0.042 per Gy).  Consequently there
was no evidence that the cumulative incidence of such nodules increased significantly with increasing dose
(p = 0.46). 
F.2.d. Alternative Dose-Response Functions 
As shown in row 7 of Table IX.F-4, the estimated regression coefficient for the dose-squared term
in the linear-quadratic dose-response model [5] was 0.006 with Bonferroni-adjusted 95% confidence
interval ranging from –0.054 to 0.066.  Thus the addition of a quadratic term did not significantly improve
the fit of the model (p = 0.80).
In the analysis of any thyroid nodule based on HTDS or prior histologic or cytologic evidence,
i.e., the primary criterion for defining cases with any thyroid nodule, the regression parameter for the effect
of dose in the sex-stratified logistic regression model [2] was estimated as −0.09 with Bonferroni-adjusted
95% confidence interval ranging from –0.81 to 0.63 (Table IX.F-4, row 8).  Thus there was no evidence
from the logistic regression model that cumulative incidence of any thyroid nodule increased with
increasing dose (p = 0.62).
F.2.e. Effect of Excluding Participants in High Dose Categories
As shown in rows 9 and 10 of Table IX.F-4, when participants in high dose categories were
excluded, there was no evidence that the cumulative incidence of any thyroid nodule increased with
increasing dose.
F.2.f. Effect of Excluding Okanogan and Ferry/Stevens Geostrata
Excluding Okanogan and Ferry/Stevens geostrata had no effect on the dose-response results,
namely, there was no evidence that cumulative incidence of any thyroid nodule increased with increasing
dose (p = 0.56; Table IX.F-4, row 11).
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F.2.g. Analysis of Any Thyroid Nodule in Relation to Alternative Dose Estimates
When the first set of alternative dose estimates were used, the estimated slope B was -0.010 per
Gy with Bonferroni-adjusted 95% confidence interval ranging from less than –0.024 to 0.036 (Table IX.F-
4, row 12).  For the second set of alternative dose estimates the estimated slope B was –0.015 per Gy with
Bonferroni adjusted 95% confidence interval ranging from less than –0.028 to 0.021 (Table IX.F-4, row
13).  Thus, for neither set of alternative dose estimates was there any evidence that the cumulative
incidence of any thyroid nodule increased with increasing dose (p = 0.74 and 0.88 for the first and second
set of alternative dose estimates, respectively).
F.2.h. Scoping Analysis Regarding Out-of-Area Participants
See section VIII.C.1.a.3 for a description of the scoping analyses that were performed to assess the
possible impact of including the 249 out-of-area participants.  As shown in rows 14 and 15 of Table IX.F-4,
for neither scoping analysis was there any evidence that the cumulative incidence of any thyroid nodule
increased with increasing dose (p = 0.64 and 0.66 for the first and second scoping analyses, respectively).
F.2.i. Analysis of Any Thyroid Nodule in Relation to Alternative Representations of
Exposure
In both the analyses by geostratum and by dichotomous exposure variable, the sex and age-
adjusted comparisons of cumulative incidence were performed as described in section VIII.C.2.a.2.
F.2.i.1. Analysis by Geostratum
As shown in Table IX.F-5, among the entire 3440 living evaluable participants, the proportions
with any thyroid nodule (based on an HTDS or prior histologic or cytologic diagnosis) ranged from 12/75
(16.0% in the Okanogan County geostratum) to 14/179 (7.8%, Richland) for women, and from 14/156
(9.0%, Adams County) to 2/76 (2.6%, Franklin County) for men (p = 0.032 for heterogeneity among the
nine geostrata).  In particular the percentages with any thyroid nodule were somewhat higher in the
Okanogan and Ferry/Stevens geostrata (15.4% for women, 6.7% for men) than in the remaining geostrata
(10.7% and 5.1%, respectively; p = 0.010).  Since it was likely that participants in the Okanogan and
Ferry/Stevens geostrata tended to have lower thyroid doses from Hanford’s 131I than those in other
geostrata, it does not appear that these differences can be attributed to an effect of Hanford’s 131I. 
Table IX.F-5. Diagnoses of Any Thyroid Nodule with at Least One Outcome Based On Histologic
or Cytologic Evidence from or Prior to the HTDS
Female Male Total
Geostratum No. Cases % No. Cases % No. Cases %
Richland 179 14 7.8 173 8 4.6 352 22 6.3
Pasco/Kennewick 508 49 9.6 501 16 3.2 1009 65 6.4
Benton County 376 45 12.0 358 25 7.0 734 70 9.5
Franklin County 73 7 9.6 76 2 2.6 149 9 6.0
Adams County 165 20 12.1 156 14 9.0 321 34 10.6
Walla Walla (city) 133 15 11.3 131 6 4.6 264 21 8.0
Walla Walla County 170 21 12.4 164 8 4.9 334 29 8.7
Okanogan County 75 12 16.0 64 5 7.8 139 17 12.2
Ferry/Stevens Counties 68 10 14.7 70 4 5.7 138 14 10.1
Total 1747 193 11.0 1693 88 5.2 3440 281 8.2
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F.2.i.2. Analysis by Dichotomous Exposure Variable
A total of 118 (9.4%) of the 1257 participants included in these analyses had a diagnosis of any
thyroid nodule based on an HTDS or prior histologic or cytologic examination (see Table IX.F-6).  These
included 57/580 (9.8%) in the high exposure group and 61/677 (9.0%) in the low exposure group.  After
adjusting for the effects of sex and age at HTDS clinic in the logistic regression analysis, there was no
evidence of greater cumulative incidence of any thyroid nodule in the high exposure group (p = 0.38).
Table IX.F-6. Diagnoses of Any Thyroid Nodule Based on HTDS or Prior Histologic or Cytologic 
Evidence, by Exposure Group and Sex 
Female  Male  Total
Exposure Group No. Cases % No. Cases % No. Cases %
Low 351 42 12.0 326 19 5.8 677 61 9.0
High 298 39 13.1 282 18 6.4 580 57 9.8
Total 649 81 12.5 608 37 6.1 1257 118 9.4
F.2.j. Confounding and Effect Modification
As described in section VIII above, additional sex-stratified logistic regression models were
investigated to examine the possibility that the primary dose-response results might be influenced by
confounding, and to search for factors that might modify a radiation dose-response.  These analyses were
based on the primary definition of any thyroid nodule, i.e., those with an HTDS or prior histologic or
cytologic diagnosis, and on the primary dose estimates.  Table IX.F-7 displays results for models including
sex, age at first exposure to Hanford 131I (prenatal, or < 180 days), age at HTDS examination, estimated
dose from the NTS, history of any cancer other than thyroid, and HTDS interview type.  
Note that sex was not analyzed as a possible confounder since its effect was already adjusted for in
the sex-stratified model.  It is evident from Table IX.F-7 that the model was not significantly improved by
adjusting for any of the other factors as a potential confounder: none produced a significantly better fit to
the data.  Since the estimated slope was virtually unaffected by such adjustments, it does not appear that
omitting these factors introduces any important bias in the dose-response results.
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Table IX.F-7. Confounding and Effect Modification by Sex, Age at Exposure or HTDS
Examination, Estimated Thyroid Dose from NTS, History of Any Cancer Other
Than Thyroid and Interview Type: Any Thyroid Nodule
Estimated Dose-Response Coefficient (per Gy)
Covariate Yes / Adjusted for Including Effect Modification
 (0=No, 1=Yes) Total Unadjusted Confounding Group 0 Group 1 P
Female? 
1622 /
3191
−.087 ± .301
(−.808, .634)
Not
Applicable
−.311 ± .555
(−1.70, 1.08)
.016 ± .357
(−.875, .908) .62
Prenatal
exposure?
1034 /
3191
−.087 ± .301
(−.808, .634)
−.150 ± .308
(−.943, .643)
−.064 ± .340
(−.962, .834)
 −.461 ± .685
(−2.26, 1.35) .58
1st exposure
before age 180
days?
1478 /
3191
−.087 ± .301
(−.808, .634)
−.103 ± .310
(−.901, .695)
−.292 ± .510
(−1.64, 1.05)
.008 ± .375
(−.983, .998) .64
Age at exam 
 > 50?
2001 /
3191
−.087 ± .301
(−.808, .634)
−.180 ± .313
(−.987, .627)
−.064 ± .570
(−1.57, 1.44)
−.227 ± .373
(−1.21, .757) .81
NTS 131I
dose > 5.3 mGy?
1566 /
3187
−.092 ± .303
(−.816, .633)
−.084 ± .308
(−.878, .711)
.183 ± .375
(−.805, 1.17)
−.551 ± .567
(−2.05, .944) .26
History of any
cancer other than
thyroid?
248 /
3186
−.087 ± .301
(−.807, .634)
−.083 ± .303
(−.863, .698)
−.234 ± .344
(−1.14, .673)
.483 ± .560
(−.994, 1.96) .31
Expanded in-
person interview?
1212 /
3191
−.087 ± .301
(−.808, .634)
.012 ± .303
(−.768, .793)
.050 ± .459
(−1.16, 1.26)
−.016 ± .408
(−1.09, 1.06) .91
Entries in the table are estimate ± standard error for the regression coefficient, with Bonferroni-adjusted 95% confidence interval in
parentheses, based on sex-stratified logistic regression models.  P-values indicate the statistical significance of two-tailed comparison
of estimated coefficients between Groups 0 and 1.
Tables IX.F-8 and IX.F-9 display similar results from analyses including history of medical or
dental x-ray exposure or occupational exposure as potential confounding or effect modifying factors.  The
estimates of the regression coefficient calculated with adjustment for confounding are all close to the
unadjusted estimates.  Moreover the adjusted estimates all remained less than zero.  Thus there was no
evidence that a confounding effect of any of these covariates has obscured a positive dose-response for the
outcome of any thyroid nodule.
There is no evidence of any statistically significant effect modification by any of the covariates in
Tables IX.F-8 and IX.F-9, with two possible exceptions.  
• The estimated dose-response coefficient was markedly negative (−2.22) for the 398 participants with
histories of intravenous pyelograms (IVPs), but not markedly different for the majority of participants
without such histories (0.113 with confidence interval ranging from −0.675 to 0.900; p = 0.040).
• The estimated dose-response coefficient was markedly negative (−2.75) for the 442 participants with
histories of occupations that might have involved exposure to radioactive materials or x-rays, but not
markedly different for the majority of participants without such histories (0.103 with confidence
interval ranging from −0.711 to 0.918; p= 0.031).
The statistical significance of these differences must be interpreted with caution due to the large
number of such comparisons that were performed.  Moreover, neither of these two covariates identified a
group of participants with a significantly positive dose-response.  
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Table IX.F-8. Confounding and Effect Modification by History of Medical and Dental
Radiation Exposures: Any Thyroid Nodule
Have You
Estimated Dose-Response Coefficient (per Gy)
Ever Had: Yes / Adjusted for Including Effect Modification
 (0=No, 1=Yes) Total Unadjusted Confounding Group 0 Group 1 P
CAT scan of the
upper body?
775 /
3149
−.115 ± .305
(−.844, .615)
−.110 ± .303
(−.890, .669)
.073 ± .306
(−.735, .881)
−1.32± .89
(−3.66, 1.02) .12
Diagnostic x-rays
of the head?
1191 /
3155
−.060 ± .300
(−.777, .658)
−.062 ± .299
(−.833, .709)
.131 ± .339
(−.763, 1.02)
−.554 ± .602
(−2.14, 1.03) .31
Diagnostic x-rays
of the neck?
966 /
3167
−.081 ± .301
(−.801, .640)
−.104 ± .302
(−.882, .675)
.111 ± .394
(−.928, 1.15)
−.393 ± .501
(−1.72,.930) .42
Diagnostic x-rays
of chest or upper
body, including
mammograms?
2821 /
3173
−.090 ± .302
(−.813, .632)
−.077 ± .302
(−.854, .700)
−.215 ± 1.23
(−3.46, 3.03)
−.068 ± .311
(−.888, .752) .91
Diagnostic x-rays
of the stomach or
mid-back?
692 /
3120
−.109 ± .308
(−.848, .629)
−.111 ± .308
(−.906, .683)
−.138 ± .347
(−1.05, .778)
−.007 ± .675
(−1.79, 1.77) .86
Barium enema?
825 /
3159
−.094 ± .301
(−.815, .628)
−.093 ± .302
(−.869, .684)
−.056 ± .348
(−.974, .862)
−.198 ± .604
(−1.79, 1.40) .84
Upper GI?
1146 /
3177
−.110 ± .304
(−.838, .618)
−.113 ± .304
(−.897, .671)
.041 ± .364
(−.920, 1.00)
−.401 ± .535
(−1.81, 1.01) .49
Intravenous
pyelogram?
398 /
3157
−.090 ± .303
(−.814, .635)
−.078 ± .303
(−.859, .703)
.113 ± .299
(−.675, .900)
−2.22 ± 1.22
(−5.45, 1.01) .040
Fluoroscopy of 
the upper body?
246 /
3161
−.057 ± .300
(−.776, .662)
−.061 ± .301
(−.836, .714)
.054 ± .300
(−.738, .847)
−1.90 ± 1.45
(−5.73, 1.92) .14
Nuclear scan
(excluding thyroid
scan)?
217 /
3162
−.086 ± .302
(−.809, .636)
−.084 ± .302
(−.862, .694)
.021 ± .300
(−.771, .814)
−2.30 ± 1.71
(−6.80, 2.20) .13
Dental x-rays that
did not usually
include a lead
shield over the
neck area?
1648 /
3191
−.087 ± .301
(−.808, .634)
−.088 ± .301
(−.865, .688)
.344 ± .375
(−.645, 1.33)
−.662 ± .506
(−2.00, .674) .103
Entries in the table are estimate ± standard error for the regression coefficient, with Bonferroni-adjusted 95% confidence interval in
parentheses, based on sex-stratified logistic regression models.  P-values indicate the statistical significance of two-tailed comparison
of estimated coefficients between Groups 0 and 1.
Table IX.F-9. Confounding and Effect Modification by Occupational History: Any Thyroid
Nodule
Have You Ever
Worked in Any of
the Following: Yes/
Estimated Dose-Response Coefficient (per Gy)
                            Adjusted for              Including Effect Modification
 (0=No, 1=Yes) Total Unadjusted Confounding Group 0 Group 1 P
Any metal
industry?
238 /
3191
−.087 ± .301
(−.808, .634)
−.079 ± .300
(−.853, .695)
−.085 ± .305
(−.890, .720)
.144 ± 1.77
(−4.53, 4.82) .90HTDS Final Report: June 21, 2002 – Section IX.F page 310
Any nuclear
facility?
371 /
3191
−.087 ± .301 −.080 ± .303
(−.860, .701) (−1.09, .713) (−1.33, 2.16) .44
or occupation
where you may
have been exposed
to radioactive
materials or x-
rays?
442 /
3191 (−.808, .634) (−.887, .677) (−.711, .918) (−6.80, 1.30)
Any of the above
industries or
occupations?
892 /
3191 (−.808, .634) (−.832, .717) (−1.06, .827) .74
Entries in the table are estimate ± standard error for the regression coefficient, with Bonferroni-adjusted 95% confidence interval in
parentheses, based on sex-stratified logistic regression models.  P-values indicate the statistical significance of two-tailed comparison
of estimated coefficients between Groups 0 and 1.
(−.808, .634)
−.187 ± .341 .418 ± .661
Any other industry
−.087 ± .301 −.105 ± .304 .103 ± .309 −2.75 ± 1.53
.031
−.087 ± .301 −.057 ± .301 −.118 ± .358 −.097 ± .547
(−1.35, 1.54)
Table IX.F-10 displays the results of analyses of possible confounding or effect modification by
smoking variables.  There was no evidence that the dose-response was significantly confounded by either
smoking variable, or that there was a dose-response that differed significantly according to smoking
history.
Table IX.F-10. Confounding and Effect Modification by Smoking: Any Thyroid Nodule
Have You Ever
Smoked Any of
Estimated Dose-Response Coefficient (per Gy)
the Following: Yes / Adjusted for Including Effect Modification
(0=No, 1=Yes) Total Unadjusted Confounding Group 0 Group 1 P
Cigarettes
(unfiltered or
filtered)?
1854 /
3183
−.083 ± .301
(−.803, .637)
−.083 ± .301
(−.858, .691)
−.198 ± .520
(−1.57, 1.17)
−.024 ± .364
(−.984, .936) .78
Any of cigarettes,
cigar or pipe?
1900 /
3183
−.083 ± .301
(−.803, .637)
−.083 ± .301
(−.858, .691)
−.105 ± .523
(−1.48, 1.27)
−.072 ± .367
(−1.04, .895) .96
Entries in the table are estimate ± standard error for the regression coefficient, with Bonferroni-adjusted 95% confidence interval in
parentheses, based on sex-stratified logistic regression models.  P-values indicate the statistical significance of two-tailed comparison
of estimated coefficients between Groups 0 and 1.
F.2.k. Uncertainty
The estimated slopes of the sex-stratified linear dose-response model for any thyroid nodule are
shown in Figure IX.F-1 for each of the 100 dose realizations produced by the CIDER model.  The
confidence intervals in that figure are calculated at the 98.33% confidence level, i.e., are adjusted by the
Bonferroni technique for the simultaneous estimation of the slope and two sex-specific background rates. 
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Figure IX.F-1. Plot of Estimated Slope and 95% CI by Dose Realization: Any Thyroid Nodule
Figure IX.F-2 displays the distribution of the 5000 estimates of the logistic regression coefficient
obtained by the simulation procedures described in section VIII.C.2.b.3 above. It is evident from the figure
that most of the estimates were between about –2.0 and 1.0. The estimate was less than or equal to 0 for
3800 of the 5000 replications, implying an empirical one-tailed p-value of 0.76.  The median estimate was
−.303 and the upper and lower percentiles corresponding to the Bonferroni-adjusted 95% confidence
interval were −1.65 and 0.62.  These may be compared to the estimates of −.09 with confidence interval
(−.81, .63) obtained using the median dose estimates without adjustment for uncertainty. Thus, this method
of adjusting the estimated logistic regression coefficient for the uncertainty in the dose estimates did not
provide evidence that the cumulative incidence of any thyroid nodule increased with increasing dose.
While the point estimate of the slope is greater than 0 for 32 of the 100 realizations, the confidence interval
includes 0 for all 100 of the realizations.  Also shown in Figure IX.F-1 (to the right of realization 100) are
the estimates and confidence intervals calculated using (from left to right) the median, geometric mean and
mean of each participant’s 100 dose realizations. In summary, for none of the 100 realizations of the
estimated doses was there a statistically significant dose-response, and for the majority of realizations the
estimated slope was less than 0.
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Figure IX.F-2. Distribution of Simulation Estimates of Logistic Regression Coefficient: Any 
Thyroid Nodule
slope sample: 5000
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G. Hypothyroidism 
G.1. Occurrence of Hypothyroidism
The primary and alternative definitions for hypothyroidism were as follows:
• Primary definition: HTDS evaluation or medical records with supporting documentation (267 cases)
• Alternative definition #1: HTDS evaluation or medical records with or without supporting
documentation  (372 cases)
• Alternative definition #2: HTDS evaluation, any medical records, or inferred from past/current therapy
(402 cases)
• Alternative definition #3: Any diagnosis or participant/respondent report (595 cases).
Two hundred and sixty-seven (7.8%) living evaluable participants had a diagnosis of
hypothyroidism based on the HTDS evaluation or on medical records with supporting documentation, with
204 (11.7%) women and 63 (3.7%) men having this diagnosis, respectively (Table IX.G-1).  An additional
105 (3.1%) living evaluable participants had a diagnosis of hypothyroidism based on medical records but
without supporting documentation, and 30 (0.9%) were inferred from past or current therapy.  There were
193 (5.6%) reports of hypothyroidism from the participant or his/her CATI respondent. 
It should be noted that Alternative definition #1 includes cases from medical records without
supporting documentation; this category includes many participants who have been treated with thyroid
hormone for many years, had normal thyroid function on the HTDS lab evaluation, and yet had no early
documentation of an elevated TSH in their medical records.  This category therefore very likely includes an
unknown number of valid diagnoses for hypothyroidism for which adequate diagnostic information was not
available.
Table IX.G-1. Basis for Diagnosis of Hypothyroidism, by Sex
       Female   Male              Total
Diagnosis of Hypothyroidism No. % No. % No. %
Yes 481 27.5 114 6.7 595 17.3
HTDS evaluation 97 5.6 49 2.9 146 4.2
Medical records with supporting
documentation
107 6.1 14 0.8 121 3.5
Medical records without
supporting documentation
91 5.2 14 0.8 105 3.1
Inferred from past/current
therapy
27 1.5 3 0.2 30 0.9
Participant/respondent report 159 9.1 34 2.0 193 5.6
No 1250 71.6 1575 93.0 2825 82.1
Unknown 16 0.9 4 0.2 20 0.6
Total 1747 100.0 1693 100.0 3440 100.0
       
       
 
      
 
      
 
Twenty living evaluable participants were classified as “unknown” with regard to diagnosis of
hypothyroidism.  These twenty did not have medical record reports of such a diagnosis.  Seven of these 20
participants did not have a blood draw, thirteen had participant/respondent report of unknown thyroid
disease with 11 taking some kind of medication for this unknown thyroid disease.   Therefore, no HTDS
evaluation could be made for these twenty participants who were included as non-cases in analyses of the
dose-response for hypothyroidism.
Of those with a diagnosis of hypothyroidism, 531 (89.2%) had no known contributing cause
(Table IX.G-2).  However, among those with a contributing cause, about half were due to thyroid or
parathyroid surgery, followed by 131I  therapy (21), and lithium therapy (6).  Ten participants had some
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other contributing cause, with four of the 10 being unknown or uncertain, while two were related to
subacute thyroiditis.
Table IX.G-2. Frequency Distribution of Possible Contributing Causes of Hypothyroidism, by Sex
      Female    Male              Total
Contributing Cause No. % No. % No. %
No Known Contributing Cause 427 88.8 104 91.2 531 89.2
Contributing Cause 54 11.2 10 8.8 64 10.8
131I therapy 20 4.2 1 0.9 21 3.5
Thyroid/parathyroid surgery 25 5.2 5 4.4 30 5.0
Lithium Therapy 4 0.8 2 1.8 6 1.0
Other 8 1.7 2 1.8 10 1.7
Total 481 100.0 114 100.0 595 100.0
Note:  A participant can have more than one possible contributing cause
G.1.a. Permanent Hypothyroidism
An additional outcome of hypothyroidism was defined to exclude those with transient
hypothyroidism.  Transient (temporary) hypothyroidism can occur from certain types of thyroiditis such as
viral subacute thyroiditis or postpartum thyroiditis.  Transient forms of hypothyroidism usually resolve
completely and do not require further treatment.  In contrast, permanent hypothyroidism, such as that
produced from Hashimoto’s thyroiditis, 131I therapy, or thyroid surgery, requires lifelong thyroid hormone
replacement. The definition of permanent hypothyroidism included participants with a diagnosis of
hypothyroidism based on the HTDS evaluation.  Permanent hypothyroidism also included those based on
medical records with supporting documentation, excluding those who had a normal TSH value at the time
of the HTDS clinic and were not currently on thyroid hormone replacement.  Two hundred and fifty seven
participants (7.5%) had a diagnosis of permanent hypothyroidism (Table IX.G-3).  These cases represented
96% of the cases of hypothyroidism according to the primary definition (i.e., diagnosed from the HTDS
evaluation or medical records with supporting documentation).
Table IX.G-3. Permanent Hypothyroidism, by Sex
      Female    Male              Total
Permanent Hypothyroidism No. % No. % No. %
Yes 196 11.2 61 3.6 257 7.5
No 1551 88.8 1632 96.4 3183 92.6
Total 1747 100.0 1693 100.0 3440 100.0
G.2. Analysis of Hypothyroidism Risk
G.2.a. Primary Analysis
Of the 267 participants with a diagnosis of hypothyroidism based on the HTDS examination or
medical records with supporting documentation, 21 were out-of-area participants.  The number of cases and
proportion with hypothyroidism are shown by sex, in-area status, and dose group in Tables IX.G-4 and
IX.G-5.  
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 Table IX.G-4. Diagnoses of Hypothyroidism by Sex, Dose Category, and Basis for Diagnosis
 
 A.  Female
 
 
 
 Thyroid
Radiation
Dose 
 
 
 Living
Evaluable
Female
 Primary Definition:
Cases Based on
HTDS or Medical
Record with
Supporting Document
 
 1st Alternative Definition:
 Cases Based on HTDS or
Med. Rec. with or without
Supporting Document
 
 2nd Alternative Definition:
 Cases Based on HTDS or
Medical Record, or
Inferred from Medication
3rd Alternative Definition:
 Cases Based on Any
Diagnosis or Participant or
CATI Report
 
 (mGy)   No.   No.   %  No.  %.  No.  %  No.    %
 OOA   125   14  11.2   20   125   23  18.4   31 24.8
 < 10   182   19  10.4   26   182   29  15.9   42 23.1
 10-49   320   34  10.6   42   320   47  14.7   67 20.9
 50-99   313   40  12.8   64   313   68  21.7 106 33.9
 100-149   220   22  10.0   34   220   37  16.8   61 27.7
 150-199   126   14  11.1   21   126   21  16.7   31 24.6
 200-299   139   20  14.4   28   139   32  23.0   46 33.1
 300-399   144   22  15.3   31   144   34  23.6   49 34.0
 400-999   171   18  10.5   27   171   29  17.0   46 26.9
 1000+       7     1  14.3     2       7     2  28.6     2 28.6
 Total  1747  204  11.7  295  1747  322  18.4 481 27.5
 OOA = out of area participant
HTDS Final Report: June 21, 2002 – Section IX.G page 315
 B.  Male
 
 
 
 Thyroid
Radiation
Dose
 
 
 Living
Evaluable
Male
 Primary Definition:
Cases Based on
HTDS or Medical
Record with
Supporting Document
 1st Alternative Definition:
 Cases Based on HTDS or
Med. Rec. with or without
Supporting Document
 2nd Alternative
Definition:
 Cases Based on HTDS or
Medical Record, or
Inferred from Medication
3rd Alternative
Definition:
 Cases Based on Any
Diagnosis or Participant
or CATI Report
 (mGy)    No.  No.  %  No.   %  No.    %  No.  %
 OOA   124   7  5.6   7   125   31   125   10   8.1
 < 10   186   8  4.3  10   182   42   182   13   7.0
 10-49   314  10  3.2  12   320   67   320   18   5.7
 50-99   310  11  3.5  12   313 106   313   19   6.1
 100-149   171   7  4.1   8   220   61   220   12   7.0
 150-199   109   2  1.8   2   126   31   126     5   4.6
 200-299   148   7  4.7   8   139   46   139   11   7.4
 300-399   160   7  4.4  10   144   49   144   13   8.1
 400-999   154   4  2.6   7   171   46   171   11   7.1
 1000+     17   0   --   1       7     2       7     2 11.8
 Total  1693  63  3.7  77  1747 481 1747 114   6.7
 OOA = out of area participant
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Table IX.G-5. Additional Disease Outcomes Related to Hypothyroidism by Sex and Estimated
Dose (cases based on HTDS examination or medical records with supporting
documentation only)
 
 A.  Female
 
 Thyroid
Radiation
Dose 
Living
Evaluable
Female Permanent Hypothyroidism
(mGy)   No.  No.    %
OOA   125   14 11.2
< 10   182   18   9.9
10-49   320   34 10.6
50-99   313   36 11.5
100-149   220   20   9.1
150-199   126   14 11.1
200-299   139   19 13.7
300-399   144   22 15.3
400-999   171   18 10.5
1000+       7     1 14.3
Total 1747 196 11.2
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 B.  Male
 
 Thyroid
Radiation
Dose 
 Living
Evaluable
Male  Permanent Hypothyroidism
 (mGy)    No.  No.   %
 OOA   124   7 5.6
 < 10   186   7 3.8
 10-49   314 10 3.2
 50-99   310 11 3.5
 100-149   171   6 3.5
 150-199   109   2 1.8
 200-299   148   7 4.7
 300-399   160   7 4.4
 400-999   154   4 2.6
 1000+     17   0  --
 Total  1693 61 3.6
 OOA = out of area participant
Parameter estimates for the linear dose-response model based on the 3191 in-area participants are
shown in row 1 of Table IX.G-6 below.  Based on maximum likelihood analysis of the sex-stratified linear
probability model, the estimated slope B was slightly less than zero (–0.006 per Gy) with Bonferroni-
adjusted 95% CI ranging from less than −0.016 to 0.047 per Gy, providing no evidence that cumulative
incidence increased with increasing dose (one-tailed p = 0.61).  The corresponding estimated background
rates for diagnosis of benign thyroid nodule were 0.118 with confidence interval (0.097, 0.139) for women
and 0.037 with confidence interval (0.023, 0.050) for men. Similar results were obtained when the model
was fit by the method of least squares using ungrouped or grouped data, although the estimates of the slope
were slightly greater than zero: 0.006 per Gy with confidence interval (−0.044, 0.056 per Gy) with
ungrouped data, and 0.002 per Gy with confidence interval (−0.055, 0.060 per Gy) with grouped data
(Table IX.G-6, rows 2 and 3 respectively).
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Table IX.G-6. Dose-Response Results for Diagnoses of Hypothyroidism
Dose-
Response Dose
Exclusions /
Additional
Method
of Estimated Background Rates 
Estimated
Slope of Dose-
Statistical Significance
of Dose-Response
Row Outcome Model Estimates Inclusions Analysis Female Male Response (per Gy) (one-tailed p-value)
1.
Primary definition
(HTDS evaluation or
medical record with
documentation)
Linear Primary None MLE
.118 ± .009
(.097, .139)
.037 ± .006
(.023, .050)
−.006 ± .019
(< −.016, .047) 0.61
2. Primary definition Linear Primary None LSU
.116 ± .008
(.098, .134)
.035 ± .008
(.016, .053)
.006 ± .021
(−.044, .056) 0.39
3. Primary definition Linear Primary None LSG
.117 ± .008
(.098, .135)
.035 ± .008
(.016, .054)
.002 ± .024
(−.055, .060) 0.46
4.
Alternative def. #1
(HTDS evaluation or
medical records with or
without documentation)
Linear Primary None MLE
.165 ± .010
(.141, .189)
.040 ± .006
(.025, .055)
.026 ± .023
(< -.020, .086)
0.12
5.
Alternative def. #2
(HTDS evaluation or
medical record, or
inferred from
medication 
Linear Primary None MLE
.180 ± .010
(.155, .205)
.042 ± .006
(.026, .057)
.025 ± .024
(< -.020, .087)
0.13
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, “>”
indicates that the upper confidence limit is greater than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are
not given for estimated background rates from logistic regression model.  
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
Okanogan, F/S = Ferry/Stevens, OOA = out of area
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Table continued next page
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Table IX.G-6. Dose-Response Results for Diagnoses of Hypothyroidism (continued)
Dose-
Response Dose
Exclusions /
Additional
Method
of Estimated Background Rates 
Estimated
Slope of Dose-
Statistical Significance
of Dose-Response
Row Outcome Model Estimates Inclusions Analysis Female Male Response (per Gy) (one-tailed p-value)
6.
Alternative def. #3
(Any diagnosis or
participant/respondent
report)
Linear Primary None MLE
.271 ± .012
(.242, .300)
.060 ± .008
(.042, .078)
.038 ± .028
( -.023, .108)
0.076
7.
Permanent
hypothyroidism 
Linear Primary None MLE
.112 ± .009
(.092, .133)
.035 ± .006
(.021, .048)
-.001 ± .020
(< -.015, .053)
0.52
8. Primary definition LQ Primary None LSU
.117 ± .008
(.097, .138)
.036 ± .008
(.015, .057)
Lin: −.006 ± .035
(−.094, .082)
Quad: .010 ± .023
(−.049, .068)
Quad: 0.68
9. Primary definition Logistic Primary None MLE
.116
(.095, .140)
.035
(.025, .049)
.08 ± .29
(-.62, .78)
0.39
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, “>”
indicates that the upper confidence limit is greater than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are
not given for estimated background rates from logistic regression model.  
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
Okanogan, F/S = Ferry/Stevens, OOA = out of area
Table continued on next page
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Table IX.G-6. Dose-Response Results for Diagnoses of Hypothyroidism (continued)
Dose-
Response Dose
Exclusions /
Additional
Method
of Estimated Background Rates 
Estimated
Slope of Dose-
Statistical Significance
of Dose-Response
Row Outcome Model Estimates Inclusions Analysis Female Male Response (per Gy) (one-tailed p-value)
10. Alternative def. #1 Logistic Primary None MLE
.161
(.137, .188)
.042
(.031, .056)
.37 ± .23
(-.19, .93)
0.065
11. Alternative def. #2 Logistic Primary None MLE
.176
(.151, .204)
.043
(.032, .058)
.34 ± .23
(-.22, .89)
0.08
12. Alternative def. #3 Logistic Primary None MLE
.266
(.236, .298)
.062
(.049, .080)
.33 ± .21
(-.16, .83)
0.055
13. Primary definition Linear Primary
Exclude dose
> 1000 mGy
MLE
.117 ± .009
(.096, .139)
.036 ± .006
(.022, .051)
-.002 ± .023
(< -.047, .060)
0.53
14. Primary definition Linear Primary
Exclude dose
> 400 mGy
MLE
.113± .010
 (.089,.136)
.032 ± .006
(.017, .047)
.047 ± .041 
(-.045, .151)
0.12
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, “>”
indicates that the upper confidence limit is greater than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are
not given for estimated background rates from logistic regression model.  
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
Okanogan, F/S = Ferry/Stevens, OOA = out of area
Table continued on next page
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Table IX.G-6. Dose-Response Results for Diagnoses of Hypothyroidism (continued)
Dose-
Response Dose
Exclusions /
Additional
Method
of Estimated Background Rates 
Estimated
Slope of Dose-
Statistical Significance
of Dose-Response
Row Outcome Model Estimates Inclusions Analysis Female Male Response (per Gy) (one-tailed p-value)
15. Primary definition Linear Primary
Exclude 
Ok and F/S
geostrata
MLE
.115 ± .009
(.093, .138)
.031 ± .006
(.017, .045)
.004 ± .021
(<-.014, .060)
0.42
16. Primary definition Linear Alt. #1 None MLE
.120 ± .009
(.098, .141)
.038 ± .006
(.024, .051)
-.011 ± .017
(< -.016, .037)
0.74
17. Primary definition Linear Alt. #2 None MLE
.117 ± .009
(.096, .138)
.036 ± .006
(.022, .050)
.0002 ± .020
(< -.017, .053)
0.50
18. Primary definition Linear Primary
Include OOA
(scoping
analysis #1)
MLE
.118 ± .008
(.098, .138)
.038 ± .005
(.025, .051)
-.008 ± .019
(< -.016, .044)
0.66
19. Primary definition Linear Primary
Include OOA
(scoping
analysis #2)
MLE
.118 ± .008
(.098, .138)
.039 ± .005
(.026, .052)
-.010 ± .018
(< -.016, >.041)
0.69
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, “>”
indicates that the upper confidence limit is greater than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are
not given for estimated background rates from logistic regression model.
  
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
Okanogan, F/S = Ferry/Stevens, OOA = out of area
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G.2.b. Alternative Definitions for Diagnosis of Hypothyroidism  
Each of the three alternative definitions of hypothyroidism (section IX.G.1. above) added
substantial numbers of cases.
Parameter estimates for the linear dose-response model are shown in rows 4 and 5 of Table IX.G-6
above for each of the three alternative definitions of hypothyroidism.  For none of the three alternative
definitions was there a clearly statistically significant increase of cumulative incidence with increasing
dose.
G.2.c. Permanent Hypothyroidism  
In the analyses described above, participants with transient hypothyroidism were included among
the cases.  An additional analysis was performed in which participants with transient hypothyroidism only
were excluded from the cases.  The results are shown in row 7 of Table IX.G-6 above.  The cumulative
incidence of permanent hypothyroidism decreased slightly with increasing dose, with an estimated slope of
−0.001 per Gy and confidence interval ranging from less than −0.015 to 0.053 per Gy (p = 0.52).
G.2.d. Alternative Dose-Response Functions
As shown in row 8 of Table IX.G-6, the estimated regression coefficient for the dose-squared term
in the linear-quadratic dose-response model [5] was 0.010 with Bonferroni-adjusted 95% confidence
interval ranging from –0.049 to 0.068.  Thus the addition of a quadratic term did not significantly improve
the fit of the model (p = 0.68).
In the analysis of hypothyroidism based on the HTDS or medical records with supporting
documentation, i.e., the primary criterion for defining cases with hypothyroidism, the regression parameter
for the effect of dose in the sex-stratified logistic regression model [2] was estimated as 0.08, with
Bonferroni-adjusted 95% confidence limits ranging from −0.62 to 0.78 (Table IX.G-6, row 9).  Thus in the
primary analysis of hypothyroidism, there was no evidence from the logistic regression model that
cumulative incidence increased significantly with increasing dose (p = 0.39).  However in logistic
regression analyses using the alternative criteria for defining cases with hypothyroidism, the estimated
regression coefficients were larger but did not achieve statistical significance (see rows 10, 11 and 12 of
Table IX.G-6).
G.2.e. Effect of Excluding Participants in High Dose Categories
When those with an estimated dose > 1000 mGy were excluded, the estimated slope B was −0.002
per Gy with Bonferroni-adjusted 95% confidence interval ranging from less than −0.047 to 0.060 per Gy,
providing no evidence that the cumulative incidence of hypothyroidism increased with increasing dose
(p = 0.53; Table IX.G-6, row 13).  When participants with estimated dose > 400 mGy were excluded, the
estimated slope was 0.047 per Gy with confidence interval ranging from −0.045 to 0.151 per Gy, and there
was no evidence that the cumulative incidence increased with increasing dose (p = 0.12; Table IX.G-6, row
14).
G.2.f. Effect of Excluding Okanogan and Ferry/Stevens Geostrata
When Okanogan and Ferry/Stevens geostrata were excluded from the analyses, the estimated
slope of the dose-response increased from −0.006 per Gy to the slightly positive value of 0.004 per Gy,
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with confidence interval ranging from less than −0.014 to 0.060 per Gy (Table IX.G-6, row 15).  Thus the
cumulative incidence of hypothyroidism did not increase significantly with increasing dose (p = 0.42).
G.2.g. Analysis of Hypothyroidism in Relation to Alternative Dose Estimates 
In the analysis using the first set of alternative dose estimates (Table IX.G-6, row 16), the
estimated slope B was −0.011 per Gy, with Bonferroni-adjusted 95% confidence interval ranging from less
than -0.016 to 0.037 per Gy, providing no evidence that the cumulative incidence of hypothyroidism
increased with increasing dose (p = 0.74).  The results for the second set of alternative dose estimates were
similar (Table IX.G-6, row 17), with an estimated slope B of 0.0002 per Gy, with Bonferroni-adjusted 95%
confidence interval ranging from less than -0.017 to 0.053 per Gy, providing no evidence that the
cumulative incidence increased with increasing dose (p = 0.50).
G.2.h. Scoping Analysis Regarding Out-of-Area Participants
See section VIII.C.1.a.3 for a description of the scoping analyses that were performed to assess the
possible impact of including the 249 out-of-area participants.  As summarized in rows 18 and 19 of Table
IX.G-6, in both analyses the inclusion of the out-of-area participants slightly decreased the estimated slope
of the dose-response, but did not materially change the dose-response results.  In particular, the estimated
slope of the dose-response was slightly negative in both scoping analyses, providing no evidence that
cumulative incidence increased with increasing dose.
G.2.i. Analysis of Hypothyroidism in Relation to Alternative Representations of
Exposure
In the analyses by geostratum and by dichotomous exposure, the sex and age-adjusted
comparisons of cumulative incidence were performed as described in section VIII.C.2.a.2.
G.2.i.1. Analysis by Geostratum
The proportions of women with hypothyroidism (HTDS or medical record with documentation)
ranged from 11/75 (14.7%) in the Okanogan geostratum to 15/165 (9.1%) in the Adams geostratum (Table
IX.G-7).  For men they ranged from 7/70 (10.0%) in the Ferry/Stevens geostratum to 8/501 (1.6%) in the
Pasco/Kennewick geostratum.  However the heterogeneity among the nine geostrata was not statistically
significant (p = 0.51).  Hypothyroidism was somewhat more common in the Okanogan and Ferry/Stevens
geostrata (13.3% and 8.2% for women and men, respectively) compared to the other geostrata (11.5% and
3.3%, respectively), but this difference was not statistically significant (p = 0.12).
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Table IX.G-7. Diagnoses of Hypothyroidism Based on the HTDS Evaluation or on Medical
Records with Supporting Documentation
Female Male Total
Geostratum No. Cases % No. Cases % No. Cases %
Richland 179 21 11.7 173 7 4.0 352 28 8.0
Pasco/Kennewick 508 58 11.4 501 8 1.6 1009 66 6.5
Benton County 376 45 12.0 358 16 4.5 734 61 8.3
Franklin County 73 10 13.7 76 6 7.9 149 16 10.7
Adams County 165 15 9.1 156 5 3.2 321 20 6.2
Walla Walla (city) 133 16 12.0 131 3 2.3 264 19 7.2
Walla Walla County 170 20 11.8 164 7 4.3 334 27 8.1
Okanogan County 75 11 14.7 64 4 6.3 139 15 10.8
Ferry/Stevens Counties 68 8 11.8 70 7 10.0 138 15 10.9
Total 1747 204 11.7 1693 63 3.7 3440 267 7.8
Because of the large numbers of cases added by the alternative criteria for defining cases of
hypothyroidism (see IX.G-1 above), results for the alternative definitions of hypothyroidism are also
presented (Tables IX.G-8 to IX.G-10, below).  Generally, similar degrees of heterogeneity among the
geostrata were observed in the analyses using the alternative definitions as compared to the primary
definition, (p = 0.57, p = 0.55, and p = 0.017 for the first, second and third alternative definitions,
respectively).  Only when diagnoses that were reported by participants or CATI respondents but not
confirmed by the HTDS evaluation were included (Table IX.G-10) was there evidence of significant
heterogeneity among geostrata.  The tendency toward higher proportions of cases in the Okanogan and
Ferry/Stevens geostrata was observed in all three alternatives.
Table IX.G-8. Diagnoses of Hypothyroidism Based on the HTDS Evaluation or Medical Records
with or without Supporting Documentation (1st Alternative Definition), by
Geostratum and Sex
Female Male Total
Geostratum No. Cases % No. Cases % No. Cases %
Richland 179 28 15.6 173 7 4.0 352 35 9.9
Pasco/Kennewick 508 87 17.1 501 15 3.0 1009 102 10.1
Benton County 376 60 16.0 358 16 4.5 734 76 10.4
Franklin County 73 13 17.8 76 6 7.9 149 19 12.8
Adams County 165 27 16.4 156 6 3.8 321 33 10.3
Walla Walla (city) 133 20 15.0 131 5 3.8 264 25 9.5
Walla Walla County 170 32 18.8 164 9 5.5 334 41 12.3
Okanogan County 75 17 22.7 64 5 7.8 139 22 15.8
Ferry/Stevens Counties 68 11 16.2 70 8 11.4 138 19 13.8
Total 1747 295 16.9 1693 77 4.5 3440 372 10.8
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Table IX.G-9. Diagnoses of Hypothyroidism Based on the HTDS Evaluation, or on Medical
Records with or without Supporting Documentation (2nd Alternative Definition), or
Inferred from Past/Current Therapy, by Geostratum and Sex
Female Male Total
Geostratum No. Cases % No. Cases % No. Cases %
Richland 179 30 16.8 173 7 4.0 352 37 10.5
Pasco/Kennewick 508 95 18.7 501 16 3.2 1009 111 11.0
Benton County 376 65 17.3 358 18 5.0 734 83 11.3
Franklin County 73 14 19.2 76 6 7.9 149 20 13.4
Adams County 165 29 17.6 156 6 3.8 321 35 10.9
Walla Walla (city) 133 23 17.3 131 5 3.8 264 28 10.6
Walla Walla County 170 34 20.0 164 9 5.5 334 43 12.9
Okanogan County 75 19 25.3 64 5 7.8 139 24 17.3
Ferry/Stevens Counties 68 13 19.1 70 8 11.4 138 21 15.2
Total 1747 322 18.4 1693 80 4.7 3440 402 11.7
Table IX.G-10. Diagnoses of Hypothyroidism Based on Any Source (3rd Alternative Definition), by
Geostratum and Sex
Female Male Total
Geostratum No. Cases % No. Cases % No. Cases %
Richland 179 47 26.3 173 10 5.8 352 57 16.2
Pasco/Kennewick 508 135 26.6 501 24 4.8 1009 159 15.8
Benton County 376 94 25.0 358 24 6.7 734 118 16.1
Franklin County 73 27 37.0 76 8 10.5 149 35 23.5
Adams County 165 41 24.8 156 8 5.1 321 49 15.3
Walla Walla (city) 133 39 29.3 131 8 6.1 264 47 17.8
Walla Walla County 170 55 32.4 164 16 9.8 334 71 21.3
Okanogan County 75 23 30.7 64 7 10.9 139 30 21.6
Ferry/Stevens Counties 68 20 29.4 70 9 12.9 138 29 21.0
Total 1747 481 27.5 1693 114 6.7 3440 595 17.3
G.2.i.2. Analysis by Dichotomous Exposure Variable
A total of 96 (7.6%) of the 1257 participants included in these analyses had a diagnosis of
hypothyroidism based on the HTDS examination or a medical record with supporting documentation (see
Table IX.G-11).  These included 35/580 (6.0%) in the high exposure group and 61/677 (9.0%) in the low
exposure group.  Thus there was no evidence that the cumulative incidence of hypothyroidism was
significantly higher in the high exposure group (p = 0.97).
Table IX.G-11. Diagnoses of Hypothyroidism Based on HTDS or Medical Record with Supporting
Documentation, by Exposure Group and Sex 
Female Male Total
Exposure Group No Cases % No. Cases % No. Cases %
Low 351 40 11.4 326 21 6.4 677 61 9.0
High 298 31 10.4 282 4 1.4 580 35 6.0
Total 649 71 10.9 608 25 4.1 1257 96 7.6
HTDS Final Report: June 21, 2002 – Section IX.G Page 326
Because of the large numbers of cases added by the three alternative definitions for
hypothyroidism (see section IX.G.1 above), results for these alternatives are also presented briefly.  The
first alternative definition added 41 cases with diagnoses based on medical records without supporting
documentation, for a total of 137 (10.9%).  The second alternative added 11 cases with diagnoses inferred
from medication, for a total of 148 (11.8%).  The third alternative added 60 further cases with diagnoses
reported by the participant or his/her CATI respondent, for a total of 208 (16.5%).  In none of the
alternative analyses was the cumulative incidence of hypothyroidism found to be elevated in the high
exposure group (p = 0.86, 0.94, and 0.73 for the first, second, and third alternatives, respectively).
G.2.j. Confounding and Effect Modification
As described in section VIII above, additional sex-stratified logistic regression models were
investigated to examine the possibility that the primary dose-response results might be influenced by
confounding, and to search for factors that might modify a radiation dose-response.  These analyses were
based on the primary definition of hypothyroidism, i.e., those based on the HTDS evaluation or on medical
records with supporting documentation, and on the primary dose estimates.  Table IX.G-12 displays results
for models including sex, age at first exposure to Hanford 131I (prenatal, or < 180 days), age at HTDS
examination, estimated dose from the NTS, history of any cancer other than thyroid, and HTDS interview
type.  Note that sex was not analyzed as a possible confounder since its effect was already adjusted for in
the sex-stratified model.  It is evident from Table IX.G-12 that the model was not significantly improved by
adjusting for any of the other factors as a potential confounder: none produced a significantly better fit to
the data.  Since the estimated slope was virtually unaffected by such adjustments, it does not appear that
omitting these factors introduces any important bias in the dose-response results.
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Table IX.G-12. Confounding and Effect Modification by Sex, Age at Exposure or HTDS
Examination, Estimated Thyroid Dose from NTS, History of Any Cancer Other
Than Thyroid, and Interview Type: Hypothyroidism
Estimated Dose-Response Coefficient (per Gy)
Covariate Yes / Adjusted for Including Effect Modification
 (0=No, 1=Yes) Total Unadjusted Confounding Group 0 Group 1 P
Female?
1622 /
3191
.082 ± .293
(−.620, .785)
Not
Applicable
−.508 ± .704
(−2.27, 1.25)
.240 ± .321
(−.563, 1.04) .31
Prenatal
exposure?
1034 /
3191
.082 ± .293
(−.620, .785)
.063 ± .297
(−.702, .829)
.023 ± .346
(−.891, .936)
.187 ± .589
(−1.37, 1.74) .81
1st exposure
before age 180
days?
1478 /
3191
.082 ± .293
(−.620, .785)
.097 ± .297
(−.669, .863)
−.630 ± .568
(−2.14, .859)
.386 ± .317
(−.451, 1.22) .11
Age at exam 
>50?
2001 /
3191
.082 ± .293
(−.620, .785)
.149 ± .292
(−.604, .902)
.369 ± .445
(−.805, 1.54)
.004 ± .386
(−1.01, 1.02) .54
NTS 131I
dose > 5.3 mGy?
1563 /
3181
.084 ± .297
(−.627, .795)
.002 ± .311
(−.800, .804)
−.184 ± .422
(−1.30, .929)
.248 ± .445
(−.925, 1.42) .49
History of any
cancer other than
thyroid?
248 /
3186
.083 ± .293
(−.620, .785)
.081 ± .293
(−.674, .836)
.043 ± .330
(−.828, .914)
.224 ± .614
(−1.40, 1.84) .80
Expanded In-
Person Interview?
1212 /
3191
.082 ± .293
(−.620, .785)
.119 ± .298
(−.648, .885)
−.603 ± .541
(−2.03, .826)
.456 ± .325
(−.402, 1.31) .089
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses, based on sex-
stratified logistic regression models.  P-values reflect the significance of the improved fit for models including confounding or effect
modification, relative to the unadjusted model.
Tables IX.G-13 and IX.G-14 display similar results from analyses including history of medical or
dental x-ray exposure or of occupational exposures as potential confounding or effect modifying factors.
The estimates of the regression coefficient calculated with adjustment for confounding are all close to the
unadjusted estimates.  Thus there was no evidence that a confounding effect of any of these covariates has
obscured a positive dose-response for hypothyroidism. 
There is no evidence of any statistically significant effect modification by any of the covariates in
Tables IX.G-13 and IX.G-14.
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Table IX.G-13. Confounding and Effect Modification by History of Medical and Dental Radiation
Exposures: Hypothyroidism
Have You
Estimated Dose-Response Coefficient (per Gy)
Ever Had: Yes / Adjusted for Including Effect Modification
 (0=No, 1=Yes) Total Unadjusted Confounding Group 0 Group 1 P
CAT scan of the
upper body?
775 /
3149
.046 ± .297
(−.664, .757)
.034 ± .299
(−.736, .803)
−.044 ± .342
(−.945, .857)
.356 ± .675
(−1.42, 2.14) .60
Diagnostic x-rays
of the head?
1191 /
3155
.083 ± .296
(−.625, .791)
.080 ± .296
(−.684, .843)
.103 ± .362
(−.852, 1.06)
.033 ± .514
(−1.32, 1.39) .91
Diagnostic x-rays
of the neck?
966 /
3167
.059 ± .297
(−.652, .770)
.070 ± .296
(−.692, .832)
−.264 ± .437
(−1.42, .888)
.375 ± .376
(−.616, 1.37) .27
Diagnostic x-rays
of chest or upper
body, including
mammograms?
2821 /
3173
.080 ± .294
(−.624, .784)
.090 ± .294
(−.667, .847)
.907 ± 1.22
(−2.31, 4.12)
.047 ± .305
(−.757, .852) .52
Diagnostic x-rays
of the stomach or
mid-back?
692 /
3120
.102 ± .294
(−.603, .807)
.099 ± .295
(−.660, .858)
−.087 ± .353
(−1.02, .843)
.678 ± .554
(−.785, 2.14) .26
Barium enema?
825 /
3159
.085 ± .295
(−.622, .792)
.084 ± .295
(−.677, .845)
.272 ± .329
(−.595, 1.14)
−.495 ± .658
(−2.23, 1.24) .28
Upper GI?
1146 /
3177
.066 ± .296
(−.642, .773)
.066 ± .295
(−.695, .827)
.146 ± .357
(−.796, 1.09)
−.090 ± .519
(−1.46, 1.28) .71
Intravenous
pyelogram?
398 /
3157
.007 ± .304
(−.721, .734)
.013 ± .304
(−.770, .796)
−.101 ± .337
(−.990, .788)
.804 ± .824
(−1.37, 2.98) .32
Fluoroscopy of 
the upper body?
246 /
3161
.072 ± .295
(−.635, .779)
.078 ± .295
(−.682, .839)
.094 ± .304
(−.707, .895)
−.154 ± 1.19
(−3.28, 2.97) .84
Nuclear scan
(excluding thyroid
scan)?
217 /
3162
.089 ± .292
(−.611, .789)
.098 ± .292
(−.653, .849)
.137 ± .293
(−.636, .909)
−1.19 ± 1.89
(−6.17, 3.80) .46
Dental x-rays that
did not usually
include a lead
shield over the
neck area?
1648 /
3191
.082 ± .293
(−.620, .785)
.083 ± .294
(−.674, .839)
−.372 ± .493
(−1.67, .930)
.391 ± .357
(−.551, 1.33) .20
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses, based on sex-
stratified logistic regression models.  P-values reflect the significance of the improved fit for models including confounding or effect
modification, relative to the unadjusted model.
Table IX.G-14. Confounding and Effect Modification by Occupational History: Hypothyroidism
Have You Ever
Worked in Any of
Estimated Dose-Response Coefficient (per Gy)
the Following: Yes / Adjusted for Including Effect Modification
 (0=No, 1=Yes) Total Unadjusted Confounding Group 0 Group 1 P
Any metal
industry?
238 /
3191
.082 ± .293
(−.620, .785)
.082 ± .293
(−.673, .838)
.154 ± .290
(−.611, .920)
−3.53 ± 2.83
(−11.0, 3.94) .11
Any nuclear 371 / .082 ± .293 .071 ± .297 .103 ± .315 −.158 ± .871HTDS Final Report: June 21, 2002 – Section IX.G Page 329
facility? 3191 (−.620, .785) (−.695, .837) (−.729, .935) (−2.45, 2.14) .77
Any other industry
or occupation
where you may
have been exposed
to radioactive
materials or x-
rays?
442 /
3191
.082 ± .293
(−.620, .785)
.081 ± .294
(−.676, .838)
.164 ± .314
(−.665, .992)
−.476 ± .965
(−3.02, 2.07) .49
Any of the above
industries or
occupations?
892 /
3191
.082 ± .293
(−.620, .785)
.079 ± .294
(−.678, .837)
.295 ± .326
(−.566, 1.16)
−.617 ± .686
(−2.43, 1.19) .20
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses, based on sex-
stratified logistic regression models.  P-values reflect the significance of the improved fit for models including confounding or effect
modification, relative to the unadjusted model.
Table IX.G-15 displays the results of analyses of possible confounding or effect modification by
smoking variables.  There was no evidence that the dose-response was significantly confounded by either
smoking variable, or that there was a dose-response that differed significantly according to smoking
history.
Table IX.G-15. Confounding and Effect Modification by Smoking: Hypothyroidism
Have You Ever
Smoked Any of
Estimated Dose-Response Coefficient (per Gy)
the Following: Yes / Adjusted for Including Effect Modification
(0=No, 1=Yes) Total Unadjusted Confounding Group 0 Group 1 P
Cigarettes
(unfiltered or
filtered)?
1854 /
3183
.086 ± .294
(−.617, .790)
.099 ± .296
(−.663, .860)
.078 ± .474
(−1.17, 1.33)
.112 ± .377
(−.883, 1.11) .96
Any of cigarettes,
cigar or pipe?
1900 /
3183
.086 ± .294
(−.617, .790)
.098 ± .296
(−.663, .860)
.071 ± .476
(−1.18, 1.33)
.116 ± .376
(−.875, 1.11) .94
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses, based
on sex-stratified logistic regression models.  P-values reflect the significance of the improved fit for models including confounding or
effect modification, relative to the unadjusted model.
G.2.k. Uncertainty
The estimated slopes of the sex-stratified linear dose-response model for hypothyroidism are
shown in Figure IX.G-1 for each of the 100 dose realizations produced by the CIDER model.  The
confidence intervals in that figure are calculated at the 98.33% confidence level, i.e., are adjusted by the
Bonferroni technique for the simultaneous estimation of the slope and two sex-specific background rates.
While the point estimate of the slope is greater than 0 for 32 of the 100 realizations, the confidence interval
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includes 0 for all 100 realizations.  Also shown in Figure IX.G-1 (to the right of realization 100) are the
estimates and confidence intervals calculated using (from left to right) the median, geometric mean and
mean of each participant’s 100 dose realizations. In summary, for none of the 100 realizations of the
estimated doses was there a statistically significant dose-response, and for the majority of realizations the
estimated slope was less than 0.
Figure IX.G-2 displays the distribution of the 5000 estimates of the logistic regression coefficient
obtained by the simulation procedures described in section VIII.C.2.b.3 above.  It is evident from the figure
that most of the estimates were between about –2.0 and 1.0.  The estimate was less than or equal to 0 for
2368 of the 5000 replications, implying an empirical one-tailed p-value of 0.47.  The median estimate was
0.028, and the upper and lower percentiles corresponding to the Bonferroni-adjusted 95% confidence
interval were –1.40 and 0.86.  These may be compared to the estimates of −.08 with confidence interval
(−0.62, 0.78) obtained using the median dose estimates without adjustment for uncertainty. Thus, this
method of adjusting the estimated logistic regression coefficient for the uncertainty in the dose estimates
did not provide evidence that the cumulative incidence of hypothyroidism increased with increasing dose.
Figure IX.G-1 Plot of Estimated Slope and 95% CI by Dose Realization: Hypothyroidism
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Figure IX.G-2. Distribution of Simulation Estimates of Logistic Regression Coefficient: 
Hypothyroidism
slope sample: 5000
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H. Autoimmune (Hashimoto’s) Thyroiditis 
 
H.1. Occurrence of Autoimmune (Hashimoto’s) Thyroiditis 
 
The primary and alternative definitions for autoimmune (Hashimoto’s) thyroiditis were as follows: 
 
 Primary definition: HTDS evaluation or medical records with supporting documentation (625 cases) 
 Alternative definition #1: HTDS evaluation or medical records with or without supporting 
documentation  (628 cases) 
 Alternative definition #2: Any diagnosis or participant/respondent report (629 cases). 
 
 Of the 3440 living evaluable participants, 629 (18.3%) had diagnoses of autoimmune thyroiditis 
(Table IX.H-1), with all but four based on the HTDS evaluation or medical records with supporting 
documentation.   
 
Table IX.H-1. Basis for Diagnosis of Autoimmune Thyroiditis, by Sex 
 
 Female Male              Total 
Basis for Diagnosis No. % No. % No. % 
Yes 407 23.3 222 13.1 629 18.3
 HTDS evaluation 402 23.0 221 13.1 623 18.1 
 Medical records with supporting 
documentation 1 0.1 1 0.1 2 0.1 
 Medical records without 
supporting documentation 3 0.2 0 -- 3 0.1 
 Participant/respondent report 1 0.1 0 -- 1 0.0 
No 1333 76.3 1469 86.8 2802 81.5 
Unknown 7 0.4 2 0.1 9 0.3 
Total 1747 100.0 1693 100.0 3440 100.0 
 
 
Nine living evaluable participants were classified as “unknown” with regard to diagnosis of 
autoimmune thyroiditis.  These nine did not have medical record or participant/respondent reports of such 
diagnoses, and did not have a blood draw (8) or had an insufficient quantity of blood drawn to perform the 
AMA or anti-TPO test (1) and therefore no HTDS evaluation could be made.  These nine participants were 
included as non-cases in analyses of the dose-response for autoimmune thyroiditis. 
 
 
H.1.a. Additional Outcomes Related to Assay for Anti-Thyroid Immune Response 
 
Late in the course of the study, it was decided to assay anti-thyroid globulin antibody (anti-TG) 
levels in the serum specimens that had been provided by nearly all study participants and stored in frozen 
form.  The anti-TG test, although not considered to be the best test of autoimmune thyroiditis, provides an 
additional marker of antithyroid immune response.  This made it possible to define additional outcomes of 
autoimmune thyroiditis based on the combined results of AMA/anti-TPO and anti-TG, or on anti-TG alone.  
Two additional outcomes were defined: 
 
 Positive antibodies on the AMA/anti-TPO and/or the anti-TG test. A total of 779 living evaluable 
participants were antibody-positive based on either or both of their AMA/anti-TPO results and their 
anti-TG results or had a diagnosis of autoimmune thyroiditis based on medical records with supporting 
documentation.  These 779 comprised 22.6% of the 3440 living evaluable participants (Table IX.H-2). 
 
 Positive antibodies on the anti-TG test, without regard to the AMA/anti-TPO results or a diagnosis of 
autoimmune thryoiditis based on medical records with supporting documentation.  A total of 507 
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living evaluable participants met these criteria and comprised 14.7% of the 3440 living evaluable 
participants (Table IX.H-3). 
 
Table IX.H-2. Diagnosis of Autoimmune Thyroiditis Based on AMA/anti-TPO and/or anti-TG, or 
Medical Records with Supporting Documentation, by Sex 
 
      Female   Male              Total 
Autoimmune Thyroiditis No. % No. % No. % 
Yes 500 28.6 279 16.5 779 22.6 
No 1247 71.4 1414 83.5 2661 77.4 
Total 1747 100.0 1693 100.0 3440 100.0 
 
Table IX.H-3. Diagnosis of Autoimmune Thyroiditis Based on anti-TG, or Medical Records with 
Supporting Documentation, by Sex 
 
      Female   Male                 Total 
Autoimmune Thyroiditis No. % No. % No. % 
Yes 327 18.7 180 10.6 507 14.7 
No 1420 81.3 1513 89.4 2933 85.3 
Total 1747 100.0 1693 100.0 3440 100.0 
 
 
H.1.b. Additional Outcomes Related to Autoimmune Thyroiditis and Hypothyroidism 
 
Two additional outcomes of autoimmune thyroiditis in combination with hypothyroidism were 
defined to narrow the definition of autoimmune thyroiditis to include both an immune marker for 
autoimmune thyroid disease and hypothyroidism.  These outcomes would represent the most advanced 
stages of the autoimmune process (hypothyroidism).  These additional outcomes were added to determine if 
a dose-response might be seen with these most advanced stages but missed in the broader category of 
autoimmune thyroiditis where hypothyroidism had not yet occurred.  For this purpose, the diagnoses of 
autoimmune thyroiditis and hypothyroidism in these additional outcomes were based on the primary 
definitions, i.e., on the HTDS evaluation or medical records with supporting documentation.  The two 
additional outcomes were: 
 
• Autoimmune thyroiditis (positive AMA/anti-TPO) in participants who also had a diagnosis of 
hypothyroidism.  There were 175 (5.1%) such cases (Table IX.H-4).   
 
• Autoimmune thyroiditis (positive AMA/anti-TPO) in participants who also had a diagnosis of non-
iatrogenic, permanent hypothyroidism.  This outcome was similar to the first, but excluded those with 
an iatrogenic cause of hypothyroidism (surgery or 131I therapy) or with transient hypothyroidism.  One 
hundred and sixty-one (4.7%) living evaluable participants met this definition (Table IX.H-5). 
 
Table IX.H-4. Cross-tabulation of Disease Status with Respect to Diagnosis of Autoimmune 
Thyroiditis in combination with Hypothyroidism, by Sex 
 
Autoimmune Thyroiditis       Female    Male              Total 
with Hypothyroidism No. % No. % No. % 
Yes 135 7.7 40 2.4 175 5.1 
No 1612 92.3 1653 97.6 3265 94.9 
Total 1747 100.0 1693 100.0 3440 100.0 
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Table IX.H-5. Autoimmune Thyroiditis in Combination with Non-Iatrogenic, Permanent 
Hypothyroidism, by Sex 
 
Autoimmune Thyroiditis with     Female    Male              Total 
Non-iatrogenic Hypothyroidism No. % No. % No. % 
Yes 122 7.0 39 2.3 161 4.7 
No 1625 93.0 1654 97.7 3279 95.3 
Total 1747 100.0 1693 100.0 3440 100.0 
 
 
H.2. Analysis of Autoimmune (Hashimoto’s) Thyroiditis Risk 
 
H.2.a. Primary Analysis 
 
Of the 625 participants with a diagnosis of autoimmune thyroiditis based on the HTDS 
examination or medical records with supporting documentation, 43 were out-of-area participants for whom 
the CIDER program could not calculate dose estimates.  The proportions with autoimmune thyroiditis 
according to the primary and two alternative definitions are shown by sex, dose category and basis for 
diagnosis in Table IX.H-6. 
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Table IX.H-6. Diagnoses of Autoimmune (Hashimoto’s) Thyroiditis by Sex, Estimated Dose, and 
Basis for Diagnosis  
 
A.  Female 
 
 
Thyroid 
Radiation 
Dose 
(mGy) 
 
 
Living 
Evaluable 
Female 
Primary Definition: 
Cases Based on HTDS 
or Med. Rec. with 
Supporting 
Documentation 
1st Alternative Definition: 
Cases based on HTDS or 
Med. Rec. with or without 
Supporting 
Documentation 
 
2nd Alternative Definition: 
Cases Based on Any 
Diagnosis or Participant or 
CATI Report 
 No. No. % No.           % No.        % 
Out of Area 125 22 17.6 22 17.6 22 17.6 
< 10 182 44 24.2 44 24.2 45 24.7 
10-49 320 71 22.2 71 22.2 71 22.2 
50-99 313 81 25.9 82 26.2 82 26.2 
100-149 220 53 24.1 54 24.5 54 24.5 
150-199 126 36 28.6 36 28.6 36 28.6 
200-299 139 29 20.9 29 20.9 29 20.9 
300-399 144 33 22.9 34 23.6 34 23.6 
400-999 171 32 18.7 32 18.7 32 18.7 
1000+ 7 2 28.6 2 28.6 2 28.6 
Total 1747 403 23.1 406 23.2 407 23.3 
 
 
B.  Male 
 
 
 
Thyroid 
Radiation 
Dose 
(mGy) 
 
 
 
Living 
Evaluable 
Male 
 
Primary Definition: 
Cases Based on HTDS 
or Med. Rec. with 
Supporting 
Documentation 
1st Alternative 
Definition: 
Cases Based on HTDS 
or Med. Rec. with or 
without Supporting 
Documentation 
 
 
2nd Alternative Definition: 
Cases Based on Any 
Diagnosis or Participant or 
CATI Report 
 No. No.            % No.        % No.    % 
Out of Area 124 21 16.9 21 16.9 21 16.9 
< 10 186 26 14.0 26 14.0 26 14.0 
10-49 314 40 12.7 40 12.7 40 12.7 
50-99 310 47 15.2 47 15.2 47 15.2 
100-149 171 17 9.9 17 9.9 17 9.9 
150-199 109 12 11.0 12 11.0 12 11.0 
200-299 148 18 12.2 18 12.2 18 12.2 
300-399 160 20 12.5 20 12.5 20 12.5 
400-999 154 20 13.0 20 13.0 20 13.0 
1000+ 17 1 5.9 1 5.9 1 5.9 
Total 1693 222 13.1 222 13.1 222 13.1 
 
 
 Table IX.H-7 displays the numbers of participants with diagnoses of autoimmune thyroiditis when 
anti-TG was used in addition to AMA/anti-TPO to identify antithyroid immune response, or when anti-TG 
was used alone. 
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Table IX.H-7. Additional Disease Outcomes Related to Autoimmune Thyroiditis 
  by Sex and Estimated Dose (cases based on HTDS examination or medical records 
  with supporting documentation only) 
 
A.  Female 
 
 
Thyroid 
Radiation 
Dose 
(mGy) 
 
 
Living 
Evaluable 
Female 
HTDS Diagnosis from 
AMA/anti-TPO and/or 
anti-TG, or Medical Record 
with Supporting 
Documentation 
 
HTDS Diagnosis from 
anti-TG, or Medical Record 
with Supporting 
Documentation 
 No. No.      % No.     % 
Out of Area 125 25 20.0 13 10.4 
< 10 182 62 34.1 45  24.7 
10-49 320 91 28.4 57  17.8 
50-99 313 89 28.4 49 15.7 
100-149 220 72 32.7 57  25.9 
150-199 126 42 33.3 27  21.4 
200-299 139 35 25.2 24  17.3 
300-399 144 38 26.4 28  19.4 
400-999 171 44 25.7 25 14.6 
1000+ 7 2 28.6 2 28.6 
Total 1747 500 28.6 327 18.7 
 
 
B.  Male 
 
 
Thyroid 
Radiation 
Dose 
(mGy) 
 
 
Living 
Evaluable 
Male 
HTDS Diagnosis from 
AMA/anti-TPO and/or 
anti-TG, or Medical 
Record with Supporting 
Documentation 
 
HTDS Diagnosis from 
anti-TG, or Medical Record 
with Supporting 
Documentation 
 No. No.        % No.     % 
Out of Area 124 26 21.0 20 16.1 
< 10 186 33 17.7 26 14.0 
10-49 314 51 16.2 29  9.2 
50-99 310 58 18.7 35  11.3 
100-149 171 21 12.3 13 7.6 
150-199 109 17 15.6 10 9.2 
200-299 148 24 16.2 18 12.2 
300-399 160 24 15.0 16  10.0 
400-999 154 24 15.6 13 8.4 
1000+ 17 1 5.9 0 -- 
Total 1693 279 16.5 180  10.6 
 
 
 Table IX.H-8 displays the numbers of participants with diagnoses of autoimmune thyroiditis 
together with diagnoses of hypothyroidism. 
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Table IX.H-8. Disease Outcomes Related to Autoimmune Thyroiditis with Hypothyroidism by Sex 
and Estimated Dose (cases based on HTDS examination or medical records with 
supporting documentation only) 
 
A.  Female 
 
Thyroid 
Radiation 
Dose 
(mGy) 
 
Living 
Evaluable 
Female 
 
Autoimmune 
Thyroiditis with Any 
Hypothyroidism 
 
Autoimmune Thyroiditis 
with Non-Iatrogenic, 
Permanent Hypothyroidism 
 No. No. % No.        % 
Out of Area 125 10 8.0 9 7.2 
< 10 182 14 7.7 12 6.6 
10-49 320 25 7.8 22 6.9 
50-99 313 27 8.6 23 7.3 
100-149 220 11 5.0 10 4.5 
150-199 126 10 7.9 10 7.9 
200-299 139 14 10.1 13 9.4 
300-399 144 13 9.0 12 8.3 
400-999 171 10 5.8 10 5.8 
1000+ 7 1 14.3 1 14.3 
Total 1747 135 7.7 122 7.0 
 
 
B. Male 
 
Thyroid 
Radiation 
Dose 
(mGy) 
 
Living 
Evaluable 
Male 
 
Autoimmune 
Thyroiditis with Any 
Hypothyroidism 
 
Autoimmune Thyroiditis 
with Non-Iatrogenic, 
Permanent Hypothyroidism 
 No. No. % No.        % 
Out of Area 124 5 4.0 5 4.0 
< 10 186 4 2.2 4 2.2 
10-49 314 6 1.9 6 1.9 
50-99 310 8 2.6 8 2.6 
100-149 171 3 1.8 3 1.8 
150-199 109 1 0.9 1 0.9 
200-299 148 4 2.7 4 2.7 
300-399 160 5 3.1 5 3.1 
400-999 154 4 2.6 3 1.9 
1000+ 17 0 -- 0 -- 
Total 1693 40 2.4 39 2.3 
 
 
Parameter estimates for the linear dose-response model based on the 3191 in-area participants are 
shown in Table IX.H-9 below.  Based on maximum likelihood analysis of the sex-stratified linear 
probability model, and using the primary dose estimates, the estimated slope of the dose-response was 
slightly less than zero (–0.026 per Gy; row 1 of Table IX.H-9) with Bonferroni-adjusted 95% confidence 
interval ranging from less than –0.057 to 0.044 per Gy, providing no evidence that cumulative incidence 
increased with increasing dose (p = 0.82).  The corresponding estimated background rates for diagnosis of 
benign thyroid nodule were 0.239 with confidence interval (0.212, 0.267) for women and 0.133 with 
confidence interval (0.109, 0.156) for men.  Very similar results were obtained when the model was fit by 
the method of least squares using ungrouped or grouped data (Table IX.H-9, rows 2 and 3). 
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Table IX.H-9. Summary of Dose-Response Results for Diagnoses of Autoimmune Thyroiditis 
 
  Dose-
Response 
 
Dose 
Exclusions / 
Additional 
Method 
of 
 
Estimated Background Rates  
Estimated 
Slope of Dose- 
Statistical Significance 
of Dose-Response 
Row Outcome Model Estimates Inclusions Analysis Female  Male Response (per Gy) (one-tailed p-value) 
1. 
Primary definition 
(HTDS evaluation or 
medical record with 
documentation) 
Linear Primary None MLE
.239 ± .012 
(.212, .267)  
.133 ± .010 
(.109, .156) 
−.026 ± .026 
(< −.057, .044) 0.82 
2. Primary definition Linear Primary None LSU
.240 ± .011 
(.214, .266)  
.133 ± .011 
(.107, .160) 
−.029 ± .030 
(−.102, .043) 0.83 
3. Primary definition Linear Primary None LSG
.243 ± .011 
(.216, .270)  
.137 ± .012 
(.109, .164) 
−.048 ± .035 
(−.131, .035) 0.92 
4. 
Alternative def. #1 
(HTDS or medical 
record with or without 
documentation) 
Linear Primary None MLE
.241 ± .012 
(.213, .269)  
.133 ± .010 
(.109, .156) 
−.025 ± .026 
(< −.057, .044) 0.82 
5. 
Alternative def. #2  
(Any diagnosis or 
participant/respondent 
report) 
Linear Primary None MLE
.242 ± .012 
(.214, .269)  
.133 ± .010 
(.109, .156) 
−.026 ± .026 
(< −.057, .044) 0.83 
6. 
Diagnoses based on 
AMA/anti-TPO  
and/or anti-TG 
Linear Primary None MLE
.300 ± .012 
(.270, .329) 
.168 ± .011 
(.143, .194) 
−.039 ± .029 
(< −.071, .036) 0.90 
     
    
      
      
    
    
    
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, “>” 
indicates that the upper confidence limit is greater than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are 
not given for estimated background rates from logistic regression model.  
 
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok = 
Okanogan, F/S = Ferry/Stevens, OOA = out of area 
 
Table continued on next page
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Table IX.H-9. Summary of Dose-Response Results for Diagnoses of Autoimmune Thyroiditis (continued) 
 
   Dose-
Response 
 
Dose 
Exclusions / 
Additional 
Method 
of 
 
Estimated Background Rates  
Estimated 
Slope of Dose- 
Statistical Significance 
of Dose-Response 
Row Outcome Model Estimates Inclusions Analysis Female  Male Response (per Gy) (one-tailed p-value) 
7. 
Diagnoses based on 
anti-TG, without regard 
to AMA/anti-TPO 
Linear Primary None MLE
.199 ± .011 
(.174, .225) 
.107 ± .009 
(.087, .128) 
−.032 ± .022 
(< −.045, .030) 0.90 
8. 
Autoimmune thyroiditis 
with any 
hypothyroidism 
Linear Primary None MLE
.077 ± .007 
(.060, .094) 
.022 ± .005 
(.011, .033) 
.000 ± .015 
(< −.010, >.015) 0.50 
9. 
Autoimmune thyroiditis 
with non-iatrogenic, 
permanent 
hypothyroidism 
Linear Primary None MLE
.070 ± .007 
(.053, .086) 
.022 ± .004 
(.011, .032) 
.001 ± .015 
(< −.010, .043) 0.48 
10. Primary definition LQ Primary None LSU
.246 ± .012 
(.217, .276) 
.140 ± .012 
(.110, .170) 
Lin: −.090 ± .051 
(−.218, .038) 
 
Quad: .050 ± .034 
(−.035, .134) 
Quad: 0.14 
11. Primary definition Logistic Primary None MLE
.242 
(.212, .273) 
.132 
(.111, .157) 
−.22 ± .22 
(-.74, .31) 
0.84 
     
    
    
    
      
      
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, “>” 
indicates that the upper confidence limit is greater than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are 
not given for estimated background rates from logistic regression model.   
 
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok = 
Okanogan, F/S = Ferry/Stevens, OOA = out of area 
 
Table continued on next page 
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Table IX.H-9. Summary of Dose-Response Results for Diagnoses of Autoimmune Thyroiditis (continued) 
 
  Dose-
Response Dose Additional of Slope of Dose- of Dose-Response 
Row       
    
Outcome Model Estimates Inclusions Analysis Female Male Response (per Gy) (one-tailed p-value) 
12. Primary definition Linear Primary
Exclude dose 
> 1000 mGy 
MLE 
.241 ± .012 
(.212, .269) 
.135 ± .011 
(.110, .161) 
−.038 ± .034 
(−.113, .048) 0.86 
13.    
    
    
    
Primary definition Linear Primary
Exclude dose 
> 400 mGy 
MLE 
.245 ± .013 
(.213, .277) 
.134 ± .012 
(.105, .162) 
−.042 ± .064 
(−.191, .116) 0.74 
14. Primary definition Linear Primary
Exclude  
Ok and F/S 
geostrata 
MLE 
.238 ± .012 
(.209, .267) 
.133 ± .010 
(.108, .157) 
−.025 ± .027 
(< −.057, .047) 0.81 
 
15. Primary definition Linear Alt. #1 None MLE 
.238 ± .012 
(.210, .267) 
.131 ± .010 
(.107, .155) 
-.016 ± .027 
(<-.057, .055) 
0.72 
16. Primary definition Linear Alt. #2 None MLE 
.240 ± .012 
(.212, .268) 
.134 ± .010 
(.110, .158) 
-.030 ± .027 
(<-.062, .041) 
0.85 
17. Primary definition Linear Primary
Include OOA 
(scoping 
analysis #1) 
MLE 
.234 ± .011 
(.208, .261) 
.135 ± .009 
(.113, .157) 
-.023 ± .026 
(<-.057, .046) 
0.80 
18. Primary definition Linear Primary
Include OOA 
(scoping 
analysis #2) 
MLE 
.235 ± .011 
(.209, .261) 
.135 ± .009 
(.113, .158) 
-.027 ± .026 
(<-.057, >.041) 
0.84 
 Exclusions / Method Estimated Background Rates  Estimated Statistical Significance 
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, “>” 
indicates that the upper confidence limit is greater than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are 
not given for estimated background rates from logistic regression model.   
 
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok = 
Okanogan, F/S = Ferry/Stevens, OOA = out of area 
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H.2.b. Alternative Definitions for Diagnosis of Autoimmune (Hashimoto’s) Thyroiditis   
 
Two alternative definitions for cases of autoimmune thyroiditis were considered.  The first 
alternative added three participants with diagnoses based on medical records without supporting 
documentation, for a total of 628 (585 in-area, 43 out-of-area) cases.  These three cases had estimated doses 
of 396, 107, and 77 mGy.   
 
The second alternative added a single case based on a report from the participant or his/her CATI 
respondent, bringing the total to 629 (586 in-area, 43 out-of-area) cases.  This case had an estimated dose of 
8 mGy. 
 
As shown in rows 4 and 5 of Table IX.H-9, the parameter estimates for the linear dose-response 
model for these alternative definitions were essentially identical to those obtained in the primary analysis 
(row 1).  In particular there was no evidence for either alternative definition that the cumulative incidence 
of autoimmune thyroiditis increased with increasing dose. 
 
 
H.2.b.1. Additional Outcomes Related to Assay for Antithyroid Immune Response   
 
The HTDS diagnoses of autoimmune thyroiditis in the analyses described above were based on 
the AMA or anti-TPO values that were obtained as part of the participants’ HTDS examinations.  Since 
anti-TG measurements were also available, additional analyses were performed to assess the impact of 
incorporating anti-TG into the diagnostic criterion.  Two additional diagnostic criteria were considered.  
The first required a positive AMA/anti-TPO, a positive anti-TG, or both, or medical records with 
supporting documentation, and increased the number of cases to 779.  As shown in row 6 of Table IX.H-9, 
the estimated slope of the dose-response for this outcome was less than zero (–0.039 per Gy) with 
Bonferroni-adjusted 95% confidence interval ranging from less than –0.071 to 0.036 per Gy, providing no 
evidence that cumulative incidence increased with increasing dose (p = 0.90). 
 
The second additional criterion required only a positive anti-TG or medical records with 
supporting documentation, resulting in a total of 507 cases. As shown in row 7 of Table IX.H-9, the 
estimated slope of the dose-response for this outcome was less than zero (–0.032 per Gy) with Bonferroni-
adjusted 95% confidence interval ranging from less than –0.045 to 0.030 per Gy, providing no evidence 
that cumulative incidence increased with increasing dose (p = 0.90). 
 
 
H.2.b.2. Additional Outcomes Related to Autoimmune (Hashimoto’s) Thyroiditis and Hypothyroidism   
 
Further analyses were made to examine the dose-responses for diagnoses of autoimmune 
thyroiditis with hypothyroidism.  The sex-stratified linear model [1] was fit using the primary criteria for 
defining cases with both autoimmune thyroiditis and hypothyroidism (HTDS examination or medical 
record with supporting documentation).  Two definitions of the outcome, varying in characteristics of 
hypothyroidism allowed, were considered (see section IX.H.1.b above).  As shown in rows 8 and 9 of 
Table IX.H-9 above, for both definitions the estimated slope of the sex-stratified linear dose-response 
model was not significantly greater than zero (p = 0.50 and 0.48). 
 
 
H.2.c. Alternative Dose-Response Functions  
 
As shown in row 10 of Table IX.H-9, the estimated regression coefficient for the dose-squared 
term in the linear-quadratic dose-response model [5] was 0.050 with Bonferroni-adjusted 95% confidence 
interval ranging from –0.035 to 0.134.  Thus the addition of a quadratic term did not significantly improve 
the fit of the model (p = 0.14). 
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In the analysis of autoimmune thyroiditis based on the HTDS examination or medical records with 
supporting documentation, i.e., the primary criterion for defining cases with autoimmune thyroiditis, the 
regression parameter for the effect of dose in the sex-stratified logistic regression model [2] was estimated 
as −0.22 with Bonferroni-adjusted 95% confidence interval ranging from –0.74 to 0.31 (Table IX.H-9, row 
11).  Thus there was no evidence from the logistic regression model that cumulative incidence of 
autoimmune thyroiditis increased with increasing dose (p = 0.84). 
 
 
H.2.d. Effect of Excluding Participants in High Dose Categories 
 
 When participants with the highest doses were excluded, there was still no evidence that the 
cumulative incidence of autoimmune thyroiditis increased with increasing dose, as shown in rows 12 and 
13 of Table IX.H-9. 
 
 
H.2.e. Effect of Excluding Okanogan and Ferry/Stevens Geostrata 
 
 When Okanogan and Ferry/Stevens geostrata were excluded the estimated slope B was −0.025 per 
Gy, with Bonferoni-adjusted 95% confidence interval ranging from less than –0.057 to 0.047 per Gy, 
providing no evidence that the cumulative incidence of autoimmune thyroiditis increased with increasing 
dose (p = 0.81; row 14 of Table IX.H-9). 
 
 
H.2.f. Analysis of Autoimmune (Hashimoto’s) Thyroiditis in Relation to Alternative 
Dose Estimates 
 
 As shown in rows 15 and 16 of Table IX.H-9, there was no major change in the dose-response 
results when the alternative dose estimates were used, and in neither case was there evidence that the 
cumulative incidence increased with increasing dose (p = 0.72 and p = 0.85 for the first and second set of 
dose estimates, respectively). 
 
 
H.2.g. Scoping Analysis Regarding Out-of-Area Participants 
 
See section VIII.C.1.a.3 for a description of the scoping analyses that were performed to assess the 
possible impact of including the 249 out-of-area participants.  In neither of the scoping analyses was there 
evidence that the cumulative incidence increased with increasing dose (p = 0.80 and p = 0.84 for the first 
and second scoping analyses, respectively; Table IX.H-9, rows 17 and 18). 
 
 
H.2.h. Analysis of Autoimmune (Hashimoto’s) Thyroiditis in Relation to Alternative 
Representations of Exposure 
 
In the analyses by geostratum and by dichotomous exposure variable, the sex and age-adjusted 
comparisons of cumulative incidence were performed as described in section VIII.C.2.a.2. 
 
 
H.2.h.1. Analysis by Geostratum 
 
As shown in Table IX.H-10, the proportions of women with autoimmune thyroiditis (by HTDS or 
medical record with documentation) ranged from 21/75 (28.0%) for the Okanogan geostratum to 35/170 
(20.6%) for the Walla Walla County geostratum.  For men the proportion ranged from 57/358 (15.9%) to 
51/501 (10.2%) for the Benton County and Pasco/Kennewick geostrata, respectively.  This heterogeneity 
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among the nine geostrata was not considered statistically significant (p = 0.073).  The percentages with 
autoimmune thyroiditis were somewhat higher in the Okanogan and Ferry/Stevens geostrata (26.6% for 
women, 14.2% for men) than in the remaining geostrata (22.8% and 13.0%), but this heterogeneity between 
combined geostrata was not statistically significant (p = 0.12). 
 
Table IX.H-10. Diagnoses of Autoimmune Thyroiditis Based on the HTDS Evaluation or on 
Medical Records with Supporting Documentation, by Geostratum and Sex 
 
 Female Male Total 
Geostratum No. Cases % No. Cases % No. Cases % 
Richland 179 43 24.0 173 24 13.9 352 67 19.0 
Pasco/Kennewick 508 106 20.9 501 51 10.2 1009 157 15.6 
Benton County 376 92 24.5 358 57 15.9 734 149 20.3 
Franklin County 73 19 26.0 76 11 14.5 149 30 20.1 
Adams County 165 35 21.2 156 23 14.7 321 58 18.1 
Walla Walla (city) 133 35 26.3 131 18 13.7 264 53 20.1 
Walla Walla County 170 35 20.6 164 19 11.6 334 54 16.2 
Okanogan County 75 21 28.0 64 10 15.6 139 31 22.3 
Ferry/Stevens Counties 68 17 25.0 70 9 12.9 138 26 18.8 
Total 1747 403 23.1 1693 222 13.1 3440 625 18.2 
 
 
H.2.h.2. Analysis by Dichotomous Exposure Variable 
 
Of the 1257 participants included in these analyses, 210 (16.7%) had a diagnosis of autoimmune 
thyroiditis based on the HTDS examination or medical records with supporting documentation (see Table 
IX.H-11).  These included 92/580 (15.9%) in the high exposure group and 118/677 (17.4%) in the low 
exposure group.  The cumulative incidence of autoimmune thyroiditis was not significantly higher in the 
high exposure group (p = 0.86). 
 
Table IX.H-11. Diagnoses of Autoimmune Thyroiditis Based on HTDS or Medical Record with 
Supporting Documentation, by Exposure Group and Sex  
 
 Female Male Total 
Exposure Group No. Cases % No. Cases % No. Cases % 
Low 351 70 19.9 326 48 14.7 677 118 17.4 
High 298 60 20.1 282 32 11.3 580 92 15.9 
Total 649 130 20.0 608 80 13.2 1257 210 16.7 
 
 
H.2.i. Confounding and Effect Modification 
 
As described in section VIII above, additional sex-stratified logistic regression models were 
investigated to examine the possibility that the primary dose-response results might be influenced by 
confounding, and to search for factors that might modify a radiation dose-response.  These analyses were 
based on the primary definition of Hashimoto’s thyroiditis, i.e., those based on an HTDS diagnosis or on 
medical records with documented diagnoses, and on the primary dose estimates.  Table IX.H-12 displays 
results for models including sex, age at first exposure to Hanford 131I (prenatal, or < 180 days), age at 
HTDS examination, estimated dose from the NTS, history of any cancer other than thyroid, and HTDS 
interview type.   
 
Note that sex was not analyzed as a possible confounder since its effect was already adjusted for in 
the sex-stratified model.  None of the other factors in Table IX.H-12 appears to be a confounder: for none 
does the adjusted estimate of the regression coefficient differ markedly from the unadjusted estimate.  
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Therefore, it does not appear that omitting these factors introduces any important bias in the dose-response 
results.  
 
The analyses of effect modification address the question of whether the dose-response might vary 
according to other characteristics of the study participants.  This was tested by comparing the estimated 
regression coefficients for the groups defined by each covariate.  As shown in Table IX.H-12, the 
regression coefficients did not differ significantly between the groups defined by any of the covariates, 
suggesting that none of them was a significant modifier of a radiation dose-response for Hashimoto’s 
thyroiditis. 
 
Table IX.H-12. Confounding and Effect Modification by Sex, Age at Exposure or HTDS 
Examination, Estimated Thyroid Dose from NTS, History of Any Cancer Other 
than Thyroid, and Interview Type: Autoimmune Thyroiditis 
 
  Estimated Dose-Response Coefficient (per Gy) 
 
Covariate Yes /  Adjusted for Including Effect Modification 
 (0=No, 1=Yes) Total Unadjusted Confounding Group 0 Group 1 P 
Female? 1622 / 3191 
−.215 ± .220 
(−.742, .313) 
Not 
Applicable 
−.223 ± .354 
(−1.11, .660) 
−.210 ± .282 
(−.913, .494) .98 
Prenatal 
exposure? 
1034 / 
3191 
−.215 ± .220 
(−.742, .313) 
−.255 ± .224 
(−.832, .322) 
−.183 ± .252 
(−.849, .483) 
−.491 ± .473 
(−1.74, .756) .56 
1st exposure 
before age 180 
days? 
1478 / 
3191 
−.215 ± .220 
(−.742, .313) 
−.211 ± .222 
(−.782, .360) 
−.781 ± .395 
(−1.82, .260) 
.059 ± .251 
(−.602, .720) .071 
Age at exam > 
50? 
2001 / 
3191 
−.215 ± .220 
(−.742, .313) 
−.310 ± .229 
(−.900, .280) 
−.659 ± .484 
(−1.94, .617) 
−.193 ± .261 
(−.882, .496) .38 
NTS 131I 
dose > 5.3 mGy? 
1567 / 
3189 
−.214 ± .220 
(−.741, .313) 
−.222 ± .226 
(−.803, .360) 
−.354 ± .306 
(−1.16, .454) 
−.056 ± .328 
(−.922, .810) .51 
History of  any 
cancer other than 
thyroid? 
248 / 
3186 
−.206 ± .220 
(−.733, .320) 
−.201 ± .221 
(−.769, .367) 
−.145 ± .234 
(−.762, .472) 
−.661 ± .762 
(−2.67, 1.35) .49 
Expanded In-
Person Interview? 
1212 / 
3191 
−.215 ± .220 
(−.742, .313) 
−.273 ± .226 
(−.855, .309) 
−.783 ± .382 
(−1.79, .226) 
.015 ± .264 
(−.681, .712) .084 
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses, based on sex-
stratified logistic regression models.  P-values reflect the significance of the improved fit for models including confounding or effect 
modification, relative to the unadjusted model. 
 
 
Tables IX.H-13 and IX.H-14 display similar results from analyses including history of medical or 
dental x-ray exposure or of occupational exposures as potential confounding or effect modifying factors. 
The estimates of the regression coefficient calculated with adjustment for confounding are all close to the 
unadjusted estimates.  Moreover the adjusted estimates all remained less than zero.  Thus there was no 
evidence that a confounding effect of any of these covariates has obscured a positive dose-response for 
autoimmune thyroiditis.  
 
There is no evidence of any statistically significant effect modification by any of the covariates in 
Tables IX.H-13 and IX.H-14. 
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Table IX.H-13. Confounding and Effect Modification by History of Medical and Dental Radiation 
Exposures: Autoimmune Thyroiditis 
 
 
Have You 
 Estimated Dose-Response Coefficient (per Gy) 
 
Ever Had: Yes /  Adjusted for Including Effect Modification 
 (0=No, 1=Yes) Total Unadjusted Confounding Group 0 Group 1 P 
CAT scan of the 
upper body? 
775 / 
3149 
−.209 ± .221 
(−.738, .320) 
−.211 ± .221 
(−.780, .358) 
−.225 ± .246 
(−.874, .423) 
−.149 ± .509 
(−1.49, 1.19) .89 
Diagnostic x-rays 
of the head? 
1191 / 
3155 
−.207 ± .222 
(−.739, .325) 
−.213 ± .223 
(−.787, .360) 
−.197 ± .274 
(−.920, .526 
−.245 ± .381 
(−1.25, .761) .92 
Diagnostic x-rays 
of the neck? 
966 / 
3167 
−.204 ± .221 
(−.732, .325) 
−.199 ± .222 
(−.770, .373) 
−.369 ± .301 
(−1.16, .424) 
.014 ± .318 
(−.824, .852) .38 
Diagnostic x-rays 
of chest or upper 
body, including 
mammograms? 
2821 / 
3173 
−.199 ± .220 
(−.725, .327) 
−.198 ± .220 
(−.765, .368) 
.048 ± .773 
(−1.99, 2.09) 
−.219 ± .230 
(−.827, .388) .74 
Diagnostic x-rays 
of the stomach or 
mid-back? 
692 / 
3120 
−.224 ± .224 
(−.760, .311) 
−.229 ± .224 
(−.806, .348) 
−.238 ± .250 
(−.898, .422) 
−.192 ± .503 
(−1.52, 1.14) .94 
Barium enema? 825 / 3159 
−.235 ± .223 
(−.768, .298) 
−.236 ± .223 
(−.810, .337) 
−.065 ± .248 
(−.719, .588) 
−.811 ± .498 
(−2.13, .504) .17 
Upper GI? 1146 / 3177 
−.233 ± .222 
(−.764, .298) 
−.227 ± .222 
(−.798, .344) 
−.156 ± .271 
(−.872, .559) 
−.360 ± .382 
(−1.37, .648) .66 
Intravenous 
pyelogram? 
398 / 
3157 
−.223 ± .222 
(−.756, .309) 
−.213 ± .222 
(−.784, .359) 
−.201 ± .234 
(−.818, .415) 
−.311 ± .700 
(−2.16, 1.53) .88 
Fluoroscopy of  
the upper body? 
246 / 
3161 
−.224 ± .221 
(−.755, .306) 
−.221 ± .221 
(−.791, .349) 
−.191 ± .228 
(−.792, .409) 
−.639 ± .886 
(−2.98, 1.70) .62 
Nuclear scan 
(excluding thyroid 
scan)? 
217 / 
3162 
−.185 ± .219 
(−.709, .339) 
−.178 ± .219 
(−.742, .386) 
−.155 ± .224 
(−.746, .436) 
−.579 ± .968 
(−3.13, 1.97) .66 
History of  any 
cancer other than 
thyroid? 
248 / 
3186 
−.206 ± .220 
(−.733, .320) 
−.201 ± .221 
(−.769, .367) 
−.145 ± .234 
(−.762, .472) 
−.661 ± .762 
(−2.67, 1.35) .49 
Dental x-rays that 
did not usually 
include a lead 
shield over the 
neck area? 
1648 / 
3191 
−.215 ± .220 
(−.742, .313) 
−.216 ± .220 
(−.783, .351) 
.092 ± .294 
(−.684, .869) 
−.554 ± .336 
(−1.44, .332) .15 
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses, based on sex-
stratified logistic regression models.  P-values reflect the significance of the improved fit for models including confounding or effect 
modification, relative to the unadjusted model. 
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Table IX.H-14. Confounding and Effect Modification by Occupational History: Autoimmune  
Thyroiditis 
 
Have You Ever 
Worked in Any of 
 Estimated Dose-Response Coefficient (per Gy) 
the Following: Yes /  Adjusted for Including Effect Modification 
 (0=No, 1=Yes) Total Unadjusted Confounding Group 0 Group 1 P 
Any metal 
industry? 
238 / 
3191 
−.215 ± .220 
(−.742, .313) 
−.217 ± .220 
(−.785, .351) 
−.144 ± .222 
(−.730, .442) 
−1.75 ± 1.15 
(−4.78, 1.27) .14 
Any nuclear 
facility? 
371 / 
3191 
−.215 ± .220 
(−.742, .313) 
−.226 ± .222 
(−.798, .346) 
−.196 ± .242 
(−.835, .442) 
−.377 ± .561 
(−1.86, 1.10) .77 
Any other industry 
or occupation 
where you may 
have been exposed 
to radioactive 
materials or x-
rays? 
442 / 
3191 
−.215 ± .220 
(−.742, .313) 
−.210 ± .220 
(−.777, .358) 
−.079 ± .233 
(−.693, .534) 
−1.26 ± .800 
(−3.37, .848) .12 
 
Any of the above 
industries or 
occupations? 
892 / 
3191 
−.215 ± .220 
(−.742, .313) 
−.223 ± .221 
(−.792, .346) 
−.015 ± .255 
(−.688, .658) 
−.746 ± .448 
(−1.93, .435) .14 
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses, based on sex-
stratified logistic regression models.  P-values reflect the significance of the improved fit for models including confounding or effect 
modification, relative to the unadjusted model. 
 
 
Table IX.H-15 displays the results of analyses of possible confounding or effect modification by 
smoking variables.  There was no evidence that the dose-response was significantly confounded by either 
smoking variable, or that there was a dose-response that differed significantly according to smoking 
history. 
 
Table IX.H-15. Confounding and Effect Modification by Smoking: Autoimmune Thyroiditis 
 
Have You Ever 
Smoked Any of 
 Estimated Dose-Response Coefficient (per Gy) 
 
the Following: Yes /  Adjusted for Including Effect Modification 
(0=No, 1=Yes) Total Unadjusted Confounding Group 0 Group 1 P 
Cigarettes 
(unfiltered or 
filtered)? 
1854 / 
3183 
−.210 ± .220 
(−.736, .317) 
−.214 ± .220 
(−.781, .352) 
−.664 ± .393 
(−1.70, .373) 
.009 ± .257 
(−.668, .686) .15 
Any of cigarettes, 
cigar or pipe? 
1900 / 
3183 
−.210 ± .220 
(−.736, .317) 
−.214 ± .220 
(−.781, .352) 
−.609 ± .394 
(−1.65, .430) 
−.021 ± .258 
(−.701, .658) .21 
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses, based on sex-
stratified logistic regression models.  P-values reflect the significance of the improved fit for models including confounding or effect 
modification, relative to the unadjusted model. 
 
H.2.j. Uncertainty 
 
The estimated slopes of the sex-stratified linear dose-response model for autoimmune thyroiditis 
are shown in Figure IX.H-1 for each of the 100 dose realizations produced by the CIDER model.  The 
confidence intervals in that figure are calculated at the 98.33% confidence level, i.e., are adjusted by the 
Bonferroni technique for the simultaneous estimation of the slope and two sex-specific background rates. 
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The point estimate of the slope was greater than zero for only 13 of the 100 realizations, and the confidence 
interval included zero for all 100 realizations.  Also shown in Figure IX.H-1 (to the right of realization 100) 
are the estimates and confidence intervals calculated using (from left to right) the median, geometric mean 
and mean of each participant's 100 dose realizations. In summary, for none of the 100 realizations of the 
estimated doses was there a statistically significant dose-response, and for most realizations the estimated 
slope was less than 0. 
 
Figure IX.H-1. Plot of Estimated Slope and 95% CI by Dose Realization: Autoimmune Thyroiditis 
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Figure IX.H-2 displays the distribution of the 5000 estimates of the logistic regression coefficient 
obtained by the simulation procedures described in section VIII.C.2.b.3 above. It is evident from the figure 
that most of the estimates were between about –1.5 and 0.5. The estimate was less than or equal to 0 for 
4453 of the 5000 replications, implying an empirical one-tailed p-value of 0.89.  The median estimate was 
–0.36, and the upper and lower percentiles corresponding to the Bonferroni-adjusted 95% confidence 
interval ranging from –1.35 to 0.32.  These may be compared to the estimates of −0.22 (with confidence 
interval ranging from −0.74 to 0.31) obtained using the median dose estimates without adjustment for 
uncertainty. Thus, this method of adjusting the estimated logistic regression coefficient for the uncertainty 
in the dose estimates did not provide evidence that the cumulative incidence of autoimmune thyroiditis 
increased with increasing dose. 
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Figure IX.H-2. Distribution of Simulation Estimates of Logistic Regression Coefficient:  
Autoimmune Thyroiditis 
slope sample: 5000
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I. Graves Disease
I.1. Occurrence of Graves Disease
The primary and alternative definitions of Graves disease were as follows:
• Primary definition: HTDS evaluation or medical records with supporting documentation (34 cases)
• Alternative definition #1: HTDS evaluation or medical records with or without supporting
documentation  (37 cases)
• Alternative definition #2: Any diagnosis or participant/respondent report (50 cases).
Thirty-four (1.0%) living evaluable participants had a diagnosis of Graves Disease based on the
HTDS evaluation or on medical records with supporting documentation (Table IX.I-1).  Three (0.1%)
living evaluable participants had a diagnosis of Graves Disease based on medical records without
supporting documentation, and an additional thirteen (0.4%) were based on a participant or his/her CATI
respondent report.  
Table IX.I-1. Basis for Diagnosis of Graves Disease, by Sex
      Female   Male              Total
Basis for Diagnosis No. % No. % No. %
Yes 37 2.1 13 0.8 50 1.5
HTDS evaluation 5 0.3 2 0.1 7 0.2
Medical records with supporting
documentation
23 1.3 4 0.2 27 0.8
Medical records without
supporting documentation
3 0.2 0 -- 3 0.1
Participant/respondent report 6 0.3 7 0.4 13 0.4
No 1698 97.2 1673 98.8 3371 98.0
Unknown 12 0.7 7 0.4 19 0.6
Total 1747 100.0 1693 100.0 3440 100.0
      
       
 
      
 
      
 
Nineteen living evaluable participants were classified as “unknown” with regard to diagnosis of
Graves disease.  These 19 did not have medical records or participant/respondent reports of such diagnoses,
and did not have an HTDS evaluation due to lack of blood draw (8) or diagnosis of hyperthyroidism with
unknown etiology (potentially Graves) (11).  These 19 participants were included as non-cases in analyses
of the dose-response for Graves disease.
I.2. Analysis of Graves Disease Risk
I.2.a. Primary Analysis
Of the 34 living evaluable participants with a diagnosis of Graves disease based on the HTDS
examination or medical records with supporting documentation, two were out-of-area participants for
whom the CIDER program could not calculate dose estimates.  The proportions with Graves disease are
shown by sex, dose category and basis for diagnosis in Table IX.I-2.
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Table IX.I-2. Diagnoses of Graves Disease by Sex, Estimated Dose, and Basis for Diagnosis
A.  Female
 
 
 Thyroid
Radiation
Dose
(mGy)
Living
Evaluable
Female
Primary Definition:
Cases Based on
HTDS or Med.
Rec. with
Supporting
Documentation
1st Alternative
Definition:
Cases Based on HTDS
or Med. Rec. with or
without Supporting
Documentation
2nd Alternative
Definition:
Cases Based on Any
Diagnosis or Participant
or CATI Report
 No. No. % No.            % No.    %
Out of Area 125 2 1.6 2 1.6 2 1.6
< 10 182 5 2.7 7 3.8 7 3.8
10-49 320 4 1.3 4 1.3 5 1.6
50-99 313 3 1.0 4 1.3 7 2.2
100-149 220 2 0.9 2 0.9 2 0.9
150-199 126 0 -- 0 -- 0 --
200-299 139 4 2.9 4 2.9 5 3.6
300-399 144 2 1.4 2 1.4 3 2.1
400-999 171 6 3.5 6 3.5 6 3.5
1000+     7 0 -- 0 -- 0 --
Total 1747 28 1.6            31 1.8 37 2.1
B.  Male
 
 
 Thyroid
Radiation
Dose
(mGy)
Living
Evaluable
Female
Primary Definition:
Cases Based on
HTDS or Med.
Rec. with
Supporting
Documentation
1st Alternative
Definition:
Cases Based on HTDS
or Med. Rec. with or
without Supporting
Documentation
2nd Alternative
Definition:
Cases Based on Any
Diagnosis or Participant
or CATI Report
 No. No. % No.          % No.    %
Out of Area 124 0 -- 0 -- 0 --
< 10 186 1 0.5 1 0.5 1 0.5
10-49 314 1 0.3 1 0.3 2 0.6
50-99 310 2 0.6 2 0.6 2 0.6
100-149 171 0 -- 0 -- 1 0.6
150-199 109 1 0.9 1 0.9 2 1.8
200-299 148 0 -- 0 -- 2 1.4
300-399 160 1 0.6 1 0.6 3 1.9
400-999 154 0 -- 0 -- 0 --
1000+ 17 0 -- 0 -- 0 --
Total 1693 6 0.4 6 0.4 13 0.8
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Parameter estimates for the linear dose-response model based on the 3191 in-area participants are
shown in Table IX.I-3 below.  Based on the maximum likelihood analysis of the sex-stratified linear
probability model, the estimated slope B was slightly less than zero (−0.001 per Gy) with Bonferroni-
adjusted 95% CI ranging from less than −0.002 to 0.024 per Gy, providing no evidence that cumulative
incidence increased with increasing dose (one-tailed p=0.56; row 1 of Table IX.I-3).  The corresponding
estimated background rates for diagnosis of Graves disease were 0.016 with confidence interval (0.008,
0.025) for women and 0.004 with confidence interval (0, 0.009) for men.  
As shown in rows 2 and 3 of Table IX.I-3, generally similar results were obtained when the model
was fit by the method of least squares.  The estimates of the slope were slightly but not significantly greater
than zero (p = 0.26 and 0.13 for ungrouped and grouped data, respectively).
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Table IX.I-3. Summary of Dose-Response Results for Diagnoses of Graves Disease
Dose-
Response Dose
Exclusions /
Additional
Method
of Estimated Background Rates 
Estimated
Slope of Dose-
Statistical Significance
of Dose-Response
Row Outcome Model Estimates Inclusions Analysis Female Male Response (per Gy) (one-tailed p-value)
1.
Primary definition
(HTDS evaluation or
medical record with
documentation)
Linear Primary None MLE
.016 ± .004
(.008, .025)
.004 ± .002
(0*, .009)
−.001 ± .009
(< −.002, .024) 0.56
2. Primary definition Linear Primary None LSU
.015 ± .003
(.008, .022) 
.003 ± .003
(0*, .010)
.005 ± .008
(−.014, .024) 0.26
3. Primary definition Linear Primary None LSG
.014 ± .003
(.007, .021) 
.002 ± .003
(0*, .009)
.010 ± .009
(−.012, .032) 0.13
4.
Alternative def. #1
(HTDS or medical
record with or without
documentation) 
Linear Primary None MLE
.018 ± .004
(.009, .027)
.004 ± .002
(0*, .009)
–.002 ± .009
(NE, .020)
0.64
5.
Alternative def. #2 
(Any diagnosis or
participant/respondent
report)
Linear Primary None MLE
.021 ± .004
(.011, .032)
.008 ± .003
(.001, .016)
.001 ± .013
(< –.004, .034)
0.48
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value “>”
indicates that the upper confidence limit is greater than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are
not given for estimated background rates from logistic regression model.  “0*” indicates that the lower confidence limit for a background rate was less than 0.
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
Okanogan, F/S = Ferry/Stevens, OOA = out of area
Table continued on next page
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Table IX.I-3. Summary of Dose-Response Results for Diagnoses of Graves Disease (continued)
Dose-
Response Dose
Exclusions /
Additional
Method
of Estimated Background Rates 
Estimated
Slope of Dose-
Statistical Significance
of Dose-Response
Row Outcome Model Estimates Inclusions Analysis Female Male Response (per Gy) (one-tailed p-value)
6. Primary definition LQ Primary None LSU
.014 ± .003
(.007, .022)
.002 ± .003
(0*, .010)
Lin: .014 ± .013
(−.020, .047)
Quad: −.007 ± .009
(−.029, .015)
Quad: 0.43
7. Primary definition Logistic Primary None MLE
.015
(.008, .026)
.004
(.001, .010)
.42 ± .65
(-1.13, 1.96)
0.28
8. Primary definition Linear Primary
Exclude dose
> 1000 mGy
MLE
.016 ± .004
(.007, .025)
.004 ± .002
(0*, .008)
.001 ± .009
(<-.005, .029)
0.44
9. Primary definition Linear Primary
Exclude dose
> 400 mGy
MLE
.014 ± .003
(.006, .022)
.004 ± .002
(0*, .010)
.0005 ± .012
( −.023, .037) 0.48
10. Primary definition Linear Primary
Exclude 
Ok and F/S
geostrata
MLE
.015 ± .004
(.006, .024)
.002 ± .002
(0*, .006)
.003 ± .008
(< −.001, .027) 0.36
11. Primary definition Linear Alt. #1 None MLE
.016 ± .003
(.008, .025)
.004 ± .002
(0*, .009)
−.002 ± .008
(NE, .015)
0.70
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value “>”
indicates that the upper confidence limit is greater than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are
not given for estimated background rates from logistic regression model.  “0*” indicates that the lower confidence limit for a background rate was less than 0.
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
Okanogan, F/S = Ferry/Stevens, OOA = out of area
Table continued on next page
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Table IX.I-3. Summary of Dose-Response Results for Diagnoses of Graves Disease
Dose-
Response Dose
Exclusions /
Additional
Method
of Estimated Background Rates 
Estimated
Slope of Dose-
Statistical Significance
of Dose-Response
Row Outcome Model Estimates Inclusions Analysis Female Male Response (per Gy) (one-tailed p-value)
12. Primary definition Linear Alt. #2 None MLE
.015 ± .004
(.007, .024)
.003 ± .002
(0*, .008)
.003 ± .008
(< −.002, .026) 0.34
13. Primary definition Linear Primary
Include OOA
(scoping
analysis #1)
MLE
.016 ± .003
(.008, .024)
.004 ± .002
(0*, .008)
.000 ± .008
(< −.002, >.025) 0.50
14. Primary definition Linear Primary
Include OOA
(scoping
analysis #2)
MLE
.016 ± .003
(.008, .024)
.004 ± .002
(0*, .008)
−.0003 ± .008
(< −.002, >.024) 0.51
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value “>”
indicates that the upper confidence limit is greater than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are
not given for estimated background rates from logistic regression model.  “0*” indicates that the lower confidence limit for a background rate was less than 0.
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
Okanogan, F/S = Ferry/Stevens, OOA = out of area
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I.2.b. Alternative Definitions for Diagnosis of Graves Disease
Two alternative definitions for cases of Graves disease were considered.  The first alternative
added three cases with diagnoses based on medical records without supporting documentation, for a total of
37 cases.  The second alternative criterion for defining cases of Graves disease added another 13 cases
based solely on a report from the participant or his/her CATI respondent, for a total of 50 cases.  As shown
in rows 4 and 5 of Table IX.I-3 above, for neither of these alternative definitions was there any evidence
that the cumulative incidence of Graves disease increased significantly with increasing dose (p = 0.64 and
p = 0.48 for the first and second alternative criteria respectively).
I.2.c. Alternative Dose-Response Functions 
As shown in row 6 of Table IX.I-3, the estimated regression coefficient for the dose-squared term
in the linear-quadratic dose-response model [5] was −0.007 with Bonferroni-adjusted 95% confidence
interval ranging from –0.029 to 0.015.  Thus the addition of a quadratic term did not significantly improve
the fit of the model (p = 0.43).
In the analysis of Graves disease based on the HTDS examination or medical records with
supporting documentation, i.e., the primary definition of Graves disease, the regression parameter for the
effect of dose in the sex-stratified logistic regression model was estimated as 0.42 with Bonferroni-adjusted
95% confidence interval ranging from −1.13 to 1.96 (row 7 of Table IX.I-3).  Thus the cumulative
incidence of Graves disease did not increase significantly with increasing dose (p = 0.28).
I.2.d. Effect of Excluding Participants in High Dose Categories
As shown in row 8 of Table IX.I-3, when participants with estimated dose > 1000 mGy were
excluded, the estimated slope B was not significantly greater than zero (0.001 per Gy, with Bonferroni-
adjusted 95% confidence interval ranging from less than –0.005 to 0.029 per Gy; p = 0.44).  Similar results
were obtained when participants with estimated dose > 400 mGy were excluded (Table IX.I-3, row 9).
I.2.e. Effect of Excluding Okanogan and Ferry/Stevens Geostrata
As shown in row 10 of Table IX.I-3, when Okanogan and Ferry/Stevens geostrata were excluded,
the estimated slope B was not significantly greater than zero (0.003 per Gy, with Bonferroni-adjusted 95%
confidence interval ranging from less than –0.001 to 0.027 per Gy; p = 0.36).
I.2.f. Analysis of Graves Disease in Relation to Alternative Dose Estimates 
For neither set of alternative dose estimates did the cumulative incidence increase significantly
with increasing dose (p = 0.70 and p = 0.34 for the first and second set of alternative dose estimates,
respectively; Table IX.I-3, rows 11 and 12).
I.2.g. Scoping Analysis Regarding Out-of-Area Participants
See section VIII.C.1.a.3 for a description of the scoping analyses that were performed to assess the
possible impact of including the 249 out-of-area participants.  As summarized in rows 13 and 14 of Table
IX.I-3, in neither scoping analysis was there any evidence that the cumulative incidence of Graves Disease
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increased with increasing dose (p = 0.50 and p = 0.51 for the first and second scoping analyses,
respectively).
I.2.h. Analysis of Graves Disease in Relation to Alternative Representations of
Exposure
In the analyses by geostratum and by dichotomous exposure variable, the sex and age-adjusted
comparisons of cumulative incidence were performed as described in section VIII.C.2.a.2.
I.2.h.1. Analysis by Geostratum
There were too few participants (34) with diagnoses of Graves disease (from the HTDS
examination or medical records with documentation) for a definitive conclusion regarding heterogeneity
among the geostrata (see Table IX.I-4).  The absence of significant heterogeneity (p = 0.43) was not strong
evidence against the possibility that the cumulative incidence of Graves disease might vary among
geostrata.  The percentages with Graves disease were somewhat higher in the Okanogan and Ferry/Stevens
geostrata (2.8% for women, 1.5% for men) than in the remaining geostrata (1.5% and 0.3%), but this
heterogeneity between combined geostrata was also not statistically significant (p = 0.13).
Table IX.I-4. Diagnoses of Graves Disease Based on the HTDS Evaluation or on Medical Records
with Supporting Documentation, by Geostratum and Sex 
Female Male Total
Geostratum No. Cases % No. Cases % No. Cases %
Richland 179 3 1.7 173 0 -- 352 3 0.9
Pasco/Kennewick 508 10 2.0 501 1 0.2 1009 11 1.1
Benton County 376 5 1.3 358 1 0.3 734 6 0.8
Franklin County 73 1 1.4 76 1 1.3 149 2 1.3
Adams County 165 3 1.8 156 1 0.6 321 4 1.2
Walla Walla (city) 133 1 0.8 131 0 -- 264 1 0.4
Walla Walla County 170 1 0.6 164 0 -- 334 1 0.3
Okanogan County 75 2 2.7 64 1 1.6 139 3 2.2
Ferry/Stevens Counties 68 2 2.9 70 1 1.4 138 3 2.2
Total   1747 28 1.6 1693 6 0.4 3440 34 1.0
I.2.h.2. Analysis by Dichotomous Exposure Variable
Only 13 (1.0%) of the 1257 participants included in these analyses had a diagnosis of Graves
disease based on the HTDS examination or medical records with supporting documentation (see Table
IX.I-5).  These included 7/580 (1.2%) in the high exposure group and 6/677 (0.9%) in the low exposure
group.  The cumulative incidence of Graves disease was not significantly greater in the high exposure
group (p = 0.24).
Table IX.I-5. Diagnoses of Graves Disease based on HTDS or Medical Record with Supporting
Documentation, by Exposure Group and Sex 
Female Male Total
Exposure Group No. Cases % No. Cases % No. Cases %
Low 351 5 1.4 326 1 0.3 677 6 0.9
High 298 6 2.0 282 1 0.4 580 7 1.2
Total 649 11 1.7 608 2 0.3 1257 13 1.0
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I.2.i. Confounding and Effect Modification
As described in section VIII above, additional sex-stratified logistic regression models were
investigated to examine the possibility that the primary dose-response results might be influenced by
confounding, and to search for factors that might modify a radiation dose-response.  These analyses were
based on the primary definition of Graves Disease; those based on an HTDS diagnosis or on medical
records with documented diagnoses, and on the primary dose estimates.  Table IX.I-6 displays results for
models including sex, age at first exposure to Hanford 131I (prenatal, or < 180 days), age at HTDS
examination, estimated dose from the NTS, history of any cancer other than thyroid, and HTDS interview
type.  
Note that sex was not analyzed as a possible confounder since its effect was already adjusted for in
the sex-stratified model.  None of the other factors in Table IX.I-6 appears to be a confounder: for none
does the adjusted estimate of the regression coefficient differ markedly from the unadjusted estimate.
Therefore, it does not appear that omitting these factors introduces any important bias in the dose-response
results. 
The analyses of effect modification address the question of whether the dose-response might vary
according to other characteristics of the study participants.  This was tested by comparing the estimated
regression coefficients for the groups defined by each covariate.  As shown in Table IX.I-6, the regression
coefficients did not differ significantly between the groups defined by any of the covariates, suggesting that
none of them was a significant modifier of a radiation dose-response for Graves disease.
Table IX.I-6. Confounding and Effect Modification by Sex, Age at Exposure or HTDS
Examination, Estimated Thyroid Dose from NTS, History of Any Cancer Other
than Thyroid, and Interview Type: Graves Disease
Estimated Dose-Response Coefficient (per Gy)
Covariate Yes / Adjusted for Including Effect Modification
 (0=No, 1=Yes) Total Unadjusted Confounding Group 0 Group 1 P
Female?
1622 /
3191
.415 ± .646
(−1.13, 1.96)
Not
Applicable
−1.78 ± 2.83
(−8.85, 5.29)
.635 ± .622
(−.918, 2.19) .32
Prenatal
exposure?
1034 /
3191
.415 ± .646
(−1.13, 1.96)
.370 ± .659
(−1.33, 2.07)
.440 ± .704
(−1.42, 2.30)
.038 ± 1.67
(−4.37, 4.44) .82
1st exposure
before age 180
days?
1478 /
3191
.415 ± .646
(−1.13, 1.96)
.393 ± .643
(−1.26, 2.05)
2.03 ± 1.01
(−.633, 4.69)
-.771 ± 1.32
(−4.26, 2.72) .071
Age at exam >
50?
2001 /
3191
.415 ± .646
(−1.13, 1.96)
.493 ± .625
(−1.12, 2.10)
.267 ± 1.11
(−2.66, 3.20)
.628 ± .765
(−1.39, 2.64) .78
NTS 131I
dose > 5.3 mGy?
1567 /
3189
.415 ± .646
(−1.13, 1.96)
.319 ± .691
(−1.46, 2.10)
.770 ± .679
(−1.02, 2.56)
−2.08 ± 2.52
(−8.72, 4.56) .19
History of any
cancer other than
thyroid?
248 /
3186
.415 ± .646
(−1.13, 1.96)
.508 ± .682
(−1.25, 2.26)
.508 ± .682
(−1.29, 2.31)
0.0 ± 1115
(−2943,
2943)
1.0
Expanded In-
Person Interview?
1212 /
3191
.415 ± .646
(−1.13, 1.96)
.499 ± .651
(−1.18, 2.18)
1.40 ± .992
(−1.22, 4.01)
-.275 ± 1.27
(−3.64, 3.09) .26
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses, based on sex-
stratified logistic regression models.  P-values reflect the significance of the improved fit for models including confounding or effect
modification, relative to the unadjusted model.
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Tables IX.I-7 and IX.I-8 display similar results from analyses including history of medical or
dental x-ray exposure or of occupational exposures as potential confounding or effect modifying factors.
The estimates of the regression coefficient calculated with adjustment for confounding are all close to the
unadjusted estimates. Thus there was no evidence that omitting these factors introduces any important bias
in the dose-response results for Graves Disease. 
There is no evidence of any statistically significant effect modification by any of the covariates in
Tables IX.I-7 and IX.I-8, with the possible exception of history of diagnostic x-rays of the chest or upper
back, including mammograms (Table IX.I-7).  However the regression parameter for the 352 participants
without such histories is extremely negative, −275, with an extremely wide confidence interval (−817, 267),
since only two participants in this group had diagnoses of Graves disease (both women with doses less than
10 mGy).  Therefore the p-value of 0.002 for effect modification must be interpreted cautiously.  It is
noteworthy that the regression parameter for the larger group of participants with histories of chest or upper
body diagnostic x-rays or mammograms (0.534 with confidence interval ranging from –1.07 to 2.14) differs
little from the overall estimate of 0.414 with confidence interval (–1.13, 1.96).
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Table IX.I-7. Confounding and Effect Modification by History of Medical and Dental Radiation
Exposures: Graves Disease
Have You
Estimated Dose-Response Coefficient (per Gy)
Ever Had: Yes / Adjusted for Including Effect Modification
 (0=No, 1=Yes) Total Unadjusted Confounding Group 0 Group 1 P
CAT scan of the
upper body?
775 /
3149
.423 ± .650
(−1.13, 1.98)
.433 ± .654
(−1.25, 2.12)
.421 ± .716
(−1.47, 2.31)
.500 ± 1.66
(−3.88, 4.88) .97
Diagnostic x-rays
of the head?
1191 /
3155
.423 ± .642
(−1.11, 1.96)
.421 ± .635
(−1.22, 2.06)
.246 ± .852
(−2.00, 2.50)
.721 ± .973
(−1.84, 3.29) .72
Diagnostic x-rays
of the neck?
966 /
3167
.376 ± .670
(−1.23, 1.98)
.329 ± .669
(−1.39, 2.05)
.212 ± 1.14
(−2.79, 3.21)
.392 ± .804
(−1.73, 2.51) .90
Diagnostic x-rays
of chest or upper
body, including
mammograms?
2821 /
3173
.414 ± .646
(−1.13, 1.96)
.439 ± .641
(−1.21, 2.09)
−275 ± 205
(−817, 267)
.534 ± .608
(−1.07, 2.14) .002
Diagnostic x-rays
of the stomach or
mid-back?
692 /
3120
.427 ± .642
(−1.11, 1.96)
.412 ± .644
(−1.25, 2.07)
.362 ± .714
(−1.52, 2.24)
.669 ± 1.48
(−3.23, 4.57) .86
Barium enema?
825 /
3159
.368 ± .673
(−1.24, 1.98)
.375 ± .675
(−1.36, 2.11)
.685 ± .699
(−1.16, 2.53)
−.650 ± 1.69
(−5.10, 3.80) .42
Upper GI?
1146 /
3177
.417 ± .645
(−1.13, 1.96)
.409 ± .647
(−1.26, 2.08)
.536 ± .744
(−1.43, 2.50)
.120 ± 1.25
(−3.17, 3.41) .77
Intravenous
pyelogram?
398 /
3157
.376 ± .670
(−1.23, 1.98)
.382 ± .664
(−1.33, 2.09)
.386 ± .681
(−1.41, 2.18)
.318 ± 2.87
(−7.26, 7.90) .98
Fluoroscopy of 
the upper body?
246 /
3161
.381 ± .667
(−1.22, 1.98)
.393 ± .667
(−1.33, 2.11)
.336 ± .713
(−1.54, 2.22)
1.13 ± 2.35
(−5.08, 7.34) .76
Nuclear scan
(excluding thyroid
scan)?
217 /
3162
.418 ± .643
(−1.12, 1.96)
.417 ± .640
(−1.23, 2.07)
.382 ± .659
(−1.36, 2.12)
2.11 ± 4.02
(−8.48, 12.7) .69
History of any
cancer other than
thyroid cancer?
248 /
3186
.415 ± .646
(−1.13, 1.96)
.508 ± .682
(−1.25, 2.26)
.508 ± .682
(−1.29, 2.31)
0.0 ± 1115
(−2943,
2943)
1.0
Dental x-rays that
did not usually
include a lead
shield over the
neck area?
1648 /
3191
.415 ± .646
(−1.13, 1.96)
.403 ± .654
(−1.28, 2.09)
.271 ± .914
(−2.14, 2.68)
.558 ± .91
(−1.83, 2.95) .82
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses, based on sex-
stratified logistic regression models.  P-values reflect the significance of the improved fit for models including confounding or effect
modification, relative to the unadjusted model.
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Table IX.I-8. Confounding and Effect Modification by Occupational History: Graves Disease
Have You Ever
Worked in Any of
Estimated Dose-Response Coefficient (per Gy)
the Following: Yes / Adjusted for Including Effect Modification
 (0=No, 1=Yes) Total Unadjusted Confounding Group 0 Group 1 P
Any metal
industry?
238 /
3191
.415 ± .646
(−1.13, 1.96)
.423 ± .643
(−1.23, 2.08)
.329 ± .687
(−1.48, 2.14)
3.33 ± 3.19
(−5.09, 11.8) .40
Any nuclear
facility?
371 /
3191
.415 ± .646
(−1.13, 1.96)
.390 ± .674
(−1.35, 2.13)
.399 ± .699
(−1.44, 2.24)
.292 ± 2.40
(−6.04, 6.63) .97
Any other industry
or occupation
where you may
have been exposed
to radioactive
materials or x-
rays?
442 /
3191
.415 ± .646
(−1.13, 1.96)
.434 ± .631
(−1.19, 2.06)
.242 ± .804
(−1.88, 2.36)
.801 ± .93
(−1.64, 3.24) .66
Any of the above
industries or
occupations?
892 /
3191
.415 ± .646
(−1.13, 1.96)
.402 ± .649
(−1.27, 2.07)
.361 ± .811
(−1.78, 2.50)
.480 ± 1.07
(−2.35, 3.31) .93
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses, based on sex-
stratified logistic regression models.  P-values reflect the significance of the improved fit for models including confounding or effect
modification, relative to the unadjusted model.
Table IX.I-9 displays the results of analyses of possible confounding or effect modification by
smoking variables.  There was no evidence that the dose-response was significantly confounded by either
smoking variable, or that there was a dose-response that differed significantly according to smoking
history.
Table IX.I-9. Confounding and Effect Modification by Smoking: Graves Disease
Have You Ever
Smoked Any of
Estimated Dose-Response Coefficent (per Gy)
the Following: Yes / Adjusted for Including Effect Modification
(0=No, 1=Yes) Total Unadjusted Confounding Group 0 Group 1 P
Cigarettes
(unfiltered or
filtered)?
1854 /
3183
.407 ± .658
(−1.17, 1.98)
.439 ± .666
(−1.28, 2.15)
.665 ± 1.05
(−2.11, 3.44)
.300 ± .90
(−2.08, 2.68) .79
Any of cigarettes,
cigar or pipe?
1900 /
3183
.407 ± .658
(−1.17, 1.98)
.441 ± .666
(−1.28, 2.16)
.663 ± 1.052
(−2.11, 3.44)
.303 ± .90
(−2.08, 2.69) .80
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses, based on sex-
stratified logistic regression models.  P-values reflect the significance of the improved fit for models including confounding or effect
modification, relative to the unadjusted model.
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I.2.j. Uncertainty
The estimated slopes of the sex-stratified linear dose-response model for Graves disease are shown
in Figure IX.I-1 for each of the 100 dose realizations produced by the CIDER model.  The confidence
intervals in that figure are calculated at the 98.33% confidence level, i.e., are adjusted by the Bonferroni
technique for the simultaneous estimation of the slope and two sex-specific background rates.  The point
estimate of the slope was greater than 0 for 48 of the 100 realizations, and the confidence interval included
0 for all 100 realizations.  Also shown in Figure IX.I-1 (to the right of realization 100) are the estimates and
confidence intervals calculated using (from left to right) the median, geometric mean and mean of each
participant's 100 dose realizations. In summary, for none of the 100 realizations of the estimated doses was
there a statistically significant dose-response, and for about half of the realizations the estimated slope was
less than 0.
Figure IX.I-2 displays the distribution of the 5000 estimates of the logistic regression coefficient
obtained by the simulation procedures described in section VIII.C.2.b.3 above. It is evident from the figure
that most of the estimates were between about –1.5 and 0.5. The estimate was less than or equal to 0 for
2068 of the 5000 replications, implying an empirical one-tailed p-value of 0.41.  The median estimate was
0.21, and the upper and lower percentiles corresponding to the Bonferroni-adjusted 95% confidence
interval were –3.21 and 1.87.  These may be compared to the estimate of 0.42 with confidence interval
(−1.13, 1.96) obtained using the median dose estimate without adjustment for uncertainty. Thus, this
method of adjusting the estimated logistic regression coefficient for the uncertainty in the dose estimates
did not provide evidence that the cumulative incidence of Graves disease increased with increasing dose.
Figure IX.I-1. Plot of estimated Slope and 95% CI by Dose Realization: Graves Disease
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Figure IX.I-2. Distribution of Simulation Estimates of Logistic Regression Coefficient: Graves
Disease
slope sample: 5000
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J. Autoimmune Thyroid Disease
J.1. Occurrence of Autoimmune Thyroid Disease
Autoimmune thyroid disease was defined by diagnosis of autoimmune (Hashimoto’s) thyroiditis
or Graves disease.  The primary and alternative definitions of autoimmune thyroid disease were as follows:
• Primary definition: Diagnosis of autoimmune thyroiditis or Graves disease based on HTDS evaluation
or medical records with supporting documentation (659 cases)
• Alternative definition #1: HTDS evaluation or medical records with or without supporting
documentation  (663 cases)
• Alternative definition #2: Any diagnosis or participant/respondent report (674 cases).
Of the 3440 living evaluable participants, 659 (19.2%) had a diagnosis of autoimmune thyroid
disease based on the HTDS evaluation or medical records with supporting documentation (Table IX.J-1).
These included 625 with autoimmune (Hashimoto’s) thyroiditis (see section IX.H) and 34 others with
diagnoses of Graves disease (see section IX.I).  An additional 4 (0.1%) living evaluable participants had a
diagnosis of autoimmune thyroid disease based on medical records without supporting documentation
(three with autoimmune thyroiditis, one with Graves disease).  Eleven other participants (0.3%) were based
on a report by the participant or his/her CATI respondent (one with autoimmune thyroiditis, 10 with Graves
disease).  
Table IX.J-1. Basis for Diagnosis of Autoimmune Thyroid Disease, by Sex
     Female Male              Total
Basis for Diagnosis No. % No. % No. %
Yes 442 25.3 232 13.7 674 19.6
HTDS Evaluation 421 24.1 226 13.3 647 18.8
Medical Records with
supporting documentation
10 0.6 2 0.1 12 0.3
Medical Records without
supporting documentation
4 0.2 0 -- 4 0.1
Participant/respondent report 7 0.4 4 0.2 11 0.3
No 1296 74.2 1454 85.9 2750 79.9
Unknown 9 0.5 7 0.4 16 0.5
Total 1747 100.0 1693 100.0 3440 100.0
      
       
 
      
 
      
 
Sixteen living evaluable participants were classified as “unknown” with regard to diagnosis of
autoimmune thyroid disease.  These sixteen did not have medical record or participant/respondent reports
of such diagnoses, and did not have an HTDS evaluation due to lack of a blood draw (N=8), insufficient
amount of blood drawn to obtain the antibody level (N=1), and a diagnosis of hyperthyroidism with an
uncertain etiology (potentially Graves) (N=7).  These sixteen participants were included as non-cases in
analyses of the dose-response for autoimmune thyroid disease.
J.2. Analysis of Autoimmune Thyroid Disease Risk
J.2.a. Primary Analysis
Of the 659 living evaluable participants with a diagnosis of autoimmune thyroid disease based on
the HTDS examination or medical records with supporting documentation, 45 were out-of-area
participants.  The proportions with autoimmune thyroid disease are shown by sex, dose category and basis
for diagnosis in Table IX.J-2. 
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Table IX.J-2. Diagnoses of Autoimmune Thyroid Disease by Sex, Estimated Dose, and Basis for
Diagnosis
A.  Female
 
 Thyroid
Radiation
Dose
(mGy)
Living
Evaluable
Female
Primary Definition
Cases Based on HTDS
or Med. Rec. with
Supporting
Documentation
1st Alternative Definition:
Cases Based on HTDS or
Med. Rec. with or without
Supporting
Documentation
2nd Alternative Definition:
Cases Based on Any
Diagnosis or Participant or
CATI Report
 No. No. % No.         % No.       %
Out of Area 125 24 19.2 24 19.2 24 19.2
< 10 182 49 26.9 49 26.9 50 27.5
10-49 320 75 23.4 75 23.4 76 23.8
50-99 313 84 26.8 86 27.5 89 28.4
100-149 220 55 25.0 56 25.5 56 25.5
150-199 126 36 28.6 36 28.6 36 28.6
200-299 139 33 23.7 33 23.7 34 24.5
300-399 144 35 24.3 36 25.0 37 25.7
400-999 171 38 22.2 38 22.2 38 22.2
1000+ 7 2 28.6 2 28.6 2 28.6
Total 1747 431 24.7 435 24.9 442 25.3
B.  Male
 
 Thyroid
Radiation
Dose
(mGy)
Living
Evaluable
Male
Primary Definition:
Cases Based on
HTDS or Med. Rec.
with Supporting
Documentation
1st Alternative Definition:
Cases Based on HTDS or
Med. Rec. with or without
Supporting
Documentation
2nd Alternative Definition
Cases Based on Any
Diagnosis or Participant or
CATI Report
 No. No. % No.         % No.     %
Out of Area 124 21 16.9 21 16.9 21 16.9
< 10 186 27 14.5 27 14.5 27 14.5
10-49 314 41 13.1 41 13.1 41 13.1
50-99 310 49 15.8 49 15.8 49 15.8
100-149 171 17 9.9 17 9.9 18 10.5
150-199 109 13 11.9 13 11.9 14 12.8
200-299 148 18 12.2 18 12.2 20 13.5
300-399 160 21 13.1 21 13.1 21 13.1
400-999 154 20 13.0 20 13.0 20 13.0
1000+ 17 1 5.9 1 5.9 1 5.9
Total 1693 228 13.5 228 13.5 232 13.7
Since nearly all of the cases of autoimmune thyroid disease were in fact autoimmune thyroiditis, it
was to be expected that dose-response results for these two disease outcomes would be quite similar.
Parameter estimates for the linear dose-response model based on the 3191 in-area participants are shown in
Table IX.J-3 below. Based on maximum likelihood analysis of the sex-stratified linear probability model,
and using the primary dose estimates, the estimated slope B was slightly less than zero (–0.024 per Gy; row
1 of Table IX.J-3) with Bonferroni-adjusted 95% confidence interval ranging from less than –0.058 to
0.048, providing no evidence that cumulative incidence of autoimmune thyroid disease increased with
increasing dose (p = 0.80). The corresponding estimated background rates for diagnosis of autoimmune
thyroid disease were 0.255 with confidence interval (0.227, 0.283) for women and 0.136 with confidence
interval (0.112, 0.160) for men.  Very similar results were obtained when the model was fit by the method
of least squares using ungrouped or grouped data (Table IX.J-3, rows 2 and 3).
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Table IX.J-3. Summary of Dose-Response Results for Diagnoses of Autoimmune Thyroid Disease
Dose-
Response Dose
Exclusions /
Additional
Method
of Estimated Background Rates 
Estimated
Slope of Dose-
Statistical Significance
of Dose-Response
Row Outcome Model Estimates Inclusions Analysis Female Male Response (per Gy) (one-tailed p-value)
1.
Primary definition
(HTDS evaluation or
medical record with
documentation)
Linear Primary None MLE
.255 ± .012
(.227, .283)
.136 ± .010
(.112, .160)
–.024 + .027
(<-.058, .048)
0.80
2. Primary definition Linear Primary None LSU
.255 ± .011
(.229, .282)
.136 ± .011
(.109, .163)
–.024 + .031
(–.098, .049)
0.79
3. Primary definition Linear Primary None LSG
.257 ± .011
(.230, .285)
.139 ± .012
(.111, .167)
–.038 + .036
(–.123, .047)
0.86
4.
Alternative def. #1
(HTDS or medical
record with or without
documentation)
Linear Primary None MLE
.258 ± .012
(.229, .286)
.136 ± .010
(.112, .160)
–.024 ± .027
(<-.058, .048)
0.80
5.
Alternative def. #2 
(Any diagnosis or
participant/respondent
report)
Linear Primary None MLE
.262 ± .012
(.234, .291)
.139 ± .010
(.115, .163)
–.026 ± .028
(-<.059, .047)
0.81
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, “>”
indicates that the upper confidence limit is less than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are not
given for estimated background rates from logistic regression model.  
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
Okanogan, F/S = Ferry/Stevens, OOA = out of area
Table continued on next page
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Table IX.J-3 Summary of Dose-Response Results for Diagnoses of Autoimmune Thyroid Disease (continued)
Dose-
Response Dose
Exclusions /
Additional
Method
of Estimated Background Rates 
Estimated
Slope of Dose-
Statistical Significance
of Dose-Response
Row Outcome Model Estimates Inclusions Analysis Female Male Response (per Gy) (one-tailed p-value)
6. Primary definition LQ Primary None LSU
.261 ± .012
(.231, .290)
.142 ± .012
(.112, .172)
Lin: −.076 ± .052
(−.207, .054)
Quad: .043 ± .035
(−.044, .129)
Quad: 0.22
7. Primary definition Logistic Primary None MLE
.256
(.227, .288)
.135
(.114, .160)
–.17 ± .21 
(-.68, .34)
0.79
8. Primary definition Linear Primary
Exclude dose
> 1000 mGy
MLE
.256 ± .012
(.227, .285)
.138 ±.011
(.113, .163)
-.031 ± .035
(<-.109, .057)
0.81
9. Primary definition Linear Primary
Exclude dose
> 400 mGy
MLE
.259 ± .014
(.226, .292)
.138 ± .012
(.109, .166)
-.041 ± .065
(-.191, .119)
0.74
10. Primary definition Linear Primary
Exclude 
Ok and F/S
geostrata
MLE
.252 ± .012
(.223, .282)
.134 ± .010
(.110, .159)
-.020 ± .028
(<-.058, .054)
0.76
11. Primary definition Linear Alt. #1 None MLE
.255 ± .012
(.226, .284)
.136 ± .010
(.112, .160)
-.021 + .028
(<-.058, .051)
0.76
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, “>”
indicates that the upper confidence limit is less than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are not
given for estimated background rates from logistic regression model.  
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
Okanogan, F/S = Ferry/Stevens, OOA = out of area
Table continued on next page
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Table IX.J-3. Summary of Dose-Response Results for Diagnoses of Autoimmune Thyroid Disease (continued)
Dose-
Response Dose
Exclusions /
Additional
Method
of Estimated Background Rates 
Estimated
Slope of Dose-
Statistical Significance
of Dose-Response
Row Outcome Model Estimates Inclusions Analysis Female Male Response (per Gy) (one-tailed p-value)
12. Primary definition Linear Alt. #2 None MLE
.255 ± .012
(.226, .284)
.136 ± .010
(.112, .161)
-.023 + .029
(<-.064, .050)
0.78
13. Primary definition Linear Primary
Include OOA
(scoping
analysis #1)
MLE
.250 ± .011
(.223, .277)
.138 ± .009
(.115, .161)
-.021 + .027
(<-.059, >.051)
0.77
14. Primary definition Linear Primary
Include OOA
(scoping
analysis #2)
MLE
.251 ± .011
(.224, .278)
.139 ± .009
(.116, .161)
-.024 + .027
(<-.059, >.046)
0.81
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, “>”
indicates that the upper confidence limit is less than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are not
given for estimated background rates from logistic regression model.  
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
Okanogan, F/S = Ferry/Stevens, OOA = out of area
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J.2.b. Alternative Definitions for Diagnosis of Autoimmune Thyroid Disease
Two alternative definitions for cases of autoimmune thyroid disease were considered.  The first
alternative added four cases with diagnoses based on medical records without supporting documentation,
for a total of 663 cases.  The second added another 11 cases based solely on a report from the participant or
his/her CATI respondent, for a total of 674 cases.  As shown in rows 4 and 5 of Table IX.J-3 above, the
parameter estimates for the linear dose-response model were essentially identical to those obtained in the
primary analysis.  In particular there was no evidence in either the primary or alternative analyses that the
cumulative incidence of autoimmune thyroid disease increased with increasing dose.
J.2.c. Alternative Dose-Response Functions 
As shown in row 6 of Table IX.J-3, the estimated regression coefficient for the dose-squared term
in the linear-quadratic dose-response model [5] was 0.043 with Bonferroni-adjusted 95% confidence
interval ranging from –0.044 to 0.129.  Thus the addition of a quadratic term did not significantly improve
the fit of the model (p = 0.22).
In the analysis of autoimmune thyroid disease based on the HTDS examination or medical records
with supporting documentation, i.e., the primary criterion for defining cases with autoimmune thyroid
disease, the regression parameter for the effect of dose in the sex-stratified logistic regression model [2]
was estimated as –0.17 with Bonferroni-adjusted 95% confidence interval ranging from –0.68 to 0.34
(Table IX.J-3, row 7).  Thus there was no evidence from the logistic regression model that cumulative
incidence of autoimmune thyroid disease increased with increasing dose (p = 0.79).
J.2.d. Effect of Excluding Participants in High Dose Categories
The results were essentially unchanged if participants in the high dose categories were excluded.
As shown in row 8 of Table IX.J-3, if participants with estimated doses over 1000 mGy were excluded, the
estimated slope of the sex-stratified linear dose-response model was less than zero (–0.031 per Gy) with
Bonferroni-adjusted 95% confidence interval ranging from less than –0.109 to 0.057 per Gy. Thus there
was no evidence that the cumulative incidence of autoimmune thyroid disease increased with increasing
dose (p = 0.81).  Similar results were obtained if participants with estimated doses exceeding 400 mGy
were excluded (p = 0.74; Table IX.J-3, row 9).
J.2.e. Effect of Excluding Okanogan and Ferry/Stevens Geostrata 
As shown in row 10 of Table IX.J-3, if the Okanogan and Ferry/Stevens geostrata were excluded,
the estimated slope increased slightly from –0.024 to –0.020 per Gy, but there was no evidence that the
cumulative incidence of autoimmune thyroid disease increased with increasing dose (p = 0.76).
J.2.f. Analysis of Autoimmune Thyroid Disease in Relation to Alternative Dose
Estimates 
As shown in rows 11 and 12 of Table IX.J-3, for neither set of alternative dose estimates was there
any evidence that the cumulative incidence of autoimmune thyroid disease increased with increasing dose
(p = 0.76 and p = 0.78 for the first and second dose set estimates, respectively).
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J.2.g. Scoping Analysis Regarding Out-of-Area Participants
See section VIII.C.1.a.3 for a description of the scoping analyses that were performed to assess
the possible impact of including the 249 out-of-area participants.  As shown in rows 13 and 14 of Table
IX.J-3 above, for neither of the scoping analyses was there any evidence that the cumulative incidence of
autoimmune thyroid disease increased with increasing dose (p = 0.77 and p = 0.81 for the first and second
scoping analyses, respectively).
J.2.h. Analysis of Autoimmune Thyroid Disease in Relation to Alternative 
Representations of Exposure
In the analyses by geostratum and by dichotomous exposure variable, the sex and age-adjusted
comparisons of cumulative incidence were performed as described in section VIII.C.2.a.2.
J.2.h.1. Analysis by Geostratum
As shown in Table IX.J-4, among the entire 3440 living evaluable participants, the proportions
with autoimmune thyroid disease ranged from 23/75 (30.7% in the Okanogan County geostratum) to
36/170 (21.2%, Walla Walla County) for women, and from 11/64 (17.2%, Okanogan County) to 52/501
(10.4%, Pasco/Kennewick) for men (p = 0.083 for heterogeneity among the nine geostrata).  In particular
the percentages with autoimmune thyroid disease were somewhat higher in the Okanogan and
Ferry/Stevens geostrata (29.4% for women, 15.7% for men) than in the remaining geostrata (24.3% and
13.3%, respectively; p = 0.048).  Since it was likely that participants in the Okanogan and Ferry/Stevens
geostrata tended to have lower thyroid doses from Hanford’s 131I than those in other geostrata, it does not
appear that these differences can be attributed to an effect of Hanford’s 131I. 
Table IX.J-4. Diagnoses of Autoimmune Thyroid Disease based on the HTDS Evaluation or on
Medical Records with Supporting Documentation, by Geostratum and Sex 
  Female                  Male Total
Geostratum No. Cases % No. Cases % No. Cases %
Richland 179 46 25.7 173 24 13.9 352 70 19.9
Pasco/Kennewick 508 116 22.8 501 52 10.4 1009 168 16.7
Benton County 376 97 25.8 358 58 16.2 734 155 21.1
Franklin County 73 20 27.4 76 12 15.8 149 32 21.5
Adams County 165 38 23.0 156 24 15.4 321 62 19.3
Walla Walla (city) 133 36 27.1 131 18 13.7 264 54 20.5
Walla Walla County 170 36 21.2 164 19 11.6 334 55 16.5
Okanogan County 75 23 30.7 64 11 17.2 139 34 24.5
Ferry/Stevens Counties 68 19 27.9 70 10 14.3 138 29 21.0
Total 1747 431 24.7 1693 228 13.5 3440 659 19.2
J.2.h.2. Analysis by Dichotomous Exposure Variable
A total of 223 (17.7%) of the 1257 participants included in these analyses had a diagnosis of
autoimmune thyroid disease based on the HTDS examination or medical records with supporting
documentation (see Table IX.J-5).  These included 99/580 (17.1%) in the high exposure group and 124/677
(18.3%) in the low exposure group.  The cumulative incidence of autoimmune thyroid disease was not
significantly higher in the high exposure group (p = 0.80).
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Table IX.J-5. Diagnoses of Autoimmune Thyroid Disease based on the HTDS evaluation or on
Medical Records with Supporting Documentation, by Exposure Group and Sex 
Female Male Total
Exposure Group No. Cases % No. Cases % No. Cases %
Low 351 75 21.4 326 49 15.0 677 124 18.3
High 298 66 22.1 282 33 11.7 580 99 17.1
Total 649 141 21.7 608 82 13.5 1257 223 17.7
J.2.i. Confounding and Effect Modification
As described in section VIII above, additional sex-stratified logistic regression models were
investigated to examine the possibility that the primary dose-response results might be influenced by
confounding, and to search for factors that might modify a radiation dose-response.  These analyses were
based on the primary definition of autoimmune thyroid disease, i.e., those based on an HTDS diagnosis or
on medical records with documented diagnoses, and on the primary dose estimates.  Table IX.J-6 displays
results for models including sex, age at first exposure to Hanford 131I (prenatal, or < 180 days), age at
HTDS examination, estimated dose from the NTS, history of any cancer other than thyroid disease, and
HTDS interview type.
Note that sex was not analyzed as a possible confounder since its effect was already adjusted for in
the sex-stratified model.  None of the other factors in Table IX.J-6  appears to be a confounder: for none
does the adjusted estimate of the regression coefficient differ markedly from the unadjusted estimate.
Therefore, it does not appear that omitting these factors introduces any important bias in the dose-response
results. 
The analyses of effect modification address the question of whether the dose-response might vary
according to other characteristics of the study participants.  This was tested by comparing the estimated
regression coefficients for the groups defined by each covariate.  As shown in Table IX.J-6, the regression
coefficients did not differ significantly between the groups defined by any of the covariates, suggesting that
none of them was a significant modifier of a radiation dose-response for autoimmune thyroid disease.
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Table IX.J-6. Confounding and Effect Modification by Sex, Age at Exposure or HTDS
Examination, Estimated Thyroid Dose from NTS, History of Any Cancer Other
than Thyroid, and Interview Type: Autoimmune Thyroid Disease
Estimated Dose-Response Coefficient (per Gy)
Covariate Yes / Adjusted for Including Effect Modification
 (0=No, 1=Yes) Total Unadjusted Confounding Group 0 Group 1 P
Female?
1622 /
3191
−.170 ± .213
(−.680, .341)
Not
Applicable
−.259 ± .353
(−1.14, .622)
−.116 ± .268
(−.785, .553) .74
Prenatal
exposure?
1034 /
3191
−.170 ± .213
(−.680, .341)
−.211 ± .217
(−.770, .347)
−.134 ± .244
(−.777, .509)
−.467 ± .461
(−1.68, .748) .52
1st exposure
before age 180
days?
1478 /
3191
−.170 ± .213
(−.680, .341)
−.167 ± .214
(−.719, .385)
−.550 ± .377
(−1.55, .445)
.019 ± .249
(−.638, .676) .21
Age at exam >
50?
2001 /
3191
−.170 ± .213
(−.680, .341)
−.250 ± .221
(−.818, .319)
−.574 ± .457
(−1.78, .633)
−.136 ± .253
(−.805, .532) .39
NTS 131I
dose > 5.3 mGy?
1567 /
3189
−.169 ± .213
(−.679, .342)
−.185 ± .219
(−.749, .379)
−.239 ± .291
(−1.01, .529)
−.114 ± .330
(−.984, .756) .78
History of any
cancer other than
thyroid?
248 /
3186
−.161 ± .213
(−.671, .348)
−.154 ± .214
(−.704, .397)
−.094 ± .227
(−.692, .504)
−.661 ± .762
(−2.67, 1.35)
Expanded In-
Person Interview?
1212 /
3191
−.170 ± .213
(−.680, .341)
−.218 ± .218
(−.781, .345)
−.595 ± .364
(−1.55, .365)
.002 ± .261
(−.688, .691) .18
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses, based on sex-
stratified logistic regression models.  P-values reflect the significance of the improved fit for models including confounding or effect
modification, relative to the unadjusted model.
Tables IX.J-7 and IX.J-8 display similar results from analyses including history of medical or
dental x-ray exposure or of occupational exposures as potential confounding or effect modifying factors.
The estimates of the regression coefficient calculated with adjustment for confounding are all close to the
unadjusted estimates.  Moreover the adjusted estimates all remained less than zero.  Thus there was no
evidence that a confounding effect of any of these covariates has obscured a positive dose-response for
autoimmune disease. 
There is no evidence of any statistically significant effect modification by any of the covariates in
Tables IX.J-7 and IX.J-8.
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Table IX.J-7. Confounding and Effect Modification by History of Medical and Dental Radiation
Exposures: Autoimmune Thyroid Disease 
Have You
Estimated Dose-Response Coefficient (per Gy)
Ever Had: Yes / Adjusted for Including Effect Modification
 (0=No, 1=Yes) Total Unadjusted Confounding Group 0 Group 1 P
CAT scan of the
upper body?
775 /
3149
−.164 ± .214
(−.676, .348)
−.166 ± .214
(−.717, .385)
−.181 ± .238
(−.808, .447)
−.100± .495
(−1.41, 1.21) .88
Diagnostic x-rays
of the head?
1191 /
3155
−.160 ± .215
(−.674, .354)
−.166 ± .215
(−.720, .388)
−.168 ± .266
(−.870, .534)
−.162 ± .366
(−1.13, .803) .99
Diagnostic x-rays
of the neck?
966 /
3167
−.164 ± .214
(−.676, .349)
−.162 ± .215
(−.715, .392)
−.343 ± .294
(−1.12, .432)
.057 ± .306
(−.749, .864) .35
Diagnostic x-rays
of chest or upper
body, including
mammograms?
2821 /
3173
−.154 ± .213
(−.663, .355)
−.152 ± .213
(−.700, .397)
−.091 ± .787
(−2.17, 1.99)
−.156 ± .221
(−.740, .427) .94
Diagnostic x-rays
of the stomach or
mid-back?
692 /
3120
−.176 ± .216
(−.694, .342)
−.182 ± .216
(−.739, .376)
−.192 ± .241
(−.829, .444)
−.136 ± .489
(−1.43, 1.15) .92
Barium enema?
825 /
3159
−.194 ± .216
(−.711, .323)
−.195 ± .216
(−.751, .361)
−.007 ± .240
(−.640, .626)
−.821 ± .485
(−2.10, .458) .12
Upper GI?
1146 /
3177
−.186 ± .215
(−.700, .327)
−.181 ± .214
(−.733, .371)
−.101 ± .262
(−.791, .590)
−.333 ± .371
(−1.31, .646) .61
Intravenous
Pyelogram?
398 /
3157
−.182 ± .215
(−.698, .333)
−.171 ± .215
(−.725, .383)
−.159 ± .226
(−.755, .438)
−.285 ± .687
(−2.10, 1.53) .86
Fluoroscopy of 
the upper body?
246 /
3161
−.183 ± .215
(−.697, .331)
−.179 ± .215
(−.731, .374)
−.157 ± .221
(−.740, .427)
−.487 ± .846
(−2.72, 1.74) .70
Nuclear scan
(excluding thyroid
scan)?
217 /
3162
−.141 ± .212
(−.648, .367)
−.134 ± .212
(−.680, .412)
−.115 ± .217
(−.687, .457)
−.482 ± .947
(−2.98, 2.02) .70
Dental x-rays that
did not usually
include a lead
shield over the
neck area?
1648 /
3191
−.170 ± .213
(−.680, .341)
−.172 ± .213
(−.721, .377)
.111 ± .286
(−.643, .866)
−.484 ± .325
(−1.34, .372) .17
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses, based on sex-
stratified logistic regression models.  P-values reflect the significance of the improved fit for models including confounding or effect
modification, relative to the unadjusted model.
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Table IX.J-8. Confounding and Effect Modification by Occupational History: Autoimmune
Thyroid Disease
Have You Ever
Worked in Any of
Estimated Dose-Response Coefficient (per Gy)
the Following: Yes / Adjusted for Including Effect Modification
 (0=No, 1=Yes) Total Unadjusted Confounding Group 0 Group 1 P
Any metal
industry?
238 /
3191
−.170 ± .213
(−.680, .341)
−.171 ± .213
(−.720, .379)
−.111 ± .216
(−.680, .458)
−1.42 ± 1.08
(−4.27, 1.43) .21
Any nuclear
facility?
371 /
3191
−.170 ± .213
(−.680, .341)
−.184 ± .215
(−.739, .371)
−.152 ± .234
(−.769, .465)
−.351 ± .550
(−1.80, 1.10) .74
Any other industry
or occupation
where you may
have been exposed
to radioactive
materials or x-
rays?
442 /
3191
−.170 ± .213
(−.680, .341)
−.162 ± .213
(−.711, .387)
−.059 ± .227
(−.658, .540)
−.895 ± .710
(−2.77, .977) .22
Any of the above
industries or
occupations?
892 /
3191
−.170 ± .213
(−.680, .341)
−.178 ± .214
(−.729, .373)
.014 ± .248
(−.641, .669)
−.654 ± .429
(−1.79, .477) .16
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses, based on sex-
stratified logistic regression models.  P-values reflect the significance of the improved fit for models including confounding or effect
modification, relative to the unadjusted model.
Table IX.J-9 displays the results of analyses of possible confounding or effect modification by
smoking variables.  There was no evidence that the dose-response was significantly confounded by either
smoking variable, or that there was a dose-response that differed significantly according to smoking
history.
Table IX.J-9. Confounding and Effect Modification by Smoking: Autoimmune Thyroid Disease
Have You Ever
Smoked Any of
Estimated Dose-Response Coefficient (per Gy)
the Following: Yes / Adjusted for Including Effect Modification
(0=No, 1=Yes) Total Unadjusted Confounding Group 0 Group 1 P
Cigarettes
(unfiltered or
filtered)?
1854 /
3183
−.167 ± .213
(−.677, .344)
−.170 ± .213
(−.719, .379)
−.563 ± .378
(−1.56, .433)
.028 ± .251
(−.634, .691) .19
Any of cigarettes,
cigar or pipe?
1900 /
3183
−.167 ± .213
(−.677, .344)
−.170 ± .213
(−.719, .379)
−.510 ± .378
(−1.51, .488)
−.001 ± .252
(−.665, .663) .26
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses, based on sex-
stratified logistic regression models.  P-values reflect the significance of the improved fit for models including confounding or effect
modification, relative to the unadjusted model.
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J.2.j. Uncertainty
The estimated slopes of the sex-stratified linear dose-response model for autoimmune thyroid
disease are shown in Figure IX.J-1 for each of the 100 dose realizations produced by the CIDER model.
The confidence intervals in that figure are calculated at the 98.33% confidence level, i.e., are adjusted by
the Bonferroni technique for the simultaneous estimation of the slope and two sex-specific background
rates.  While the point estimate of the slope is greater than 0 for only 16 of the 100 realizations, the
confidence interval includes 0 for all 100 realizations.  Also shown in Figure IX.J-1 (to the right of
realization 100) are the estimates and confidence intervals calculated using (from left to right) the median,
geometric mean and mean of each participant's 100 dose realizations. In summary, for none of the 100
realizations of the estimated doses was there a statistically significant dose-response, and for most of the
realizations the estimated slope was less than 0.
Figure IX.J-1. Plot of Estimated Slope and 95% CI by Dose Realization: Autoimmune Thyroid 
Disease
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Figure IX.J-2 displays the distribution of the 5000 logistic regression coefficient estimates
obtained by the simulation procedures described in section VIII.C.2.b.3 above. It is evident from the figure
that most of the estimates were between about –1.5 and 0.5. The estimate was less than or equal to 0 for
4226 of the 5000 replications, implying an empirical one-tailed p-value of 0.85.  The median estimate was
−0.31, and the upper and lower percentiles corresponding to the Bonferroni-adjusted 95% confidence
interval were –1.08 and 0.35.  These may be compared to the estimate of −0.17 with confidence interval
(−0.68, 0.34) obtained using the median dose estimates without adjustment for uncertainty. Thus, this
method of adjusting the estimated logistic regression coefficient for the uncertainty in the dose estimates
did not provide evidence that the cumulative incidence of autoimmune thyroid disease increased with
increasing dose.
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Figure IX.J-2. Distribution of Simulation Estimates of Logistic Regression Coefficient:
Autoimmune Thyroid Disease
slope sample: 5000
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K. Hyperthyroidism
K.1. Occurrence of Hyperthyroidism
The primary and alternative definitions for hyperthyroidism were as follows:
• Primary definition: HTDS evaluation or medical records with supporting documentation (161 cases)
• Alternative definition #1: HTDS evaluation or medical records with or without supporting documentation  (175
cases)
• Alternative definition #2: Any diagnosis or participant/respondent report (196 cases).
There were 161 (4.7%) cases of hyperthyroidism based on the HTDS evaluation or medical records with
supporting documentation (Table IX.K-1).  An additional 14 (0.4%) living evaluable participants had a diagnosis of
hyperthyroidism based on medical records without supporting documentation, and 21 (0.6%) were based on a
participant or his/her CATI respondent report.  The cumulative incidence of hyperthyroidism was higher for women
(9.0%) than men (2.3%).
It is important to understand that these 196 cases included a substantial number of iatrogenic cases (these
are discussed below).  Since endogenous hyperthyroidism was of particular importance, analyses that focused on
cases of non-iatrogenic hyperthyroidism were given particular emphasis in this study.
Table IX.K-1. Basis for Diagnosis of Hyperthyroidism, by Sex
    Female    Male             Total
Basis for Diagnosis No. % No. % No. %
Yes 157 9.0 39 2.3 196 5.7
HTDS evaluation 77 4.4 18 1.1 95 2.8
Medical records with supporting
documentation
57 3.3 9 0.5 66 1.9
Medical records without
supporting documentation
12 0.7 2 0.1 14 0.4
Participant/respondent report 11 0.6 10 0.6 21 0.6
No 1572 90.0 1649 97.4 3221 93.6
Unknown 18 1.0 5 0.3 23 0.7
Total 1747 100.0 1693 100.0 3440 100.0
      
       
 
      
 
      
 
Twenty-three living evaluable participants were classified as "unknown" with regard to diagnosis of
hyperthyroidism.  These participants did not have a medical record indicating hyperthyroidism, but 13 had a
participant report of an unknown thyroid problem, with most indicating it was either an over or under active thyroid
for which they took some type of medication.  Eight others had no blood draw and for two others a diagnosis of
hyperthyroidism could not be ruled out.  These 23 participants were included as non-cases in analyses of the dose-
response for hyperthyroidism.
One or more possible etiologies were identified for all of the 196 participants with hyperthyroidism.
Exogenous thyroid medication was the most common etiology (59.2%) (Table IX.K-2).  Graves disease (19.9%)
was the second most frequent etiology of hyperthyroidism, followed by uncertain (14.3%).  Six of the eight living
evaluable participants with hyperthyroidism and an etiology of other were due to possible subacute thyroiditis, while
two were due to possible Graves disease.
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Table IX.K-2. Etiologies of Hyperthyroidism, by Sex
     Female Male              Total
Etiology No. % No. % No. %
Graves disease 32 20.4 7 17.9 39 19.9
Toxic nodular goiter 2 1.3 0 -- 2 1.0
Solitary autonomous nodule 1 0.6 1 2.6 2 1.0
Subacute thyroiditis 3 1.9 2 5.1 5 2.6
Silent/post-partum thyroiditis 1 0.6 0 -- 1 0.5
Exogenous thyroid medication 102 65.0 14 35.9 116 59.2
Uncertain 13 8.3 15 38.5 28 14.3
Other 8 5.1 0 -- 8 4.1
Total with  hyperthyroidism 157 100.0 39 100.0 196 100.0
Note: A participant can have >1 etiology
K.1.a. Non-iatrogenic Hyperthyroidism
Since the inclusion of iatrogenic hyperthyroidism might mask an effect of radiation on risk of endogenous
hyperthyroidism, an additional disease outcome of non-iatrogenic hyperthyroidism was also defined.  A total of 50
living evaluable participants had diagnoses of non-iatrogenic hyperthyroidism based on their HTDS evaluations or
on medical records with supporting documentation (Table IX.K-3).
Table IX.K-3. Non-Iatrogenic Hyperthyroidism, by Sex
Female Male              Total
Non-iatrogenic Hyperthyroidism No. % No. % No. %
Yes 37 2.1 13 0.8 50 1.4
No 1710 97.9 1680 99.2 3390 98.5
Total 1747 100.0 1693 100.0 3440 100.0
K.2. Analysis of Hyperthyroidism Risk
K.2.a. Primary Analysis
Of the 161 living evaluable participants with a diagnosis of hyperthyroidism based on the HTDS
examination or medical records with supporting documentation, six were out-of-area participants for whom the
CIDER program could not calculate dose estimates.  The proportions with hyperthyroidism are shown by sex, dose
category and basis for diagnosis in Table IX.K-4.  The numbers and proportions with diagnoses of non-iatrogenic
hyperthyroidism are also shown.
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Table IX.K-4. Diagnoses of Hyperthyroidism by Sex, Estimated Dose, and Basis for Diagnosis
A.  Female
 
 
 Thyroid
Radiation
Dose
(mGy)
Living
Evaluable
Female
Primary
Definition: Cases
Based on HTDS
or Med. Rec. with
Supporting
Documentation
1st Alternative
Definition:
Cases based on HTDS
or Med. Rec. with or
without Supporting
Documentation
2nd Alternative
Definition:
Cases Based on Any
Diagnosis or
Participant or CATI
Report
Non-iatrogenic
Hyperthyroidism
(Primary
Definition)
 No. No. % No.        % No. % No. %
Out of Area 125 6 4.8 6 4.8 7 5.6 2 1.6
< 10 182 10 5.5 12 6.6 13 7.1 5 2.7
10-49 320 27 8.4 29 9.1 29 9.1 6 1.9
50-99 313 30 9.6 32 10.2 36 11.5 9 2.9
100-149 220 9 4.1 10 4.5 12 5.5 2 0.9
150-199 126 11 8.7 14 11.1 16 12.7 0 0.0
200-299 139 13 9.4 15 10.8 15 10.8 4 2.9
300-399 144 14 9.7 14 9.7 15 10.4 4 2.8
400-999 171 13 7.6 13 7.6 13 7.6 5 2.9
1000+ 7 1 14.3 1 14.3 1 14.3 0 --
Total 1747 134 7.7 146 8.4 157 9.0 37 2.1
Table IX.K-4. Diagnoses of Hyperthyroidism by Sex, Estimated Dose, and Basis for Diagnosis (continued)
B.  Male
 
 
 Thyroid
Radiation
Dose
(mGy)
Living
Evaluable
Male
Primary
Definition: Cases
Based on HTDS
or Med. Rec. with
Supporting
Documentation
1st Alternative
Definition:
Cases based on HTDS
or Med. Rec. with or
without Supporting
Documentation
2nd Alternative
Definition:
Cases Based on Any
Diagnosis or
Participant or CATI
Report
Non-iatrogenic
Hyperthyroidism
(Primary
Definition)
 No. No. % No.       % No. % No. %
Out of Area 124 0 -- 0 -- 0 -- 0 --
< 10 186 5 2.7 5 2.7 5 2.7 2 1.1
10-49 314 4 1.3 4 1.3 6 1.9 2 0.6
50-99 310 3 1.0 5 1.6 6 1.9 2 0.6
100-149 171 4 2.3 4 2.3 5 2.9 4 2.3
150-199 109 1 0.9 1 0.9 2 1.8 1 0.9
200-299 148 1 0.7 1 0.7 2 1.4 1 0.7
300-399 160 6 3.8 6 3.8 7 4.4 1 0.6
400-999 154 2 1.3 2 1.3 5 3.2 0 --
1000+ 17 1 5.9 1 5.9 1 5.9 0 --
Total 1693 27 1.6 29 1.7 39 2.3 13 0.8
Parameter estimates for the linear dose-response model based on the 3191 in-area participants are shown in
Table IX.K-5 below. Based on maximum likelihood analysis of the sex-stratified linear probability model, and using
the primary dose estimates, the estimated slope B was 0.011 per Gy; row 1 of Table IX.K-5).  The Bonferroni-
adjusted 95% confidence interval ranged from less than –0.008 to 0.052, thus the cumulative incidence of
hyperthyroidism did not increase significantly with increasing dose (p = 0.22). The corresponding estimated
background rates for diagnosis of hyperthyroidism were 0.077 with confidence interval (0.060, 0.094) for women
and 0.015 with confidence interval (0.006, 0.025) for men.  Similar results were obtained when the model was fit by
the method of least squares using ungrouped or grouped data (Table IX.K-5, rows 2 and 3). 
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Table IX.K-5. Summary of Dose-Response Results for Diagnoses of Hyperthyroidism
Row Outcome
Dose 
Response
Model
Dose
Estimates
Exclusions
Additional
Inclusions
Method 
of 
Analysis
Estimated Background Rates
Female              Male
Estimated Slope 
of  Dose-Response
(per Gy)
Statistical Significance 
of Dose-Response
(one-tailed p-value)
1.
Primary definition
(HTDS evaluation or
medical record with
documentation)
Linear Primary None MLE
.077 ± .007
(.060, .094)
.015 ± .004
(.006, .025)
.011 ± .015
(<-.008, .052)
0.22
2. Primary definition Linear Primary None LSU
.076 ± .006
(.062, .090)
.014 ± .006
(0*, .029)
.018 ± .017
(-.022, .058)
0.15
3. Primary definition Linear Primary None LSG
.077 ± .006
(.062, .092)
.015 ± .006
(0*, .030)
.012 ± .019
(-.034, .059)
0.26
4.
Alternative def.
#1(HTDS or medical
record with or without
documentation)
Linear Primary None MLE
.085 ± .007
(.067, .103)
.017 ± .004
(.007, .027)
.007 ± .015
(<-.008, .049)
0.32
5.
Alternative def. #2 
(Any diagnosis or
participant/respondent
report)
Linear Primary None MLE
.090 ± .008
(.071, .109)
.022 ± .005
(.011, .034)
.015 ± .018
(<-.011, .063)
0.19
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, “>” indicates
that the upper confidence limit is greater than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are not given for
estimated background rates from logistic regression model.  “0*” indicates that the lower confidence limit for a background rate was less than 0.
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok = Okanogan, F/S
= Ferry/Stevens, OOA = out of area
Table continued on next page
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Table IX.K-5. Summary of Dose-Response Results for Diagnoses of Hyperthyroidism (continued)
Estimated Background Rates 
Row Outcomes
Dose-
Response
Model
Dose 
Estimates
Exclusions/
Additional
Inclusions 
Method 
of
Analysis Female Male
Estimated
Slope of Dose-
Response (per Gy)
Statistical Significance
of Dose-Response
(one-tailed p-value)
6.
Non-iatrogenic
hyperthyroidism 
Linear Primary None MLE
.022 ± .004
(.012, .033) 
.009 ± .003
(.002, .015)
-.004 ± .013
(NE, .019)
0.78
7. Primary definition LQ Primary None LSU
.077 ± .007
(.061, .093)
.015 ± .007
(0*, .032)
Lin: .009 ± .029
(−.062, .080)
Quad: .007 ± .019
(−.040, .054)
Quad: 0.71
8. Primary definition Logistic Primary None MLE
.074
(.058, .095)
.016
(.010, .026)
0.35 ± 0.32 
(-.43, 1.12)
0.16
9. Primary definition Linear Primary
Exclude dose
 > 1000 mGy
MLE
.078 ± .007
(.060, .096)
.016 ± .004
(.006, .027)
.003 ± .018
(<-.021, .051)
0.44
10. Primary definition Linear Primary
Exclude dose
> 400 mGy
MLE
.076 ± .008
(.057, .094)
.014 ± .004
(.004, .024)
.028 ± .027
(-.029, .101)
0.13
11. Primary definition Linear Primary
Exclude 
Ok and F/S
geostrata
MLE
.073 ± .007
(.055, .090)
.009 ± .004
(.0004, .018)
.025 ± .016
(<-.006, .067)
0.046
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, “>” indicates
that the upper confidence limit is greater than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are not given for
estimated background rates from logistic regression model.  “0*” indicates that the lower confidence limit for a background rate was less than 0.
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok = Okanogan, F/S
= Ferry/Stevens, OOA = out of area
Table continued on next page
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Table IX.K-5. Summary of Dose-Response Results for Diagnoses of Hyperthyroidism (continued)
Estimated Background Rates 
Row Outcome
Dose-
Response
Model
Dose 
Estimates
Exclusions/
Additional
Inclusions
Method 
of
Analysis Female Male
Estimated
Slope of Dose-
Response (per Gy)
Statistical Significance
of Dose-Response
(one-tailed p-value)
12. Primary definition Linear Alt. #1 None MLE
.080 ± .007
(.062, .098)
.018 ± .004
(.008, .028)
-.005 ± .015
(<-.008, .034)
0.63
13. Primary definition Linear Alt. #2 None MLE
.079 ± .007
(.062, .097)
.018 ± .004
(.007, .028)
-.002 ± .015
(<-.008, .037)
0.55
14. Primary definition Linear Primary
Include OOA
(scoping
analysis #1)
MLE
.074 ± .007
(.057, .090)
.013 ± .004
(.005, .022)
.017 ± .015
(<-.007,>.059)
0.11
15. Primary definition Linear Primary
Include OOA
(scoping
analysis #2)
MLE
.074 ± .007
(.058, .090)
.013 ± .004
(.005, .022)
.016 ± .015
(<-.007,> .058)
0.12
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, “>” indicates
that the upper confidence limit is greater than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are not given for
estimated background rates from logistic regression model.  “0*” indicates that the lower confidence limit for a background rate was less than 0.
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok = Okanogan, F/S
= Ferry/Stevens, OOA = out of area
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K.2.b. Alternative Definitions for Diagnosis of Hyperthyroidism
Two alternative definitions for cases of hyperthyroidism were considered.  The first alternative
added 14 cases with diagnoses based on medical records without supporting documentation, for a total of
175 cases.   The resulting dose-response had estimated slope of 0.007 per Gy with Bonferoni-adjusted
confidence interval ranging from less than -0.008 to 0.049 per Gy (Table IX.K-5, row 4). The second
alternative criterion for defining cases of hyperthyroidism added another 21 participants based solely on a
report from the participant or his/her CATI respondent, for a total of 196 cases, estimated slope of 0.015
per Gy, and confidence interval ranging from less than – 0.011 to 0.063 per Gy (Table IX.K-5, row 5).  The
parameter estimates for the linear dose-response model [1] were not significantly greater than zero
(p = 0.32 and p = 0.19), showing no evidence that the cumulative incidence of hyperthyroidism increased
with increasing dose for either alternative criterion of hyperthyroidism.
K.2.b.1. Non-iatrogenic Hyperthyroidism  
In the analyses described above, the participants with iatrogenic hyperthyroidism were included
among the cases.  In order to focus on endogenous outcomes, an additional analysis was performed in
which participants with iatrogenic hyperthyroidism only were excluded from the cases.  This left a total of
48 cases of non-iatrogenic hyperthyroidism based on the HTDS examination or medical records with
supporting documentation among the 3191 in-area evaluable participants.  As shown in row 6 of Table
IX.K-5, the dose-response was slightly negative, with estimated slope – 0.004 per Gy and upper 95%
confidence limit 0.019 per Gy (p=0.78).
K.2.c Alternative Dose-Response Functions 
As shown in row 7 of Table IX.K-5, the estimated regression coefficient for the dose-squared term
in the linear-quadratic dose-response model [5] was 0.007 with Bonferroni-adjusted 95% confidence
interval ranging from –0.040 to 0.054.  Thus the addition of a quadratic term did not significantly improve
the fit of the model (p = 0.71).
In the analysis of hyperthyroidism based on the HTDS examination or medical records with
supporting documentation, i.e., the primary criterion for defining cases with hyperthyroidism, the
regression parameter for the effect of dose in the sex-stratified logistic regression model [2] was estimated
as 0.35 with Bonferroni-adjusted 95% confidence interval ranging from –0.43 to 1.12 (Table IX.K-5, row
8).  Thus the cumulative incidence of hyperthyroidism did not increase significantly with increasing dose (p
= 0.16).
K.2.d. Effect of Excluding Participants in High Dose Categories
As shown in rows 9 and 10 of Table IX.K-5, when participants in high dose categories were
excluded, the cumulative incidence of hyperthyroidism did not increase significantly with increasing dose
(p = 0.44 and p = 0.13 when participants with estimated dose > 1000 mGy and > 400 mGy were excluded,
respectively).
K.2.e. Effect of Excluding Okanogan and Ferry/Stevens Geostrata
When the Okanogan and Ferry/Stevens geostrata were excluded, the estimated slope of the
sex-stratified linear dose-response model was 0.025 per Gy with Bonferroni-adjusted 95% confidence
interval ranging from less than –0.006 to 0.067 per Gy (Table IX.K-5, row 11).  While this result might be
regarded as evidence that the cumulative incidence of hyperthyroidism increased with increasing dose
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among the participants in the remaining geostrata (p = 0.046), it is not considered statistically significant in
view of the large number of significance tests that were performed.
K.2.f. Analysis of Hyperthyroidism in Relation to Alternative Dose Estimates
As shown in rows 12 and 13 of Table IX.K-5, the slope of the dose-response was slightly negative
when estimated in relation to either of the alternative dose estimates.  Thus there was no evidence from
these analyses that risk of hyperthyroidism increased significantly with increasing dose (p = 0.63 and
p = 0.55 for the first and second alternative dose estimates, respectively).
K.2.g. Scoping Analysis Regarding Out-of-Area Participants
See section VIII.C.1.a.3 for a description of the scoping analyses that were performed to assess the
possible impact of including the 249 out-of-area participants.  As summarized in rows 14 and 15 of Table
IX.K-5, in neither scoping analysis did the cumulative incidence of hyperthyroidism increase significantly
with increasing dose (p = 0.11 and p = 0.12 for the first and second scoping analyses, respectively).
K.2.h. Analysis of Hyperthyroidism in Relation to Alternative Representations of
Exposure
In the analyses by geostratum and by dichotomous exposure variable, the sex and age-adjusted
comparisons of cumulative incidence were performed as described in section VIII.C.2.a.2.
K.2.h.1. Analysis by Geostratum
As shown in Table IX.P-18, among the 3429 living evaluable in area or out-of-area participants
with ultrasound results, the proportions with palpable UDAs ranged from 9/68 (13.2% in the Stevens/Ferry
Counties geostratum) to 9/177 (5.1%, Richland) for women, and from 5/63 (7.9%, Okanogan County) to
13/501 (2.6%, Pasco/Kennewick) for men (p = 0.051 for heterogeneity among the nine geostrata).  In
particular the percentages with palpable UDAs were somewhat higher in the Okanogan and Ferry/Stevens
geostrata (12.6% for women, 6.8% for men) than in the remaining geostrata (8.5% and 3.9%, respectively;
p = 0.0086).  Since it was likely that participants in the Okanogan and Ferry/Stevens geostrata tended to
have lower thyroid doses from Hanford’s 131I than those in other geostrata, it does not appear that these
differences can be attributed to an effect of Hanford’s 131I. 
Table IX.K-6. Diagnoses of Hyperthyroidism Based on the HTDS Evaluation or on Medical 
Records with Supporting Documentation, by Geostratum and Sex
Female Male Total
Geostratum No. Cases % No. Cases % No. Cases %
Richland 179 13 7.3 173 2 1.2 352 15 4.3
Pasco/Kennewick 508 37 7.3 501 6 1.2 1009 43 4.3
Benton County 376 30 8.0 358 4 1.1 734 34 4.6
Franklin County 73 4 5.5 76 1 1.3 149 5 3.4
Adams County 165 14 8.5 156 2 1.3 321 16 5.0
Walla Walla (city) 133 7 5.3 131 4 3.1 264 11 4.2
Walla Walla County 170 14 8.2 164 1 0.6 334 15 4.5
Okanogan County 75 8 10.7 64 3 4.7 139 11 7.9
Ferry/Stevens Counties 68 7 10.3 70 4 5.7 138 11 8.0
Total 1747 134 7.7 1693 27 1.6 3440 161 4.7
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K.2.h.2. Analysis by Dichotomous Exposure Variable
Fifty-six (4.5%) of the 1257 participants included in these analyses had a diagnosis of
hyperthyroidism based on the HTDS examination or medical records with supporting documentation (see
Table IX.K-7).  These included 28/580 (4.8%) in the high exposure group and 28/677 (4.1%) in the low
exposure group.  The cumulative incidence of hyperthyroidism was not significantly higher in the high
exposure group (p = 0.074).
Table IX.K-7. Diagnoses of Hyperthyroidism Based on HTDS or Medical Record with Supporting
Documentation, by Exposure Group and Sex 
Female Male Total
Exposure Group No. Cases % No. Cases % No. Cases %
Low 351 22 6.3 326 6 1.8 677 28 4.1
High 298 24 8.1 282 4 1.4 580 28 4.8
Total 649 46 7.1 608 10 1.6 1257 56 4.5
The second alternative criterion for defining cases of hyperthyroidism included all possible cases
(see section IX.K.1 above).  Among the 1257 participants included in these analyses, use of the second
alternative added three cases based on medical records without supporting documentation and five others
based on a report from the participant or his/her CATI respondent, for a total of 64 (5.1%). Since the
number of added cases was small, the logistic regression analysis with adjustment for the effects of sex and
age at HTDS examination gave essentially the same results as that based on the primary definition for
hyperthyroidism.  In particular, the cumulative incidence of hyperthyroidism was not significantly higher in
the high exposure group (p = 0.062).
K.2.i. Confounding and Effect Modification
As described in section VIII above, additional sex-stratified logistic regression models were
investigated to examine the possibility that the primary dose-response results might be influenced by
confounding, and to search for factors that might modify a radiation dose-response.  These analyses were
based on the primary definition of hyperthyroidism; those based on an HTDS diagnosis or on medical
records with documented diagnoses, and on the primary dose estimates.  Table IX.K-8 displays results for
models including sex, age at first exposure to Hanford 131I (prenatal, or < 180 days), age at HTDS
examination, estimated dose from the NTS, history of any cancer other than thyroid, and HTDS interview
type.  
Note that sex was not analyzed as a possible confounder since its effect was already adjusted for in
the sex-stratified model.  None of the other factors in Table IX.K-8 appears to be a confounder: for none
does the adjusted estimate of the regression coefficient differ markedly from the unadjusted estimate.
Therefore, it does not appear that omitting these factors introduces any important bias in the dose-response
results. 
The analyses of effect modification address the question of whether the dose-response might vary
according to other characteristics of the study participants.  This was tested by comparing the estimated
regression coefficients for the groups defined by each covariate.  As shown in Table IX.K-8, the regression
coefficients did not differ significantly between the groups defined by any of the covariates, with the
possible exception of estimated NTS dose.  The estimated regression coefficient was 0.828 with confidence
interval (–0.174, 1.83) for the 1622 participants with estimated NTS dose ≤ 5.3 mGy, compared to –1.18
with confidence interval (–3.58, 1.22) for those with higher estimated NTS doses.  The p-value for
comparing these two slopes, 0.019, should be interpreted with caution in view of the large number of
significance tests that were performed, and of the extensive overlap of the two estimates’ confidence
intervals.
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Table IX.K-8. Confounding and Effect Modification by Sex, Age at Exposure or HTDS 
Examination, Estimated Thyroid Dose from NTS, History of Any Cancer Other
than Thyroid, and Interview Type: Hyperthyroidism
Estimated Dose-Response Coefficient (per Gy)
Covariate Yes / Adjusted for Including Effect Modification
 (0=No, 1=Yes) Total Unadjusted Confounding Group 0 Group 1 P
Female?
1622 /
3191
.346 ± .325
(−.432, 1.12)
Not
Applicable
.282 ± .760
(−1.62, 2.18)
.361 ± .360
(−.538, 1.26) .92
Prenatal
exposure?
1034 /
3191
.346 ± .325
(−.432, 1.12)
.333 ± .328
(−.512, 1.18)
.439 ± .356
(−.501, 1.38)
-.089 ± .774
(−2.13, 1.95) .52
1st exposure
before age 180
days?
1478 /
3191
.346 ± .325
(−.432, 1.12)
.355 ± .329
(−.491, 1.20)
.829 ± .582
(−.706, 2.36)
.136 ± .435
(−1.01, 1.28) .34
Age at exam >
50?
2001 /
3191
.346 ± .325
(−.432, 1.12)
.392 ± .323
(−.441, 1.23)
.249 ± .564
(−1.24, 1.74)
.471 ± .397
(−.577, 1.52) .74
NTS 131I
dose > 5.3 mGy?
1567 /
3189
.346 ± .325
(−.432, 1.12)
.314 ± .334
(−.547, 1.18)
.828 ± .380
(−.174, 1.83)
−1.18 ± .909
(−3.58, 1.22) .019
History of any
cancer other than
thyroid cancer?
248 /
3186
.346 ± .325
(−.432, 1.12)
.384 ± .331
(−.469, 1.24)
.489 ± .345
(−.421, 1.40)
−1.43 ± 2.51
(−8.04, 5.19) .30
Expanded In-
Person Interview?
1212 /
3191
.346 ± .325
(−.432, 1.12)
.463 ± .327
(−.380, 1.31)
.520 ± .547
(−.924, 1.96)
.431 ± .413
(−.659, 1.52) .90
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses, based on sex-
stratified logistic regression models.  P-values reflect the significance of the improved fit for models including confounding or effect
modification, relative to the unadjusted model.
Tables IX.K-9 and IX.K-10 display similar results from analyses including history of medical or
dental x-ray exposure or of occupational exposures as potential confounding or effect modifying factors.
The estimates of the regression coefficient calculated with adjustment for confounding are all close to the
unadjusted estimates.  Thus there was no evidence that a confounding effect of any of these covariates has
obscured a positive dose-response for hyperthyroidism. 
There is no evidence of any statistically significant effect modification by any of the covariates in
Tables  IX.K-9 and IX.K-10, with the possible exception of history of diagnostic x-rays of chest or upper
body, including mammograms (p = 0.031; Table IX.K-9). The estimated dose-response coefficient was
markedly negative (−7.82) for the 352 participants without such histories, and not markedly different from
zero for the majority of participants (0.432 with confidence interval ranging from −0.407 to 1.27).  The
statistical significance of this difference must be interpreted with caution due to the large number of such
comparisons that were performed.  Moreover the difference consists of a very negative dose-response in a
minority of participants. Therefore it does not appear that any of the covariates in Tables IX.K-9 and
IX.K-10 identified a group in which a clearly significant dose-response was present.
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Table IX.K-9. Confounding and Effect Modification by History of Medical and Dental Radiation 
Exposures: Hyperthyroidism
Have You
Estimated Dose-Response Coefficient (per Gy)
Ever Had: Yes / Adjusted for Including Effect Modification
 (0=No, 1=Yes) Total Unadjusted Confounding Group 0 Group 1 P
CAT scan of the
upper body?
775 /
3149
.347 ± .325
(−.430, 1.13)
.349 ± .329
(−.497, 1.20)
.400 ± .354
(−.534, 1.33)
.107± .797
(−2.00, 2.21) .74
Diagnostic x-rays
of the head?
1191 /
3155
.356 ± .324
(−.419, 1.13)
.367 ± .323
(−.467, 1.20)
.149 ± .452
(−1.04, 1.34)
.667 ± .480
(−.598, 1.93) .43
Diagnostic x-rays
of the neck?
966 /
3167
.345 ± .327
(−.439, 1.13)
.348 ± .329
(−.500, 1.20)
.190 ± .511
(−1.16, 1.54)
.464 ± .417
(−.637, 1.57) .68
Diagnostic x-rays
of chest or upper
body, including
mammograms?
2821 /
3173
.345 ± .325
(−.433, 1.12)
.347 ± .325
(−.490, 1.18)
−7.82 ± 5.01
(−21.0, 5.41)
.432 ± .318
(−.407, 1.27) .031
Diagnostic x-rays
of the stomach or
mid-back?
692 /
3120
.310 ± .334
(−.489, 1.11)
.302 ± .334
(−.559, 1.16)
.107 ± .401
(−.952, 1.17)
.945 ± .639
(−.741, 2.63) .28
Barium enema?
825 /
3159
.330 ± .327
(−.454, 1.11)
.332 ± .328
(−.512, 1.18)
.586 ± .360
(−.364, 1.53)
−.478 ± .785
(−2.55, 1.59) .19
Upper GI?
1146 /
3177
.348 ± .324
(−.428, 1.12)
.343 ± .325
(−.494, 1.18)
.541 ± .381
(−.464, 1.55)
−.054 ± .606
(−1.65, 1.54) .39
Intravenous
pyelogram?
398 /
3157
.322 ± .330
(−.468, 1.11)
.322 ± .332
(−.533, 1.18)
.374 ± .346
(−.539, 1.29)
−.082 ± 1.01
(−2.74, 2.57) .66
Fluoroscopy of 
the upper body?
246 /
3161
.329 ± .329
(−.458, 1.12)
.338 ± .330
(−.512, 1.19)
.382 ± .336
(−.506, 1.27)
−.250 ± 1.30
(−3.68, 3.18) .63
Nuclear scan
(excluding thyroid
scan)?
217 /
3162
.379 ± .322
(−.391, 1.15)
.378 ± .321
(−.449, 1.20)
.399 ± .323
(−.452, 1.25)
−.481 ± 2.20
(−6.29, 5.33) .68
Dental x-rays that
did not usually
include a lead
shield over the
neck area?
1648 /
3191
.346 ± .325
(−.432, 1.12)
.342 ± .327
(−.499, 1.18)
.561 ± .422
(−.554, 1.68)
.055 ± .539
(−1.37, 1.48) .45
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses, based on sex-
stratified logistic regression models.  P-values reflect the significance of the improved fit for models including confounding or effect
modification, relative to the unadjusted model.
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Table IX.K-10. Confounding and Effect Modification by Occupational History: Hyperthyroidism
Have You Ever
Worked in Any of
Estimated Dose-Response Coefficient (per Gy)
the Following: Yes / Adjusted for Including Effect Modification
 (0=No, 1=Yes) Total Unadjusted Confounding Group 0 Group 1 P
Any metal
industry?
238 /
3191
.346 ± .325
(−.432, 1.12)
.351 ± .325
(−.485, 1.19)
.329 ± .332
(−.546, 1.20)
1.12 ± 1.85
(−3.76, 6.00) .68
Any nuclear
facility?
371 /
3191
.346 ± .325
(−.432, 1.12)
.372 ± .326
(−.468, 1.21)
.372 ± .341
(−.528, 1.27)
.366 ± 1.10
(−2.54, 3.27) 1.00
Any other industry
or occupation
where you may
have been exposed
to radioactive
materials or
x-rays?
442 /
3191
.346 ± .325
(−.432, 1.12)
.355 ± .325
(−.481, 1.19)
.265 ± .372
(−.716, 1.25)
.681 ± .648
(−1.03, 2.39) .59
Any of the above
industries or
occupations?
892 /
3191
.346 ± .325
(−.432, 1.12)
.352 ± .325
(−.486, 1.19)
.320 ± .389
(−.706, 1.35)
.430 ± .592
(−1.13, 1.99) .88
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses, based on sex-
stratified logistic regression models.  P-values reflect the significance of the improved fit for models including confounding or effect
modification, relative to the unadjusted model.
Table IX.K-11 displays the results of analyses of possible confounding or effect modification by
smoking variables.  There was no evidence that the dose-response was significantly confounded by either
smoking variable, or that there was a dose-response that differed significantly according to smoking
history.
Table IX.K-11. Confounding and Effect Modification by Smoking: Hyperthyroidism
Have You Ever
Smoked Any of
Estimated Dose-Response Coefficient (per Gy)
the Following: Yes / Adjusted for Including Effect Modification
(0=No, 1=Yes) Total Unadjusted Confounding Group 0 Group 1 P
Cigarettes
(unfiltered or
filtered)?
1854 /
3183
.344 ± .326
(−.436, 1.12)
.333 ± .325
(−.505, 1.17)
.296 ± .613
(−1.32, 1.91)
.347 ± .382
(−.661, 1.35) .94
Any of cigarettes,
cigar or pipe?
1900 /
3183
.344 ± .326
(−.436, 1.12)
.333 ± .325
(−.505, 1.17)
.294 ± .612
(−1.32, 1.91)
.349 ± .383
(−.661, 1.36) .94
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses, based on sex-
stratified logistic regression models.  P-values reflect the significance of the improved fit for models including confounding or effect
modification, relative to the unadjusted model.
K.2.j. Uncertainty
The estimated slopes of the sex-stratified linear dose-response model for hyperthyroidism are
shown in Figure IX.K-1 for each of the 100 dose realizations produced by the CIDER model.  The
confidence intervals in that figure are calculated at the 98.33% confidence level, i.e., are adjusted by the
Bonferroni technique for the simultaneous estimation of the slope and two sex-specific background rates.
While the point estimate of the slope is greater than 0 for 81 of the 100 realizations, the confidence interval
includes 0 for all 100 realizations.  Also shown in Figure IX.K-1 (to the right of realization 100) are the
estimates and confidence intervals calculated using (from left to right) the median, geometric mean and
mean of each participant's 100 dose realizations. In summary, for none of the 100 realizations of the
estimated doses was there a statistically significant dose-response, although the estimated slope was greater
than 0 for most realizations.
Figure IX.K-1. Plot of estimated Slope and 95% CI by Dose Realization: Hyperthyroidism
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Figure IX.K-2 displays the distribution of the 5000 logistic regression coefficient estimates
obtained by the simulation procedures described in section VIII.C.2.b.3 above. It is evident from the figure
that most of the estimates were between about –1.0 and 1.5. The estimate was less than or equal to 0 for
1193 of the 5000 replications, implying an empirical one-tailed p-value of 0.24.  The median estimate was
0.33, and the upper and lower percentiles corresponding to the Bonferroni-adjusted 95% confidence
interval were –0.97 and 1.27.  These may be compared to the estimates of 0.35 with the confidence interval
(−0.43, 1.12) obtained using the median dose estimate without adjustment for uncertainty. Thus, this
method of adjusting the estimated logistic regression coefficient for the uncertainty in the dose estimates
did not provide evidence that the cumulative incidence of hypothyroidism increased with increasing dose.
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Figure IX.K-2. Distribution of Simulation Estimates of Logistic Regression Coefficient: 
Hyperthyroidism
slope sample: 5000
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L. Multinodular Thyroid Gland
L.1. Occurrence of Multinodular Thyroid Gland
The primary and alternative definitions for multinodular thyroid gland were as follows:
• Primary definition: HTDS evaluation (95 cases)
• Alternative definition #1: HTDS evaluation or medical records (114 cases)
• Alternative definition #2: Any diagnosis or participant/respondent report (115 cases).
Of the 3440 living evaluable participants, 95 (2.8%) had a diagnosis of multinodular thyroid gland
based on the HTDS evaluation (Table IX.L-1).  An additional 19 (0.6%) living evaluable participants had a
diagnosis of multinodular thyroid gland based on medical records, and 1 had a participant/respondent report
of multinodular thyroid gland.  
Table IX.L-1. Basis for Diagnosis of Multinodular Thyroid Gland, by Sex
      Female     Male         Total
Basis for Diagnosis No. % No. % No. %
Yes 90 5.2 25 1.5 115 3.3
HTDS evaluation 73 4.2 22 1.3 95 2.8
Medical record 16 0.9 3 0.2 19 0.6
Participant/respondent report 1 0.1 0 -- 1 0.0
No 1656 94.8 1668 98.5 3324 96.6
Unknown 1 0.1 000 -- 1 0.0
Total 1747 100.0 1693 100.0 3440 100.0
      
       
       
 
One living evaluable participant was classified as “unknown” with regard to diagnosis of
multinodular thyroid gland.  This participant did not have medical record or participant/respondent report
indicating multinodular thyroid gland, and did not have an HTDS evaluation due to physician disagreement
on the diagnosis, with one physician assigning a diagnosis of multinodular gland while the other assigned a
diagnosis of solitary nodule.  This participant was included as a non-case in analyses of the dose-response
for multinodular thyroid gland.
As shown in Table IX.L-2, the most common etiology of multinodular thyroid gland was other
(65.2%), followed by Hashimoto’s thyroiditis (32.2%), and hypothyroidism (13.0%).
Table IX.L-2. Etiologies of Multinodular Thyroid Gland, by Sex
    Female      Male        Total
Etiology No. % No. % No. %
Graves disease 3 3.3 0 -- 3 2.6
Hashimoto’s thyroiditis 30 33.3 7 28.0 37 32.2
Hypothyroidism 14 15.6 1 4.0 15 13.0
Other 56 62.2 19 76.0 75 65.2
Total with multinodular thyroid gland 90 100.0 25 100.0 115 100.0
Note: A participant can/may have more than one etiology
Of the 75 with an other etiology for multinodular thyroid gland, 47 (62.7%) were
unknown/uncertain, 11 (14.7%) were colloid nodule, and 10 (13.3%) were probable/possible Hashimoto’s
thyroiditis (Table IX.L-3).
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Table IX.L-3. “Other” Etiologies of Multinodular Thyroid Gland, by Sex
      Female    Male              Total
Other Etiologies No. % No. % No. %
Unknown/uncertain 37 66.1 10 52.6 47 62.7
Probable/possible Hashimoto’s
thyroiditis
7 12.5 3 15.8 10 13.3
Colloid nodules 6 10.7 5 26.3 11 14.7
Colloid goiter 1 1.8 1 5.3 2 2.7
Papillary/follicular cancer 2 3.6 0 -- 2 2.7
Possible hypothyroidism 1 1.8 0 -- 1 1.3
Probable medical radiation 1 1.8 0 -- 1 1.3
Multiple etiologies* 1 1.8 0 -- 1 1.3
Total with an other etiology of
multinodular thyroid gland
56 100.0 19 100.0 75 100.0
* Includes: 1) adenomatous nodules, 2) focus of papillary cancer, 3) focus of Hashimoto’s
L.2. Analysis of Multinodular Thyroid Gland Risk
L.2.a. Primary Analysis
Of the 95 living evaluable participants with a diagnosis of multinodular thyroid gland based on the
HTDS examination, 10 were out-of-area participants for whom the CIDER program could not calculate
dose estimates.  The proportions with multinodular thyroid gland are shown by sex, dose category and basis
for diagnosis in Table IX.L-4. 
Table IX.L-4. Diagnoses of Multinodular Thyroid Gland by Sex, Estimated Dose, and Basis for
Diagnosis
A.  Female
 Thyroid
Radiation
Dose
(mGy)
Living
Evaluable
Female
Primary Definition:
Cases Based on
HTDS Examination
1st Alternative Definition
Cases Based on HTDS
Examination or Medical
Records
2nd Alternative Definition:
Cases Based on Any
Diagnosis or Participant or
CATI Report
 No. No. % No.            % No.        %
Out of Area 125 9 7.2 9 7.2 9 7.2
< 10 182 10 5.5 10 5.5 10 5.5
10-49 320 13 4.1 16 5.0 16 5.0
50-99 313 12 3.8 17 5.4 17 5.4
100-149 220 10 4.5 12 5.5 12 5.5
150-199 126 3 2.4 3 2.4 3 2.4
200-299 139 3 2.2 7 5.0 8 5.8
300-399 144 6 4.2 6 4.2 6 4.2
400-999 171 7 4.1 9 5.3 9 5.3
1000+ 7 0 -- 0 -- 0 --
Total 1747 73 4.2 89 5.1 90 5.2
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Table IX.L-4. Diagnoses of Multinodular Thyroid Gland by Sex, Estimated Dose, and Basis for 
Diagnosis  (continued)
B.  Male
 Thyroid
Radiation
Dose
(mGy)
Living
Evaluable
Male
Primary Definition:
Cases Based on
HTDS Examination
1st Alternative Definition
Cases Based on HTDS
Examination or Medical
Records
2nd Alternative Definition:
Cases Based on Any
Diagnosis or Participant or
CATI Report
No. No. % No.          % No.        %
Out of Area 124 1 0.8 2 1.6 2 1.6
< 10 186 4 2.2 4 2.2 4 2.2
10-49 314 5 1.6 5 1.6 5 1.6
50-99 310 4 1.3 4 1.3 4 1.3
100-149 171 2 1.2 3 1.8 3 1.8
150-199 109 1 0.9 1 0.9 1 0.9
200-299 148 2 1.4 2 1.4 2 1.4
300-399 160 2 1.3 2 1.3 2 1.3
400-999 154 1 0.6 2 1.3 2 1.3
1000+ 17 0 -- 0 -- 0 --
Total 1693 22 1.3 25 1.5 25 1.5
 
Parameter estimates for the linear dose-response model based on the 3191 in-area participants are
shown in Table IX.L-5 below. Based on maximum likelihood analysis of the sex-stratified linear
probability model, and using the primary dose estimates, the estimated slope B was –0.006 per Gy; row 1
of Table IX.L-5).  The lower limit of the Bonferroni-adjusted 95% confidence interval was not estimated,
but the upper limit was 0.014 per Gy, and the cumulative incidence of multinodular thyroid gland did not
increase significantly with increasing dose (p = 0.88). The corresponding estimated background rates for
diagnosis of multinodular thyroid gland were 0.040 with confidence interval ( 0.027, 0.053) for women and
0.014 with confidence interval (0.006, 0.023) for men.  When the model was fit by the method of least
squares, the estimated slope using either ungrouped or grouped data was even more negative than the
maximum likelihood estimate (Table IX.L-5, rows 2 and 3), thereby providing no evidence that risk of
multinodular thyroid gland increased with increasing dose (p = 0.89 and 0.83).
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Table IX.L-5. Summary of Dose-Response Results for Diagnoses of Multinodular Thyroid Gland
Row Outcome
Dose
Response
Model
Dose
Estimates
Exclusions/
Additional
Inclusions
Method
of
Analysis
Estimated Background Rates
Female              Male
Estimated Slope of
Dose-Response
(per Gy)
Statistical Significance
of Dose-Response
(one-tailed p-value)
1.
Primary definition
(HTDS evaluation)
Linear Primary None MLE
.040 ± .005
(.027, .053)
.014 ± .004
(.006, .023)
-.006 ± .016
(NE, .014)
0.88
2. Primary definition Linear Primary None LSU
.042 ± .005
(.031, .053)
.016 ± .005
(.005, .027)
-.016 ± .013
(-.046, .015)
0.89
3. Primary definition Linear Primary None LSG
.042 ± .005
(.031, .053)
.016 ± .005
(.004, .027)
-.014 ± .015
(-.049, .021)
0.83
4.
Alternative def. #1
(HTDS or medical
record)
Linear Primary None MLE
.050 ± .006
(.037, .065)
.016 ± .004
(.006, .025)
-.006 ± .016
(NE, .018)
0.86
5.
Alternative def. #2 
(Any diagnosis or
participant/respondent
report)
Linear Primary None MLE
.051 ± .006
(.037, .065)
.016 ± .004
(.006, .025)
-.006 ± .016
(NE, .018)
0.86
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, “>”
indicates that the upper confidence limit is greater than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are
not given for estimated background rates from logistic regression model.  
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
Okanogan, F/S = Ferry/Stevens, OOA = out of area
Table continued on next page
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Table IX.L-5. Summary of Dose-Response Results for Diagnoses of Multinodular Thyroid Gland (continued)
Row Outcome
Dose-
Response
Model
Dose
Estimates
Exclusions/
Additional
Inclusions
Method
of
Analysis
Estimated Background Rates
    Female               Male
Estimated Slope of
Dose-Response
(per Gy)
Statistical Significance
of Dose-Response
(one-tailed p-value)
6. Primary definition LQ Primary None LSU
.043 ± .005
(.031, .055)
.017 ± .005
(.004, .029)
Lin: −.021 ± .022
(−.075, .032)
Quad: .005 ± .014
(−.031, .040)
Quad: 0.75
7. Primary definition Logistic Primary None MLE
.045
(.031, .064)
.015
(.009, .027)
–.82 ± .65
(-2.37, .72)
0.92
8. Primary definition Linear Primary
Exclude dose
> 1000 mGy
MLE
.042 ± .005
(.029, .055)
.016 ± .004
(.007, .025)
-.016 ± .014
(NE, >.016)
0.92
9. Primary definition Linear Primary
Exclude dose
> 400 mGy
MLE
.042 ± .006
(.028, .056)
.017 ± .004
(.007, .028)
-.025 ± .023
(<-.059, .035)
0.86
10. Primary definition Linear Primary
Exclude 
Ok and F/S
geostrata
MLE
.039 ± .006
(.026, .053)
.015 ± .004
(.005, .024)
-.006 ± .016
(NE, .015)
0.88
11. Primary definition Linear Alt. #1 None MLE
.040 ± .005
(.027, .053)
.014 ± .004
(.004, .024)
-.006 ± .018
(NE, .010)
0.92
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, “>”
indicates that the upper confidence limit is greater than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are
not given for estimated background rates from logistic regression model.  
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
Okanogan, F/S = Ferry/Stevens, OOA = out of area
Table continued on next page
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Table IX.L-5. Summary of Dose-Response Results for Diagnoses of Multinodular Thyroid Gland (continued)
Row Outcome
Dose-
Response
Model
Dose
Estimates
Exclusions/
Additional
Inclusions
Method
of
Analysis
Estimated Background Rates
    Female               Male
Estimated Slope of
Dose-Response
(per Gy)
Statistical Significance
of Dose-Response
(one-tailed p-value)
12. Primary definition Linear Alt. #2 None MLE
.040 ± .005
(.028, .053)
.014 ± .004
(.006, .023)
-.006 ± .010
(NE, .015)
0.86
13. Primary definition Linear Primary
Include OOA
(scoping
analysis #1)
MLE
.043 ± .005
(.030, .055)
.014 ± .003
(.006, .022)
-.006 ± .015
(NE, .014)
0.88
14. Primary definition Linear Primary
Include OOA
(scoping
analysis #2)
MLE
.043 ± .005
(.030, .055)
.014 ± .003
(.006, .022)
-.006 ± .015
(NE, >.013)
0.88
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, “>”
indicates that the upper confidence limit is greater than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are
not given for estimated background rates from logistic regression model. 
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
Okanogan, F/S = Ferry/Stevens, OOA = out of area
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L.2.b. Alternative Definitions for Diagnosis of Multinodular Thyroid Gland 
Two alternative definitions for cases of multinodular thyroid gland were considered.  The first
alternative added 19 cases with diagnoses based on medical records, for a total of 114 cases.  The second
added a single case based solely on a report from the participant or his/her CATI respondent, for a total of
115 cases.  This last case had an estimated dose of 254 mGy.    
As shown in rows 4 and 5 of Table IX.L-5, the slope of the dose-response in the sex-stratified
linear model estimated for both alternative definitions of multinodular thyroid gland were nearly identical
to the estimate based on the primary definition (estimated slope –0.006 per Gy with Bonferoni-adjusted
95% upper confidence limit 0.018 per Gy).  Thus for neither alternative definition did the cumulative
incidence of multinodular thyroid gland increase significantly with increasing dose (p = 0.86 for both
alternatives).
L.2.c. Alternative Dose-Response Functions 
As shown in row 6 of Table IX.L-5, the estimated regression coefficient for the dose-squared term
in the linear-quadratic dose-response model [5] was 0.005 with Bonferroni-adjusted 95% confidence
interval ranging from –0.031 to 0.040.  Thus the addition of a quadratic term did not significantly improve
the fit of the model (p = 0.75).
In the analysis of multinodular thyroid gland based on the HTDS examination, i.e., the primary
criterion for defining cases with multinodular thyroid gland, the regression parameter for the effect of dose
in the sex-stratified logistic regression model [2] was estimated as –0.82 with Bonferroni-adjusted 95%
confidence interval ranging from -2.37 to 0.72 (Table IX.L-5, row 7).  Thus the cumulative incidence of
multinodular thyroid gland did not increase significantly with increasing dose (p = 0.92).
L.2.d. Effect of Excluding Participants in High Dose Categories
Rows 8 and 9 of Table IX.L-5 show the effect of excluding patients in high dose categories from
the analysis of the sex-stratified linear dose-response model.  When participants with estimated dose >
1000 mGy were excluded from the analysis, the estimated slope of the dose-response decreased to –0.016
per Gy, providing no evidence that the cumulative incidence of multinodular gland increased with
increasing dose (p = 0.92).   Similarly, when participants with estimated dose > 400 mGy were excluded,
the estimated slope B was even more negative (–0.025, with Bonferroni-adjusted 95% confidence interval
ranging from less than –0.059 to 0.035), providing no evidence that the cumulative incidence increased
with increasing dose (p = 0.86).
L.2.e. Effect of Excluding Okanogan and Ferry/Stevens Geostrata 
When participants in the Ferry/Stevens geostrata were excluded, the estimated slope B was
virtually unchanged (–0.006 per Gy, Table IX.L-5, row 10), providing no evidence that the cumulative
incidence of multinodular thyroid gland increased with increasing dose (p = 0.88).
L.2.f. Analysis of Multinodular Thyroid Gland in Relation to Alternative Dose Estimates
Rows 11 and 12 of Table IX.L-5 show that the estimated dose-response was almost unchanged
when the two alternative sets of dose estimates were used in place of the primary doses.  In particular there
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was no evidence that cumulative incidence of multinodular thyroid gland increased with increasing doses
from either of the alternative dose sets (p = 0.92 and p= 0.86 for alternative dose sets 1 and 2, respectively).
L.2.g. Scoping Analysis Regarding Out-of-Area Participants
See section VIII.C.1.a.3 for a description of the scoping analyses that were performed to assess the
possible impact of including the 249 out-of-area participants.  As summarized in rows 13 and 14 of Table
IX.L-5, in neither scoping analysis did the cumulative incidence of multinodular thyroid gland increase
significantly with increasing dose (p = 0.88 for both scoping analyses).
L.2.h. Analysis of Multinodular Thyroid Gland in Relation to Alternative
Representations of Exposure
In the analyses by geostratum and by dichotomous exposure variable, the sex and age-adjusted
comparisons of cumulative incidence were performed as described in section VIII.C.2.a.2.
L.2.h.1. Analysis by Geostratum
As shown in Table IX.L-6, the proportions of participants with multinodular thyroid gland (from
the HTDS examination) ranged from 6/75 (8.0%) in the Okanogan geostratum to 0/179 (0%) in the
Richland geostratum for women, and from 5/156 (3.2%) in the Adams geostratum to 0/70 (0%) in the
Ferry/Stevens geostratum for men.  The heterogeneity among the nine geostrata was not statistically
significant (p=0.058).  The proportions with multinodular thyroid gland were somewhat higher for women
in the Okanogan and Ferry/Stevens geostrata (7.0%) compared to the other strata (3.9%), but this was not
the case for men (0.7% for Okanogan and Ferry/Stevens versus 1.3% for the others, p = 0.29).
Table IX.L-6. Diagnoses of Multinodular Thyroid Gland Based on the HTDS Evaluation,
by Geostratum and Sex 
Female Male Total
Geostratum No. Cases % No. Cases % No. Cases %
Richland 179 0 -- 173 4 2.3 352 4 1.1
Pasco/Kennewick 508 17 3.3 501 2 0.4 1009 19 1.9
Benton County 376 16 4.3 358 3 0.8 734 19 2.6
Franklin County 73 2 2.7 76 2 2.6 149 4 2.7
Adams County 165 8 4.8 156 5 3.2 321 13 4.0
Walla Walla (city) 133 10 7.5 131 1 0.8 264 11 4.2
Walla Walla County 170 10 5.9 164 4 2.4 334 14 4.2
Okanogan County 75 6 8.0 64 1 1.6 139 7 5.0
Ferry/Stevens Counties 68 4 5.9 70 0 -- 138 4 2.9
Total 1747 73 4.2 1693 22 1.3 3440 95 2.8
L.2.h.2. Analysis by Dichotomous Exposure Variable
Forty-six (3.7%) of the 1257 participants included in these analyses had a diagnosis of
multinodular thyroid gland based on the HTDS examination (see Table IX.L-7).  These included 19/580
(3.3%) in the high exposure group and 27/677 (4.0%) in the low exposure group.  Thus the cumulative
incidence of multinodular thyroid gland was not significantly higher in the high exposure group (p = 0.74).
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Table IX.L-7. Diagnoses of Multinodular Thyroid Gland Based on HTDS Examination, by
Exposure Group and Sex 
Female Male Total
Exposure Group No. Cases % No. Cases % No. Cases %
Low 351 23 6.6 326 4 1.2 677 27 4.0
High 298 16 5.4 282 3 1.1 580 19 3.3
Total 649 39 6.0 608 7 1.2 1257 46 3.7
L.2.i. Confounding and Effect Modification
As described in section VIII above, additional sex-stratified logistic regression models were
investigated to examine the possibility that the primary dose-response results might be influenced by
confounding, and to search for factors that might modify a radiation dose-response.  These analyses were
based on the primary definition of multinodular thyroid gland  (HTDS diagnosis), and on the primary dose
estimates.  Table IX.L-8 displays results for models including sex, age at first exposure to Hanford 131I
(prenatal, or < 180 days), age at HTDS examination, estimated dose from the NTS, history of any cancer
other than thyroid, and HTDS interview type.  
Note that sex was not analyzed as a possible confounder since its effect was already adjusted for in
the sex-stratified model.  None of the other factors in Table IX.L-8 appears to be a confounder: for none
does the adjusted estimate of the regression coefficient differ markedly from the unadjusted estimate.
Therefore, it does not appear that omitting these factors introduces any important bias in the dose-response
results. 
The analyses of effect modification address the question of whether the dose-response might vary
according to other characteristics of the study participants.  This was tested by comparing the estimated
regression coefficients for the groups defined by each covariate.  As shown in Table IX.L-8, the regression
coefficients did not differ significantly between the groups defined by any of the covariates.   For two
covariates the effect modification approached statistical significance: age at first exposure to Hanford’s 131I
within the HEDR domain (p = 0.061), and estimated NTS dose (p = 0.053).  However, for neither covariate
was there evidence of a significant dose-response within a subgroup of participants.  In fact for both of
these covariates, the difference was due primarily to a very negative regression coefficient in one group.
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Table IX.L-8. Confounding and Effect Modification by Sex, Age at Exposure or HTDS
Examination, Estimated Thyroid Dose from NTS, History of Any Cancer Other
than Thyroid, and Interview Type: Multinodular Thyroid Gland
Estimated Dose-Response Coefficient (per Gy)
Covariate Yes / Adjusted for Including Effect Modification
 (0=No, 1=Yes) Total Unadjusted Confounding Group 0 Group 1 P
Female?
1622 /
3191
−.824 ± .647
(−2.37, .724)
Not
Applicable
−1.97 ± 1.57
(−5.89, 1.94)
−.513 ± .698
(−2.26, 1.23) .37
Prenatal
exposure?
1034 /
3191
−.824 ± .647
(−2.37, .724)
−.862 ± .656
(−2.55, .828)
−.740 ± .751
(−2.72, 1.24)
−1.21 ± 1.33
(−4.72, 2.30) .76
1st exposure
before age 180
days?
1478 /
3191
−.824 ± .647
(−2.37, .724)
−.840 ± .653
(−2.52, .843)
.319 ± .824
(−1.86, 2.49)
−2.42 ± 1.25
(−5.72, .874) .052
Age at exam >
50?
2001 /
3191
−.824 ± .647
(−2.37, .724)
−.672 ± .641
(−2.32, .978)
−.970 ± 1.16
(−4.02, 2.08)
−.521 ± .774
(−2.56, 1.52) .74
NTS 131I
dose > 5.3 mGy?
1567 /
3189
−.824 ± .647
(−2.37, .724)
−.750 ± .656
(−2.44, .941)
.063 ± .681
(−1.73, 1.86)
−2.93 ± 1.54
(−7.00, 1.15) .053
History of any
cancer other than
thyroid cancer?
248 /
3186
−.823 ± .646
(−2.37, .724)
−.828 ± .647
(−2.50, .839)
−.686 ± .670
(−2.45, 1.08)
−2.52 ± 2.84
(−10.0, 4.98) .48
Expanded In-
Person Interview?
1212 /
3191
−.824 ± .647
(−2.37, .724)
−.549 ± .640
(−2.20, 1.10)
−.366 ± .796
(−2.47, 1.73)
−.870 ± 1.13
(−3.85, 2.11) .71
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses, based on sex-
stratified logistic regression models.  P-values reflect the significance of the improved fit for models including confounding or effect
modification, relative to the unadjusted model.
Tables IX.L-9 and IX.L-10 display similar results from analyses including history of medical or
dental x-ray exposure or of occupational exposure as potential confounding or effect modifying factors.
The estimates of the regression coefficient calculated with adjustment for confounding are all close to the
unadjusted estimates.  Thus there was no evidence that a confounding effect of any of these covariates has
obscured a positive dose-response for hyperthyroidism. 
There is no evidence of any statistically significant effect modification by any of the covariates in
Tables IX.L-9 and IX.L-10, with the possible exception of history of diagnostic x-rays of chest or upper
body, including mammograms (p = 0.033; Table IX.L-9). The estimated dose-response coefficient was
markedly negative (−13.3) for the 352 participants without such histories, but closer to zero for the majority
of participants (−0.568).  The statistical significance of this difference must be interpreted with caution due
to the large number of such comparisons that were performed.  Moreover the difference consists of a very
negative dose-response in a minority of participants, compared to a less negative coefficient in the
remaining participants. Therefore it does not appear that any of the covariates in Tables IX.L-9 and IX.L-10
identified a group in which a clearly significant dose-response was present.
HTDS Final Report: June 21, 2002 – Section IX.L page 398
Table IX.L-9. Confounding and Effect Modification by History of Medical and Dental Radiation
Exposures: Multinodular Thyroid Gland
Have You
Estimated Dose-Response Coefficient (per Gy)
Ever Had: Yes / Adjusted for Including Effect Modification
 (0=No, 1=Yes) Total Unadjusted Confounding Group 0 Group 1 P
CAT scan of the
upper body?
775 /
3149
−.895 ± .659
(−2.47, .684)
−.866 ± .656
(−2.56, .823)
−1.19 ± .791
(−3.28, .895)
.182 ± 1.27
(−3.17, 3.54) .37
Diagnostic x-rays
of the head?
1191 /
3155
−.754 ± .641
(−2.29, .780)
−.704 ± .636
(−2.34, .934)
−.647 ± .835
(−2.85, 1.56)
−.779 ± .98
(−3.36, 1.80) .62
Diagnostic x-rays
of the neck?
966 /
3167
−.813 ± .645
(−2.36, .731)
−.794 ± .643
(−2.45, .864)
−.688 ± .785
(−2.76, 1.38)
−1.00 ± 1.15
(−4.03, 2.03) .82
Diagnostic x-rays
of chest or upper
body, including
mammograms?
2821 /
3173
−.824 ± .646
(−2.37, .723)
−.785 ± .645
(−2.45, .876)
−13.3 ± 8.01
(−34.4, 7.83)
−.568 ± .62
(−2.21, 1.08) .033
Diagnostic x-rays
of the stomach or
mid-back?
692 /
3120
−.885 ± .663
(−2.47, .702)
−.900 ± .662
(−2.61, .807)
−.729 ± .686
(−2.54, 1.08)
−2.28 ± 2.23
(−8.17, 3.60) .48
Barium enema?
825 /
3159
−.790 ± .644
(−2.33, .752)
−.789 ± .644
(−2.45, .871)
−.473 ± .704
(−2.33, 1.38)
−1.79 ± 1.44
(−5.58, 2.00) .39
Upper GI?
1146 /
3177
−.818 ± .646
(−2.36, .727)
−.821 ± .645
(−2.48, .841)
−.316 ± .706
(−2.18, 1.55)
−1.98 ± 1.29
(−5.38, 1.41) .24
Intravenous
pyelogram?
398 /
3157
−.896 ± .662
(−2.48, .689)
−.888 ± .663
(−2.59, .819)
−587 ± .658
(−2.32, 1.15)
−4.13 ± 2.86
(−11.7, 3.42) .16
Fluoroscopy of 
the upper body?
246 /
3161
−.876 ± .659
(−2.45, .701)
−.880 ± .659
(−2.58, .818)
−.672 ± .657
(−2.41, 1.06)
−4.68 ± 3.96
(−15.1, 5.75) .22
Nuclear scan
(excluding thyroid
scan)?
217 /
3162
−.888 ± .660
(−2.47, .692)
−.868 ± .660
(−2.57, .832)
−.727 ± .654
(−2.45, .999)
−6.45 ± 6.18
(−22.8, 9.84) .24
Dental x-rays that
did not usually
include a lead
shield over the
neck area?
1648 /
3191
−.824 ± .647
(−2.37, .724)
−.828 ± .649
(−2.50, .842)
−2.36 ± 1.16
(−5.43, .709)
.134 ± .67
(−1.64, 1.91) .057
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses, based on sex-
stratified logistic regression models.  P-values reflect the significance of the improved fit for models including confounding or effect
modification, relative to the unadjusted model.
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Table IX.L-10. Confounding and Effect Modification by Occupational History: Multinodular
Thyroid Gland
Have You Ever
Worked in Any of
Estimated Dose-Response Coefficient (per Gy)
the Following? Yes / Adjusted for Including Effect Modification
 (0=No, 1=Yes) Total Unadjusted Confounding Group 0 Group 1 P
Any metal
industry?
238 /
3191
−.824 ± .647
(−2.37, .724)
−.814 ± .647
(−2.48, .852)
−.814 ± .647
(−2.52, .892) --* --
Any nuclear
facility?
371 /
3191
−.824 ± .647
(−2.37, .724)
−.774 ± .649
(−2.45, .897)
−.753 ± .686
(−2.56, 1.06)
−.947 ± 1.98
(−6.17, 4.28) .93
Any other industry
or occupation
where you may
have been exposed
to radioactive
materials or
x-rays?
442 /
3191
−.824 ± .647
(−2.37, .724)
−.876 ± .651
(−2.55, .802)
−.753 ± .664
(−2.50, .998)
−2.82 ± 3.22
(−11.3, 5.68) .48
Any of the above
industries or
occupations?
892 /
3191
−.824 ± .647
(−2.37, .724)
−.746 ± .645
(−2.41, .914)
−.570 ± .674
(−2.35, 1.21)
−1.95 ± 2.02
(−7.29, 3.39) .49
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses, based on sex-
stratified logistic regression models.  P-values reflect the significance of the improved fit for models including confounding or effect
modification, relative to the unadjusted model.
* Dose-response coefficient not estimable as none of the living evaluable in-area participants with a diagnosis of multinodular thyroid
gland ever worked in any metal industry.
Table IX.L-11 displays the results of analyses of possible confounding or effect modification by
smoking variables.  There was no evidence that the dose-response was significantly confounded by either
smoking variable, or that there was a dose-response that differed significantly according to smoking
history.
Table IX.L-11. Confounding and Effect Modification by Smoking: Multinodular Thyroid Gland
Have You Ever
Smoked Any of
Estimated Dose-Response Coefficient (per Gy)
the Following: Yes / Adjusted for Including Effect Modification
(0=No, 1=Yes) Total Unadjusted Confounding Group 0 Group 1 P
Cigarettes
(unfiltered or
filtered)?
1854 /
3183
−.805 ± .647
(−2.35, .744)
−.804 ± .647
(−2.47, .863)
−.053 ± .822
(−2.22, 2.12)
−1.66 ± 1.04
(−4.41, 1.09) .22
Any of cigarettes,
cigar or pipe?
1900 /
3183
−.805 ± .647
(−2.35, .744)
−.804 ± .647
(−2.47, .863)
.036 ± .814
(−2.11, 2.18)
−1.75 ± 1.05
(−4.51, 1.01) .17
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses, based on sex-
stratified logistic regression models.  P-values reflect the significance of the improved fit for models including confounding or effect
modification, relative to the unadjusted model.
L.2.j. Uncertainty
The estimated slopes of the sex-stratified linear dose-response model for multinodular thyroid
gland are shown in Figure IX.L-1 for each of the 100 dose realizations produced by the CIDER model.  The
confidence intervals in that figure are calculated at the 98.33% confidence level, i.e., are adjusted by the
Bonferroni technique for the simultaneous estimation of the slope and two sex-specific background rates.
The point estimate of the slope was greater than 0 for only 8 of the 100 realizations, and the confidence
interval included 0 for all 100 realizations.  Also shown in Figure IX.L-1 (to the right of realization 100)
are the estimates and confidence intervals calculated using (from left to right) the median, geometric mean
and mean of each participant's 100 dose realizations. In summary, for none of the 100 realizations of the
estimated doses was there a statistically significant dose-response, and for most of the realizations the
estimated slope was less than 0.
Figure IX.L-1. Plot of Estimated Slope and 95% CI by Dose Realization: Multinodular Thyroid 
Gland
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Figure IX.L-2 displays the distribution of the 5000 estimates of the logistic regression coefficient
obtained by the simulation procedures described in section VIII.C.2.b.3 above. It is evident from the figure
that most of the estimates were between about –5.0 and 1.0. The estimate was less than or equal to 0 for
4770 of the 5000 replications, implying an empirical one-tailed p-value of 0.89.  The median estimate was
−1.41, and the upper and lower percentiles corresponding to the Bonferroni-adjusted 95% confidence
interval were –4.37 and 0.39.  These may be compared to the estimate of −0.82 with confidence interval
(−2.37, 0.72) obtained using the median dose estimates without adjustment for uncertainty. Thus, this
method of adjusting the estimated logistic regression coefficient for the uncertainty in the dose estimates
did not provide evidence that the cumulative incidence of multinodular thyroid gland increased with
increasing dose.
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Figure IX.L-2. Distribution of Simulation Estimates of Logistic Regression Coefficient: 
Multinodular Thyroid Gland
slope sample: 5000
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M. Simple Goiter
M.1. Occurrence of Simple Goiter
The primary and alternative definitions for simple goiter were as follows:
• Primary definition: HTDS evaluation (14 cases)
• Alternative definition #1: HTDS evaluation or medical records (42 cases)
• Alternative definition #2: Any diagnosis or participant/respondent report (70 cases).
The diagnosis of simple goiter was uncommon, with only 14 (0.4%) living evaluable participants
having this diagnosis based on HTDS evaluation, 28 (0.8%) based on medical records, and 28 (0.8%) based
on a report by the participant or his/her CATI respondent (Table IX.M-1). It should be noted that since this
outcome is based solely on physical examination, diagnoses based on medical records are subject to wide
variability since exams were done by many different types of providers with differing levels of consistency
and frequency and differing criteria for simple goiter. Simple goiter was more commonly diagnosed among
women than men.  
Table IX.M-1. Basis for Diagnosis of Simple Goiter, by Sex
      Female      Male               Total
Basis for Diagnosis No. % No. % No. %
Yes 62 3.5 8 0.5 70 2.0
HTDS evaluation 9 0.5 5 0.3 14 0.4
Medical record 27 1.5 1 0.1 28 0.8
Participant/respondent report 26 1.5 2 0.1 28 0.8
No 1684 96.4 1685 99.5 3369 97.9
Unknown 1 0.1 0 -- 1 0.0
Total 1747 100.0 1693 100.0 3440 100.0
      
       
       
 
One living evaluable participant was classified as “unknown” with regard to diagnosis of simple
goiter.  This participant did not have a medical record indicating simple goiter, but had a participant report
of an unknown diagnosis which might have been goiter. This participant was included as a non-case in
analyses of the dose-response for simple goiter.
In 30.0% of the cases, simple goiter had one or more of the following etiologies: Graves disease,
Hashimoto’s thyroiditis, hypothyroidism and/or hyperthyroidism (Table IX.M-2).
Table IX.M-2. Etiologies of Simple Goiter, by Sex
       Female      Male                Total
Etiology No. % No. % No. %
Graves disease 9 14.5 0 -- 9 12.9
Hashimoto’s thyroiditis 6 9.7 2 25.0 8 11.4
Hypothyroidism 6 9.7 2 25.0 8 11.4
Hyperthyroidism 1 1.6 0 -- 1 1.4
Other 43 69.4 6 75.0 49 70.0
Total with simple goiter 62 100.0 8 100.0 70 100.0
Note: A participant can have >1 etiology
Of those with an other etiology of simple goiter, 44 (89.8%) had no certain etiology, while 4
(8.2%) were due to probable/possible Hashimoto’s, and 1 (2.0%) to possible Graves disease
(Table IX.M-3).
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Table IX.M-3. “Other” Etiologies of Simple Goiter, by Sex
      Female       Male                Total
Etiology No. % No. % No. %
Uncertain/unknown 39 90.7 5 83.3 44 89.8
Probable/possible Hashimoto’s 3 7.0 1 16.7 4 8.2
Probable Graves disease 1 2.3 0 -- 1 2.0
Total with an other etiology of simple
goiter
43 100.0 6 100.0 49 100.0
M.2. Analysis of Simple Goiter Risk
M.2.a. Primary Analysis
All of the 14 living evaluable participants with a diagnosis of simple goiter based on the HTDS
examination, were in-area participants.  The proportions with simple goiter are shown by sex, dose
category and basis for diagnosis in Table IX.M-4. 
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Table IX.M-4. Diagnoses of Simple Goiter by Sex, Estimated Dose, and Basis for Diagnosis
A.  Female
 Thyroid
Radiation
Dose
(mGy)
Living
Evaluable
Female
Primary Definition:
Cases Based on HTDS
examination
1st Alternative Definition:
Cases Based on HTDS
Examination or Medical
Records 
2nd Alternative Definition:
Cases Based on Any
Diagnosis or Participant or
CATI Report 
No. No. % No.            % No.       %
Out of Area 125 0 -- 2 1.6 5 4.0
< 10 182 1 0.5 3 1.6 7 3.8
10-49 320 1 0.3 8 2.5 10 3.1
50-99 313 2 0.6 5 1.6 10 3.2
100-149 220 3 1.4 5 2.3 8 3.6
150-199 126 0 -- 2 1.6 3 2.4
200-299 139 1 0.7 2 1.4 5 3.6
300-399 144 1 0.7 4 2.8 7 4.9
400-999 171 0 -- 5 2.9 7 4.1
1000+ 7 0 -- 0 -- 0 --
Total 1747 9 0.5 36 2.1 62 3.5
 
B.  Male
 
 Thyroid
Radiation
Dose (mGy
Living
Evaluable
Male
Primary Definition:
Cases Based on
HTDS Examination
1st Alternative Definition:
Cases Based on HTDS
Examination or Medical
Records 
2nd Alternative Definition:
Cases Based on Any
Diagnosis or Participant or
CATI Report 
No. No. % No.           % No.         %  
Out of Area 124 0 -- 0 -- 0 --
< 10 186 1 0.5 1 0.5 2 1.1
10-49 314 1 0.3 1 0.3 1 0.3
50-99 310 1 0.3 2 0.6 3 1.0
100-149 171 1 0.6 1 0.6 1 0.6
150-199 109 0 -- 0 -- 0 --
200-299 148 0 -- 0 -- 0 --
300-399 160 0 -- 0 -- 0 --
400-999 154 1 0.6 1 0.6 1 0.6
1000+ 17 0 -- 0 -- 0 --
Total 1693 5 0.3 6 0.4 8 0.5
 
Parameter estimates for the linear dose-response model based on the 3191 in-area participants are
shown in Table IX.M-5 below. Based on maximum likelihood analysis of the sex-stratified linear
probability model, and using the primary dose estimates, the estimated slope B was –0.001 per Gy (row 1
of Table IX.M-5).  The lower limit of the Bonferroni-adjusted 95% confidence interval was not estimated,
but the upper limit was 0.012 per Gy, and the cumulative incidence of simple goiter did not increase
significantly with increasing dose (p = 0.74). The corresponding estimated background rates for diagnosis
of simple goiter were 0.006 with confidence interval (0.001, 0.011) for women and 0.003 with confidence
interval (0, 0.008) for men.  When the model was fit by the method of least squares, the estimated slope
using either ungrouped or grouped data was even more negative than the maximum likelihood estimate
(Table IX.M-5, rows 2 and 3), thereby providing no evidence that risk of simple goiter increased with
increasing dose (p = 0.79 and 0.70) for the ungrouped and grouped data, respectively.
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Table IX.M-5. Summary of Dose-Response Results for Diagnoses of Simple Goiter
Dose- Exclusions/ Method Estimated Slope of Statistical Significance
Response Dose Additional of Estimates Background Rates Dose-Response of Dose-Response
Row Outcome Model Estimates Inclusions Analysis      Female              Male (per Gy) (one-tailed p-value)
1.
Primary definition
(HTDS evaluation)
Linear Primary None MLE
.006 ± .002
(.001, .011)
.003 ± .002
(0*, .008)
–.001 ± .008
(NE, .012)
0.74
2. Primary definition Linear Primary None LSU
.006 ± .002
(.002, .011)
.004 ± .002
(0*, .009)
–.004 ± .005
(–.017, .008)
0.79
3. Primary definition Linear Primary None LSG
.006 ± .002
(.002, .011)
.004 ± .002
(0*, .009)
-.003 ± .006
(-.018, .011)
0.70
4.
Alternative def. #1
(HTDS or medical
record)
Linear Primary None MLE
.021 ± .004
(.012, .031)
.004 ± .002
(-.001, .009)
-.002 ± .009
(NE, .019)
0.68
Alternative def. #2 
5.
(Any diagnosis or
participant/respondent
report)
Linear Primary None MLE
.036 ± .005
(.023, .048)
.005 ± .002
(0*, .011)
-.002 ± .011
(NE, .018)
0.74
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, “>”
indicates that the upper confidence limit is greater than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are
not given for estimated background rates from logistic regression model.  “0*” indicates that the lower confidence limit for a background rate was less than 0.
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
Okanogan, F/S = Ferry/Stevens, OOA = out of area
Table continued on next page
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Table IX.M-5. Summary of Dose-Response Results for Diagnoses of Simple Goiter (continued)
Dose-
Response Dose
Exclusions /
Additional
Method
of Estimated Background Rates
Estimated
Slope of Dose-
Statistical Significance
of Dose-Response
Row Outcome Model Estimates Inclusions Analysis Female Male Response (per Gy) (one-tailed p-value)
6. Primary definition LQ Primary None LSU
.006 ± .002
(.001, .011)
.004 ± .002
(0*, .009)
Lin: −.005 ± .009
(−.028, .017)
Quad: .001 ± .006
(−.014, .016)
Quad: 0.88
7. Primary definition Logistic Primary None MLE
.007
(.003, .018)
.004
(.001, .013)
–1.56 ± 1.83 
(-5.94, 2.81)
0.83
8. Primary definition Linear Primary
Exclude dose
> 1000 mGy
MLE
.006 ± .002
(.001, .011)
.004 ± .002
(0*, .009)
-.004 ± .008
(NE, .014)
0.80
9. Primary definition Linear Primary
Exclude dose
> 400 mGy
MLE
.007 ± .003
(0*, .015)
.003 ± .002
(0*, .008)
-.009 ± .016
(NE, .024)
0.84
10. Primary definition Linear Primary
Exclude 
Ok and F/S
geostrata
MLE
.006 ± .002
(.000, .011)
.003 ± .002
(0*, .008)
-.001 ± .008
(NE, .015)
0.70
11. Primary definition Linear Alt. #1 None MLE
.006 ± .002
(.001, .010)
.003 ± .002
(-.001, .008)
-.001 ± .005
(<-.001, .014)
0.55
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, “>”
indicates that the upper confidence limit is greater than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are
not given for estimated background rates from logistic regression model.  “0*” indicates that the lower confidence limit for a background rate was less than 0.
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
Okanogan, F/S = Ferry/Stevens, OOA = out of area
Table continued on next page
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Table IX.M-5. Summary of Dose-Response Results for Diagnoses of Simple Goiter (continued)
Row Outcome
Dose-
Response
Model
Dose
Estimates
Exclusions/
Additional
Inclusions
Method
of
Analysis
Estimates Background Rates
     Female              Male
Estimated Slope of
Dose-Response
(per Gy)
Statistical Significance
of Dose-Response
(one-tailed p-value)
12. Primary definition Linear Alt. #2 None MLE
.006 ± .002
(.001, .010)
.003 ± .002
(0*, .008)
-.001 ± .005
(<-.002, .016)
0.56
13. Primary definition Linear Primary
Include OOA
(scoping
analysis #1)
MLE
.005 ± .002
(.001, .010)
.003 ± .002
(0*, .007)
-.001 ± .008
(NE, .014)
0.71
14. Primary definition Linear Primary
Include OOA
(scoping
analysis #2)
MLE
.005 ± .002
(.001, .010)
.003 ± .002
(-.001, .007)
-.001 ± .008
(NE, >.014)
0.71
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, “>”
indicates that the upper confidence limit is greater than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are
not given for estimated background rates from logistic regression model.  “0*” indicates that the lower confidence limit for a background rate was less than 0.
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
Okanogan, F/S = Ferry/Stevens, OOA = out of area
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M.2.b. Alternative Definitions for Diagnosis of Simple Goiter
Two alternative definitions for cases of simple goiter were considered.  The first alternative added
28 cases with diagnoses based on medical records, for a total of 42 cases.  The second added another 28
cases based solely on a report from the participant or his/her CATI respondent, for a total of 70 cases.  As
shown in rows 4 and 5 of Table IX.M-5, for neither alternative definition was there evidence that the
cumulative incidence of simple goiter increased with increasing dose (p = 0.68 and 0.74 for the first and
second alternative analyses, respectively). 
M.2.c. Alternative Dose-Response Functions 
As shown in row 6 of Table IX.M-5, the estimated regression coefficient for the dose-squared
term in the linear-quadratic dose-response model [5] was 0.001 with Bonferroni-adjusted 95% confidence
interval ranging from –0.014 to 0.016.  Thus the addition of a quadratic term did not significantly improve
the fit of the model (p = 0.88).
In the analysis of simple goiter based on the HTDS examination, i.e., the primary criterion for
defining cases with simple goiter, the regression parameter for the effect of dose in the sex-stratified
logistic regression model [2] was estimated as –1.56 with Bonferroni-adjusted 95% confidence interval
ranging from –5.94 to 2.81.  Thus the cumulative incidence of simple goiter did not increase significantly
with increasing dose (p = 0.83; Table IX.M-5, row 7).
M.2.d. Effect of Excluding Participants in High Dose Categories
Rows 8 and 9 of Table IX.M-5 show the effect of excluding patients in high dose categories from
the analysis of the sex-stratified linear dose-response model.  When participants with estimated dose >
1000 mGy were excluded from the analysis, the estimated slope of the dose-response decreased to –0.004
per Gy, providing no evidence that the cumulative incidence of simple goiter increased with increasing
dose (p = 0.80).   Similarly, when participants with estimated dose > 400 mGy were excluded, the
estimated slope B was even more negative (–0.009 per Gy), providing no evidence that the cumulative
incidence increased with increasing dose (p = 0.84).
M.2.e. Effect of Excluding Okanogan and Ferry/Stevens Geostrata
When participants in the Okanogan and Ferry/Stevens geostrata were excluded the estimated slope
B was essentially unchanged at –0.001 per Gy, providing no evidence that the cumulative incidence of
simple goiter increased significantly with increasing dose (p = 0.70; Table IX.M-5, row 10).
M.2.f. Analysis of Simple Goiter in Relation to Alternative Dose Estimates
As shown in rows 11 and 12 of Table IX.M-5, substituting either of the alternative sets of dose
estimates for the primary doses caused very little change in the estimated slope of the dose-response.  In
particular there was no evidence that cumulative incidence of simple goiter increased with increasing doses
from either of the alternative dose sets (p = 0.55 and p = 0.56 for alternative dose sets 1 and 2,
respectively). 
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M.2.g. Scoping Analysis Regarding Out-of-Area Participants
See section VIII.C.1.a.3 for a description of the scoping analyses that were performed to assess the
possible impact of including the 249 out-of-area participants.  The results of both scoping analyses (Table
IX.M-5, rows 13 and 14) were very similar to those of the primary analysis of the in-area participants
(Table IX.M-5, row 1).  In particular both estimates of the slope were slightly less than zero, providing no
evidence that the cumulative incidence of simple goiter increased with increasing dose  (p = 0.71 for both
scoping analyses).
M.2.h. Analysis of Simple Goiter in Relation to Alternative Representations of Exposure
In analyses by geostratum and by dichotomous exposure variable, the sex and age-adjusted
comparisons of cumulative incidence were performed as described in section VIII.C.2.a.2.
M.2.h.1. Analysis by Geostratum
There were too few participants (14) with diagnoses of simple goiter (based on the HTDS
examination) for a definitive conclusion regarding heterogeneity among the geostrata (see Table IX.M-6).
Therefore, the analysis was based on the second alternative definition of simple goiter, i.e., including all
diagnoses or reports of simple goiter.  The results are shown in Table IX.M-7 below.  There was no
significant heterogeneity among the nine geostrata (p=0.26).  The percentages with simple goiter were
somewhat higher in the Okanogan and Ferry/Stevens geostrata (5.6% for women, 1.5% for men) than in the
remaining geostrata (3.4% and 0.4%), but this heterogeneity between combined geostrata was also not
statistically significant (p=0.095).
Table IX.M-6. Diagnoses of Simple Goiter Based on the HTDS Evaluation, by Geostratum and Sex
Female Male Total
Geostratum No. Cases % No. Cases % No. Cases %
Richland 179 1 0.6 173 2 1.2 352 3 0.9
Pasco/Kennewick 508 2 0.4 501 1 0.2 1009 3 0.3
Benton County 376 3 0.8 358 1 0.3 734 4 0.5
Franklin County 73 0 -- 76 0 -- 149 0 --
Adams County 165 0 -- 156 0 -- 321 0 --
Walla Walla (city) 133 0 -- 131 0 -- 264 0 --
Walla Walla County 170 2 1.2 164 0 -- 334 2 0.6
Okanogan County 75 0 -- 64 1 1.6 139 1 0.7
Ferry/Stevens Counties 68 1 1.5 70 0 -- 138 1 0.7
Total 1747 9 0.5 1693 5 0.3 3440 14 0.4
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Table IX.M-7. Diagnoses of Simple Goiter Based on Any Source, by Geostratum and Sex 
Female Male Total
Geostratum No. Cases % No. Cases % No. Cases %
Richland 179 6 3.4 173 2 1.2 352 8 2.3
Pasco/Kennewick 508 22 4.3 501 2 0.4 1009 24 2.4
Benton County 376 13 3.5 358 2 0.6 734 15 2.0
Franklin County 73 3 4.1 76 0 -- 149 3 2.0
Adams County 165 2 1.2 156 0 -- 321 2 0.6
Walla Walla (city) 133 4 3.0 131 0 -- 264 4 1.5
Walla Walla County 170 4 2.4 164 0 -- 334 4 1.2
Okanogan County 75 3 4.0 64 1 1.6 139 4 2.9
Ferry/Stevens Counties 68 5 7.4 70 1 1.4 138 6 4.3
Total 1747 62 3.5 1693 8 0.5 3440 70 2.0
M.2.h.2. Analysis by Dichotomous Exposure Variable
See section VIII.B.3.b.2 above for a description of the high and low exposure categories.   Only
five (0.4%) of the 1257 participants included in these analyses had a diagnosis of simple goiter based on the
HTDS examination (see Table IX.M-8).  This was too few for a meaningful comparison between the high
and low exposure groups.  Therefore the analysis was based on the second alternative definition for
diagnoses of simple goiter (section IX.M.1, above), i.e., any diagnosis based on HTDS, medical records, or
participant or CATI respondent report.  As shown in Table IX.M-9, 24 (1.9%) of the 1257 participants had
diagnoses of simple goiter based on this alternative criterion, including 9/580 (1.6%) and 15/677 (2.2%) in
the high and low exposure groups, respectively.  The cumulative incidence of simple goiter based on this
alternative definition was not significantly elevated in the high exposure group (p = 0.75).
Table IX.M-8. Diagnoses of Simple Goiter Based on HTDS Examination, by Exposure Group and
Sex 
Female Male Total
Exposure Group No. Cases % No. Cases % No. Cases %
Low 351 1 0.3 326 2 0.6 677 3 0.4
High 298 1 0.3 282 1 0.4 580 2 0.3
Total 649 2 0.3 608 3 0.5 1257 5 0.4
Table IX.M-9. Diagnoses of Simple Goiter Based on Any Source, by Exposure Group and Sex 
Female Male Total
Exposure Group No. Cases % No. Cases % No. Cases %
Low 351 13 3.7 326 2 0.6 677 15 2.2
High 298 8 2.7 282 1 0.4 580 9 1.6
Total 649 21 3.2 608 3 0.5 1257 24 1.9
M.2.i. Confounding and Effect Modification
There were too few participants with diagnoses of simple goiter to permit meaningful analysis of
confounding or effect modification.
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M.2.j. Uncertainty
The estimated slopes of the sex-stratified linear dose-response model for simple goiter are shown
in Figure IX.M-1 for each of the 100 dose realizations produced by the CIDER model.  The confidence
intervals in that figure are calculated at the 98.33% confidence level, i.e., are adjusted by the Bonferroni
technique for the simultaneous estimation of the slope and two sex-specific background rates. The point
estimate of the slope was greater than zero for only 13 of the 100 realizations, and the confidence interval
included zero for all 100 realizations.  Also shown in Figure IX.M-1 (to the right of realization 100) are the
estimates and confidence intervals calculated using (from left to right) the median, geometric mean and
mean of each participant's 100 dose realizations. In summary, for none of the 100 realizations of the
estimated doses was there a statistically significant dose-response, and for most of the realizations the
estimated slope was less than 0.
Figure IX.M-2 displays the distribution of the 5000 logistic regression coefficient estimates
obtained by the simulation procedures described in section VIII.C.2.b.3 above. It is evident from the figure
that most of the estimates were between about –15.0 and 2.0. The estimate was less than or equal to 0 for
4536 of the 5000 replications, implying an empirical one-tailed p-value of 0.91.  The median estimate was
–2.63, and the upper and lower percentiles corresponding to the Bonferroni-adjusted 95% confidence
interval ranging from –14.8 to 1.16.  These may be compared to the estimate of −1.56 with confidence
interval (−5.94, 2.81) obtained using the median dose estimates without adjustment for uncertainty. Thus,
this method of adjusting the estimated logistic regression coefficient for the uncertainty in the dose
estimates did not provide evidence that the cumulative incidence of simple goiter increased with increasing
dose.
Figure IX.M-1. Plot of Estimated Slope and 95% CI by Dose Realization: Simple Goiter
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Figure IX.M-2. Distribution of Simulation Estimates of Logistic Regression Coefficient: Simple 
Goiter
slope sample: 5000
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N. Other Thyroid Disease 
N.1. Occurrence of Other Thyroid Disease
The primary and alternative definitions for other thyroid disease were as follows:
• Primary definition: HTDS examination or medical records with supporting documentation (4 cases)
• Alternative definition #1: HTDS examination or medical records with or without supporting
documentation (6 cases)
• Alternative definition #2: Any diagnosis or participant/respondent report (26 cases).
 Four living evaluable participants, all in the in-area group, had diagnoses of other thyroid disease
based on their HTDS examinations or medical records with supporting documentation.  These included two
cases of subacute thyroiditis in women with estimated doses of 342 and 336 mGy; one case of familial
thyroglobulin binding deficiency in a male with an estimated dose 102 mGy; and a case of secondary
hypothyroidism in a female with an estimated dose 109 mGy.
 
 The first alternative definition added only two cases with diagnoses based on medical records
without supporting documentation.  Both were cases of subacute thyroiditis in women with estimated doses
of 70 and 50 mGy.
 
 For both the primary and first alternative definition of other thyroid disease, there were too few
cases for meaningful estimation of the radiation dose-response.
 
 The second alternative definition added 20 participants, primarily with participant or CATI
respondent reports of past thyroid disease of unknown type.  This brought the total number of cases to 26,
of whom four were out-of-area participants. The number of cases and proportions with other thyroid
disease are shown by sex and dose category in Table IX.N-1. 
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 Table IX.N-1. Diagnoses of Other Thyroid Disease by Sex, Dose Category, and Basis for Diagnosis
 
 A.  Female
 
 
 
 
 Thyroid
Radiation
Dose 
 
 
 
 Living
Evaluable
Female
 Primary Definition:
Cases Based on
HTDS Examination
or Medical Records
with Supporting
Documentation
 1st Alternative Definition:
 Cases Based on HTDS
Examination or Medical
Records with or without
Supporting
Documentation
 
 2nd Alternative
Definition:
 Cases Based on Any
Diagnosis or Participant
or CATI Report
 (mGy)     No.  No.  %  No.  %  No.  %
 Out of Area   125  0   --  0   --   1  0.8
 < 10   182  0   --  0   --   1  0.5
 10-49   320  0   --  0   --   1  0.3
 50-99   313  0   --  2  0.6   5  1.6
 100-149   220  1  0.5  1  0.5   2  0.9
 150-199   126  0   --  0   --   1  0.8
 200-299   139  0   --  0   --   2  1.4
 300-399   144  2  1.4  2  1.4   2  1.4
 400-999   171  0   --  0   --   2  1.2
 1000+       7  0   --  0   --   0   --
 Total  1747  3  0.2  5  0.3  17  1.0
 
 
 B.  Male
 
 
 
 
 Thyroid
Radiation
Dose 
 
 
 
 Living
Evaluable
Male
 Primary Definition:
Cases Based on HTDS
Examination or
Medical Records with
Supporting
Documentation
 1st Alternative Definition:
 Cases Based on HTDS
Examination or Medical
Records with or without
Supporting
Documentation
 
 2nd Alternative
Definition:
 Cases Based on Any
Diagnosis or Participant
or CATI Report
 (mGy)     No.  No.  %  No.  %  No.  %
 Out of Area   124  0    --  0    --  3  2.4
 < 10   186  0    --  0    --  1  0.5
 10-49   314  0    --  0    --  0    --
 50-99   310  0    --  0    --  2  0.6
 100-149   171  1  0.6  1  0.6  1  0.6
 150-199   109  0    --  0    --  0    --
 200-299   148  0    --  0    --  1  0.7
 300-399   160  0    --  0    --  0    --
 400-999   154  0    --  0    --  1  0.6
 1000+     17  0    --  0    --  0    --
 Total  1693  1  0.1  1  0.1  9  0.5
 
 
Parameter estimates for the linear dose-response model based on the 3191 in-area participants, and
using the second alternative definition of other thyroid disease, are shown in Table IX.N-2 below. Based on
maximum likelihood analysis of the sex-stratified linear probability model, the estimated slope B was
slightly greater than zero (0.002 per Gy) with Bonferroni-adjusted 95% CI ranging from less than −0.002 to
0.024 per Gy, providing no evidence that cumulative incidence increased significantly with increasing dose
(one-tailed p = 0.39).  The corresponding estimated background rates for diagnosis of other thyroid disease
were 0.010 with confidence interval (0.003, 0.016) for women and 0.003 with confidence interval ( 0,
0.008) for men.
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Table IX.N-2. Dose-Response Results for Diagnoses of Other Thyroid Disease
Estimated Background Rates 
Estimated
Slope of Dose-
Statistical Significance
of Dose-Response
Analysis Female Male Response (per Gy) (one-tailed p-value)
Alternative Definition 2:
  Maximum Likelihood
(Any diagnosis or
participant/respondent
report)
.010 ± .003
(.003, .016)
.003 ± .002
(0*, .008)
.002 ± .007
(< −.002, .024) 0.39
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses.
(“<” indicates that the lower confidence limit is less than the indicated value).  “0*” indicates that the lower confidence limit
for a background rate was less than 0. 
In view of the small number of cases, and their heterogeneous and mostly unknown diagnoses,
further analyses of this outcome were not performed.
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O. Hyperparathyroidism
O.1. Occurrence of Hyperparathyroidism
 
 
The primary and alternative definitions of hyperparathyroidism were as follows:
• Primary definition: HTDS evaluation or medical records with supporting documentation (12 cases)
• Alternative definition #1: Any diagnosis or participant/respondent report (14 cases).
Fourteen (0.4%) living evaluable participants had diagnoses of hyperparathyroidism (Table
IX.O-1), with 11 being based on the HTDS evaluation, 1 on medical records with supporting
documentation, and 2 on a participant or his/her CATI respondent report. 
One additional living evaluable participant who did not meet the study’s criteria for
hyperparathyroidism nevertheless had an elevated calcium in the presence of a high normal PTH level,
when the PTH should have been suppressed, highly suggestive of hyperparathyroidism.  This participant
was included as a case in an additional analysis.
Table IX.O-1. Basis for Diagnosis of Hyperparathyroidism, by Sex
      Female Male            Total
Basis for Diagnosis No. % No. % No. %
Yes 10 0.6 4 0.2 14 0.4
HTDS evaluation 9 0.5 2 0.1 11 0.3
Medical records with supporting
documentation
1 0.1 0 -- 1 0.0
Participant/respondent report 0 -- 2 0.1 2 0.1
No 1729 99.0 1687 99.6 3416 99.3
Unknown 8 0.5 2 0.1 10 0.3
Total 1747 100.0 1693 100.0 3440 100.0
      
       
 
      
 
Ten living evaluable participants were classified as “unknown” with regard to diagnosis of
hyperparathyroidism.  These 10 did not have medical record or participant/respondent reports of such
diagnoses, and did not have an HTDS evaluation due to the lack of a blood draw (8) or a sufficient amount
of blood drawn to determine the serum calcium level (2). These 10 participants were included as non-cases
in analyses of the dose-response for hyperparathyroidism.
O.2. Analysis of Hyperparathyroidism Risk
O.2.a. Primary Analysis
Of the 12 living evaluable participants with a diagnosis of hyperparathyroidism based on the
HTDS examination or medical records with supporting documentation, one was an out-of-area participant
for whom the CIDER program could not calculate a dose estimate.  The proportions with
hyperparathyroidism are shown by sex, dose category and basis for diagnosis in Table IX.O-2.
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Table IX.O-2. Diagnoses of Hyperparathyroidism by Sex, Estimated Dose, and Basis for Diagnosis
A.  Female
 
 Thyroid
Radiation
Dose
(mGy)
Living
Evaluable
Female
Primary Definition:
Cases Based on
HTDS or Med. Rec.
with Supporting
Documentation
Alternative Definition:
Cases Based on Any
Diagnosis or Participant
or CATI Report
 No. No. % No.          %
Out of Area 125 0 -- 0 --
< 10 182 1 0.5 1 0.5
10-49 320 2 0.6 2 0.6
50-99 313 2 0.6 2 0.6
100-149 220 1 0.5 1 0.5
150-199 126 1 0.8 1 0.8
200-299 139 2 1.4 2 1.4
300-399 144 1 0.7 1 0.7
400-999 171 0 -- 0 --
1000+ 7 0 -- 0 --
Total 1747 10 0.6 10 0.6
B.  Male
 
 Thyroid
Radiation
Dose
(mGy)
Living
Evaluable
Male
Primary Definition:
Cases Based on
HTDS or Med. Rec.
with Supporting
Documentation
Alternative Definition:
Cases Based on Any
Diagnosis or Participant
or CATI Report
 No. No. % No.         %
Out of Area 124 1 0.8 1 0.8
< 10 186 0 -- 0 --
10-49 314 0 -- 0 --
50-99 310 0 -- 1 0.3
100-149 171 1 0.6 1 0.6
150-199 109 0 -- 0 --
200-299 148 0 -- 0 --
300-399 160 0 -- 0 --
400-999 154 0 -- 1 0.6
1000+ 17 0 -- 0 --
Total 1693 2 0.1 4 0.2
Parameter estimates for the linear dose-response model based on the 3191 in-area participants are
shown in Table IX.O-3 below. Based on maximum likelihood analysis of the sex-stratified linear
probability model, and using the primary dose estimates, the estimated slope B was –0.000 per Gy (row 1
of Table IX.O-3).  The lower limit of the Bonferroni-adjusted 95% confidence interval was not estimated,
but the upper limit was 0.013 per Gy, and the cumulative incidence of hyperparathyroidism did not increase
significantly with increasing dose (p = 0.61). The corresponding estimated background rates for diagnosis
of hyperparathyroidism were 0.006 with confidence interval (0, 0.013) for women and 0.001 with
confidence interval (0, 0.006) for men.  When the model was fit by the method of least squares, the
estimated slope using either ungrouped or grouped data was slightly more negative than the maximum
likelihood estimate (Table IX.O-3, rows 2 and 3), thereby providing no evidence that risk of
hyperparathyroidism increased with increasing dose (p = 0.74 and 0.75).
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Table IX.O-3. Summary of Dose-Response Results for Diagnoses of Hyperparathyroidism
Row Outcome
Dose
Response
Model
Dose
Estimates
Exclusion:
Additional
Inclusions
Method
of
Analysis
Estimated Background Rates
     Female              Male
Estimated Slope of
Dose Response
(per Gy)
Statistical Significance
of Dose-Response
(one-tailed p-value)
1.
Primary definition
(HTDS evaluation)
Linear Primary None MLE
.006 ± .003
(0*, .013)
.001 ± .002
(0*, .006)
−.000 ± .018
(NE, .013)
0.61
2. Primary definition Linear Primary None LSU
.007 ± .002
(.003, .011)
.001 ± .002
(0*, .005)
−.003 ± .005
(−.014, .008) 0.74
3. Primary definition Linear Primary None LSG
.007 ± .002
(.003, .011)
.001 ± .002
(0*, .006)
−.004 ± .005
(−.016, .009) 0.75
4.
Alternative def. #1
(Any diagnosis or
participant/respondent
report)
Linear Primary None MLE
.006 ± .002
(.001, .011)
.002 ± .002
(0*, .006)
.000 ± .006
(< −.001, .021) 0.47
5.
Hyperparathyroidism
plus probable case
Linear Primary None MLE
.006 ± .002
(.001, .011)
.003 ± .002
(0*, .008)
−.001 ± .007
(< −.001, .023) 0.54
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, “>”
indicates that the upper confidence limit is greater than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are
not given for estimated background rates from logistic regression model.  “0*” indicates that the lower confidence limit for a background rate was less than 0.
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
Okanogan, F/S = Ferry/Stevens, OOA = out of area
Table continued on next page
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Table IX.O-3. Summary of Dose-Response Results for Diagnoses of Hyperparathyroidism (continued)
Dose-
Response Dose
Exclusions /
Additional
Method
of Estimated Background Rates
Estimated
Slope of Dose-
Statistical Significance
of Dose-Response
Row Outcome Model Estimates Inclusions Analysis Female Male Response (per Gy) (one-tailed p-value)
6. Primary definition LQ Primary None LSU
.007 ± .002
(.002, .011)
.001 ± .002
(0*, .006)
Lin: −.003 ± .008
(−.023, .017)
Quad: .000 ± .005
(−.013, .013)
Quad: 0.99
7. Primary definition Logistic Primary None MLE
.008
(.003, .020)
.001
(.0001, .009)
–1.34 ±  2.00 
(-6.14, 3.46)
0.77
8. Primary definition Linear Primary
Exclude dose
> 1000 mGy
MLE
.006 ± .003
(0*, .014)
.001 ± .002
(0*, .006)
-.001 ± .018
(NE, .014)
0.67
9. Primary definition Linear Primary
Exclude dose
> 400 mGy
MLE
.006 ± .003
(0*, .014)
.000 ± .003
(0*, .006)
.006 ± .022
(<.000, .031)
0.31
10. Primary definition Linear Primary
Exclude 
Ok and F/S
geostrata
MLE
.006 ± .003
(0*, .014)
.001 ± .002
(0*, .006)
-.0003 ± .018
(NE, .013)
0.62
11. Primary definition Linear Alt. #1 None MLE
.006 ± .003
(0*, .013)
.000 ± .005
(0*, .012)
-.0002 ± .018
(<-.0003, .013)
0.42
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, “>”
indicates that the upper confidence limit is greater than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are
not given for estimated background rates from logistic regression model.  “0*” indicates that the lower confidence limit for a background rate was less than 0.
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
Okanogan, F/S = Ferry/Stevens, OOA = out of area
Table continued on next page
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Table IX.O-3. Summary of Dose-Response Results for Diagnoses of Hyperparathyroidism
Row Outcome
Dose
Response
Model
Dose
Estimates
Exclusion:
Additional
Inclusions
Method
of
Analysis
Estimated Background Rates
     Female              Male
Estimated Slope of
Dose Response
(per Gy)
Statistical Significance
of Dose-Response
(one-tailed p-value)
12. Primary definition Linear Alt. #2 None MLE
.006 ± .003
(0*, .013)
.001 ± .001
(0*, .004)
-.0003 ± .011
(NE, .013)
0.60
13. Primary definition Linear Primary
Include OOA
(scoping
analysis #1)
MLE
.006 ± .002
(.0002, .011)
.001 ± .001
(0*, .004)
-.0005 ± .011
(NE, .011)
0.68
14. Primary definition Linear Primary
Include OOA
(scoping
analysis #2)
MLE
.006 ± .002
(.000, .011)
.001 ± .001
(0*, .004)
-.0005 ± .011
(NE, >.010)
0.68
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, “>”
indicates that the upper confidence limit is greater than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are
not given for estimated background rates from logistic regression model.  “0*” indicates that the lower confidence limit for a background rate was less than 0.
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
Okanogan, F/S = Ferry/Stevens, OOA = out of area
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O.2.b. Alternative Definitions for Diagnosis of Hyperparathyroidism  
One alternative definition for cases of hyperparathyroidism was considered.  This alternative
added two cases based solely on reports from the participant or his/her CATI respondent, bringing the total
to 14 cases.  The two added cases had estimated doses of 475 and 92 mGy.  As shown in row 4 of Table
IX.O-3 above, in the alternative analysis the cumulative incidence of hyperparathyroidism did not increase
significantly with increasing dose (p = 0.47), with an estimated slope of 0.000 per Gy and Bonferroni-
adjusted 95% confidence interval ranging from less than –0.001 to 0.021 per Gy.
O.2.b.1 Effect of Including Probable Diagnoses of Hyperparathyroidism  
As described in IX.O.1 above, one living evaluable participant who wasn’t counted as a case of
hyperparathyroidism might truly have been a case.  This participant was not counted as a case in the
primary analysis of hyperparathyroidism to avoid introducing a possible reporting bias.  However in view
of the importance of hyperparathyroidism as a disease outcome, an additional analysis in which this
participant was counted as a case was performed.  This participant was in the in-area group, with an
estimated thyroid radiation dose of 159 mGy.  Counting this participant as a case rather than a noncase in
the dose-response analysis had almost no impact on the results (Table IX.O-3, row 5): the estimated slope
of the dose-response was slightly less than zero (–0.001 per Gy, with confidence interval ranging from less
than –0.001 to 0.023 per Gy) providing no evidence of a positive dose-response (p=0.54).
O.2.c. Alternative Dose-Response Functions  
As shown in row 6 of Table IX.O-3, the estimated regression coefficient for the dose-squared term
in the linear-quadratic dose-response model [5] was 0.000 with Bonferroni-adjusted 95% confidence
interval ranging from –0.013 to 0.013.  Thus the addition of a quadratic term did not significantly improve
the fit of the model (p = 0.99).
The regression parameter for the effect of dose in the sex-stratified logistic regression model [2]
was estimated as –1.34, with Bonferroni-adjusted 95% confidence limits –6.14 and 3.46, indicating that the
cumulative evidence of hyperparathyroidism did not increase significantly with increasing dose (p = 0.77;
see row 7 of Table IX.O-3).
O.2.d. Effect of Excluding Participants in High Dose Categories
As shown in rows 8 and 9 of Table IX.O-3, when participants in high dose categories were
excluded, the cumulative incidence of hyperparathyroidism did not increase significantly with increasing
dose (p = 0.67 and p = 0.31 when those with doses >1000 mGy and >400 mGy were excluded,
respectively).
O.2.e. Effect of Excluding Okanogan and Ferry/Stevens Geostrata 
When participants in the Okanogan and Ferry/Stevens were excluded, the estimated slope B was
slightly less than zero (-0.0003 with Bonferroni-adjusted 95% CI upper confidence limit of 0.013),
providing no evidence that the cumulative incidence of hyperparathyroidism increased with increasing dose
(p = 0.62; Table IX.O-3, row 10).
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O.2.f. Analysis of Hyperparathyroidism in Relation to Alternative Dose Estimates
As shown in rows 11 and 12 of Table IX.O-3 above, for neither set of alternative dose estimates
did the cumulative incidence of hyperparathyroidism increase significantly with increasing dose (p = 0.42
and 0.60 for dose alternatives 1 and 2, respectively).
O.2.g. Scoping Analysis Regarding Out-of-Area Participants
See section VIII.C.1.a.3 for a description of the scoping analyses that were performed to assess the
possible impact of including the 249 out-of-area participants.  As shown in rows 13 and 14 of Table IX.O-
3, the results of both scoping analyses were very similar to those of the primary analysis (row 1).  In
particular, neither scoping analysis provided evidence that the risk of hyperparathyroidism increased with
increased thyroid dose (p = 0.68 for both scoping analyses).
O.2.h. Analysis of Hyperparathyroidism in Relation to Alternative Representations of
Exposure
In the analyses by geostratum and by dichotomous exposure variable, the sex and age-adjusted
comparisons of cumulative incidence were performed as described in section VIII.C.2.a.2.
O.2.h.1. Analysis by Geostratum
Since there were only 12 participants with hyperparathyroidism diagnosed according to the
primary definition (HTDS or medical records with documentation), the test for heterogeneity among the 9
geostrata had little statistical power.  Therefore the absence of significant heterogeneity (p = 0.71) was not
strong evidence against the possibility that the cumulative incidence of hyperparathyroidism might in fact
vary among the geostrata.
Table IX.O-4. Diagnoses of Hyperparathyroidism Based on the HTDS Evaluation or on Medical
Records with Supporting Documentation, by Geostratum and Sex
Female Male Total
Geostratum No. Cases % No. Cases % No. Cases %
Richland 179 0 -- 173 0 -- 352 0 --
Pasco/Kennewick 508 4 0.8 501 1 0.2 1009 5 0.5
Benton County 376 3 0.8 358 0 -- 734 3 0.4
Franklin County 73 0 -- 76 0 -- 149 0 --
Adams County 165 0 -- 156 1 0.6 321 1 0.3
Walla Walla (city) 133 1 0.8 131 0 -- 264 1 0.4
Walla Walla County 170 1 0.6 164 0 -- 334 1 0.3
Okanogan County 75 0 -- 64 0 -- 139 0 --
Ferry/Stevens Counties 68 1 1.5 70 0 -- 138 1 0.7
Total 1747 10 0.6 1693 2 0.1 3440 12 0.3
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O.2.h.2. Analysis by Dichotomous Exposure Variable
See section VIII.B.3.b.2 above for a description of the high and low exposure categories.  Only six
(0.5%) of the 1257 participants included in these analyses had a diagnosis of hyperparathyroidism based on
the HTDS examination.  Therefore the comparison between the high and low exposure groups was based
on the alternative definition for diagnoses of hyperparathyroidism (section IX.O.1 above), i.e., any
diagnosis based on the HTDS examination, medical records, or participant or CATI respondent report.  As
shown in Table IX.O-5 below, using the alternative criterion increased the number of cases to only seven
(0.6%).  Four of these cases occurred among the 580 participants in the high exposure category (0.7%),
compared to three (0.4%) among 677 participants in the low exposure group.  Consequently the cumulative
incidence of hyperparathyroidism was not significantly elevated in the high exposure group (p = 0.43).
Table IX.O-5. Diagnoses of Hyperparathyroidism Based on HTDS Any Diagnosis or
Participant/CATI Respondent Report, by Exposure Group and Sex 
Female Male Total
Exposure Group No. Cases % No. Cases % No. Cases %
Low 351 2 0.6 326 1 0.3 677 3 0.4
High 298 2 0.7 282 2 0.7 580 4 0.7
Total 649 4 0.6 608 3 0.5 1257 7 0.6
O.2.i. Confounding and Effect Modification
There were too few participants with diagnoses of hyperparathyroidism to permit meaningful
analysis of confounding or effect modification.
O.2.j. Uncertainty
The estimated slopes of the sex-stratified linear dose-response model for hyperparathyroidism are
shown in Figure IX.O-1 for each of the 100 dose realizations produced by the CIDER model.  The
confidence intervals in that figure are calculated at the 98.33% confidence level, i.e., are adjusted by the
Bonferroni technique for the simultaneous estimation of the slope and two sex-specific background rates.
The point estimate of the slope was greater than zero for 51 of the 100 realizations, and the confidence
interval included zero for 97 of the 100 realizations.  Also shown in Figure IX.O-1 (to the right of
realization 100) are the estimates and confidence intervals calculated using (from left to right) the median,
geometric mean and mean of each participant's 100 dose realizations. In summary, for only three of the 100
realizations of the estimated doses was there a statistically significant dose-response, and for about half of
the realizations the estimated slope was less than 0.
Figure IX.O-1. Plot of Estimated Slope and 95% CI by Dose Realization: Hyperparathyroidism 
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Figure IX.O-2 displays the distribution of the 5000 estimates of the logistic regression coefficient
obtained by the simulation procedures described in section VIII.C.2.b.3 above. It is evident from the figure
that most of the estimates were between about –15.0 and 2.0. The estimate was less than or equal to 0 for
4378 of the 5000 replications, implying an empirical one-tailed p-value of 0.88.  The median estimate was
–2.56, and the upper and lower percentiles corresponding to the Bonferroni-adjusted 95% confidence
interval ranging from –15.9 to 1.42.  These may be compared to the estimate of −1.34 with confidence
interval (−6.14, 3.46) obtained using the median dose estimates without adjustment for uncertainty. Thus,
this method of adjusting the estimated logistic regression coefficient for the uncertainty in the dose
estimates did not provide evidence that the cumulative incidence of hyperparathyroidism increased with
increasing dose.
Figure IX.O-2. Distribution of Simulation Estimates of Logistic Regression Coefficient:
Hyperparathyroidism
slope sample: 5000
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P. Ultrasound-Detected Abnormalities of the Thyroid (Thyroid UDAs)
P.1. Occurrence of Ultrasound-Detected Abnormalities of the Thyroid
 The thyroid gland was visible in the ultrasound examinations of 3429 of the 3440 living evaluable
participants.  For 11 participants the thyroid was not visible, 10 because of thyroid surgery and one because
the sonographer couldn’t adequately visualize the thyroid.  Among the 3429 whose thyroids were visible,
1596 (46.5%) had one or more ultrasound-detected abnormalities (Table IX.P-1), including palpable
thyroid UDAs (224 or 6.5%), nonpalpable focal  thyroid UDAs (1309 or 38.2%), and diffuse thyroid UDAs
(458 or 13.4%).  All three types of thyroid UDA were more frequent among women than men.  Ultrasound-
detected thyroid abnormalities were based only on the HTDS evaluation, not on any prior ultrasounds.  
 
 Table IX.P-1. Ultrasound-Detected Abnormalities, by Sex and Type of Abnormality
Female Male Total
Ultrasound Finding No. % No. % No. %
Thyroid gland visible on ultrasound 1738 100.0 1691 100.0 3429 100.0
Normal ultrasound 774 44.5 1059 62.6 1833 53.5
Any abnormality 964 55.5 632 37.4 1596 46.5
Palpable thyroid UDAs 154 8.9 70 4.1 224 6.5
Nonpalpable focal thyroid UDAs 784 45.1 525 31.0 1309 38.2
Diffuse thyroid UDAs 306 17.6 152 9.0 458 13.4
       
       
       
       
       
       
Note: a participant can have more than one of palpable, nonpalpable focal and diffuse thyroid UDAs.
 
 
 P.1.a. Additional Outcomes Related to Ultrasound-Detected Abnormalities of the
Thyroid
 
 P.1.a.1 Thyroid UDAs by Size
 
 To determine whether the size of thyroid UDAs detected increased in relation to estimated dose,
three additional outcomes were defined.  These included the presence of a focal thyroid UDA with
maximum dimension at least 5 mm, the presence of a focal thyroid UDA with maximum dimension of at
least 10 mm, and the presence of a focal thyroid UDA with average dimension of at least 15 mm.  Among
the 3429 participants whose thyroids were visible, 1142 (33.3%) had a focal thyroid UDA with maximum
dimension ≥ 5 mm, 622 (18.1%) had a focal thyroid UDA with maximum dimension ≥ 10 mm, and 166
(4.8%) had a focal thyroid UDA with average dimension ≥ 15 mm (Table IX.P-2).
 
Table IX.P-2. Ultrasound-Detected Abnormalities, by Sex and Size of Abnormality
 
   Female    Male         Total
Ultrasound Findings No. % No. % No. %
Thyroid gland visible on ultrasound 1738 100.0 1691 100.0 3429 100.0
UDA ≥ 5 mm maximum dimension 701 40.3 441 26.1 1142 33.3
UDA ≥ 10 mm maximum dimension 390 22.4 232 13.7 622 18.1
UDA ≥ 15 mm average dimension 105 6.0 61 3.6 166 4.8
 
 
 P.2. Analysis of Any Ultrasound-Detected Abnormality Risk
P.2.a. Primary Analysis 
Among the 3429 participants whose thyroids were visible on ultrasound, 1596 (46.5%) had some
type of ultrasound-detected abnormality. These included 3181 in-area participants, of whom 1481 (46.6%)
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had any thyroid UDAs, and 248 out of area participants, of whom 115 (46.4%) had thyroid UDAs.  The
proportions with any thyroid UDA are shown by sex and dose category in Table IX.P-3.  The prevalence of
thyroid UDAs was higher among women (55.5%) compared to men (37.4%). The numbers and proportions
of cases of additional outcomes related to UDAs are also shown in Table IX.P-3.
Table IX.P-3. Any Ultrasound-Detected Abnormality by Sex and Dose Category
A.  Female
   
 Thyroid
Radiation
Dose
L.E. with
Ultrasound
Any Thyroid
UDA
Focal Thyroid
UDA with
Maximum
Dimension
> 5mm
Focal Thyroid
UDAs with
Maximum
Dimension
> 10 mm
Focal Thyroid
UDAs with
Average
Dimension 
> 15 mm
(mGy)    No.   No.     % No. % No. % No. %
Out of Area   124   64 51.6   50 40.3 26 21.0 4 3.2
< 10   182 100 54.9   73 40.1 43 23.6 10 5.5
10-49   318 171 53.8 126 39.6 73 23.0 16 5.0
50-99   311 172 55.3 118 37.9 65 20.9 16 5.1
100-149   220 131 59.5   97 44.1 53 24.1 13 5.9
150-199   125   65 52.0   49 39.2 32 25.6 14  11.2
200-299   137   79 57.7   59 43.1 26 19.0   6    4.4
300-399   143   80 55.9   55 38.5 26 18.2 11 7.7
400-999   171 100 58.5   73 42.7 46 26.9 15 8.8
1000+     7     2 28.6     1 14.3   0     --   0   --
Total 1738 964 55.5 701 40.3  390 22.4   105 6.0
 
 
 
 
 
 
 
 
 
 
 
 
       
 
 
 
 
 
 
 
 
 
 
 
 L.E. = living evaluable participants
B.  Male
 
 Thyroid
Radiation
Dose 
L.E. with 
Ultrasound 
 
Any Thyroid 
UDA
Focal Thyroid 
UDA with
Maximum
Dimension 
> 5mm 
 
Focal Thyroid 
UDA with
Maximum
Dimension
> 10 mm 
Focal Thyroid 
UDA with
Average
Dimension  
> 15 mm 
(mGy)    No.   No.     % No. % No. % No. % 
Out of  Area
< 10 
10-49 
50-99 
100-149 
150-199 
200-299 
300-399 
400-999 
1000+ 
Total 
  124
  185
  314
  310
  171
  109
  148
  160
  153
    17
1691
  51
  72
111
103
  64
  46
  66
  65
  44
  10
632
41.1
38.9
35.4
33.2
37.4
42.2
44.6
40.6
28.8
58.8
37.4
39
52
78
72
40
34
53
40
27
  6
 441
31.5
28.1
24.8
23.2
23.4
31.2
35.8
25.0
17.6
35.3
26.1
17
29
47
40
23
16
29
18
10
  3
 232
13.7
15.7
15.0
12.9
13.5
14.7
19.6
11.3
 6.5
17.6
13.7
 2
 9
14
12
 4
 5
 9
 4
 1
 1
61
1.6
4.9
4.5
3.9
2.3
4.6
6.1
2.5
0.7
5.9
3.6
L.E. = living evaluable participants
Parameter estimates for the linear dose-response model based on the 3181 in-area participants with
ultrasound results are shown in Table IX.P-4.  Based on maximum likelihood analysis of the sex-stratified
linear probability model, the risk of having any type of thyroid UDA did not increase significantly with
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estimated dose (p = 0.21), with an estimated slope B of 0.031 per Gy, and 95% CI ranging from −0.059 to
0.116 per Gy (Table IX.P-4, row 1).  Estimation by least squares using the ungrouped data gave nearly
identical results, and the least squares fit to the grouped data were similar (Table IX.P-4, rows 2 and 3).
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Table IX.P-4. Dose-Response Results for Diagnoses of Any Thyroid UDA
Estimated Background Rates
Row Outcome
Dose-
Response
Model
Dose
Estimates
Exclusions /
Additional
Inclusions
Method
of
Analysis Female Male
Estimated
Slope of Dose-
Response (per Gy)
Statistical
Significance of Dose-
Response
(one-tailed p-value)
1. Primary definition Linear Primary None MLE
.552 ± .014
(.519, .586)
.365 ± .014
(.332, .399)
.031 ± .038
(−.059, .116) 0.21
2. Primary definition Linear Primary None LSU
.552 ± .014
(.519, .585)
.365 ± .014
(.331, .399)
.032 ± .039
(−.061, .125) 0.21
3. Primary definition Linear Primary None LSG
.556 ± .014
(.522, .591)
.369 ± .015
(.334, .405)
.008 ± .045
(−.099, .115) 0.43
4.
Focal thyroid UDA
with max dimension ≥ 5
mm
Linear Primary None MLE
.406 ± .014
(.373, .438) 
.259 ± .013
(.228, .290)
-.013 ± .037
(-.097, .077)
0.64
5.
Focal thyroid UDA
with max dimension ≥
10 mm
Linear Primary None MLE
.231 ± .011
(.204, .258)
.143 ± .010
(.119, .167)
-.033 ± .026
(<-.061, .038)
0.88
Entries in the tables are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, “>”
indicates that the upper confidence limit is greater than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are
not given for estimated background rates from logistic regression model. 
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
Okanogan, F/S = Ferry/Stevens, OOA = out of area
Table continued on next page
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Table IX.P-4. Dose-Response Results for Diagnoses of Any Thyroid UDA (continued)
Estimated Background Rates 
Row Outcome
Dose-
Response
Model
Dose
Estimates
Exclusions /
Additional
Inclusions
Method
of
Analysis Female Male
Estimated
Slope of Dose-
Response (per Gy)
Statistical Significance
of Dose-Response
(one-tailed p-value)
6.
Focal thyroid UDA
with average dimension
≥ 15 mm
Linear Primary None MLE
.063 ± .007
(.047, .079)
0.038 ± .005
(.025, .051)
-.001 ± .015
(<-.017, .044)  
0.53
7. Primary definition LQ Primary None LSU
.546 ± .015
(.509, .584)
.359 ± .015
(.321, .397)
Lin: .086 ± .067
(−.078, .250)
Quad: −.045 ± .044
(−.153, .064)
Quad: 0.30
8. Primary definition Logistic Primary None MLE
.552
(.518, .586)
.365
(.333, .399)
.133 ± .162
(−.254, .520) 0.21
9. Primary definition Linear Primary
Exclude dose
> 1000 mGy
MLE
.552 ± .015
(.517, .587)
.362 ± .015
(.327, .397)
.042 ± .049
(<−.075, >.159) 0.20
10. Primary definition Linear Primary
Exclude dose
> 400 mGy
MLE
.535 ± .016
(.496, .575)
.356 ± .016
(.317, .395)
.179 ± .086
( −.027, .384) 0.019
11. Primary definition Linear Primary
Exclude
OK and F/S
geostrata
MLE
.547 ± .015
(.512, .583)
.353 ± .015
(.318, .387)
.047 ± .038
( −.045, .130) 0.11
Entries in the tables are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, “>”
indicates that the upper confidence limit is greater than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are
not given for estimated background rates from logistic regression model.
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
Okanogan, F/S = Ferry/Stevens, OOA = out of area
Table continued on next page
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Table IX.P-4. Dose-Response Results for Diagnoses of Any Thyroid UDA (continued)
Estimated Background Rates 
Row Outcome
Dose-
Response
Model
Dose
Estimates
Exclusions /
Additional
Inclusions
Method
of
Analysis Female Male
Estimated
Slope of Dose-
Response (per Gy)
Statistical
Significance of Dose-
Response
(one-tailed p-value)
12. Primary definition Linear Alt. #1 None MLE
.556 ± .014
(.521, .590)
.369 ± .014
(.335, .403)
.009 ± .038
(−.080, .097) 0.40
13. Primary definition Linear Alt. #2 None MLE
.555 ± .014
(.521, .590)
.368 ± .014
(.335, .402)
.012 ± .038
(−.078, .103) 0.37
14. Primary definition Linear Primary
Include OOA
(scoping
analysis #1)
MLE
.549 ± .013
(.518, .581)
.368 ± .013
(.337, .400)
.033 ± .037
(<-.056, .017)
0.19
15. Primary definition Linear Primary
Include OOA
(scoping
analysis #2)
MLE
.550 ± .013
(.518, .582)
.369 ± .013
(.338, .401)
.027 ± .037
(−.062, .112) 0.24
Entries in the tables are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, “>”
indicates that the upper confidence limit is greater than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are
not given for estimated background rates from logistic regression model. 
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
Okanogan, F/S = Ferry/Stevens, OOA = out of area
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P.2.b. Effect of Using Alternative Size Criteria for Thyroid UDAs
To assess whether the dose-response results might be affected by the size of focal thyroid UDAs,
three additional outcomes were analyzed.  These included the presence of a focal thyroid UDA with
maximum dimension at least 5 mm, the presence of a focal thyroid UDA with maximum dimension at least
10 mm, and the presence of a focal thyroid UDA with average dimension at least 15 mm.  These additional
analyses applied only to palpable and nonpalpable focal thyroid UDAs, since diffuse thyroid UDAs were
not defined by any size criterion.  In none of these additional analyses was there any evidence that the risk
of having a focal thyroid UDA of a particular size increased with increasing dose (p = 0.64, 0.88 and 0.53
for the presence of focal thyroid UDA with maximum dimension of 5 mm, maximum dimension of 10 mm
and average dimension of 15 mm, respectively; Table IX.P-4, rows 4, 5, and 6).
P.2.c. Alternative Dose-Response Functions 
As shown in row 7 of Table IX.P-4, the estimated regression coefficient for the dose-squared term
in the linear-quadratic dose-response model [5] was −0.045 with Bonferroni-adjusted 95% confidence
interval ranging from –0.153 to 0.064.  Thus the addition of a quadratic term did not significantly improve
the fit of the model (p = 0.30).
The regression parameter for the effect of dose in the sex-stratified logistic regression model [2]
was estimated as 0.133, with Bonferroni-adjusted 95% confidence limits –0.254 and 0.520, indicating that
the prevalence of any thyroid UDA did not increase significantly with increasing dose (p = 0.21; Table
IX.P-4, row 8).
P.2.d. Effect of Excluding Participants in High Dose Categories
In the analyses excluding participants with estimated dose > 1000 mGy (Table IX.P-4, row 9), the
estimated slope B was not significantly greater than zero (0.042 per Gy, with Bonferroni-adjusted 95% CI
ranging from less than −0.075 to greater than 0.159) providing no evidence that the prevalence of any
thyroid UDA increased with increasing dose (p = 0.20).  When all participants with estimated dose > 400
mGy were excluded (Table IX.P-4, row 10), the estimated slope B was not significantly greater than zero
(0.179 per Gy, with Bonferroni-adjusted 95% CI ranging from −0.027 to 0.384). Although there was some
evidence that the prevalence of any thyroid UDA increased with increasing dose (p = .019), this finding
was not considered statistically significant given the large number of such tests that were performed. 
P.2.e. Effect of Excluding Okanogan and Ferry/Stevens Geostrata
As shown in row 11 of Table IX.P-4, excluding Okanogan and Ferry/Stevens slightly reduced the
estimated background rates for both men and women.  The reductions are small, because the Okanogan and
Ferry/Stevens geostrata account for only 255 (8.0%) of the 3181 in-area living evaluable participants with
ultrasound results.  As a result of these reductions in the background rates and the fact that Okanogan and
Ferry/Stevens geostrata tend to have low doses, the estimated slope increased slightly, from 0.031 to 0.047,
and the statistical significance of the dose-response changed from p = 0.21 to p = 0.11.
P.2.f. Analysis of Ultrasound-Detected Abnormalities in Relation to Alternative Dose
Estimates
As shown in row 12 of Table IX.P-4, using the first alternative dose estimates, the estimated slope
B was not significantly greater than zero (0.009 per Gy with Bonferroni-adjusted 95% CI ranging from 
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-0.080 to 0.097), providing no evidence that prevalence increased with increasing dose (p = 0.40; Table
IX.P-4, row 12).  Similar results were found with the second set of alternative dose estimates (Table IX.P-
4, row 13).
P.2.g. Scoping Analysis Regarding Out-of-Area Participants
See section VIII.C.1.a.3 for a description of the scoping analyses that were performed to assess the
possible impact of the 249 out-of-area participants. The results of both scoping analyses were virtually the
same as the primary analysis and provided no evidence that the prevalence of any thyroid UDA increased
with increasing dose (Table IX.P-4, rows 14 and 15).
P.2.h. Analysis of Any Thyroid UDAs In Relation to Alternative Representations of
Exposure
In the analyses by geostratum and by dichotomous exposure variable, the sex and age-adjusted
comparisons of prevalence were performed as described in section VIII.C.2.a.2.
P.2.h.1. Analysis by Geostratum
As shown in Table IX.P-5, among the 3429 living evaluable in area or out-of-area participants
with ultrasound results, the proportions with any UDAs ranged from 83/131 (63.4% in the Walla Walla
City geostratum) to 92/177 (52.0%, Richland) for women, and from 32/63 (50.8%, Okanogan County) to
41/164 (25.0%, Walla Walla County) for men (p = 0.014 for heterogeneity among the nine geostrata).  In
particular the percentages with any UDAs were somewhat higher in the Okanogan and Ferry/Stevens
geostrata (58.7% for women, 48.1% for men) than in the remaining geostrata (55.2% and 36.5%,
respectively; p = 0.012).  Since it was likely that participants in the Okanogan and Ferry/Stevens geostrata
tended to have lower thyroid doses from Hanford’s 131I than those in other geostrata, it does not appear that
these differences can be attributed to an effect of Hanford’s 131I.
Table IX.P-5. Any Ultrasound-Detected Abnormality, by Geostratum and Sex
Female Male Total
Geostratum No. Cases % No. Cases % No. Cases %
Richland 177 92 52.0 172 60 34.9 349 152 43.6
Pasco/Kennewick 505 273 54.1 501 176 35.1 1006 449 44.6
Benton County 375 206 54.9 358 146 40.8 733 352 48.0
Franklin County 73 42 57.5 76 36 47.4 149 78 52.3
Adams County 165 93 56.4 156 66 42.3 321 159 49.5
Walla Walla (city) 131 83 63.4 131 43 32.8 262 126 48.1
Walla Walla County 169 91 53.8 164 41 25.0 333 132 39.6
Okanogan County 75 43 57.3 63 32 50.8 138 75 54.3
Ferry/Stevens Counties 68 41 60.3 70 32 45.7 138 73 52.9
Total 1738 964 55.5 1691 632 37.4 3429 1596 46.5
P.2.h.2. Analysis by Dichotomous Exposure Variable
Ultrasound was not evaluable for 2 of the 1257 living evaluable participants included in these
analyses.  Of the 1255 participants included in these analyses, 611 (48.7%) had one or more thyroid UDAs
(Table IX.P-6).  These included 291/580 (50.2%) in the high exposure group, and 320/675 (47.4%) in the
low exposure group.  Based on the logistic regression analysis with adjustment for the effect of sex and age
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at HTDS examination, the proportion of participants with any thyroid UDA was not significantly elevated
in the high exposure group (p = 0.11).
Table IX.P-6. Any Ultrasound-Detected Abnormality, by Exposure Group and Sex 
Exposure Female Male Total
Group No. Cases     % No. Cases    %  No. Cases     %
Low 350 192 54.9 325 128 39.4   675 320   47.4
High 298 183 61.4 282 108 38.3   580 291 50.2
Total 648 375 57.9 607 236 38.9 1255 611 48.7
P.2.i. Confounding and Effect Modification
As described in section VIII above, additional sex-stratified logistic regression models were
investigated to examine the possibility that the primary dose-response results for any thyroid UDA might
be influenced by confounding, and to search for factors that might modify a radiation dose-response.  Table
IX.P-7 displays results for models including sex, age at first exposure to Hanford I-131 (prenatal, or < 180
days), age at HTDS examination, estimated dose from the NTS, history of any cancer other than thyroid,
and HTDS interview type.  
Note that sex was not analyzed as a possible confounder since its effect was already adjusted for in
the sex-stratified model.  None of the other factors in Table IX.P-7 appears to be a confounder: for none
does the adjusted estimate of the regression coefficient differ markedly from the unadjusted estimate.
Therefore, it does not appear that omitting these factors introduced any important bias in the dose-response
results.
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Table IX.P-7. Confounding and Effect Modification by Sex, Age at Exposure or HTDS
Examination, Estimated Thyroid Dose from NTS, History of Any Cancer Other
than Thyroid, and Interview Type: Any Ultrasound-Detected Abnormality
Estimated Dose-Response Coefficient (per Gy)
Covariate Yes / Unadjusted Incl. Confounding Including Effect Modification
(0=No, 1=Yes) Total Estimate Estimate Group 0 Group 1 P
Female?
1614 /
3181
.133 ± .162
(−.254, .520) Not Applicable
.198 ± .226
(−.368, .763)
.067 ± .228
(−.504, .637) .68
Prenatal
exposure?
1031 /
3181
.133 ± .162
(−.254, .520)
.087 ± .163
(−.332, .506)
.190 ± .188
(−.305, .685)
−.235 ± .333
(−1.12, .644) .26
1st exposure
before age 180
days?
1474 /
3181
.133 ± .162
(−.254, .520)
.121 ± .162
(−.297, .539)
.373 ± .279
(−.362, 1.11)
−.010 ± .200
(−.538, .519) .26
Age at exam >
50?
1993 /
3181
.133 ± .162
(−.254, .520)
.178 ± .164
(−.246, .601)
−.038 ± .297
(−.822, .746)
.271 ± .197
(−.248, .791) .39
NTS I-131
dose > 5.3 mGy?
1563 /
3179
.127 ± .162
(−.260, .514)
.111 ± .165
(−.314, .536)
.106 ± .219
(−.471, .682)
.118 ± .251
(−.544, .781) .97
History of any
cancer other than
thyroid?
248 /
3176
.138 ± .162
(−.249, .525)
.141 ± .162
(−.276, .557)
.219 ± .176
(−.244, .683)
−.300 ± .427
(−1.43, .827) .25
Expanded In-
Person Interview?
1205 /
3181
.133 ± .162
(−.254, .520)
.159 ± .165
(−.266, .584)
.277 ± .263
(−.416, .970)
.083 ± .211
(−.475, .640) .56
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses, based on sex-
stratified logistic regression models.  P-values indicate the statistical significance of two-tailed comparison of estimated coefficients
between Groups 0 and 1.
Tables IX.P-8 and IX.P-9 display similar results from analyses including history of medical or
dental x-ray exposure or occupational exposure as potential confounding or effect modifying factors.
Specifically, none of the factors in these tables appears to be a confounder or an effect modifier.
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Table IX.P-8. Confounding and Effect Modification by History of Medical and Dental Radiation
Exposures: Any Ultrasound-Detected Abnormality
Have You
Estimated Dose-Response Coefficient (per Gy)
Ever Had: Yes / Unadjusted Incl. Confounding Including Effect Modification
(0=No, 1=Yes) Total Estimate Estimate Group 0 Group 1 P
CAT scan of the
upper body?
775 /
3139
.130 ± .162
(−.257, .518)
.130 ± .162
(−.288, .548)
.064 ± .178
(−.406, .533)
.450 ± .391
(−.581, 1.48) .37
Diagnostic x-rays
of the head?
1188 /
3145
.133 ± .163
(−.257, .523)
.129 ± .163
(−.291, .549)
.257 ± .204
(−.280, .795)
−.110 ± .279
(−.845, .625) .29
Diagnostic x-rays
of the neck?
960 /
3157
.126 ± .162
(−.263, .515)
.129 ± .163
(−.290, .548)
.016 ± .211
(−.541, .574)
.299 ± .263
(−.394, .993) .40
Diagnostic x-rays
of chest or upper
body, including
mammograms?
2811 /
3163
.130 ± .162
(−.257, .518)
.141 ± .162
(−.276, .558)
.503 ± .573
(−1.01, 2.01)
.110 ± .169
(−.335, .555) .51
Diagnostic x-rays
of the stomach or
mid-back?
691 /
3110
.175 ± .164
(−.218, .567)
.178 ± .164
(−.244, .601)
.141 ± .183
(−.342, .625)
.327 ± .370
(−.649, 1.30) .65
Barium enema?
821 /
3149
.122 ± .162
(−.266, .510)
.123 ± .162
(−.295, .540)
.200 ± .189
(−.298, .698)
−.097 ± .318
(−.937, .743) .42
Upper GI?
1140 /
3167
.126 ± .162
(−.262, .513)
.122 ± .162
(−.295, .539)
.067 ± .204
(−.471, .604)
.216 ± .267
(−.488, .921) .66
Intravenous
pyelogram?
396 /
3147
.143 ± .162
(−.246, .532)
.146 ± .163
(−.273, .565)
.090 ± .173
(−.366, .545)
.585 ± .482
(−.686, 1.86) .33
Fluoroscopy of the
upper body?
246 /
3151
.140 ± .162
(−.249, .528)
.141 ± .162
(−.278, .559)
.125 ± .169
(−.319, .570)
.335 ± .601
(−1.25, 1.92) .74
Other nuclear
scan?
216 /
3152
.132 ± .162
(−.256, .520)
.134 ± .162
(−.284, .552)
.216 ± .168
(−.228, .660)
−1.15 ± .698
(−2.99, .693) .049
Dental x-rays that
did not usually
include a lead
shield over the
neck area?
1644 /
3181
.133 ± .162
(−.254, .520)
.131 ± .162
(−.285, .547)
.280 ± .231
(−.330, .890)
−.013 ± .227
(−.611, .585) .36
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses, based on sex-
stratified logistic regression models.  P-values indicate the statistical significance of two-tailed comparison of estimated coefficients
between Groups 0 and 1.
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Table IX.P-9. Confounding and Effect Modification by Occupational History: Any Ultrasound-
Detected Abnormality
Have You Ever
Worked in Any of
Estimated Dose-Response Coefficient (per Gy)
the Following: Yes / Unadjusted Incl. Confounding Including Effect Modification
(0=No, 1=Yes) Total Estimate Estimate Group 0 Group 1 P
Any metal
industry?
238 /
3181
.133 ± .162
(−.254, .520)
.130 ± .162
(−.286, .546)
.114 ± .166
(−.325, .553)
.385 ± .665
(−1.37, 2.14) .69
Any nuclear
facility?
370 /
3181
.133 ± .162
(−.254, .520)
.119 ± .163
(−.300, .539)
.063 ± .180
(−.412, .538)
.370 ± .379
(−.630, 1.37) .46
Any othe industry
or occupation
where you may
have been exposed
to radioactive
materials or x-
rays?
442 /
3181
.133 ± .162
(−.254, .520)
.132 ± .162
(−.284, .548)
.236 ± .179
(−.237, .709)
−.345 ± .398
(−1.40, .706) .17
Any of the above
industries or
occupations?
891 /
3181
.133 ± .162
(−.254, .520)
.138 ± .162
(−.280, .555)
.154 ± .200
(−.374, .683)
.106 ± .276
(−.622, .834) .89
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses, based on sex-
stratified logistic regression models.  P-values indicate the statistical significance of two-tailed comparison of estimated coefficients
between Groups 0 and 1.
Table IX.P-10 displays the results of analyses of possible confounding or effect modification by
smoking variables.  There was some evidence that the dose-response coefficient differed between
participants with versus without histories of smoking cigarettes (p = 0.034) or any of cigarettes, cigars or
pipes (p = 0.024). The estimated dose-response coefficients were greater than zero among nonsmokers, but
negative for smokers.  However the Bonferroni-adjusted 95% confidence intervals for the smokers’ and
nonsmokers’ estimated coefficients overlapped, including the value of zero in the overlap.  In view of the
modest significance levels of the effect modification and the large number of comparisons performed in
these analyses, these results do not provide compelling evidence of a statistically significant dose-response
within the nonsmoking cohort.
Table IX.P-10. Confounding and Effect Modification by Smoking: Any Ultrasound-Detected
Abnormality
Have You Ever
Smoked Any of
Estimated Dose-Response Coefficient (per Gy)
the Following: Yes / Unadjusted Incl. Confounding Including Effect Modification
(0=No, 1=Yes) Total Estimate Estimate Group 0 Group 1 P
Cigarettes
(unfiltered or
filtered)?
1850 /
3173
.140 ± .162
(−.248, .527)
.139 ± .162
(−.278, .556)
.620 ± .281
(−.120, 1.36)
−.109 ± .200
(−.637, .420) .034
Any of cigarettes,
cigar or pipe?
1896 /
3173
.140 ± .162
(−.248, .527)
.139 ± .162
(−.278, .556)
.661 ± .285
(−.092, 1.41)
−.118 ± .199
(−.643, .407) .024
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses, based on sex-
stratified logistic regression models.  P-values indicate the statistical significance of two-tailed comparison of estimated coefficients
between Groups 0 and 1.
P.2.j. Uncertainty
The estimated slopes of the sex-stratified linear dose-response model for the outcome of any
thyroid UDA are shown in Figure IX.P-1 for each of the 100 dose realizations produced by the CIDER
model.  The confidence intervals in that figure are calculated at the 98.33% confidence level, i.e., are
adjusted by the Bonferroni technique for the simultaneous estimation of the slope and two sex-specific
background rates.  While the point estimate of the slope is greater than 0 for 87 of the 100 realizations, the
confidence interval includes 0 for all but 1 of the realizations.  Also shown in Figure IX.P-1 (to the right of
realization 100) are the estimates and confidence intervals calculated using (from left to right) the median,
geometric mean and mean of each participant's 100 dose realizations. In summary, for only one of the 100
realizations of the estimated doses was there a statistically significant dose-response, although for most of
the realizations the estimated slope was greater than 0.
Figure IX.P-1. Plot of Estimated Slope and 95% CI by Dose Realization: Any Ultrasound-Detected 
Abnormality
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Figure IX.P-2 displays the distribution of the 5000 logistic regression coefficient estimates
obtained by the simulation procedures described in section VIII.C.2.b.3 above. It is evident from the figure
that most of the estimates were between about –0.5 and 1.0. The estimate was less than or equal to 0 for
759 of the 5000 replications, implying an empirical one-tailed p-value of 0.15.  The median estimate was
0.22, and the upper and lower percentiles corresponding to the Bonferroni-adjusted 95% confidence
interval were –0.29 and 0.74.  These may be compared to the p-value of 0.21 and the estimate of 0.13 with
confidence internal (−0.25, 0.52) obtained using the median dose estimates without adjustment for
uncertainty. Thus, this method of adjusting the estimated logistic regression coefficient for the uncertainty
in the dose estimates did not provide evidence that the prevalence of any thyroid UDA increased
significantly with increasing dose.
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Figure IX.P-2. Distribution of Simulation Estimates of Logistic Regression Coefficient: Any 
Ultrasound-Detected Abnormality
slope sample: 5000
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P.2.k. Analyses of Numbers of Thyroid UDAs
In the analyses described above, participants were classified according to whether they did or did
not have any thyroid UDAs.  Additional analyses were performed to investigate whether the number of
thyroid UDAs detected in individual participants might increase in relation to estimated thyroid radiation
dose.  For each living evaluable participant with an HTDS ultrasound examination, the numbers of focal
thyroid UDAs with maximum dimension ≥ 5 mm, maximum dimension ≥ 10 mm, and average dimension ≥
15 mm were counted.  These numbers of thyroid UDAs are summarized in Tables IX.P-11 through IX.P-13
below.  As shown in Table IX.P-11, study participants had as many as nine thyroid UDAs with maximum
dimension ≥ 5 mm, although the majority (60% of the women and 74% of the men) had no such thyroid
UDAs.  The overall average number of thyroid UDAs of this size was 0.84 per person for women, and 0.47
per person for men.
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Table IX.P-11. Number of Ultrasound-Detected Abnormalities of the Thyroid with Maximum
Dimension ≥ 5 mm, by Sex and Dose Category
A.  Female
Number of Ultrasound-Detected Abnormalities of the Thyroid with Maximum Dimension ≥ 5 mm
Thyroid
Radiation
Dose
(mGy)
Living
Evaluable
Female
No. Avg. 0 1 2 3 4 5 6 7 8 9
OOA* 124 0.94
    74
59.7%
  26
21.0%
    9
7.3%
  6
4.8%
  2
1.6%
  2
1.6%
1
0.8%
  2
1.6%
1
0.8%
1
0.8%
< 10 182 0.82
  109
59.9%
  40
22.0%
  13
7.1%
  9
4.9%
  5
2.7%
2
1.1%
2
1.1%
2
1.1%
0 0
10-49 318 0.83
  192
60.4%
  66
20.8%
  22
6.9%
15
4.7%
13
4.1%
4
1.3%
5
1.6%
1
0.3%
0 0
50-99 311 0.81
  193
62.1%
  59
19.0%
  26
8.4%
15
4.8%
  6
1.9%
4
1.3%
6
1.9%
1
0.3%
1
0.3%
0
100-149 220 0.89
  123
55.9%
  55
25.0%
  19
8.6%
  8
3.6%
  9
4.1%
2
0.9%
0
1
0.5%
2
0.9%
1
0.5%
150-199 125 0.83
    76
60.8%
  27
21.6%
    9
7.2%
  2
1.6%
  6
4.8%
2
1.6%
2
1.6%
1
0.8%
0 0
200-299 137 0.86
    78
56.9%
  29
21.2%
  17
12.4%
  5
3.6%
  4
2.9%
1
0.7%
2
1.5%
1
0.7%
0 0
300-399 143 0.81
    88
61.5%
  30
21.0%
    9
6.3%
10
7.0%
  1
0.7%
  1
0.7%
  1
0.7%
  1
0.7%
2
1.4%
0
400-999 171 0.82
    98
57.3%
  38
22.2%
  19
11.1%
  8
4.7%
  5
2.9%
1
0.6%
1
0.6%
0 0
1
0.6%
1000+ 7 0.14
      6
85.7%
    1
14.3%
    
0
  
0
  
0 0 0 0 0 0
Total 1738 0.84
1037
59.7%
371
21.4%
143
8.2%
78
4.5%
51
2.9%
19
1.1%
20
1.2%
10
0.6%
6
0.4%
3
0.2%
*OOA = Out of Area
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Table IX.P-11. Number of Ultrasound-Detected Abnormalities of the Thyroid with Maximum
Dimension ≥ 5 mm, by Sex and Dose Category (continued)
B.  Male
Number of Ultrasound-Detected Abnormalities of the Thyroid with Maximum Dimension ≥ 5 mm
Thyroid
Radiation
Dose
(mGy)
Living
Evaluable
Male
No. Avg. 0 1 2 3 4 5 6 7 8 9
OOA 124 0.56
85
68.6%
22
17.7%
11
8.9%
3
2.4%
1
0.8%
0
1
0.8%
1
0.8%
0 0
< 10 185 0.49
133
71.9%
30
16.2%
12
6.5%
3
1.6%
7
3.8%
0 0 0 0 0
10-49 314 0.44
236
75.2%
50
15.9%
13
4.1%
5
1.6%
6
1.9%
3
1.0%
0 0 0
1
0.3%
50-99 310 0.42
238
76.8%
46
14.8%
12
3.9%
6
1.9%
3
1.0%
1
0.3%
3
1.0%
0
1
0.3%
0
100-149 171 0.42
131
76.6%
25
14.6%
8
4.7%
1
0.6%
3
1.8%
3
1.8%
0 0 0 0
150-199 109 0.53
75
68.8%
21
19.3%
5
4.6%
6
5.5%
1
0.9%
1
0.9%
0 0 0 0
200-299 148 0.72
95
64.2%
30
20.3%
14
9.5%
2
1.4%
2
1.4%
0
3
2.0%
1
0.7%
0
1
0.7%
300-399 160 0.47
120
75.0%
25
15.6%
6
3.8%
4
2.5%
2
1.3%
1
0.6%
1
0.6%
1
0.6%
0 0
400-999 153 0.22
126
82.4%
22
14.4%
4
2.6%
0
1
0.7%
0 0 0 0 0
1000+ 17 0.82
11
64.7%
3
17.7%
1
5.9%
1
5.9%
0 0
1
5.9%
0 0 0
Total 1691 0.47
1250
73.9%
274
16.2%
86
5.1%
31
1.8%
26
1.5%
9
0.5%
9
0.5%
3
0.2%
1
0.1%
2
0.1%
*OOA = Out of Area
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Focal thyroid UDAs of larger sizes were necessarily less frequent.  As shown in Table IX.P-12,
participants had as many as eight focal thyroid UDAs with maximum dimension ≥ 10 mm.  Again, the
majority (78% of women and 86% of men) had no such thyroid UDAs, and the overall average number of
thyroid UDAs of this size was 0.34 for women and 0.19 for men.
Table IX.P-12. Number of Ultrasound-Detected Abnormalities of the Thyroid with Maximum
Dimension ≥ 10 mm, by Sex and Dose Category
A.  Female
Number of Ultrasound-Detected Abnormalities of the Thyroid with Maximum
Dimension ≥ 10 mm
Thyroid
Radiation
Dose
(mGy)
Living
Evaluable
Female
No. Avg. 0 1 2 3 4 5 6 8
OOA 124 0.34
98
79.0%
17
13.7%
6
4.8%
0
2
1.6%
1
0.8%
0 0
< 10 182 0.36
139
76.4%
29
15.9%
8
4.4%
4
2.2%
2
1.1%
0 0 0
10-49 318 0.33
245
77.0%
51
16.0%
14
4.4%
6
1.9%
2
0.6%
0 0 0
50-99 311 0.30
246
79.1%
48
15.4%
12
3.9%
2
0.6%
1
0.3%
2
0.6%
0 0
100-149 220 0.40
167
75.9%
33
15.0%
13
5.9%
4
1.8%
2
0.9%
0 0
1
0.5%
150-199 125 0.42
93
74.4%
22
17.6%
5
4.0%
1
0.80
3
2.4%
1
0.8%
0 0
200-299 137 0.26
111
81.0%
20
14.6%
4
2.9%
1
0.7%
1
0.7%
0 0 0
300-399 143 0.31
117
81.8%
15
10.5%
9
6.3%
0
1
0.7%
0 0
1
0.7%
400-999 171 0.43
125
73.1%
30
17.5%
11
6.4%
1
0.6%
2
1.2%
1
0.6%
1
0.6%
0
1000+ 7 0.00
7
100%
0 0 0 0 0 0 0
Total 1738 0.34
1348
77.6%
265
15.3%
82
4.7%
19
1.1%
16
0.9%
5
0.3%
1
0.1%
2
0.1%
*OOA = Out of Area
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Table IX.P-12. Number of Ultrasound-Detected Abnormalities of the Thyroid with Maximum
Dimension ≥ 10 mm, by Sex and Dose Category (continued)
B.  Male
Number of Ultrasound-Detected Abnormalities of the Thyroid with Maximum
Dimension ≥ 10 mm
Thyroid
Radiation
Dose
(mGy)
Living
Evaluable
Male
No. Avg. 0 1 2 3 4 5 6 8
OOA 124 0.16
107
86.3%
14
11.3%
3
2.4%
0 0 0 0 0
< 10 185 0.20
156
84.3%
22
11.9%
6
3.2%
1
0.5%
0 0 0 0
10-49 314 0.18
267
85.0%
40
12.7%
5
1.6%
2
0.6%
0 0 0 0
50-99 310 0.19
270
87.1%
31
10.0%
4
1.3%
4
1.3%
0 0 0
1
0.3%
100-149 171 0.17
148
86.6%
19
11.1%
3
1.8%
0
1
0.6%
0 0 0
150-199 109 0.18
93
85.3%
14
12.8%
1
0.9%
0
1
0.9%
0 0 0
200-299 148 0.31
119
80.4%
19
12.8%
7
4.7%
1
0.7%
1
0.7%
0
1
0.7%
0
300-399 160 0.19
142
88.8%
13
8.1%
1
0.6%
2
1.3%
1
0.6%
1
0.7%
0 0
400-999 153 0.07
143
93.5%
9
5.9%
1
0.7%
0 0 0 0
0
1000+ 17 0.35
14
82.4%
2
11.8%
0 0
1
5.9%
0 0 0
Total 1691 0.19
1459
86.3%
183
10.8%
31
1.8%
10
0.6%
5
0.3%
1
0.1%
1
0.1%
1
0.1%
*OOA = Out of Area
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As shown in Table IX.P-13 participants had as many as six focal thyroid UDAs with average
dimension ≥ 15 mm.  Again, the majority (94% of women and 96% of men) had no such thyroid UDAs,
and the overall average number of thyroid UDAs of this size was 0.07 for women and 0.05 for men.
Table IX.P-13. Number of Ultrasound-Detected Abnormalities of the Thyroid with Average
Dimension ≥ 15 mm, by Sex and Dose Category
A.  Female
Number of Ultrasound-Detected Abnormalities of the Thyroid
with Average Dimension ≥ 15 mm
Thyroid
Radiation
Dose
(mGy)
Living
Evaluable
Female
No. Avg. 0 1 2 3 6
OOA 124 0.03
120
96.8%
4
3.2%
0 0 0
< 10 182 0.06
172
94.5%
9
5.0%
1
0.6%
0 0
10-49 318 0.06
302
95.0%
13
4.1%
3
0.9%
0 0
50-99 311 0.06
295
94.9%
14
4.5%
1
0.3%
1
0.3%
0
100-149 220 0.08
207
94.1%
10
4.6%
2
0.9%
1
0.5%
0
150-199 125 0.12
111
88.8%
13
10.4%
1
0.8%
0 0
200-299 137 0.05
131
95.6%
5
3.7%
1
0.7%
0 0
300-399 143 0.08
132
92.3%
10
7.0%
1
0.7%
0 0
400-999 171 0.12
156
91.2%
11
6.4%
3
1.8%
1
0.6%
0
1000+ 7 0.00
7
100%
0 0 0 0
Total 1738 0.07
1633
94.0%
89
5.1%
13
0.8%
3
0.2%
0
*OOA = Out of Area
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Table IX.P-13. Number of Ultrasound-Detected Abnormalities of the Thyroid with Average
Dimension ≥ 15 mm, by Sex and Dose Category (continued)
B.  Male
Number of Ultrasound-Detected Abnormalities of the Thyroid
with Average Dimension  ≥ 15 mm
Thyroid
Radiation
Dose
(mGy)
Living
Evaluable
Male
No. Avg. 0 1 2 3 6
OOA 124 0.02
122
98.4%
1
0.8%
1
0.8%
0 0
< 10 185 0.06
176
95.1%
7
3.8%
1
0.5%
1
0.5%
0
10-49 314 0.05
300
95.5%
13
4.1%
1
0.32%
0 0
50-99 310 0.06
298
96.1%
10
3.2%
1
0.3%
0
1
0.3%
100-149 171 0.03
167
97.7%
3
1.8%
1
0.6%
0 0
150-199 109 0.05
104
95.4%
5
4.6%
0 0 0
200-299 148 0.09
139
93.9%
5
3.4%
3
2.0%
1
0.7%
0
300-399 160 0.03
156
97.5%
4
2.5%
0 0 0
400-999 153 0.01
152
99.4%
1
0.7%
0 0 0
1000+ 17 0.06
16
94.1%
1
5.9%
0 0 0
Total 1691 0.05
1630
96.4%
50
3.0%
8
0.5%
2
0.1%
1
0.1%
*OOA = Out of Area
Figure IX.P-3 below shows how the average numbers of thyroid UDAs per person, for each of the
three size criteria, varied in relation to sex and estimated dose for living evaluable in-area participants.  Due
to the small number of participants in the 1000+ mGy dose category, it is combined with the 400-999 mGy
category in Figure IX.P-3.
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Figure IX.P-3. Average Number of Thyroid UDAs per Person, by Sex, Dose Category, and UDA
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Results of fitting sex-stratified Poisson regression models for the relationship between estimated
thyroid radiation dose and number of focal thyroid UDAs are summarized in Table IX.P-14 below.  In this
table, the estimated dose-response parameter represents the multiplicative change per Gy in the average
number of thyroid UDAs per person.  For none of these three size criteria did the average number of
thyroid UDAs per person increase significantly with increasing estimated dose.  For example, for focal
thyroid UDAs with maximum dimension ≥ 5 mm, the average number of such thyroid UDAs per person
decreased by an estimated factor of 1– 0.92 = 0.08 or 8% for each increase of 1 Gy in the estimated dose. 
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Consequently the average number of such thyroid UDAs per person did not increase significantly with
estimated dose (p = 0.80).  The Bonferroni-adjusted 95% confidence interval for the dose-response
parameter ranged from 0.72 to 1.17, encompassing a range from a 28% decrease to a 17% increase per Gy.
Table IX.P-14. Poisson Regression Analyses of Numbers of Thyroid UDAs
Size Criterion
For Focal Thyroid
UDAs
Estimated Background Averages
Female                             Male
Estimated 
Dose-response
Parameter (per Gy)
Statistical
Significance of
Dose-response
(one-tailed p-
value)
Max ≥ 5 mm 0.84  (0.78, 0.91) 0.47  (0.42, 0.51) 0.92  (0.72, 1.17) 0.80
Max ≥ 10 mm 0.34  (0.30, 0.39) 0.19  (0.16, 0.22) 1.01  (0.70, 1.46) 0.48
Avg ≥ 15 mm 0.07  (0.06, 0.10) 0.05  (0.03, 0.06) 1.05  (0.50, 2.23) 0.43
For focal UDAs with average diameter ≥ 15 mm, the average number of such UDAs per person
increased by an estimated factor of 1.05 – 1 = 0.05 or 5% for each increase of 1 Gy in the estimated dose
(p = 0.43).  The Bonferroni-adjusted 95% confidence interval for the dose-response parameter
encompassed a range from a 50% decrease to a 123% increase per Gy.
P.3. Palpable Ultrasound-Detected Abnormalities of the Thyroid
 Of the 3429 living evaluable participants whose thyroids were visible on the HTDS ultrasound,
224 (6.5%) had palpable ultrasound-detected abnormalities (Table IX.P-15).  The ultrasound-detected
thyroid abnormalities were based only on the HTDS evaluation.
 
 Table IX.P-15. Proportion of Participants with HTDS Ultrasound Findings of Palpable Thyroid
UDAs, by Sex
 
  Female Male                  Total
Ultrasound Finding No. % No. % No. %
Thyroid Gland visible on ultrasound 1738 100.0 1691 100.0 3429 100.0
Palpable thyroid UDAs 154 8.9 70 4.1 224 6.5
 
       
       
       
 
 
P.3.a. Primary Analysis 
The number and proportion of living evaluable participants with palpable thyroid UDAs is shown
by sex, in-area status, and dose group in Table IX.P-16.
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Table IX.P-16. Palpable Ultrasound-Detected Abnormalities by Sex and Estimated Dose
 
 Thyroid
Female Male
Radiation
Dose
L.E. with
Ultrasound
Palpable Thyroid
UDA
L.E. with
Ultrasound
Palpable Thyroid
UDA
(mGy)        No.      No.      %      No.    No.     %
Out of Area     124     14 11.3   124   6 4.8
< 10     182     17   9.3   185   8 4.3
10-49     318     28   8.8   314 17 5.4
50-99     311     27   8.7   310 15 4.8
100-149     220     18   8.2   171   5 2.9
150-199     125     12   9.6   109   4 3.7
200-299     137     11   8.0   148 10 6.8
300-399     143       9   6.3   160   3 1.9
400-999     171     18 10.5   153   2 1.3
1000+         7       0     --     17   0   --
Total   1738   154   8.9 1691 70 4.1
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 L.E. = living evaluable participants
Of the 224 living evaluable participants with a palpable thyroid UDA, 20 were out-of-area
participants.  Parameter estimates for the linear dose-response model based on the 3181 in-area participants
with ultrasound results are shown in Table IX.P-17.  Based on maximum likelihood analysis of the
sex-stratified linear probability model, the risk of having palpable thyroid UDA did not increase
significantly with estimated dose (p = 0.95), with a negative estimated slope B of −0.018 per Gy (Table
IX.P-17, row 1).  The Bonferroni-adjusted lower 95% confidence limit was not estimated due to the
magnitude of the negative slope estimate, however the upper confidence limit was 0.015 per Gy.
Estimation by least squares using either the ungrouped or grouped data gave nearly identical results (Table
IX.P-17, rows 2 and 3).
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Table IX.P-17. Dose-Response Results for Diagnoses of Palpable Thyroid UDA
Estimated Background Rates 
Row Outcome
Dose-
Response
Model
Dose
Estimates
Exclusions /
Additional
Inclusions
Method
of
Analysis Female Male
Estimated
Slope of Dose-
Response (per Gy)
Statistical Significance
of Dose-Response
(one-tailed p-value)
1. Primary definition Linear Primary None MLE
.090 ± .008
(.070, .110)
.043 ± .006
(.029, .057)
−.018 ± .023
(NE, .015)
0.95
2. Primary definition Linear Primary None LSU
.090 ± .007
(.074, .107)
.044 ± .007
(.027, .061)
−.020 ± .019
(−.066, .027) 0.85
3. Primary definition Linear Primary None LSG
.091 ± .007
(.074, .109)
.046 ± .007
(.028, .063)
−.027 ± .022
(−.080, .026) 0.89
4. Primary definition LQ Primary None MLE
.090 ± .008
(.072, .109)
.045 ± .008
(.026, .064)
Lin: −.022 ± .033
(−.103, .060)
Quad: .002 ± .022
(−.053, .056)
Quad: 0.94
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, “NE”
indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are not given for estimated background rates from logistic regression model. 
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
Okanogan, F/S = Ferry/Stevens, OOA = out of area
Table continued on next page
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Table IX.P-17. Dose-Response Results for Diagnoses of Palpable Thyroid UDA (continued)
Estimated Background Rates 
Row Outcome
Dose-
Response
Model
Dose
Estimates
Exclusions /
Additional
Inclusions
Method
of
Analysis Female Male
Estimated
Slope of Dose-
Response (per Gy)
Statistical Significance
of Dose-Response
(one-tailed p-value)
5. Primary definition Logistic Primary None MLE
.092
(.073, .115)
.043
(.031, .060)
−.38 ± .37
(−1.27, .51) 0.86
6. Primary definition Linear Primary
Exclude
dose > 1000
mGy
MLE
.093 ± .008
(.073, .113)
.045 ± .006
(.031, .060)
−.030 ± .022
(< −.049, >.028) 0.90
7. Primary definition Linear Primary
Exclude
dose > 400
mGy
MLE
.091 ± .009
(.070, .112)
.051 ± .008
(.032, .069)
−.053 ± .040
(−.142, .049) 0.90
8. Primary definition Linear Primary
Exclude
OK and F/S
geostrata
MLE
.088 ± .009
(.067, .109)
.041 ± .006
(.026, .056)
−.017 ± .023
(NE, .021)
0.92
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, “NE”
indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are not given for estimated background rates from logistic regression model. 
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
Okanogan, F/S = Ferry/Stevens, OOA = out of area
Table continued on next page
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Table IX.P-17. Dose-Response Results for Diagnoses of Palpable Thyroid UDA (continued)
Estimated Background Rates 
Row Outcome
Dose-
Response
Model
Dose
Estimates
Exclusions /
Additional
Inclusions
Method
of
Analysis Female Male
Estimated
Slope of Dose-
Response (per Gy)
Statistical Significance
of Dose-Response
(one-tailed p-value)
9. Primary definition Linear Alt. #1 None MLE
.090 ± .008
(.071, .109)
.044 ± .006
(.029, .059)
-.018 ± .020
(NE, .011)
0.96
10. Primary definition Linear Alt. #2 None MLE
.090 ± .008
(.070, .110)
.043 ± .006
(.029, .058)
-.019 ± .023
(NE, .003)
0.99
11. Primary definition Linear Primary
Include
OOA
(scoping
analysis #1)
MLE
.092 ± .008
(.073, .111)
.043 ± .006
(.030, .057)
-.018 ± .023
(NE, .014)
0.95
12. Primary definition Linear Primary
Include
OOA
(scoping
analysis #2)
MLE
.092 ± .008
(.073, .111)
.043 ± .006
(.030, .057)
-.018 ± .023
(NE, .012)
0.96
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, “NE”
indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are not given for estimated background rates from logistic regression model. 
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
Okanogan, F/S = Ferry/Stevens, OOA = out of area
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P.3.b. Alternative Dose-Response Functions
As shown in row 4 of Table IX.P-17, the estimated regression coefficient for the dose-squared
term in the linear-quadratic dose-response model [5] was 0.002 with Bonferroni-adjusted 95% confidence
interval ranging from –0.053 to 0.056.  Thus the addition of a quadratic term did not significantly improve
the fit of the model (p = 0.94).
The regression parameter for the effect of dose in the sex-stratified logistic regression model [2]
was estimated as −0.38 with Bonferroni-adjusted 95% confidence interval ranging from −1.27 to 0.51
(Table IX.P-17, row 5).  Thus there was no evidence from the logistic regression model that prevalence of
palpable thyroid UDAs increased with increasing dose (p = 0.86).
P.3.c. Effect of Excluding Participants in High Dose Categories
In the analyses excluding participants with estimated dose > 1000 mGy, the estimated slope B was
negative (−0.030 per Gy, with Bonferroni-adjusted 95% CI ranging from less than −0.049 to greater than
0.028 per Gy), providing no evidence that the prevalence of palpable thyroid UDA increased with
increasing dose (p = 0.90; Table IX.P-17, row 6).  When participants with estimated dose > 400 mGy were
excluded, the estimated slope B was again less than zero (−0.053 per Gy, with Bonferroni-adjusted 95% CI
ranging from −0.142 to 0.049 per Gy), again providing no evidence that the prevalence of palpable thyroid
UDA increased with increasing dose (p = 0.90; Table IX.P-17, row 7).
P.3.d. Effect of Excluding Okanogan and Ferry/Stevens Geostrata
In the analyses excluding participants from the Okanogan and Ferry/Stevens Geostrata, the
estimated slope B was negative, −0.017 per Gy, providing no evidence that the prevalence of palpable
thyroid UDAs increased with increasing dose (p = 0.92; Table IX.P-17, row 8).  The Bonferroni-adjusted
lower 95% confidence limit was not estimated due to the magnitude of the negative slope estimate,
however the upper confidence limit was 0.021 per Gy.
P.3.e. Analysis of Palpable Thyroid UDAs in Relation to Alternative Dose Estimates
For both alternative dose estimates the results were virtually the same as the primary analysis,
providing no evidence that the prevalence of palpable thyroid UDAs increased with increasing dose (Table
IX.P-17, rows 9 and 10).
P.3.f. Scoping Analysis Regarding Out-of-Area Participants
See section VIII.C.1.a.3 for a description of the scoping analyses that were performed to assess the
possible impact of the 249 out-of-area participants. For neither of the two scoping analyses was there any
evidence that the prevalence of palpable thyroid UDAs increased with increasing dose (p = 0.95 and p =
0.96 for the first and second scoping analyses, respectively; Table IX.P-17, rows 11 and 12).
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P.3.g. Analysis of Palpable Thyroid UDAs In Relation to Alternative Representations of
Exposure
In the analyses by geostratum and by dichotomous exposure variable, the sex and age-adjusted
comparisons of prevalence were performed as described in section VIII.C.2.a.2.
P.3.g.1. Analysis By Geostratum
As shown in Table IX.P-18, among the 3429 living evaluable in area or out-of-area participants
with ultrasound results, the proportions with palpable UDAs ranged from 9/68 (13.2% in the Ferry/Stevens
Counties geostratum) to 9/177 (5.1%, Richland) for women, and from 5/63 (7.9%, Okanogan County) to
13/501 (2.6%, Pasco/Kennewick) for men (p = 0.051 for heterogeneity among the nine geostrata).  In
particular the percentages with palpable UDAs were somewhat higher in the Okanogan and Ferry/Stevens
geostrata (12.6% for women, 6.8% for men) than in the remaining geostrata (8.5% and 3.9%, respectively;
p = 0.0086).  Since it was likely that participants in the Okanogan and Ferry/Stevens geostrata tended to
have lower thyroid doses from Hanford’s 131I than those in other geostrata, it does not appear that these
differences can be attributed to an effect of Hanford’s 131I.).
Table IX.P-18. Palpable Ultrasound-Detected Abnormalities, by Geostratum and Sex 
Female Male Total
Geostratum No. Cases % No. Cases % No. Cases %
Richland 177 9 5.1 172 5 2.9 349 14 4.0
Pasco/Kennewick 505 40 7.9 501 13 2.6 1006 53 5.3
Benton County 375 35 9.3 358 20 5.6 733 55 7.5
Franklin County 73 7 9.6 76 2 2.6 149 9 6.0
Adams County 165 14 8.5 156 10 6.4 321 24 7.5
Walla Walla (city) 131 14 10.7 131 5 3.8 262 19 7.3
Walla Walla County 169 17 10.1 164 6 3.7 333 23 6.9
Okanogan County 75 9 12.0 63 5 7.9 138 14 10.1
Ferry/Stevens Counties 68 9 13.2 70 4 5.7 138 13 9.4
Total 1738 154 8.9 1691 70 4.1 3429 224 6.5
P.3.g.2. Analysis by Dichotomous Exposure Variable
Ninety-five (7.6%) of the 1255 participants in these analyses had palpable thyroid UDAs,
including 43/580 (7.4%) in the high exposure group and 52/675 (7.7%) in the low exposure group (Table
IX.P-19).  Thus the proportion of participants with palpable thyroid UDAs was not significantly elevated in
the high exposure group (p = 0.67).
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Table IX.P-19. Palpable Ultrasound-Detected Abnormalities, by Exposure Group and Sex 
Female Male Total
Exposure Group No. Cases % No. Cases % No. Cases %
Low 350 36 10.3 325 16 4.9 675 52 7.7
High 298 32 10.7 282 11 3.9 580 43 7.4
Total 648 68 10.5 607 27 4.4 1255 95 7.6
P.3.h. Confounding and Effect Modification
As described in section VIII above, additional sex-stratified logistic regression models were
investigated to examine the possibility that the primary dose-response results for palpable thyroid UDA
might be influenced by confounding, and to search for factors that might modify a radiation dose-response.
Table IX.P-20 displays results for models including sex, age at first exposure to Hanford 131I  (prenatal, or
< 180 days), age at HTDS examination, estimated dose from the NTS, history of any cancer other than
thyroid, and HTDS interview type.  Note that sex was not analyzed as a possible confounder since its effect
was already adjusted for in the sex-stratified model.  It is evident from Table IX.P-20 that the model was
not significantly improved by adjusting for any of the other factors as a potential confounder: none
produced a significantly better fit to the data.  Since the estimated slope was virtually unaffected by such
adjustments, it does not appear that omitting these factors introduces any important bias in the dose-
response results.
There is no evidence of any statistically significant effect modification by any of the covariates in
Table IX.P-20, with one possible exception.  The dose-response was higher for the 1567 males (0.198) than
for the 1614 females (0.067).  The statistical significance of this difference must be interpreted with caution
due to the large number of such comparisons that were performed.  Moreover, neither males nor females
had a significantly positive dose-response. Therefore, it does not appear that any of the covariates in Table
IX.P-20 were significant effect modifiers for the outcome of palpable ultrasound-detected thyroid
abnormalities. 
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Table IX.P-20. Confounding and Effect Modification by Sex, Age at Exposure or HTDS
Examination, Estimated Thyroid Dose from NTS, History of Any Cancer Other
Than Thyroid, and Interview Type: Palpable Thyroid UDAs
Estimated Dose-Response Coefficient (per Gy)
Covariate Yes / Unadjusted Incl. Confounding Including Effect Modification
(0=No, 1=Yes) Total Estimate Estimate Group 0 Group 1 P
Female?
1614 /
3181
-.382 ± .373
(−1.27, .510) Not Applicable
.198 ± .226
(−4.28, .252)
.067 ± .228
(−.847, 1.07) .019
Prenatal
exposure?
1031 /
3181
-.382 ± .373
(−1.27, .510)
−.451 ± .381
(−1.43, .531)
−.441 ± .439
(−1.60, .719)
-.481 ± .763
(−2.49, 1.53) .96
1st exposure
before age 180
days?
1474 /
3181
-.382 ± .373
(−1.27, .510)
−.421 ± .383
(−1.41, .567)
−.167 ± .563
(−1.65, 1.32)
−.638 ± .552
(−2.09, .818) .55
Age at exam >
50?
1993 /
3181
-.382 ± .373
(−1.27, .510)
−.413 ± .381
(−1.39, .568)
−.578 ± .738
(−2.53, 1.37)
−.348 ± .446
(−1.53, .829) .79
NTS I-131
dose > 5.3 mGy?
1563 /
3179
-.382 ± .373
(−1.27, .511)
−.385 ± .382
(−1.37, .600)
−.243 ± .479
(−1.51, 1.02)
−.615 ± .648
(−2.33, 1.10) .64
History of any
cancer other than
thyroid?
248 /
3176
−.381 ± .373
(−1.27, .510)
−.381 ± .375
(−1.35, .585)
−.434 ± .406
(−1.51, .638)
−.072 ± .886
(−2.41, 2.26) .72
Expanded In-
Person Interview?
1205 /
3181
-.382 ± .373
(−1.27, .510)
−.318 ± .376
(−1.29, .651)
.068 ± .515
(−1.29, 1.43)
−.744 ± .604
(−2.34, .849) .30
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses, based on sex-
stratified logistic regression models.  P-values indicate the statistical significance of two-tailed comparison of estimated coefficients
between Groups 0 and 1.
Tables IX.P-21 and IX.P-22 display similar results from analyses including history of medical or
dental x-ray exposure or occupational exposure as potential confounding or effect modifying factors.  There
is no evidence of any confounding or statistically significant effect modification. 
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Table IX.P-21. Confounding and Effect Modification by History of Medical and Dental Radiation
Exposures: Palpable Thyroid UDAs
Have You
Estimated Dose-Response Coefficient (per Gy)
Ever Had: Yes / Unadjusted Incl. Confounding. Including Effect Modification
(0=No, 1=Yes) Total Estimate Estimate Group 0 Group 1 P
CAT scan of the
upper body?
775 /
3139
−.424 ± .381
(−1.34, .488)
−.407 ± .376
(−1.38, .562)
−.240 ± .383
(−1.25, .772)
−1.59 ± 1.15
(−4.62, 1.43) .24
Diagnostic x-rays
of the head?
1188 /
3145
−.335 ± .370
(−1.22, .550)
−.337 ± .369
(−1.29, .614)
−.285 ± .442
(−1.45, .882)
−.449 ± .665
(−2.20, 1.31) .84
Diagnostic x-rays
of the neck?
960 /
3157
−.362 ± .371
(−1.25, .527)
−.362 ± .373
(−1.32, .599)
−.020 ± .447
(−1.20, 1.16)
−1.05 ± .738
(−3.00, .891) .21
Diagnostic x-rays
of chest or upper
body, including
mammograms?
2811 /
3163
−.372 ± .372
(−1.26, .519)
−.352 ± .372
(−1.31, .607)
−1.57 ± 1.66
(−5.94, 2.81)
−.272 ± .377
(−1.27, .723) .42
Diagnostic x-rays
of the stomach or
mid-back?
691 /
3110
−.411 ± .385
(−1.33, .510)
−.413 ± .385
(−1.40, .578)
−.159 ± .393
(−1.20, .879)
−2.04 ± 1.20
(−5.21, 1.14) .11
Barium enema?
821 /
3149
−.378 ± .373
(−1.27, .514)
−.375 ± .373
(−1.34, .585)
−.368 ± .427
(−1.50, .759)
−.398 ± .763
(−2.41, 1.61) .97
Upper GI?
1140 /
3167
−.368 ± .372
(−1.26, .522)
−.367 ± .372
(−1.32, .591)
−.001 ± .411
(−1.09, 1.08)
−1.20 ± .730
(−3.13, .721) .14
Intravenous
pyelogram?
396 /
3147
−.391 ± .376
(−1.29, .508)
−.378 ± .376
(−1.35, .591)
−.266 ± .387
(−1.29, .754)
−1.31 ± 1.23
(−4.55, 1.92) .40
Fluoroscopy of the
upper body?
246 /
3151
−.349 ± .373
(−1.24, .544)
−.352 ± .373
(−1.31, .610)
−.242 ± .374
(−1.23, .745)
−2.27 ± 1.91
(−7.31, 2.76) .24
Other nuclear
scan?
216 /
3152
−.386 ± .375
(−1.28, .511)
−.395 ± .375
(−1.36, .571)
−.307 ± .378
(−1.31, .691)
−1.92 ± 1.85
(−6.80, 2.95) .35
Dental x-rays that
did not usually
include a lead
shield over the
neck area?
1644 /
3181
.382 ± .373
(−1.27, .510)
−.385 ± .374
(−1.35, .578)
−.173 ± .483
(−1.45, 1.10)
−.658 ± .589
(−2.21, .895) .52
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses, based on sex-
stratified logistic regression models.  P-values indicate the statistical significance of two-tailed comparison of estimated coefficients
between Groups 0 and 1.
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Table IX.P-22. Confounding and Effect Modification by Occupational History: Palpable Thyroid 
UDAs
Have You Ever
Worked in Any of
Estimated Dose-Response Coefficient (per Gy)
the Following: Yes / Unadjusted Incl. Confounding Including Effect Modification
(0=No, 1=Yes) Total Estimate Estimate Group 0 Group 1 P
Any metal
industry?
238 /
3181
.382 ± .373
(−1.27, .510)
−.373 ± .372
(−1.33, .586)
−.379 ± .378
(−1.38, .619)
−.166 ± 2.14
(−5.81, 5.48) .92
Any nuclear
facility?
370 /
3181
.382 ± .373
(−1.27, .510)
−.378 ± .375
(−1.34, .589)
−.212 ± .386
(−1.23, .807)
−1.67 ± 1.27
(−5.01, 1.67) .24
Any other industry
or occupation
where you may
have been exposed
to radioactive
materials or x-rays?
442 /
3181
.382 ± .373
(−1.27, .510)
−.402 ± .375
(−1.37, .563)
−.186 ± .379
(−1.18, .813)
−3.30 ± 1.89
(−8.30, 1.69) .06
Any of the above
industries or
occupations?
891 /
3181
.382 ± .373
(−1.27, .510)
−.346 ± .372
(−1.30, .612)
−.111 ± .398
(−1.16, .938)
−1.34 ± .957
(−3.86, 1.18) .21
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses, based on sex-
stratified logistic regression models.  P-values indicate the statistical significance of two-tailed comparison of estimated coefficients
between Groups 0 and 1.
Table IX.P-23 displays the results of analyses of possible confounding or effect modification by
smoking variables.  There was no evidence that the dose-response was significantly confounded by either
smoking variable, or that there was a dose-response that differed significantly according to smoking
history.
Table IX.P-23. Confounding and Effect Modification by Smoking: Palpable Thyroid UDAs
Estimated Dose-Response Coefficient (per Gy)Have You Ever
Smoked Any of
the Following: Yes / Unadjusted Incl. Confounding Including Effect Modification
(0=No, 1=Yes) Total Estimate Estimate Group 0 Group 1 P
Cigarettes
(unfiltered or
filtered)?
1850 /
3173
−.371 ± .372
(−1.26, .520)
−.373 ± .372
(−1.33, .585)
−.416 ± .608
(−2.02, 1.19)
−.346 ± .468
(−1.58, .888) .93
Any of cigarettes,
cigar or pipe?
1896 /
3173
−.371 ± .372
(−1.26, .520)
−.372 ± .372
(−1.33, .585)
−.291 ± .607
(−1.89, 1.31)
−.421 ± .474
(−1.67, .829) .87
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses, based on sex-
stratified logistic regression models.  P-values indicate the statistical significance of two-tailed comparison of estimated coefficients
between Groups 0 and 1.
P.3.i. Uncertainty
The estimated slopes of the sex-stratified linear dose-response model for the outcome of palpable
thyroid UDA are shown in Figure IX.P-4 for each of the 100 dose realizations produced by the CIDER
model.  The confidence intervals in that figure are calculated at the 98.33% confidence level, i.e., are
adjusted by the Bonferroni technique for the simultaneous estimation of the slope and two sex-specific
background rates.  While the point estimate of the slope is greater than 0 for 1 of the 100 realizations, the
confidence interval includes 0 for all of the realizations.  Also shown in Figure IX.P-4 (to the right of
realization 100) are the estimates and confidence intervals calculated using (from left to right) the median,
geometric mean and mean of each participant’s 100 dose realizations. In summary, for none of the 100
realizations of the estimated doses was there a statistically significant dose-response, and for all but one
realization the estimated slope was less than 0.
Figure IX.P-4. Plot of Estimated Slope and 95% CI by Dose Realization: Palpable Thyroid UDAs
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Figure IX.P-5 displays the distribution of the 5000 logistic regression coefficient estimates
obtained by the simulation procedures described in section VIII.C.2.b.3 above. It is evident from the figure
that most of the estimates were between about –3.0 and 0.3. The estimate was less than or equal to 0 for
4735 of the 5000 replications, implying an empirical one-tailed p-value of 0.95.  The median estimate was
–0.80, and the upper and lower percentiles corresponding to the Bonferroni-adjusted 95% confidence
interval were –2.42 and 0.33.  These may be compared to the p-value of 0.21 and the estimate of −0.38 with
confidence interval (−1.27, 0.51) obtained using the median dose estimates without adjustment for
uncertainty. Thus, this method of adjusting the estimated logistic regression coefficient for the uncertainty
in the dose estimates did not provide evidence that the prevalence of palpable thyroid UDA increased with
increasing dose.
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Figure IX.P-5. Distribution of Simulation Estimates of Logistic Regression Coefficient: Palpable 
Thyroid UDAs
slope sample: 5000
   -4.0    -2.0     0.0     2.0
    0.0
    0.2
    0.4
    0.6
    0.8
P.4. Nonpalpable Focal Ultrasound-Detected Abnormalities of the Thyroid
 Among the 3429 whose thyroids were visible, 1309 (38.2%) had nonpalpable focal thyroid UDAs.
The ultrasound-detected thyroid abnormalities were based only on the HTDS evaluation (Table IX.P-24).
 
 Table IX.P-24. Proportion of Participants with HTDS Ultrasound Findings of Nonpalpable Focal
Thyroid UDAs, by Sex
 
 Fem ale  Male                     Total
 Ultrasound Finding No . % No .  %  No.  %
 Thyroid gland visible on ultrasound  1738  100.0  1691  100.0  3429  100.0
      Nonpalpable focal thyroid UDAs  784  45.1  525  31.0  1309  38.2
P.4.a. Primary Analysis 
The proportion with nonpalpable focal thyroid UDAs is shown by sex, in-area status, and dose
group in Table IX.P-25.
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Table IX.P-25. Nonpalpable Ultrasound-Detected Abnormalities by Sex, and Estimated Dose:
Participants with Ultrasound Only
 Female
 
 Male 
 
 Thyroid
Radiation
Dose
L.E. with
Ultrasound
Nonpalpable
Focal Thyroid
UDA
L.E. with
Ultrasound
Nonpalpable
Focal Thyroid
UDA
(mGy)      No.     No.      %      No. No. %
Out of Area   124   49 39.5   124   43 34.7
< 10   182   81 44.5   185   57 30.8
10-49   318 138 43.4   314   91 29.0
50-99   311 140 45.0   310   84 27.1
100-149   220 109 49.5   171   52 30.4
150-199   125   53 42.4   109   38 34.9
200-299   137   70 51.1   148   56 37.8
300-399   143   65 45.5   160   58 36.3
400-999   171   78 45.6   153   36 23.5
1000+       7     1 14.3     17   10 58.8
Total 1738 784 45.1 1691 525 31.0
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 L.E. = living evaluable participants
Of the 1309 living evaluable participants with a nonpalpable focal thyroid UDA, 92 were out-of-
area participants.  Parameter estimates for the linear dose-response model based on the 3181 in-area
participants are show in Table IX.P-26 below.  The estimated slope B was not significantly greater than
zero (0.027 per Gy, with Bonferroni-adjusted 95% confidence interval ranging from -0.061 to 0.115),
providing no evidence that the prevalence of nonpalpable thyroid UDAs increased with increasing dose (p
= 0.23; Table IX.P-26, row 1).  Estimation by least squares using either the ungrouped or grouped data
gave similar results (Table IX.P-26, rows 2 and 3).
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Table IX.P-26. Dose-Response Results for Diagnoses of Nonpalpable Focal Thyroid UDAs
Row Outcome
Dose-
Response
Model
Dose
Estimates
Exclusions /
Additional
Inclusions
Method
of
Analysis
Estimated Background Rates
     Female              Male
Estimated
Slope of Dose-
Response (per Gy)
Statistical
Significance of Dose-
Response
(one-tailed p-value)
1. Primary definition Linear Primary None MLE
.451 ± .014
(.417, .484)
.303 ± .013
(.270, .335)
.027 ± .037
(-.061, .115)
0.23
2. Primary definition Linear Primary None LSU
.451 ± .014
(.419, .484)
.303 ± .014
(.270, .337)
.024 ± .038
(−.067, .115) 0.27
3. Primary definition Linear Primary None LSG
.453 ± .014
(.419, .487)
.305 ± .014
(.271, .340)
.014 ± .044
(−.091, .119) 0.38
4. Primary definition LQ Primary None LSU
.442 ± .015
(.405, .479)
.294 ± .015
(.256, .331)
Lin: .111 ± .064
(−.050, .272)
Quad: −.072 ± .043
(−.178, .035)
Quad: 0.093
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, “>”
indicates that the upper confidence limit is greater than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are
not given for estimated background rates from logistic regression model. 
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
Okanogan, F/S = Ferry/Stevens, OOA = out of area
Table continued on next page
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Table IX.P-26. Dose-Response Results for Diagnoses of Nonpalpable Focal Thyroid UDAs (continued)
Estimated Background Rates 
Row Outcome
Dose-
Response
Model
Dose
Estimates
Exclusions /
Additional
Inclusions
Method
of
Analysis Female Male
Estimated
Slope of Dose-
Response (per Gy)
Statistical Significance
of Dose-Response
(one-tailed p-value)
5. Primary definition Logistic Primary None MLE
.451
(.417, .485)
.304
(.273, .336)
.10 ± .16
(-.29, .49)
0.27
6. Primary definition Linear Primary
Exclude
dose
> 1000 mGy
MLE
.452 ± .015
(.417, .487)
.300 ± .014
(.266, .333)
.029 ± .048
(<-.085, .145)
0.27
7. Primary definition Linear Primary
Exclude
dose 
> 400 mGy
MLE
.431 ± .016
(.392, .470)
.285 ± .016
(.247, .323)
.228 ± .085
(.026, .431)
0.003
8. Primary definition Linear Primary
Exclude
OK and F/S
geostrata
MLE
.449 ± .015
(.413, .484)
.295 ± .014
(.261, .329)
.037 ± .038
(-.053, .125)
0.16
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, “>”
indicates that the upper confidence limit is greater than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are
not given for estimated background rates from logistic regression model
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
Okanogan, F/S = Ferry/Stevens, OOA = out of area 
Table continued on next page
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Table IX.P-26. Dose-Response Results for Diagnoses of Nonpalpable Focal Thyroid UDAs (continued)
Estimated Background Rates 
Row Outcome
Dose-
Response
Model
Dose
Estimates
Exclusions /
Additional
Inclusions
Method
of
Analysis Female Male
Estimated
Slope of Dose-
Response (per Gy)
Statistical Significance
of Dose-Response
(one-tailed p-value)
9. Primary definition Linear Alt. #1 None MLE
.454 ± .014
(.420, .488)
.306 ± .014
(.273, .339)
.007 ± .037
(-.079, .095)
0.43
10. Primary definition Linear Alt. #2 None MLE
.446 ± .014
(.412, .480)
.298 ± .014
(.265, .330)
.052 ± .038
(-.038, .142)
0.085
11. Primary definition Linear Primary
Include
OOA
(scoping
analysis #1)
MLE
.446 ± .013
(.414, .478)
.305 ± .013
(.275, .336)
.031 ± .037
(-.056, >.117)
0.20
12. Primary definition Linear Primary
Include
OOA
(scoping
analysis #2)
MLE
.447 ± .013
(.415, .479)
.306 ± .013
(.276, .337)
.025 ± .037
(<-.062, .111)
0.25
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, “>”
indicates that the upper confidence limit is greater than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are
not given for estimated background rates from logistic regression model.
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
Okanogan, F/S = Ferry/Stevens, OOA = out of area 
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P.4.b. Alternative Dose-Response Functions
As shown in row 4 of Table IX.P-26, the estimated regression coefficient for the dose-squared
term in the linear-quadratic dose-response model [5] was −0.072 with Bonferroni-adjusted 95% confidence
interval ranging from –0.178 to 0.035.  Thus the addition of a quadratic term did not significantly improve
the fit of the model (p = 0.093).
The regression parameter for the effect of dose in the sex-stratified logistic regression model [2]
was estimated as 0.10, with Bonferroni-adjusted 95% confidence interval ranging from –0.29 to 0.49
(Table IX.P-26, row 5).  Thus there was no evidence from the logistic regression model that prevalence of
nonpalpable focal thyroid UDA increased significantly with increasing dose (p = 0.27).
P.4.c. Effect of Excluding Participants in High Dose Categories
As shown in row 7 of Table IX.P-26 above, the estimated slope of the dose-response for
nonpalpable focal thyroid UDAs was larger if participants with highest estimated doses were excluded.  In
particular, when participants with estimated dose > 400 mGy were excluded, the estimated slope B
increased from 0.027 to 0.228 per Gy (p = 0.003).  Excluding the small number of participants with
estimated dose > 1000 mGy had very little effect on the estimated dose-response (Table IX.P-26, row 6).
P.4.d. Effect of Excluding Okanogan and Ferry/Stevens Geostrata
As shown in row 8 of Table IX.P-26, excluding Okanogan and Ferry/Stevens slightly reduced the
estimated background rates for both men and women.  The reductions were small, because the Okanogan
and Ferry/Stevens geostrata account for only 255 (8.0%) of the 3181 in-area living evaluable participants
with ultrasound results.  As a result of these reductions in the background rates and the fact that Okanogan
and Ferry/Stevens geostrata tend to have low doses, the estimated slope changed slightly, from 0.027 to
0.037 per Gy, but remained statistically nonsignificant (p = 0.16).
P.4.e. Analysis of Nonpalpable Focal Thyroid UDAs in Relation to Alternative Dose
Estimates
Using the first alternative set of dose estimates, the estimated slope changed slightly, to 0.007 per
Gy, with Bonferroni-adjusted 95% confidence limits –0.079 and 0.095 per Gy, which does not represent a
statistically significant dose-response for nonpalpable focal thyroid UDAs (p = 0.43; Table IX.P-26, row
9).  Similar results were obtained using the second alternative dose estimates, with estimated slope 0.052
per Gy and 95% CI ranging from –0.038 to 0.142 (p = 0.085; Table IX.P-26, row 10).
P.4.f. Scoping Analysis Regarding Out-of-Area Participants
See section VIII.C.1.a.3 for a description of the scoping analyses that were performed to assess the
possible impact of the 249 out-of-area participants. The results of both scoping analyses were virtually the
same as the primary analysis and provided no evidence that the prevalence of nonpalpable focal thyroid
UDA increased with increasing dose (Table IX.P-7).  For neither set of scoping analyses was there
evidence that the proportion with nonpalpable focal thyroid UDAs increased with increasing dose (p = 0.20
for the first scoping analysis, and p = 0.25 for the second scoping analysis; Table IX.P-26, rows 11 and 12).
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P.4.g. Analysis of Nonpalpable Focal Thyroid UDAs in Relation to Alternative
Representations of Exposure
In the analyses by geostratum and by dichotomous exposure variable, the sex and age-adjusted
comparisons of prevalence were performed as described in section VIII.C.2.a.2.
P.4.g.1. Analysis by Geostratum
The proportions of women with nonpalpable focal thyroid UDAs ranged from 69/131 (52.7%) in
the Walla Walla city geostratum to 75/177 (42.4%) in the Richland geostratum (Table IX.P-27).  For men
they ranged from 32/76 (42.1%) in the Franklin geostratum to 31/164 (18.9%) in the Walla Walla County
geostratum.  The heterogeneity among the nine geostrata was not statistically significant (p = 0.083).  The
proportions were somewhat higher in the Okanogan and Ferry/Stevens geostrata (46.2% and 38.3% for
women and men, respectively) compared to the other geostrata (45.0% and 30.4%, respectively), also a
nonsignificant difference for the heterogeneity between combined geostrata (p = 0.082).
Table IX.P-27. Nonpalpable Focal Ultrasound-Detected Abnormalities, by Geostratum and Sex
Female Male Total
Geostratum No. Cases % No. Cases % No. Cases %
Richland 177 75 42.4 172 48 27.9 349 123 35.2
Pasco/Kennewick 505 227 45.0 501 156 31.1 1006 383 38.1
Benton County 375 164 43.7 358 114 31.8 733 278 37.9
Franklin County 73 35 47.9 76 32 42.1 149 67 45.0
Adams County 165 74 44.8 156 57 36.5 321 131 40.8
Walla Walla (city) 131 69 52.7 131 36 27.5 262 105 40.1
Walla Walla County 169 74 43.8 164 31 18.9 333 105 31.5
Okanogan County 75 33 44.0 63 26 41.3 138 59 42.8
Ferry/Stevens Counties 68 33 48.5 70 25 35.7 138 58 42.0
Total 1738 784 45.1 1691 525 31.0 3429 1309 38.2
P.4.g.2. Analysis by Dichotomous Exposure Variable
A total of 494 (39.4%) of the 1255 participants in these analyses had nonpalpable focal thyroid
UDAs, including 240/580 (41.4%) in the high exposure group and 254/675 (37.6%) in the low exposure
group (Table IX.P-28).  Based on the logistic regression analysis with adjustment for the effect of sex and
age at HTDS examination, the proportion of participants with nonpalpable focal thyroid UDA was not
significantly elevated in the high exposure group (p = 0.081).
Table IX.P-28. Nonpalpable Focal Ultrasound-Detected Abnormalities, by Exposure Group and 
Sex 
Female Male Total
Exposure Group No. Cases % No. Cases % No. Cases %
Low 350 154 44.0 325 100 30.8 675 254 37.6
High 298 149 50.0 282 91 32.3 580 240 41.4
Total 648 303 46.8 607 191 31.5 1255 494 39.4
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P.4.h. Confounding and Effect Modification
As described in section VIII above, additional sex-stratified logistic regression models were
investigated to examine the possibility that the primary dose-response results might be influenced by
confounding, and to search for factors that might modify a radiation dose-response.  Table IX.P-29 displays
results for models including sex, age at first exposure to Hanford I-131 (prenatal, or < 180 days), age at
HTDS examination, estimated dose from the NTS, history of any cancer other than thyroid, and HTDS
interview type.  Note that sex was not analyzed as a possible confounder since its effect was already
adjusted for in the sex-stratified model.  
It is evident from Table IX.P-29 that the estimated slope was virtually unaffected by adjustments
for possible confounding.  Therefore, it does not appear that omitting these factors introduces any important
bias in the dose-response results.  In addition, the regression coefficients did not differ significantly
between the groups defined by any of the covariates, suggesting that none of them were significant
modifiers of a radiation dose-response for nonpalpaple UDAs.
Table IX.P-29. Confounding and Effect Modification by Sex, Age at Exposure or HTDS
Examination, Estimated Thyroid Dose from NTS, History of Any Cancer Other
Than Thyroid, and Interview Type: Nonpalpable Focal Ultrasound-Detected
Abnormalities
Estimated Dose-Response Coefficient (per Gy)
Covariate Yes / Unadjusted Incl. Confounding. Including Effect Modification
(0=No, 1=Yes) Total Estimate Estimate Group 0 Group 1 P
Female?
1614 /
3181
.102 ± .164
(−.290, .494) Not Applicable
.198 ± .226
(−.208, .949)
.067 ± .228
(−.724, .422) .11
Prenatal
exposure?
1031 /
3181
.102 ± .164
(−.290, .494)
.045 ± .165
(−.381, .471)
.137 ± .189
(−.360, .634)
−.261 ± .349
(−1.18, .659) .31
1st exposure
before age 180
days?
1474 /
3181
.102 ± .164
(−.290, .494)
.092 ± .165
(−.333, .517)
.516 ± .280
(−.224, 1.26)
−.135 ± .210
(−.690, .419) .062
Age at exam >
50?
1993 /
3181
.102 ± .164
(−.290, .494)
.111 ± .166
(−.317, .538)
−.183 ± .308
(−.996, .630)
.236 ± .198
(−.286, .758) .25
NTS I-131
dose > 5.3 mGy?
1563 /
3179
.096 ± .164
(−.296, .488)
.063 ± .167
(−.368, .495)
.116 ± .221
(−.467, .698)
−.007 ± .258
(−.689, .675) .72
History of any
cancer other than
thyroid?
248 /
3176
.103 ± .164
(−.289, .495)
.107 ± .164
(−.315, .529)
.193 ± .177
(−.275, .661)
−.413 ± .474
(−1.66, .837) .21
Expanded In-
Person Interview?
1205 /
3181
.102 ± .164
(−.290, .494)
.106 ± .167
(−.324, .535)
.401 ± .266
(−.300, 1.10)
−.085 ± .217
(−.658, .488) .16
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses, based on sex-
stratified logistic regression models.  P-values indicate the statistical significance of two-tailed comparison of estimated coefficients
between Groups 0 and 1.
Tables IX.P-30 and IX.P-31 display similar results from analyses including history of medical or
dental x-ray exposure or occupational exposure as potential confounding or effect modifying factors.  There
was no evidence of confounding, or of clearly significant effect modification, by any of these variables.
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Table IX.P-30. Confounding and Effect Modification by History of Medical and Dental Radiation
Exposures: Nonpalpable Focal Ultrasound-Detected Abnormalities
Have You
Estimated Dose-Response Coefficient (per Gy)
Ever Had: Yes / Unadjusted Incl. Confounding. Including Effect Modification
(0=No, 1=Yes) Total Estimate Estimate Group 0 Group 1 P
CAT scan of the
upper body?
775 /
3139
.102 ± .164
(−.292, .495)
.102 ± .164
(−.321, .525
−.030 ± .182
(−.509, .450)
.746± .397
(−.302, 1.79) .08
Diagnostic x-rays
of the head?
1188 /
3145
.103 ± .165
(−.292, .498)
.099 ± .165
(−.327, .524)
.242 ± .204
(−.296, .779)
−.181 ± .290
(−.947, .584) .23
Diagnostic x-rays
of the neck?
960 /
3157
.094 ± .165
(−.300, .487)
.100 ± .165
(−.325, .525)
.012 ± .217
(−.560, .585)
.223 ± .257
(−.454, .900) .53
Diagnostic x-rays
of chest or upper
body, including
mammograms?
2811 /
3163
.098 ± .164
(−.294, .491)
.103 ± .164
(−.320, .526)
.270 ± .590
(−1.29, 1.83)
.089 ± .171
(−.361, .540) .77
Diagnostic x-rays
of the stomach or
mid-back?
691 /
3110
.128 ± .166
(−.268, .524)
.131 ± .166
(−.296, .557)
.068 ± .186
(−.423, .559)
.379 ± .370
(−.596, 1.35) .45
Barium enema?
821 /
3149
.104 ± .164
(−.289, .497)
.105 ± .164
(−.318, .528)
.104 ± .191
(−.400, .608)
.107 ± .321
(−.740, .954) .99
Upper GI?
1140 /
3167
.100 ± .164
(−.292, .493)
.099 ± .164
(−.323, .521)
.009 ± .208
(−.539, .557)
.252 ± .270
(−.459, .964) .47
Intravenous
pyelogram?
396 /
3147
.102 ± .165
(−.292, .496)
.104 ± .165
(−.320, .528)
.108 ± .175
(−.354, .569)
.072 ± .487
(−1.21, 1.36) .94
Fluoroscopy of the
upper body?
246 /
3151
.118 ± .164
(−.275, .511)
.119 ± .164
(−.305, .542)
.090 ± .171
(−.361, .542)
.477 ± .603
(−1.11, 2.07) .54
Other nuclear
scan?
216 /
3152
.092 ± .164
(−.301, .486)
.093 ± .164
(−.331, .516)
.155 ± .169
(−.291, .602)
−.903 ±.709
(−2.77, .966) .13
Dental x-rays that
did not usually
include a lead
shield over the
neck area?
1644 /
3181
.102 ± .164
(−.290, .494)
.103 ± .164
(−.319, .524)
.212 ± .233
(−.403, .827)
−.003 ± .230
(−.610, .605) .51
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses, based on sex-
stratified logistic regression models.  P-values indicate the statistical significance of two-tailed comparison of estimated coefficients
between Groups 0 and 1.
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Table IX.P-31. Confounding and Effect Modification by Occupational History: Nonpalpable Focal 
Ultrasound-Detected Abnormalities
Estimated Dose-Response Coefficient (per Gy)
Have You Ever
Worked in Any of
the Following: Yes / Unadjusted Incl. Confounding Including Effect Modification
 (0=No, 1=Yes) Total Estimate Estimate Group 0 Group 1 P
Any metal
industry?
238 /
3181
.102 ± .164
(−.290, .494)
.098 ± .164
(−.323, .520)
.071 ± .169
(−.374, .516)
.565 ± .685
(−1.24, 2.37) .49
Any nuclear
facility?
370 /
3181
.102 ± .164
(−.290, .494)
.099 ± .165
(−.326, .525)
−.010 ± .183
(−.493, .474)
.588 ± .385
(−.427, 1.60) .16
Any other industry
or occupation
where you may
have been exposed
to radioactive
materials or x-rays?
442 /
3181
.102 ± .164
(−.290, .494)
.101 ± .164
(−.321, .522)
.176 ± .180
(−.300, .652)
−.260 ± .413
(−1.35, .829) .32
Any of the above
industries or
occupations?
891 /
3181
.102 ± .164
(−.290, .494)
.110 ± .164
(−.312, .533)
.047 ± .202
(−.487, .580)
.233 ± .280
(−.506, .972) .59
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses, based on sex-
stratified logistic regression models.  P-values reflect the significance of the improved fit for models including confounding or effect
modification, relative to the unadjusted model.
Table IX.P-32 displays the results of analyses of possible confounding or effect modification by
smoking variables.  There was some evidence that the dose-response coefficient differed between
participants with versus without histories of smoking cigarettes (p = 0.033) or any of cigarettes, cigars or
pipes (p = 0.019). The estimated dose-response coefficients were greater than zero among nonsmokers, but
negative for smokers.  However, the Bonferroni-adjusted 95% confidence intervals for the smokers’ and
nonsmokers’ estimated coefficients overlapped, including the value of zero in the overlap.  In view of the
significance levels of these two tests for effect modification and the large number of comparisons
performed in these analyses, these results do not provide compelling evidence of a statistically significant
dose-response within the nonsmoking cohort.
Table IX.P-32. Confounding and Effect Modification by Smoking: Nonpalpable Focal Ultrasound-
Detected Abnormalities
Have You Ever
Smoked Any of
Estimated Dose-Response Coefficient (per Gy)
the Following: Yes / Adjusted for Including Effect Modification
(0=No, 1=Yes) Total Estimate Estimate Group 0 Group 1 P
Cigarettes
(unfiltered or
filtered)?
1850 /
3173
.108 ± .164
(−.284, .500)
.107 ± .164
(−.315, .529)
.589 ± .279
(−.148, 1.33)
−.150 ± .208
(−.699, .398) .033
Any of cigarettes,
cigar or pipe?
1896 /
3173
.108 ± .164
(−.284, .500)
.107 ± .164
(−.315, .529)
.648 ± .284
(−.100, 1.40)
−.172 ± .207
(−.718, .375) .019
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses, based on sex-
stratified logistic regression models.  P-values reflect the significance of the improved fit for models including confounding or effect
modification, relative to the unadjusted model.
P.4.i. Uncertainty
The estimated slopes of the sex-stratified linear dose-response model for the outcome of
nonpalpable focal thyroid UDA are shown in Figure IX.P-6 for each of the 100 dose realizations produced
by the CIDER model.  The confidence intervals in that figure are calculated at the 98.33% confidence level,
i.e., are adjusted by the Bonferroni technique for the simultaneous estimation of the slope and two sex-
specific background rates.  While the point estimate of the slope is greater than 0 for 85 of the 100
realizations, the confidence interval includes 0 for all but 1 of the realizations.  Also shown in Figure IX.P-
6 (to the right of realization 100) are the estimates and confidence intervals calculated using (from left to
right) the median, geometric mean and mean of each participant's 100 dose realizations. In summary, for
only one of the 100 realizations of the estimated doses was there a statistically significant dose-response,
although for most of the realizations the estimated slope was greater than 0.
Figure IX.P-6. Plot of Estimated Slope and 95% CI by Dose Realization: Nonpalpable Focal
Ultrasound-Detected Abnormalities 
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Figure IX.P-7 displays the distribution of the 5000 logistic regression coefficient estimates
obtained by the simulation procedures described in section VIII.C.2.b.3 above. It is evident from the figure
that most of the estimates were between about –0.5 and 1.0. The estimate was less than or equal to 0 for
604 of the 5000 replications, implying an empirical one-tailed p-value of 0.12.  The median estimate was –
0.25, and the upper and lower percentiles corresponding to the Bonferroni-adjusted 95% confidence
interval were –0.27 and 0.84.  These may be compared to the p-value of 0.27 and the estimate of 0.10 with
confidence interval (−0.29, 0.49) obtained using the median dose estimates without adjustment for
uncertainty. Thus, this method of adjusting the estimated logistic regression coefficient for the uncertainty
in the dose estimates did not provide evidence that the prevalence of nonpalpable focal thyroid UDA
increased significantly with increasing dose.
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Figure IX.P-7. Distribution of Simulation Estimates of Logistic Regression Coefficient: 
Nonpalpable Focal Ultrasound-Detected Abnormalities
slope sample: 5000
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P.5. Diffuse Ultrasound-Detected Abnormalities of the Thyroid
Of the 3429 living evaluable participants whose thyroids were visible, 458 (13.4%) had diffuse
ultrasound-detected thyroid abnormalities (Table IX.P-33).
 Table IX.P-33. Proportion of Participants with HTDS Ultrasound Findings of Diffuse Thyroid
UDAs, by Sex
 
  Female  Male     Total
 Ultrasound Finding  No.  %  No.  %  No.  %
 Thyroid gland visible on ultrasound  1738  100.0  1691  100.0  3429  100.0
      Diffuse thyroid UDAs  306  17.6  152  9.0  458  13.4
P.5.a. Primary Analysis 
Of the 458 living evaluable participants with a diagnosis of diffuse thyroid UDAs, 30 were out-of-
area participants.  The proportions with diffuse thyroid UDAs are shown by sex, in-area status and dose
group in Table IX.P-34.
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Table IX.P-34. Diffuse Ultrasound-Detected Abnormalities by Sex, and Estimated Dose: 
Participants with Ultrasound Only
 Female Male
Thyroid
Radiation
Dose (mGy)
L.E. with
Ultrasound
Diffuse
Ultrasound-
Detected
Abnormality
L.E. with
Ultrasound
Diffuse
Ultrasound
Detected
Abnormality
No. No. % No. No. %
Out of Area 124 18 14.5 124 12 9.7
< 10 182 29 15.9 185 19 10.3
10-49 318 53 16.7 314 21 6.7
50-99
100-149
311
220
47
52
15.1
23.6
310
171
22
17
7.1
9.9
150-199 125 25 20.0 109 9 8.3
200-299 137 24 17.5 148 21 14.2
300-399 143 30 21.0 160 18 11.3
400-999 171 27 15.8 153 11 7.2
1000+ 7 1 14.3 17 2 11.8
Total 1738 306 17.6 1691 152 9.0
 
L.E. = living evaluable participants
Parameter estimates for the linear dose-response model based on the 3181 in-area participants with
a visible thyroid are shown in Table IX.P-35 below.  The estimated slope B was not significantly greater
than zero (0.029 per Gy with Bonferroni-adjusted 95% confidence interval ranging from 0.029 to 0.100)
providing no evidence that the proportion with diffuse thyroid UDAs increased with increasing dose (p =
0.14; Table IX.P-35, row 1).  Estimating by least squares using either the ungrouped or grouped data gave
similar results (Table IX.P-35, rows 2 and 3). 
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Table IX.P-35. Dose-Response Results for Diagnoses of Diffuse Ultrasound Abnormalities
Estimated Background Rates 
Row Outcome
Dose-
Response
Model
Dose
Estimates
Exclusions /
Additional
Inclusions
Method
of
Analysis Female Male
Estimated
Slope of Dose-
Response (per Gy)
Statistical Significance
of Dose-Response
(one-tailed p-value)
1. Primary definition Linear Primary None MLE
.174 ± .011
(.148, .199)
.084 ± .009
(.064, .105)
.029 ± .028
(-.029, .100)
0.14
2. Primary definition Linear Primary None LSU
.174 ± .010
(.151, .197)
.085 ± .010
(.061, .108)
.026 ± .027
(-.039, .090)
0.17
3. Primary definition Linear Primary None LSG
.176 ± .010
(.153, .200)
.087 ± .010
(.063, .111)
.013 ± .031
(-.061, .086)
0.34
4. Primary definition LQ Primary None LSU
.174 ± .010
(.148, .200)
.085 ± .011
(.058, .111)
Lin: .027 ± .045
(−.086, .140)
Quad: −.001 ± .030
(−.076, .074)
Quad: 0.97
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, “>”
indicates that the upper confidence limit is greater than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are
not given for estimated background rates from logistic regression model. 
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
Okanogan, F/S = Ferry/Stevens, OOA = out of area
Table continued on next page
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Table IX.P-35. Dose-Response Results for Diagnoses of Diffuse Ultrasound Abnormalities (continued)
Estimated Background Rates 
Row Outcome
Dose-
Response
Model
Dose
Estimates
Exclusions /
Additional
Inclusions
Method
of
Analysis Female Male
Estimated
Slope of Dose-
Response (per Gy)
Statistical Significance
of Dose-Response
(one-tailed p-value)
5. Primary definition Logistic Primary None MLE
.173
(.149, .201)
.086
(.070, .107)
.21 ± .22
(-.32, .74)
0.17
6. Primary definition Linear Primary
Exclude
dose
> 1000 mGy
MLE
.173 ± .011
(.147, .199)
.084 ± .009
(.062, .105)
.033 ± .034
(<-.043, >.118)
0.16
7. Primary definition Linear Primary
Exclude
dose
> 400 mGy
MLE
.164 ± .012
(.136, .193)
.074 ± .010
(.051, .097)
.146 ± .059
(.010, .291)
0.005
8. Primary  definition Logistic Primary
Exclude
OK and F/S
geostrata
MLE
.172 ± .011
(.146, .199)
.075 ± .009
(.054, .097)
.042 ± .029
(-.021, .115)
0.065
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, “>”
indicates that the upper confidence limit is greater than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are
not given for estimated background rates from logistic regression model. 
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
Okanogan, F/S = Ferry/Stevens, OOA = out of area
Table continued on next page
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Table IX.P-35. Dose-Response Results for Diagnoses of Diffuse Ultrasound Abnormalities (continued)
Estimated Background Rates 
Row Outcome
Dose-
Response
Model
Dose
Estimates
Exclusions /
Additional
Inclusions
Method
of
Analysis Female Male
Estimated
Slope of Dose-
Response (per Gy)
Statistical Significance
of Dose-Response
(one-tailed p-value)
9. Primary definition Linear Alt. #1 None MLE
.176 ± .011
(.151, .202)
.087 ± .009
(.066, .108)
.010 ± .026
(<-.041, .078)
0.34
10. Primary definition Linear Alt. #2 None MLE
.176 ± .011
(.151, .201)
.087 ± .009
(.066, .108)
.013 ± .026
(-.037, .080)
0.30
11. Primary definition Linear Primary
Include
OOA
(scoping
analysis #1)
MLE
.171 ± .010
(.147, .195)
.085 ± .008
(.065, .104)
.031 ± .027
(-.027, >.101)
0.12
12. Primary definition Linear Primary
Include
OOA
(scoping
analysis #2)
MLE
.172 ± .010
(.148, .196)
.085 ± .008
(.066, .105)
.028 ± .027
(<-.029, >.097)
0.14
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that the lower confidence limit is less than the indicated value, “>”
indicates that the upper confidence limit is greater than the indicated value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  Standard errors are
not given for estimated background rates from logistic regression model. 
Abbreviations: MLE = maximum likelihood estimation, LSU = least squares estimation with ungrouped doses, LSG = least squares estimation with grouped doses, LQ = linear-quadratic, Ok =
Okanogan, F/S = Ferry/Stevens, OOA = out of area
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P.5.b. Alternative Dose-Response Functions
As shown in row 4 of Table IX.P-35, the estimated regression coefficient for the dose-squared
term in the linear-quadratic dose-response model [5] was −0.001 with Bonferroni-adjusted 95% confidence
interval ranging from –0.076 to 0.074.  Thus the addition of a quadratic term did not significantly improve
the fit of the model (p = 0.97).
The regression parameter for the effect of dose in the sex-stratified logistic regression model [2]
was estimated as 0.21, with Bonferroni-adjusted 95% confidence interval ranging from –0.32 to 0.74
(Table IX.P-35, row 5).  Thus there was no evidence from the logistic regression model that prevalence of
diffuse thyroid UDA increased significantly with increasing dose (p = 0.17).
P.5.c. Effect of Excluding Participants in High Dose Categories
As shown in row 7 of Table IX.P-35 above, the estimated slope of the dose-response for
nonpalpable focal thyroid UDAs was larger if participants with highest estimated doses were excluded.  In
particular, when participants with estimated dose > 400 mGy were excluded, the estimated slope B
increased from 0.029 to 0.146 per Gy (p = 0.005).  Excluding the small number of participants with
estimated dose > 1000 mGy had very little effect on the estimated dose-response (Table IX.P-35, row 6).
P.5.d. Effect of Excluding Okanogan and Ferry/Stevens Geostrata
The effect of excluding the Okanogan and Ferry/Stevens geostrata was to increase the estimated
slope, from 0.029 to 0.042 per Gy.  The statistical significance of the dose-response changed from p = 0.14
to p = 0.065 (Table IX.P-35, row 8).
P.5.e. Analysis of Diffuse Thyroid UDAs in Relation to Alternative Dose Estimates
Using the first alternative dose estimates, the estimated slope B was not significantly greater than
zero (0.010 per Gy with Bonferroni-adjusted  95% CI ranging from less than -0.041 to 0.078 per Gy),
providing no evidence that prevalence increased with increasing dose (p = 0.34; Table IX.P-35, row 9).
Similar results were found with the second set of alternative dose estimates, with an estimated slope of
(0.013 per Gy with Bonferroni-adjusted  95% CI ranging from -0.037 to 0.080), and no evidence that the
proportion with diffuse thyroid UDAs increased with increasing dose (p = 0.30; Table IX.P-35, row 10). 
P.5.f. Scoping Analysis Regarding Out-of-Area Participants
See section VIII.C.1.a.3 for a description of the scoping analyses that were performed to assess the
possible impact of the 249 out-of-area participants. The results of both scoping analyses were virtually the
same as the primary analysis and provided no evidence that the prevalence of diffuse thyroid UDA
increased with increasing dose (Table IX.P-35; rows 11 and 12).  
P.5.g. Analysis of Diffuse Thyroid UDAs in Relation to Alternative Representations of
Exposure
In the analyses by geostratum and by dichotomous exposure variable, the sex and age-adjusted
comparisons of prevalence were performed as described in section VIII.C.2.a.2.
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P.5.g.1. Analysis by Geostratum
Among women, the proportions with diffuse thyroid UDAs ranged from 28/131 (21.4%) in the
Walla Walla City geostratum to 26/177 (14.7%) in the Richland geostratum (Table IX.P-36).  For men they
ranged from 11/70 (15.7%) in the Ferry/Stevens geostratum to 9/164 (5.5%) in the Walla Walla County
geostratum.  The heterogeneity among the nine geostrata was not statistically significant (p = 0.60).
Among men diffuse thyroid UDAs were rather more common in the Okanogan and Ferry/Stevens geostrata
(14.3%) compared to the other geostrata (8.5%).  However among women the proportions were nearly
identical (16.8% and 17.7%).  The difference between the Okanogan and Ferry/Stevens geostrata versus the
other geostrata was not statistically significant (p = 0.32).
Table IX.P-36. Diffuse Ultrasound-Detected Abnormalities, by Geostratum and Sex
Female Male Total
Geostratum No. Cases % No. Cases % No. Cases %
Richland 177 26 14.7 172 13 7.6 349 39 11.2
Pasco/Kennewick 505 96 19.0 501 40 8.0 1006 136 13.5
Benton County 375 62 16.5 358 39 10.9 733 101 13.8
Franklin County 73 12 16.4 76 10 13.2 149 22 14.8
Adams County 165 32 19.4 156 14 9.0 321 46 14.3
Walla Walla (city) 131 28 21.4 131 8 6.1 262 36 13.7
Walla Walla County 169 26 15.4 164 9 5.5 333 35 10.5
Okanogan County 75 13 17.3 63 8 12.7 138 21 15.2
Ferry/Stevens Counties 68 11 16.2 70 11 15.7 138 22 15.9
Total 1738 306 17.6 1691 152 9.0 3429 458 13.4
P.5.g.2. Analysis by Dichotomous Exposure Variable
Of the 1255 participants included in these analyses, 175 (13.9%) had diffuse thyroid UDA (Table
IX.P-37).  These included 83/580 (14.3%) in the high exposure group, and 92/675 (13.6%) in the low
exposure group.  Based on the logistic regression analysis with adjustment for the effect of sex and age at
HTDS examination, the proportion of participants with diffuse thyroid UDAs was not significantly elevated
in the high exposure group (p = 0.25).
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Table IX.P-37. Diffuse Ultrasound-Detected Abnormalities, by Exposure Group and Sex 
Female Male Total
Exposure Group No. Cases % No. Cases % No. Cases %
Low 350 57 16.3 325 35 10.8 675 92 13.6
High 298 58 19.5 282 25 8.9 580 83 14.3
Total 648 115 17.7 607 60 9.9 1255 175 13.9
P.5.h. Confounding and Effect Modification
As described in section VIII above, additional sex-stratified logistic regression models were
investigated to examine the possibility that the primary dose-response results might be influenced by
confounding, and to search for factors that might modify a radiation dose-response.  Table IX.P-38 displays
results for models including sex, age at first exposure to Hanford I-131 (prenatal, or < 180 days), age at
HTDS examination, estimated dose from the NTS, history of any cancer other than thyroid, and HTDS
interview type.  Note that sex was not analyzed as a possible confounder since its effect was already
adjusted for in the sex-stratified model.  It is evident from Table IX.P-38 that the model was not
significantly improved by adjusting for any of the other factors as a potential confounder: none produced a
significantly better fit to the data.  Since the estimated slope was virtually unaffected by such adjustments,
it does not appear that omitting these factors introduces any important bias in the dose-response results.
Table IX.P-38. Confounding and Effect Modification by Sex, Age at Exposure or HTDS
Examination, Estimated Thyroid Dose from NTS, History of Any Cancer Other
than Thyroid, and Interview Type: Diffuse Ultrasound-Detected Abnormalities
Estimated Dose-Response Coefficient (per Gy)
Covariate Yes / Unadjusted Incl. Confounding Including Effect Modification
(0=No, 1=Yes) Total Estimate Estimate Group 0 Group 1 P
Female?
1614 /
3181
.211 ± .220
(−.317, .738) Not Applicable
.392 ± .343
(−.464, 1.25)
.095 ± .286
(−.621, .810) .51
Prenatal
exposure?
1031 /
3181
.211 ± .220
(−.317, .738)
.188 ± .223
(−.385, .762)
.364 ± .242
(−.274, 1.00)
−.510 ± .534
(−1.92, .898) .12
1st exposure
before age 180
days?
1474 /
3181
.211 ± .220
(−.317, .738)
.211 ± .223
(−.363, .785)
.254 ± .392
(−.779, 1.29)
.190 ± .273
(−.529, .909) .89
Age at exam >
50?
1993 /
3181
.211 ± .220
(−.317, .738)
.292 ± .220
(−.275, .859)
.479 ± .359
(−.469, 1.43)
.185 ± .282
(−.559, .928) .52
NTS I-131
dose > 5.3 mGy?
1563 /
3179
.211 ± .220
(−.316, .739)
.179 ± .226
(−.404, .763)
.358 ± .286
(−.396, 1.11)
−.107 ± .390
(−1.14, .922) .33
History of any
cancer other than
thyroid ?
248 /
3176
.220 ± .220
(−.307, .746)
.219 ± .220
(−.348, .785)
.213 ± .244
(−.431, .857)
.243 ± .508
(−1.10, 1.58) .96
Expanded In-
Person Interview?
1205 /
3181
.211 ± .220
(−.317, .738)
.232 ± .224
(−.346, .810)
.450 ± .361
(−.503, 1.40)
.097 ± .296
(−.684, .877) .45
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses, based on sex-
stratified logistic regression models.  P-values indicate the statistical significance of two-tailed comparison of estimated coefficients
between Groups 0 and 1.
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Tables IX.P-39 and IX.P-40 display similar results from analyses including history of medical or
dental x-ray exposure or occupational exposure as potential confounding or effect modifying factors.  There
is no evidence of any confounding or statistically significant effect modification.
Table IX.P-39. Confounding and Effect Modification by History of Medical and Dental Radiation
Exposures: Diffuse Ultrasound-Detected Abnormalities
Estimated Dose-Response Coefficient (per Gy)
Have You
Ever Had: Yes / Unadjusted Incl. Confounding Including Effect Modification
(0=No, 1=Yes) Total Estimate Estimate Group 0 Group 1 P
CAT scan of the
upper body?
775 /
3139
.195 ± .222
(−.228, .727)
.192 ± .223
(−.381, .766)
.155 ± .247
(−.496, .806)
.376± .539
(−1.04, 1.80) .71
Diagnostic x-rays
of the head?
1188 /
3145
.215 ± .222
(−.316, .745)
.217 ± .221
(−.353, .787)
.242 ± .272
(−.477, .961)
.169 ± .380
(−.834, 1.17) .88
Diagnostic x-rays
of the neck?
960 /
3157
.229 ± .221
(−.299, .757)
.249 ± .221
(−.320, .819)
−.152 ± .325
(−1.01, .705)
.662 ± .304
(−.141, 1.46) .066
Diagnostic x-rays
of chest or upper
body, including
mammograms?
2811 /
3163
.218 ± .220
(−.309, .745)
.241 ± .220
(−.326, .808)
.563 ± .800
(−1.55, 2.67)
.216 ± .230
(−.390, .822) .68
Diagnostic x-rays
of the stomach or
mid-back?
691 /
3110
.247 ± .220
(−.280, .775)
.248 ± .220
(−.319, .816)
.155 ± .254
(−.515, .825)
.578 ± .456
(−.625, 1.78) .42
Barium enema?
821 /
3149
.183 ± .224
(−.353, .718)
.182 ± .224
(−.395, .758)
.338 ± .252
(−.326, 1.00)
−.312 ± .493
(−1.61, .990) .22
Upper GI?
1140 /
3167
.204 ± .222
(−.327, .735)
.201 ± .222
(−.370, .773)
.256 ± .275
(−.470, .981)
.105 ± .374
(−.881, 1.09) .75
Intravenous
pyelogram?
396 /
3147
.213 ± .223
(−.321, .746)
.222 ± .223
(−.352, .795)
.143 ± .239
(−.489, .774)
.919 ± .673
(−.855, 2.69) .29
Fluoroscopy of the
upper body?
246 /
3151
.193 ± .223
(−.341, .727)
.196 ± .223
(−.378, .771)
.239 ± .228
(−.363, .840)
−.459 ± .945
(−2.95, 2.03) .46
Other nuclear
scan?
216 /
3152
.239 ± .220
(−.287, .765)
.248 ± .219
(−.318, .813)
.325 ± .220
(−.255, .905)
−2.19 ± 1.53
(−6.22, 1.84) .063
Dental x-rays that
did not usually
include a lead
shield over the
neck area?
1644 /
3181
.211 ± .220
(−.317, .738)
.207 ± .220
(−.361, .775)
.308 ± .309
(−.508, 1.12)
.108 ± .316
(−.726, .942) .65
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses, based on sex-
stratified logistic regression models.  P-values indicate the statistical significance of two-tailed comparison of estimated coefficients
between Groups 0 and 1.
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Table IX.P-40. Confounding and Effect Modification by Occupational History: Diffuse Ultrasound-
Detected Abnormalities
Estimated Dose-Response Coefficient (per Gy)Have You Ever
Worked in Any of
the Following: Yes / Unadjusted Incl. Confounding Including Effect Modification
(0=No, 1=Yes) Total Estimate Estimate Group 0 Group 1 P
Any metal
industry?
238 /
3181
.211 ± .220
(−.317, .738)
.214 ± .220
(−.354, .782)
.253 ± .223
(−.337, .842)
−.669 ± 1.14
(−3.67, 2.33) .41
Any nuclear
facility?
370 /
3181
.211 ± .220
(−.317, .738)
.195 ± .222
(−.377, .767)
.096 ± .252
(−.568, .760)
.606 ± .479
(−.658, 1.87) .36
Any other industry
or occupation
where you may
have been exposed
to radioactive
materials or x-rays?
442 /
3181
.211 ± .220
(−.317, .738)
.219 ± .220
(−.348, .786)
.327 ± .237
(−.299, .953)
−.436 ± .698
(−2.28, 1.41) .25
Any of the above
industries or
occupations?
891 /
3181
.211 ± .220
(−.317, .738)
.200 ± .221
(−.370, .770)
.283 ± .266
(−.417, .984)
.023 ± .403
(−1.04, 1.09) .59
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses, based on sex-
stratified logistic regression models.  P-values indicate the statistical significance of two-tailed comparison of estimated coefficients
between Groups 0 and 1.
Table IX.P-41 displays the results of analyses of possible confounding or effect modification by
smoking variables.  There was no evidence that the dose-response was significantly confounded by either
smoking variable, or that there was a dose-response that differed significantly according to smoking
history.
Table IX.P-41. Confounding and Effect Modification by Smoking: Diffuse Ultrasound-Detected 
Abnormalities
Estimated Dose-Response Coefficient (per Gy)Have You Ever
Smoked Any of
the Following: Yes / Unadjusted Incl. Confounding. Including Effect Modification
(0=No, 1=Yes) Total Estimate Estimate Group 0 Group 1 P
Cigarettes
(unfiltered or
filtered)?
1850 /
3173
.218 ± .220
(−.309, .744)
.224 ± .221
(−.344, .792)
.285 ± .366
(−.680, 1.25)
.190 ± .278
(−.545, .924) .84
Any of cigarettes,
cigar or pipe?
1896 /
3173
.218 ± .220
(−.309, .744)
.224 ± .221
(−.345, .793)
.217 ± .370
(−.759, 1.19)
.228 ± .275
(−.497, .953) .98
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses, based on sex-
stratified logistic regression models.  P-values indicate the statistical significance of two-tailed comparison of estimated coefficients
between Groups 0 and 1.
P.5.i. Uncertainty
The estimated slopes of the sex-stratified linear dose-response model for the outcome of diffuse
thyroid UDA are shown in Figure IX.P-8 for each of the 100 dose realizations produced by the CIDER
model.  The confidence intervals in that figure are calculated at the 98.33% confidence level, i.e., are
adjusted by the Bonferroni technique for the simultaneous estimation of the slope and two sex-specific
background rates.  While the point estimate of the slope is greater than 0 for 88 of the 100 realizations, the
confidence interval includes 0 for all but 1 of the realizations.  Also shown in Figure IX.P-8 (to the right of
realization 100) are the estimates and confidence intervals calculated using (from left to right) the median,
geometric mean and mean of each participant's 100 dose realizations. In summary, for only one of the 100
realizations of the estimated doses was there a statistically significant dose-response, although for most of
the realizations the estimated slope was greater than 0.
Figure IX.P-8. Plot of Estimated Slope and 95% CI by Dose Realization: Diffuse Ultrasound-
Detected Abnormalities
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Figure IX.P-9 displays the distribution of the 5000 logistic regression coefficient estimates
obtained by the simulation procedures described in section VIII.C.2.b.3 above.  It is evident from the figure
that most of the estimates were between about –0.5 and 1.0. The estimate was less than or equal to 0 for
713 of the 5000 replications, implying an empirical one-tailed p-value of 0.14.  The median estimate was
0.30, and the upper and lower percentiles corresponding to the Bonferroni-adjusted 95% confidence
interval were –0.42 and 0.96.  These may be compared to the p-value of 0.17 and the estimate of 0.21 with
confidence interval (−0.32, 0.74) obtained using the median dose estimates without adjustment for
uncertainty. Thus, this method of adjusting the estimated logistic regression coefficient for the uncertainty
in the dose estimates did not provide evidence that the prevalence of diffuse thyroid UDA increased with
increasing dose.
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Figure IX.P-9. Distribution of Simulation Estimates of Logistic Regression Coefficient: Diffuse 
Ultrasound-Detected Abnormalities
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Q. Laboratory Values 
 
Associations between laboratory values and estimated thyroid radiation dose were investigated by 
fitting the linear dose-response model [4], described in section VIII.C.1.a above.  The regression 
coefficient B in this model plays a role analogous to that in the model [1] for cumulative incidence.  In 
particular the direction and magnitude of each estimated dose-response relationship is represented by the 
estimate of the regression coefficient.  An estimate of B greater than 0 indicates that the mean of the 
laboratory value tended to increase with increasing dose, while an estimate less than 0 indicates that the 
mean tended to decrease with increasing dose.  The statistical significance of the dose-response was tested 
using the likelihood ratio statistic.   
 
The p-values used to characterize the statistical significance of associations between lab values 
and estimated radiation dose were reported for two-tailed tests.  This differed from the use of one-sided p-
values in the tests for association with disease outcomes. 
 
Of the 3191 living evaluable in-area participants, 3183 (99.7%) consented to provide a blood 
specimen at their HTDS clinic. 
 
 
Q.1. Thyroid Stimulating Hormone (TSH) 
 
Of the 3183 living evaluable in-area participants who provided blood samples, 222 were receiving 
exogenous thyroid hormone at the time of their HTDS clinic.  These 222 were excluded from the analyses 
of TSH levels.  Among the remaining 2961 living evaluable participants, 584 had TSH measured by RIA, 
810 by EIA-1, and 1567 by EIA-2.  Table IX.Q-1 displays the minimum, maximum, and median TSH 
levels of the 584 participants for whom RIA was used.   
 
Table IX.Q-1. Distributions of TSH Levels Measured by RIA, by Sex 
 
 TSH (µIU/ml) measured by RIA 
 Female (N = 281) 
Male 
(N = 303) 
Total 
(N = 584) 
Minimum   0.1     0.3     0.1 
Maximum 52.9 100.0 100.0 
Median   2.3     2.3     2.3 
 
 
Tables IX.Q-2 and IX.Q-3 display similar results for the participants whose TSH levels were 
measured by either of the two EIA assays.  For two participants with TSH measured by EIA-1 and six with 
TSH measured by EIA-2, the TSH levels were reported simply as < 0.03 µIU/ml and < 0.04 µIU/ml, 
respectively.  Such measurements are “left-censored”, that is, their specific values are not known, and they 
are known only to be less than the specified value.  
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Table IX.Q-2. Distributions of TSH Levels Measured by EIA-1, by Sex 
 
 TSH (µIU/ml) measured by EIA-1 
 Female (N = 376) 
Male 
(N = 434) 
Total 
(N = 810) 
Minimum     < 0.03    0.21 < 0.03 
Maximum      50.34  28.77  50.34 
Median        1.59    1.37    1.49 
Number (%) below lower 
measurement limit (< 0.03 µIU/ml)     2 (0.5%)   0 (0%)     2 (0.2%) 
 
Table IX.Q-3. Distributions of TSH Levels Measured by EIA-2, by Sex 
 
 TSH (µIU/ml) measured by EIA-2 
 Female (N = 766) 
Male 
(N = 801) 
Total 
(N = 1567) 
Minimum < 0.04 < 0.04 < 0.04 
Maximum  24.12  22.46  24.12 
Median    1.49    1.22    1.35 
Number (%) below lower 
measurement limit (< 0.04 µIU/ml)     5 (0.7%)     1 (0.1%)     6 (0.4%) 
 
 
It is evident from Tables IX.Q-1 through IX.Q-3 above that the distributions of TSH values were 
quite skewed to the right, since the median values are much closer to the minima than the maxima. 
Therefore the regression model was applied to the logarithms of the TSH values.  Figures IX.Q-1 through 
IX.Q.3 display the TSH values, plotted on the logarithmic scale, in relation to estimated thyroid radiation 
dose. 
 
Figure IX.Q-1. Scatter Plot of TSH by RIA and Estimated Dose 
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Figure IX.Q-2. Scatter Plot of TSH by EIA-1 and Estimated Dose 
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Figure IX.Q-3. Scatter Plot of TSH by EIA-2 and Estimated Dose 
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The results of fitting the sex-stratified linear dose-response model for log(TSH) are summarized 
for the three types of assays in Table IX.Q-4 below.  In the table, parameter estimates are converted from 
the scale of log(TSH) back to TSH.  So, for example, the estimated average RIA-based TSH for women of 
2.45 µIU/ml is in fact an estimate of the geometric mean.  Also, the radiation dose effect is represented by 
the percentage change per Gy.  For example, the estimated average (geometric mean) TSH level for women 
based on EIA-1 increased from 1.58 µIU/ml at 0 Gy to 1.58 × 1.1422 = 2.06 µIU/ml at 2 Gy (2000 mGy).  
For none of the three assays was there a significant trend in relation to estimated radiation dose. 
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Table IX.Q-4. Parameter Estimates for Dose-Response Models: TSH 
 
Parameter RIA (µIU/ml) EIA – 1 (µIU/ml) EIA – 2 (µIU/ml) 
No. of living evaluable participants 584 810 1567 
No. with left-censored values 0 2 6 
Estimated average background TSH 
for women 
2.45 
(2.22, 2.71) 
1.58 
(1.45, 1.72) 
1.48 
(1.39, 1.57) 
Estimated average background TSH 
for men 
2.43 
(2.20, 2.68) 
1.36 
(1.26, 1.48) 
1.26 
(1.18, 1.34) 
Estimated percentage change in 
average TSH per Gy 
+2.0% 
(−30.0%, +48.9%) 
+14.2% 
(−12.0%, +48.0%) 
+1.5% 
(−12.2%, +17.2%) 
Statistical significance of dose-response 
(two-tailed p-value) 0.90 0.22 0.82 
Entries in the table for model parameters are the parameter estimate, with Bonferroni-adjusted 95% confidence interval in parentheses, 
based on sex-stratified linear model for log (TSH). 
 
 
 Since the average levels of TSH differed rather substantially among the three assays, it was not 
considered appropriate to simply combine all three groups and attempt to fit the simple sex-stratified linear 
regression model [4].  Therefore a generalization of the sex-stratified linear model was examined, in which 
the mean values of log(TSH) were assumed to differ between the sexes and according to the type of assay.  
When this model was fit to the data for all 2961 living evaluable participants with TSH measurements, 
there was still no significant trend of average log(TSH) in relation to estimated thyroid radiation dose.  If a 
common slope was assumed for all three assays, the estimated regression coefficient was +4.5% per Gy 
with Bonferroni-adjusted 95% confidence limits −8.4% and +19.1% per Gy, which was not significantly 
different from zero (two-tailed p = 0.42).   
  
 
Q.1.a. Uncertainty 
 
The estimated slopes of the sex-stratified linear dose-response model for log (TSH) by RIA, 
EIA-1, and EIA-2 are shown in Figures IX.Q-4  through IX.Q-6 for each of the 100 dose realizations 
produced by the CIDER model.  The confidence intervals in these figures were calculated at the 98.33% 
confidence level, i.e., were adjusted by the Bonferroni technique for the simultaneous estimation of the 
slope and two sex-specific background rates.   The point estimate of the slope was greater than 0 for 59, 94, 
and 65 of the 100 realizations for TSH by RIA, EIA-1, and EIA-2, respectively.  However the confidence 
intervals included 0 for all 100 realizations for TSH by RIA and EIA-2, and for 96 of  the 100 realizations 
for EIA-1. 
 
Also shown in Figures IX.Q-4 through IX.Q-6 (to the right of realization 100) are the estimates 
and confidence intervals calculated using (from left to right) the median, geometric mean, and mean of 
each participant’s 100 dose realizations. 
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Figure IX.Q-4. Estimated Dose-Response for TSH by RIA, by Dose Realization 
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Figure IX.Q-5. Estimated Dose-Response for TSH by EIA-1, by Dose Realization 
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Figure IX.Q-6. Estimated Dose-Response for TSH by EIA-2, by Dose Realization 
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Q.2. Total Thyroxine (T4) 
 
The 222 living evaluable in-area participants who were receiving exogenous thyroid hormone at 
the time of their HTDS clinic were excluded from the primary analysis of T4.  The T4 values were 
unknown for two additional in-area participants due to insufficient volumes of collected blood.  Table 
IX.Q-5 displays the minimum, maximum, and median T4 levels of the 2959 participants for whom data 
were available.  For two of these participants the T4 levels were left censored, reported as < 1.0 µg/dl.  All 
other T4 levels were 3.1 µg/dl or greater.  Therefore the distribution of T4 levels was somewhat skewed to 
the right, and consequently the regression model was applied to the logarithms of the T4 values. 
 
Table IX.Q-5. Distributions of Total Thyroxine (T4) Levels, by Sex 
 
 T4 (µg/dl) 
 Female (N = 1422) 
Male 
(N = 1537) 
Total 
(N = 2959) 
Minimum  < 1.0   < 1.0    < 1.0 
Maximum   19.1    15.2     19.1 
Median     7.5      6.6       7.0 
Number (%) below lower 
measurement limit (< 1.0 µg/dl)   1 (0.07%)    1 (0.07%)     2 (0.07%) 
 
 
T4 values, plotted on the logarithmic scale, are shown by estimated dose in Figure IX.Q-7.   
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Figure IX.Q-7. Scatter Plot of T4 and Estimated Dose 
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The results of fitting the sex-stratified linear dose-response model for log(T4) are summarized in 
Table IX.Q-6 below.  In the table, parameter estimates are converted from the scale of log(T4) back to T4.  
So, for example, the estimated average T4 of 7.52 µg/dl for women is in fact an estimate of the geometric 
mean.  Also, the radiation dose effect is represented by the percentage change per Gy.  For example, the 
estimated average (geometric mean) T4 level for women decreased from 7.52 µg/dl at 0 Gy to 7.52 × 
0.9962 = 7.46 µg/dl at 2 Gy (2000 mGy).  There was no significant trend of T4 in relation to estimated 
radiation dose (two-tailed p = 0.84). 
 
Table IX.Q-6. Parameter Estimates for Dose-Response Models: T4 
 
Parameter T4 (µg/dl) 
No. of living evaluable participants 2959 
No. with left-censored values 2 
Estimated average background T4 
for women 
7.52 
(7.41, 7.64) 
Estimated average background T4 
for men 
6.58 
(6.48, 6.67) 
Estimated percentage change in 
average T4 per Gy 
−0.4% 
(−4.5%, +4.0%) 
Statistical significance of dose-response 
(two-tailed p-value) 0.84 
Entries for model parameters (background means and slope) in the table are estimate ± standard error, with Bonferroni-adjusted 95% 
confidence interval in parentheses. 
 
 
Q.2.a. Uncertainty 
 
The estimated slopes of the sex-stratified linear dose-response model for log of T4 are shown in 
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Figure IX.Q-8 for each of the 100 dose realizations produced by the CIDER model.  The confidence 
intervals in that figure were calculated at the 98.33% confidence level, i.e., were adjusted by the 
Bonferroni technique for the simultaneous estimation of the slope and two sex-specific background rates.  
While the point estimate of the slope was greater than 0 for 42 of the 100 realizations, the confidence 
interval included 0 for all of the 100 realizations.  Also shown in Figure IX.Q-8 (to the right of realization 
100) are the estimates and confidence intervals calculated using (from left to right) the median, geometric 
mean, and mean of each participant’s 100 dose realizations. 
 
Figure IX.Q-8. Estimated Dose-Response for T4, by Dose Realization 
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Q.3. Triiodothyronine Resin Uptake (T3RU) 
 
The 222 living evaluable in-area participants who were receiving exogenous thyroid hormone at 
the time of their HTDS clinic were excluded from the analyses of T3RU.  The T3RU values were unknown 
for two additional in-area participants, the same two whose T4 values were unknown due to insufficient 
volumes of collected blood.  Table IX.Q-7 displays the minimum, maximum, and median T3RU levels of 
the 2959 participants for whom data were available.  For one of these participants the T3RU level was left 
censored, reported as < 0.4 µg/dl.  All other T3RU levels were 0.49 µg/dl or greater.  The distribution of 
T3RU levels was somewhat skewed to the right, and therefore the regression model was applied to the 
logarithms of the T3RU values. 
 
HTDS Final Report: June 21, 2002 – Section IX.Q  page 446  
Table IX.Q-7. Distributions of T3 Resin Uptake (T3RU), by Sex 
 
 T3RU (µg/dl) 
 Female (N = 1422) 
Male 
(N = 1537) 
Total 
(N = 2959) 
Minimum    0.49  < 0.4   < 0.4 
Maximum    1.87   1.86    1.87 
Median    1.00         0.86    0.92 
Number (%) below lower 
measurement limit (< 0.4)    0 (0%)     1 (0.1%)    1 (0.03%) 
 
 
T3RU values, plotted on the logarithmic scale, are shown by estimated dose in Figure IX.Q-9. 
 
Figure IX.Q-9. Scatter Plot of T3RU and Estimated Dose 
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The results of fitting the sex-stratified linear dose-response model for log(T3RU) are summarized 
in Table IX.Q-8 below.  In the table, parameter estimates are converted from the scale of log(T3RU) back 
to T3RU.  So, for example, the estimated average T3RU of 1.02 µg/dl for women is in fact an estimate of 
the geometric mean.  Also, the radiation dose effect is represented by the percentage change per Gy.  For 
example, the estimated average (geometric mean) T3RU level for women decreased from 1.02 µg/dl at 0 
Gy to 1.02 × 0.9882 = 1.00 µg/dl at 2 Gy (2000 mGy).  There was no significant trend of T3RU in relation 
to estimated radiation dose (two-tailed p = 0.36). 
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Table IX.Q-8. Parameter Estimates for Dose-Response Models: T3RU 
 
Parameter T3RU (µg/dl) 
No. of living evaluable participants 2959 
No. with left-censored values 1 
Estimated average background T3RU 
for women 
1.02 
(1.01, 1.03) 
Estimated average background T3RU 
for men 
0.85 
(0.84, 0.86) 
Estimated percentage change in 
average T3RU per Gy 
−1.2% 
(−4.3%, +2.0%) 
Statistical significance of dose-response 
(two-tailed p-value) 0.36 
Entries for model parameters (background means and slope) in the table are estimate ± standard error, with Bonferroni-adjusted 95% 
confidence interval in parentheses. 
 
 
Q.3.a. Uncertainty 
 
The estimated slopes of the sex-stratified linear dose-response model for log of T3RU values are 
shown in Figure IX.Q-10 for each of the 100 dose realizations produced by the CIDER model.  The 
confidence intervals in that figure were calculated at the 98.33% confidence level, i.e., were adjusted by 
the Bonferroni technique for the simultaneous estimation of the slope and two sex-specific background 
rates.  While the point estimate of the slope was greater than 0 for 15 of the 100 realizations, the 
confidence interval included 0 for all of the 100 realizations.  Also shown in Figure IX.Q-10 (to the right 
of realization 100) are the estimates and confidence intervals calculated using (from left to right) the 
median, geometric mean, and mean of each participant’s 100 dose realizations. 
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Figure IX.Q-10. Estimated Dose-Response for T3RU, by Dose Realization 
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Q.4. Free Thyroxine Index (FTI) 
 
The 222 living evaluable in-area participants who were receiving exogenous thyroid hormone at 
the time of their HTDS clinic were excluded from the primary analyses of FTI.  The FTI values were 
unknown for five additional in-area participants: the two with unknown T4 and T3RU, and three others for 
whom either T4 or T3RU was below its level of detection.  Table IX.Q-9 displays the minimum, 
maximum, and median FTI values of the 2956 participants for whom data were available.  Since the 
distribution of FTI values was somewhat skewed to the right, regression modeling of the dose-response 
was applied to the logarithms of the FTI values. 
 
Table IX.Q-9. Distributions of Free Thyroxine Index (FTI), by Sex 
 
 FTI 
 Female (N = 1421) 
Male 
(N = 1535) 
Total 
(N = 2956) 
Minimum   2.7   3.9   2.7 
Maximum 23.3 15.4 23.3 
Median   7.4   7.8   7.6 
 
 
FTI values, plotted on the logarithmic scale, are shown by estimated dose in Figure IX.Q-11. 
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Figure IX.Q-11. Scatter Plot of FTI and Estimated Dose 
 
1
10
100
0.001 0.01 0.1 1 10 100 1000 10000
Median Dose (mGy)
Fr
ee
 T
hy
ro
xi
ne
 In
de
x
Male Female
 
The results of fitting the sex-stratified linear dose-response model for log(FTI) are summarized in 
Table IX.Q-10 below.  In the table, parameter estimates are converted from the scale of log(FTI) back to 
FTI.  So, for example, the estimated average FTI of 7.38 for women is in fact an estimate of the geometric 
mean.  Also, the radiation dose effect is represented by the percentage change per Gy.  For example, the 
estimated average (geometric mean) FTI level for women increased from 7.38 at 0 Gy to 7.38 × 1.0162 = 
7.62 at 2 Gy (2000 mGy).  There was no significant trend of FTI in relation to estimated radiation dose 
(two-tailed p = 0.23). 
 
Table IX.Q-10. Parameter Estimates for Dose-Response Models: FTI 
 
Parameter FTI 
No. of living evaluable participants 2956 
Estimated average background FTI 
for women 
7.38 
(7.29, 7.46) 
Estimated average background FTI 
for men 
7.72 
(7.63, 7.81) 
Estimated percentage change in 
average FTI per Gy 
+1.6% 
(−1.6%, +4.9%) 
Statistical significance of dose-response 
(two-tailed p-value) 0.23 
Entries for model parameters (background means and slope) in the tableare estimate ± standard error, with Bonferroni-adjusted 95% 
confidence interval in parentheses. 
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Q.4.a. Uncertainty 
 
The estimated slopes of the sex-stratified linear dose-response model for log of FTI are shown 
in Figure IX.Q-12 for each of the 100 dose realizations produced by the CIDER model.  The confidence 
intervals in that figure were calculated at the 98.33% confidence level, i.e., were adjusted by the 
Bonferroni technique for the simultaneous estimation of the slope and two sex-specific background rates.  
While the point estimate of the slope was greater than 0 for 94 of the 100 realizations, the confidence 
interval included 0 for all of the 100 realizations.  Also shown in Figure IX.Q-12 (to the right of realization 
100) are the estimates and confidence intervals calculated using (from left to right) the median, geometric 
mean, and mean of each participant’s 100 dose realizations. 
 
Figure IX.Q-12. Estimated Dose-Response for FTI, by Dose Realization 
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Q.5. Anti-Thyroid Autoimmune Response 
 
Anti-TPO or AMA values were used to measure the anti-thyroid autoimmune responses of 1562 
and 1620 in-area living evaluable participants, respectively.  Neither assay result was available for eight 
participants who declined to provide a blood sample, and for one other whose sample was of insufficient 
volume.  Tables IX.Q-11 and IX.Q-12 display the minimum, maximum, and median anti-TPO or AMA 
values of the participants for whom data were available.  For both assays, the majority of participants had 
values below the lower measurement limits: 80% with anti-TPO < 2.0 IU/ml, and 78% with AMA < 20 
IU/ml.  In addition, 6% of the participants assayed by AMA had values above the upper measurement 
limit, i.e., > 700 U/ml.   Since the distributions of these values were skewed to the right, they were log-
transformed for regression modeling of the dose-responses. 
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Table IX.Q-11. Distributions of Anti-TPO, by Sex 
 
 Anti-TPO (IU/ml) 
 Female (N = 812) 
Male 
(N = 750) 
Total 
(N = 1562) 
Minimum     < 2.0     < 2.0    < 2.0 
Maximum  9569.7  1631.7      9569.7 
Median     < 2.0     < 2.0    < 2.0 
Number (%) below lower 
measurement limit (< 2.0 IU/ml)    594 (73%)    651 (87%)  1245 (80%) 
 
 
Table IX.Q-12. Distributions of AMA, by Sex 
 
 AMA (U/ml) 
 Female (N = 803) 
Male 
(N = 817) 
Total 
(N = 1620) 
Minimum     < 20       < 20   < 20 
Maximum   > 700     > 700 > 700 
Median     < 20       < 20   < 20 
Number (%) below lower 
measurement limit (< 20 U/ml)     590 (73%)    674 (82%)      1264 (78%) 
Number (%) above upper 
measurement limit (> 700 U/ml)       63 (8%)    30 (4%)    93 (6%) 
 
 
Anti-TPO and AMA results, plotted on logarithmic scales, are shown by estimated dose in Figures 
IX.Q-13 and IX.Q-14. 
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Figure IX.Q-13. Scatter Plot of Anti-TPO and Estimated Dose 
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Figure IX.Q-14. Scatter Plot of AMA and Estimated Dose 
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The results of fitting the sex-stratified linear dose-response models for log(anti-TPO) and 
log(AMA) are summarized in Table IX.Q-13 below.  In the table, parameter estimates are converted from 
the scales of logarithmically transformed values back to the original scales.  So, for example, the estimated 
average anti-TPO of 0.03 IU/ml for women is in fact an estimate of the geometric mean.  Also, the 
radiation dose effect is represented by the percentage change per Gy, with estimates less than zero 
indicating that the assay value decreased with increasing estimated thyroid dose.   Since the majority of 
participants had anti-TPO or AMA values below their respective lower limits of measurement, the 
estimated parameter values have little meaning.  Nevertheless these regression results provide no evidence 
that either value tended to increase sharply with increasing estimated dose (two-tailed p = 0.66 for 
anti-TPO, p = 0.52 for AMA). 
 
Table IX.Q-13. Parameter Estimates for Dose-Response Models: Anti-TPO and AMA 
 
Parameter Anti-TPO (IU/ml) AMA (U/ml) 
No. of living evaluable participants 1562 1620 
No. with left-censored values 1245 1264 
No. with right-censored values 0 93 
Estimated average background  
for women 
0.03 
(0.01, 0.07) 
1.30 
(0.63, 2.68) 
Estimated average background  
for men 
0.001 
(0.000, 0.005) 
0.29 
(0.12, 0.70) 
Estimated percentage change in 
average per Gy 
−32.1% 
(−91.7%, +453%) 
−39.9% 
(−91.2%, +312%) 
Statistical significance of dose-response 
(two-tailed p-value) 0.66 0.52 
Entries for model parameters (background means and slope) in the table are estimate ± standard  
error, with Bonferroni-adjusted 95% confidence interval in parentheses. 
 
 
Q.5.a. Uncertainty 
 
The estimated slopes of the sex-stratified linear dose-response models for log of Anti-TPO and 
log of AMA are shown in Figures IX.Q-15 and IX.Q-16 for each of the 100 dose realizations produced by 
the CIDER model.  The confidence intervals in these figures were calculated at the 98.33% confidence 
level, i.e., were adjusted by the Bonferroni technique for the simultaneous estimation of the slope and two 
sex-specific background rates.  While the point estimate of the slope was greater than 0 for 30 of the 100 
realizations for anti-TPO and for 18 realizations for AMA, the confidence intervals for both assays 
included 0 for all of the 100 dose realizations.  Also shown in Figures IX.Q-15 and IX.Q-16 (to the right of 
realization 100) are the estimates and confidence intervals calculated using (from left to right) the median, 
geometric mean, and mean of each participant’s 100 dose realizations. 
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Figure IX.Q-15. Estimated Dose-Response for Anti-TPO, by Dose Realization 
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Figure IX.Q-16.Estimated Dose-Response for AMA, by Dose Realization 
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Q.6. Anti-Thyroglobulin Antibody (anti-TG) 
 
Anti-TG values were not available for 13 of the 3183 living evaluable in area participants who 
provided blood specimens due to insufficient volume and broken tubes.  Table IX.Q-14 displays the 
minimum, maximum, and median anti-TG values of the 3170 participants for whom data were available.  
The lower limit of measurement for anti-TG was 1.0 IU/ml, and the majority of participants (85%) had 
values reported as < 1.0 IU/ml.  Since the distribution of anti-TG values was skewed to the right, 
regression modeling of the dose-response was applied to the logarithms of the anti-TG values. 
 
Table IX.Q-14. Distributions of Anti-TG, by Sex 
 
 Anti-TG (IU/ml) 
 Female (N = 1607) 
Male 
(N = 1563) 
Total 
(N = 3170) 
Minimum       < 1.0      < 1.0     < 1.0 
Maximum       4300      4500     4500 
Median       < 1.0      < 1.0     < 1.0 
Number (%) below lower 
measurement limit (< 1.0 IU/ml)      1281 (80%)    1400 (90%)       2681 (85%) 
 
 
Anti-TG values, plotted on a logarithmic scale, are shown by estimated dose in Figure IX.Q-17.   
For clarity, the 2681 values that were below the lower measurement limit of 1.0 IU/ml are plotted at 
0.5 IU/ml. 
 
Figure IX.Q-17. Scatter Plot of Anti-TG and Estimated Dose 
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 The results of fitting the sex-stratified linear dose-response model for log(anti-TG) are 
summarized in Table IX.Q-15 below.  In the table, parameter estimates are converted from the scale of 
log(anti-TG) back to anti-TG.  So, for example, the estimated average anti-TG of 0.02 IU/ml for women is 
in fact an estimate of the geometric mean.  Also, the radiation dose effect is represented by the percentage 
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change per Gy, with the estimate less than zero indicating that the average anti-TG level decreased with 
increasing estimated thyroid dose.   Since the majority of participants had anti-TG values below the lower 
limit of measurement, the estimated parameter values have little meaning.  Nevertheless these regression 
results provide no evidence that average anti-TG levels tended to increase sharply with increasing 
estimated dose (two-tailed p = 0.20). 
 
Table IX.Q-15. Parameter Estimates for Dose-Response Models: Anti-TG 
 
Parameter Anti-TG (IU/ml) 
No. of living evaluable participants 3170 
No. with left-censored values 2681 
Estimated average background anti-TG 
for women 
0.02 
(0.01, 0.03) 
Estimated average background anti-TG 
for men 
0.003 
(0.002, 0.007) 
Estimated percentage change in anti-TG 
Average per Gy 
−47.3% 
(−84.2%, +75.5%) 
Statistical significance of dose-response 
(two-tailed p-value) 0.20 
Entries for model parameters (background means and slope) in the table are estimate ± standard  
error, with Bonferroni-adjusted 95% confidence interval in parentheses. 
 
 
Q.6.a. Uncertainty 
 
The estimated slopes of the sex-stratified linear dose-response model for log of anti-TG are shown 
in Figure IX.Q-18 for each of the 100 dose realizations produced by the CIDER model.  The confidence 
intervals in that figure were calculated at the 98.33% confidence level, i.e., were adjusted by the 
Bonferroni technique for the simultaneous estimation of the slope and two sex-specific background rates.  
While the point estimate of the slope was greater than 0 for 3 of the 100 realizations, the confidence 
interval included 0 for 97 of the 100 realizations.  Also shown in Figure IX.Q-18 (to the right of realization 
100) are the estimates and confidence intervals calculated using (from left to right) the median, geometric 
mean, and mean of each participant’s 100 dose realizations. 
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Figure IX.Q-18. Estimated Dose-Response for Anti-TG, by Dose Realization 
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Q.7. Serum Calcium 
 
Of the 3183 living evaluable in-area participants who provided blood samples, 227 with diagnoses 
of hypothyroidism or hyperthyroidism based on the HTDS examination were excluded from the primary 
analysis of serum calcium levels.  Two additional participants did not have serum calcium data due to 
insufficient volumes of collected blood.   Table IX.Q-16 displays the minimum, maximum, and median 
serum calcium levels of the 2954 participants for whom data were available. 
 
Table IX.Q-16. Distributions of Serum Calcium, by Sex 
 
 Serum Calcium (mg/dl) 
 Female (N = 1448) 
Male 
(N = 1506) 
Total 
(N = 2954) 
Minimum   7.8   7.8   7.8 
Maximum 11.7 10.5 11.7 
Median   9.1   9.2   9.2 
 
 
Serum calcium levels are shown by estimated dose in Figure IX.Q-19. 
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Figure IX.Q-19. Scatter Plot of Serum Calcium and Estimated Dose 
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As can be seen in Figure IX.Q-19, the overall distribution of serum calcium levels was fairly 
symmetrically distributed, therefore the sex-stratified linear dose-response model [4] was fit without 
logarithmic transformation.  The results are summarized in Table IX.Q-17 below.  There was a statistically 
significant trend of decreasing serum calcium level in relation to increasing radiation dose (p = 0.0074).  
The estimated background means were 9.17 mg/dl for female and 9.19 mg/dl for male, with Bonferroni-
adjusted 95% confidence intervals (9.14, 9.20) and (9.16, 9.22), respectively.  The estimated slope of the 
dose-response was –0.09 mg/dl per Gy, with confidence interval ranging from –0.16 to –0.01 mg/dl per 
Gy, implying that the mean decreased by an average of 0.09 mg/dl with each incremental dose of 1 Gy 
(1000 mGy).  Although this trend is statistically significant, it is small enough in magnitude that the 
average serum calcium levels remain within the normal range of 8.4 – 10.2 mg/dl.  For example, at 3 Gy 
(3000 mGy), which is larger than the largest dose estimate of any study participant, the average serum 
calcium level predicted by the regression model for female is 9.17 – 0.09 × 3 = 8.90 mg/dl. 
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Table IX.Q-17. Parameter Estimates for Linear Dose-Response Models: Serum Calcium 
 
Parameter Serum Calcium (mg/dl) 
No. of living evaluable participants 2954 
Estimated average background serum 
calcium for women 
9.17 ± .01 
(9.14, 9.20) 
Estimated average background serum 
calcium for men 
9.19 ± .01 
(9.16, 9.22) 
Estimated slope of dose-response 
(per Gy) 
–.09 ± .03 
(-.16, -.01) 
Statistical significance of dose-
response 
(two-tailed p-value) 
0.0074 
Entries for model parameters (background means and slope) in the table are estimate ± standard error, with Bonferroni-adjusted 95% 
confidence interval in parentheses. 
 
Q.7.a. Uncertainty 
 
The estimated slopes of the sex-stratified linear dose-response model for serum calcium are shown 
in Figure IX.Q-20 for each of the 100 dose realizations produced by the CIDER model.  The confidence 
intervals in that figure were calculated at the 98.33% confidence level, i.e., were adjusted by the 
Bonferroni technique for the simultaneous estimation of the slope and two sex-specific background rates.  
While the point estimate of the slope was less than 0 for all 100 realizations, the confidence interval 
included 0 for 61 of the 100 realizations.  Also shown in Figure IX.Q-20 (to the right of realization 100) 
are the estimates and confidence intervals calculated using (from left to right) the median, geometric mean, 
and mean of each participant’s 100 dose realizations. 
 
Figure IX.Q-20. Estimated Dose-Response for Serum Calcium, by Dose Realization 
 
-0.34
-0.32
-0.30
-0.28
-0.26
-0.24
-0.22
-0.20
-0.18
-0.16
-0.14
-0.12
-0.10
-0.08
-0.06
-0.04
-0.02
0.00
0.02
0.04
0.06
0 10 20 30 40 50 60 70 80 90 100 103
 
HTDS Final Report: June 21, 2002 – Section IX.Q  page 460  
Q.8. Thyroid Mass 
 
Estimates of thyroid mass were available for 3153 were in-area participants.  Table IX.Q-18 
displays the minimum, maximum, and median estimates of thyroid mass of these 3153 participants. 
 
Table IX.Q-18. Distributions of Estimated Thyroid Mass, by Sex 
 
 Thyroid Mass (gm) 
 Female (N = 1592) 
Male 
(N = 1561) 
Total 
(N = 3153) 
Minimum     0.39      1.53     0.39 
Maximum 108.62  149.78 149.78 
Median     7.81     11.4     9.53 
 
 
Thyroid mass, plotted on the logarithmic scale, is shown by estimated dose in Figure IX.Q-21 for 
these 3153 living evaluable in-area participants. 
 
Figure IX.Q-21. Scatter Plot of Estimated Thyroid Mass and Estimated Dose 
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The results of fitting the sex-stratified linear dose-response model for log-transformed values of 
thyroid mass are summarized in Table IX.Q-19 below.  In the table, parameter estimates are converted 
from the logarithmically transformed scale back to the scale of thyroid mass in grams.  So, for example, the 
estimated average thyroid mass of 7.69 gm for women is in fact an estimate of the geometric mean.  Also, 
the radiation dose effect is represented by the percentage change per Gy.  For example, the estimated 
average (geometric mean) thyroid mass level for women decreased from 7.69 gm at 0 Gy to 7.69 × 0.9992 
= 7.67 gm at 2 Gy (2000 mGy).  There was no significant trend of thyroid mass in relation to estimated 
radiation dose (two-tailed p = 0.98). 
 
HTDS Final Report: June 21, 2002 – Section IX.Q  page 461  
Table IX.Q-19. Parameter Estimates for Dose-Response Models: Thyroid Mass 
 
Parameter Thyroid Mass (gm) 
No. of living evaluable participants 3153 
Estimated average background thyroid 
mass for women 
7.69 
(7.43, 7.96) 
Estimated average background thyroid 
mass for men 
11.51 
(11.11, 11.92) 
Estimated percentage change in 
average thyroid mass per Gy 
−0.1% 
(−9.3%, +10.0%) 
Statistical significance of dose-response 
(two-tailed p-value) 0.98 
Entries for model parameters (background means and slope) in the tableare estimate ± standard error, with Bonferroni-adjusted 95% 
confidence interval in parentheses. 
 
 
Q.8.a. Uncertainty 
 
The estimated slopes of the sex-stratified linear dose-response model for log of thyroid mass are 
shown in Figure IX.Q-22 for each of the 100 dose realizations produced by the CIDER model.  The 
confidence intervals in that figure were calculated at the 98.33% confidence level, i.e., were adjusted by 
the Bonferroni technique for the simultaneous estimation of the slope and two sex-specific background 
rates.  While the point estimate of the slope was greater than 0 for 45 of the 100 realizations, the 
confidence interval included 0 for all of the 100 realizations.  Also shown in Figure IX.Q-22 (to the right 
of realization 100) are the estimates and confidence intervals calculated using (from left to right) the 
median, geometric mean, and mean of each participant’s 100 dose realizations. 
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Figure IX.Q-22. Estimated Dose-Response for Thyroid Mass, by Dose Realization 
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R. Summary of Dose-Response Results
The primary evaluation of dose-response relationships focused on twelve categories of thyroid
disease, hyperparathyroidism, and ultrasound-detected thyroid abnormalities of the thyroid. For each of
these 14 outcome categories a primary case definition was specified based on the most definitive and valid
diagnostic criteria available. The principal dose-response analysis used this primary definition of outcome,
individual radiation dose estimates (the median for each individual) based on individual residence history,
and on dietary consumption data from the CATI when available or on HEDR default values when CATI
data were not available. The results from these analyses using the primary outcome definition constitute the
principal findings of the HTDS. These results are summarized in Table IX.R-1 which shows that there are
no significant dose-responses for the outcomes considered.
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Table IX.R-1. Summary of Dose-Response Results for Thyroid Disease Outcomes
Estimated Background Rates 
Estimated
Slope of Dose-
Statistical Significance of
Dose-Response
Thyroid Disease Female Male Response (per Gy) (one-tailed p-value)
Thyroid Cancer
.006 ± .002
(.001, .011)
.002 ± .001
(0*, .005)
.002 ± .004
 (< −.001, .017) 0.25
Benign thyroid nodule
.100 ± .008
(.081, .119)
.049 ± .006
(.034, .064)
−.008 ± .015
(< −.022, .041) 0.68
Total thyroid neoplasia
.011 ± .003
(.004, .018)
.006 ± .002
(.001, .012)
.001 ± .006
(< −.003, .022) 0.42
Any thyroid nodule
.112 ± .008
(.092, .132)
.053 ± .006
(.038, .068)
−.007 ± .016
(< −.023, .043) 0.65
Hypothyroidism
.118 ± .009
(.097, .139)
.037 ± .006
(.023, .050)
−.006 ± .019
(< −.016, .047) 0.61
Autoimmune thyroiditis
.239 ± .012
(.212, .267) 
.133 ± .010
(.109, .156)
−.026 ± .026
(< −.057, .044) 0.82
Graves disease
.016 ± .004
(.008, .025)
.004 ± .002
(0*, .009)
−.001 ± .009
(< −.002, .024) 0.56
Autoimmune thyroid disease
.255 ± .012
(.227, .283)
.136 ± .010
(.112, .160)
–.024 ± .027
(< −.058, .048) 0.80
Hyperthyroidism
.077 ± .007
(.060, .094)
.015 ± .004
(.006, .025)
.011 ± .015
(< −.008, .052) 0.22
Multinodular thyroid gland
.040 ± .005
(.027, .053)
.014 ± .004
(.006, .023)
−.006 ± .016
(NE, .014)
0.88
Simple goiter
.006 ± .002
(.001, .011)
.003 ± .002
(0*, .008)
–.001 ± .008
(NE, .012)
0.74
Other thyroid disease
.010 ± .003
(.003, .016)
.003 ± .002
(0*, .008)
.002 ± .007
(< −.002, .024) 0.39
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that
the lower confidence limit is less than the indicated value, “>” indicates that the upper confidence limit is greater than the indicated
value, “NE” indicates the confidence limit was not estimated due to its close proximity to the point estimate).  “0*” indicates that the
lower confidence limit for a background rate was less than 0.
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Table IX.R-1. Summary of Dose-Response Results for Thyroid Disease Outcomes (continued)
Estimated Background Rates 
Estimated
Slope of Dose-
Statistical Significance of
Dose-Response
Thyroid Disease Female Male Response (per Gy) (one-tailed p-value)
Hyperparathyroidism
.006 ± .003
(0*, .013)
.001 ± .002
(0*, .006)
−.000 ± .018
(NE, .013)
0.61
Any UDA
.552 ± .014
(.519, .586)
.365 ± .014
(.332, .399)
.031 ± .038
(−.059, .116) 0.21
Palpable UDA
.090 ± .008
(.070, .110)
.043 ± .006
(.029, .057)
−.018 ± .023
(NE, .015)
0.95
Nonpalpable focal UDA
.451 ± .014
(.417, .484)
.303 ± .013
(.270, .335)
.027 ± .037
(−.061, .115) 0.23
Diffuse UDA
.174 ± .011
(.148, .199)
.084 ± .009
(.064, .105)
.029 ± .028
(−.029, .100) 0.14
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses (“<” indicates that
the lower confidence limit is less than the indicated value, “NE” indicates the confidence limit was not estimated due to its close
proximity to the point estimate).  “0*” indicates that the lower confidence limit for a background rate was less than 0.
Less definitive criteria to identify cases were also defined for each outcome category using less
definitive diagnostic criteria. Dose-response analyses were also conducted for each of these alternative
definitions. In addition, dose-response analyses were conducted for six outcome categories based on the
results of laboratory assays, and for thyroid mass estimated from the ultrasound scan (Table IX.R-2). The
primary analysis for each outcome used the method of maximum likelihood to estimate the background
rates or averages for women and men, and the slope of the sex-stratified linear models. Estimates of the
parameters were also calculated using the method of least squares, once with doses treated as a continuous
quantitative variable (“ungrouped analysis”), and again with doses treated as a categorical variable
(“grouped analysis”). Linear quadratic and logistic dose-response models were also considered as
alternatives to the linear model. Dose-response analyses for all outcomes were repeated using two
alternative sets of individual dose estimates, and two alternative representations of exposure that did not
use the HEDR models to estimate individual radiation dose. Efforts were also made to evaluate the
influence of uncertainties in individual dose estimates on the fitted dose-response relationships for the
primary case definition in each outcome category.
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Table IX.R-2. Summary of Dose-Response Results for Laboratory Values and Thyroid Mass
Estimated Background Rates 
Estimated
Slope of Dose-
Statistical Significance of
Dose-Response
Outcome Female Male Response (per Gy) (two-tailed p-value)
TSH by RIA (µIU/ml) .90 ± .04
(.80, 1.00)
.89 ± .04
(.79, .99)
.02 ± .16
(−.36, .40) 0.90
TSH by EIA-1 (µIU/ml) .46 ± .03
(.37, .54)
.31 ± .03
(.23, .39)
.13 ± .11
(−.13, .39) 0.22
TSH by EIA-2 (µIU/ml) .39 ± .02
(.33, .45)
.23 ± .03
(.17, .29)
.01 ± .06
(−.13, .16) 0.82
T4 (µg/dl) 2.02 ± .01
(2.00, 2.03)
1.88 ± .01
(1.87, 1.90)
–.004 ± .02
(−.05, .04) 0.84
T3RU (µg/dl) .021 ± .005
(.009, .032)
–.160 ± .005
(-.170, -.149)
–.01 ± .01
(−.04, .02) 0.36
FTI
1.998 ± .005
(1.99, 2.01)
2.044 ± .005
(2.03, 2.05)
.02 ± .01
(−.02, .05) 0.23
Anti-TPO (IU/ml)
–3.64 ± .42
(–4.65, 2.64)
–6.65 ± .54
(–7.95, -5.35)
–.39 ± .88
(–2.48, 1.71)
0.66
AMA (U/ml)
0.26 ± .30
(–.46, .99)
–1.24 ± .36
(–2.11, -.36)
–.51 ± .80
(–2.43, 1.42)
0.52
Anti-TG (IU/ml)
–4.01 ± .23
(–4.57, –3.45)
–5.71 ± .29
(–6.42, -5.01)
–.64 ± .50
(–1.84, 0.56)
0.20
Serum calcium (mg/dl)
9.2 ± .01
(9.14, 9.20)
9.2 ± .01
(9.16, 9.22)
–.09 ± .03
(−.16, −.01) 0.0074
Thyroid mass (gm)
2.04 ± .01
(2.00, 2.07)
2.44 ± .01
(2.41, 2.48)
–.00 ± .04
(–.10, .10)
0.98
Entries in the table are estimate ± standard error, with Bonferroni-adjusted 95% confidence interval in parentheses.
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In overall summary of the dose-response results, there was no evidence of a statistically significant
association between estimated thyroid radiation dose from Hanford and the cumulative incidence of any of
the 14 primary thyroid or parathyroid disease outcomes or the prevalence of thyroid UDAs. There was also
no evidence of any statistically significant dose-response relationship for any of the alternative definitions
of outcome. The findings were essentially unchanged for analyses based on either of the two alternative
sets of individual dose estimates. The results remained the same after taking into account (adjusting for the
effects of) several factors that could potentially confound the relationship between radiation dose and the
outcome of interest. There was no evidence of any statistically significant dose-response for any outcome
that might be different from the linear model used in the primary analyses (e.g., a linear quadratic
relationship). Incorporation of uncertainty in the dose estimates did not materially change the primary
results for any of the outcomes. 
The study also found no statistically significant associations between estimated thyroid dose from
Hanford’s 131I and the average values of tests for thyroid function (TSH, T4, T3RU, FTI), of tests for
anti-thyroid immune response (anti-TPO, AMA, anti-TG), or of thyroid mass.  Only serum calcium, which
was measured as a screening test for hyperparathyroidism, was found to vary significantly in relation to
estimated thyroid dose from Hanford’s 131I: average calcium levels decreased significantly with increasing
estimated thyroid radiation dose.  However the decrease was small enough that calcium levels remained
within the normal range, and less than 1% of the study participants were hypocalcemic.
Presented below are more detailed summaries of the results for each of the primary outcomes
investigated.
Thyroid Cancer
 
Twenty (0.6%) of the 3440 living evaluable participants were diagnosed with thyroid cancer; 13
women (0.7%) and 7 men (0.4%). In all but one case, the diagnosis was based on histologic evidence from
the HTDS examination (12) or prior histologic evidence (7). 
Using the primary definition (19 total cases; 14 in-area) and maximum likelihood analysis of the
sex-stratified linear probability model, the risk of thyroid cancer did not increase significantly with
estimated dose (p = 0.25), with an estimated slope of 0.002 per Gy, and Bonferroni-adjusted 95% CI
ranging from less than −0.001 to 0.017 per Gy. Results obtained by least squares analysis using ungrouped
or grouped data were similar. There was no evidence from the linear-quadratic or logistic regression model
that the cumulative incidence of thyroid cancer increased significantly with increasing dose. Analyses
which considered less definitive criteria to identify cases and alternative dose estimates or representations
of exposure revealed no evidence of a dose-response relationship. Incorporation of uncertainty in the dose
estimates did not materially change the primary results. 
Benign Thyroid Nodule
Two hundred and forty-nine (7.2%) of the 3440 living evaluable participants had a diagnosis of
benign thyroid nodule based on histologic or cytologic evidence arising from the HTDS examination or
from a prior diagnosis; 170 (9.7%) women and 79 (4.7%) men. An additional 38 (1.1%) participants had
diagnoses classified as clinical, and another 10 (0.3%) had diagnoses based solely on a report by the
participant or his/her CATI respondent. 
Using the primary definition (249 total cases; 235 in-area), and maximum likelihood analysis of
the sex-stratified linear probability model, the risk of benign thyroid nodule did not increase significantly
with estimated dose (p = 0.68), with an estimated slope of -0.008 per Gy, and Bonferroni-adjusted 95% CI
ranging from less than −0.022 to 0.041 per Gy. Results obtained by least squares analysis using ungrouped
or grouped data were similar. There was no evidence from the linear-quadratic or logistic regression model
that the cumulative incidence of benign thyroid nodule increased with increasing dose.  Analyses which
HTDS Final Report: June 21, 2002 – Section IX.R page 510
considered less definitive criteria to identify cases, as well as other disease outcomes related to benign
nodules (e.g., benign nodules and nodules suspicious for follicular neoplasm, benign nodule excluding non-
neoplastic disease, solitary nodule detected without ultrasound, benign nodule excluding colloid-only
nodules, and benign colloid nodules), and analyses which considered alternative dose estimates or
representations of exposure, revealed no evidence of a dose-response relationship. Accounting for potential
confounding or effect modification, and incorporation of uncertainty in the dose estimates, did not
materially change the primary results. 
Total Thyroid Neoplasia
This outcome was defined to include participants with thyroid cancer based on HTDS or prior
histology or benign thyroid nodule with a histologic type of follicular adenoma, based on HTDS or prior
histology. A total of 33 (1.0%) of the 3440 living evaluable participants were included in this category; 20
(1.1%) women and 13 (0.8%) men.  
Using the primary definition (33 total cases; 28 in-area), and maximum likelihood analysis of the
sex-stratified linear probability model, the risk of total thyroid neoplasia did not increase significantly with
estimated dose (p = 0.42), with an estimated slope of 0.001 per Gy, and Bonferroni-adjusted 95% CI
ranging from less than −0.003 to 0.022 per Gy. Results obtained by least squares analysis using ungrouped
or grouped data were similar. There was no evidence from the linear-quadratic or logistic regression model
that the cumulative incidence of total thyroid neoplasia increased with increasing dose.  Analyses using
alternative dose estimates or representations of exposure revealed no evidence of a dose-response
relationship. Incorporation of uncertainty in the dose estimates, did not materially change the primary
results.
Any Thyroid Nodule
This outcome was defined by the diagnosis of one or more of the following: benign thyroid
nodule, thyroid cancer, or nodule suspicious for follicular neoplasm.  A total of 281 (8.2%) of the 3440
living evaluable participants had this outcome based on histologic or cytologic evidence arising from the
HTDS examination or from a prior diagnosis: 193 (11.0%) women and 88 (5.2%) men. Another 39 (1.1%)
were based on clinical diagnoses by the HTDS or prior (palpable nodule with no available cytology or
histology), and there were 10 living evaluable participants with a diagnosis of any thyroid nodule based
solely on reports from the participant or his/her CATI respondent.
Using the primary definition (281 total cases; 261 in-area), and maximum likelihood analysis of
the sex-stratified linear probability model, the risk of any thyroid nodule did not increase significantly with
estimated dose (p = 0.65), with an estimated slope of −0.007 per Gy, and Bonferroni-adjusted 95% CI
ranging from less than −0.023 to 0.043 per Gy. Results obtained by least squares analysis using ungrouped
or grouped data were similar. There was no evidence from the linear-quadratic or logistic regression model
that the cumulative incidence of any thyroid nodule increased with increasing dose.  Analyses which
considered less definitive criteria to identify cases and alternative dose estimates or representations of
exposure revealed no evidence of a dose-response relationship. Accounting for potential confounding or
effect modification, and incorporation of uncertainty in the dose estimates, did not materially change the
primary results.
Hypothyroidism
Two hundred and sixty-seven (7.8%) of the 3440 living evaluable participants had a diagnosis of
hypothyroidism based on the HTDS evaluation or on medical records with supporting documentation; 204
(11.7%) women and 63 (3.7%) men.  An additional 105 (3.1%) living evaluable participants had a
diagnosis of hypothyroidism based on medical records but without supporting documentation, and 30
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(0.9%) were inferred from past or current thyroxine therapy.  There were 193 (5.6%) cases based solely on
reports of hypothyroidism from the participant or his/her CATI respondent. 
Using the primary definition (267 total cases; 246 in-area), and maximum likelihood analysis of
the sex-stratified linear probability model, the risk of hypothyroidism did not increase significantly with
estimated dose (p = 0.61).  With an estimated slope of −0.006 per Gy, and Bonferroni-adjusted 95% CI
ranging from less than −0.016 to 0.047 per Gy. Similar results were obtained using the least squares
analyses of grouped or ungrouped data.  There was no evidence from the linear-quadratic or logistic
regression model that the cumulative incidence of hypothyroidism increased with increasing dose. Analyses
which considered less definitive criteria to identify cases, as well as permanent hypothyroidism, and
analyses which considered alternative dose estimates or representations of exposure, revealed no evidence
of a dose-response relationship, although the estimated regression coefficients from logistic regression
analyses using less definitive criteria to identify cases were somewhat larger. Accounting for potential
confounding or effect modification, and incorporation of uncertainty in the dose estimates, did not
materially change the primary results.
Autoimmune (Hashimoto's) Thyroiditis
A total of 625 (18.2%) of the 3440 living evaluable participants had a diagnosis of autoimmune
thyroiditis based on the HTDS evaluation or medical records with supporting documentation; 403 (23.1%)
women and 222 (13.1%) men. Another three cases were based on medical records without supporting
documentation, and one case was based solely on a report by the participant or his/her CATI respondent. 
Using the primary definition (625 total cases; 582 in-area), and maximum likelihood analysis of
the sex-stratified linear probability model, the risk of autoimmune thyroiditis did not increase significantly
with estimated dose (p = 0.82), with an estimated slope of −0.026 per Gy, and Bonferroni-adjusted 95% CI
ranging from less than −0.057 to 0.044 per Gy. Similar results were obtained when the least squares model
was fit using ungrouped or grouped data. There was no evidence from the linear-quadratic or logistic
regression model that the cumulative incidence of autoimmune thyroiditis increased with increasing dose.
Analyses which considered less definitive criteria to identify cases, additional outcomes related to the assay
for antithyroid immune response, and autoimmune thyroiditis in combination with non-iatrogenic,
permanent hypothyroidism, as well as analyses which considered alternative dose estimates or
representations of exposure, revealed no evidence of a dose-response relationship. Accounting for potential
confounding or effect modification, and incorporation of uncertainty in the dose estimates, did not
materially change the primary results.
Graves Disease
A total of 34 (1.0%) of the 3440 living evaluable participants had a diagnosis of Graves Disease
based on the HTDS evaluation or on medical records with supporting documentation; 28 (1.6%) women
and 6 (0.4%) men.  Three (0.1%) living evaluable participants had a diagnosis of Graves Disease based on
medical records without supporting documentation, and an additional thirteen (0.4%) were based solely on
a report from the participant or his/her CATI respondent.  
Using the primary definition (34 total cases; 32 in-area), and maximum likelihood analysis of the
sex-stratified linear probability model, the risk of Graves Disease did not increase significantly with
estimated dose (p = 0.56), with an estimated slope of −0.001 per Gy, and Bonferroni-adjusted 95% CI
ranging from less than −0.002 to 0.024 per Gy. Results obtained by least squares analysis using ungrouped
or grouped data were similar. There was no evidence from the linear-quadratic or logistic regression model
that the cumulative incidence of Graves Disease increased with increasing dose. Analyses which
considered less definitive criteria to identify cases and alternative dose estimates or representations of
exposure revealed no evidence of a dose-response relationship. Accounting for potential confounding or
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effect modification, and incorporation of uncertainty in the dose estimates, did not materially change the
primary results.
Autoimmune Thyroid Disease
Autoimmune thyroid disease was defined by a diagnosis of autoimmune (Hashimoto’s) thyroiditis
or Graves disease based on the HTDS evaluation or medical records with supporting documentation.  A
total of 659 (19.2%) of the 3440 living evaluable participants were included in this category; 431 (24.7%)
women and 228 (13.5%) men. These included 625 with autoimmune (Hashimoto’s) thyroiditis and 34
others with diagnoses of Graves disease.  An additional 4 (0.1%) living evaluable participants had a
diagnosis of autoimmune thyroid disease based on medical records without supporting documentation
(three with autoimmune thyroiditis, one with Graves disease).  Eleven others (0.3%) were based solely on a
report by the participant or his/her CATI respondent (one with autoimmune thyroiditis, 10 with Graves
disease).
Using the primary definition (659 total cases; 614 in-area), and maximum likelihood analysis of
the sex-stratified linear probability model, the risk of autoimmune thyroid disease did not increase
significantly with estimated dose (p = 0.80), with an estimated slope of −0.024 per Gy, and Bonferroni-
adjusted 95% CI ranging from less than −0.058 to 0.048 per Gy. Similar results were obtained when the
least squares model was fit using ungrouped or grouped data. There was no evidence from the linear-
quadratic or logistic regression model that the cumulative incidence of autoimmune thyroid disease
increased with increasing dose. Analyses which considered less definitive criteria to identify cases and
alternative dose estimates or representations of exposure revealed no evidence of a dose-response
relationship. Accounting for potential confounding or effect modification, and incorporation of uncertainty
in the dose estimates, did not materially change the primary results.
Hyperthyroidism
A total of 161 (4.7%) of the 3440 living evaluable participants were diagnosed with
hyperthyroidism based on the HTDS evaluation or medical records with supporting documentation; 134
(7.7%) women and 27 (1.6%) men.  An additional 14 (0.4%) living evaluable participants had a diagnosis
of hyperthyroidism based on medical records without supporting documentation, and 21 (0.6%) were based
solely on a report from the participant or his/her CATI respondent.  It is important to note that these 196
cases included a substantial number of iatrogenic cases (caused by excess thyroid hormone replacement).
Since endogenous hyperthyroidism was of particular importance, analyses that focused on cases of non-
iatrogenic hyperthyroidism were emphasized in this study.
Using the primary definition (161 total cases; 155 in-area), and maximum likelihood analysis of
the sex-stratified linear probability model, the risk of hyperthyroidism did not increase significantly with
estimated dose (p = 0.22), with an estimated slope of 0.011 per Gy, and Bonferroni-adjusted 95% CI
ranging from less than −0.008 to 0.052 per Gy. Similar results were obtained when the least squares model
was fit using ungrouped or grouped data. There was no evidence from the linear-quadratic or logistic
regression model that the cumulative incidence of hyperthyroidism increased with increasing dose.
Analyses which considered less definitive criteria to identify cases, as well as non-iatrogenic
hyperthyroidism, and analyses which considered alternative dose estimates or representations of exposure,
revealed no evidence of a dose-response relationship. Accounting for potential confounding or effect
modification, and incorporation of uncertainty in the dose estimates, did not materially change the primary
results.
Multinodular Thyroid Gland 
A total of 95 (2.8%) of the 3440 living evaluable participants had a diagnosis of multinodular
thyroid gland based on the HTDS evaluation; 73 (4.2 %) women and 22 (1.3 %) men.  An additional
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nineteen (0.6%) living evaluable participants had a diagnosis of multinodular thyroid gland based on
medical records, and one diagnosis was based solely on a report from the participant or his/her CATI
respondent. 
Using the primary definition (95 total cases; 85 in-area), and maximum likelihood analysis of the
sex-stratified linear probability model, the risk of multinodular thyroid gland did not increase significantly
with estimated dose (p = 0.88), with an estimated slope of -0.006 per Gy. The lower limit of the
Bonferroni-adjusted 95% confidence interval was not estimated, but the upper limit was 0.014 per Gy.
When the model was fit by the method of least squares, the estimated slope using either ungrouped or
grouped data was even more negative than the maximum likelihood estimate, thereby providing no
evidence that risk of multinodular gland increased with increasing dose (p = 0.89 and 0.83, respectively).
There was no evidence from the linear-quadratic or logistic regression model that the cumulative incidence
of multinodular thyroid gland increased with increasing dose. Analyses which considered less definitive
criteria to identify cases and alternative dose estimates or representations of exposure revealed no evidence
of a dose-response relationship. Accounting for potential confounding or effect modification, and
incorporation of uncertainty in the dose estimates, did not materially change the primary results.
Simple Goiter
The diagnosis of simple goiter was uncommon, with only 14 (0.4%) of the 3440 living evaluable
participants having this diagnosis based on HTDS evaluation; 9 (0.5%) women and 5 (0.3%) men. Another
28 (0.8%) had diagnoses based on medical records, and for an additional 28 (0.8%) the diagnosis was based
solely on a report by the participant or his/her CATI respondent. 
Using the primary definition (14 total cases; all in-area), and maximum likelihood analysis of the
sex-stratified linear probability model, the risk of simple goiter did not increase significantly with estimated
dose (p = 0.74), with an estimated slope of -0.001 per Gy. The lower limit of the Bonferroni-adjusted 95%
confidence interval was not estimated, but the upper limit was 0.012 per Gy. When the model was fit by the
method of least squares, the estimated slope using either ungrouped or grouped data was even more
negative than the maximum likelihood estimate, thereby providing no evidence that risk of simple goiter
increased with increasing dose (p = 0.79 and 0.70, respectively). There was no evidence from the linear-
quadratic or logistic regression model that the cumulative incidence of simple goiter increased with
increasing dose. Analyses which considered less definitive criteria to identify cases and alternative dose
estimates or representations of exposure revealed no evidence of a dose-response relationship.
Incorporation of uncertainty in the dose estimates, did not materially change the primary results.
Other Thyroid Disease
 Four living evaluable participants, all in the in-area group, had diagnoses of other thyroid disease
based on their HTDS examinations or medical records with supporting documentation.  These included two
cases of subacute thyroiditis in women; one case of familial thyroglobulin binding deficiency in a male;
and one case of secondary hypothyroidism in a female. The first alternative definition added only two cases
with diagnoses based on medical records without supporting documentation.  Both were cases of subacute
thyroiditis in women. For both the primary and first alternative definition of other thyroid disease, there
were too few cases for meaningful estimation of the radiation dose-response.
 
The second alternative definition added 20 participants, primarily with participant or CATI
respondent reports of past thyroid disease of unknown type.  This brought the total number of cases to 26,
of whom four were out-of-area participants. Based on maximum likelihood analysis of the sex-stratified
linear probability model using this case definition, the estimated slope was slightly greater than zero (0.002
per Gy) with Bonferroni-adjusted 95% CI ranging from less than −0.002 to 0.024 per Gy, providing no
evidence that cumulative incidence increased significantly with increasing dose (one-tailed p = 0.39).
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Because the number of cases in this category was small, and the diagnoses were heterogeneous and mostly
unknown, further analyses of this outcome were not performed.
 
 
Hyperparathyroidism
A total of 12 (0.3%) living evaluable participants had a diagnosis of hyperparathyroidism based on
the HTDS evaluation or on medical records with supporting documentation; 10 (0.6 %) women and 2
(0.1%) men. Another two diagnoses were based on a report from the participant or his/her CATI
respondent. One additional living evaluable participant who did not meet the study’s criteria for
hyperparathyroidism nevertheless had an elevated calcium in the presence of a high normal PTH level,
when the PTH should have been suppressed, highly suggestive of hyperparathyroidism.  This participant
was included as a case in an additional analysis.
Using the primary definition (12 total cases; 11 in-area), and maximum likelihood analysis of the
sex-stratified linear probability model, the risk of hyperparathyroidism did not increase significantly with
estimated dose (p = 0.61), with an estimated slope of −0.0001 per Gy. The lower limit of the Bonferroni-
adjusted 95% confidence interval was not estimated, but the upper limit was 0.013 per Gy. When the model
was fit by the method of least squares, the estimated slope using either ungrouped or grouped data was
slightly more negative than the maximum likelihood estimate, thereby providing no evidence that risk of
hyperparathyroidism increased with increasing dose (p = 0.74 and 0.75, respectively). There was no
evidence from the linear-quadratic or logistic regression model that the cumulative incidence of any thyroid
nodule increased with increasing dose. Analyses which considered less definitive criteria to identify cases
and alternative dose estimates or representations of exposure revealed no evidence of a dose-response
relationship. Incorporation of uncertainty in the dose estimates, did not materially change the primary
results.
Ultrasound-Detected Abnormalities of the Thyroid (Thyroid UDAs)
 The thyroid gland was visible in the ultrasound examinations of 3429 of the 3440 living evaluable
participants.  For 11 participants the thyroid was not visible, 10 because of thyroid surgery and one because
the sonographer couldn’t adequately visualize the thyroid.   Among the 3429 whose thyroids were visible,
1596 (46.5%) had one or more ultrasound-detected thyroid abnormalities (thyroid UDAs); 964 (55.5 %)
women and 632 (37.4 %) men. Ultrasound findings were categorized as palpable thyroid UDAs (224 or
6.5%), nonpalpable focal thyroid UDAs (1309 or 38.2%), and diffuse thyroid UDAs (458 or 13.4%).  All
three types of UDA were more frequent among women than men.  Ultrasound-detected thyroid
abnormalities were based only on the HTDS evaluation, not on any prior ultrasounds.  
For any UDA (1596 total cases; 1481 in-area), and maximum likelihood analysis of the
sex-stratified linear probability model, the risk of any UDA did not increase significantly with estimated
dose (p = 0.21), with an estimated slope of 0.031 per Gy, and Bonferroni-adjusted 95% CI ranging from
−0.059 to 0.116 per Gy. Estimation by least squares using the ungrouped data gave nearly identical results,
and the least squares fit to the grouped data were similar. There was no evidence from the linear-quadratic
or logistic regression model that the cumulative incidence of any UDA increased with increasing dose.
Analyses which considered alternative dose estimates or representations of exposure revealed no evidence
of a dose-response relationship. Accounting for potential confounding or effect modification, and
incorporation of uncertainty in the dose estimates, did not materially change the primary results.
For palpable UDAs (224 total cases; 204 in-area), and maximum likelihood analysis of the
sex-stratified linear probability model, the risk of a palpable UDA did not increase significantly with
estimated dose (p = 0.95), with an estimated slope of -0.018 per Gy. The Bonferroni-adjusted lower 95%
confidence limit was not estimated due to the magnitude of the negative slope estimate, however the upper
confidence limit was 0.015 per Gy.  Estimation by least squares using either the ungrouped or grouped data
gave nearly identical results. There was no evidence from the linear-quadratic or logistic regression model
that the prevalence of palpable thyroid UDAs increased with increasing dose. Analyses which considered
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alternative dose estimates or representations of exposure revealed no evidence of a dose-response
relationship. Accounting for potential confounding or effect modification, and incorporation of uncertainty
in the dose estimates, did not materially change the primary results.
For nonpalpable focal UDA (1309 total cases; 1217 in-area), and maximum likelihood analysis of
the sex-stratified linear probability model, the risk of a nonpalpable focal UDA did not increase
significantly with estimated dose (p = 0.23), with an estimated slope of 0.027 per Gy, and Bonferroni-
adjusted 95% CI ranging from −0.061 to 0.115 per Gy. Estimation by least squares using either the
ungrouped or grouped data gave nearly identical results. There was no evidence from the linear-quadratic
or logistic regression model that the prevalence of nonpalpable focal thyroid UDAs increased with
increasing dose. Analyses which considered alternative dose estimates or representations of exposure
revealed no evidence of a dose-response relationship. Accounting for potential confounding or effect
modification, and incorporation of uncertainty in the dose estimates, did not materially change the primary
results.
To assess whether the dose-response results might be affected by the size of focal thyroid UDAs,
three additional outcomes were analyzed.  These included the presence of a focal UDA with maximum
dimension at least 5 mm, the presence of a focal UDA with maximum dimension at least 10 mm, and the
presence of a focal UDA with average dimension at least 15 mm.  These additional analyses applied only to
palpable and nonpalpable focal thyroid UDAs, since diffuse UDAs were not defined by any size criterion.
In none of these additional analyses was there any evidence that the risk of having a focal UDA of a
particular size increased with increasing dose (p=0.64, 0.88 and 0.53 for the presence of focal UDA with
maximum dimension of 5 mm, maximum dimension of 10 mm and average dimension of 15 mm,
respectively).
Additional analyses were performed to investigate whether the number of thyroid UDAs detected
in individual participants might increase in relation to estimated thyroid radiation dose.  For each living
evaluable participant with an HTDS ultrasound examination, the numbers of focal thyroid UDAs with
maximum dimension ≥ 5 mm, maximum dimension ≥ 10 mm, and average dimension ≥ 15 mm were
counted. Study participants had as many as nine thyroid UDAs with maximum dimension ≥ 5 mm,
although the majority (60% of the women and 74% of the men) had no such thyroid UDAs.  The overall
average number of thyroid UDAs of this size was 0.84 per person for women, and 0.47 per person for men.
Results of fitting sex-stratified Poisson regression models for the relationship between estimated thyroid
radiation dose and number of focal thyroid UDAs indicated that the average number of such thyroid UDAs
per person did not increase significantly with estimated dose (p = 0.80, 0.48 and 0.43 for the number of
thyroid UDAs with maximum dimension of 5mm, maximum dimension of 10 mm and average dimension
of 15 mm, respectively.).  The Bonferroni-adjusted 95% confidence interval for the dose-response
parameter for number of thyroid UDAs with maximum dimension of 5 mm ranged from 0.72 to 1.17,
encompassing a range from 28% decrease to 17% increase per Gy. The results for the number of thyroid
UDAs with maximum dimension of 10 mm and average dimension of 15 mm were similar.
Using the primary definition of diffuse UDA (458 total cases; 428 in-area), and maximum
likelihood analysis of the sex-stratified linear probability model, the risk of a diffuse UDA did not increase
significantly with estimated dose (p = 0.14), with an estimated slope of 0.029 per Gy, and Bonferroni-
adjusted 95% CI ranging from −0.029 to 0.100 per Gy. Estimation by least squares using either the
ungrouped or grouped data gave nearly identical results. There was no evidence from the linear-quadratic
or logistic regression model that the prevalence of diffuse thyroid UDAs increased with increasing dose.
Analyses which considered alternative dose estimates or representations of exposure revealed no evidence
of a dose-response relationship. Accounting for potential confounding or effect modification, and
incorporation of uncertainty in the dose estimates, did not materially change the primary results.
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Laboratory Tests
Of the 3191 living evaluable in-area participants, 3183 (99.7%) consented to provide a blood
specimen at their HTDS clinic. Several laboratory assays were conducted to evaluate thyroid function, anti-
thyroid antibody response, and serum calcium level. In addition to the dose-response analyses conducted of
specific thyroid disease outcomes which incorporated information from these tests in the determination of
the diagnosis, dose-response analyses were also conducted to investigate whether there were associations
between the laboratory values from these tests and estimated thyroid radiation dose from Hanford (i.e.,
regardless of thyroid disease diagnosis).
Thyroid stimulating hormone (TSH) levels were determined according to three different tests over
the course of the study. Of the 3183 living evaluable in-area participants who provided blood samples, 222
were receiving exogenous thyroid hormone at the time of their HTDS clinic.  These 222 were excluded
from the analyses of TSH.  Among the remaining 2961 living evaluable participants, 584 had TSH
measured by RIA, 810 by EIA-1, and 1567 by EIA-2. There was no evidence of a significant trend in
relation to estimated radiation dose for any of the three assays considered individually (p = 0.90, 0.22, and
0.82 for RIA, EIA-1, and EIA-2, respectively).  When a generalization of the sex-stratified model was
examined using all 2961 living evaluable participants with TSH measurements, in which the mean values
of log(TSH) were assumed to differ between the sexes and to differ according to the type of assay, there
was still no significant trend of average log(TSH) in relation to estimated thyroid radiation dose (p = 0.42).
Analyses of total thyroxine (T4) and triiodothyronine resin uptake (T3RU) were also conducted
excluding the 222 living evaluable in-area participants who were receiving exogenous thyroid hormone at
the time of their HTDS clinic. Additionally, the T4 and T3RU values were unknown for two in-area
participants due to insufficient volumes of collected blood. There was no significant trend of either T4 or
T3RU in relation to estimated radiation dose (p = 0.84 and 0.36, respectively). 
Free thyroxine index (FTI) was analyzed excluding the 222 living evaluable in-area participants
who were receiving exogenous thyroid hormone at the time of their HTDS clinic. The FTI values were
unknown for six additional in-area participants: the two with unknown T4 and T3RU, and four others for
whom either T4 or T3RU was below its level of detection. There was no significant trend of FTI in relation
to estimated radiation dose (p = 0.23).
Anti-TPO or AMA values were used for the anti-thyroid autoimmune response evaluations of
1562 and 1620 in-area living evaluable participants, respectively.  Neither assay result was available for
eight participants who declined to provide a blood sample, and for one other whose sample was of
insufficient volume. There was no significant trend of either assay result in relation to estimated radiation
dose (p = 0.66 for anti-TPO, 0.52 for AMA). Anti-thyroglobulin antibody (anti-TG) values were available
for 3170 of the in-area living evaluable participants. There was no significant trend of anti-TG in relation to
estimated radiation dose (two-tailed p = 0.20).
Serum calcium levels were measured in an effort to identify study participants with hypercalcemia
which might be secondary to hyperparathyroidism. Of the 3183 living evaluable in-area participants who
provided blood samples, 227 with diagnoses of hypothyroidism or hyperthyroidism based on the HTDS
examination were excluded from the primary analysis of serum calcium levels.  Two additional participants
did not have serum calcium data due to insufficient volumes of collected blood. There was a statistically
significant trend of decreasing serum calcium level in relation to increasing radiation dose (p = 0.0074),
with an estimated slope of -0.09 per Gy and Bonferroni-adjusted 95% CI ranging from -0.16 to -0.01.
Although there is no readily apparent explanation for this result, this finding deserves further comment.
First, it should be noted that the laboratory test used measured the total serum calcium and not ionized
calcium, which is the true measure of normal calcium levels in the blood.  Thus, it cannot be certain that a
dose effect would be present if ionized calcium rather than total calcium had been measured.  Second, the
outcome for which calcium was being measured, hyperparathyroidism, was not found to be associated with
radiation dose. Third, the dose effect occurred primarily in the normal calcium range. For both women and
men, the estimated background means were about 9.2 ± .01, consistent with the normal range of the test
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(8.4-10.2). Only 0.9% of the cohort had low calcium levels less than 8.4 mg/dl (hypocalcemia).  There was
no statistically significant relationship between hypocalcemia and radiation dose.  Even at a dose of 3 Gy
(3000 mGy), which is larger than the maximum estimated dose of any study participant, average calcium
levels predicted by the regression model were will within the normal range.  Therefore, despite the
statistically significant decrease in calcium levels with increasing dose, the resulting effect or clinical
impact does not appear to be clinically significant.
Estimates of thyroid mass were available for 3400 living evaluable participants for whom both
lobes of the thyroid were visible on ultrasound; 3153 were in-area participants. There was no significant
trend of thyroid mass in relation to estimated radiation dose (p = 0.98).
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X. DISCUSSION
A. Summary of Study Design and Execution
The purpose of the Hanford Thyroid Disease Study was to determine whether thyroid morbidity is
increased among people exposed to atmospheric releases of 131I from the Hanford Nuclear Site between
1944 and 1957. The primary objective of the research was to describe in what way any increase in thyroid
disease observed is related to the dose of radiation received (that is, to describe the characteristics of any
dose-response relationship). Additional objectives of the project were to: 1) determine whether
hyperparathyroidism is increased among people exposed to the Hanford radiation releases; 2) assess the
methods used to carry out such a study, and the degree to which such an investigation can be successfully
planned and executed; and 3) provide information to residents of the surrounding communities regarding
the conduct of the study and the findings and results. 
In order to achieve the primary objective stated above, the study was conducted as a retrospective
follow-up (cohort) study. As described more fully in section IV.A above, this design entailed the selection
of a relatively large cohort of people who would have been exposed to Hanford radiation as young children,
and who would represent the full range of possible doses to the thyroid from Hanford. The overall goal of
the study was to locate all individuals in the cohort, obtain their consent to participate in the project, collect
detailed information regarding their early childhood in order to estimate the dose of radiation they received
to the thyroid from Hanford, and determine whether they have developed any form of thyroid disease or
hyperparathyroidism since their exposure. The primary determination of whether there has been an increase
in thyroid disease as a result of radiation exposure from Hanford was made by assessing the cumulative
incidence of thyroid disease in relation to the level of individual thyroid radiation dose (i.e., the radiation
dose-response), within members of the cohort.
This approach of using one population comprised of individuals with different levels of exposure
to radiation has been used extensively in assessing the effects of radiation exposure in human populations.
It is a common design in epidemiology, and has been of particular value in studies of atomic bomb
survivors in Japan, in numerous studies of people exposed to radiation through medical procedures, and in
the study of people exposed to radiation from atmospheric testing in Utah.  This method is superior to the
alternative approach of attempting to compare thyroid disease occurrence in a cohort under extensive study
such as the HTDS cohort with that in a separate population presumed to be unexposed to radiation. This is
because thyroid disease rates may be a function of a number of factors other than exposure to radiation,
which may differ considerably between different populations. This is particularly true if one population is
under careful study and diagnostic evaluation. Such differences can include: 1) the methods of diagnosis
employed; 2) the extent to which diagnostic tests are implemented in a population (i.e., the thoroughness of
the diagnostic process); 3) the dietary practices of the population; 4) the level of iodine in the diet; and 5)
the composition of the population according to age, gender, and ethnicity. To the extent differences in such
factors exist, it would be impossible to attribute any differences in thyroid disease rates observed to
Hanford radiation exposure, as opposed to one or more of these other factors. The approach used in the
HTDS is also superior to one which would implement the full HTDS protocol in a population
geographically removed from the Hanford site, in an attempt to include people with no exposure from
Hanford radiation. Although the methods and thoroughness of the diagnostic evaluation would be
comparable under such circumstances, it would still not be possible to ensure comparability between the
two study populations regarding the other types of possible differences listed above that could influence
thyroid disease occurrence. Thus, to ensure as much comparability as possible regarding factors other than
radiation that can influence the occurrence of thyroid disease, all comparisons of thyroid disease rates in
relation to thyroid radiation dose level were made within the defined cohort. 
The study cohort was defined based on place and year of birth in a manner designed to identify
people with a full range of possible thyroid doses from Hanford. This was difficult to do, as no information
was available regarding exposure or estimated dose to specific individuals. Using preliminary information
available at the time of the design of the HTDS from the HEDR Project regarding the timing of the
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radiation releases, movement of radioactive materials through the environment, and uptake by humans, a
sampling scheme was developed to select individuals born in one of seven counties in the region around
Hanford between 1940 and 1946. 
From the outset it was recognized that such a design would present substantial challenges. The
study would require that: 1) people be traced and located over a period of more than 40 years, based only
on information contained on their birth certificate; 2) a person knowledgeable of each participant’s early
childhood be located, and be willing and able to provide detailed information about the person’s childhood
residence history and dietary habits; 3) participants be willing to travel to the Northwest and undergo a
thorough medical evaluation for thyroid disease, including an ultrasound scan, blood tests, and potentially a
thyroid biopsy; and 4) participants be willing to provide consent for independent review of prior medical
records and diagnostic evaluations. Since no study of this type had ever been attempted before, it was not
clear that such an approach would prove feasible. 
As described more fully in section V above, the field components of the study were highly
successful. A roster of 12,706 births was constructed from Washington State birth certificates, and 5199
individuals were selected for inclusion in the cohort. Of these, 4350 individuals (84%) were located alive
and their identity confirmed, and 527 (10%) were confirmed as deceased. Importantly, success in locating
individuals did not vary appreciably by sex, geographic region at the time of birth, or year of birth. Of those
known to be deceased or who died prior to participation (16), a death certificate was obtained for
verification of cause of death for 504 (93%). 
Once contacted, individuals were cooperative and interested in participating. Of 4239 people
contacted by phone to request participation, 3564 (84%) agreed to participate. Only 634 (15%) refused.
Forty-one living located cohort members (0.9%) were determined to be unable to fully participate and were
consequently not included in the study regardless of willingness to participate. Agreement to participate did
not vary appreciably according to sex, geographic region at the time of birth, year of birth, or location of
current residence. Of the 3564 who agreed to participate, 2712 participants identified a possible CATI
respondent. Interviews were completed for 2266 (84%). However, not all of those for whom a CATI was
completed attended a clinic.  Thus, of the 3440 living evaluable participants included in the analysis, 2123
(62%) had a CATI interview that was used as the basis for dose estimation. Quality assessment of the
respondent's ability to answer the interview questions was also performed (see section V.D).  Following
each section of the interview, interviewers recorded their assessment of how reliable the responses were for
questions within that section.  Assessments were recorded as: 1) Very Reliable; 2) Somewhat Reliable, or
3) Unreliable.  Overall, the interviewers rated the quality of the data obtained in the CATI as very reliable. 
It proved feasible to hold all clinics in the Pacific Northwest (all but one site was located in
Washington), and participants were willing to travel from throughout the United States and even from
abroad to attend clinics. Of those who agreed to participate, and who did not withdraw from the study at a
later time, 97% (3447 of 3564) attended a HTDS clinic. Success in scheduling people for clinics did not
vary substantially by sex, geographic area of birth, year of birth, or even current residence. Of those
attending a clinic, almost all (> 99 %) participated in all aspects of the evaluation: In-Person Interview,
thyroid ultrasound, blood tests, and clinical examination. Of the 272 participants for whom a fine needle
aspiration biopsy of the thyroid was recommended, 259 (95%) underwent the procedure. 
It also proved feasible to locate and retrieve prior medical records and materials. Attempting to
locate and obtain records from as long ago as fifty years was expected to be one of the most difficult
aspects of the HTDS. A total of 694 participants identified prior medical records of potential interest, and
provided consent to the HTDS to request 1259 separate medical records. Of these, 795 (63%) were
received by the HTDS from 494 of the 694 participants (71%). Pathology or cytology slides were requested
for 52 of the 694 individuals identifying historical material. Of these, slides were received from 42 (81%). 
The results of the field components of the HTDS reflect a relatively uniform and high level of
success in achieving the objectives set forth for each. It proved feasible to identify a large group of people
exposed at varying levels to radiation releases from Hanford, to locate and contact them, to enroll them in
the study, to collect information needed to estimate their individual radiation dose to the thyroid, to
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examine them for the presence or history of thyroid disease, and to review prior medical records relevant to
prior evaluations or diagnoses of thyroid disease. Given the eligibility criteria for inclusion in this study,
there was no evidence that success in these various tasks varied appreciably according to a person’s sex,
where they were born, when they were born, or where they currently live. Because these operational results
provide no indication of substantial differential success in aspects of the study related to subject selection,
inclusion, and data collection that might potentially bias or influence dose-response relationships, they
provide an important framework for interpreting the specific findings regarding radiation dose and the
thyroid outcomes under study.  
B. Summary of Dose-Response Results
The primary evaluation of dose-response relationships focused on twelve categories of thyroid
disease, ultrasound-detected abnormalities of the thyroid, and hyperparathyroidism. For each of these 14
outcome categories a primary case definition was specified based on the most definitive and valid
diagnostic criteria available. The diagnostic information used for each primary outcome definition was
obtained at the time of the participant’s clinical evaluation at an HTDS clinic site.  This information
included results from thyroid physical examinations, laboratory tests, ultrasound scans, and thyroid biopsy
results. For most outcomes, if a participant’s prior medical records confirmed a diagnosis with the same
diagnostic methods as those used at the HTDS clinic evaluation, such information was classified as having
met the criteria for the primary outcome definition. The principal dose-response analysis used this primary
definition of outcome, individual radiation dose estimates (the median for each individual) based on
individual residence history, dietary consumption data from the CATI or expanded In-Person Interview
when available, and HEDR default values when such data were not available. The results from these
analyses using the primary outcome definition constitute the principal findings of the HTDS. The primary
analysis for each outcome used the method of maximum likelihood to estimate the background rates or
averages for women and men, and the slope of the sex-stratified linear models. Estimates of the parameters
were also calculated using the method of least squares, once with doses treated as a continuous quantitative
variable (“ungrouped analysis”), and again with doses treated as a categorical variable (“grouped
analysis”). Linear quadratic and logistic dose-response models were also considered as alternatives to the
linear model.
Alternative case definitions were also specified for each outcome category using less definitive
diagnostic criteria.  The diagnostic information used for the alternative case definitions did not meet the
HTDS primary outcome criteria, but was obtained from additional sources.  These sources included
statements from medical records for which the diagnosis could not be confirmed, or reports from the
participant or his or her CATI respondent of a diagnosis for which no medical records could be found.
Dose-response analyses were also conducted for each of these alternative definitions. In those instances
where an alternative definition resulted in a substantially greater number of people in the analysis than the
primary definition, the dose-response results for the alternative definition are also presented in the Results
section. In addition, dose-response analyses were conducted for six outcome categories based on the results
of laboratory assays, and for thyroid mass estimated from the ultrasound scan. 
All dose-response analyses for all outcome definitions were repeated using two alternative sets of
individual dose estimates: 1) individual residence history, and only HEDR default data regarding dietary
consumption (i.e., no data from the CATI or expanded In-Person Interview); and 2)individual residence
history, dietary consumption data from the CATI or expanded In-Person Interview when available, and
default values based on the HTDS CATI data when such individual data were not available (with the
exception of consumption other than milk for expanded IPIs for which HEDR defaults were used). Further,
two alternative representations of exposure were defined which did not use the HEDR models to estimate
individual radiation dose.  Although these categorizations of exposure were more crude than the individual
quantitative estimates of dose, such analyses were performed as an alternative means of investigating a
possible relationship between the thyroid outcomes under study and exposure to Hanford radiation that
would be independent of the HEDR models and assumptions. 
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Because the primary focus of the HTDS analysis was to investigate possible dose-response
relationships, and because individual radiation doses estimated in this study were characterized by some
degree of uncertainty due to the uncertain nature of many of the parameters that determine dose, efforts
were also made to evaluate the influence of dose uncertainties on the fitted dose-response relationships for
the primary case definition in each outcome category. Two different approaches were used. First, the linear
dose-response models were fit using each of the 100 realizations of thyroid dose obtained from the HEDR
models. The estimate of, and 95% confidence interval for, the slope of the dose-response from each of
these 100 analyses were displayed graphically to illustrate how the estimated radiation effect varied among
the 100 realizations of dose, and how these estimates compared to the results based on the median or other
average dose estimate. 
In the second approach, Bayesian analysis was used to estimate the parameters of the logistic
dose-response model that were adjusted for the effect of the dose uncertainty.  This approach used the
Gibbs sampling technique to estimate the marginal posterior distribution of the model parameters,
conditional on the observed data, from the joint conditional distribution of the parameters and unobserved
true doses. For each primary outcome definition, the estimated marginal posterior distribution of the
regression coefficient was displayed.  Also the median and appropriate percentiles of that distribution were
used to derive uncertainty-adjusted point and confidence interval estimates of the dose-response coefficient,
for comparison to the corresponding unadjusted estimates.  As expected, the effect of this adjustment for
uncertainty was generally to increase the magnitude of the estimated dose-response coefficient.  That is, if
the unadjusted estimate was less than 0, then the adjusted estimate was even more negative.  Similarly, if
the unadjusted estimate was greater than zero, the adjusted estimate was even larger.  Also as expected,
however, the adjustment for uncertainty reduced the precision with which the regression coefficient was
estimated, i.e., the uncertainty-adjusted confidence intervals were wider than the corresponding unadjusted
intervals.  Consequently for none of the outcomes did the adjustment for dose uncertainty reveal a
significant dose-response that was obscured in the unadjusted analyses.
In overall summary of the dose-response results, there was no evidence of a statistically significant
association between estimated thyroid radiation dose from Hanford and the cumulative incidence of any of
the 14 primary outcomes. There was also no evidence of any statistically significant dose-response
relationship for any of the alternative definitions of outcome. These results were remarkably uniform. The
findings were essentially unchanged for analyses based on either of the two alternative sets of individual
dose estimates. The results remained the same after taking into account (adjusting for the effects of) several
factors that could potentially confound the relationship between radiation dose and the outcome of interest.
There was no evidence of any statistically significant dose-response for any outcome that might be different
from the linear model used in the primary analyses (e.g., a linear-quadratic relationship). Incorporation of
uncertainty in the dose estimates did not materially change the primary results for any of the outcomes. 
C. Consideration of Factors Related to Study Design and Execution
In interpreting the findings of an epidemiologic study like the HTDS, it is important to consider
the possible influence on the results of factors other than those directly accounted for in the analysis. Of
particular concern is the possibility that the results could be due in part (or entirely) to artifacts or flaws in
either the design or conduct of the study. A number of different factors are considered below in an attempt
to better understand the absence of any dose-response relationships found with any of the outcomes
investigated in this study. 
C.1. Factors Related to Cohort Definition and Selection 
A fundamental consideration in interpreting these results is the adequacy and appropriateness of
the study group upon which all analyses are based. Two principal aspects of this question must be
addressed: 1) was the definition and selection of the study group adequate in order to achieve the primary
research objective; and 2) were the analyses based on an unbiased representation of this group? 
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The primary research objective of this study was to determine whether thyroid disease is increased
among people exposed to atmospheric releases of radioactive iodine from the Hanford Nuclear Site
between 1944 and 1957. A study group was defined with the intention of identifying individuals who could
have been exposed based on their proximity to the site during the times when the releases were highest.
Further, to have the greatest likelihood of detecting an effect of exposure, the study group was restricted to
include people who would have been young children at the time of greatest exposure. This was based on
the assumption that young children receive a higher dose to the thyroid from 131I for the same level of
exposure than do adolescents or adults, and that the thyroid gland in young children may be more
susceptible to the effects of a given dose than in older people. 
A study group was therefore defined based on births that occurred in the region. A roster of births
to mothers living in a seven-county area between 1940 and 1946 was constructed from Washington State
birth records. The HTDS cohort was selected from this roster using a stratified random sampling technique.
Thus, the study group of 5199 individuals selected for inclusion in the HTDS reflects a random sample of a
complete listing of births, and as such provides a population of people who could have been exposed to the
Hanford releases at young ages. It does not define the total population in the region who could have been
exposed, nor even the total population of the age range encompassed by the selected birth cohort who could
have been exposed.  However, in order to achieve the objectives set forth using a cohort study design, it is
not necessary to investigate the entire population at risk or even a representative sample thereof.  In this
instance, restricting the definition of the cohort in some manner (in this case as a birth cohort) is not of
concern in terms of introducing a possible bias in the dose-response. The more important issue is whether
the study group is defined in a manner that will include people representing the entire range of possible
doses, that will include adequate numbers of people with the highest as well as the lowest doses, and that
will allow for uniform and complete follow-up to ascertain thyroid disease status for everyone in the group
in the same manner. Based on what is known about the Hanford radiation releases and possible exposures
to people in the region, the definition and selection of the HTDS cohort should be quite adequate to achieve
the primary research objectives. 
 A more critical consideration is the question of who actually ended up participating in the study
and contributing to the analyses of dose-response. Ideally, the analysis would reflect a complete evaluation
of all 5199 members of the defined cohort. However, loss of information occurs for several reasons,
particularly in a study such as this one where the exposure occurred so long ago: inability to locate people,
refusal to participate, inability to participate for other reasons, and mortality within the cohort. The primary
concern with such losses is the possibility that people who are not included in the final analyses are
somehow different in a systematic way that might be related to both: 1) radiation dose from Hanford; and
2) one of the thyroid outcomes under study. If so, failure to include such people could potentially result in a
misleading or incorrect estimate of any dose-response relationship. 
This study was successful in locating members of the cohort. As reported in section V.B.4.,
approximately 94% of the 5199 individuals originally identified were located: 4350 alive and 527 deceased.
Furthermore, there was no evidence of an appreciable difference in ability to locate people according to
sex, year of birth (and thus age at exposure), or geographic area of birth within the Hanford region. The
proportion located in each of these subgroups was high (over 90%), and relatively uniform. 
Once located and contacted approximately 84% of those contacted agreed to participate. This high
level of cooperation was also relatively uniform among the various subgroups defined by sex, year of birth,
and geographic area of birth. There was no evidence of any subgroup of the cohort being substantially more
or less likely to agree to participate. This pattern also was apparent according to geographic area of current
residence. There was no indication that people who live outside of the region were less likely to agree to
participate. Across all areas of the country, the proportion agreeing to participate was uniformly around
80%.  
Approximately 15% of those contacted refused participation, or withdrew from participation (even
though they initially agreed to participate). An attempt was made to identify a reason for each refusal or
withdrawal based on responses to the refusal questionnaire (if the person was willing to provide such
information) and the recruiter’s assessment of the interaction with the person.  The majority of the refusals
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and withdrawals were because the person was not interested, or did not have time. Very few refused
because they were opposed to the study. Potentially of more interest is the group who refused or withdrew
because of illness or impairment, which precluded them from participating. The principal concern would be
that people in this group were more likely to have one of the outcomes under study. In only one case was
current thyroid disease given as a reason for non-participation. Further, in reviewing the types of illnesses
and impairments cited, there is no indication that people who refused or withdrew were more or less likely
to have any of the disease outcomes investigated in the study. Although it is not possible to say with
certainty from these data that people who chose not to participate are no different regarding the outcomes
of interest than those who did participate, these responses provide some assurance that such is the case. In
addition, given the relatively small proportion of people who refused or withdrew, and the uniformity of
this proportion among subgroups of the cohort, it is unlikely that such losses could have materially biased
the dose-response analyses. 
Loss of information also occurs because of mortality within the cohort. Of potential concern is the
possibility that such loss is related to one or more of the outcomes of interest. In this study, 527 (10.1%) of
the 5199 individuals originally identified were confirmed as deceased and an additional 16 (0.3%) who
were located alive died before participating in the HTDS. A death certificate was obtained for 504 (93% of
the 543) in order to determine the cause of death for each person. There were 199 deaths in females and
344 deaths in males, with no known age of death for two of the males. For both sexes, the largest
proportion of deaths occurred under one year of age (36% for both males and females).  Most of these
deaths were due to conditions in the perinatal period or congenital anomalies. Approximately 31% of the
deaths in females were due to these two causes, as were approximately 27% of the deaths in males. 
An analysis was conducted to investigate whether the mortality experience in this cohort overall
was unusually high, relative to what would be expected based on the mortality experience of the regional
population from the same time period, and to determine whether there was any indication of an excess in
mortality from conditions that might be related to one or more of the primary thyroid outcomes of interest.
The detailed results of this analysis are shown in Mortality Appendix 23. In summary, there was no overall
increase in total mortality over what would be expected based on the mortality experience of the population
of Washington State during the same time period (standardized mortality ratio (SMR) = 0.97; 95%
Confidence Interval (CI) = 0.89, 1.06).  This was true for both females (SMR = 0.96) and males (SMR =
0.98).  However, there was an excess in deaths due to conditions of the perinatal period (SMR = 1.69, 95%
CI = 1.39, 2.04), which was found in both females (SMR = 1.70) and males (SMR = 1.68). 
Further analyses were performed to investigate whether there was any excess in mortality
according to geostratum of birth, or in birth years concentrated around the time of the peak releases from
Hanford (i.e., in the birth cohorts defined by the period 1945-46). The only excess in mortality observed by
geostratum was among people born in Franklin County (SMR = 1.61, 95% CI = 1.15, 2.20). This excess
was found for males (SMR = 1.66, 95% CI = 1.09, 2.44), but was only suggestive for females (SMR =
1.53, 95% CI = 0.83, 2.56). There was essentially no difference in mortality seen between the 1945-46 birth
cohorts and the 1940-1944 birth cohorts. Analyses were also conducted according to year of death,
classified as before 1945 (beginning of Hanford operations) and 1945 or later. For total mortality, there was
little difference in the SMRs for deaths before 1945 and for the period from 1945 on (SMR = 1.06 vs. 0.95,
respectively), and neither was statistically significant. This pattern was similar in males and females, and
was observed for conditions of the perinatal period and for congenital anomalies. 
Of primary interest in considering the results of these exploratory analyses regarding mortality in
the HTDS cohort is whether the loss of cohort members through death could in some way bias the dose-
response analyses. Given the principal findings of the study, the primary concern would be that this loss
attenuated a true dose-response (i.e., biased the estimate of effect toward the null), and that is why no
association is observed between increasing radiation dose from Hanford and the outcomes under study. In
order for the exclusion of participants lost to death to mask a true dose-response, one of three
circumstances would have to be operative among the group of 543 deceased individuals: 1) they would
have had to have experienced disproportionately higher doses and higher rates of the outcomes under
study, thereby “pulling up” the high end of the dose-response curve; 2) they would have had to have
experienced disproportionately low doses and low rates of the outcomes under study, thereby “pulling
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down” the low end of the dose-response curve; or 3) they would have had to have experienced the full
range of possible doses, but exhibited a very strong dose-response over the full dose range. Given the
relatively small proportion of the cohort lost due to deaths (10%) and the consistency of findings of an
absence of a radiation dose-response across all outcomes, it is highly unlikely that the absence of a dose-
response is due to any of the these three circumstances. In fact, there is little difference in overall mortality
among cohort members compared to what might be expected based on mortality rates in the same region
over the same period of follow-up, and no evidence to suggest that cohort members born in the years of the
peak radiation releases from Hanford experienced higher than expected overall mortality. 
An alternative but related explanation of how the loss of deceased members of the cohort could
attenuate a dose-response might be that those who died were somehow more likely to have developed
thyroid disease had they lived (sometimes referred to as a “healthy survivor” effect), or perhaps died with
undiagnosed or unrecognized thyroid disease. However, in order for such explanations to contribute to or
account for the absence of a dose-response, it must be assumed that those who do not survive experienced
high or at least appreciable doses. Although it proved impractical to estimate individual doses for the
deceased in this study, a number of additional analyses were undertaken among subgroups of people
defined by cause of death, year of death, area of birth, and time of birth in an attempt to investigate patterns
of mortality that might conceivably be related to thyroid dose. Mortality in excess of that expected occurred
primarily at very young ages, concentrated in causes related to the perinatal period, but the excess was
apparent for deaths that occurred prior to the beginning of Hanford operations, and were similar in
magnitude to the excess seen for deaths that occurred in 1945 or later. This would argue against the cause
of such excess at young ages (or conditions of the perinatal period) to be related to exposures from Hanford
operations. Similarly there was little evidence that any excess mortality was concentrated in people more
likely to experience higher dose based on geography. Finally, there was no indication that deaths were
concentrated in categories that might be related to the development of the outcomes under study, and there
was no mention of thyroid diseases on any of the death certificates. Thus, although it is not possible to
know whether those who died had higher doses and might have been more likely to develop thyroid
diseases had they lived, or had unrecognized thyroid disease at the time of their death, there is no indication
of such based on examination of the data available. 
In summary, a total of 3440 (66.2%) of the 5199 individuals initially selected for inclusion in the
HTDS cohort were evaluable and provided data for the analysis. The proportion of those originally selected
who attended a clinic and were evaluable was remarkably uniform across the factors that defined the
selection: sex (males 64.1%, females 68.3%), year of birth (1940: 67.3%, 1941: 69.5%, 1942: 69.3%, 1943:
66.6%, 1944: 65.3%, 1945: 63.0%, 1946: 66.2%), and geostratum (Richland: 64.9%, Pasco/Kennewick:
64.8%, Walla Walla City: 64.1%, Benton County: 65.2%, Franklin County: 63.7%, Walla Walla County:
71.7%, Okanogan: 65.9%, Ferry/Stevens: 63.9%, Adams: 73.8%). Thus, although the final dose-response
results are based on approximately two-thirds of the people originally identified for study, it appears that
the degree of loss of individuals from the group was relatively uniform across subgroups defined by sex,
year of birth, geographic area of birth, and geographic area of current residence. There is no indication that
people were less likely to participate because they had thyroid disease, and in more general terms, illness
was infrequently given as a reason for non-participation. Further, there is no indication of a substantial loss
due to mortality in ways that are likely related to both exposure (dose) and the development of any of the
outcomes of interest (i.e., in ways that would substantially affect the estimates of dose-response). Although
one cannot rule out the possibility that the dose-response results might be biased in some way as a result of
non-participation by nearly one-third of the cohort, no patterns of non-response or loss to follow-up are
apparent from the data available that would suggest such is the case. In order for such a bias to have an
important influence in producing the pattern of results seen in the HTDS (lack of a dose-response), one
would have to postulate that people who did not participate were more likely to have one of the outcomes
under study and to have received higher doses. As noted above, there is no evidence of such selection bias
in the HTDS cohort. 
HTDS Final Report: June 21, 2002 – Section X page 525
C.2. Factors Related to Outcome Definition
An important element of a cohort study such as the HTDS is that the outcomes of interest are
ascertained in a comprehensive and unbiased manner. That is, it is important that all cases of a given
outcome are identified, and that the identification of cases is not influenced by or related to exposure or
dose.  The clinical component of the HTDS was designed to ensure that such was the case. Because of the
long time period between the Hanford exposures and present day, and because the thyroid diseases under
study can often be difficult to diagnose or even go undetected, it was felt essential that each participant
undergo a thorough examination and evaluation for the presence of each of the outcomes under
investigation as part of their participation in the study. Great care was taken to ensure that each person
received the most complete evaluation possible by using highly experienced thyroid specialists. Further,
two different physicians examined each participant separately, consulted with each other, and reached
agreement on their findings before the participant left the clinic. State of the art technology was used in the
form of thyroid ultrasound to help ensure that all thyroid nodules were identified. Nearly all participants
who attended a study clinic completed all aspects of the evaluation, including providing a blood sample for
laboratory tests and undergoing a fine needle aspiration biopsy when recommended. Analyses of the
“pathways to diagnoses” of thyroid cancer, benign thyroid nodules, and nodules suspicious for follicular
neoplasm demonstrated that the numbers of such cases were increased by the comprehensive clinical
evaluation provided to each participant.  Given this design, and the success experienced in carrying out the
clinical component of the study, it is felt that the ascertainment of outcomes in the cohort is essentially
complete. It is highly unlikely that substantial numbers of cases of any of the primary outcomes of interest
were undetected, or that there is any substantial misclassification of outcomes. 
The study was also designed to try to minimize the possibility that the physicians or sonographers
could be influenced in their evaluation by knowledge of the participant’s possible level of exposure to
Hanford radiation. As outlined in section V.F.2.d, a number of measures were taken to prevent this from
happening. At the clinic, participants were instructed not to make the physicians or sonographer aware of
any personal circumstances that would suggest what their radiation exposure history might be. They were
also asked not to wear clothing items that might provide any such indication.  A variety of clinic locations
were used, and participants were scheduled into clinics in a way that purposely did not correspond to prior
residence history or the likelihood of exposure. Thus, when an individual physician examined a participant,
he had no knowledge of what that particular participant’s past history was in relation to the Hanford
radiation releases (or any other potential radiation exposures). The same was true for the sonographer. As a
check to see whether these precautions were effective in blinding the physicians to possible exposure, each
physician was required to indicate at the conclusion of their evaluation whether they had any indication of
possible exposure for that individual. In only 15 instances (of the 3440 living evaluable participants) did the
physician suspect some knowledge of past exposure. Precautions were also taken to blind the physician
reviewers of past medical records to any mention of radiation exposure. As described elsewhere, this was
done in a manner that made it impossible for the reviewer to know for any given medical record whether
there was any indication of previous exposure to radiation (either from medical or environmental sources).
In summary, based on the success of the various approaches used, it is not likely that the determination of
outcomes was influenced in any substantive way by knowledge of exposure. 
C.3. Factors Related to the Estimation of Thyroid Radiation Dose
Just as it is important to accurately define outcomes, it is critical to accurately classify study
participants according to exposure or dose. In this study, substantial misclassification of study participants
according to radiation dose would tend to attenuate any true dose-response relationship (i.e., bias the
estimate of effect towards the null). One approach to minimizing the likelihood of substantial exposure
misclassification in a study such as this one where dose is estimated (reconstructed) based on historical
information is to utilize individual-level information as much as possible to “tailor” each individual’s
estimate of dose to his or her own specific circumstances. The HTDS was designed from the beginning to
use this approach. The cornerstone of the method was to elicit detailed information for each respondent
regarding those factors most crucial in determining thyroid radiation dose from Hanford, and to use that
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information to estimate an individual dose for each person. This was difficult to do because of the level of
detail required, the long period of time that has elapsed since the exposures, and the fact that participants
were young children during the time period that is most relevant for estimating dose. A considerable effort
was made to structure the collection of individual information in a way that would enhance a person’s
ability to recall the information accurately by using a cognitive approach to interviewing, and to do so in a
manner that would not be biased by the participant’s knowledge of thyroid disease status. The
administration of both the CATI and In-Person Interviews prior to the clinical evaluations probably aided in
avoiding bias in recall to some extent. However, there is no way to directly assess the degree of potential
misclassification of exposure that occurred using the approaches taken in this study. 
Therefore, we repeated all of the analyses using alternative methods of assigning exposure to see if
the results changed in any substantial way. First, we developed two alternative dose schemes that
maintained an individual level dose estimate for each participant, using the HEDR models to estimate dose.
The primary analyses were based on doses estimated using individual residence histories, individual
responses to the CATI (or Expanded In-Person Interview), and HEDR default values when CATI responses
were not available. The first alternative individual dose scheme used individual residence histories, and
HEDR defaults exclusively (that is, no data from CATI or Expanded In-Person Interviews). The second
alternative dose scheme was the same as the primary scheme, but HTDS default values were used when
CATI responses were not available instead of HEDR default values (with the exception of consumption
other than milk for Expanded In-Person Interviews, for which HEDR defaults were used). These HTDS
default values for food and milk consumption data were defined based on the experience of the participants
in the HTDS for whom a completed CATI interview was available. None of the dose-response results for
any of the outcomes changed appreciably from the primary results using either of these alternative methods
of estimating individual thyroid dose. This provides some assurance that the absence of a dose-response
found in the primary analyses is not due to misclassification of exposure introduced by difficulties in recall
from the distant past. 
Second, two alternative representations of exposure were defined which were independent from
the HEDR dosimetry system altogether, and therefore did not use the HEDR models to estimate individual
radiation dose.  One was simply the geostratum used to define the sampling frame for selecting the cohort
(i.e., the mother’s usual place of residence at the time of the participant’s birth as determined from the
participant’s birth certificate). Although this is clearly an imperfect surrogate indicator for Hanford
radiation dose, and does not take into account individual circumstances (e.g., movement patterns and
dietary habits), it might provide at least a crude way to distinguish people more or less likely to have
received substantial exposures. 
For the primary definition of each outcome, analyses were conducted to see whether there was
heterogeneity of outcomes across geostrata, and whether the proportion with the outcome in the two
geostrata defined by Okanogan and Ferry/Stevens counties was different than that in the remaining seven
geostrata.  In summary, there was little evidence of significant heterogeneity in the cumulative incidence of
any of the outcomes across all geostrata. Those outcomes showing the greatest degree of variation across
geostrata were benign nodules, any thyroid nodules, any thyroid UDAs, and palpable thyroid UDAs. 
Of more interest was the generally consistent finding that the proportion of participants with a
given outcome was somewhat higher in the Okanogan and Ferry/Stevens geostrata than in the other seven
geostrata. This pattern was apparent for the most part across all primary outcomes, although for those with
very few cases (e.g., thyroid cancer, simple goiter, Graves disease, hyperparathyroidism) there was very
little statistical power to evaluate the relationship. Insofar as geostratum serves as a surrogate indication of
radiation exposure (and dose), and the underlying hypothesis is that radiation exposure from Hanford is
associated with an increase in the thyroid disease outcomes under study, these results were quite
unexpected because the Okanogan and Ferry/Stevens geostrata were defined in an attempt to identify
people who were likely to have been relatively unexposed to Hanford radiation releases. Indeed, according
to the individual dose estimates derived using the HEDR models, it appears that the sampling strategy was
successful in that regard because the average doses for living evaluable in area participants in these two
geostrata were the lowest of all nine geostrata (see Table IX.B-4, section IX.B: Okanogan, 11 mGy;
Ferry/Stevens, 36 mGy).
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It is not readily apparent why the cumulative incidence of the thyroid diseases under study would
be slightly higher among people born in these three counties. Based on individual dose estimates that
account for a person’s movements and lifestyle, it appears that those selected from the Okanogan and
Ferry/Stevens geostrata have the lowest doses in the cohort. There is also no evidence that this group is
unusual in terms of selection or participation in the study, or ascertainment of disease status. Further, all of
the analyses by geostrata were adjusted for differences by sex and age at examination. It is also difficult to
imagine that some other aspect of birth, early life, or living in these areas is related to the risk of developing
thyroid disease, as the apparent effect is seen across all outcomes (including hyperparathyroidism and
thyroid UDAs). One would have to postulate that such an influence is related to all the different forms of
thyroid disease included in this study, which seems exceedingly unlikely. A possible exception might be
iodine deficiency. Geographical differences in the distribution of iodine intake (e.g., endemic goiter belts)
could result in geographic differences in the rates of one or more of the thyroid diseases under study. 
As described in section IV above, there is very little information available describing either
estimates of soil iodine concentrations or iodine intake on a geographical basis.  Probably the most useful
data in this regard are those reported by Oddie et al. (119). He reported estimates of average dietary iodine
intake derived from thyroidal radioiodine uptakes in approximately 30,000 euthyroid subjects in 133
locations throughout the United States.  Although average daily iodine intake varied considerably
throughout the United States (from 240 to 740 micrograms per day), the Pacific Northwest was relatively
uniform in the distribution of daily intake estimates.  Mean values were reported for fifteen areas in the
Northwest centered by two degrees latitude and longitude (approximately 140 by 120 miles).  All values in
the six HTDS Pilot Study counties were between 345 and 379 micrograms per day (a very narrow range
compared to the overall distribution of values).  These findings provide some evidence that iodine intake
was adequate and relatively uniform in the past in the areas from which study participants were selected.
As such, they suggest that iodine deficiency is not a likely explanation of the relatively higher proportions
of thyroid disease among people selected from the Okanogan and Ferry/Stevens geostrata. 
Nevertheless, because the cumulative incidence of disease was consistently higher in the
Okanogan and Ferry/Stevens geostrata in a manner possibly related to dose, it was decided to repeat the
primary dose-response analyses omitting people born in these two geostrata. If thyroid disease rates were
truly elevated in the population from which people in these geostrata were selected, and such people tended
to have lower Hanford doses, the dose-response analyses might be biased toward the null (i.e., the dose-
response might be underestimated). Generally, the effect was to increase the regression coefficient (slope of
the dose-response). However, none of the changes were substantial enough to suggest a significant dose-
response relationship. The largest changes were for the outcomes related to thyroid UDAs. For any thyroid
UDAs, the regression coefficient increased from 0.031 per Gy to 0.046 per Gy, and the p-value changed
from 0.21 to 0.11. Thus, although the effect of excluding participants from these geostrata had the
anticipated effect on the dose-response results, it did not materially change the overall findings or
conclusions. It should be emphasized that analyses that excluded the Okanogan and Ferry/Stevens geostrata
were not included in the original analysis plan, but were conducted only after the higher cumulative
incidence rates in these two geostrata were observed. Given the data-driven nature of this additional
analysis, there is no evidence to suggest that the somewhat higher cumulative incidence of disease in the
Okanogan and Ferry/Stevens geostrata led to a significant underestimate of the dose-response for any of the
primary outcomes under study. 
The second alternative representation of exposure which did not use the HEDR models to estimate
individual dose was based on the assumption that two factors are particularly important in determining
radiation dose from Hanford: a person’s residence history and history of milk consumption. A dichotomous
representation of possible exposure (high, low) was defined based on this information. For this analysis, the
high exposure group was defined to include those living evaluable participants who:1) were born prior to
July 2, 1945;2) lived for at least 180 days in Benton, Franklin or Adams counties (excluding Richland)
during 1945; and 3) consumed on average at least one serving of milk per day during 1945.  The low
exposure group was defined to include: 1) all out-of-area participants (OOA); 2) participants who lived
only in Ferry, Stevens or Okanogan counties or OOA in 1945 and who never lived in Benton, Franklin or
Adams counties between 1946 and 1951 inclusive;3) participants born in 1946 who never lived in Benton,
Franklin or Adams counties between 1946 and 1951 inclusive; or 4) participants who lived outside of
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Benton, Franklin or Adams counties from the later of the participant’s birthday and 12/15/44, until
12/31/51, and consumed on average less than one serving of milk per day in 1945 (includes only
participants with CATI as the dose source).
Using this dichotomous representation of possible exposure (high, low) and the primary definition
of each outcome, analyses were conducted to see whether the cumulative incidence of each outcome was
greater among those in the high dose category relative to the low dose category. In summary, there was no
evidence of a significant relationship between exposure, as represented in this manner, and the cumulative
incidence of any of the outcomes. There was a slightly higher proportion of participants with thyroid UDAs
in the high group relative to the low group (50.3% vs. 47.4%), but not significantly so (p = 0.10), and this
relationship was somewhat more pronounced when the analysis was restricted to nonpalpable focal thyroid
UDAs (41.5% vs. 37.6%, p = 0.079). 
Although this approach for assigning exposure is also crude, it incorporates at least some of the
information about each individual’s circumstances that is thought to be important in the determination of
dose. As such, this surrogate indicator should be somewhat more capable of distinguishing people who
received relatively higher doses from those who received relatively lower doses than the simple geostratum
designation. If so, it nevertheless does not provide any evidence of a statistically significant association
between higher Hanford radiation dose to the thyroid and an increase in any of the primary outcomes under
study. 
A limitation of the dosimetry system available for this study was its inability to calculate dose
estimates for participants who did not live within the HEDR domain between December 1944 and the end
of 1957.  As a result, the primary dose-response results of this study refer to dose received while living in
the HEDR domain between December 1944 and the end of 1957.  Individual dose estimates could not be
calculated for the 249 participants who lived outside the HEDR domain during that period, the so-called
“out-of-area” participants.  It is reasonable to assume that the out-of-area participants received generally
low doses.  In particular those who lived only at great distance from Hanford during this time period
probably received virtually no dose from Hanford.  However many out-of-area participants lived in places
not far outside the HEDR domain.  It is probably inappropriate to simply assume that such people received
no exposure from Hanford.
Therefore, scoping analyses were performed to assess whether inclusion of the out-of-area
participants in the primary analyses, had that been possible, might have substantially changed the dose-
response results.  These analyses assigned crude estimates of a dose for the out-of-area participants, based
on residence during the 1944-1957 exposure period.  Out-of-area participants who lived in the four states or
two Canadian provinces closest to Hanford were assigned doses of either 0 mGy, or the highest dose that
they would have been assigned had they lived on the border of the HEDR region in the direction of the
state or province (which would likely overestimate the dose they could have actually received), depending
on their disease outcome status.  Those who lived outside that four-state/two-province region were assigned
doses of 0 mGy. A scoping analysis of each disease outcome was then performed in which all out-of-area
participants with the outcome were assigned their “border dose,” while those without the outcome were
assigned 0 mGy.  This imposes a strong dose-response relationship among the out-of-area participants.
However when the in-area and out-of-area participants were combined in these scoping analyses, there
were no important changes in the estimated dose-responses.  This was true even in the analysis of thyroid
cancer, for which five of the 19 cases based on HTDS or prior histology were out-of-area participants. A
second scoping analysis assigned doses in the reverse order, so that out-of-area participants with the
outcome received a dose of 0 mGy and those without the outcome their “border dose.” This did not
materially change the estimated dose-response for any outcome either. 
It is perhaps not surprising that neither of the scoping analyses which included the out-of-area
participants had much impact on estimated dose-responses, since the out-of-area participants comprised
only 7.2% (249/3440) of the living evaluable participants.  Moreover the crude dose estimates that they
were assigned ranged from 9 to 48 mGy, well below the mean dose of 174 mGy observed for the 3191 in-
area participants.
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In summary, a number of attempts were made to use alternative approaches for characterizing
study participants in terms of their exposure to Hanford radiation, including both alternative quantitative
and qualitative schemes. This was done so that the investigation of a possible relationship between Hanford
radiation exposure and thyroid disease would be as complete and comprehensive as possible, would rely on
multiple types and sources of data, and would not be limited to only one dose assessment approach and the
associated assumptions. It was recognized from the beginning of the study that there would be limitations
in the quantitative dose estimation program developed by HEDR, and that alternatives based only on
residence location would provide crude indicators of exposure at best. The decision to use both approaches,
and to look for consistency in results, was felt to provide a more thorough assessment of a possible
relationship between radiation exposure and thyroid disease. Analyses of all of the primary outcomes were
repeated for each alternative approach. None of these analyses produced evidence of a statistically
significant relationship between any of the primary outcomes and exposure to Hanford radiation (or dose).
The principal findings of the primary analyses using individual doses estimated by the HEDR dosimetry
system were not materially changed by any of these alternative analyses. In addition, all primary analyses
were repeated using the arithmetic mean, and the geometric mean, of the 100 dose realizations for each
participant rather than the median dose estimate. This did not change the results. All primary analyses were
also conducted fitting sex-stratified linear-quadratic and logistic dose-response models. The addition of the
quadratic term did not significantly improve the fit of the dose-response model for any of the outcomes
under study, and neither the linear-quadratic or logistic models provided any evidence of a significant
radiation dose-response. 
For many of the disease outcomes, the numbers of cases among participants with the highest dose
estimates tended to be relatively low.  As a result, estimated slopes of the dose-response relationships were
slightly, though not significantly, negative for these outcomes.  Additional analyses were performed to
assess whether these results might be unduly influenced by the relatively small proportion of participants
with the highest doses.  In particular, the primary analyses of disease outcomes were replicated twice: once
excluding participants with estimated doses above 1000 mGy, and a second time excluding those with
doses above 400 mGy.  The first alternative analysis had very little impact on the fitted dose-response
models.  A somewhat stronger impact was seen in the analysis that excluded participants with estimated
doses over 400 mGy.  For most disease outcomes, the slope of the dose-response tended to be greater when
based on the limited set of participants, although in general the increases were not large enough to suggest a
statistically significant dose-response.  For two outcomes, the exclusion of participants with estimated
doses over 400 mGy increased the estimated slope of the dose-response substantially.  For nonpalpable
focal thyroid UDAs the estimated slope increased from 0.027 per Gy (p = 0.23) to 0.228 per Gy (p =
0.003).  For diffuse thyroid UDAs the estimated slope increased from 0.029 per Gy (p=0.14) to 0.146 per
Gy (p=0.005).
While the magnitudes of the dose-responses for these two ultrasound outcomes excluding
participants with estimated doses over 400 mGy are considerably larger than the estimates among all study
participants, the statistical significance of these results must be interpreted with caution. First, this is a
secondary, exploratory analysis that only shows a significant effect when people with the highest thyroid
doses are excluded. Second, it should be kept in mind that this result was found in the context of
conducting many secondary and alternative analyses and significance tests. Third, such abnormalities are
quite common. Numerous investigations in populations throughout the world have reported that 20-50% of
individuals may have one or more such findings on ultrasound examination.  Fourth, and perhaps most
importantly, the health significance of nonpalpable focal and diffuse thyroid UDAs is unclear. Whereas
thyroid UDAs that are palpable can be classified as thyroid disease, the high prevalence of those that are
not palpable may not represent clinical disease. Since no dose effect was detected for recognized thyroid
disorders such as thyroid cancer, benign thyroid neoplasia, and hypothyroidism, it would seem unlikely that
the focal and diffuse ultrasound findings would be clinically significant. Could these ultrasound findings
represent subclinical thyroid disease?  In other words, very mild abnormalities that do not cause symptoms
but might be destined to become clinical disease over time? If this were true, one might expect to see 2
types of dose-response results in the HTDS: an increase in the number of ultrasound abnormalities with
increasing dose, and an increase in the risk of having an ultrasound abnormality of a particular size with
increasing dose.  The HTDS examined both of these possibilities.  First, there was no relationship found
between the number of ultrasound abnormalities on a participant’s ultrasound scan with increasing dose. 
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Second, there was no increased risk of having larger, focal ultrasound abnormalities (maximum size 5mm,
maximum size 10 mm, or average size at least 15 mm) with increasing dose.  Thus, these results do not
suggest that these ultrasound findings represent early manifestations of thyroid disease.   In summary,
based on the above factors, it would seem very unlikely that the dose-response seen for nonpalpable focal
and diffuse ultrasound abnormalities, found only after secondary, exploratory analyses, and only after
excluding participants with the highest doses, truly represents a significant dose effect in the HTDS.
C.4. Potential for Confounding or Effect Modification
Although relatively few factors have been well established as important in the etiology of the
thyroid diseases under study, an attempt was made to collect as much information as possible from study
participants regarding aspects of their personal history and lifestyle that might potentially influence the risk
of developing thyroid disease. As described in section VIII, this information was used to construct several
variables for inclusion as covariates in the dose-response analyses. Analyses were conducted for all
outcomes with sufficient numbers of cases to evaluate whether any of these factors confounded the
relationship between the outcome of interest and estimated Hanford radiation dose, or whether any dose-
effect was modified by levels of the factor (e.g., for sex, whether the effect was different in males and
females). 
None of the covariates investigated materially changed the estimates of the dose-response for any
of the outcomes under study. There was no evidence of confounding by any of the factors, nor was there
any evidence of effect modification by any of the factors assessed. This included the covariate reflecting
exposure to radiation from the Nevada Test Site. These rather extensive analyses provide no evidence that
there is a significant dose-response for any of the outcomes under study, or evidence of a significant dose-
response among subgroups of participants defined by any of the covariates investigated.
C.5. Statistical Power of the Study
Of critical importance in the interpretation of these results is the ability of the study to detect an
increase in disease risk if it is present, i.e., the statistical power of the study. In order for the findings of an
absence of an effect to be very meaningful, there must be adequate statistical power to detect an effect of
the magnitude that might be expected based on existing knowledge, and that is relevant and meaningful to
the population exposed. As described more fully in section VIII, the HTDS was designed to have relatively
high power to detect a positive dose-response as small or smaller in magnitude than any existing published
findings regarding each outcome. These projections of study power, which were based on the results of the
Pilot Study, were actually exceeded in the Full Study (as shown in Table IX.B-14 above). Nevertheless,
because uncertainties in the individual dose estimates could be expected to reduce study power, we
undertook a simulation analysis to estimate the impact on study power of incorporating such uncertainties
in the dose estimates (see section IX.B-4). Although the effect of dose uncertainty was, as expected, to
reduce the statistical power of the study, the reduction was modest. Even after accounting for uncertainty in
doses, the HTDS had greater than 80% power to evaluate each of the hypotheses originally specified. 
To interpret the study’s power properly, it is important to consider not only the level of power, but
also the size of the dose-response effect for which that power is obtained.  As described in section IX.B.4
above, after accounting for the impact of dose uncertainty, the study’s one-sided tests at critical level
α = 0.05 had estimated power of about 85% to 86% to detect linear dose responses corresponding to
relative risks (average for both sexes) of 2.04, 1.30, and 1.05 at the study participants’ average dose of 174
mGy, for the exemplary outcomes with low (thyroid cancer), intermediate (any thyroid nodule), or high
(thyroid UDA) background rates, respectively. 
For comparison to results of other studies, the magnitudes of radiation effects can be expressed as
the relative risks at 1000 mGy (1 Gy).  For the low background rate example of thyroid cancer, a slope of
2.5% per Gy, for which HTDS had about 86% power (Table IX.B-16above), corresponds to a relative risk
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(average of both sexes) of 6.95 at 1 Gy.  This is a substantially smaller effect than that observed in the Utah
Thyroid Study, for which the relative risk was estimated as about 25 at 1 Gy after accounting for dose
uncertainties (134).  A recent analysis suggested that the adjustment should perhaps be smaller: Mallick
and colleagues analyzed the Utah Study’s data concerning thyroid neoplasms and concluded that the
estimated relative risk at 1 Gy should be approximately doubled, rather than tripled, to account for dose
uncertainties (140).  Assuming this conclusion applies to thyroid cancer, the estimated relative risk would
be about 17 at 1 Gy.  The HTDS clearly had adequate statistical power to detect an effect of this magnitude.
For example, after accounting for dose uncertainty there was an estimated 92% power to detect a linear
dose-response with a slope of 3.5% per Gy for thyroid cancer (Table IX.B-16 above), which corresponds to
an average relative risk (both sexes combined) of 9.33 at 1 Gy, well below the estimated effect from the
Utah Study.
D. Comparison of Results with Findings in Other Populations Exposed to Radiation
Although there is a substantial literature regarding the role of ionizing radiation in the induction of
thyroid disease in humans, the findings reported to date do not provide a clear and consistent
characterization of the relationship between radiation exposure and risk. This is due in part to the fact that a
number of factors are probably important in determining risk: the type of radiation, the dose received, the
rate at which the dose was received, a person’s age at the time of exposure, a person’s age at the time of
disease occurrence, and iodine deficiency. Thus, in comparing the results of the present study with those
published, it is important to keep in mind the characteristics of the Hanford exposures and the basic design
features of the HTDS. The exposure was environmental, and occurred over a period of up to approximately
13 years, although much of the dose was delivered in a considerably shorter period of time, and many
people may have received most of their dose over periods of several months. The design of the HTDS
resulted in a study group that consisted of people who were young children (under age 5) at the time of the
peak exposures, and follow-up occurred over a period of up to more than 50 years. Radiation dose to the
thyroid from 131I was estimated for each individual, based on historical reconstruction of events. Estimated
doses for the study group were relatively low (median dose = 97 mGy, mean dose = 174 mGy). Thus, it is
within this context that the present results are considered in relation to the published literature. The primary
goal of this comparison is to evaluate how well the current findings “fit in” with what is currently known
about radiation-induced thyroid disease. To the extent possible, specific analyses have been tailored to be
as comparable as possible to published results, for the explicit purpose of direct comparison. 
A more detailed presentation of the published literature is contained in sections II.B through II.D
above. It is not the intent to repeat those descriptions here, but rather to highlight the principal points for
comparison with the HTDS findings. There is clear evidence from a number of studies that people exposed
to external sources of gamma radiation or x-rays are at an increased risk of developing thyroid neoplasia.
There is also evidence to suggest that the risk is greater for people exposed at younger ages. Most of this
evidence comes from studies of people treated medically with radiation, and from studies of the survivors
of the atomic bombings in Japan. Thus, in both circumstances, doses were generally considerably higher
than those in the HTDS, were generally delivered at a much higher dose rate, and reflect external
exposures. Nevertheless, one study of children irradiated for tinea capitis provides some evidence of an
increased risk associated with much lower doses (average dose = 90 mGy). 
Of much more relevance to the Hanford circumstances are studies which have evaluated the
effects of exposure to radioactive iodine. Unfortunately, much less information is available in this regard,
especially in human populations. Two types of information exist: findings based on people exposed in
medical settings, and findings based on people exposed environmentally. People exposed therapeutically to
radioactive iodine (primarily for the treatment of Graves disease) generally received very high doses.
However, there is no clear evidence that such exposures result in a subsequent increase in thyroid
neoplasia. People exposed for diagnostic purposes generally received much lower doses, but the doses are
still relatively high compared to the Hanford doses (typically 500 – 1000 mGy). There is no convincing
evidence that exposures at these levels result in increased thyroid neoplasia. Although the rates of thyroid
cancer were elevated in some of the above studies, the authors concluded that the increase was more likely
related to the underlying thyroid disease than to the radioiodine exposure.
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Information regarding the effect of environmental exposure to radioactive iodine comes from
studies of three principal populations: people exposed to fallout from atmospheric nuclear testing in the
Marshall Islands in the 1950s, people exposed to releases from the Chernobyl Power Station accident in the
Former Soviet Union in 1986, and people exposed to fallout from atmospheric nuclear testing at the
Nevada Test Site in the 1950s and early 1960s. The experiences in the Marshall Islands and at Chernobyl
are less directly comparable to the Hanford experience because the exposure in each instance consisted of a
broader and different mixture of radionuclides, and the dose rates were relatively high (short time of
exposure). Nevertheless, in the Marshall Islands there has been an increase observed in thyroid neoplasia
associated with the more highly exposed areas, with doses much higher than those around Hanford. Around
Chernobyl there has been reported a dramatically increased occurrence of thyroid cancer in young children.
Unfortunately, there are no epidemiologic studies available with quantitative estimates of individual thyroid
radiation dose from Chernobyl to better elucidate the nature of any dose-response in this regard. However,
a number of attempts to estimate radiation doses on a population basis suggest that the doses were generally
much higher than those around Hanford. 
The study of people exposed to fallout from the Nevada Test Site, the so-called “Utah Study”(133,
134), is probably the most comparable to the Hanford situation. The mean dose for all 3545 participants
who were included in any phase of the Utah Study was 98 mGy, compared to 174 mGy for the 3191 living
evaluable in-area HTDS participants.  The maximum estimated thyroid dose in the Utah Study was 4600
mGy (2823 mGy for HTDS), although only 10 participants (0.3%) had estimated doses greater than 1000
mGy (24 or 0.8% for HTDS).  However, there was likely a greater contribution from short-lived
radioiodines and external radiation in the Nevada Test Site exposures compared to exposures at Hanford.
Moreover, the participants in the Utah Study received most of their dose in short time periods after one or
more test detonations.  In contrast, most Hanford exposures were continuous and prolonged over months or
years. A statistically significant dose-response was reported for total neoplasms (benign follicular
neoplasms and thyroid cancer) in the 2473 participants who were included in the Utah Study’s analysis of
period prevalence between 1965 and 1986.  Based on the linear relative risk model, the excess relative risk
was estimated to be 0.070 per mGy, with unadjusted 95% confidence interval ranging from 0.007, 0.33 per
mGy (p = 0.019). A relative risk of 3.4 (95% confidence interval 0.5, 26.9) was reported for all thyroid
neoplasms for people with a dose of greater than 400 mGy. Although there were positive dose-responses
for thyroid cancer and total nodules when these two outcomes were analyzed separately in the Utah Study,
they were not statistically significant (p = 0.16 and 0.096, respectively).  
Analyses that adjusted for the effect of dose uncertainties were also performed for the Utah Study.
The dosimetry model and the approach to estimating doses for the Utah Study were, broadly speaking,
similar to the HEDR model and HTDS approach.  The size of the dose uncertainties was summarized as
follows for the Utah Study: the geometric standard deviations (GSDs) for over 90% of the Utah Study
participants were between 1.75 and 3.75 (133).  This is generally similar to the magnitude of dose
uncertainties for HTDS participants, whose GSDs ranged from 1.56 to 5.42, with a mean of 2.18 (see
Section IX.B-2).  The Utah Study investigators performed additional analyses in an attempt to adjust for the
effect of dose uncertainties, which yielded adjusted estimates of the dose-response coefficients that were
roughly three times greater than the unadjusted estimates.  The standard errors of the estimates also
increased in approximate proportion to the estimates, so the statistical significance of the dose-responses
was essentially unchanged (133, 134).  A recent reanalysis that attempted to account for the correlation of
uncertainties in the Utah Study’s dose estimates suggested that the adjustment should in fact have been
somewhat smaller (139).
A number of other thyroid diseases investigated in the HTDS have also been linked to radiation
exposure. It is clear that exposure to external gamma radiation, x-rays, or  131I at high doses increases the
risk of developing hypothyroidism. There is no evidence, however, that exposure to radioactive iodine, at
lower doses similar to those estimated in the HTDS cohort, has the same effect. The HTDS found no
statistically significant evidence of such an effect. This is consistent with the results of the Utah Study,
which found no evidence that the risk of hypothyroidism increased with increasing estimated dose from the
Nevada Test Site’s fallout (10479).
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Two recent studies have suggested that autoimmune thyroiditis may be radiation-induced. These
findings come from studies of the Japanese atomic bomb survivors and people exposed around Chernobyl.
As indicated above, they reflect very different types of exposures than at Hanford: external sources of
exposure, higher doses, and higher dose rates.  Nevertheless, for comparison purposes, we conducted an
additional dose-response analysis that would correspond more directly to the analysis reported by Nagataki
et al. (15). For that analysis we defined autoimmune thyroiditis to include only those cases associated with
non-iatrogenic permanent hypothyroidism (see section IX.H above). The results of this analysis provided
no evidence of a significant dose-response (slope of the dose-response = 0.001 ± 0.015; p-value = 0.48). It
should be noted, however, that there were 161 cases of autoimmune thyroiditis in the HTDS cohort
according to this definition (cumulative incidence of 4.7%), which is considerably higher than reported by
Nagataki et al.. They report 27 clinical cases (1.0%) and 38 subclinical cases (1.5%) in their group of 2587.
Unfortunately, insufficient detail is provided in the published paper to discern exactly how their cases were
defined. Thus, it may be that the results of our alternative analysis are not truly comparable to those of
Nagataki et al., and the reason that the HTDS was not able to confirm their findings may be in part due to
the use of different criteria for the diagnosis.  
The outcomes of hyperthyroidism, thyroiditis, and goiter were also investigated in the Utah Study,
and for none of these were statistically significant dose responses observed (133).  While these findings,
taken at face value, appear to be consistent with the results of the HTDS, it is important to recognize that
the definitions and diagnostic criteria used for these outcomes differed somewhat between the two studies.
There is also reasonably clear evidence that exposure to head and neck irradiation in childhood
increases the risk of developing hyperparathyroidism. However, this evidence is based on situations in
which the exposure was due to external sources and the doses and dose rates were generally quite high.
There has been no convincing evidence in humans regarding the effect of exposure to radioactive iodine.
However, it is estimated that the radiation dose to the parathyroid glands is less than that of the dose to the
thyroid from a given exposure to radioactive iodine. Thus, given the thyroid dose distribution in the HTDS,
it would be expected that parathyroid doses to members of the HTDS cohort were very low. 
Relatively little is known about whether ionizing radiation causes an increase in thyroid
abnormalities detected by ultrasound prior to the development of clinical disease. Schneider reported that
exposure to external radiation was associated with a high prevalence of thyroid UDAs (112). In 54 exposed
individuals followed in his study, 87% (47/54) had abnormal ultrasound scans.  In this cohort, radiation
exposure was due to external sources. The authors concluded that 1) thyroid nodules continued to develop
in radiation-exposed individuals many years after exposure and 2) although thyroid UDAs were quite
common in the general population, they were more prevalent in radiation-exposed populations. 
Other studies have also suggested that thyroid UDAs are more common in exposed populations.
Antonelli compared ultrasound scans among 50 hospital workers with occupational radiation exposure
(external radiation) in a hospital setting to 100 controls without such exposure (113). Thyroid UDAs were
detected in 38% of the exposed people and only 13% of the controls.  Similarly, Sugenoya and colleagues
(114) compared 299 children who were exposed to Chernobyl radiation to 323 children who were
unexposed.  Although none of the children in either group had palpable abnormalities, 34 of the exposed
(11.4%) had thyroid UDAs compared to 4 unexposed children (1.2%).  
There are no published estimates of the risk of developing thyroid UDAs as defined by the HTDS
in relation to exposure to radioactive iodine. 
Thus, in considering the HTDS dose-response findings in the context of the literature on radiation-
induced thyroid disease, it is important to keep in mind the principal differences between the Hanford
exposures and those in other populations that have been studied. The Chernobyl exposures occurred in a
relatively short period of time and were substantially greater. Doses in populations around Chernobyl
studied to date have generally been higher, and dose rates were much higher than at Hanford. The mix of
radionuclides released was also different from Hanford, and there is some evidence that iodine deficiency
may be contributing to the excess in thyroid cancer observed thus far. The Marshall Island experience is
somewhat similar to the Chernobyl experience, insofar as doses were generally much higher and dose rates
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much higher than at Hanford. The mix of radionuclides was also more varied than at Hanford. The
exposures in Utah from the Nevada Test Site were also due to a broader mix of radionuclides than at
Hanford, although resulting doses were similar to those at Hanford. The dose rate for any given individual
in the Utah study was also relatively high, compared to that at Hanford, even though the exposures
occurred over many years. That is because the exposures resulted from individual nuclear tests, which
delivered the radioactive contamination in discrete, short periods of time. In contrast, exposures at Hanford
were relatively constant over time (although concentrated in the early years of operation). Considered in
total, the differences summarized above may largely explain why no dose-effects were observed in the
HTDS analyses. 
E. Comparison of the Occurrence of Thyroid Disease Outcomes With Other
Findings in the Literature
The section above considered the thyroid disease dose-response results of the HTDS in the context
of reported findings in other populations exposed to ionizing radiation. It is also important to consider the
findings of the clinical component of the HTDS (the determination of thyroid disease outcomes) in relation
to what is known about the occurrence of thyroid disease in other populations around the world. That is,
how does the magnitude of thyroid disease occurrence found in the HTDS cohort (the cumulative
incidence) compare with the levels of thyroid disease observed in other populations? Of particular interest
is whether the occurrence of thyroid disease in the HTDS cohort is greater than has generally been found in
other populations not exposed to 131I from Hanford. If so, this might be considered evidence of a possible
effect of Hanford radiation exposure, even in the absence of any dose-response relationships.
This is an exceedingly difficult question to answer because, as noted previously, the magnitude of
thyroid disease rates observed in any given population depends upon a number of different factors. First,
the recognition and diagnosis of thyroid disease in a population depends to a large extent on how
aggressively one looks for disease. Sometimes referred to as the “screening effect”, a concerted effort to
screen for a disease in a population, including the implementation of a comprehensive diagnostic protocol
as part of a research study like was done in the case of the HTDS, will result in higher rates of disease than
would be observed with normal medical care practices in the same population. This is particularly so for
thyroid neoplasia, which may not result in clinical symptoms and therefore can remain undetected, or
functional forms of thyroid disease such as hypothyroidism which may go unrecognized as thyroid disease
because of non-specific symptoms. Second, the extent to which thyroid disease is identified in a population
may depend on the diagnostic methods used or the criteria for diagnosis that are employed. For example,
the use of thyroid ultrasound will substantially increase the level of nodular thyroid disease detected in a
population compared to that found by physical examination (palpation) alone. Similarly, different
thresholds for laboratory values used to define a case of hypothyroidism could result in apparent
differences in disease occurrence that simply reflect differences in diagnostic definition. Such detection
effects can be substantial. For example, there is direct evidence in the HTDS of a large “screening effect”
for thyroid cancer. Twelve of the 20 cases of thyroid cancer among the 3440 evaluable study participants
were detected as a result of the HTDS examinations, and 2 of the 12 cases were diagnosed by palpation
only after the ultrasound scan was reviewed and the participants were re-examined. The resulting
cumulative incidence for thyroid cancer was 2.5 times greater than what it would have been had it been
based on cases identified through the normal medical care system. 
Third, populations with different characteristics or different exposures which might affect the
occurrence of thyroid disease can exhibit very different disease rates. For example, rates of most forms of
thyroid disease are higher for females than males, and increase with increasing age. Thus, all other factors
being comparable, two populations with different age and gender structures might exhibit very different
rates of thyroid disease. Similarly, people living in an iodine deficient environment would likely have
different rates of some forms of thyroid disease than people who are iodine sufficient. 
Despite these substantial obstacles to making valid comparisons between the cumulative incidence
of specific outcomes determined in the HTDS and estimates found in the published literature, we attempted
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to assemble the most comparable information possible for the most important outcome categories studied.
A summary of this information is presented in the subsections below, with special attention given to
differences between specific studies and the HTDS which could account in part or entirely for differences
in reported disease rates. Although admittedly imperfect, these data provide at least a frame of reference
within which the cumulative incidence data from the HTDS can be evaluated. 
E.1. Prevalence of Thyroid Cancer
The occurrence of thyroid cancer varies widely worldwide, is more common among females, and
increases sharply with increasing age. Annual incidence rates have been reported to range from a high of
104 cases per million in women in Hawaii to a low of 14 cases per million in women in Poland (140). The
age-adjusted annual incidence in the United States is 55 cases per million people (80 per million in women
and 29 per million in men)(140). Further, the incidence of thyroid cancer in the United States has steadily
increased over the last several decades, perhaps in part due to improved methods of diagnosis (140).
Although it might be preferable to compare the occurrence of thyroid cancer in the HTDS cohort to that in
other populations using incidence data, the retrospective nature of the HTDS design precluded us from
accurately determining a date of diagnosis for each case, and therefore from calculating an incidence rate in
the cohort. 
It is possible to use incidence data to predict the cumulative incidence of thyroid cancer that might
be expected in the HTDS cohort, although such predictions must be interpreted cautiously.  In fact this was
done at the beginning of the study to assist in developing the study design.  As described in Appendix H of
the HTDS Protocol (1), the cumulative incidence of thyroid cancer for the HTDS cohort was estimated
using age- and sex-specific incidence rates from the Cancer Surveillance System (CSS), a population-based
registry for the thirteen northwestern counties of Washington State.  To account for the screening effect of
the HTDS clinical examinations, the CSS incidence rates were multiplied by three, using a value suggested
by the National Council on Radiation Protection and Measurements (141).  The predicted cumulative
incidence of thyroid cancer was 0.0068 (0.68%) for women and 0.0025 (0.25%) for men.  These
predictions are in good agreement with the observed values of 0.7% for women and 0.4% for men (see
Section IX.C above).  While this may be viewed as evidence that overall thyroid cancer rates for the HTDS
cohort are not higher than expected, it must be recognized that incidence rates in the population covered by
the CSS may differ from the background rates of the HTDS cohort, and that the factor of three assumed for
the screening effect may not be appropriate for the HTDS clinical evaluation.
Unfortunately, there is very little information available regarding the prevalence of thyroid cancer
in the general population. This is due primarily to two reasons. First, because the absolute frequency of
incident cases is quite low, screening programs in the general population are not very feasible and are
generally not considered an appropriate use of resources.  Second, it can be difficult to discriminate
between clinically significant thyroid cancer and that which does not adversely impact a person’s health.
The latter is usually referred to as occult or microscopic cancer.
There have been a number of studies of patients with thyroid nodules who are referred for surgery
(142). Very high prevalence rates of thyroid cancer (5-24%) have been reported from these studies.
However, such surgical series have a high likelihood of selection bias since such patients are usually
referred because of high suspicion for thyroid cancer.  Consequently, these studies almost certainly
overestimate the true prevalence of thyroid cancer in the general population.
  The best data for estimating the frequency of “occult” or microscopic thyroid cancer come from
autopsy studies, where microscopic thyroid cancer is found in people who died of other causes.  Crapo and
Wang summarized a series of nine autopsy studies, performed from 1952-1977, which showed a mean
prevalence of thyroid cancer to be 3.6% among 3744 cases (range of prevalence 0.45-13.0%) (142).  These
studies were chosen in part because they all were carefully performed, each examining 1-3 mm slices of
thyroid tissue.  
In contrast to clinically important thyroid cancer, most studies show that occult thyroid cancer
does not seem to vary by age or gender.  These studies also show that the correlation between prevalence of
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occult thyroid cancer and mortality is poor.  Countries such as Japan have a high prevalence of occult
thyroid cancer but low mortality, whereas other countries have both low prevalence and low mortality. For
example, Fukunaga reported a 24-28% prevalence of occult thyroid cancer from autopsy studies of
Japanese and yet there is a low mortality rate from thyroid cancer in Japan (143).  
In summary, there are no good estimates of thyroid cancer prevalence to which the cumulative
incidence findings in the HTDS cohort can be compared. The prevalence estimates that are available are
most certainly overestimates of what might reasonably be expected in the HTDS cohort, as they are derived
from either patients referred for surgery, or from autopsy studies of occult cancer. 
E.2. Prevalence of Thyroid Nodules
It is well known that thyroid nodules are a common finding in the general population (reviewed in
142).  The primary determinant of the variation in prevalence estimates of thyroid nodules is the method of
detection. Estimates vary widely, depending on whether the method of detection is palpation, ultrasound, or
autopsy. 
The oldest and most widely quoted study of thyroid nodularity in the general adult population is
the Framingham Study, which began in 1948 and employed palpation as the method of detection (144).
The initial cohort was composed of 5127 randomly selected individuals from the town of Framingham,
Massachusetts who were given careful thyroid physical examinations to determine the prevalence of
thyroid nodules. The age range was 30-59 and the geographical area was not felt to be iodine deficient. The
criteria for a definite solitary thyroid nodule was one that was palpable by at least two examiners, while
suspected nodules were those palpable by only one examiner.  The average diameter of nodules was 1 cm.
The prevalence of definite single nodules detected over a 5 year examination period was 1.9% (2.7% for
females; 0.8% for males), while the combined prevalence of definite and suspected solitary nodules was
3.0% (4.6% for females, 1.1% for males). An additional 1.1% of the cohort had multiple palpable nodules
(1.7% for females, 0.4% for males).  Thus, of the total 5127 people examined, 218 people, or 4.2% had
palpable thyroid nodules (6.4% for females, 1.5% for males).
A 15-year follow-up study of this cohort was subsequently published in 1968 (145).  Of the 218
people found to have thyroid nodules in the initial survey, 139 people still had nodules which were
unchanged at the 15-year follow-up. Of the remaining 79 people, 45 had nodules excised during the follow-
up period (all were benign), 15 had died (none of thyroid related causes), and 19 had nodules that were
excised prior to the initial survey (all benign).  Of 4909 people who were free of palpable thyroid disease at
the initial survey, 67 people (1.4%) developed new nodules during the 15 year follow-up.  Although none
of these new nodules were reported to have thyroid cancer, only 13 people actually had surgery; the
remainder were thought to be clinically benign.
Thus, the cumulative incidence of palpable thyroid nodules at the end of the 15 year follow-up
period in the Framingham Study was 5.6% (285/5127 people); for females the cumulative incidence was
8.1% (230/2845) and for males 2.4% (55/2282).  Of the total 285 people with nodules, all were thought to
be clinically benign.  Although only 27% had surgical excision, none showed any evidence of malignancy.
The initial study attempted to discriminate between solitary nodules and multiple nodules (73% were
solitary), however the follow-up study did not and included all nodules in the prevalence data whether they
were thought solitary or multiple. These estimates of nodule prevalence are probably the most comparable
to the HTDS experience found in the world literature: they represent reasonably long-term follow-up, the
age range at the end of follow-up is approximately 45-74, most people were examined by multiple
physicians, the estimates include people with prior surgery, and the population under study is a randomly
selected group. 
A similar study by Whickham et al. documented the prevalence of thyroid disorders in 2779 adults
who were age and sex matched to the British population (146, 147).  Although this study provides some of
the highest quality information regarding thyroid dysfunction and autoimmune thyroid disease in an
unselected population (see below), the results of the 20 year follow-up study published in 1995 regarding
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the prevalence of thyroid nodules is of limited value because the study was not designed to assess nodular
thyroid disease. The original Whickham study published in 1977 contained one brief statement that thyroid
nodules were detected in 5.3% of women and 0.8% of men.  However, no details regarding the
characterization of nodule size or data regarding thyroid cancer in this cohort were reported (146).
There are no other population-based studies of thyroid nodularity in adults.  Ezzat (99) reported
results from a small series of adult volunteers who responded to an employee bulletin board and who were
given thyroid examinations by two examiners as well as ultrasound and laboratory evaluations.  Of the 100
people participating, 21 (21%) had palpable nodules which were confirmed by ultrasound. The high
prevalence is likely influenced by the predominance of females (84%), and perhaps the wide age range of
25-77 years. 
The use of ultrasonography has greatly increased the sensitivity of detecting anatomical
abnormalities or variations of normal in the human thyroid.  This technology has raised an important
question of whether the high frequency of thyroid UDAs in the general population constitute clinical
disease or whether many of these abnormalities represent variations in anatomy that do not adversely affect
health.  Section X.E.6 below considers the prevalence of thyroid UDAs. 
Estimates of the prevalence of thyroid nodules have also been reported based on autopsy findings.
One of the most quoted studies of thyroid nodules detected in people dying of non-thyroid disease was
published in 1955 by Mortenson (107).  These authors performed 821 consecutive autopsies (age range 0-
99) and found a prevalence of thyroid nodules to be 49.5%.  An older study (147) in 1938 (age range 0-89)
found a prevalence of only 8.2% but limited their findings to nodules greater than 2 cm.  In 1965 Oertel
reported a thyroid nodule prevalence of 13% in previously healthy military men dying from non-thyroid
causes  (n=113) (149). Other studies by Rice and Hull have found an even higher prevalence of nodules at
autopsy (57% and 65% respectively), but were conducted in endemic goiter areas which might explain the
high rates of nodularity (150, 151).
In summary, the prevalence of thyroid nodules identified in the HTDS cohort (7.2% overall; 9.7%
in females and 4.7% in males) is similar in magnitude to that found in the two population-based studies
reported in the literature. The slightly lower prevalence in the Framingham cohort most likely reflects a
considerably shorter period of follow-up, younger age range, and the absence of the ultrasound screening
effect demonstrated for benign nodules in the HTDS.  The latter effect of excluding ultrasound has been
demonstrated in the HTDS cohort: the cumulative incidence of benign nodules by palpation only (not
influenced by ultrasound) is 4.8% for females and 2.0% for males.  This value is in quite good agreement
with the Framingham prevalence figures. Estimates of prevalence of thyroid nodules based solely on
ultrasound detection, or autopsy findings, are considerably higher than in the HTDS cohort and should
probably be regarded as an indication of the upper bound of possible prevalence in human populations. 
E.3. Prevalence of Hypothyroidism
Hypothyroidism is generally classified into two categories based on severity.  Overt
hypothyroidism usually produces symptoms and is diagnosed by both elevated TSH levels and decreased
levels of circulating thyroid hormone.  Subclinical hypothyroidism may or may not produce overt
symptoms.  It is generally agreed that subclinical hypothyroidism is present when the TSH is between 5
and 10 µIU/ml and thyroid hormone levels are normal.  The degree to which subclinical hypothyroidism is
included in prevalence studies of hypothyroidism can greatly influence the magnitude of the estimates.   In
addition, age, gender, and the presence of iodine deficiency or autoimmune thyroid disease also influence
the magnitude of the prevalence estimates. 
Perhaps the most thorough evaluation of the prevalence of hypothyroidism in an unselected
population is the Whickham study and its 20-year follow-up study (146, 147).  In a review by Wang and
Crapo, they indicate it is “the only study that has surveyed a representative sample of the entire adult
population of a large community for thyroid disease by employing detailed medical histories, rigorous
physical examination, and sophisticated laboratory testing” (142).  
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The Whickham survey sample was randomly selected from an electoral register of adults older
than 18 years in Great Britain.  Of the initial sample of 3538 people, 2779 people participated in the study,
1285 men and 1494 women.  The age, sex, and social class of the sample generally reflected that of Great
Britain. In addition to detailed history and physical examination, each participant was tested for TSH by
RIA, free thyroxine index, antithyroid thyroglobulin antibody, and AMA (antithyroid microsomal
antibodies).  The prevalence of subclinical hypothyroidism (TSH>6 µIU/ml) was 7.5% in women and 2.8%
in men (combined, 5.3%).  The TSH levels increased with age in women but not in men.  The increase with
age in women was also seen primarily in those women with positive antithyroid antibodies.
One of the important aspects of the Whickham cohort is that it was followed for 20 years to
evaluate the natural history of thyroid disease.  Some type of follow-up information was available in over
95% of the original cohort.  The results showed that, after a median follow-up of 19 years, the prevalence
of hypothyroidism increased significantly.  This was in contrast to hyperthyroidism, which remained almost
unchanged.  The prevalence of spontaneous hypothyroidism in the cohort at the end of follow-up was 4.7%
(7.7% in women and 1.3% in men).  The overall median age was 58 (38-93), with a median age of 58 for
men and 59 for women. These numbers increased further with older women with a prevalence of 10.4% for
women older than 45 and 17.5% for women older than 75.
Sawin and colleagues evaluated the Framingham cohort in 1985 and assessed the frequency of
hypothyroidism (152).  The age range of this cohort, begun in 1948, was between 60 and 89 years of age.
For the total cohort of 2139 people at the end of the 15-year follow-up period, 10.3% had an elevated TSH
(13.6% for women, 5.7% of men).  Excluding those with subclinical hypothyroidism (TSH 5-10 µIU/ml),
those with clearly elevated TSH levels (>10 µIU/ml) included 4.4% of the total cohort (5.8% for women
and 2.4% in men).  Thus, in an unselected aging population, the total prevalence of hypothyroidism was
quite high at over 10%.
More recently (1993), Geul and colleagues conducted a population survey in the Netherlands
which corroborates the Whickham results regarding risk factors for progression of hypothyroidism (10188).
TSH and AMA were measured in 423 randomly selected women from the Netherlands, age 40-60, and
were repeated ten years later. The prevalence of hypothyroidism at the end of 10 years in the cohort was
7.3% for women, mean age 65.
Several other studies have investigated thyroid deficiency in population based settings.  One recent
study (1999) evaluated 1411 people representing the majority of individuals from the population of
Pescopagano, an iodine deficient community in southern Italy (153).  This cohort represented a relatively
young population with only 28% of people older than 46 and 30% younger than age 15.  Overt
hypothyroidism occurred in only 0.2% whereas subclinical hypothyroidism (TSH > 3.7 µIU/ml) occurred
in 3.8%.  Although this was reported not to be significantly different from that reported in the Whickham
study, it is lower than a number of other reports including Framingham and likely reflects the relatively
young age of the cohort and perhaps iodine deficiency in the population. 
A population-based survey of Danish centenarians has provided interesting information about the
effect of very old age on thyroid dysfunction (154).  A total of 140 people older than 100 years agreed to
have blood tests taken. The number of people with subclinical hypothyroidism was fairly small at 2.9%.
An additional 2.9% reported previous hypothyroid disease.  The authors concluded that the level of thyroid
dysfunction in people older than 100 years was not significantly increased over older people younger than
age 100, and that thyroid function in centenarians was well preserved.
The recently published Colorado Health Study involved screening of thyroid function in over
25,000 people at a Health Fair (155).  The mean age of the group screened was 56 years with women
representing 56%.  An elevated TSH was detected in 2450 people (9.5%).  Of this group, 1799 people
(7.0%) had subclinical hypothyroidism (TSH between 5.1-10 µIU/ml) and 619 people (2.4%) had a TSH
greater than 10 µIU/ml.  For the age group 45-54, the prevalence of elevated TSH levels was 5% for males
and 9% for females; for the 55-64 age group the prevalence increased to 6% for males and 13% for females
and continuing increasing with age to about 21% for women greater than age 74.
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Finally, Hollowell and coworkers recently reported the results of a large screening study of thyroid
abnormalities in a population sampled to represent the geographic and ethnic distribution of the US
population (156).  The cohort consisted of 31,000 people age 6 and older.  The mean TSH was 1.49 µIU/ml
for those above 12 years who did not report thyroid disease or thyroid medication.  For the age range 40-49,
the percentage of people with TSH above 4.5 µIU/ml was 5.7% for females and 3.7% for males, whereas
the frequency of positive TPO antibodies was 17.2% in females and 11.3% in males.  For the age range 50-
59, TSH was greater than 4.5 µIU/ml in 8.1% of females and 2.4% of males; the prevalence of positive
TPO antibodies was 18.2% in females and 10.5% in males.  While the prevalence of elevated TSH levels
was greater among females than males, this difference was not significant after controlling for TPO
antibodies.  This result is consistent with the results of the Whickham and Geul studies reported above.  
In summary, there is considerable information available in the published literature regarding the
prevalence of hypothyroidism (both overt and subclinical) in a number of population-based samples of
individuals. Estimates of prevalence from the major studies are in reasonable agreement with each other,
and define a range which encompasses the estimates derived in the HTDS (7.8% overall; 11.7% in females
and 3.7% in males).  
E.4. Prevalence of Autoimmune Thyroiditis
Estimating the prevalence of autoimmune thyroiditis is particularly challenging because the
antibody assays for detecting autoimmune thyroiditis have changed over time. These assays have ranged
from antithyroglobulin measurement via agglutination techniques to antithyroid antimicrosomal antibodies
to current and refined methods for detecting thyroid peroxidase antibodies.  The reported prevalence of
autoimmune thyroiditis in any given study depends on a number of factors, but especially the type of assay
used.
The prevalence of antibody positivity in the general population is generally much higher than the
prevalence of clinical disease.  Although the ability to detect individuals with positive antithyroid
antibodies has greatly enhanced the ability to predict risk for developing hypothyroidism, it is nevertheless
difficult to predict which individuals with antibody positivity will develop clinical disease. In part, the
probability of developing disease is related to the magnitude of the positive test.  Summarized below are
results from studies of the prevalence of antibody positivity in the general population, with an emphasis on
those studies in the last 10-15 years which have utilized more highly sensitive antibody assays.
The Whickham study (reviewed above) also provides important results regarding autoimmune
thyroiditis. At the 20-year follow-up, 19% of the cohort had positive antithyroid antibodies (147).  The
prevalence in women was 26.4% and in men 8.8%. These antibodies were later reported by the authors to
be TPO antibodies (10332).
An important study by Spencer and colleagues evaluated antibody positivity in thyroid cancer
patients and compared them to a group of 4453 people representing the general population who were
undergoing routine multiphasic health examinations (157).  The mean age of the healthy participants was
45 with a range of 12-99, and a male to female ratio of 0.69.  Antibodies to both thyroid peroxidase (TPO)
and thyroglobulin were measured.  The prevalence of anti-TPO alone was 4.0%, anti-TG was 3.1%, and
both TPO and TG antibodies was 7.0%. The prevalence of having any antibody positivity was 14.1%.
The Pescopagano study (described in section X.E.3 above) also assessed antithyroid antibody
positivity.  The overall prevalence of people positive for both TPO and TG antibody tests was 12.6%
(females 17.3%; males 7.0%).  Positive antibody tests showed an age effect with a prevalence of 2.4% in
children, increasing to 22% in people aged 46-55.  No further increases were seen in older people.
Although low titer antibody positivity was quite frequent in this cohort, the authors concluded that the
spectrum of thyroid disease was not different from that observed in iodine-sufficient areas.
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Five additional studies provide data on the prevalence of anti-thyroid antibodies in a healthy
unselected population.  The Geul study from the Netherlands (discussed in section X.E.3 above) showed
that the progression to hypothyroidism was strongly influenced by the presence of autoimmune thyroiditis
(158).  In a group of 427 women with mean age of 55 (40-60), AMA (antithyroid microsomal antibodies)
were measured at the start of the study.  The prevalence of positive AMA was 11%.  Prentice measured
TPO antibodies in 698 female blood donors from seven towns in Great Britain and reported that 18% were
positive.  The prevalence rose from 15% in women of age 18-24 to 24% in women of age 55-64 (159).
Lazarus found similar results in screening 414 asymptomatic elderly women over age 70.  The prevalence
of positive TPO antibodies was 15% and anti-thyroglobulin antibodies 13% (160).  An even higher
frequency of positive TG antibodies was found in a small study of patients with thyroid disease compared
to 140 healthy volunteers.  The volunteer group consisted of 80 women (median age 50) and 60 men
(median age 48) in whom care was taken to exclude the presence of thyroid disease.  In this group, 27%
had positive TG antibodies (161).  This is one of the highest frequencies of positive thyroid antibodies
reported in a healthy population, although these results are somewhat limited by a very small number of
people screened. Finally, the Danish centenarians (described in section X.E.3 above) were also assessed for
antithyroid antibodies (154). They were classified into two groups; dependent or independent based on their
need for assistance for daily living activities.  Those classified as dependent had higher rates of positivity
(TPO 11.1%; TG 14.8%; both 22.2%) than those classified as independent (TPO 6.8%; TG 5.1%; both
8.5%). 
In summary, there is also considerable information available regarding the prevalence of positive
anti-thyroid antibodies in the general population. Estimates range from 3-27%, but are highly variable and
are dependent on a number of factors including age, gender, geographical location, type of antibody assay,
and perhaps ethnic background and iodine sufficiency as well. Nevertheless, the cumulative incidence
estimates for autoimmune thyroiditis in the HTDS cohort (18.2% overall; 23.1% in females and 13.1% in
males) are consistent with these estimates in other populations. 
E.5. Prevalence of Hyperparathyroidism 
The parathyroid glands, located in the back of the thyroid gland, contribute to the regulation of
calcium levels in the body through the production of parathyroid hormone (PTH).  The most common
parathyroid disorder is hyperparathyroidism, which results in high circulating calcium levels due to high
levels of PTH secreted from one or more of the parathyroid glands. This disorder is uncommon in
comparison to thyroid disease. 
Primary hyperparathyroidism has traditionally been defined as an elevated calcium level in the
presence of an elevated PTH level.   However, because accurate tests of PTH have only become available
in the last 10-15 years, early studies have used variable definitions for the disease.  Even with the accurate
PTH tests available today, the frequency of hyperparathyroidism found from one study to another depends
greatly on the cut-off points used by the investigators.  For example, a high normal PTH level in the
presence of a high calcium is not truly normal and usually represents primary hyperparathyroidism.
However, differences in the actual cut-off used from one study to another will result in variable prevalence
rates being reported across populations.
Early studies reported a prevalence of hyperparathyroidism of between 0.29% and 1.03% in
Swedish men and women age 50-63 (162), and a prevalence of 1.5% in women older than 60 (163).
However, these estimates did not reflect a sample of the general population. The prevalence of
hyperparathyroidism in the unexposed control group from the studies of atomic bomb survivors in Japan
has been reported to be 0.1% in men and 0.3% in women over age 41 (164).
Lundgren and colleagues evaluated 5202 women attending a population-based mammography
screening program in Sweden (165).  Several definitions of hyperparathyroidism were employed which
varied the cutoff points of calcium and PTH.  The prevalence of primary hyperparathyroidism in women
age 55-75 was 2.1%.  This prevalence exceeded that reported by Christensson, which required indisputable
hypercalcemia (greater than 2.78 mmole/L) for the diagnosis of hyperparathyroidism rather than high
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normal calcium levels in the presence of an increased PTH.  Lundgren concluded that the use of current
biochemical criteria results in under-diagnosis of primary hyperparathyroidism.
A recent population-based study by Jorde and colleagues from Norway measured serum calcium
in approximately 25,000 people who participated in a broad health survey (166).  In people with calcium
levels greater than 2.59 mmol/L, PTH was also measured.  The prevalence of primary hyperparathyroidism
in this group (ages 25-75) was 0.17% for men and 0.45% for women (p<.001).  A subgroup analysis was
performed in older women between ages 50 and 75.  Using the criteria for the main study, the prevalence of
hyperparathyroidism was 8.8%.   However, the prevalence varied dramatically from 3.6% to 13.9% when
the criteria for hyperparathyroidism were varied.  
Despite the substantial difficulties in comparing prevalence estimates of hyperparathyroidism in
different populations due to differences in diagnostic definitions used, the cumulative incidence estimates
from the HTDS (0.3% overall; 0.6% in females and 0.1% in males) are well within the range of estimates
found in the published literature. 
E.6. Prevalence of Thyroid Ultrasound-Detected Abnormalities of the Thyroid
(Thyroid UDAs)
During the last 15 years, high-frequency ultrasound has increasingly been used in the evaluation of
thyroid nodules.  Although the traditional definition of a thyroid “nodule” has been based on clinical
palpation, the greater sensitivity of ultrasonography has led to its increased use and consequently the
detection of nonpalpable, millimeter-size abnormalities.  This has raised several important issues: 1)
thyroid UDAs have been shown to occur frequently in the general population, without an adequate
understanding of their risk of malignancy or biologic significance; 2) thyroid UDAs have often been
classified as “nodules” regardless of size.  This has resulted in uncertainty about whether palpable
ultrasound-detected nodules are biologically different than the large numbers of nonpalpable ultrasound-
detected “nodules”; 3) the use of ultrasound in defining criteria for thyroid nodules has made it difficult to
compare clinical thyroid outcomes across epidemiological studies if they use different criteria for thyroid
nodularity; and 4) although ultrasound has exceptional sensitivity, recent data regarding specificity (the
ability to distinguish benign from malignant nodules) suggests that the increases in specificity of
ultrasonography are associated with significant decreases in the sensitivity.  
A number of studies have shown that the prevalence of thyroid UDAs is high in the general
population. Tan et al. have recently reviewed the literature and reported a range of prevalence of 17-67%
(97).   In 1000 people evaluated for hypercalcemia, in whom 8% had a nodular goiter, 46% had discrete
lesions on ultrasound and 38% were reported to have nodules (98).  The study reporting the highest
prevalence of thyroid UDAs was a prospective study of 100 employees responding to a notice on a bulletin
board:  67% of these women, mean age 43, showed abnormal thyroid ultrasound scans (10114). Thyroid
UDAs in populations without apparent thyroid disease have also been documented outside the US with
prevalence figures ranging 17-27% (100, 101, 102). Most of these studies have been consistent in showing
that nonpalpable thyroid UDAs are generally small and that solitary nodules on clinical examination are
often associated with multiple other thyroid UDAs. Both Tan (103) and Brander (100) have demonstrated
that in patients with known palpable thyroid nodules greater than 1 cm, 48% harbored additional thyroid
nodules found on ultrasound.
Brander and colleagues have also published a comprehensive study regarding the prevalence of
thyroid UDAs. They randomly selected 253 people from a Finnish city council registry and screened for
thyroid UDAs (104).  The sample was distributed evenly among four age brackets from 20 through 50.
The community was not thought to be endemic for goiter. Thyroid UDAs were detected in 69 people
(27.3%).  These abnormalities were solitary in 57%, multiple in 22%, and diffuse in 22%. The mean age for
people with normal ultrasound scans was 35, the mean age for the group with abnormal ultrasound findings
was 37.  These abnormalities were found more often in women than men and increased with age for both
sexes.  For women, the prevalence of thyroid UDAs was 30% in the 20-29 age group, 32% in the 30-39 age
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group, and 41% in the 40-50 age group.  All participants underwent thyroid palpation prior to ultrasound
examination.  Palpable abnormalities were detected in 13 people (5.1%); three with a solitary nodule, five
with multiple nodules, and five with abnormal consistency.  Fine needle aspirations were done in 30
individuals.   All were negative for malignancy with one intermediate probably of neoplasm; that person
underwent surgery and had a follicular adenoma.  
Bruneton evaluated 1000 healthy volunteers without history of thyroid disease and performed high
frequency thyroid ultrasound examinations (106). Although selection criteria or mean age were not
provided, 57% of participants were over 50 years.  Ultrasonography was performed with 13 MHz
transducers and all ultrasound nodules greater or equal to 3 mm were counted.  One or more nodules were
detected in 34.7% of subjects. For people less than age 50 (n=431), the prevalence was 25%.  For people
greater than age 50 (n=569), prevalence was 42%.  For all ages, the prevalence in women was 44% and the
prevalence in men was 17.7%.
A Belgian study assessed thyroid ultrasound abnormalities in 300 patients who were referred for
abdominal ultrasound examinations (102).  Although this study sample is not a random representation of
the general population, there were extensive exclusion criteria for those with symptoms or signs of thyroid
disease.  Unlike the Bruneton study, this investigation used a 5.5 MHz ultrasound transducer.  The mean
age was 47 (range 1-88 years) and 55% of the participants were males.  Small echoic nodules were found in
19% of patients.  In patients in their seventh decade of life, the prevalence increased to over 40%.  The
wide age distribution of this cohort and the high percentage of males undoubtedly influenced these results.
In summary, there is considerable published evidence reporting high prevalence of thyroid
abnormalities detected by ultrasound examination in the general population. Estimates of 40%-50% or even
greater are not uncommon, depending upon the characteristics of the population screened and the
technology used. The prevalence of any UDA found in the HTDS (46.5% overall; 55.5% in females and
37.4% in males) are consistent with these estimates. 
In overall summary, a considerable effort was made to assess the world literature on the
prevalence of the major thyroid and parathyroid disease outcomes evaluated in the HTDS as well as thyroid
UDSs. This was done in order to compare the disease experience of the HTDS cohort to what might
reasonably be expected based on the experience in other populations not exposed to Hanford radiation. As
outlined at the beginning of this section, comparisons of this type are imperfect and must be interpreted
with great caution. What appear to be differences in prevalence estimates between the HTDS cohort and
other populations may well reflect differences in any of a number of factors other than exposure to
radiation from Hanford. Nevertheless, it is clear from comparisons with the most comparable studies in
other locations that for the major outcomes described above (thyroid nodules, thyroid cancer,
hypothyroidism, autoimmune thyroiditis, hyperparathyroidism, and thyroid UDAs), the estimates of
cumulative incidence or prevalence derived from the HTDS are well within the range and are consistent
with published estimates. There is no indication that the levels of disease occurrence in the HTDS cohort
are systematically different, or higher, than what has been reported around the world in a variety of
different circumstances. 
F. Summary and Conclusions
The HTDS was conducted to determine whether exposure to atmospheric releases of primarily 131I
from the Hanford Nuclear Site between 1944 and 1957 resulted in increased thyroid disease among those
exposed. The study evaluated twelve categories of thyroid disease, the results of several laboratory tests for
thyroid function, anti-thyroid antibody and serum calcium level, thyroid UDAs, thyroid mass, and
hyperparathyroidism. The primary analysis utilized an estimate of thyroid radiation dose for each
individual based on information about their residence history and dietary consumption patterns during the
times of the Hanford releases. Additional analyses were also conducted using several alternative methods
for estimating dose, both quantitative and qualitative, including methods which were independent of the
HEDR models. The primary analyses were based on a sex-stratified linear dose-response model, although
alternative models for the shape of the dose-response were also investigated. The potential effect on any
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dose-response of a number of lifestyle factors and indicators of other radiation exposure were evaluated as
covariates in the models. All primary dose-response analyses were repeated to include adjustments for
uncertainty in the individual radiation dose estimates. 
This study found no statistically significant association between dose to the thyroid from Hanford
radiation and 1) cumulative incidence of any of the disease outcomes; 2) prevalence of thyroid UDAs; or 3)
thyroid laboratory tests or thyroid mass. There was also no evidence of a dose-response for
hyperparathyroidism, although a positive dose-response was seen for serum calcium.  An increasing thyroid
dose was significantly associated with a decrease in serum calcium. Although the explanation for this result
is not clearly apparent, the finding does not appear to be of clinical significance (discussed more fully in
section IX.Q.7 above). These results remained the same when alternative methods of assessing radiation
dose were used, and after accounting for uncertainty in dose estimation. Based on data available regarding
the tracing and enrollment of study participants, there is no evidence that the absence of a dose-response
relationship is due to bias in selection of the cohort, loss to follow-up, or enrollment and participation. 
Given the principal differences between the radiation exposure circumstances at Hanford and
those of other populations studied in relation to radiation-induced thyroid disease (summarized above), the
findings of this study are not inconsistent with the current published literature regarding the effect of
exposure to radioactive iodine and the risk of thyroid and parathyroid disease. This is particularly so given
the relatively small magnitude of the estimated thyroid radiation doses in members of the HTDS cohort
(mean = 174 mGy) and the relatively protracted nature of the exposure over time. There is little evidence in
the literature to suggest that people exposed to 131I at the levels found in this study over a period of months
or years would experience higher rates of thyroid or parathyroid disease as a result of their exposure. 
Nevertheless, a lingering question for many may be whether the uncertain nature of the dose
estimation used in the primary analyses is so great that it renders the quantitative dose-response results
inconclusive. The study has attempted to address this possibility in three ways. First, alternative qualitative
methods of assigning exposure were used. Results from these analyses were consistent with those from the
quantitative dose-response analyses. Second, two different approaches were employed to evaluate the
impact of dose uncertainty on the primary risk estimates. Neither resulted in findings that were materially
different from those ignoring such uncertainty. Third, the impact of dose uncertainty on study power was
assessed using simulation methods. These analyses revealed that the reduction in statistical power due to
uncertainty in dose estimation was modest, and that even after accounting for such uncertainty the study
had adequate statistical power to detect effects as small or smaller than those in the existing published
literature. Although any epidemiologic study is limited to some extent by uncertainty in the assessment of
exposure, the impact of such uncertainty on the power of the study and the estimation of risk is seldom
addressed to the extent attempted here. Further, the fact that epidemiologic investigations are inherently
“uncertain” does not imply complete randomness or unpredictability, nor does it mean that reasonable
conclusions cannot be drawn from such studies. 
In conclusion, the results of the HTDS provide no evidence of a statistically significant association
between increasing thyroid radiation dose from Hanford and the cumulative incidence of any of the disease
outcomes studied or the prevalence of thyroid UDAs. These findings do not definitively rule out the
possibility that Hanford radiation exposures are associated with an increase in one or more of the outcomes
under investigation. However, it does mean that if such associations exist, they were likely too small to
detect using the best epidemiologic methods available. 
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